PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dublet, B; Vernet, T; van der Rest, M				Dublet, B; Vernet, T; van der Rest, M			Schmid's metaphyseal chondrodysplasia mutations interfere with folding of the C-terminal domain of human collagen X expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLOBULAR DOMAIN; ALPHA-1(X) NC1; IN-VITRO; GENE; PROCOLLAGEN; COMPLEMENT; CARTILAGE; C1Q; SEQUENCE	Human collagen X contains a highly conserved 161-amino acid C-terminal non-triple helical domain that is homologous to the C-terminal domain of collagen VIII and to the Clq module of the human C1 enzyme. We have expressed this domain (residues 545-680) in Escherichia coli as a glutathione S-transferase fusion protein, The purified fusion protein trimerizes spontaneously in vitro, and after thrombin cleavage, the purified C-terminal domain trimer (46.2 kDa) is extremely stable and trypsin-resistant. Mutations within the C terminal domain have been observed in patients with Schmid's metaphyseal chondrodysplasia (SMCD), Some of these mutations (Y598D, G618V, W651X, or H669X; X is the stop codon) were constructed by site directed mutagenesis. Each mutation had identical consequences regarding the fusion protein: 1) absence of trimeric formation, 2) copurification of the similar to 60-kDa GroEL chaperone protein, and 3) sensitivity of the monomeric fusion protein to trypsin digestion. These results show that the C-terminal domain of collagen X is sufficient to produce a very stable and compact trimer in the absence of collagen Gly-X-Y repeats. Moreover, mutations causing SMCD interfere in this system with the correct folding of the C-terminal domain. The existence of a similar mechanism in chondrocytes might explain the relative homogeneity of phenotypes in SMCD despite the diversity of mutations.	Inst Biol Struct Jean Pierre Ebel, Lab Ingenierie Macromol, CEA, CNRS,UPR 9015, F-38027 Grenoble 01, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dublet, B (corresponding author), Inst Biol Struct Jean Pierre Ebel, Lab Ingenierie Macromol, CEA, CNRS,UPR 9015, 41 Rue Jules Horowitz, F-38027 Grenoble 01, France.	dublet@ibs.fr	Vernet, Thierry/G-1118-2012					APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Chan D, 1998, MATRIX BIOL, V17, P169, DOI 10.1016/S0945-053X(98)90056-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; DAVIS JG, 1995, SCIENCE, V267, P1031, DOI 10.1126/science.7863331; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GRANT WT, 1985, J BIOL CHEM, V260, P3798; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Hegyi H, 1997, J PROTEIN CHEM, V16, P545, DOI 10.1023/A:1026382032119; HOYLAND JA, 1991, BONE MINER, V15, P151, DOI 10.1016/0169-6009(91)90005-K; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KAVETY B, 1994, MOL BRAIN RES, V27, P152, DOI 10.1016/0169-328X(94)90196-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTOSH I, 1994, HUM MOL GENET, V3, P303, DOI 10.1093/hmg/3.2.303; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; VANDERMARK K, 1992, ARTHRITIS RHEUM, V35, P806; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508	35	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18909	18915		10.1074/jbc.274.27.18909	http://dx.doi.org/10.1074/jbc.274.27.18909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383388	hybrid			2022-12-27	WOS:000081196300011
J	Befort, K; Zilliox, C; Filliol, D; Yue, SY; Kieffer, BL				Befort, K; Zilliox, C; Filliol, D; Yue, SY; Kieffer, BL			Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; 3RD INTRACELLULAR LOOP; TERNARY COMPLEX MODEL; GAMMA-S BINDING; SIGNAL-TRANSDUCTION; BETA(2)-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR; LIGAND RECOGNITION; ADENOSINE RECEPTOR	We have investigated whether transmembrane amino acid residues Asp(128) (domain III), Tyr(129) (domain II), and Tyr(308) (domain VII) in the mouse delta opioid receptor play a role in receptor activation. To do so, we have used a [S-35]GTP gamma S (where GTP gamma S is guanosine 5'-3-O-(thio)triphosphate) binding assay to quantify the activation of recombinant receptors transiently expressed in COS cells and compared functional responses of D128N, D128A, Y129F, Y129A, and Y308F point-mutated receptors to that of the wild-type receptor. In the absence of ligand, [S-35]GTP gamma S binding was increased for every mutant receptor under study (1.6-2.6-fold), suggesting that all mutations are able to enhance constitutive activity at the receptor. In support of this finding, the inverse agonist N,N-diallyl-Tyr-Aib-Aib-Phe-Leu (where Aib represents cu-aminobutyric acid) efficiently reduced basal [S-35]GTP gamma S binding in the mutated receptor preparations. The potent agonist BW373U86 stimulated [S-35]GTP gamma S binding above basal levels with similar (D128N, Y129F, and Y129A) or markedly increased (Y308F) efficacy compared with wildtype receptor. BW373U86 potency was maintained or increased, In conclusion, our results demonstrate that the mutations under study increase functional activity of the receptor. Three-dimensional modeling suggests that Asp(128) (III), and Tyr(308) (VII) interact with each other and that Tyr(129) (III) undergoes H bonding with His(278) (VI). Thus, Asp(128), Tyr(129), and Tyr(308) may be involved in a network of interhelical bonds, which contributes to maintain the delta receptor under an inactive conformation. We suggest that the mutations weaken helix-helix interactions and generate a receptor state that favors the active conformation and/or interacts with heterotrimeric G proteins more effectively.	ESBS, CNRS, URR 9050, F-67400 Illkirch Graffenstaden, France; Astra Res Ctr Montreal, Dept Chem, Montreal, PQ H4S 1Z9, Canada; Astra Res Ctr Montreal, Dept Mol Biol, Montreal, PQ H4S 1Z9, Canada	Centre National de la Recherche Scientifique (CNRS)	Kieffer, BL (corresponding author), ESBS, CNRS, URR 9050, Parc Innovat,Blvd S Brandt, F-67400 Illkirch Graffenstaden, France.							Alkorta I, 1996, PROTEIN ENG, V9, P573, DOI 10.1093/protein/9.7.573; Befort K, 1996, NEUROCHEM RES, V21, P1301, DOI 10.1007/BF02532371; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; Befort K, 1996, MOL PHARMACOL, V49, P216; CHILDERS SR, 1993, MOL PHARMACOL, V44, P827; CHILDERS SR, 1993, HDB EXPT PHARM, V104, P189; Chiu TT, 1996, MOL PHARMACOL, V50, P1651; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COTTON R, 1984, EUR J PHARMACOL, V97, P331, DOI 10.1016/0014-2999(84)90470-9; Cox B.M., 1993, HDB EXPT PHARM, V104, P145, DOI [10.1007/978-3-642-77460-7_8, DOI 10.1007/978-3-642-77460-7_8]; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Dondio G, 1997, BIOORG MED CHEM LETT, V7, P2967, DOI 10.1016/S0960-894X(97)10119-6; Fong TM, 1996, CELL SIGNAL, V8, P217; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HabibiNezhad B, 1996, J MOL MODEL, V2, P362, DOI 10.1007/s0089460020362; Jin JG, 1997, BRIT J PHARMACOL, V121, P317, DOI 10.1038/sj.bjp.0701121; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KIM JH, 1995, J BIOL CHEM, V270, P13987, DOI 10.1074/jbc.270.23.13987; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MARIE J, 1994, J BIOL CHEM, V269, P20815; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NORTH RA, 1993, HDB EXP PHARM, V104, P773; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Perez DM, 1996, MOL PHARMACOL, V49, P112; Poda G, 1998, LETT PEPT SCI, V5, P193, DOI 10.1023/A:1008826904230; Pogozheva ID, 1998, BIOPHYS J, V75, P612, DOI 10.1016/S0006-3495(98)77552-6; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Strahs D, 1997, PROTEIN ENG, V10, P1019, DOI 10.1093/protein/10.9.1019; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; YUE SY, 1997, J MOL GRAPH MODEL, V15, P403; Zhorov BS, 1998, J BIOMOL STRUCT DYN, V15, P631, DOI 10.1080/07391102.1998.10508980; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; Zuscik MJ, 1998, J BIOL CHEM, V273, P3401, DOI 10.1074/jbc.273.6.3401	56	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18574	18581		10.1074/jbc.274.26.18574	http://dx.doi.org/10.1074/jbc.274.26.18574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373467	Green Published, hybrid			2022-12-27	WOS:000081056700059
J	Fujikawa, K; Kamiya, H; Yakushiji, H; Fujii, Y; Nakabeppu, Y; Kasai, H				Fujikawa, K; Kamiya, H; Yakushiji, H; Fujii, Y; Nakabeppu, Y; Kasai, H			The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED NUCLEOTIDES; HUMAN MTH1 PROTEIN; ESCHERICHIA-COLI; DEGENERATIVE DISEASES; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; 8-OXO-DGTPASE; TAUTOMERISM; HYDROLYZES; EXPRESSION	The possibility that Escherichia coli MutT and human MTH1 (hMTH1) hydrolyze oxidized DNA precursors other than 8-hydroxy-dGTP (8-OH-dGTP) was investigated. We report here that hMTH1 hydrolyzed 2-hydroxy-dATP (2-OH-dATP) and 8-hydroxy-dATP (8-OH-dATP), oxidized forms of dATP, but not (R)-8,5'-cyclod-dATP, 5-hydroxy-dCTP, and 8-formyl-dUTP. The kinetic parameters indicated that 2-OH-dATP was hydrolyzed more efficiently and with higher affinity than 8-OH-dGTP. 8-OH-dATP was hydrolyzed as efficiently as 8-OH-dGTP. The preferential hydrolysis of 2-OH-dATP over 8-OH-dGTP was observed at all of the pH values tested (pH 7.2 to pH 8.8). In particular, a 5-fold difference in the hydrolysis efficiencies for 2-OH-dATP over 8-OH-dGTP was found at pH 7.2. However, E. coli MutT had no hydrolysis activity for either 2-OH-dATP or 8-OH-dATP. Thus, E. coli MutT is an imperfect counterpart for hMTH1. Furthermore, we found that 2-hydroxy-dADP and 8-hydroxy-dGDP competitively inhibited both the 8-OH-dATP hydrolase and 8-OH-dGTP hydrolase activities of hMTH1. The inhibitory effects of 2-hydroxy-dADP were S-fold stronger than those of 8-hydroxy-dGDP, These results suggest that the three damaged nucleotides share the same recognition site of hMTH1 and that it is a more important sanitization enzyme than expected thus far.	Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Biochem, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Japan Science & Technology Agency (JST); Kyushu University	Kasai, H (corresponding author), Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.		Kamiya, Hiroyuki/G-2383-2019; Nakabeppu, Yusaku/A-8902-2011	Kamiya, Hiroyuki/0000-0001-6866-5322; Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bialkowski K, 1998, NUCLEIC ACIDS RES, V26, P3194, DOI 10.1093/nar/26.13.3194; Cai JP, 1997, NUCLEIC ACIDS RES, V25, P1170, DOI 10.1093/nar/25.6.1170; CHENG KC, 1992, J BIOL CHEM, V267, P166; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujikawa K, 1998, NUCLEIC ACIDS RES, V26, P4582, DOI 10.1093/nar/26.20.4582; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Inoue M, 1998, J BIOL CHEM, V273, P11069, DOI 10.1074/jbc.273.18.11069; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; LEONARD GA, 1992, BIOCHEMISTRY-US, V31, P8415, DOI 10.1021/bi00151a004; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MurataKamiya N, 1997, J RADIAT RES, V38, P121, DOI 10.1269/jrr.38.121; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Saenger W., 1988, PRINCIPLES NUCL ACID; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SEELA F, 1992, HELV CHIM ACTA, V75, P2298, DOI 10.1002/hlca.19920750716; SEELA F, 1995, HELV CHIM ACTA, V78, P1843, DOI 10.1002/hlca.19950780718; SEPIOL J, 1976, Z NATURFORSCH C, V31, P361; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; UESUGI S, 1977, J AM CHEM SOC, V99, P2313, DOI 10.1021/ja00449a049; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	28	191	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18201	18205		10.1074/jbc.274.26.18201	http://dx.doi.org/10.1074/jbc.274.26.18201			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373420	hybrid			2022-12-27	WOS:000081056700012
J	Wakasugi, M; Sancar, A				Wakasugi, M; Sancar, A			Order of assembly of human DNA repair excision nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; ULTRAVIOLET-DAMAGED DNA; ANTICANCER DRUG CISPLATIN; HUMAN MISMATCH REPAIR; GROUP-C PROTEIN; BINDING-PROTEIN; PREFERENTIAL BINDING; TRANSCRIPTION FACTOR; PYRIMIDINE DIMERS; XPG PROTEIN	Human excision nuclease removes DNA damage by concerted dual incisions bracketing the lesion. The dual incisions are accomplished by sequential and partly overlapping actions of six repair factors, RPA, XPA, XPC, TFIIH, XPG, and XPF.ERCC1. Of these, RPA, XPA, and XPC have specific binding affinity for damaged DNA, To learn about the role of these three proteins in damage recognition and the order of assembly of the excision nuclease, we measured the binding affinities of XPA, RPA, and XPC to a DNA fragment containing a single (6-4) photoproduct and determined the rate of damage excision under a variety of reaction conditions. We found that XPC has the highest affinity to DNA and that RPA has the highest selectivity for damaged DNA. Under experimental conditions conducive to binding of either XPA + RPA or XPC to damaged DNA, the rate of damage removal was about 5-fold faster for reactions in which XPA + RPA was the first damage recognition factor presented to DNA compared with reactions in which XPC was the first protein that had the opportunity to bind to DNA, We conclude that RPA and XPA are the initial damage sensing factors of human excision nuclease.	Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Sch Med, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.		Wakasugi, Mitsuo/D-8417-2015	Wakasugi, Mitsuo/0000-0001-9593-0566	NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASASHINA H, 1994, MUTAT RES, V315, P229; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Coin F, 1998, MOL CELL BIOL, V18, P3907, DOI 10.1128/MCB.18.7.3907; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; GUNTZ D, 1996, J BIOL CHEM, V271, P25089; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MATSUTANI C, 1996, MOL CELL BIOL, V17, P6915; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Rodriguez K, 1998, J BIOL CHEM, V273, P34180, DOI 10.1074/jbc.273.51.34180; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V93, P6443; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	56	171	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18759	18768		10.1074/jbc.274.26.18759	http://dx.doi.org/10.1074/jbc.274.26.18759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373492	hybrid, Green Published			2022-12-27	WOS:000081056700084
J	Corrette-Bennett, SE; Parker, BO; Mohlman, NL; Lahue, RS				Corrette-Bennett, SE; Parker, BO; Mohlman, NL; Lahue, RS			Correction of large mispaired DNA loops by extracts of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-DIRECTED REPAIR; SMALL HETEROLOGOUS SEQUENCES; SINGLE-STRANDED LOOPS; SIMPLE REPETITIVE DNA; BASE-PAIR MISMATCHES; HETERODUPLEX DNA; MAMMALIAN-CELLS; ESCHERICHIA-COLI; GENE CONVERSION; MEIOTIC RECOMBINATION	Single base mispairs and small loops are corrected by DNA mismatch repair, but little is known about the corrrection of large loops. In this paper, large loop repair was examined in nuclear extracts of yeast, Biochemical assays showed that repair activity occurred on loops of 16, 27, and 216 bases, whereas a G-T mispair and an 8-base loop were poorly corrected under these conditions. Two modes of loop repair were revealed by comparison of heteroduplexes that contained a site-specific nick or were covalently closed. A nick-stimulated repair mode directs correction to the discontinuous strand, regardless of which strand contains the leap. An alternative mode is nick-independent and preferentially removes the loop. Both outcomes of repair were largely eliminated when DNA replication was inhibited, suggesting a requirement for repair synthesis. Excision tracts of 100-200 nucleotides, spanning the position of the loop, were observed on each strand under conditions of limited DNA repair synthesis. Both repair modes were independent of the mismatch correction genes 2MSH2, MSH3, MLH1, and PMS1, as judged by activity in mutant extracts. Together the loop specificity and mutant results furnish evidence for a large loop repair pathway in yeast that is distinct from mismatch repair.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01655 USA	University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Lahue, RS (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,600 S 42nd St, Omaha, NE 68198 USA.	rlahue@unmc.edu		Lahue, Robert/0000-0002-8870-5616	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018922] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA36727] Funding Source: Medline; NIGMS NIH HHS [GM18922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BOLLAG RJ, 1992, MOL CELL BIOL, V12, P1546, DOI 10.1128/MCB.12.4.1546; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 1999, METH MOL B, V113, P121; CROUSE GF, 1996, DNA DAMAGE REPAIR, V1, P411; DENG WP, 1994, MOL CELL BIOL, V14, P400, DOI 10.1128/MCB.14.1.400; DETLOFF P, 1992, MOL CELL BIOL, V12, P1805, DOI 10.1128/MCB.12.4.1805; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DOHET C, 1986, P NATL ACAD SCI USA, V83, P3395, DOI 10.1073/pnas.83.10.3395; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FINK GR, 1974, GENETICS, V77, P231; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; GASC AM, 1987, MOL GEN GENET, V210, P369, DOI 10.1007/BF00325708; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Luhr B, 1998, MOL GEN GENET, V257, P362, DOI 10.1007/s004380050658; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1991, GENETICS, V129, P669; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROSE MD, 1988, METHODS YEAST GENETI; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; Taghian DG, 1998, GENETICS, V148, P1257; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1996, GENETICS, V143, P1579; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619	52	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17605	17611		10.1074/jbc.274.25.17605	http://dx.doi.org/10.1074/jbc.274.25.17605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364197	hybrid			2022-12-27	WOS:000080974300033
J	Jayaraman, G; Kumar, TKS; Yu, C				Jayaraman, G; Kumar, TKS; Yu, C			Binding of nucleotide triphosphates to cardiotoxin analogue II from the Taiwan cobra venom (Naja naja atra) - Elucidation of the structural interactions in the dATP-cardiotoxin analogue II complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHEMICAL MODIFICATION; NMR; DYNAMICS; SPECTROSCOPY; INHIBITION; RESIDUES; MOTIFS; CHAIN	Snake venom cardiotoxins have been recently shown to block the enzymatic activity of phospholipid protein kinase and Na+,K+-ATPase. To understand the molecular basis for the inhibitory effects of cardiotoxin on the action of these enzymes, the nucleotide triphosphate binding ability of cardiotoxin analogue II (CTX II) from the Taiwan cobra (Naja naja atra) venom is investigated using a variety of spectroscopic techniques such as fluorescence, circular dichroism, and two-dimensional NMR. CTX II is found to bind to all the four nucleotide triphosphates (ATP, UTP, GTP, and CTP) with similar affinity, Detailed studies of the binding of dATP to CTX II indicated that the toxin molecule is significantly stabilized in the presence of the nucleotide, Molecular modeling, based on the NOEs observed for the dATP.CTX II complex, reveals that dATP binds to the CTX II molecule at the groove enclosed between the Nand C-terminal ends of the toxin molecule. Based on the results obtained in the present study, a molecular mechanism to account for the inhibition of the enzymatic activity of the phospholipid-sensitive protein kinase and Na+,K+-ATPase is also proposed.	Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan	National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan.		Jayaraman, G./AAA-6219-2019; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Suresh Thallapuranam/R-5606-2016; Kumar, Dr Suresh/HHZ-2615-2022	Jayaraman, G./0000-0001-5729-2719; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Kumar, Dr Suresh/0000-0002-2539-6553				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BHASKARAN R, 1994, J BIOL CHEM, V269, P23500; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHIOU SH, 1993, BIOCHEMISTRY-US, V32, P2062, DOI 10.1021/bi00059a025; DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321; GARIN J, 1988, FEBS LETT, V242, P172; GRISHAM CM, 1988, METHOD ENZYMOL, V156, P353; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; Jang JY, 1997, BIOCHEMISTRY-US, V36, P14635, DOI 10.1021/bi971107a; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kobayashi N, 1997, NAT STRUCT BIOL, V4, P6, DOI 10.1038/nsb0197-6; Kumar TKS, 1997, J BIOMOL STRUCT DYN, V15, P431, DOI 10.1080/07391102.1997.10508957; Kumar TKS, 1998, J TOXICOL-TOXIN REV, V17, P183, DOI 10.3109/15569549809009249; KUMAR TKS, 1996, NAT TOXINS, P114; KUMAR TKS, 1999, P NATL SCI COUNC ROC, V23, P1; KUO JF, 1983, FEBS LETT, V153, P183, DOI 10.1016/0014-5793(83)80144-6; Lee CS, 1998, BIOCHEMISTRY-US, V37, P155, DOI 10.1021/bi971979c; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; ROUMESTAND C, 1994, J MOL BIOL, V243, P719, DOI 10.1016/0022-2836(94)90043-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHIAU SYL, 1976, J PHARMACOL EXP THER, V196, P758; Sivaraman T, 1998, J BIOL CHEM, V273, P10181, DOI 10.1074/jbc.273.17.10181; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Ubbink M, 1997, BIOCHEMISTRY-US, V36, P6326, DOI 10.1021/bi963199u; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG CC, 1981, TOXICON, V19, P645, DOI 10.1016/0041-0101(81)90102-1	29	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17869	17875		10.1074/jbc.274.25.17869	http://dx.doi.org/10.1074/jbc.274.25.17869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364232	hybrid			2022-12-27	WOS:000080974300068
J	Li, B; Holloszy, JO; Semenkovich, CF				Li, B; Holloszy, JO; Semenkovich, CF			Respiratory uncoupling induces delta-aminolevulinate synthase expression through a nuclear respiratory factor-1-dependent mechanism in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSCRIPTION FACTOR; DNA-BINDING PROTEIN; SKELETAL-MUSCLE; GENE; NRF-1; RAT; ACTIVATION; EXERCISE; PHOSPHORYLATION; INITIATION	Nuclear respiratory factor (NRF)-1 appears to be important for the expression of several respiratory genes, but there is no direct evidence that NRF-1 transduces a physiological signal into the production of an enzyme critical for mitochondrial biogenesis. We generated HeLa cells containing plasmids allowing doxycycline-inducible expression of uncoupling protein (UCP)-1. In the absence of doxycycline, UCP-1 mRNA and protein were undetectable. In the presence of doxycycline, UCP-1 was expressed and oxygen consumption doubled. This rise in oxygen consumption was associated with an increase in NRF-1 mRNA. It was also associated with an increase in NRF-1 protein binding activity as determined by electrophoretic mobility shift assay using a functional NRF-1 binding site from the delta-aminolevulinate (ALA) synthase promoter, Respiratory uncoupling also caused a time-dependent increase in protein levels of ALA synthase, an early marker for mitochondrial biogenesis. ALA synthase induction by respiratory uncoupling was prevented by transfecting cells with an oligonucleotide antisense to the region of the NRF-1 initiation codon; a scrambled oligonucleotide with the same base composition had no effect. Respiratory uncoupling increases oxygen consumption and lowers energy reserves. In HeLa cells, uncoupling also increases ALA synthase, an enzyme critical for mitochondrial respiration, but only if translatable mRNA for NRF-1 is available. These data suggest that the transcription factor NRF-1 plays a key role in cellular adaptation to energy demands by translating physiological signals into an increased capacity for generating energy.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8046, St Louis, MO 63110 USA.	semenkov@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R37AG000425, R56AG000425] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG00425] Funding Source: Medline; NIDDK NIH HHS [DK53198] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESSIG DA, 1990, AM J PHYSIOL, V259, pC310, DOI 10.1152/ajpcell.1990.259.2.C310; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; HAYASHI N, 1980, J BIOCHEM-TOKYO, V88, P921, DOI 10.1093/oxfordjournals.jbchem.a133079; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; KAPPAS A, 1989, METABOLIC BASIS INHE, V6, P1305; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LEE YP, 1965, J BIOL CHEM, V240, P1427; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; MAY BK, 1986, CURR TOP CELL REGUL, V28, P233; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Murakami T, 1998, BBA-GEN SUBJECTS, V1381, P113, DOI 10.1016/S0304-4165(98)00018-X; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Quaggin SE, 1997, J CLIN INVEST, V99, P718, DOI 10.1172/JCI119216; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	35	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17534	17540		10.1074/jbc.274.25.17534	http://dx.doi.org/10.1074/jbc.274.25.17534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364186	hybrid			2022-12-27	WOS:000080974300022
J	Saleh, A; Srinivasula, SM; Acharya, S; Fishel, R; Alnemri, ES				Saleh, A; Srinivasula, SM; Acharya, S; Fishel, R; Alnemri, ES			Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASES; APOPTOSIS; DEATH; CED-4	To elucidate the mechanism of activation of procaspase-9 by Apaf-1, we produced recombinant full-length Apaf-1 and purified it to complete homogeneity, Here we show using gel filtration that full-length Apaf-1 exists as a monomer that can be transformed to an oligomeric complex made of at least eight subunits after binding to cytochrome c and dATP, Apaf-1 binds to cytochrome c in the absence of dATP but does not form the oligomeric complex. However, when dATP is added to the cytochrome c-bound Apaf-1 complex, complete oligomerization occurs, suggesting that oligomerization is driven by hydrolysis of dATP, This was supported by the observation that ATP, but not the nonhydrolyzable adenosine 5'-O-(thiotriphosphate), can induce oligomerization of the Apaf-1-cytochrome c complex. Like the spontaneously oligomerizing Apaf-530, which lacks its WD-40 domain, the oligomeric full-length Apaf-1-cytochrome c complex can bind and process procaspase-9 in the absence of additional dATP or cytochrome c, However, unlike the truncated Apaf-530 compiler, the full-length Apaf-1 complex can release the mature caspase-9 after processing. Once released, mature caspase-9 can process procaspase-3, setting into motion the caspase cascade. These observations indicate that cytochrome c and dATP are required for oligomerization of Apaf-1 and suggest that the WD-40 domain plays an important role in oligomerization of full-length Apaf-1 and the release of mature caspase-9 from the Apaf-1 oligomeric complex.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, 904 Bluemle Life Sci Bldg,233 S 10th, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010	Saleh, Ayman M/0000-0003-1126-6018	NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	16	398	427	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17941	17945		10.1074/jbc.274.25.17941	http://dx.doi.org/10.1074/jbc.274.25.17941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364241	hybrid			2022-12-27	WOS:000080974300077
J	Elbehti, A; Nitschke, W; Tron, P; Michel, C; Lemesle-Meunier, D				Elbehti, A; Nitschke, W; Tron, P; Michel, C; Lemesle-Meunier, D			Redox components of cytochrome bc-type enzymes in acidophilic prokaryotes I. Characterization of the cytochrome bc(1)-type complex of the acidophilic ferrous ion-oxidizing bacterium Thiobacillus ferrooxidans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; BLUE COPPER PROTEIN; IRON-SULFUR CLUSTER; ELECTRON-TRANSFER; RESPIRATORY-CHAIN; PURIFICATION; OXIDATION; INHIBITORS; MEMBRANE; MITOCHONDRIA	The redox components of the cytochrome bc(1) complex from the acidophilic chemolithotrophic organism Thiobacillus ferrooxidans were investigated by potentiometric and spectroscopic techniques. Optical redox titrations demonstrated the presence of two b-type hemes with differing redox midpoint potentials at pH 7.4 (-169 and +20 mV for b(L) and b(H), respectively). At pH 3.5, by contrast, both hemes appeared to titrate at about +20 mV, Antimycin A, 2-heptyl-4-hydroxyquinoline N-oxide, and stigmatellin induced distinguishable shifts of the b hemes' alpha-bands, providing evidence for the binding of antimycin A and 2-heptyl-4-hydroxyquinoline N-oxide near heme b(H) (located on the cytosolic side of the membrane) and of stigmatellin near heme b(L) (located on the periplasmic side of the membrane). The inhibitors stigmatellin, 5-(n-undecyl)-6-hydroxy-4,7-dioxobenzothiazole, and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone affected the EPR spectrum of the Rieske iron-sulfur center in a way that differs from what has been observed for cytochrome bc(1) or b(6)f complexes. The results obtained demonstrate that the T. ferrooxidans complex, although showing most of the features characteristic for be, complexes, contains unique properties that are most probably related to the chemolithotrophicity and/or acidophilicity of its parent organism. A speculative model for reverse electron transfer through the T, ferrooxidans complex is proposed.	CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Lemesle-Meunier, D (corresponding author), CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	lemesle@ibsm.cnrs-mrs.fr	Nitschke, Wolfgang/C-4812-2012	MICHEL, Caroline/0000-0002-0515-4637; Nitschke, Wolfgang/0000-0003-2084-3032				Appia-Ayme C, 1998, FEMS MICROBIOL LETT, V167, P171, DOI 10.1111/j.1574-6968.1998.tb13224.x; APPIAAYME C, 1998, THESIS U MARSEILLE 2; BODO C, 1974, CAN J MICROBIOL, V20, P1647, DOI 10.1139/m74-256; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BROWN RC, 1973, AM J CLIN PATHOL, V60, P234; BRUNGNA M, 1999, J BIOL CHEM, V274, P16766; CAVAZZA C, 1995, FEMS MICROBIOL LETT, V130, P193; Cavazza C, 1996, EUR J BIOCHEM, V242, P308, DOI 10.1111/j.1432-1033.1996.0308r.x; COBLEY JG, 1975, FEBS LETT, V60, P29, DOI 10.1016/0014-5793(75)80411-X; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; COX JC, 1979, BIOCHEM J, V178, P195, DOI 10.1042/bj1780195; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; Elbehti A, 1996, FEMS MICROBIOL LETT, V136, P51; ELBEHTI A, 1997, BIOMINE; EWART DK, 1991, ADV INORG CHEM, V36, P103, DOI 10.1016/S0898-8838(08)60038-0; FUKUMORI Y, 1988, FEMS MICROBIOL LETT, V50, P169; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INGLEDEW WJ, 1980, BIOCHIM BIOPHYS ACTA, V590, P141, DOI 10.1016/0005-2728(80)90020-1; KAI M, 1992, J BIOCHEM-TOKYO, V112, P816; KAMENSKII YA, 1985, BIOL MEMBR, V2, P100; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; KELLY DP, 1971, ANNU REV MICROBIOL, V25, P177, DOI 10.1146/annurev.mi.25.100171.001141; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MEUNIERLEMESLE D, 1989, BIOCHIMIE PARIS, V71, P1145; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NUNZI F, 1993, BIOCHIM BIOPHYS ACTA, V1162, P28, DOI 10.1016/0167-4838(93)90123-9; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; PECK HD, 1968, ANNU REV MICROBIOL, V22, P489, DOI 10.1146/annurev.mi.22.100168.002421; PETTIGREW GW, 1988, BIOCHEM J, V252, P427, DOI 10.1042/bj2520427; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; SATO A, 1989, BIOCHIM BIOPHYS ACTA, V976, P129, DOI 10.1016/S0005-2728(89)80221-X; SHAFIA F, 1969, J BACTERIOL, V97, P256, DOI 10.1128/JB.97.1.256-260.1969; SHORT SA, 1969, J BACTERIOL, V99, P142, DOI 10.1128/JB.99.1.142-150.1969; SILVERMAN MP, 1959, J BACTERIOL, V77, P642, DOI 10.1128/JB.77.5.642-647.1959; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; TAMEGAI H, 1994, FEMS MICROBIOL LETT, V119, P147; THIKONOVA GB, 1967, BIOKIMYA, V32, P725; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TSAI AL, 1985, BIOCHIM BIOPHYS ACTA, V806, P418, DOI 10.1016/0005-2728(85)90249-X; VALKOVAVALCHANOVA MB, 1994, FEMS MICROBIOL LETT, V121, P61, DOI 10.1016/0378-1097(94)90146-5; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; VONJAGOW G, 1981, FEBS LETT, V136, P19, DOI 10.1016/0014-5793(81)81206-9	47	36	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16760	16765		10.1074/jbc.274.24.16760	http://dx.doi.org/10.1074/jbc.274.24.16760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358017	hybrid			2022-12-27	WOS:000080780400016
J	Miyake, S; Mullane-Robinson, KP; Lill, NL; Douillard, P; Band, H				Miyake, S; Mullane-Robinson, KP; Lill, NL; Douillard, P; Band, H			Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation - A critical role for Cbl tyrosine kinase-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-CBL; FACTOR-ALPHA RECEPTOR; FACTOR BETA-RECEPTOR; ACTIVATED T-CELLS; EGF RECEPTOR; SIGNAL-TRANSDUCTION; V-CBL; PHOSPHORYLATION; PROTEIN; RAS	The Cbl proto-oncogene product has emerged as a novel negative regulator of receptor and non-receptor tyrosine kinases, Our previous observations that Cbl overexpression in NIH3T3 cells enhanced the ubiquitination and degradation of the platelet-derived growth factor receptor-alpha (PDGFR alpha) and that the expression of oncogenic Cbl mutants up-regulated the PDGFRa signaling machinery strongly suggested that Cbl negatively regulates PDGFR alpha signaling. Here, we show that, similar to PDGFR alpha, selective stimulation of PDGFR beta induces Cbl phosphorylation, and its physical association with the receptor. Overexpression of wild type Cbl in NIH3T3 cells led to an enhancement of the ligand-dependent ubiquitination and subsequent degradation of the PDGFR beta, as observed with PDGFR alpha. We show that Cbl-dependent negative regulation of PDGFR alpha and beta results in a reduction of PDGF-induced cell proliferation and protection against apoptosis. A point mutation (G306E) that inactivates the tyrosine kinase binding domain in the N-terminal transforming region of Cbl compromised the PDGF-inducible tyrosine phosphorylation of Cbl although this mutant could still associate with the PDGFR. More importantly, the G306E mutation abrogated the ability of Cbl to enhance the ligand-induced ubiquitination and degradation of the PDGFR and to inhibit the PDGF-dependent cell proliferation and protection from apoptosis. These results demonstrate that Cbl can negatively regulate PDGFR-dependent biological responses and that this function requires the conserved tyrosine kinase binding domain of Cbl.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med,Div Rheumatol Immunol & Allergy, Lymphocyte Biol Sect, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, H (corresponding author), Smith Bldg,Room 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA075075, R01CA076118] Funding Source: NIH RePORTER; NCI NIH HHS [CA76118, CA75075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	40	146	149	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16619	16628		10.1074/jbc.274.23.16619	http://dx.doi.org/10.1074/jbc.274.23.16619			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347229	hybrid			2022-12-27	WOS:000080668600089
J	Alvarez-Fernandez, M; Barrett, AJ; Gerhartz, B; Dando, PM; Ni, JA; Abrahamson, M				Alvarez-Fernandez, M; Barrett, AJ; Gerhartz, B; Dando, PM; Ni, JA; Abrahamson, M			Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; EGG-WHITE CYSTATIN; RAY CRYSTAL-STRUCTURE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; CHICKEN CYSTATIN; ASPARAGINYL ENDOPEPTIDASE; GEL ELECTROPHORESIS; STEFIN-A; CLONING	We have investigated the inhibition of the recently identified family C13 cysteine peptidase, pig legumain, by human cystatin C, The cystatin was seen to inhibit enzyme activity by stoichiometric 1:1 binding in competition with substrate. The K-i value for the interaction was 0.20 nM, i.e. cystatin C had an affinity for legumain similar to that for the papain-like family C1 cysteine peptidase, cathepsin B, However, cystatin C variants with alterations in the N-terminal region and the "second hairpin loop" that rendered the cystatin inactive against cathepsin B, still inhibited legumain with K-i values 0.2-0.3 nM. Complexes between cystatin C and papain inhibited legumain activity against benzoyl-Asn-NHPhNO2, as efficiently as did cystatin C alone, Conversely, cystatin C inhibited papain activity against benzoyl-Arg-NHPhNO2 whether or not the cystatin had been incubated with legumain, strongly indicating that the cystatin inhibited the two enzymes with non-overlapping sites. A ternary complex between legumain, cystatin C, and papain was demonstrated by gel filtration supported by immunoblotting. Screening of a panel of cystatin superfamily members showed that type 1 inhibitors (cystatins A and B) and low M-r kininogen (type 3) did not inhibit pig legumain, Of human type 2 cystatins, cystatin D was non-inhibitory, whereas cystatin E/M and cystatin F displayed strong (K-i 0.0016 nM) and relatively weak (K-i 10 nM) affinity for legumain, respectively. Sequence alignments and molecular modeling led to the suggestion that a loop located on the opposite side to the papain-binding surface, between the alpha-helix and the first strand of the main beta-pleated sheet of the cystatin structure, could be involved in legumain binding. This was corroborated by analysis of a cystatin C variant with substitution of the Asn(39) residue in this loop (N39K-cystatin C); this variant showed a slight reduction in affinity for cathepsin B (K-i 1.5 nM) but much greater than 5,000-fold lower affinity for legumain (K-i much greater than 1,000 nM) than wild-type cystatin C.	Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden; Babraham Inst, MRC, Mol Enzymol Lab, Cambridge CB2 4AT, England; Human Genome Sci Inc, Rockville, MD 20850 USA	Lund University; Skane University Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; GlaxoSmithKline; Human Genome Sciences Inc	Abrahamson, M (corresponding author), Univ Lund Hosp, Inst Lab Med, Dept Clin Chem, S-22185 Lund, Sweden.	Magnus.Abrahamson@klinkem.lu.se	Abrahamson, Magnus/CAG-9507-2022; Barrett, Alan J/G-8970-2013	Barrett, Alan J/0000-0002-6082-4437				ABE Y, 1993, J BIOL CHEM, V268, P3525; Abola EE, 1997, METHOD ENZYMOL, V277, P556, DOI 10.1016/S0076-6879(97)77031-9; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; Bjarnadottir M, 1998, J CLIN PATHOL-MOL PA, V51, P317, DOI 10.1136/mp.51.6.317; BJORK I, 1989, BIOCHEM J, V260, P61; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; Gerhartz B, 1998, BIOCHEMISTRY-US, V37, P17309, DOI 10.1021/bi980873u; Glazer A., 1971, ENZYMES, P501; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; Guex, 1996, PROTEIN DATA BANK Q, V77, P7; Guex N., 1996, Experientia (Basel), V52, pA26; Halfon S, 1998, J BIOL CHEM, V273, P16400, DOI 10.1074/jbc.273.26.16400; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HARANISHIMURA T, 1998, HDB PROTEOLYTIC ENZY, P746; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; MACHLEIDT W, 1983, H-S Z PHYSIOL CHEM, V364, P1481, DOI 10.1515/bchm2.1983.364.2.1481; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MARTIN JR, 1995, J MOL BIOL, V246, P331, DOI 10.1006/jmbi.1994.0088; MIN W, 1994, STRUCT BIOL, V1, P502; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNITTGER S, 1993, GENOMICS, V16, P50, DOI 10.1006/geno.1993.1139; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Woessner J. F., 1998, HDB PROTEOLYTIC ENZY, P749; [No title captured]	55	233	241	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19195	19203		10.1074/jbc.274.27.19195	http://dx.doi.org/10.1074/jbc.274.27.19195			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383426	hybrid			2022-12-27	WOS:000081196300049
J	Dong, MQ; Wang, Y; Hadac, EM; Pinon, DI; Holicky, E; Miller, LJ				Dong, MQ; Wang, Y; Hadac, EM; Pinon, DI; Holicky, E; Miller, LJ			Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE (PTH)/PTH-RELATED PEPTIDE; AGONIST-BINDING; VIP RECEPTOR; CHOLECYSTOKININ RECEPTOR; EXTRACELLULAR DOMAIN; PROTEIN-RECEPTOR; CROSS-LINKING; FAMILY; SITE	Photoaffinity labeling is a powerful tool for the characterization of the molecular basis of ligand binding. We recently used this technique to demonstrate the proximity between a residue within the carboxyl-terminal half of a secretin-like ligand and the amino-terminal domain of the secretin receptor (Dong, M,, Wang, Y,, Pinon, D, I., Hadac, E. M., and Miller, L. J, (1999) J. Biol, Chem. 274, 903-909), In this work, we have developed another novel radioiodinatable secretin analogue ([Bpa(6),Tyr(10)]rat secretin-27) that incorporates a photolabile p-benzoyl-L-phenylalanine (Bpa) residue into position 6 of the amino terminal half of the ligand and used this to identify a specific receptor residue proximate to it, This probe specifically bound to the secretin receptor with high affinity (IC50 = 13.2 +/- 2.5 nM) and was a potent stimulant of cAMP accumulation in secretin receptor-bearing Chinese hamster ovary-SecR cells (EC50 = 720 +/- 230 pM). It covalently labeled the secretin receptor in a saturable and specific manner. Cyanogen bromide cleavage of this molecule yielded a single labeled fragment that migrated on an SDS-polyacrylamide gel at M-r = 19,000 that shifted to 10 after deglycosylation, most consistent with either of two glycosylated fragments within the aminoterminal tail. By immunoprecipitation with antibody directed to epitope tags incorporated into each of the two candidate fragments, the most distal fragment at the amino terminus was identified as the domain of labeling. The labeled domain was further refined to the first 16 residues by endoproteinase Lys-C cleavage and by cyanogen bromide cleavage of another receptor construct in which Val(16) was mutated to Met. Radiochemical sequencing of photoaffinity-labeled secretin receptor fragments established that Val(4) was the specific site of covalent attachment. This provides the first residue-residue contact between a secretin Ligand and its receptor and will contribute substantially to the molecular understanding of this interaction.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Guggenheim 17, Rochester, MN 55905 USA.				NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577, R56DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; BODANSZKY M, 1986, PEPTIDES, V7, P43, DOI 10.1016/0196-9781(86)90162-2; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CLORE GM, 1988, EUR J BIOCHEM, V171, P479, DOI 10.1111/j.1432-1033.1988.tb13814.x; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Gourlet P, 1996, PEPTIDES, V17, P825, DOI 10.1016/0196-9781(96)00107-6; GRONENBORN AM, 1987, FEBS LETT, V215, P88, DOI 10.1016/0014-5793(87)80119-9; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; ROBBERECHT P, 1984, BIOCHIM BIOPHYS ACTA, V773, P271, DOI 10.1016/0005-2736(84)90091-9; ROBINSON RM, 1982, BIOPOLYMERS, V21, P1217, DOI 10.1002/bip.360210615; ROLAND PE, 1994, HUMAN BRAIN MAPPING, V2, P1; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 1997, ANN NY ACAD SCI, V812, P71, DOI 10.1111/j.1749-6632.1997.tb48147.x; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Strader CD, 1996, J MED CHEM, V39, P1; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	38	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19161	19167		10.1074/jbc.274.27.19161	http://dx.doi.org/10.1074/jbc.274.27.19161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383421	hybrid			2022-12-27	WOS:000081196300044
J	Raychaudhuri, S; Niu, LH; Conrad, J; Lane, BG; Ofengand, J				Raychaudhuri, S; Niu, LH; Conrad, J; Lane, BG; Ofengand, J			Functional effect of deletion and mutation of the Escherichia coli ribosomal RNA and tRNA pseudouridine synthase RluA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE CENTER; NUCLEOTIDE RESOLUTION; MIAA GENE; 16S RNA; RESIDUES; MUTAGENESIS; CLONING; SUBUNIT; K-12	The Escherichia coli gene rluA, coding for the pseudouridine synthase RIuA that forms 23 S rRNA pseudouridine 746 and tRNA pseudouridine 32, was deleted in strains MG1655 and BL21/DE3. The rluA deletion mutant failed to form either 23 S RNA pseudouridine 746 or tRNA pseudouridine 32. Replacement of rluA in trans on a rescue plasmid restored both pseudouridines. Therefore, RluA is the sole protein responsible for the in vivo formation of 23 S RNA pseudouridine 746 and tRNA pseudouridine 32, Plasmid rescue of both rluA(-) strains using an rluA gene carrying asparagine or threonine replacements for the highly conserved aspartate 64 demonstrated that neither mutant could form 23 S RNA pseudouridine 746 or tRNA pseudouridine 32 in vivo, showing that this conserved aspartate is essential for enzyme-catalyzed formation of both pseudouridines. In vitro assays using overexpressed wild-type and mutant synthases confirmed that only the wild-type protein was active despite the overexpression of mild-type and mutant syntheses in approximately equal amounts. There was no difference in exponential growth rate between wild-type and MG1655(rluA(-)) either in rich or minimal medium at 24, 37, or 42 degrees C, but when both strains were grown together, a strong selection against the deletion strain was observed.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Miami; University of Toronto	Ofengand, J (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058879] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58879] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKIN A, 1994, NUCLEIC ACIDS RES, V22, P3681, DOI 10.1093/nar/22.18.3681; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Bakin AV, 1998, METH MOL B, V77, P297; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; COHN WE, 1960, J BIOL CHEM, V235, P1488; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Conrad J, 1999, RNA, V5, P751, DOI 10.1017/S1355838299990167; Conrad J, 1998, J BIOL CHEM, V273, P18562, DOI 10.1074/jbc.273.29.18562; DEUTSCHE.MP, 1974, J BACTERIOL, V118, P621, DOI 10.1128/JB.118.2.621-627.1974; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Horie N, 1999, BIOCHEMISTRY-US, V38, P207, DOI 10.1021/bi981865g; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; KING TC, 1983, J BIOL CHEM, V258, P2034; Massenet S, 1999, MOL CELL BIOL, V19, P2142; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; Miller J. H., 1992, SHORT COURSE BACTERI, P357; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; OFENGAND J, 1993, TRANSLATIONAL APPARATUS, P489; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; PERSSON BC, 1992, P NATL ACAD SCI USA, V89, P3995, DOI 10.1073/pnas.89.9.3995; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; SANTER M, 1993, BIOCHEMISTRY-US, V32, P5539, DOI 10.1021/bi00072a007; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; WRZESINSKI J, 1995, RNA, V1, P437; ZYSKIND JW, 1992, RECOMBINANT DNA LAB, P187	32	75	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18880	18886		10.1074/jbc.274.27.18880	http://dx.doi.org/10.1074/jbc.274.27.18880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383384	hybrid			2022-12-27	WOS:000081196300007
J	Yamagata, K; Andreasson, KI; Sugiura, H; Maru, E; Dominique, M; Irie, Y; Miki, N; Hayashi, Y; Yoshioka, M; Kaneko, K; Kato, H; Worley, PF				Yamagata, K; Andreasson, KI; Sugiura, H; Maru, E; Dominique, M; Irie, Y; Miki, N; Hayashi, Y; Yoshioka, M; Kaneko, K; Kato, H; Worley, PF			Arcadlin is a neural activity-regulated cadherin involved in long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER TRANSCRIPTION FACTOR; CELL-CELL INTERACTIONS; FACTOR MESSENGER-RNAS; SYNAPTIC PLASTICITY; ADHESION MOLECULE; BRAIN NEURONS; GROWTH-FACTOR; RAT-BRAIN; PROTEIN; NCAM	Neural activity results in long term changes that underlie synaptic plasticity. To examine the molecular basis of activity-dependent plasticity, we have used differential cloning techniques to identify genes that are rapidly induced in brain neurons by synaptic activity. Here, we identify a novel cadherin molecule Arcadlin (activity-regulated cadherin-like protein), arcadlin mRNA is rapidly and transiently induced in hippocampal granule cells by seizures and by N-methyl-D-aspartate-dependent synaptic activity in long term potentiation. The extracellular domain of Arcadlin is most homologous to protocadherin-8; however, the cytoplasmic region is distinct from that of any cadherin family member. Arcadlin protein is expressed at the synapses and shows a homophilic binding activity in a Ca2+-dependent manner. Furthermore, application of Arcadlin antibody reduces excitatory postsynaptic potential amplitude and blocks long term potentiation in hippocampal slices. Its close homology with cadherins, its rapid inducibility by neural activity, and its involvement in synaptic transmission suggest that Arcadlin may play an important role in activity-induced synaptic reorganization underlying long term memory.	Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Fuchu, Tokyo 183, Japan; Johns Hopkins Univ, Sch Med, Dept Neurol & Neurosci, Baltimore, MD 21205 USA; Nippon Med Univ, Sch Med, Dept Physiol 2, Tokyo 113, Japan; Ctr Med Univ Geneva, Dept Pharmacol, CH-1211 Geneva 4, Switzerland; Osaka Univ, Sch Med, Dept Pharmacol 1, Suita, Osaka 565, Japan; Nagano Nursing Univ, Komagane 39941, Japan; Yamagata Univ, Sch Med, Dept Physiol 2, Yamagata 99023, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Johns Hopkins University; Nippon Medical School; University of Geneva; Osaka University; Yamagata University	Yamagata, K (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, 2-6 Musashidai, Fuchu, Tokyo 183, Japan.							Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DESMOND NL, 1986, J COMP NEUROL, V253, P466, DOI 10.1002/cne.902530404; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MARU E, 1989, BRAIN RES, V478, P112, DOI 10.1016/0006-8993(89)91482-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SCHACHER S, 1993, NEURON, V10, P1079, DOI 10.1016/0896-6273(93)90056-W; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; THIEL G, 1994, J BIOL CHEM, V269, P15294; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yamagata K, 1994, Learn Mem, V1, P140	36	134	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19473	19479		10.1074/jbc.274.27.19473	http://dx.doi.org/10.1074/jbc.274.27.19473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383464	hybrid			2022-12-27	WOS:000081196300087
J	Davison, TS; Vagner, C; Kaghad, M; Ayed, A; Caput, D; Arrowsmith, CH				Davison, TS; Vagner, C; Kaghad, M; Ayed, A; Caput, D; Arrowsmith, CH			p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; OLIGOMERIZATION DOMAIN; HUMAN CANCERS; GENE-THERAPY; TETRAMERIZATION; MUTATIONS; PROTEIN; HOMOLOG; MUTANT	Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human cancers, Recent identification of two human homologues of p53 has raised the prospect of functional interactions between family members via a conserved oligomerization domain. Here we report in vitro and in vivo analysis of homo- and hetero-oligomerization of p53 and its homologues, p63 and p73, The oligomerization domains of p63 and p73 can independently fold into stable homotetramers, as previously observed for p53, However, the oligomerization domain of p53 does not associate with that of either p73 or p63, even when p53 is in 15-fold excess. On the other hand, the oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro, In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63, These data suggest that mutant p53 in cancer cells will not interact with endogenous or exogenous p63 or p73 via their respective oligomerization domains. It also establishes that the multiple isoforms of p63 as well as those of p73 are capable of interacting via their common oligomerization domain.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Sanofi Rech, F-31280 Labege, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sanofi-Aventis; Sanofi France	Arrowsmith, CH (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN JY, 1993, ONCOGENE, V8, P2159; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Nielsen LL, 1998, CLIN CANCER RES, V4, P835; Nielsen LL, 1998, CANCER GENE THER, V5, P52; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Sambrook J., 1989, MOL CLONING, pA1; SchreiberAgus N, 1997, CURR TOP MICROBIOL, V224, P159; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	27	140	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18709	18714		10.1074/jbc.274.26.18709	http://dx.doi.org/10.1074/jbc.274.26.18709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373484	hybrid			2022-12-27	WOS:000081056700076
J	Fishburn, CS; Herzmark, P; Morales, J; Bourne, HR				Fishburn, CS; Herzmark, P; Morales, J; Bourne, HR			G beta gamma and palmitate target newly synthesized G alpha(z) to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; LIPID MODIFICATIONS; POLYBASIC DOMAIN; TYROSINE KINASE; PALMITOYLATION; CELLS; MYRISTOYLATION; LOCALIZATION	The subcellular location of a signaling protein determines its ability to transmit messages accurately and efficiently. Three different lipid modifications tether heterotrimeric G proteins to membranes: alpha subunits are myristoylated and/or palmitoylated, and gamma subunits are prenylated, In a previous study, we examined the role of lipid modifications in maintaining the membrane attachment of a G protein alpha subunit, alpha(z), which is myristoylated and palmitoylated (Morales, J., Fishburn, C. S., Wilson, P. T., and Bourne, H. R. (1998) Mel. Biol. Cell 9, 1-14), Now we extend this analysis by characterizing the mechanisms that target newly synthesized alpha(z) to the plasma membrane (PM) and analyze the role of lipid modifications in this process. In comparison with newly synthesized alpha(s), which is palmitoylated but not myristoylated, alpha(z) moves more rapidly to the membrane fraction following synthesis in the cytosol, Newly synthesized alpha(z) associates randomly with cellular membranes, but with time accumulates at the PM. Palmitoylated alpha(z) is present only in PM-enriched fractions, whereas a nonpalmitoylated mutant of alpha(z) (alpha(z) C3A) associates less stably with the PM than does wild-type alpha(z). Expression of a C-terminal fragment of the beta-adrenoreceptor kinase, which sequesters free beta gamma, impairs association of both alpha(z) and alpha(z) C3A with the PM, suggesting that the alpha subunit must bind beta gamma in order to localize at the PM. Based on these findings, we propose a model in which, following synthesis on soluble ribosomes, myristoylated a, associates randomly and reversibly with membranes; upon association with the PM, alpha(z) binds beta gamma, which promotes its palmitoylation, thus securing it in the proper place for transmitting the hormonal signal.	Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Mol & Cellular Pharmacol, S-1212,Box 0450, San Francisco, CA 94143 USA.							Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JONES TLZ, 1994, G PROTEINS, P49; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	47	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18793	18800		10.1074/jbc.274.26.18793	http://dx.doi.org/10.1074/jbc.274.26.18793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373496	hybrid			2022-12-27	WOS:000081056700088
J	Hong, Y; Ohishi, K; Watanabe, R; Endo, Y; Maeda, Y; Kinoshita, T				Hong, Y; Ohishi, K; Watanabe, R; Endo, Y; Maeda, Y; Kinoshita, T			GPI1 stabilizes an enzyme essential in the first step of glycosylphosphatidylinositol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; ANCHORED MEMBRANE-PROTEINS; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; PHOSPHATIDYLINOSITOL; YEAST; MUTANTS; CLONING; IDENTIFICATION	Attachment of glycosylphosphatidylinositol (GPI) is essential for the surface expression of many proteins. Biosynthesis of glycosylphosphatidylinositol is initiated by the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol. In mammalian cells, this reaction is mediated by a complex of PIG-A, PIG-H, PIG-C, and GPI1. This complexity may be relevant for regulation and for usage of a particular phosphatidylinositol. However, the functions of the respective components have been unclear. Here we cloned the mouse GPI1 gene and disrupted it in F9 embryonal carcinoma cells. Disruption of the GPI1 gene caused a severe but not complete defect in the generation of glycosylphosphatidylinositol-anchored proteins, indicating some residual biosynthetic activity. A complex of PIG-A, PIG-H, and PIG-C decreased to a nearly undetectable level, whereas a complex of PIG-A and PIG-H was easily detected. A lack of GPI1 also caused partial decreases of PIG-C and PIG-H. Therefore, GPI1 stabilizes the enzyme by tying up PIG-C with a complex of PIG-A and PIG-H.	Microbial Dis Res Inst, Dept Immunol Regulat, Suita, Osaka 5650871, Japan; Fukushima Med Coll, Dept Biochem, Fukushima 9601295, Japan	Fukushima Medical University	Kinoshita, T (corresponding author), Microbial Dis Res Inst, Dept Immunol Regulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.		Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702				BESSLER M, 1994, HUM MOL GENET, V3, P751, DOI 10.1093/hmg/3.5.751; Blake JA, 1998, NUCLEIC ACIDS RES, V26, P130, DOI 10.1093/nar/26.1.130; Colussi PA, 1997, YEAST, V13, P139, DOI 10.1002/(SICI)1097-0061(199702)13:2<139::AID-YEA69>3.3.CO;2-J; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Inoue N, 1996, BIOCHEM BIOPH RES CO, V226, P193, DOI 10.1006/bbrc.1996.1332; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MORAN P, 1991, J BIOL CHEM, V266, P1250; Nozaki M, 1999, LAB INVEST, V79, P293; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGITA Y, 1993, J BIOCHEM-TOKYO, V114, P473, DOI 10.1093/oxfordjournals.jbchem.a124202; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Tiede A, 1998, BIOCHEM J, V334, P609, DOI 10.1042/bj3340609; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18582	18588		10.1074/jbc.274.26.18582	http://dx.doi.org/10.1074/jbc.274.26.18582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373468	hybrid			2022-12-27	WOS:000081056700060
J	Steimle, PA; Hoffert, JD; Adey, NB; Craig, SW				Steimle, PA; Hoffert, JD; Adey, NB; Craig, SW			Polyphosphoinositides inhibit the interaction of vinculin with actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; TALIN-BINDING; TAIL DOMAINS; PROTEIN; MUSCLE; SITES; HEAD; PHOSPHORYLATION; DISRUPTION	Binding of vinculin to adhesion plaque proteins is restricted by an intramolecular association of vinculin's head and tail regions. Results of previous work suggest that polyphosphoinositides disrupt this interaction and thereby promote binding of vinculin to both talin and actin. However, data presented here show that phosphatidylinositol 4,5-bisphosphate (PI4,5P(2)) inhibits the interaction of purified tail domain with F-actin. Upon re-examining the effect of PI4,5P(2) on the actin and talin-binding activities of intact vinculin, we find that when the experimental design controls for the effect of magnesium on aggregation of PI4,5P(2) micelles, polyphosphoinositides promote interactions with the talin-binding domain, but block interactions of the actin-binding domain. In contrast, if vinculin is trapped in an open confirmation by a peptide specific for the talin-binding domain of vinculin, actin binding is allowed. These results demonstrate that activation of the actin-binding activity of vinculin requires steps other than or in addition to the binding of PI4,5P(2).	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Myriad Genet, Salt Lake City, UT 84108 USA	Johns Hopkins University; Myriad Genetics, Inc	Steimle, PA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	pas5@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adey NB, 1997, BIOCHEM J, V324, P523, DOI 10.1042/bj3240523; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Flanagan LA, 1997, BIOPHYS J, V73, P1440, DOI 10.1016/S0006-3495(97)78176-1; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 1996, J MUSCLE RES CELL M, V17, P1, DOI 10.1007/BF00140319; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RA, 1995, ENVIRONMETRICS, V6, P341, DOI 10.1002/env.3170060403; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; Schwienbacher C, 1996, FEBS LETT, V384, P71, DOI 10.1016/0014-5793(96)00286-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; VOLBERG T, 1995, J CELL SCI, V108, P2253; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; WEIMING X, 1998, J CELL SCI, V111, P1535; WEIMING X, 1998, DEVELOPMENT, V125, P327; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042	37	94	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18414	18420		10.1074/jbc.274.26.18414	http://dx.doi.org/10.1074/jbc.274.26.18414			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373448	hybrid, Green Submitted			2022-12-27	WOS:000081056700040
J	Stolz, J; Sauer, N				Stolz, J; Sauer, N			The fenpropimorph resistance gene FEN2 from Saccharomyces cerevisiae encodes a plasma membrane H+-pantothenate symporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ERGOSTEROL BIOSYNTHESIS; CATABOLITE REPRESSION; TRANSPORT PROTEIN; BAKERS-YEAST; WILD-TYPE; EXPRESSION; CLONING	The product of the FEN2 gene of Saccharomyces cerevisiae has previously been described as a protein conferring sensitivity to the antifungal agent fenpropimorph, Fen2p was postulated to act as a common regulator of carbon and nitrogen catabolite repression and of amino acid and ergosterol biosynthesis. In this paper, we present experimental evidence characterizing Fen2p as a plasma membrane-localized transporter for the vitamin pantothenate. The high affinity transport system (K-m = 3.5 mu M) is sensitive to uncouplers, suggesting a H+-pantothenate cotransport, Pantothenate transport rates in yeast are modulated by extracellular pantothenate, being maximal at low pantothenate concentrations. It is demonstrated that beta-alanine can suppress the growth defect of FEN2 wild-type and fen2 mutant cells on pantothenate-free medium. Evidence is presented that p-alanine is transported by the general amino acid permease Gap1p. The relation among pantothenate transport, nitrogen catabolite repression, and sensitivity to the antifungal agent fenpropimorph is discussed.	Univ Erlangen Nurnberg, Lehrstuhl Bot 2, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Bot 2, Staudtstr 5, D-91058 Erlangen, Germany.	nsauer@biologie.uni-erlangen.de						ANDRE B, 1993, MOL GEN GENET, V237, P17; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; BLATTNA J, 1965, VITAMINE CHEMIE BIOC, P1232; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; CARBONE MLA, 1992, YEAST, V8, P805, DOI 10.1002/yea.320080915; CROWLEY JH, 1994, ANTIMICROB AGENTS CH, V38, P1004, DOI 10.1128/AAC.38.5.1004; Engels AJG, 1998, CURR GENET, V33, P145, DOI 10.1007/s002940050320; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRENSON M, 1972, BIOCHEM BIOPH RES CO, V48, P749, DOI 10.1016/0006-291X(72)90670-5; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KELLY DE, 1994, FEMS MICROBIOL LETT, V122, P223, DOI 10.1016/0378-1097(94)00326-2; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; Leonian LH, 1942, AM J BOT, V29, P459, DOI 10.2307/2437311; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; Marcireau C, 1996, YEAST, V12, P531, DOI 10.1002/(SICI)1097-0061(199605)12:6<531::AID-YEA934>3.3.CO;2-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nielsen N, 1938, BIOCHEM Z, V295, P211; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Opekarova M, 1996, FEBS LETT, V386, P181, DOI 10.1016/0014-5793(96)00434-6; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REIZER J, 1990, RES MICROBIOL, V141, P1069, DOI 10.1016/0923-2508(90)90080-A; REVARDEL E, 1995, BIOCHIM BIOPHYS ACTA, V19, P261; Sajbidor J, 1998, J PHARM PHARMACOL, V50, P297, DOI 10.1111/j.2042-7158.1998.tb06864.x; SARETT HP, 1945, J BACTERIOL, V49, P31, DOI 10.1128/JB.49.1.31-39.1945; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERVOUSE M, 1986, BIOCHEM J, V240, P541, DOI 10.1042/bj2400541; Silve S, 1996, MOL CELL BIOL, V16, P2719; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; WALLER JR, 1970, APPL MICROBIOL, V20, P857, DOI 10.1128/AEM.20.6.857-860.1970; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	42	46	48	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18747	18752		10.1074/jbc.274.26.18747	http://dx.doi.org/10.1074/jbc.274.26.18747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373490	hybrid			2022-12-27	WOS:000081056700082
J	Tsukamoto, N; Hattori, M; Yang, HL; Bos, JL; Minato, N				Tsukamoto, N; Hattori, M; Yang, HL; Bos, JL; Minato, N			Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-LYMPHOCYTES; DISSOCIATION STIMULATOR; DEPENDENT ACTIVATION; GENE-PRODUCT; CYCLIC-AMP; MAP KINASE; RAS; FAMILY; RHO; CRK	Rap1 GTPase is activated by a variety of stimulations in many types of cells, but its exact functions remain unknown. In this study we have shown that SPA-1 interferes with Rap1 activation by membrane-targeted C3G, C3G-F, in 293T cells through the GTPase activating protein (GAP) activity. SPA-1 transiently expressed in HeLa cells was mostly localized at the cortical cytoskeleton and induced rounding up of the cells, whereas C3G-F conversely induced extensive cell spreading. Conditional SPA-1 overexpression in HeLa cells by tetracycline-regulative system suppressed Rap1 activation upon plating on dishes coated with fibronectin and resulted in the reduced adhesion. When SPA-1 was conditionally induced after the established cell adhesion, the cells gradually rounded up and detached from the dish. Both effects were counteracted by exogenous fibronectin in a dose-dependent manner. Retroviral overexpression of SPA-1 in promyelocytic 32D cells also inhibited both activation of Rap1 and induction of cell adhesion by granulocyte colony stimulating factor without affecting differentiation. These results have indicated that Rap1 GTP is required for the cell adhesion induced by both extracellular matrix and soluble factors, which is negatively regulated by SPA-1.	Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan; Univ Utrecht, Physiol Chem Lab, NL-2584 CG Utrecht, Netherlands	Kyoto University; Utrecht University	Minato, N (corresponding author), Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan.	minato@med.kyoto-u.ac.jp						ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; Gao QS, 1999, MOL CELL BIOL, V19, P733; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Woodside DG, 1998, J EXP MED, V188, P1211, DOI 10.1084/jem.188.7.1211; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	37	144	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18463	18469		10.1074/jbc.274.26.18463	http://dx.doi.org/10.1074/jbc.274.26.18463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373454	hybrid			2022-12-27	WOS:000081056700046
J	Biemesderfer, D; Nagy, T; DeGray, B; Aronson, PS				Biemesderfer, D; Nagy, T; DeGray, B; Aronson, PS			Specific association of megalin and the Na+/H+ exchanger isoform NHE3 in the proximal tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; NEPHRITIS ANTIGENIC COMPLEX; CAMP-MEDIATED INHIBITION; HEYMANN NEPHRITIS; H+ EXCHANGER; MOLECULAR-CLONING; EPITHELIAL-CELLS; GROWTH-FACTOR; CDNA CLONING; GENE FAMILY	We investigated whether the renal brush border Na+/H+ exchanger NHE3 exists in assemblies with other proteins in native kidney membranes. To this end we generated monoclonal antibodies (mAbs) against affinity purified NHE3 protein complexes. Hybridomas were selected based on ability to immunoprecipitate NHE3, One of the resulting mAbs (10A3) labeled a high molecular mass (>200 kDa) protein and stained primarily the coated pit region of the proximal tubule in a manner similar to that described for megalin (gp330). We then confirmed that both mAb 10A3 and a known anti-megalin mAb immunoprecipitated and immunoblotted the same protein, namely megalin. mAb 10A3 specifically co-precipitated NHE3 but not villin or NaPi-2 from solubilized renal membranes, indicating specificity of the NHE3-megalin interaction. When immunoprecipitations were performed using either 10A3 or anti-NHE3 mAb 2B9 after separation of solubilized renal proteins by sucrose velocity gradient centrifugation, we found that NHE3 exists in two states with distinct sedimentation coefficients, a 9.6 S megalin-free form and a 21 S megalin-bound form, and that when NHE3 assembles with megalin, epitopes within the carboxyl-terminal 131 amino acids of NHE3 are blocked. Taken together, these findings indicate that a significant pool of NHES exists as a multimeric complex with megalin in the brush border of the proximal tubule.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033793, R01DK033793] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33793] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BAUM M, 1995, AM J PHYSIOL, V268, pC815; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; Christensen EI, 1997, CURR OPIN NEPHROL HY, V6, P20; COLLAZO R, 1998, J AM SOC NEPHROL, V9, P4; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FARQUHAR MG, 1995, J CLIN INVEST, V96, P1184, DOI 10.1172/JCI118149; Griffith O. M., 1983, TECHNIQUES PREPARATI; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; KERJASCHKI D, 1984, J CELL BIOL, V98, P1505, DOI 10.1083/jcb.98.4.1505; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; Orlando RA, 1998, J AM SOC NEPHROL, V9, P1759; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PENG Y, 1998, J AM SOC NEPHROL, V9, P10; Pizzonia JH, 1998, AM J PHYSIOL-RENAL, V275, pF510, DOI 10.1152/ajprenal.1998.275.4.F510; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; Rutherford PA, 1997, EXP NEPHROL, V5, P490; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	51	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17518	17524		10.1074/jbc.274.25.17518	http://dx.doi.org/10.1074/jbc.274.25.17518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364184	hybrid			2022-12-27	WOS:000080974300020
J	Bucher, EA; Dhoot, GK; Emerson, MM; Ober, M; Emerson, CP				Bucher, EA; Dhoot, GK; Emerson, MM; Ober, M; Emerson, CP			Structure and evolution of the alternatively spliced fast troponin T isoform gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; REPEAT-1 CR-1 ELEMENTS; AVIAN SKELETAL-MUSCLE; METAL-BINDING CLUSTER; PRE-MESSENGER-RNA; SINGLE GENE; HYPERTROPHIC CARDIOMYOPATHY; FUNCTIONAL DIFFERENCES; COMPUTER METHODS; ACID SEQUENCES	The vertebrate fast skeletal muscle troponin T gene, TnTf, produces a complexity of isoforms through differential mRNA splicing. The mechanisms that regulate splicing and the physiological significance of TnTf isoforms are poorly understood. To investigate these questions, we have determined the complete sequence structure of the quail TnTf gene, and we have characterized the developmental expression of alternatively spliced TnTf mRNAs in quail embryonic muscles. We report the following: 1) the quail TnTf gene is significantly larger than the rat TnTf gene and has 8 non-homologous exons, including a pectoral muscle-specific set of alternatively spliced exons; 2) specific sequences are implicated in regulated exon splicing; 3) a 900-base pair sequence element, composed primarily of intron sequence flanking the pectoral muscle-specific exons, is tandemly repeated 4 times and once partially, providing direct evidence that the pectoral-specific TnT exon domain arose by intragenic duplications; 4) a chicken repeat 1 retrotransposon element resides upstream of this repeated intronic/pectoral exon sequence domain Emd is implicated in transposition of this element into an ancestral genome; and 5) a large set of novel isoforms, produced by regulated exon splicing, is expressed in quail muscles, providing insights into the developmental regulation, physiological function, and evolution of the vertebrate TnTf isoforms.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Bucher, EA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.							ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; Ashiya M, 1997, RNA, V3, P996; BIRD IM, 1985, EUR J BIOCHEM, V150, P517, DOI 10.1111/j.1432-1033.1985.tb09052.x; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; BRIGGS MM, 1990, DEV BIOL, V140, P253, DOI 10.1016/0012-1606(90)90075-T; Briggs MM, 1996, AM J PHYSIOL-CELL PH, V270, pC298, DOI 10.1152/ajpcell.1996.270.1.C298; BUCHER EA, 1989, J BIOL CHEM, V264, P12482; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8443, DOI 10.1093/nar/16.17.8443; COOPER TA, 1985, J BIOL CHEM, V260, P1140; Davis MB, 1998, GENETICS, V150, P1105; DHOOT GK, 1988, J MUSCLE RES CELL M, V9, P446, DOI 10.1007/BF01774070; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Haas NB, 1997, GENE, V197, P305, DOI 10.1016/S0378-1119(97)00276-X; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOCHACHAKA PW, 1984, THESIS PRINCETON; HOLLAND SK, 1987, BIOSYSTEMS, V20, P181, DOI 10.1016/0303-2647(87)90044-X; IMAI H, 1986, J BIOCHEM, V99, P923, DOI 10.1093/oxfordjournals.jbchem.a135554; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LECUYER TJ, 1991, PEDIATR RES, V30, P232, DOI 10.1203/00006450-199109000-00006; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGILVERY RW, 1985, METABOLIC ADAPTATION; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; Ohshima K, 1996, MOL CELL BIOL, V16, P3756; PAN BS, 1992, J BIOL CHEM, V267, P23052; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perez I, 1997, RNA, V3, P764; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHAT F, 1995, DEV BIOL, V171, P233, DOI 10.1006/dbio.1995.1274; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SILVA R, 1989, MOL CELL BIOL, V9, P3563, DOI 10.1128/MCB.9.8.3563; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; STADEN R, 1984, BIOCHEM SOC T, V12, P1005, DOI 10.1042/bst0121005; Standiford DM, 1997, GENETICS, V147, P725; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; VANDERGON TL, 1994, MOL BIOL EVOL, V11, P886; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; WU QL, 1995, GENE, V155, P225, DOI 10.1016/0378-1119(94)00846-K; YAO Y, 1992, DEV BIOL, V151, P531, DOI 10.1016/0012-1606(92)90191-I; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	65	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17661	17670		10.1074/jbc.274.25.17661	http://dx.doi.org/10.1074/jbc.274.25.17661			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364205	hybrid			2022-12-27	WOS:000080974300041
J	Doran, KS; Helinski, DB; Konieczny, I				Doran, KS; Helinski, DB; Konieczny, I			A critical DnaA box directs the cooperative binding of the Escherichia coli DnaA protein to the plasmid RK2 replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE; CHROMOSOMAL REPLICATION; NUCLEOTIDE-SEQUENCE; INITIATION PROTEIN; BACILLUS-SUBTILIS; REGION; TRFA; REPLICON; INVITRO; INCOMPATIBILITY	The requirement of DnaA protein binding for plasmid RK2 replication initiation the Escherichia coli was investigated by constructing mutations in the plasmid replication origin that scrambled or deleted each of the four upstream DnaA boxes, Altered origins were analyzed for replication activity in vivo and in vitro and for binding to the E. coli DnaA protein using a gel mobility shift assay and DNase I footprinting. Most strikingly, a mutation in one of the boxes, box 4, abolished replication activity and eliminated stable DnaA protein binding to all four boxes. Unlike DnaA binding to the E. coli origin, oriC, DnaA binding to two of the boxes (boxes 4 and 3) in the RK2 origin, oriV, is cooperative with box 4 acting as the "organizer" for the formation of the DnaA-oriV nucleoprotein complex, Interestingly, the inversion of box 4 also abolished replication activity, but did not result in a loss of binding to the other boxes. However, DnaA binding to this mutant origin was no longer cooperative. These results demonstrate that the sequence, position, and orientation of box 4 are crucial for cooperative DnaA binding and the formation of a nucleoprotein structure that is functional for the initiation of replication.	Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, PL-80822 Gdansk, Poland	University of California System; University of California San Diego; Fahrenheit Universities; University of Gdansk	Helinski, DB (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dhelinski@ucsd.edu		Konieczny, Igor/0000-0002-1588-5601	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; COWAN P, 1982, PLASMID, V8, P164, DOI 10.1016/0147-619X(82)90054-3; CROSS MA, 1986, PLASMID, V15, P132, DOI 10.1016/0147-619X(86)90049-1; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; FUJITA MQ, 1989, MOL GEN GENET, V215, P381, DOI 10.1007/BF00427033; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; Giraldo R, 1998, EMBO J, V17, P4511, DOI 10.1093/emboj/17.15.4511; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Kaguni JM, 1997, MOL CELLS, V7, P145; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STENZEL TT, 1991, GENE DEV, V5, P1453, DOI 10.1101/gad.5.8.1453; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; Toukdarian AE, 1998, GENE, V223, P205, DOI 10.1016/S0378-1119(98)00370-9; VOCKE C, 1983, P NATL ACAD SCI-BIOL, V80, P6557, DOI 10.1073/pnas.80.21.6557; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; WICKNER S, 1990, J BIOL CHEM, V265, P11622; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17918	17923		10.1074/jbc.274.25.17918	http://dx.doi.org/10.1074/jbc.274.25.17918			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364238	hybrid			2022-12-27	WOS:000080974300074
J	Kikuchi, A; Sagami, H; Ogura, K				Kikuchi, A; Sagami, H; Ogura, K			Evidence for covalent attachment of diphytanylglyceryl phosphate to the cell-surface glycoprotein of Halobacterium halobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAPONICA STRAIN TR-1; DOLICHYL PHOSPHATE; POLAR LIPIDS; RAT-LIVER; PROTEIN; LAYER; VOLCANII; CLONING; GENE	In a previous study, we demonstrated the occurrence of novel proteins modified with a diphytanylglyceryl group in thioether linkage in Halobacterium halobium (Sagami, H,, Kikuchi, A., and Ogura, K, (1995) J. Biol, Chem. 270, 14851-14854), In this study, we further investigated protein isoprenoid modification in this halobacterium using several radioactive tracers such as [H-3]geranylgeranyl diphosphate. One of the radioactive bands observed on SDS-polyacrylamide gel electrophoresis corresponded to a periodic acid-Schiff stain-positive protein (200 kDa), Radioactive and periodic acid-Schiff stain-positive peptides (28 kDa) were obtained by trypsin digestion of the labeled proteins. The radioactive materials released by acid treatment of the? peptides showed a similar mobility to dolichyl (C-55) phosphate on a normal-phase thin-layer plate. However, radioactive hydrolysates obtained by acid phosphatase treatment co-migrated not with dolichol (C55-65), but with diphytanylglycerol on both reverse- and normal-phase thin-layer plates, The mass spectrum of the hydrolysate was also coincident with that of diphytanylglycerol, The partial amino acid sequences of the 28-kDa peptides were found in a fragment (amino acids 731-816) obtainable by trypsin cleavage of the known cell-surface glycoprotein of this halobacterium, These results indicate that the cell-surface glycoprotein (200 kDa) is modified with diphytanylglyceryl phosphate.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, H (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.							BAUMEISTER W, 1992, J BIOENERG BIOMEMBR, V24, P567, DOI 10.1007/BF00762349; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHAUDHARY N, 1982, LIPIDS, V17, P558, DOI 10.1007/BF02535384; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Hjertman M, 1997, FEBS LETT, V416, P235, DOI 10.1016/S0014-5793(97)01208-8; HORIKOSHI K, 1993, EXPERIENTIA, V49, P497, DOI 10.1007/BF01955151; KESSEL M, 1988, EMBO J, V7, P1549, DOI 10.1002/j.1460-2075.1988.tb02974.x; Kobayashi T, 1997, BBA-GEN SUBJECTS, V1334, P1, DOI 10.1016/S0304-4165(96)00099-2; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; KUSHWAHA SC, 1975, BIOCHIM BIOPHYS ACTA, V398, P303, DOI 10.1016/0005-2760(75)90146-0; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LECHNER J, 1985, J BIOL CHEM, V260, P860; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Mescher M F, 1977, Prog Clin Biol Res, V17, P459; MESCHER MF, 1974, J BACTERIOL, V120, P945, DOI 10.1128/JB.120.2.945-954.1974; MESCHER MF, 1976, P NATL ACAD SCI USA, V73, P2687, DOI 10.1073/pnas.73.8.2687; MESCHER MF, 1976, J BIOL CHEM, V251, P20025; MINNIKIN DE, 1975, J GEN MICROBIOL, V88, P200, DOI 10.1099/00221287-88-1-200; MOLDOVEANU N, 1988, BIOCHIM BIOPHYS ACTA, V960, P164, DOI 10.1016/0005-2760(88)90062-8; NORBERG P, 1969, J GEN MICROBIOL, V55, P251, DOI 10.1099/00221287-55-2-251; SAGAMI H, 1994, BIOCHEM BIOPH RES CO, V203, P972, DOI 10.1006/bbrc.1994.2277; SAGAMI H, 1995, J BIOL CHEM, V270, P14851, DOI 10.1074/jbc.270.25.14851; SCOTT JE, 1968, HISTOCHEMISTRY, V14, P215, DOI 10.1007/BF00306317; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; THELIN A, 1991, EUR J BIOCHEM, V195, P755, DOI 10.1111/j.1432-1033.1991.tb15763.x; Wakai H, 1997, EXTREMOPHILES, V1, P29, DOI 10.1007/s007920050012; Warren C D, 1978, Methods Enzymol, V50, P122; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	32	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18011	18016		10.1074/jbc.274.25.18011	http://dx.doi.org/10.1074/jbc.274.25.18011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364251	hybrid			2022-12-27	WOS:000080974300087
J	Klingenberg, O; Wiedlocha, A; Olsnes, S				Klingenberg, O; Wiedlocha, A; Olsnes, S			Effects of mutations of a phosphorylation site in an exposed loop in acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CELL-CYCLE; FACTOR-I; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; HEPARIN-BINDING; PROTEIN-KINASE; DIRECTED MUTAGENESIS; FACTOR MUTANT	Acidic fibroblast growth factor (aFGF) contains a phosphorylation site recognized by protein kinase C. A non-mitogenic mutant growth factor is devoid of this phosphorylation site. We have changed amino acids in and close to the phosphorylation site and studied the consequences of this for binding of the growth factor to high affinity receptors as well as to heparin. We have also studied the ability of the mutants to stimulate DNA synthesis and cell proliferation as well as phosphorylation of mitogen-activated protein kinase and the ability of the growth factor mutants to be transported to the nucleus. The results indicate that while the mutations strongly affect the ability of the growth factor to bind to heparin, they do not affect much the binding to the specific FGF receptors, activation of mitogen-activated protein kinase or transport of the growth factor to the nucleus. The mutations affect to various extents the ability of the growth factor to stimulate DNA synthesis and to induce cell multiplication. We find that phosphorylation of aFGF is not required for mitogenic activity. The data suggest that altered interaction of the growth factor with a cellular component different from the receptor, possibly a component in the nucleus, is the reason for the different mitogenicity of the different growth factor mutants.	Norwegian Radium Hosp, Canc Res Inst, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Klingenberg, O (corresponding author), Norwegian Radium Hosp, Canc Res Inst, Dept Biochem, N-0310 Oslo, Norway.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P576; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; Heldin CH, 1996, CANCER SURV, V27, P7; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zalecki P, 1998, EXP CELL RES, V244, P61, DOI 10.1006/excr.1998.4187; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	46	22	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18081	18086		10.1074/jbc.274.25.18081	http://dx.doi.org/10.1074/jbc.274.25.18081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364261	hybrid			2022-12-27	WOS:000080974300097
J	Moncrieffe, MC; Eaton, S; Bajzer, Z; Haydock, C; Potter, JD; Laue, TM; Prendergast, FG				Moncrieffe, MC; Eaton, S; Bajzer, Z; Haydock, C; Potter, JD; Laue, TM; Prendergast, FG			Rotational and translational motion of troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-FREE CALMODULIN; NMR SOLUTION STRUCTURE; X-RAY-SCATTERING; MUSCLE-CONTRACTION; FLUORESCENCE ANISOTROPY; HYDRODYNAMIC PROPERTIES; ANGSTROM RESOLUTION; DYNAMICS; COMPLEX; PROTEIN	Time resolved fluorescence anisotropy and sedimentation velocity has been used to study the rotational and translational hydrodynamic behavior of two mutants of chicken skeletal troponin C bearing a single tryptophan residue at position 78 or 154 in the metal-free-, metal-bound-, and troponin I peptide (residues 96-116 of troponin I)-ligated states. The fluorescence anisotropy data of both mutants were adequately described by two rotational correlation times, and these are compared with the theoretically expected values based on the rotational diffusion of an idealized dumbbell. These data imply that the motion of the N- and C-terminal domains of troponin C are independent. They also suggest that in the metal-free, calcium-saturated and calcium-saturated troponin I peptide-bound states, troponin C is elongated, having an axial ratio of 4-5, Calcium or magnesium binding to the high affinity sites alone reduces the axial ratio to approximately 3. However, with calcium bound to sites III and IV and in the presence of a 1:1 molar ratio of the troponin I peptide, troponin C is approximately spherical. The metal ion and troponin I peptide-induced length changes in troponin C may play a role in the mechanism by which the regulatory function of troponin C is effected.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ New Hampshire, Dept Biochem, Durham, NH 03824 USA	Mayo Clinic; University of Miami; University System Of New Hampshire; University of New Hampshire	Prendergast, FG (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034847] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37701] Funding Source: Medline; NIGMS NIH HHS [GM34847] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akima H., 1978, ACM Transactions on Mathematical Software, V4, P148, DOI 10.1145/355780.355786; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAJZER Z, 1992, METHOD ENZYMOL, V210, P200; BAJZER Z, 1995, BIOPHYS J, V69, P1148, DOI 10.1016/S0006-3495(95)79989-1; BELFORD GG, 1972, P NATL ACAD SCI USA, V69, P1392, DOI 10.1073/pnas.69.6.1392; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CATTERALL T, 1983, TIME RESOLVED FLUOES, P173; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHUANG TJ, 1972, J CHEM PHYS, V57, P5094, DOI 10.1063/1.1678194; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DELATORRE JG, 1977, BIOPOLYMERS, V16, P1747, DOI DOI 10.1002/BIP.1977.360160811; DOSTER W, 1983, BIOPHYS CHEM, V17, P97, DOI 10.1016/0301-4622(83)80002-7; EHRENBER.M, 1972, CHEM PHYS LETT, V14, P539, DOI 10.1016/0009-2614(72)87202-6; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; HAYDOCK C, 1993, J CHEM PHYS, V98, P8199, DOI 10.1063/1.464525; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; HUBBARD SR, 1988, J BIOL CHEM, V263, P4151; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAUE TM, 1993, ULTRASENSITIVE CLIN, V1895; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; O'Connor D. V., 1984, TIME CORRELATED SING; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; Shaw GS, 1996, BIOCHEMISTRY-US, V35, P7429, DOI 10.1021/bi9528006; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SMALL EW, 1988, BIOCHEMISTRY-US, V27, P419, DOI 10.1021/bi00401a063; SMALL EW, 1977, BIOPOLYMERS, V16, P1907, DOI 10.1002/bip.1977.360160907; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; VANGUNSTEREN WF, 1980, J COMPUT CHEM, V1, P266, DOI 10.1002/jcc.540010308; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WANG CK, 1993, J BIOL CHEM, V268, P14671; WANG CK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P16, DOI 10.1016/0167-4838(92)90331-7; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; [No title captured]	54	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17464	17470		10.1074/jbc.274.25.17464	http://dx.doi.org/10.1074/jbc.274.25.17464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364176	hybrid			2022-12-27	WOS:000080974300012
J	Nakamura, M; Tanigawa, Y				Nakamura, M; Tanigawa, Y			Biochemical analysis of the receptor for ubiquitin-like polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPECIFIC SUPPRESSOR FACTOR; CELL-SURFACE RECEPTORS; INDUCED 15-KDA PROTEIN; AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; ACCEPTOR PROTEINS; ALPHA-CHAIN; FACTOR MNSF; ACTIVATION; EXPRESSION	Monoclonal nonspecific suppressor factor (MNSF), a lymphokine produced by murine T cell hybridoma, possesses pleiotrophic antigen-nonspecific suppressive functions. A cDNA clone encoding MNSF-beta, an isoform of the MNSF, has been isolated and characterized. MNSF-beta cDNA encodes a fusion protein consisting of a ubiquitin-like segment (Ubi-L) and ribosomal protein S30. Ubi-L appears to be cleaved from the ribosomal protein and released extracellularly in association with T cell receptor-like polypeptide. In the current study we have characterized the biochemical nature of the Ubi-L receptor on D.10 G4.1, a murine T helper clone type 2. Biotinylated Ubi-L bound preferentially to concanavalin A-stimulated but not to unstimulated D.10 cells. Detergent-extracted membrane proteins were applied to an immobilized Ubi-L column. SDS-polyacrylamide gel electrophoresis of eluted fraction revealed a band of M-r = 82,000. Biotinylated Ubi-L specifically recognized this band, confirming that the 82-kDa protein is the Ubi-L receptor, A complex of M-r = 90,000 was visualized by immunoprecipitation of I-125-Ubi-L cross-linked to the purified receptor followed by SDS-polyacrylamide gel electrophoresis and autoradiography. In addition, a 105-kDa protein was coimmunoprecipitated by anti-Ubi-L receptor (82-kDa polypeptide) antibody, indicative of the association of this protein with the Ubi-L receptor complex. Amino acid sequence analysis of the 82-kDa polypeptide revealed that the Ubi-L receptor may be a member of a cytokine receptor family.	Shimane Med Univ, Dept Biochem, Izumo, Shimane 693, Japan	Shimane University	Nakamura, M (corresponding author), Shimane Med Univ, Dept Biochem, 89-1 Enya Cho, Izumo, Shimane 693, Japan.			Nakamura, Morihiko/0000-0003-1079-9787				ARMITAGE RJ, 1992, BLOOD, V79, P1738; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BUSHKINHARAV I, 1995, J BIOL CHEM, V270, P13422, DOI 10.1074/jbc.270.22.13422; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DORF ME, 1989, PROGR IMMUNOLOGY, V7, P874; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREEN NM, 1965, BIOCHEM J, V94, P23; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; JENSON J, 1980, BIOCHIM BIOPHYS ACTA, V624, P378, DOI 10.1016/0005-2795(80)90079-3; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KNIGHT E, 1991, J IMMUNOL, V146, P2280; Kondoh T, 1999, IMMUNOBIOLOGY, V200, P140, DOI 10.1016/S0171-2985(99)80039-4; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MORI S, 1992, J BIOL CHEM, V267, P6429; Nagata T, 1998, BBA-MOL CELL RES, V1401, P319, DOI 10.1016/S0167-4889(97)00131-6; NAKAMURA M, 1995, EUR J IMMUNOL, V25, P2417, DOI 10.1002/eji.1830250844; NAKAMURA M, 1990, CELL IMMUNOL, V130, P281, DOI 10.1016/0008-8749(90)90271-R; Nakamura M, 1996, J Immunol, V156, P532; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 1996, INT IMMUNOL, V8, P1659, DOI 10.1093/intimm/8.11.1659; NAKAMURA M, 1986, J IMMUNOL, V136, P2904; NAKAMURA M, 1987, J IMMUNOL, V138, P1799; Nakamura M, 1998, IMMUNOLOGY, V94, P142, DOI 10.1046/j.1365-2567.1998.00501.x; NAKAMURA M, 1992, CELL IMMUNOL, V139, P131, DOI 10.1016/0008-8749(92)90106-Y; Nakamura M, 1998, BIOCHEM J, V330, P683, DOI 10.1042/bj3300683; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PANCRE V, 1986, J IMMUNOL, V137, P585; PANCRE V, 1991, EUR J IMMUNOL, V21, P2735, DOI 10.1002/eji.1830211113; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; Suzuki K, 1996, IMMUNOBIOLOGY, V195, P187, DOI 10.1016/S0171-2985(96)80038-6; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	40	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18026	18032		10.1074/jbc.274.25.18026	http://dx.doi.org/10.1074/jbc.274.25.18026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364253	hybrid			2022-12-27	WOS:000080974300089
J	Nibbs, RJB; Yang, JY; Landau, NR; Mao, JH; Graham, GJ				Nibbs, RJB; Yang, JY; Landau, NR; Mao, JH; Graham, GJ			LD78 beta, a non-allelic variant of human MIP-1 alpha (LD78 alpha), has enhanced receptor interactions and potent HIV suppressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-CHEMOKINE RECEPTOR; MOLECULAR-CLONING; T-CELLS; INFECTION; RANTES; CHEMOATTRACTANT; INHIBITION; IDENTIFICATION; INDIVIDUALS	Chemokines play diverse roles in inflammatory and non-inflammatory situations via activation of heptahelical G-protein-coupled receptors. Also, many chemokine receptors can act as cofactors for cellular entry of human immunodeficiency virus (HIV) in vitro. CCR5, a receptor for chemokines MLP-1 alpha (LD78 alpha), MIP-1 beta, RAN-TES, and MCP2, is of particular importance in vivo as polymorphisms in this gene affect HIV infection and rate of progression to APDS. Moreover, the CCR5 ligands can prevent HIV entry through this receptor and likely contribute to the control of HIV infection. Here we show that a non-allelic isoform of human MIP-1 alpha (LD78 alpha), termed LD78 beta or MIP-1 alpha P, has enhanced receptor binding affinities to CCR5 (similar to 6-fold) and the promiscuous beta-chemokine receptor, D6 (similar to 15-20-fold). We demonstrate that a proline residue at position 2 of MIP-1 alpha P is responsible for this enhanced activity. Moreover, MIP-1 alpha P is by far the most potent natural CCR5 agonist described to date, and importantly, displays markedly higher HIV1 suppressive activity than all other human MIP-1 alpha isoforms examined. In addition, while RANTES has been described as the most potent inhibitor of CCR5-mediated HIV entry, MIP-1 alpha P was as potent as, if not more potent than, RANTES in HIV-1 suppressive assays. This property suggests that MLP-1 alpha P may be of importance in controlling Viral spread in HN-infected individuals.	CRC, Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Beatson Institute; Beatson Institute; Rockefeller University	Graham, GJ (corresponding author), CRC, Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Graham, Gerard/D-1240-2009; Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Nibbs, Robert/0000-0002-8150-0044; Graham, Gerard/0000-0002-7801-204X	NATIONAL CANCER INSTITUTE [R01CA072149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036057, R01AI036057] Funding Source: NIH RePORTER; NCI NIH HHS [CA72149] Funding Source: Medline; NIAID NIH HHS [AI1384, AI36057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BERTINI R, 1995, AIDS RES HUM RETROV, V11, P155, DOI 10.1089/aid.1995.11.155; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bonini JA, 1997, DNA CELL BIOL, V16, P1023, DOI 10.1089/dna.1997.16.1023; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Clapham PR, 1997, TRENDS CELL BIOL, V7, P264, DOI 10.1016/S0962-8924(97)01075-1; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUNLOP DJ, 1992, BLOOD, V79, P2221; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Graham GJ, 1992, GROWTH FACTORS, V7, P151, DOI 10.3109/08977199209046404; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; IRVING SG, 1990, NUCLEIC ACIDS RES, V18, P3261, DOI 10.1093/nar/18.11.3261; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Meyer A, 1996, J BIOL CHEM, V271, P14445, DOI 10.1074/jbc.271.24.14445; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAKAO M, 1990, MOL CELL BIOL, V10, P3646, DOI 10.1128/MCB.10.7.3646; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1998, J VIROL, V72, P396, DOI 10.1128/JVI.72.1.396-404.1998; VOLUND A, 1978, BIOMETRICS, V34, P357, DOI 10.2307/2530598; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3857, DOI 10.1073/pnas.95.7.3857	45	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17478	17483		10.1074/jbc.274.25.17478	http://dx.doi.org/10.1074/jbc.274.25.17478			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364178	hybrid			2022-12-27	WOS:000080974300014
J	Ruttimann-Johnson, C; Staples, CR; Rangaraj, P; Shah, VK; Ludden, PW				Ruttimann-Johnson, C; Staples, CR; Rangaraj, P; Shah, VK; Ludden, PW			A vanadium and iron cluster accumulates on VnfX during iron-vanadium-cofactor synthesis for the vanadium nitrogenase in Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; STRUCTURAL GENES; FIXATION SYSTEM; NIFB COFACTOR; VFE PROTEIN; PURIFICATION; DINITROGENASE	The vnf-encoded nitrogenase from Azotobacter vinelandii contains an iron-vanadium cofactor (FeV-co) in its active site. Little is known about the synthesis pathway of FeV-co, other than that some of the gene products required are also involved in the synthesis of the iron-molybdenum cofactor (FeMo-co) of the widely studied molybdenum-dinitrogenase. We have found that VnfX, the gene product of one of the genes contained in the vnf-regulon, accumulates iron and vanadium in a novel V-Fe cluster during synthesis of FeV-co. The electron paramagnetic resonance (EPR) and metal analyses of the V-Fe cluster accumulated on VnfX are consistent with a VFe7-8SX precursor of FeV-co. The EPR spectrum of VnfX with the V-Fe cluster bound strongly resembles that of isolated FeV-co and a model VFe3S4 compound. The V-Fe cluster accumulating on VnfX does not contain homocitrate. No accumulation of V-Fe cluster on VnfX was observed in strains with deletions in genes known to be involved in the early steps of FeV-co synthesis, suggesting that it corresponds to a precursor of FeV-co, VnfX purified from a nifB strain incapable of FeV-co synthesis has a different electrophoretic mobility in native anoxic gels than does VnfX, which has the V-Fe cluster bound. NifB-co, the Fe and S precursor of FeMo-co (and presumably FeV-co), binds to VnfX purified from the nifB strain, producing a shift in its electrophoretic mobility on anoxic native gels. The data suggest that a precursor of FeV-co that contains vanadium and iron accumulates on VnfX, and thus, VnfX is involved in the synthesis of FeV-co.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BISHOP PE, 1980, P NATL ACAD SCI-BIOL, V77, P7342, DOI 10.1073/pnas.77.12.7342; BISHOP PE, 1982, J BACTERIOL, V150, P1244, DOI 10.1128/JB.150.3.1244-1251.1982; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; Butler A, 1998, CURR OPIN CHEM BIOL, V2, P279, DOI 10.1016/S1367-5931(98)80070-7; CARNEY MJ, 1987, INORG CHEM, V26, P719, DOI 10.1021/ic00252a016; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; EADY RR, 1991, ADV INORG CHEM, V36, P77, DOI 10.1016/S0898-8838(08)60037-9; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GOSINK MM, 1990, J BACTERIOL, V172, P1441, DOI 10.1128/jb.172.3.1441-1447.1990; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; RUPP H, 1979, BIOCHIM BIOPHYS ACTA, V548, P16, DOI 10.1016/0005-2728(79)90183-X; Schneider K, 1997, EUR J BIOCHEM, V244, P789, DOI 10.1111/j.1432-1033.1997.t01-1-00789.x; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; Slebodnick C, 1997, STRUCT BOND, V89, P51; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; Tittsworth RC, 1996, BIOCHEMISTRY-US, V35, P479, DOI 10.1021/bi951430i; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; Zheng LM, 1997, J BACTERIOL, V179, P5963, DOI 10.1128/jb.179.18.5963-5966.1997	36	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18087	18092		10.1074/jbc.274.25.18087	http://dx.doi.org/10.1074/jbc.274.25.18087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364262	hybrid			2022-12-27	WOS:000080974300098
J	Silverman, E; Eimerl, S; Orly, J				Silverman, E; Eimerl, S; Orly, J			CCAAT enhancer-binding protein beta and GATA-4 binding regions within the promoter of the steroidogenic acute regulatory protein (StAR) gene are required for transcription in rat ovarian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; FOLLICLE-STIMULATING-HORMONE; LIPOID ADRENAL-HYPERPLASIA; MESSENGER-RIBONUCLEIC-ACID; LEYDIG TUMOR-CELLS; BOVINE CYP11A GENE; GRANULOSA-CELLS; C/EBP-BETA; CONSTITUTIVE EXPRESSION; 3-BETA-HYDROXYSTEROID DEHYDROGENASE	Steroidogenic acute regulatory protein (StAR) is a vital accessory protein required for biosynthesis of steroid hormones from cholesterol. The present study shows that in primary granulosa cells from prepubertal rat ovary, StAR transcript and protein are acutely induced by gonadotropin (FSH). To determine the sequence elements required for hormone inducibility of the StAR promoter, truncated regions of the -1002/+6 sequence of the mouse gene were ligated to pCAT-Basic plasmid and transfected by electroporation to freshly prepared cells. FSH inducibility determined over a 6-h incubation was 10-40-fold above basal levels of chloramphenicol acetyltransferase activity. These functional studies, supported by electrophoretic mobility shift assays indicated that two sites were sufficient for transcription of the StAR promoter constructs: a non-consensus binding sequence (-81/-72) for CCAAT enhancer-binding protein beta (C/EBP beta) and a consensus motif for GATA-4 binding (-61/-66). Western analyses showed that GATA-4 is constitutively expressed in the granulosa cells, while all isoforms of C/EBP beta were markedly inducible by FSH. Site-directed mutations of both binding sequences practically ablated both basal and hormone-driven chloramphenicol acetyltransferase activities to less than 5% of the parental -96/+6 construct. Unlike earlier notions, elimination of potential binding sites for steroidogenic factor-1, a well known tissue-specific transcription factor, did not impair StAR transcription. Consequently, we propose that C/EBP beta and GATA-4 represent a novel combination of transcription factors capable of conferring an acute response to hormones upon their concomitant binding to the StAR promoter.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Orly, J (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	orly@vms.huji.ac.il						Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; AUSUBEL FM, 1988, CURRENT PROTOXOLS MO; Berrier A, 1998, J IMMUNOL, V161, P2267; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Carlone DL, 1997, J STEROID BIOCHEM, V61, P223, DOI 10.1016/S0960-0760(97)80016-7; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Cherradi N, 1998, MOL ENDOCRINOL, V12, P962, DOI 10.1210/me.12.7.962; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; Furukawa A, 1998, J NEUROCHEM, V71, P2231; HALL PF, 1986, STEROIDS, V48, P133; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HONDA S, 1993, J BIOL CHEM, V268, P7494; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; LaVoie HA, 1999, ENDOCRINOLOGY, V140, P146, DOI 10.1210/en.140.1.146; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LIU JS, 1991, J BIOL CHEM, V266, P19095; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; Luo LD, 1998, BIOL REPROD, V59, P263, DOI 10.1095/biolreprod59.2.263; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; Narita N, 1997, DEVELOPMENT, V124, P3755; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; ORLY J, 1994, ENDOCRINOLOGY, V134, P2336, DOI 10.1210/en.134.6.2336; Orly J, 1996, BIOL REPROD, V54, P208, DOI 10.1095/biolreprod54.1.208; Pall M, 1997, EMBO J, V16, P5273, DOI 10.1093/emboj/16.17.5273; Parker KL, 1998, MOL CELL ENDOCRINOL, V140, P59, DOI 10.1016/S0303-7207(98)00030-6; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Pescador N, 1997, BIOL REPROD, V57, P660, DOI 10.1095/biolreprod57.3.660; Pescador N, 1996, BIOL REPROD, V55, P485, DOI 10.1095/biolreprod55.2.485; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PON LA, 1986, J BIOL CHEM, V261, P3309; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RONEN FT, 1998, ENDOCRINOLOGY, V139, P303; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1978, J BIOL CHEM, V253, P3135; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; STEVENS VL, 1993, EUR J BIOCHEM, V216, P557, DOI 10.1111/j.1432-1033.1993.tb18174.x; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 1997, STEROIDS, V62, P29, DOI 10.1016/S0039-128X(96)00155-9; Stocco DM, 1997, BIOL REPROD, V56, P328, DOI 10.1095/biolreprod56.2.328; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Sugawara T, 1997, STEROIDS, V62, P5, DOI 10.1016/S0039-128X(96)00152-3; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	72	159	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17987	17996		10.1074/jbc.274.25.17987	http://dx.doi.org/10.1074/jbc.274.25.17987			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364248	hybrid			2022-12-27	WOS:000080974300084
J	Summers, SA; Kao, AW; Kohn, AD; Backus, GS; Roth, RA; Pessin, JE; Birnbaum, MJ				Summers, SA; Kao, AW; Kohn, AD; Backus, GS; Roth, RA; Pessin, JE; Birnbaum, MJ			The role of glycogen synthase kinase 3 beta in insulin-stimulated glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ISOLATED RAT ADIPOCYTES; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE/THREONINE KINASE; GLUT4 TRANSLOCATION; SIGNALING PATHWAYS; POTENTIAL ROLE	To characterize the contribution of glycogen synthase kinase 3 beta (GSK3 beta) inactivation to insulin-stimulated glucose metabolism, wild-type (WT-GSK), catalytically inactive (KM-GSK), and uninhibitable (SSA-GSK) forms of GSK3 beta were expressed in insulin-responsive 3T3-L1 adipocytes using adenovirus technology, WT-GSK but not KM-GSK, reduced basal and insulin-stimulated glycogen synthase activity without affecting the -fold stimulation of the enzyme by insulin. S9A-GSK similarly decreased cellular glycogen synthase activity, but also partially blocked insulin stimulation of the enzyme. SSA-GSK expression also markedly inhibited insulin stimulation of IRS-1-associated phosphatidylinositol 3-kinase activity, but only weakly inhibited insulin-stimulated Akt/PKB phosphorylation and glucose uptake, with no effect on GLUT4 translocation, To further evaluate the role of GSK3 beta in insulin signaling, the GSK3 beta inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3 beta inactivation. Although lithium stimulated the incorporation of glucose into glycogen and glycogen synthase enzyme activity, the inhibitor was without effect on GLUT4 translocation and pp70 S6 kinase, Lithium stimulation of glycogen synthesis was insensitive to wortmannin, which is consistent with its acting directly on GSK3 beta downstream of phosphatidylinositol 3-kinase. These data support the hypothesis that GSK3 beta contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport.	Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Iowa; Stanford University	Birnbaum, MJ (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.		/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39615, DK33823, DK34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R01DK039615, R37DK033823, R37DK034926, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BOSCH F, 1986, J BIOL CHEM, V261, P6927; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG K, 1983, MOL CELL BIOCHEM, V56, P183; CHENG K, 1983, MOL CELL BIOCHEM, V56, P177; CLAUSEN T, 1968, BIOCHIM BIOPHYS ACTA, V150, P66, DOI 10.1016/0005-2736(68)90009-6; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; Furnsinn C, 1997, AM J PHYSIOL-ENDOC M, V273, pE514, DOI 10.1152/ajpendo.1997.273.3.E514; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; OKADA T, 1994, J BIOL CHEM, V269, P3568; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; RAMAKRISHNA S, 1985, J BIOL CHEM, V260, P2280; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SMITH RL, 1985, J BIOL CHEM, V260, P273; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Summers SA, 1997, BIOCHEM SOC T, V25, P981, DOI 10.1042/bst0250981; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	47	179	184	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17934	17940		10.1074/jbc.274.25.17934	http://dx.doi.org/10.1074/jbc.274.25.17934			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364240	hybrid			2022-12-27	WOS:000080974300076
J	Burma, S; Kurimasa, A; Xie, GF; Taya, Y; Araki, R; Abe, M; Crissman, HA; Ouyang, H; Li, GC; Chen, DJ				Burma, S; Kurimasa, A; Xie, GF; Taya, Y; Araki, R; Abe, M; Crissman, HA; Ouyang, H; Li, GC; Chen, DJ			DNA-dependent protein kinase-independent activation of p53 in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; CATALYTIC SUBUNIT; PHOSPHORYLATION; CELLS; CHECKPOINTS; EXPRESSION; MICE	Phosphorylation at serine 15 of the human p53 tumor suppressor protein is induced by DNA damage and correlates with accumulation of p53 and its activation as a transcription factor. The DNA-dependent protein kinase (DNA-PK) can phosphorylate serine 15 of human p53 and the homologous serine 18 of murine p53 in vitro, Contradictory reports exist about the requirement for DNA-PK in vivo for p53 activation and cell cycle arrest in response to ionizing radiation. While primary SCID (severe combined immunodeficiency) cells, that have defective DNA-PK, show normal p53 activation and cell cycle arrest, a transcriptionally inert form of p53 is induced in the SCID cell line SCGR11. In order to unambiguously define the role of the DNA-PK catalytic subunit (DNA-PKcs) in p53 activation, we examined p53 phosphorylation in mouse embryonic fibroblasts (MEFs) from DNA-PKcs-null mice. We found a similar pattern of serine 18 phosphorylation and accumulation of p53 in response to irradiation in both control and DNA-PKcs-null MEFs, The induced p53 was capable of sequence-specific DNA binding even in the absence of DNA-PKcs. Transactivation of the cyclin-dependent-kinase inhibitor p21, a downstream target of p53, and the G(1) cell cycle checkpoint were also found to be normal in the DNA-PKcs -/- MEFs. Our results demonstrate that DNA-PKcs, unlike the related ATM protein, is not essential for the activation of p53 and G(1) cell cycle arrest in response to ionizing radiation.	Univ Calif Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA; Natl Canc Ctr, Res Inst, Tokyo 1040045, Japan; Natl Inst Radiol Sci, Chiba 2638555, Japan; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; National Cancer Center - Japan; National Institutes for Quantum Science & Technology; Memorial Sloan Kettering Cancer Center	Chen, DJ (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, MS 74,1 Cyclotron Rd, Berkeley, CA 94720 USA.			Abe, Masumi/0000-0003-1550-2006	NCI NIH HHS [CA-50519, CA-56909, CA078497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056909, R37CA050519, R01CA078497, R01CA050519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; CRISSMAN HA, 1987, EXP CELL RES, V173, P256, DOI 10.1016/0014-4827(87)90350-8; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jongmans W, 1996, ONCOGENE, V13, P1133; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Peterson SR, 1997, J BIOL CHEM, V272, P10227; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	25	68	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17139	17143		10.1074/jbc.274.24.17139	http://dx.doi.org/10.1074/jbc.274.24.17139			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358069	hybrid			2022-12-27	WOS:000080780400068
J	Farjot, G; Sergeant, A; Mikaelian, I				Farjot, G; Sergeant, A; Mikaelian, I			A new nucleoporin-like protein interacts with both HIV-1 Rev nuclear export signal and CRM-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ORDER CHROMOSOME STRUCTURE; RESPONSE ELEMENT; ACTIVATION DOMAIN; PORE COMPLEX; VIRION EXPRESSION; GENE-EXPRESSION; MESSENGER-RNAS; IMPORTIN-BETA; LEPTOMYCIN-B	The HTV-1 Rev is a shuttling protein required for the nuclear export of unspliced and partially spliced viral mRNA. In this study, we have identified a new Rev-interacting protein, that specifically interacts with the Rev nuclear export signal both in yeast and mammalian cells. This protein has features found in nucleoporins including many phenylalanine-glycine repeats, a very high serine content, a putative zinc finger, and a coiled-coil domain; we thus called it NLP-1 (nucleoporin-like protein 1). In addition, gene expression analysis and wheat germ agglutinin chromatography experiments suggested that NLP-1 is an ubiquitous O-glycosylated nuclear protein. Recently, a cellular factor called CRM-1 has been shown to be an essential nuclear export factor interacting directly with nuclear export signals including the Rev nuclear export signal in a RanGTP-dependent manner. We show here that NLP-1, like the previously described Rev-interacting protein hRIP/Rab and several nucleoporins, also interacts with CRM-1 both in yeast and mammalian cells.	Ecole Normale Super Lyon, Virol Lab, INSERM, U 412, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mikaelian, I (corresponding author), Ecole Normale Super Lyon, Virol Lab, INSERM, U 412, 42 Allee Italie, F-69364 Lyon 07, France.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALIM MH, 1989, J VIROL, V63, P1959; Manet Evelyne, 1993, Gene Expression, V3, P49; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MIKAELIAN I, 1993, J VIROL, V67, P734; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stutz F, 1996, MOL CELL BIOL, V16, P7144; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Van Laer L, 1997, EUR J HUM GENET, V5, P397, DOI 10.1159/000484798; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	52	33	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17309	17317		10.1074/jbc.274.24.17309	http://dx.doi.org/10.1074/jbc.274.24.17309			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358091	hybrid			2022-12-27	WOS:000080780400090
J	Morrison, RF; Farmer, SR				Morrison, RF; Farmer, SR			Role of PPAR gamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ADIPOCYTE DIFFERENTIATION; CELL-CYCLE; 3T3-L1 PREADIPOCYTES; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; ECTOPIC EXPRESSION; GENE-EXPRESSION; GROWTH-ARREST; PROLIFERATION	Molecular mechanisms coupling growth arrest and cell differentiation were examined during adipogenesis, Data are presented that document a cascade expression of members of two independent families of cyclin-dependent kinase inhibitors that define distinct states of growth arrest during 3T3-L1 preadipocyte differentiation. Exit from the cell cycle into a pre-differentiation state of post-mitotic growth arrest was characterized by significant increases in p21 and p27, During onset of irreversible growth arrest associated with terminal differentiation, the level of p21 declined with a concomitant, dramatic increase in p18 and a sustained level of p27, The expression of p18 and p21, regulated at the level of protein and mRNA accumulation, was directly coupled to differentiation. Stable cell lines were engineered to express adipogenic transcription factors to examine the active role of trans-acting elements in regulating these cell cycle inhibitors. Ectopic expression of peroxisome proliferator-activated receptor (PPAR) gamma in non-precursor fibroblastic cell lines resulted in conversion to adipocytes and a coordinated increase in p18 and p21 mRNA and protein expression in a PPAR gamma ligand-associated manner. These data demonstrate a role for PPAR gamma in mediating the differentiation-dependent cascade expression of cyclin-dependent kinase inhibitors, thereby providing a molecular mechanism coupling growth arrest and adipocyte differentiation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@med-biochem.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NATIONAL CANCER INSTITUTE [F32CA069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051586, R56DK051586, P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA69765-01A1] Funding Source: Medline; NIDDK NIH HHS [DK51586, DK46200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BORTELL R, 1992, J CELL BIOCHEM, V50, P62, DOI 10.1002/jcb.240500111; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Constance CM, 1996, MOL CELL BIOL, V16, P3878; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Koh KN, 1998, J MOL CELL CARDIOL, V30, P463, DOI 10.1006/jmcc.1997.0611; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMYTH MJ, 1993, J CELL SCI, V106, P1; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	45	255	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17088	17097		10.1074/jbc.274.24.17088	http://dx.doi.org/10.1074/jbc.274.24.17088			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358062	hybrid			2022-12-27	WOS:000080780400061
J	Tang, ED; Nunez, G; Barr, FG; Guan, KL				Tang, ED; Nunez, G; Barr, FG; Guan, KL			Negative regulation of the forkhead transcription factor FKHR by Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; INSULIN-RESPONSE SEQUENCE; ALVEOLAR RHABDOMYOSARCOMA; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; FUSION PROTEIN; C-AKT; ACTIVATION; PHOSPHORYLATION; EXPRESSION	The FKHR gene was first identified from its disruption by the t(2;13) chromosomal translocation seen in the pediatric tumor alveolar rhabdomyosarcoma. It encodes for a member of the forkhead family of transcription factors. Recently, a homolog of FKHR in the nematode Caenorhabditis elegans was identified called DAF-16, which is a downstream target of two Akt homologs in an insulin-related signaling pathway. We have examined the possible role of Akt in the regulation of FKHR, We find that FKHR can bind in vitro to the insulin-responsive sequence (IRS) in the insulinlike growth factor-binding protein 1 promoter and can activate transcription from a reporter plasmid containing multiple copies of the IRS. Expression of active but not inactive Akt can suppress FKHR-mediated transcriptional activation. Akt can phosphorylate FKHR in vitro on three phosphoacceptor sites, at least a subset of which can also be phosphorylated by Akt in vivo. Importantly, mutation of these three sites to alanine residues enhances the transcriptional activity of FKHR and renders it resistant to inhibition by Akt, Expression of an Akt-resistant mutant of FKHR causes apoptosis in 293T cells in a manner dependent on DNA binding. These results suggest that FKHR may be a direct nuclear regulatory target for Akt in both metabolic and cell survival pathways.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Tang, ED (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014					Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HROMAS R, 1993, BLOOD, V81, P2854; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SASAKI H, 1993, DEVELOPMENT, V118, P47; SUBLETT JE, 1995, ONCOGENE, V11, P545; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	29	645	681	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16741	16746		10.1074/jbc.274.24.16741	http://dx.doi.org/10.1074/jbc.274.24.16741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358014	hybrid			2022-12-27	WOS:000080780400013
J	Yoshida, Y; Nakano, Y; Nezu, T; Yamashita, Y; Koga, T				Yoshida, Y; Nakano, Y; Nezu, T; Yamashita, Y; Koga, T			A novel NDP-6-deoxyhexosyl-4-ulose reductase in the pathway for the synthesis of thymidine diphosphate-D-fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTINOBACILLUS-ACTINOMYCETEMCOMITANS SEROTYPES; O-ANTIGEN VARIATION; PERIODONTAL-DISEASE; POLYSACCHARIDE SYNTHESIS; SHIGELLA-FLEXNERI; GENE-CLUSTER; SEQUENCE; RHAMNOSE; LIPOPOLYSACCHARIDE; IDENTIFICATION	The serotype-specific polysaccharide antigen of Actinobacillus actinomycetemcomitans Y4 (serotype b) consists of D-fucose and L-rhamnose. Thymidine diphosphate (dTDP)-D-fucose is the activated nucleotide sugar form of D-fucose, which has been identified as a constituent of structural polysaccharides in only a few bacteria. In this paper, we show that three dTDP-D-fucose synthetic enzymes are encoded by genes in the gene cluster responsible for the synthesis of serotype b-specific polysaccharide in A. actinomycetemcomitans. The first and second steps of the dTDP-D-fucose synthetic pathway are catalyzed by D-glucose-l-phosphate thymidylyltransferase and dTDP-D-glucose 4,6-dehydratase, which are encoded by rmlA and rmlB in the gene cluster, respectively. These two reactions are common to the well studied dTDP-L-rhamnose synthetic pathway. However, the enzyme catalyzing the last step of the dTDP-D-fucose synthetic pathway has never been reported. We identified the fed gene encoding a dTDP-4-keto-6-deoxy-D-glucose reductase, After purifying the three enzymes, their enzymatic activities were analyzed by reversed-phase high performance liquid chromatography, In addition, nuclear magnetic resonance analysis and gas-liquid chromatography analysis proved that the fed gene product converts dTDP-4-keto-6-deoxy-D-glucose to dTDP-D-fucose. Moreover, kinetic analysis of the enzyme indicated that the K-m values for dTDP-4-keto-6-deoxy-D-glucose and NADPH are 97.3 and 28.7 mu M, respectively, and that the enzyme follows the sequential mechanism. This paper is the first report on the dTDP-D-fucose synthetic pathway and dTDP-4-keto-6-deoxy-D-glucose reductase.	Kyushu Univ, Dept Prevent Dent, Fac Dent, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Prosthet Dent 1, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Nakano, Y (corresponding author), Kyushu Univ, Dept Prevent Dent, Fac Dent, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yosh@dent.kyushu-u.ac.jp	Nakano, Yoshio/J-3182-2013	Nakano, Yoshio/0000-0001-9848-3124				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AMANO K, 1989, INFECT IMMUN, V57, P2942, DOI 10.1128/IAI.57.10.2942-2946.1989; ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; ASIKAINEN S, 1991, ORAL MICROBIOL IMMUN, V6, P115, DOI 10.1111/j.1399-302X.1991.tb00462.x; Cleland W. W, 1970, ENZYMES, V2, P1; EBERSOLE JL, 1994, J CLIN PERIODONTOL, V21, P65, DOI 10.1111/j.1600-051X.1994.tb00282.x; GMUR R, 1993, ORAL MICROBIOL IMMUN, V8, P116, DOI 10.1111/j.1399-302X.1993.tb00556.x; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KAPLAN AH, 1989, REV INFECT DIS, V11, P46; KOGA T, 1991, PERIODONTAL DIS PATH, P117; KOPLIN R, 1993, J BACTERIOL, V175, P7789; KOTOWYCZ G, 1973, CHEM REV, V73, P669, DOI 10.1021/cr60286a004; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; LU H, 1993, INFECT IMMUN, V61, P2400, DOI 10.1128/IAI.61.6.2400-2407.1993; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MELO A, 1968, J BIOL CHEM, V243, P1475; MELO A, 1968, J BIOL CHEM, V243, P1467; Meyer DH, 1997, TRENDS MICROBIOL, V5, P224, DOI 10.1016/S0966-842X(97)01055-X; MORONA R, 1994, J BACTERIOL, V176, P733, DOI 10.1128/jb.176.3.733-747.1994; PAGE RC, 1991, INFECT IMMUN, V59, P3451, DOI 10.1128/IAI.59.10.3451-3462.1991; RAJAKUMAR K, 1994, J BACTERIOL, V176, P2362, DOI 10.1128/JB.176.8.2362-2373.1994; REEVES P, 1995, TRENDS MICROBIOL, V3, P381, DOI 10.1016/S0966-842X(00)88983-0; REEVES P, 1993, TRENDS GENET, V9, P17, DOI 10.1016/0168-9525(93)90067-R; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SAARELA M, 1992, ORAL MICROBIOL IMMUN, V7, P277, DOI 10.1111/j.1399-302X.1992.tb00588.x; Sambrook J, 1989, MOL CLONING LAB MANN; SATO N, 1993, CARBOHYD RES, V245, P105, DOI 10.1016/0008-6215(93)80063-K; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEGEL IH, 1975, ENZYME KINETICS, P957; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SHIBUYA N, 1991, J BIOL CHEM, V266, P16318; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; Tsukioka Y, 1997, J BACTERIOL, V179, P1126, DOI 10.1128/jb.179.4.1126-1134.1997; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WINN AM, 1993, CARBOHYD RES, V247, P249, DOI 10.1016/0008-6215(93)84257-7; Yoshida Y, 1998, INFECT IMMUN, V66, P107, DOI 10.1128/IAI.66.1.107-114.1998; ZAMBON JJ, 1983, INFECT IMMUN, V41, P19, DOI 10.1128/IAI.41.1.19-27.1983	43	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16933	16939		10.1074/jbc.274.24.16933	http://dx.doi.org/10.1074/jbc.274.24.16933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358040	hybrid			2022-12-27	WOS:000080780400039
J	Myung, CS; Yasuda, H; Liu, WW; Harden, TK; Garrison, JC				Myung, CS; Yasuda, H; Liu, WW; Harden, TK; Garrison, JC			Role of isoprenoid lipids on the heterotrimeric G protein gamma subunit in determining effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; PHOSPHOLIPASE-C ISOZYMES; BETA-ADRENERGIC-RECEPTOR; TRIMERIC G-PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; TISSUE DISTRIBUTION; CRYSTAL-STRUCTURE; PRENYL GROUP; SF9 CELLS	Post-translational prenylation of heterotrimeric G protein gamma subunits is essential for high affinity alpha-beta gamma and alpha-beta gamma-receptor interactions, suggesting that the prenyl group is an important domain in the beta gamma dimer. To determine the role of the prenyl modification in the interaction of beta gamma dimers with effecters, the CAAX (where A indicates alipathic amino acid) motifs in the gamma(1), gamma(2), and y(11) subunits were altered to direct modification with different prenyl groups. Six recombinant beta gamma dimers were overexpressed in baculovirus-infected Sf9 insect cells, purified, and examined for their ability to stimulate three phospholipase C-beta isozymes and type II adenylyl cyclase, The native beta(1)gamma(2) dimer (gamma subunit modified with geranylgeranyl) is more potent and effective in activating phospholipase C-beta than either the beta(1)gamma(1) (farnesyl) or the beta(1)gamma(11) (farnesyl) dimers. However, farnesyl modification of the gamma subunit in the beta(1)gamma(2) dimer (beta(1)gamma(2-L71S)) caused a decrement in its ability to activate phospholipase C-beta. In contrast, both the beta 1 gamma(1-S74L) (geranylgeranyl) and the beta(1)gamma(11-S73L) (geranylgeranyl) dimers were more active than the native forms. The beta(1)gamma(2) dimer activates type II adenylyl cyclase about 12-fold; however, neither the beta(1)gamma(1) nor the beta(1)gamma(11) dimers activate the enzyme. As was the case with phospholipase C-P, the beta(1)gamma(2-L71S) dimer was less able to activate adenylyl cyclase than the native beta(1)gamma(2) dimer. Interestingly, neither the beta(1)gamma(1-S74L) nor the beta(1)gamma(11-S73L) dimers stimulated adenylyl cyclase. The results suggest that both the amino acid sequence of the gamma subunit and its prenyl group play a role in determining the activity of the beta gamma-effector complex.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Garrison, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.			Myung, Chang-Seon/0000-0002-6292-2911	NCI NIH HHS [P01-CA-40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-29536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1996, METH NEUROSCI, V29, P207; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE SB, 1993, J BIOL CHEM, V268, P25952; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Myung CS, 1999, ANAL BIOCHEM, V270, P303, DOI 10.1006/abio.1999.4086; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WU DQ, 1993, J BIOL CHEM, V268, P3704; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	74	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16595	16603		10.1074/jbc.274.23.16595	http://dx.doi.org/10.1074/jbc.274.23.16595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347226	Green Published, hybrid			2022-12-27	WOS:000080668600086
J	Wood, SJ; Wypych, J; Steavenson, S; Louis, JC; Citron, M; Biere, AL				Wood, SJ; Wypych, J; Steavenson, S; Louis, JC; Citron, M; Biere, AL			alpha-synuclein fibrillogenesis is nucleation-dependent - Implications for the pathogenesis of Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; IN-VITRO; PROTEIN; MUTATION; INCLUSIONS; BINDING; NUCLEI	Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major components of which are filaments consisting of alpha-synuclein, Two recently identified point mutations in a-synuclein are the only known genetic causes of PD, alpha-Synuclein fibrils similar to the Lewy body filaments can be formed in vitro, and we have shown recently that both PD-linked mutations accelerate their formation. This study addresses the mechanism of alpha-synuclein aggregation: we show that (i) it is a nucleation-dependent process that can be seeded by aggregated alpha-synuclein functioning as nuclei, (ii) this fibril growth follows first-order kinetics with respect to alpha-synuclein concentration, and (iii) mutant alpha-synuclein can seed the aggregation of wild type alpha-synuclein, which leads us to predict that the Lewy bodies of familial PD patients with a-synuclein mutations will contain both, the mutant and the wild type protein. Finally (iv), we show that wild type and mutant forms of alpha-synuclein do not differ in their critical concentrations. These results suggest that differences in aggregation kinetics of alpha-synucleins cannot be explained by differences in solubility but are due to different nucleation rates, Consequently, alpha-synuclein nucleation may be the rate-limiting step for the formation of Lewy body alpha-synuclein fibrils in Parkinson's disease.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Biere, AL (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	abiere@amgen.com						ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hashimoto I, 1999, NEUROREPORT, V10, P3201, DOI 10.1097/00001756-199910190-00014; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Walsh D, 1897, Br Med J, V2, P272; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j	27	585	605	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19509	19512		10.1074/jbc.274.28.19509	http://dx.doi.org/10.1074/jbc.274.28.19509			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391881	hybrid			2022-12-27	WOS:000081377300001
J	Kakizawa, T; Miyamoto, T; Ichikawa, K; Kaneko, A; Suzuki, S; Hara, M; Nagasawa, T; Takeda, T; Mori, J; Kumagai, R; Hashizume, K				Kakizawa, T; Miyamoto, T; Ichikawa, K; Kaneko, A; Suzuki, S; Hara, M; Nagasawa, T; Takeda, T; Mori, J; Kumagai, R; Hashizume, K			Functional interaction between Oct-1 and retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; OCTAMER TRANSCRIPTION FACTORS; NUCLEAR-RECEPTOR; POU DOMAIN; HISTONE ACETYLTRANSFERASE; RESPONSE ELEMENTS; GLUCOCORTICOID RECEPTOR; ACTIVATION FUNCTION; BINDING ACTIVITY; N-COR	The retinoid X receptor (RXR) is a member of the nuclear hormone receptor superfamily and heterodimerizes with a variety of other family members such as the thyroid hormone receptor (TR),(1) retinoic acid receptor, vitamin D receptor, and peroxisome proliferator-activated receptor. Therefore, RXR is supposed to play a key role in a ligand-dependent regulation of gene transcription by nuclear receptors. In this study, we have identified the octamer-binding transcription factor-1 (Oct-1) as a novel interaction factor of RXR. In vitro pull-down assays using RXR deletion mutants showed that the interaction surfaces were located in the region encompassing the DNA binding domain (C domain) and the hinge domain (D domain) of RXR, We also showed that RXR interacted with the POU homeodomain but not with the POU-specific domain of Oct-1. Gel shift analysis revealed that Oct-1 reduced the binding of TR/RXR heterodimers to the thyroid hormone response element (TRE), In transient transfection assays using COS1 cells, Oct-1 repressed the T3-dependent transcriptional activity of TR/RXR heterodimers, consistent with in vitro DNA binding data; however, transcriptional activation by Gal4-TR(LBD) (LBD, ligand binding domain), which lacks its own DNA binding domain but retains responsiveness to T3, was not influenced by Oct-1. These results suggest that Oct-1 functionally interacts with RXR and negatively regulates the nuclear receptor signaling pathway by altering the DNA binding ability of the receptors.	Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, Matsumoto, Nagano 3908621, Japan	Shinshu University	Kakizawa, T (corresponding author), Shinshu Univ, Sch Med, Dept Geriatr Endocrinol & Metab, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tkaki@hsp.md.shinshu-u.ac.jp						BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P3027, DOI 10.1210/endo-129-6-3027; Miyamoto T, 1997, J BIOL CHEM, V272, P7752, DOI 10.1074/jbc.272.12.7752; MIYAMOTO T, 1994, MOL CELL ENDOCRINOL, V102, P111, DOI 10.1016/0303-7207(94)90104-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Shah PC, 1997, EMBO J, V16, P7105, DOI 10.1093/emboj/16.23.7105; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	61	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19103	19108		10.1074/jbc.274.27.19103	http://dx.doi.org/10.1074/jbc.274.27.19103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383413	hybrid			2022-12-27	WOS:000081196300036
J	Zeng, FY; Wess, J				Zeng, FY; Wess, J			Identification and molecular characterization of m3 muscarinic receptor dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; ACETYLCHOLINE-RECEPTOR; CHOLINERGIC RECEPTOR; ANTAGONIST BINDING; FUNCTIONAL RESCUE; DIMERIZATION; INTERNALIZATION; COEXPRESSION	Several studies suggest, but do not prove directly, that muscarinic receptors may be able to form dimeric or oligomeric arrays. To address this issue in a more direct fashion, we designed a series of biochemical experiments using a modified version of the rat m3 muscarinic receptor (referred to as m3') as a model system. When membrane lysates prepared from m3' receptor-expressing COS-7 cells were subjected to Western blot analysis under non-reducing conditions, several immunoreactive species were observed corresponding in size to putative receptor monomers, dimers, and oligomers, However, under reducing conditions, the monomeric receptor species represented the only detectable immunoreactive protein, consistent with the presence of disulfide-linked m3 receptor complexes. Similar results were obtained when native m3 muscarinic receptors present in rat brain membranes were analyzed. Control experiments carried out in the presence of high concentrations of the SH group alkylating agent, N-ethylmaleimide, suggested that disulfide bond formation did not occur artifactually during the preparation of cell lysates, The formation of m3' receptor dimers/multimers was confirmed in coimmunoprecipitation studies using differentially epitope-tagged m3' receptor constructs. In addition, these studies showed that m3' receptors were also able to form non-covalently associated receptor dimers and that m3' receptor dimer formation was receptor subtype-specific, Immunological studies also demonstrated that m3' receptor dimers/multimers were abundantly expressed on the cell surface. Site-directed mutagenesis studies indicated that two conserved extracellular Cys residues (Cys-140 and Cys-220) play key roles in the formation of disulfide-linked m3' receptor dimers. These results provide the first direct evidence for the existence of muscarinic receptor dimers and highlight the specificity and molecular diversity of G protein-coupled receptor dimerization/oligomerization.	NIDDKD, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDKD, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov						Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; HAGA K, 1985, J BIOL CHEM, V260, P7927; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEVEY AI, 1991, J NEUROSCI, V11, P3218; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; OHARA K, 1990, EUR J PHARM-MOLEC PH, V189, P341, DOI 10.1016/0922-4106(90)90030-2; POTTER LT, 1991, MOL PHARMACOL, V39, P211; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WATSON S, 1994, G PROTEIN LINKED REC, P1; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	42	205	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19487	19497		10.1074/jbc.274.27.19487	http://dx.doi.org/10.1074/jbc.274.27.19487			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383466	hybrid			2022-12-27	WOS:000081196300089
J	Blostein, R; Dunbar, L; Mense, M; Scanzano, R; Wilczynska, A; Caplan, MJ				Blostein, R; Dunbar, L; Mense, M; Scanzano, R; Wilczynska, A; Caplan, MJ			Cation selectivity of gastric H,K-ATPase and Na,K-ATPase chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; ALPHA-SUBUNIT; NA+,K+-ATPASE; SODIUM; SUBSTITUTES; ACTIVATION; RETICULUM; PROTONS; DOMAIN; IONS	Chimeras of the catalytic subunits of the gastric H,K-ATPase and Na,K-ATPase were constructed and expressed in LLC-PK1 cells. The chimeras included the following: (i) a control, H85N (the first 85 residues comprising the cytoplasmic N terminus of Na,K-ATPase replaced by the analogous region of H,K-ATPase); (ii) H85N/H356 -519N (the N-terminal half of the cytoplasmic M4-M5 loop also replaced); and (iii) H519N (the entire front half replaced). The latter two replacements confer a decrease in apparent affinity for extracellular K+. The 356-519 domain and, to a greater extent, the H519N replacement confer increased apparent selectivity for protons relative to Na+ at cytoplasmic sites as shown by the persistence of K+ influx when the proton concentration is increased and the Naf concentration decreased. The pH and Kf dependence of ouabain-inhibitable ATPase of membranes derived from the transfected cells indicate that the H519N and, to a lesser extent, the H356-519N substitution decrease the effectiveness of K+ to compete for protons at putative cytoplasmic H+ activation sites, Notable pH-independent behavior of H85N/H356-519N at low Na+ suggests that as pH is decreased, Na+/K+. exchange is replaced largely by (Na+ + H+)/K+ exchange. With H519N, the pH and Naf dependence of pump and ATPase activities suggest relatively active H+/K+ exchange even at neutral pH. Overall, this study provides evidence for important roles in cation selectivity for both the N-terminal half of the M4-M5 loop and the adjacent transmembrane helice(s).	McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Yale Univ, Sch Med, Dept Cell & Mol Physiol, New Haven, CT 06510 USA	McGill University; McGill University; Yale University	Blostein, R (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave,Rm L11-132, Montreal, PQ H3G 1A4, Canada.			Caplan, Michael/0000-0001-5768-4405	NIGMS NIH HHS [GM42136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BLOSTEIN R, 1992, ACTA PHYSIOL SCAND, V146, P105; BOVER PD, 1988, TRENDS BIOCHEM SCI, V12, P5; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; Canfield VA, 1998, BIOCHEMISTRY-US, V37, P7509, DOI 10.1021/bi980174h; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; HARA Y, 1986, J BIOL CHEM, V261, P2655; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; PICK U, 1982, J BIOL CHEM, V257, P6111; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POLVANI C, 1989, J BIOL CHEM, V264, P17854; Post R.L., 1967, METHODS ENZYMOLOGY, P762; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	28	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18374	18381		10.1074/jbc.274.26.18374	http://dx.doi.org/10.1074/jbc.274.26.18374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373442	hybrid			2022-12-27	WOS:000081056700034
J	Kruip, J; Karapetyan, NV; Terekhova, IV; Rogner, M				Kruip, J; Karapetyan, NV; Terekhova, IV; Rogner, M			In vitro oligomerization of a membrane protein complex - Liposome-based reconstitution of trimeric photosystem I from isolated monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SPIRULINA-PLATENSIS; SYNECHOCOCCUS SP; STRUCTURAL CHARACTERIZATION; FLUORESCENCE SPECTROSCOPY; SYNECHOCYSTIS PCC-6803; CORE COMPLEXES; ORGANIZATION; SUBUNIT; CHLOROPHYLLS; ELONGATUS	Many membrane proteins can be isolated in different oligomeric forms. Photosystem I (PSI), for example, exists in cyanobacteria either as a monomeric or as a trimeric complex. Neither the factors responsible for the specific trimerization process nor its biological role are known at present. In the filamentous cyanobacterium Spirulina platensis, trimers in contrast to monomers show chlorophyll fluorescence emission at 760 nm. To investigate the oligomerization process as well as the nature of the long wavelength chlorophylls, we describe here an in vitro reconstitution procedure to assemble trimeric PS I from isolated purified PS I monomers. Monomers (and trimers) were extracted from S. platensis with n-dodecyl p-D-maltoside and further purified by perfusion chromatography steps. The isolated complexes had the same polypeptide composition as other cyanobacteria (PsaA-PsaF and PsaI-PsaM), as determined from high resolution gels and immunoblotting. They were incorporated into proteoliposomes, which had been prepared by the detergent absorption method, starting from a phosphatidylcholine:phosphatidic acid mixture solubilized by octylglucoside. After the addition of monomeric PSI (lipid:chlorophyll, 25:1), octylglucoside was gradually removed by the stepwise addition of Biobeads. The 77 K fluorescence emission spectrum of these proteoliposomes displays a long wavelength emission at 760 nm that is characteristic of PS I trimers, which indicates for the first time the successful in vitro reconstitution of PS I trimers, In addition, a high performance liquid chromatography analysis of complexes extracted from these proteoliposomes confirms the formation of structural trimers, We also could show with this system 1) that at least one of the stromal subunits PsaC, -D, and -E is necessary for trimer formation and 2) that the extreme long wavelength emitting chlorophyll is formed as a result of trimer formation.	Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany; Russian Acad Sci, AN Bakh Biochem Inst, Moscow 117071, Russia	Ruhr University Bochum; Research Center of Biotechnology RAS; Russian Academy of Sciences	Rogner, M (corresponding author), Ruhr Univ Bochum, Fac Biol, D-44780 Bochum, Germany.							[Anonymous], 1989, PLANT BIOL; BOEKEMA EJ, 1987, FEBS LETT, V217, P283, DOI 10.1016/0014-5793(87)80679-8; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Cladera J, 1996, J BIOENERG BIOMEMBR, V28, P503, DOI 10.1007/BF02110440; Dorra D, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P587; FORD RC, 1988, EMBO J, V7, P2287, DOI 10.1002/j.1460-2075.1988.tb03071.x; FREY TG, 1994, J MOL BIOL, V237, P275, DOI 10.1006/jmbi.1994.1231; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; GOBETS B, 1994, BBA-BIOENERGETICS, V1188, P75, DOI 10.1016/0005-2728(94)90024-8; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; Gourovskaya KN, 1997, FEBS LETT, V414, P193, DOI 10.1016/S0014-5793(97)00994-0; HLADIK J, 1991, PHOTOSYNTH RES, V29, P171, DOI 10.1007/BF00036220; HOFF WD, 1995, BIOPHYS CHEM, V56, P193, DOI 10.1016/0301-4622(95)00033-T; HOSHINA S, 1987, PLANT CELL PHYSIOL, V28, P599; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JEKOW P, 1995, BBA-BIOENERGETICS, V1229, P115, DOI 10.1016/0005-2728(94)00201-F; Karapetyan NV, 1997, BIOCHEMISTRY-US, V36, P13830, DOI 10.1021/bi970386z; Koehne B, 1998, BIOCHEMISTRY-US, V37, P5494, DOI 10.1021/bi9727500; KRUIP J, 1994, PHOTOSYNTH RES, V40, P279, DOI 10.1007/BF00034777; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kruip J, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P405; KRUIP J, 1993, J BIOL CHEM, V268, P23353; Kuhl H, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1001; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; Palsson LO, 1996, PHOTOSYNTH RES, V48, P239, DOI 10.1007/BF00041014; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROGNER M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P415, DOI 10.1016/0005-2728(90)90074-E; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHUBIN VV, 1993, FEBS LETT, V334, P79, DOI 10.1016/0014-5793(93)81685-S; SHUBIN VV, 1991, BIOCHIM BIOPHYS ACTA, V1060, P28, DOI 10.1016/S0005-2728(05)80115-X; SHUBIN VV, 1992, FEBS LETT, V309, P340, DOI 10.1016/0014-5793(92)80803-O; SHUBIN VV, 1995, J PHOTOCH PHOTOBIO B, V30, P153, DOI 10.1016/1011-1344(95)07173-Y; SMITH SO, 1994, BIOCHEMISTRY-US, V33, P6327, DOI 10.1021/bi00186a036; TRISSL HW, 1993, PHOTOSYNTH RES, V35, P247, DOI 10.1007/BF00016556; TSIOTIS G, 1995, EUR J BIOCHEM, V231, P823, DOI 10.1111/j.1432-1033.1995.tb20767.x; VONGRONDELLE R, 1994, BIOCHIM BIOPHYS ACTA, V1187, P1; WENK SO, 1998, PHOTOSYNTHESIS MECH, V3, P1637	43	57	61	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18181	18188		10.1074/jbc.274.26.18181	http://dx.doi.org/10.1074/jbc.274.26.18181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373417	hybrid			2022-12-27	WOS:000081056700009
J	Oya, T; Hattori, N; Mizuno, Y; Miyata, S; Maeda, S; Osawa, T; Uchida, K				Oya, T; Hattori, N; Mizuno, Y; Miyata, S; Maeda, S; Osawa, T; Uchida, K			Methylglyoxal modification of protein - Chemical and immunochemical characterization of methylglyoxal-arginine adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAILLARD REACTION INTERMEDIATE; GLYCATION END-PRODUCT; GLYOXALASE SYSTEM; DIABETIC COMPLICATIONS; IN-VIVO; IMMUNOHISTOCHEMICAL DETECTION; MITOCHONDRIAL RESPIRATION; LIPID-PEROXIDATION; ALDOSE REDUCTASE; SERUM-ALBUMIN	Methylglyoxal (MG), an endogenous metabolite that increases in diabetes and is a common intermediate in the Maillard reaction(glycation), reacts with proteins and forms advanced-glycation end products. In the present study, we identify a novel MG-arginine adduct and also characterize the structure of a major fluorescent adduct, In addition we describe the immunochemical study on the MG-arginine addicts using monoclonal antibody directed to MG-modified protein. Upon incubation of N(alpha)-acetyl-L-arginine with MG at 37 degrees C, two non-fluorescent products and one-fluorescent product were detected as the-major products, The nonfluorescent products were identified as the N(delta)-(5-hydro-5-methyl-4-imidazolon-2-yl)-L-ornithine derivatives (5-hydro-5-methylimidazolone) and a novel MG-arginine adduct having a tetra-hydropyrimidine -moiety; N(delta)-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2 -L-ornithine). On the basis of the following chemical and spectroscopic evidence; the-major fluorescent product, putatively identified as N(delta)-(5-methylimidazolon-2-yl)-L-ornithithine (5-methylimidazolone), was found to-be identical to N(delta)-(5-hydroxy4,6-dimethylpyrimidine-2-yl)-L-ornithine (argpyrimidine): (i) the low and-high resolution fast atom bombardment mass spectrometry gave a molecular ion peak at m/z of 297 (M+H) and:a molecular formula of C(10)H(25)O(6)N(4), respectively, which coincided with pyrimidine; (ii) the (1)H NMR spectrum of this product in. d6-Me(2)SO showed a singlet at 2.10 ppm corresponding to six protons; (iii) the peak corresponding to the 5-methylimidazolone derivative was not detected by the liquid chromatography-mass spectrometry with the mode of selected ion monitoring; (iv) incubation of 5-hydro-5-methylimidazolone, a putative precursor of 5 methylimidazolone, at 37 degrees C for 14 days scarcely generated 5-methylimidazolone. On the other hand, ras an immunochemical approach to the-detection-of these MG adducts, we raised the monoclonal antibodies (mAb3C and mAb6B) directed to the MG-modified protein and found that they specifically recognized the major, fluorescent product, argpyrimidine; as the dominant epitope, The immunohistochemical analysis of-the kidneys from diabetic patients revealed the localization of argpyrimidine in intima and media of small artery walls. Furthermore, the accumulation of argpyrimidine was also observed in some arterial walls of the rat brain after middle cerebral artery occlusion followed by reperfusion. These results suggest that argpyrimidine may contribute to the progression of not only long term diabetic complications, such as nephropathy and atherosclerosis, but also the tissue injury caused by ischemia/reperfusion.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 113, Japan; Kobe Univ, Sch Med, Dept Internal Med 2, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Pathol 2, Kobe, Hyogo 6500017, Japan	Nagoya University; Juntendo University; Kobe University; Kobe University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	OYA-ITO, Tomoko/M-8906-2014	Uchida, Koji/0000-0003-3894-5299				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; Baynes JW., 1989, PROG CLIN BIOL RES, V304, P1; Biswas S, 1997, BIOCHEM J, V323, P343, DOI 10.1042/bj3230343; BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6; BRINKMANN E, 1995, J CHEM SOC P2, V2, P1; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533; Che WY, 1997, J BIOL CHEM, V272, P18453, DOI 10.1074/jbc.272.29.18453; Cordeiro C, 1996, ANAL BIOCHEM, V234, P221, DOI 10.1006/abio.1996.0076; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; HALDER J, 1993, INT J CANCER, V54, P443, DOI 10.1002/ijc.2910540315; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1965, DOI 10.1080/00021369.1986.10867692; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1959, DOI 10.1080/00021369.1986.10867691; KATO H, 1986, J NUTR SCI VITAMINOL, V32, P55, DOI 10.3177/jnsv.32.55; KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953; LO TWC, 1994, J BIOL CHEM, V269, P32299; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MONNIER VM, 1990, ADV LIF SCI, P393; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; SELWOOD T, 1993, BIOCHEM SOC T, V21, P170; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; SHINODA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1826, DOI 10.1271/bbb.57.1826; SHINOHARA M, 1996, DIABETES, V45, pA126; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P403, DOI 10.1093/oxfordjournals.jbchem.a131472; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Uchida K, 1997, FEBS LETT, V410, P313, DOI 10.1016/S0014-5793(97)00610-8; URABE T, 1996, J NEUROCHEM, V67, P256; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Westwood ME, 1997, BBA-MOL CELL RES, V1356, P84, DOI 10.1016/S0167-4889(96)00154-1; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Yoshino H, 1997, BRAIN RES, V767, P81, DOI 10.1016/S0006-8993(97)00616-1	44	314	346	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18492	18502		10.1074/jbc.274.26.18492	http://dx.doi.org/10.1074/jbc.274.26.18492			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373458	hybrid			2022-12-27	WOS:000081056700050
J	Zitzer, H; Richter, D; Kreienkamp, HJ				Zitzer, H; Richter, D; Kreienkamp, HJ			Agonist-dependent interaction of the rat somatostatin receptor subtype 2 with cortactin-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS; LOCALIZATION; BRAIN; EXPRESSION; CLONING; SUBUNIT; SYSTEM; SST2A	We report here an interaction between the C terminus of the rat somatostatin receptor subtype 2 (SSTR2) and a protein that has recently been identified as contactin-binding protein 1 (CortBP1). Interaction is mediated by the PDZ (PSD-95/discs large/ZO-1) domain of CortBP1. As shown by in situ hybridization, SSTR2 and cortactin-binding protein are coexpressed in the rat brain. The association between SSTR2 and the PDZ-domain of CortBP1 was verified by overlay assays and by coprecipitation after transfection in human embryonic kidney (HEK) cells. Analysis by confocal microscopy indicates that CortBP1 is distributed diffusely throughout the cytosol in transfected cells and that it becomes concentrated at the plasma membrane when SSTR2 is present. This process is largely increased when the receptor is stimulated by somatostatin; as CortBP1 interacts with the C terminus of SSTR2, our data suggest that the binding of agonist to the receptor increase the accessibility of the receptor C terminus to the PDZ domain of CortBP1. Our data for the first time establish a link between a G-protein coupled receptor and constituents of the cytoskeleton.	Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Boehm S, 1997, J NEUROSCI, V17, P4066; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Dournaud P, 1998, J NEUROSCI, V18, P1056; Dournaud P, 1996, J NEUROSCI, V16, P4468; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Helboe L, 1998, J NEUROSCI, V18, P4938; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; PEREZ J, 1995, NEUROSCIENCE, V64, P241, DOI 10.1016/0306-4522(94)00364-B; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182	24	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18153	18156		10.1074/jbc.274.26.18153	http://dx.doi.org/10.1074/jbc.274.26.18153			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373412	hybrid			2022-12-27	WOS:000081056700004
J	Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T; Tamura, K; Oue, S; Iizuka, T; Ogura, T; Esumi, H				Iwasaki, T; Hori, H; Hayashi, Y; Nishino, T; Tamura, K; Oue, S; Iizuka, T; Ogura, T; Esumi, H			Characterization of mouse nNOS2, a natural variant of neuronal nitric-oxide synthase produced in the central nervous system by selective alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; L-ARGININE BINDING; MESSENGER-RNA; CYTOCHROME P-450-CAM; SUBSTRATE-ANALOGS; OXYGENASE DOMAIN; ESCHERICHIA-COLI; PROXIMAL LIGAND; HEME ENZYMES; EXPRESSION	Mouse neuronal nitric-oxide synthase 2 (nNOS2) is a unique natural variant of constitutive neuronal nitric-oxide synthase (nNOS) specifically expressed in the central nervous system having a 105-amino acid deletion in the heme-binding domain as a result of in-frame mutation by specific alternative splicing. The mouse nNOS2 cDNA gene was heterologously expressed in Escherichia coli, and the resultant product was characterized spectroscopically in detail. Purified recombinant nNOS2 contained heme but showed no L-arginine- and NADPH-dependent citrulline-forming activity in the presence of Ca2+-promoted calmodulin, elicited a sharp electron paramagnetic resonance (EPR) signal at g = 6.0 indicating the presence of a high spin ferriheme as isolated and showed a peak at around 420 nm in the CO difference spectrum, instead of a 443-nm peak detected with the recombinant wild-type nNOS1 enzyme. Thus, although the heme domain of nNOS2 is capable of binding heme, the heme coordination geometry is highly abnormal in that it probably has a proximal non-cysteine thiolate ligand both in the ferric and ferrous states. Moreover, negligible spectral perturbation of the nNOS2 ferriheme was detected upon addition of either L-arginine or imidazole. These provide a possible rational explanation for the inability of nNOS2 to catalyze the cytochrome P450-type monooxygenase reaction.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; RIKEN, Inst Phys & Chem Res, Biophys Chem Lab, Wako, Saitama 3510198, Japan; Natl Canc Ctr, Res Inst E, Investigat Treatment Div, Kashiwa, Chiba 2770882, Japan	Nippon Medical School; RIKEN; National Cancer Center - Japan	Nishino, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ANDERSSON LA, 1991, STRUCT BOND, V74, P1; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DAWSON TM, 1994, PROG BRAIN RES, V103, P365; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hori H, 1997, BIOCHEM BIOPH RES CO, V234, P476, DOI 10.1006/bbrc.1997.6664; Ignarro LJ, 1996, KIDNEY INT, pS2; Iwasaki T, 1999, J BIOL CHEM, V274, P7705, DOI 10.1074/jbc.274.12.7705; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OGURA T, 1994, P 3 INT M BIOL NITR; Palmer G., 1979, PORPHYRINS, P313; Possee RD., 1992, BACULOVIRUS EXPRESSI; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; Rietjens IMCM, 1996, J BIOL INORG CHEM, V1, P372, DOI 10.1007/s007750050068; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, BIOCHEMISTRY-US, V36, P11821, DOI 10.1021/bi963003q; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Summers MD, 1987, TEXAS AGR EXPT STATI; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang Y, 1997, J BIOL CHEM, V272, P11392; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	69	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17559	17566		10.1074/jbc.274.25.17559	http://dx.doi.org/10.1074/jbc.274.25.17559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364190	hybrid			2022-12-27	WOS:000080974300026
J	Liu, ZX; Yu, YJ; Dennert, G				Liu, ZX; Yu, YJ; Dennert, G			A cell surface ADP-ribosyltransferase modulates T cell receptor association and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ANTIGEN-RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; TYROSINE KINASE; PROTEIN-KINASE; LYMPHOCYTES-T; EXPRESSION; CD45; PHOSPHORYLATION; STIMULATION	ART-1, a cell surface ADP-ribosyltransferase, is imbedded in the membrane by a glycosylphosphatidylinositol anchor. Function of this enzyme in mouse T lymphocytes is to transfer ADP-ribose groups from NAD to arginine residues, exposed on the extracellular domain of cell surface molecules. As a consequence, T cell responses are modulated. To explore the precise action of the enzyme, the T cell lymphoma EL-4 was transfected with the ART-1 gene, and its effects were examined. It is shown that ART-1 ADP-ribosylates distinct cell surface molecules, causing inhibition of T cell receptor signaling, concomitant to suppression of p56(lck) kinase activation. These effects are explained by failure of T cell receptors and co-receptors to associate into a contiguous and functional receptor cluster.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Dennert, G (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol, POB 33800,1441 Eastlake Ave,M-S 73, Los Angeles, CA 90033 USA.	dennert@hsc.usc.edu			NCI NIH HHS [CA37706] Funding Source: Medline; NIAID NIH HHS [AI43954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; BOLEN JB, 1991, ADV CANCER RES, V57, P103; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Nemoto E, 1996, J IMMUNOL, V156, P85; Okamoto S, 1998, J IMMUNOL, V160, P4190; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Poggi A, 1996, INT IMMUNOL, V8, P1947, DOI 10.1093/intimm/8.12.1947; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; Wang J, 1996, J IMMUNOL, V156, P2819; WANG J, 1994, J IMMUNOL, V153, P4048; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235	18	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17399	17401		10.1074/jbc.274.25.17399	http://dx.doi.org/10.1074/jbc.274.25.17399			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364166	hybrid			2022-12-27	WOS:000080974300002
J	Popov, M; Reithmeier, RAF				Popov, M; Reithmeier, RAF			Calnexin interaction with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger 1 (band 3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TCR-ALPHA-PROTEINS; ASPARAGINE-LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONES CALNEXIN; VIRUS-G-PROTEIN; EXTRACYTOSOLIC LOOPS; GLUCOSE-TRANSPORTER; SURFACE EXPRESSION; P-GLYCOPROTEIN; RIBONUCLEASE-B	The interaction of the endoplasmic reticulum chaperone calnexin with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger (AE1), was characterized by cell-free translation and in transfected HEK293 cells, followed by co-immunoprecipitation using anti-calnexin antibody. AE1 contains 12-14 transmembrane segments and has a single site of N-glycosylation at Asn-642 in the fourth extracytosolic loop. This site was mutated (N642D) to create a nonglycosylated protein. Calnexin showed a preferential interaction with N-glycosylated AE1 relative to nonglycosylated AE1 both in vitro and in vivo. This interaction could be blocked by inhibition of glucosidases I and II with castanospermine. Calnexin had access to novel N-glycosylated sites created in other extracytosolic loops in AE1 by site-directed or insertional mutagenesis. The interaction with AE1 was enhanced when multiple sites were introduced into the same loop or into two different loops. An association of calnexin with truncated versions of N-glycosylated AE1 was detected after release of the nascent chains from ribosomes with puromycin. The results show that the interaction of calnexin with the polytopic membrane glycoprotein AE1 was dependent on the presence but not the location of the oligosaccharide. Furthermore, calnexin was associated with AE1 after release of AE1 from the translocation machinery.	Univ Toronto, Dept Med, MRC Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, MRC Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Reithmeier, RAF (corresponding author), Univ Toronto, Dept Med, MRC Grp Membrane Biol, Rm 7344,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	r.reithmeier@utoronto.ca						Andersson H, 1996, FEBS LETT, V397, P321, DOI 10.1016/S0014-5793(96)01207-0; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Chevet E, 1998, MOL BIOL CELL, V9, p345A; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Flura T, 1997, GLYCOBIOLOGY, V7, P617, DOI 10.1093/glycob/7.5.617; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; Groves JD, 1998, FEBS LETT, V433, P223, DOI 10.1016/S0014-5793(98)00909-0; Groves JD, 1998, BIOCHEM J, V332, P161, DOI 10.1042/bj3320161; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hentges A, 1997, BIOL CHEM, V378, P1031, DOI 10.1515/bchm.1997.378.9.1031; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEPKE S, 1976, J MEMBRANE BIOL, V29, P147, DOI 10.1007/BF01868957; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PIND S, 1994, J BIOL CHEM, V269, P12784; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Popov M, 1999, BIOCHEM J, V339, P269, DOI 10.1042/0264-6021:3390269; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; Tam LY, 1996, BIOCHEM J, V318, P645, DOI 10.1042/bj3180645; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WADA I, 1994, J BIOL CHEM, V269, P7464; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	79	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17635	17642		10.1074/jbc.274.25.17635	http://dx.doi.org/10.1074/jbc.274.25.17635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364201	hybrid			2022-12-27	WOS:000080974300037
J	Qiu, JZ; Qian, Y; Chen, V; Guan, MX; Shen, BH				Qiu, JZ; Qian, Y; Chen, V; Guan, MX; Shen, BH			Human exonuclease 1 functionally complements its yeast homologues in DNA recombination, RNA primer removal, and mutation avoidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; NUCLEOTIDE EXCISION-REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; HUMAN FLAP ENDONUCLEASE-1; DOUBLE-STRAND BREAKS; MISMATCH REPAIR; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; POLYMERASE-I	Yeast exonuclease 1 (Exo1) is induced during meiosis and plays an important role in DNA homologous recombination and mismatch correction pathways. The human homolog, an 803-amino acid protein, shares 55% similarity to the yeast Exo1. In this report, we show that the enzyme functionally complements Saccharomyces cerevisiae Exo1 in recombination of direct repeat DNA fragments, UV resistance, and mutation avoidance by in vivo assays. Furthermore, the human enzyme suppresses the conditional lethality of a rad27 Delta mutant, symptomatic of defective RNA primer removal. The purified recombinant enzyme not only displays 5'-3' double strand DNA exonuclease activity, hut also shows an RNase H activity. This result indicates a back-up function of exonuclease 1 to flap endonuclease-1 in RNA primer removal during lagging strand DNA synthesis.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope; California Institute of Technology	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Binghui/0000-0002-4408-407X; Guan, Min-Xin/0000-0001-5067-6736	NCI NIH HHS [CA82468] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BOYER JC, 1995, CANCER RES, V55, P6063; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1995, DNA REPAIR MUTATGENE; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; Kornberg A., 1992, DNA REPLICATION; LEHMAN IR, 1978, ENZYME, V14, P15; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Murante RS, 1998, P NATL ACAD SCI USA, V95, P2244, DOI 10.1073/pnas.95.5.2244; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; Okinaka RT, 1997, MUTAT RES-DNA REPAIR, V385, P107, DOI 10.1016/S0921-8777(97)00031-1; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Qiu JZ, 1998, NUCLEIC ACIDS RES, V26, P3077, DOI 10.1093/nar/26.13.3077; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Schmutte C, 1998, CANCER RES, V58, P4537; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Sherman F., 1986, METHODS YEAST GENETI; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; States JC, 1998, HUM MUTAT, V12, P103, DOI 10.1002/(SICI)1098-1004(1998)12:2<103::AID-HUMU5>3.0.CO;2-6; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TAKAYAMA K, 1995, CANCER RES, V55, P5656; THOMAS BJ, 1989, GENETICS, V123, P725; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v	62	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17893	17900		10.1074/jbc.274.25.17893	http://dx.doi.org/10.1074/jbc.274.25.17893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364235	hybrid, Green Accepted			2022-12-27	WOS:000080974300071
J	Arosa, FA; de Jesus, O; Porto, G; Carmo, AM; de Sousa, M				Arosa, FA; de Jesus, O; Porto, G; Carmo, AM; de Sousa, M			Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CALCIUM-BINDING PROTEIN; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTOR; IMMATURE THYMOCYTES; LIGAND-BINDING; KDEL RECEPTOR; TAP COMPLEXES; HEAVY-CHAINS	Calreticulin is an endoplasmic reticulum resident molecule known to be involved in the folding and assembly of major histocompatibility complex (MHC) class I molecules. In the present study, expression of calreticulin was analyzed in human peripheral blood T lymphocytes. Pulse-chase experiments in [S-35]methionine-labeled T cell blasts showed that calreticulin was associated with several proteins in the endoplasmic reticulum and suggested that it was expressed at the cell surface. Indeed, the 60-kDa calreticulin was labeled by cell surface biotinylation and precipitated from the surface of activated T cells together with a protein with an apparent molecular mass of 46 kDa. Cell surface expression of calreticulin by activated T lymphocytes was further confirmed by immunofluorescence and flow cytometry, studies that showed that both CD8+ and CD4+ T cells expressed calreticulin in the plasma membrane. Low amounts of cell surface calreticulin were detected in resting T lymphocytes. By sequential immunoprecipitation using the conformation independent monoclonal antibody HC-10, we provided evidence that the cell surface 46-kDa protein co-precipitated with calreticulin is unfolded MHC I. These results show for the first time that after T cell activation, significant amounts of calreticulin are expressed on the T cell surface, where they are found in physical association with a pool of beta(2)-free MHC class I molecules.	Univ Porto, Inst Mol & Cell Biol, Lab Mol Immunol, P-4150 Porto, Portugal; Santo Antonio Gen Hosp, Dept Hematol, P-4050 Porto, Portugal	Universidade do Porto	Arosa, FA (corresponding author), Univ Porto, Inst Mol & Cell Biol, Lab Mol Immunol, Rua Campo Alegre 823, P-4150 Porto, Portugal.		Carmo, Alexandre/B-5191-2011; Porto, Graca/J-7939-2013; Arosa, Fernando A./E-5640-2010	Carmo, Alexandre/0000-0002-2508-9799; Porto, Graca/0000-0002-1923-4638; Arosa, Fernando A./0000-0002-7209-4507; de sousa, maria/0000-0002-4552-185X				Arosa FA, 1997, CLIN EXP IMMUNOL, V107, P548, DOI 10.1046/j.1365-2249.1997.d01-967.x; AROSA FA, 1994, SCAND J IMMUNOL, V39, P426, DOI 10.1111/j.1365-3083.1994.tb03396.x; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BURNS K, 1992, J BIOL CHEM, V267, P19039; CHEN A, 1994, J IMMUNOL, V153, P1430; CONRAD ME, 1993, GASTROENTEROLOGY, V104, P1700, DOI 10.1016/0016-5085(93)90648-V; Conrad ME, 1996, J CLIN INVEST, V98, P1449, DOI 10.1172/JCI118933; Coppolino MG, 1998, INT J BIOCHEM CELL B, V30, P553, DOI 10.1016/S1357-2725(97)00153-2; de Sousa Maria, 1998, Journal of Hepatology, V28, P1, DOI 10.1016/S0168-8278(98)80367-X; DEMARIA S, 1992, CELL IMMUNOL, V142, P103, DOI 10.1016/0008-8749(92)90272-Q; Denning GM, 1997, BLOOD, V90, P372; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Harris MR, 1998, J IMMUNOL, V160, P5404; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Llewellyn DH, 1997, BIOCHEM BIOPH RES CO, V240, P36, DOI 10.1006/bbrc.1997.7607; MACHY P, 1982, P NATL ACAD SCI-BIOL, V79, P4148, DOI 10.1073/pnas.79.13.4148; MACHY P, 1987, NATURE, V328, P724, DOI 10.1038/328724a0; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MCCAULIFFE DP, 1993, J INVEST DERMATOL, V100, P73; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; MONOS DS, 1983, J IMMUNOL, V131, P341; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; OLSSON L, 1994, P NATL ACAD SCI USA, V91, P9086, DOI 10.1073/pnas.91.19.9086; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P343; PERNIS B, 1985, IMMUNOL TODAY, V6, P45, DOI 10.1016/0167-5699(85)90046-5; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pickl WF, 1996, IMMUNOLOGY, V88, P104, DOI 10.1046/j.1365-2567.1996.d01-644.x; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHNABL E, 1990, J EXP MED, V171, P1431, DOI 10.1084/jem.171.5.1431; Sim RB, 1998, IMMUNOBIOLOGY, V199, P208, DOI 10.1016/S0171-2985(98)80028-4; Solheim JC, 1997, J IMMUNOL, V158, P541; Solheim JC, 1997, J IMMUNOL, V158, P2236; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SONTHEIMER RD, 1995, J INVEST MED, V43, P362; STAM NJ, 1986, J IMMUNOL, V137, P2299; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; TSE DB, 1984, J EXP MED, V159, P193, DOI 10.1084/jem.159.1.193; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; Zhang J, 1998, J IMMUNOL, V161, P2930; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHU JH, 1994, CLIN INVEST MED, V17, P196; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195	63	110	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16917	16922		10.1074/jbc.274.24.16917	http://dx.doi.org/10.1074/jbc.274.24.16917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358038	hybrid			2022-12-27	WOS:000080780400037
J	Rieke, CJ; Mulichak, AM; Garavito, RM; Smith, WL				Rieke, CJ; Mulichak, AM; Garavito, RM; Smith, WL			The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TIME-DEPENDENT INHIBITION; SELECTIVE-INHIBITION; DIFFERENTIAL INHIBITION; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; GENE-EXPRESSION; G/H SYNTHASE-1; HEME-BINDING; CYCLOOXYGENASE-2	Arg-120 is located near the mouth of the hydrophobic channel that forms the cyclooxygenase active site of prostaglandin endoperoxide H synthases (PGHSs)-1 and -2, Replacement of Arg-120 of ovine PGHS-1 with a glutamine increases the apparent K-m of PGHS-1 for arachidonate by 1,000-fold (Bhattacharyya, D. K., Lecomte, M., Rieke, C. J., Garavito, R. M., and Smith, W. L. (1996) J, Biol, Chem, 271, 2179-2184). This and other evidence indicate that the guanido group of Arg-120 forms an ionic bond with the carboxylate group of arachidonate and that this interaction is an important contributor to the overall strength of arachidonate binding to PGHS-1. In contrast, we report here that R120Q human PGHS-2 (hPGHS-2) and native hPGHS-2 have very similar kinetic properties, but R120L hPGHS-2 catalyzes the oxygenation of arachidonate inefficiently. Our data indicate that the guanido group of Arg-120 of hPGHS-2 interacts with arachidonate through a hydrogen bond rather than an ionic bond and that this interaction is much less important for arachidonate binding to PGHS-2 than to PGHS-1. The K-m values of PGHS-1 and -2 for arachidonate are the same, and all but one of the core residues of the active sites of the two isozymes are identical. Thus, the results of our studies of Arg-120 of PGHS-1 and -2 imply that interactions involved in the binding of arachidonate to PGHS-1 and -2 are quite different and that residues within the hydrophobic cyclooxygenase channel must contribute more significantly to arachidonate binding to PGHS-S than to PGHS-1. As observed previously with R120Q PGHS-1, flurbiprofen was an ineffective inhibitor of R120Q hPGHS-2, PGHS-2-specific inhibitors including NS398, DuP-697, and SC58125 had IC50 values for the R120Q mutant that were up to 1,000-fold less than those observed for native hPGHS-2; thus, the positively charged guanido group of Arg-120 interferes with the binding of these compounds. NS398 did not cause time-dependent inhibition of R120Q hPGHS-2, whereas DuP-697 and SC58125 were time-dependent inhibitors. Thus, Arg-120 is important for the time-dependent inhibition of hPGHS-2 by NS398 but not by DuP-697 or SC58125.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem, 513 Biochem Bldg, E Lansing, MI 48824 USA.				NIGMS NIH HHS [P01GM57323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Callan OH, 1996, J BIOL CHEM, V271, P3548; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P131; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; STEGEMAN R, 1999, IN PRESS ACTA CRYSTA; Wong E, 1997, J BIOL CHEM, V272, P9280; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	38	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17109	17114		10.1074/jbc.274.24.17109	http://dx.doi.org/10.1074/jbc.274.24.17109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358065	hybrid			2022-12-27	WOS:000080780400064
J	Martin, JL; Baxter, RC				Martin, JL; Baxter, RC			Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLASTS; FACTOR-I; IGF-I; RETINOIC ACID; HUMAN-PLASMA; MECHANISM; PROLIFERATION; PURIFICATION; ESTRADIOL; RECEPTORS	Insulin-like growth factor binding protein-3 (IG-FBP-3) inhibits proliferation and promotes apoptosis in normal and malignant cells. In MCF-10A human mammary epithelial cells, 30 ng/ml human plasma-derived IGFBP-3 inhibited DNA synthesis to 70% of control. This inhibition appeared IGF-independent, since neither an IGF-receptor antibody nor IGFBP-6 inhibited DNA synthesis. Malignant transformation of MCF-10A cells by transfection with Ha-ras oncogene abolished the inhibitory effect of IGFBP-3, concomitant with an increase in IGFBP-3 secretion and cell association of approximately 60 and 300%, respectively. When mitogen-activated protein (MAP) kinase activation was partially inhibited using PD 98059, IGFBP-3 sensitivity in ras-transfected cells was restored, with a significant inhibitory effect at 10 ng/ml IGFBP-3. PD 98059 had no effect on IGFBP-3 secretion or cell association by ras-transfected or parent MCF-10A cells. Hs578T, a tumor-derived breast cancer cell line that expresses activated Ha-ras, similarly has a high level of secreted and cell-associated IGFBP-3. In the absence of PD 98059, DNA synthesis by Hs578T cells was reduced to 70% of control by 1000 ng/ml IGFBP-S. PD 98059 increased sensitivity to IGFBP-3, so that this level of inhibition was achieved with 100 ng/ml IGFBP-3. These results suggest that MAP kinase activation by oncogenic ras expression causes IGFBP-3 resistance, a possible factor in the dysregulation of breast cancer cell growth.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Martin, JL (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AngellozNicoud P, 1996, GROWTH REGULAT, V6, P130; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BINOUX M, 1993, ADV EXP MED BIOL, V343, P293; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Gucev ZS, 1996, CANCER RES, V56, P1545; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; MARTIN JL, 1992, GROWTH REGULAT, V2, P88; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Salahifar H, 1997, ENDOCRINOLOGY, V138, P1683, DOI 10.1210/en.138.4.1683; SOULE HD, 1990, CANCER RES, V50, P6075; SUIKKARI AM, 1991, J CLIN ENDOCR METAB, V73, P1377, DOI 10.1210/jcem-73-6-1377	33	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16407	16411		10.1074/jbc.274.23.16407	http://dx.doi.org/10.1074/jbc.274.23.16407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347201	hybrid			2022-12-27	WOS:000080668600061
J	Farber, SA; Olson, ES; Clark, JD; Halpern, ME				Farber, SA; Olson, ES; Clark, JD; Halpern, ME			Characterization of Ca(2+)-dependent phospholipase A(2) activity during zebrafish embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A(2); P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; CALCIUM IONOPHORE; RAT-BRAIN; CELLS; IDENTIFICATION; INHIBITION	We have developed a simple fluorescent assay for detection of phospholipase A(2) (PLA(2)) activity in zebrafish embryos that utilizes a fluorescent phosphatidylcholine substrate. By using this assay in conjunction with selective PLA(2) inhibitors and Western blot analysis, we identified the principal activity in zebrafish embryogenesis as characteristic of the Ca(2+)-dependent cytosolic PLA(2) (cPLA(2)) subtype. Embryonic cPLA(2) activity remained constant from the 1-cell stage until the onset of somitogenesis, at which time it increased sharply. This increase was preceded by the expression of a previously identified zebrafish cPLA(2) homologue (Nalefski, E., Sultzman, L., Martin, D., Kriz, R., Towler, P., Knopf, J., and Clark, J. (1994) J. Biol. Chem. 269, 18239-18249). By using a quenched BODIPY-labeled phosphatidylcholine that fluoresces only upon cleavage by PLA(2), lipase activity was visualized in the cells of living embryos where it localized to perinuclear membranes.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Genet Inst Inc, Cambridge, MA 02140 USA	Carnegie Institution for Science	Farber, SA (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	Farber@mail1.ciwemb.edu	Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; Clark, James D./0000-0002-4801-0123	NINDS NIH HHS [F32 NS10326] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010326] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEPENIK KP, 1984, CALCIFIED TISSUE INT, V36, P175, DOI 10.1007/BF02405314; CHEPENIK KP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P192, DOI 10.1016/0005-2760(92)90290-C; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gallagher ML, 1998, J FISH BIOL, V52, P1218, DOI 10.1111/j.1095-8649.1998.tb00967.x; GAY SW, 1984, J EXP ZOOL, V232, P317, DOI 10.1002/jez.1402320219; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KAWASAKI M, 1993, MOL BRAIN RES, V19, P39, DOI 10.1016/0169-328X(93)90146-G; Kim TS, 1997, J BIOL CHEM, V272, P2542; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MESHULAM T, 1992, J BIOL CHEM, V267, P21465; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Navas JM, 1997, J FISH BIOL, V51, P760, DOI 10.1006/jfbi.1997.0484; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Piddington R, 1996, DIABETOLOGIA, V39, P915; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Secombes C.J., 1996, Fish Physiology, V15, P63; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SOLNICAKREZEL L, 1995, BIOESSAYS, V17, P931, DOI 10.1002/bies.950171106; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tocher Douglas R., 1995, Biochemistry and Molecular Biology of Fishes, V4, P119; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WALDMAN SA, 1984, INT J BIOCHEM, V16, P593, DOI 10.1016/0020-711X(84)90027-2; Watkins BA, 1996, IFT BAS SYM, V11, P71; Westerfield M, 1995, ZEBRAFISH BOOK; YOSHIHARA Y, 1992, BIOCHEM BIOPH RES CO, V185, P350, DOI 10.1016/S0006-291X(05)80992-1	50	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19338	19346		10.1074/jbc.274.27.19338	http://dx.doi.org/10.1074/jbc.274.27.19338			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383445	hybrid			2022-12-27	WOS:000081196300068
J	Izzo, MW; Strachan, GD; Stubbs, MC; Hall, DJ				Izzo, MW; Strachan, GD; Stubbs, MC; Hall, DJ			Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAR UPSTREAM ELEMENT; INSULIN PROMOTER; ADENOVIRUS E1A; BINDING; GENE; MAZ; CELLS; ACTIVATION; SEQUENCES; DOMAIN	ZF87/MAZ is a zinc finger-containing transcription factor that was cloned based on its ability to bind to a site within the c-myc P2 promoter. However, its role in the control of c-myc transcription has not yet been well established. Here we have analyzed the effect of ZF87/ MAZ overexpression on transcription from the murine c-myc P2 promoter. It was found that when overexpressed in COS cells, ZF87/MAZ significantly represses transcription from P2. The repression is mediated through the ME1a2 element, located at position -86 relative to the P2 transcriptional start site, and is not mediated through either the E2F or the ME1a1 sites. ZF87/ MAZ functions as a true transcriptional repressor since it can repress transcription independently of the c-myc promoter, as part of a fusion with the GAL4 protein. The repressive domain within ZF87/MAZ is located in the amino-terminal half of the protein, a region rich in proline and alanine residues. ZF87/MAZ therefore shares features (i.e. a Pro/Ala-rich region) with those of known transcriptional repressor proteins.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA	Jefferson University	Hall, DJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, Room 501 Curtis,1015 Walnut St, Philadelphia, PA 19107 USA.	hall@hendrix.jci.tju.edu		, Matthew/0000-0003-3771-7083	NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER; NCI NIH HHS [CA67032] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASSELIN C, 1989, ONCOGENE, V4, P549; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; HALL DJ, 1990, ONCOGENE, V5, P47; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HAY N, 1987, GENE DEV, V3, P293; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Kawasaki H, 1996, ARTIF ORGANS, V20, P836, DOI 10.1111/j.1525-1594.1996.tb04556.x; KENNEDY GC, 1993, BIOCHEM SOC T, V21, P178, DOI 10.1042/bst0210178; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LA RF, 1994, MOL CELL BIOL, V14, P1039; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; LOGAN T, 1993, BIOCHEM BIOPH RES CO, V192, P1204, DOI 10.1006/bbrc.1993.1544; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marcu KB, 1997, CURR TOP MICROBIOL, V224, P47; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432; WEINBERG RA, 1989, CANCER RES, V49, P3713; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	51	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19498	19506		10.1074/jbc.274.27.19498	http://dx.doi.org/10.1074/jbc.274.27.19498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383467	hybrid			2022-12-27	WOS:000081196300090
J	Reyland, ME; Anderson, SM; Matassa, AA; Barzen, KA; Quissell, DO				Reyland, ME; Anderson, SM; Matassa, AA; Barzen, KA; Quissell, DO			Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; ULTRAVIOLET-RADIATION; SIGNAL-TRANSDUCTION; SJOGRENS-SYNDROME; GAMMA-RADIATION; CANCER CELLS; JUN; DNA; INHIBITOR	We have previously shown that parotid C5 salivary acinar cells undergo apoptosis in response to etoposide treatment as indicated by alterations in cell morphology, caspase-3 activation, DNA fragmentation, sustained activation of c-Jun N-terminal kinase, and inactivation of extracellular regulated kinases 1 and 2, Here we report that apoptosis results in the caspase-dependent cleavage of protein kinase C-delta (PKC delta) to a 40-kDa fragment, the appearance of which correlates with a 9-fold increase in PKC delta activity. To understand the function of activated PKC delta in apoptosis, we have used the PKC delta-specific inhibitor, rottlerin, Pretreatment of parotid C5 cells with rottlerin prior to the addition of etoposide blocks the appearance of the apoptotic morphology, the sustained activation of c-Jun N-terminal kinase, and inactivation of extracellular regulated kinases 1 and 2, Inhibition of PKC delta also partially inhibits caspase-3 activation and DNA fragmentation. Immunoblot analysis shows that the PKC delta cleavage product does not accumulate in parotid C5 cells treated with rottlerin and etoposide together, suggesting that the catalytic activity of PKC delta may be required for cleavage. PKC alpha and PKC beta 1 activities also increase during etoposide-induced apoptosis, Inhibition of these two isoforms with Go6976 slightly suppresses the apoptotic morphology, caspase-3 activation, and DNA fragmentation, but has no effect on the sustained activation of c-Jun N-terminal kinase or inactivation of extracellular regulated kinase 1 and 2, These data demonstrate that activation of PKC delta is an integral and essential part of the apoptotic program in parotid C5 cells and that specific activated isoforms of PKC may have distinct functions in cell death.	Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Dent, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Dent, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.	mary.reyland@UCHSC.edu	Prada-Arismendy, Jeanette/GLR-4134-2022		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE012422] Funding Source: NIH RePORTER; NCI NIH HHS [CA4541] Funding Source: Medline; NIDCR NIH HHS [DE12422] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Freemerman AJ, 1996, MOL PHARMACOL, V49, P788; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kong LP, 1997, ARTHRITIS RHEUM, V40, P87, DOI 10.1002/art.1780400113; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; Liem IH, 1996, EUR J NUCL MED, V23, P1485, DOI 10.1007/BF01254473; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; MANSSONRAHEMTULLA B, 1992, ORAL SURG ORAL MED O, V73, P35, DOI 10.1016/0030-4220(92)90151-F; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsumura R, 1996, CLIN EXP RHEUMATOL, V14, P309; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PONGRACZ J, 1995, EXP CELL RES, V218, P430, DOI 10.1006/excr.1995.1176; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; SOLARY E, 1993, BLOOD, V81, P1359; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	57	233	238	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19115	19123		10.1074/jbc.274.27.19115	http://dx.doi.org/10.1074/jbc.274.27.19115			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383415	hybrid			2022-12-27	WOS:000081196300038
J	Roobol, A; Grantham, J; Whitaker, HC; Carden, MJ				Roobol, A; Grantham, J; Whitaker, HC; Carden, MJ			Disassembly of the cytosolic chaperonin in mammalian cell extracts at intracellular levels of K+ and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-BINDING DOMAINS; T-COMPLEX POLYPEPTIDE-1; CYTOPLASMIC CHAPERONIN; MOLECULAR CHAPERONE; CHROMOBINDIN-A; IN-VITRO; MITOCHONDRIAL CHAPERONIN-60; EUKARYOTIC CHAPERONIN; THERMUS-THERMOPHILUS; SUBUNIT COMPOSITION	The eukaryotic, cytoplasmic chaperonin, CCT, is essential for the biogenesis of actin- and tubulin-based cytoskeletal structures. CCT purifies as a doubly toroidal particle containing two eight-membered rings of similar to 60-kDa ATPase subunits, each encoded by an essential and highly conserved gene. However, immunofluorescence detection with subunit-specific antibodies has indicated that in cells CCT subunits do not always colocalize. We report here that CCT ATPase activity is highly dependent on K+ ion concentration and that in cell extracts, at physiological levels of K+ and ATP, there is considerable dissociation of CCT to a smaller oligomeric structure and free subunits. This dissociation is consequent to ATP hydrolysis and is readily reversed on removal of ATP. The ranking order for ease with which subunits can exit the chaperonin particle correlates well with the length of a loop structure, identified by homology modeling, in the intermediate domain of CCT subunits. K+-ATP-induced disassembly is not an intrinsic property of purified CCT over a 80-fold concentration range and requires the presence of additional factor(s) present in cell extracts.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Kent	Roobol, A (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.		Carden, Martin/D-4135-2019; Grantham, Julie/A-5002-2009	Carden, Martin/0000-0002-0609-4605; 				BAIN G, 1994, BIOESSAYS, V16, P342; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CHATELLIER J, 1998, P NATL ACAD SCI USA, V95, P15024; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CREUTZ CE, 1994, J BIOL CHEM, V269, P32035; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis R. John, 1996, P1; ELLIS RJ, 1994, CURR BIOL, V4, P633; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRANTHAM J, 1998, STUDIES CHAPERONIN C; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; Horwich AL, 1998, NAT STRUCT BIOL, V5, P333, DOI 10.1038/nsb0598-333; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX CR, 1986, BIOCHEM SOC T, V14, P9, DOI 10.1042/bst0140009; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MARTIN WH, 1987, J BIOL CHEM, V262, P2803; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; Nielsen KL, 1998, MOL CELL, V2, P93, DOI 10.1016/S1097-2765(00)80117-3; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; QUAITERANDALL E, 1995, J BIOL CHEM, V270, P28818, DOI 10.1074/jbc.270.48.28818; Roobol A, 1999, J BIOL CHEM, V274, P2408, DOI 10.1074/jbc.274.4.2408; Roobol A, 1999, EUR J CELL BIOL, V78, P21, DOI 10.1016/S0171-9335(99)80004-1; ROOBOL A, 1993, J NEUROCHEM, V60, P2327, DOI 10.1111/j.1471-4159.1993.tb03524.x; ROOBOL A, 1995, J CELL SCI, V108, P1477; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROY H, 1988, PLANT PHYSIOL, V86, P50, DOI 10.1104/pp.86.1.50; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; Taguchi H, 1997, J BIOL CHEM, V272, P18155, DOI 10.1074/jbc.272.29.18155; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Weber F, 1998, NAT STRUCT BIOL, V5, P977, DOI 10.1038/2952; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WEISSMAN JS, 1997, GUIDEBOOK MOL CHAPER, P173; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	57	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19220	19227		10.1074/jbc.274.27.19220	http://dx.doi.org/10.1074/jbc.274.27.19220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383429	hybrid			2022-12-27	WOS:000081196300052
J	Weber, J; Dunn, SD; Senior, AE				Weber, J; Dunn, SD; Senior, AE			Effect of the epsilon-subunit on nucleotide binding to Escherichia coli F-1-ATPase catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; F0F1 ATP SYNTHASE; COUPLING FACTOR; GAMMA-SUBUNIT; BETA-SUBUNIT; F1-ATPASE; HYDROLYSIS; F1; RECONSTITUTION; COOPERATIVITY	The influence of the epsilon-subunit on the nucleotide binding affinities of the three catalytic sites of Escherichia coli F-1-ATPase was investigated, using a genetically engineered Trp probe in the adenine-binding subdomain (beta-Trp-331). The interaction between epsilon and F-1 was not affected by the mutation. K-d for binding of epsilon to beta Y331W mutant F-1 was similar to 1 nM, and epsilon inhibited ATPase activity by 90%. The only nucleotide binding affinities that showed significant differences in the epsilon-depleted and epsilon-replete forms of the enzyme were those for MgATP and MgADP at the high-affinity catalytic site 1. K-d1(MgATP) and K-d1(MgADP) were an order of magnitude higher in the absence of epsilon than in its presence. In contrast, the binding affinities for MgATP and MgADP at sites 2 and 3 were similar in the epsilon-depleted and epsilon-replete enzymes, as were the affinities at all three sites for free ATP and ADP. Comparison of MgATP binding and hydrolysis parameters showed that in the presence as well as the absence of epsilon, K-m equals K-d3. Thus, in both cases, all three catalytic binding sites have to be occupied to obtain rapid (V-max) MgATP hydrolysis rates.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Rochester; Western University (University of Western Ontario)	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Alan_Senior@urmc.rochester.edu	Dunn, Stanley/D-3418-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COX GB, 1993, J MOL BIOL, V229, P1159, DOI 10.1006/jmbi.1993.1113; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; Gruber G, 1996, BIOCHEMISTRY-US, V35, P3875, DOI 10.1021/bi952949h; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Licher T, 1998, FEBS LETT, V431, P419, DOI 10.1016/S0014-5793(98)00807-2; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; RAO R, 1988, J BIOL CHEM, V263, P5569; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; STERNWEIS PC, 1978, J BIOL CHEM, V253, P3123; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P3474; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	42	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19124	19128		10.1074/jbc.274.27.19124	http://dx.doi.org/10.1074/jbc.274.27.19124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383416	hybrid			2022-12-27	WOS:000081196300039
J	Druey, KM; Ugur, O; Caron, JM; Chen, CK; Backlund, PS; Jones, TLZ				Druey, KM; Ugur, O; Caron, JM; Chen, CK; Backlund, PS; Jones, TLZ			Amino-terminal cysteine residues of RGS16 are required for palmitoylation and modulation of G(i)- and G(q)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PLASMA-MEMBRANE LOCALIZATION; ACTIVITY IN-VITRO; ALPHA-SUBUNITS; CORE DOMAIN; TRANSITION-STATE; GAIP; PHOSPHORYLATION; REGULATOR; RECEPTOR	RGS proteins (Regulators of G protein Signaling) are a recently discovered family of proteins that accelerate the GTPase activity of heterotrimeric G protein a subunits of the i, q, and 12 classes. The proteins share a homologous core domain but have divergent amino-terminal sequences that are the site of palmitoylation for RGS-GAIP and RGS4. We investigated the function of palmitoylation for RGS16, which shares conserved amino-terminal cysteines with RGS4 and RGS5. Mutation of cysteine residues at residues 2 and 12 blocked the incorporation of [H-3]palmitate into RGS16 in metabolic labeling studies of transfected cells or into purified RGS proteins in a cell-free palmitoylation assay. The purified RGS16 proteins with the cysteine mutations were still able to act as GTPase-activating protein for G(i)alpha. Inhibition or a decrease in palmitoylation did not significantly change the amount of protein that was membrane-associated. However, palmitoylation-defective RGS16 mutants demonstrated impaired ability to inhibit both G(i)-and G(q)-linked signaling pathways when expressed in HEK293T cells. These findings suggest that the aminoterminal region of RGS16 may affect the affinity of these proteins for Ga subunits in vivo or that palmitoylation localizes the RGS protein in close proximity to Ga subunits on cellular membranes.	NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06030 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Connecticut; California Institute of Technology	Jones, TLZ (corresponding author), NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.		Ugur, Özlem/J-3169-2019	Ugur, Özlem/0000-0002-5404-5242	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; *GEN COMP GROUP, 1998, WISC PACK GCG SOFTW; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	55	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18836	18842		10.1074/jbc.274.26.18836	http://dx.doi.org/10.1074/jbc.274.26.18836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373502	Green Accepted, hybrid			2022-12-27	WOS:000081056700094
J	Lin, CY; Anders, J; Johnson, M; Sang, QXA; Dickson, RB				Lin, CY; Anders, J; Johnson, M; Sang, QXA; Dickson, RB			Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; LDL-RECEPTOR; PLASMA PREKALLIKREIN; LIPOPROTEIN RECEPTOR; NUCLEOTIDE-SEQUENCE; CELL-ADHESION; GROWTH-FACTOR; GENE	A major protease from human breast cancer cells was previously detected by gelatin zymography and proposed to play a role in breast cancer invasion and metastasis, To structurally characterize the enzyme, we isolated a cDNA encoding the protease, Analysis of the cDNA reveals three sequence motifs: a carboxyl-terminal region with similarity to the trypsin-like serine proteases, four tandem cysteine-rich repeats homologous to the low density lipoprotein receptor, and two copies of tandem repeats originally found in the complement subcomponents Clr and Cls, By comparison with other serine proteases, the active-site triad was identified as His-484, Asp-539, and Ser-633. The protease contains a characteristic Arg-Val-Val-Gly-Gly motif that may serve as a proteolytic activation site. The bottom of the substrate specificity pocket was identified to be Asp-627 by comparison with other trypsin-like serine proteases, In addition, this protease exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the PI site. Thus, the protease is a mosaic protein with broad spectrum cleavage activity and two potential regulatory modules. Given its ability to degrade extracellular matrix and its trypsin-like activity, the name matriptase is proposed for the protease.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R44CA058158, R43CA058158, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [1P50CA58158, P30-CA51008, P30-CA51005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; Cseh S, 1996, MOL IMMUNOL, V33, P351, DOI 10.1016/0161-5890(95)00160-3; EMI M, 1986, GENE, V41, P305; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; HARTLEY BS, 1965, NATURE, V207, P1157, DOI 10.1038/2071157a0; HARTLEY BS, 1966, BIOCHEM J, V101, P229, DOI 10.1042/bj1010229; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KINOSHITA H, 1989, FEBS LETT, V250, P411, DOI 10.1016/0014-5793(89)80766-5; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nielsen BS, 1996, LAB INVEST, V74, P168; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; PYKE C, 1993, CANCER RES, V53, P1911; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SATO T, 1994, INT IMMUNOL, V6, P655; SHI YE, 1993, CANCER RES, V53, P1409; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	39	195	238	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18231	18236		10.1074/jbc.274.26.18231	http://dx.doi.org/10.1074/jbc.274.26.18231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373424	hybrid			2022-12-27	WOS:000081056700016
J	Lin, CY; Anders, J; Johnson, M; Dickson, RB				Lin, CY; Anders, J; Johnson, M; Dickson, RB			Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; TRYPSIN-INHIBITOR; FACTOR ACTIVATOR; PROTEINS; IDENTIFICATION; INVASION; MEMBRANE; SEQUENCE	Matriptase, a trypsin-like serine protease with two potential regulatory modules (low density lipoprotein receptor and complement C1r/s domains), was initially purified from T-47D breast cancer cells, Given its plasma membrane localization, extracellular matrix-degrading activity, and expression by breast cancer cells, this protease may be involved in multiple aspects of breast tumor progression, including cancer invasion. In breast cancer cells, matriptase was detected mainly as an uncomplexed form; however, low levels of matriptase were detected in complexes. In striking contrast, only the complexed matriptase was detected in human milk, The complexed matriptase has now been purified. Amino acid sequences obtained from the matriptase-associated proteins reveal that they are fragments of a Kunitz-type serine protease inhibitor that was previously reported to be an inhibitor of the hepatocyte growth factor activator. In addition, matriptase and its complexes were detected in milk-derived, SV40 T-antigen-immortalized mammary luminal epithelial cell lines, but not in human foreskin fibroblasts or in HT-1080 fibrosarcoma cells. These results suggest that the milk-derived matriptase complexes are likely to be produced by the epithelial components of the lactating mammary gland in vivo and that the activity and function of matriptase may be differentially regulated by its cognate inhibitor, comparing breast cancer with the lactating mammary gland.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [1P50CA58158, P30-CA51008, P30-CA51005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R44CA058158, R43CA058158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KOBAYASHI H, 1994, CANCER RES, V54, P844; KRAMER KK, 1994, J BIOL CHEM, V269, P7255; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	19	227	254	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18237	18242		10.1074/jbc.274.26.18237	http://dx.doi.org/10.1074/jbc.274.26.18237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373425	hybrid			2022-12-27	WOS:000081056700017
J	Tanner, KG; Trievel, RC; Kuo, MH; Howard, RM; Berger, SL; Allis, CD; Marmorstein, R; Denu, JM				Tanner, KG; Trievel, RC; Kuo, MH; Howard, RM; Berger, SL; Allis, CD; Marmorstein, R; Denu, JM			Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; FUNCTION IN-VIVO; CRYSTAL-STRUCTURE; YEAST GCN5P; ACETYLATION; ACTIVATION; SUPERFAMILY; CHROMATIN; PROTEIN; BINDING	Within chromatin, reversible acetylation of core histones is critical for transcriptional activation of eukaryotic target genes. The recent identification of intrinsic histone acetyltransferase (HAT) catalytic activity from a number of transcriptional co-activators (including yeast GCN5, p300/CBP, P/CAF, and TAFII250), has underscored the importance of protein acetylation in transcriptional control. The GCN5 family is the prototype for a diverse group of at least four distinct human HATs families. Although there is now a clear link between in vivo HAT catalytic activity and gene activation, little is known about the molecular mechanisms of histone acetylation. Herein, we report the first detailed biochemical study that probes the catalytic mechanism and the function of invariant glutamic acid 173 within the GCNB family of HATs, Our results suggest that the HAT reaction involves the formation of a ternary complex (histones, acetyl-CoA and enzyme) where the E-amino group of histone lysine residues directly attacks the bound acetyl-CoA, The acetylation reaction requires deprotonation of the E-amino group prior to nucleophilic attack. Employing site-directed mutagenesis, chemical modification, steady-state, and pH-dependent rate analysis, it is demonstrated that glutamic acid 173 is an essential catalytic residue, acting as a general base catalyst by deprotonating the histone substrate.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Oregon Health & Science University; University of Pennsylvania; The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Virginia	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Berger, Shelley/0000-0001-5398-4400	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R37GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jencks W. P., 1976, HDB BIOCH MOL BIOL, P305; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Segel IH, 1993, ENZYME KINETICS, P506; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; WIKTOROWICZ JE, 1982, J BIOL CHEM, V257, P2893; WIKTOROWICZ JE, 1981, BIOCHEMISTRY-US, V20, P1464, DOI 10.1021/bi00509a009; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	28	188	191	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18157	18160		10.1074/jbc.274.26.18157	http://dx.doi.org/10.1074/jbc.274.26.18157			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373413	hybrid			2022-12-27	WOS:000081056700005
J	Luo, X; Zeng, WZ; Xu, X; Popov, S; Davignon, I; Wilkie, TM; Mumby, SM; Muallem, S				Luo, X; Zeng, WZ; Xu, X; Popov, S; Davignon, I; Wilkie, TM; Mumby, SM; Muallem, S			Alternate coupling of receptors to G(s) and G(i) in pancreatic and submandibular gland cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ADENYLYL-CYCLASE; ACINAR-CELLS; BETA(2)-ADRENERGIC RECEPTOR; CALCIUM CHANNELS; CYCLIC-AMP; CA2+; BINDING; ANTIBODIES	Many G(s)-coupled receptors can activate both cAMP and Ca2+ signaling pathways. Three mechanisms for dual activation have been proposed. One is receptor coupling to both G(S) and G(15) (a G(q) class heterotrimeric G protein) to initiate independent signaling cascades that elevate intracellular levels of cAMP and Ca2+, respectively. The other two mechanisms involve cAMP-dependent protein kinase-mediated activation of phospholipase C beta either directly or by switching receptor coupling from G(S) to G(i). These mechanismswere primarily inferred from studies with transfected cell lines, In native cells we found that two G(S)-coupled receptors (the vasoactive intestinal peptide and beta-adrenergic receptors) in pancreatic acinar and submandibular gland duct cells, respectively, evoke a Ca2+ signal by a mechanism involving both G(S) and G(i). This inference was based on the inhibitory action of antibodies specific for Get,, Gari, and phosphatidylinositol 4,5-bisphosphate, pertussis toxin, RGS4, a fragment of beta-adrenergic receptor kinase and inhibitors of cAMP-dependent protein kinase. By contrast, Ca2+ signaling evoked by G(S)-coupled receptor agonists was not blocked by G(q) class-specific antibodies and was unaffected in G alpha(15) -/- knockout mice. We conclude that sequential activation of G(S) and G(i), mediated by caMP-dependent protein kinase, may represent a general mechanism in native cells for dual stimulation of signaling pathways by G(S)-coupled receptors.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5325 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047890, R01DK038939] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK47890, DK38939] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1984, J BIOL CHEM, V259, P9351; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DEHAYE JP, 1993, AM J PHYSIOL, V265, pC1356, DOI 10.1152/ajpcell.1993.265.5.C1356; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; XIAO RP, 1995, MOL PHARMACOL, V47, P322; XIN X, 1998, J BIOL CHEM, V273, P27275; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zhang Y, 1999, J BIOL CHEM, V274, P2851, DOI 10.1074/jbc.274.5.2851	41	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17684	17690		10.1074/jbc.274.25.17684	http://dx.doi.org/10.1074/jbc.274.25.17684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364208	hybrid			2022-12-27	WOS:000080974300044
J	Potsch, S; Lendzian, F; Ingemarson, R; Hornberg, A; Thelander, L; Lubitz, W; Lassmann, G; Graslund, A				Potsch, S; Lendzian, F; Ingemarson, R; Hornberg, A; Thelander, L; Lubitz, W; Lassmann, G; Graslund, A			The iron-oxygen reconstitution reaction in protein R2-tyr-177 mutants of mouse ribonucleotide reductase - EPR and electron nuclear double resonance studies on a new transient tryptophan radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SPIN-RESONANCE; 3-DIMENSIONAL STRUCTURE; ENDOR SPECTROSCOPY; R2; MECHANISM; COFACTOR; SITE; RESIDUES; SUBUNIT	The ferrous iron/oxygen reconstitution reaction in protein R2 of mouse and Escherichia coli ribonucleotide reductase (RNR) leads to the formation of a stable protein-linked tyrosyl radical and a mu-oxo-bridged diferric iron center, both necessary for enzyme activity. We have studied the reconstitution reaction in three protein R2 mutants Y177W, Y177F, and Y177C of mouse RNR to investigate if other residues at the site of the radical forming Tyr-177 can harbor free radicals. In Y177W we observed for the first time the formation of a tryptophan radical in protein R2 of mouse RNR with a Lifetime of several minutes at room temperature. We assign it to an oxidized neutral tryptophan radical on Trp-177, based on selective deuteration and EPR and electron nuclear double resonance spectroscopy in H2O and D2O solution. The reconstitution reaction at 22 degrees C in both Y177F and Y177C leads to the formation of a so-called intermediate X which has previously been assigned to an oxo (hydroxo)-bridged Fe(III)/Fe(IV) cluster. Surprisingly, in both mutants that do not have successor radicals as Trp' in Y177W, this cluster exists on a much longer time scale (several seconds) at room temperature than has been reported for X in E. coli Y122F or native mouse protein R2. All three mouse R2 mutants were enzymatically inactive, indicating that only a tyrosyl radical at position 177 has the capability to take part in the reduction of substrates.	Univ Stockholm, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden; Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10623 Berlin, Germany; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Stockholm University; Technical University of Berlin; Umea University	Graslund, A (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Biophys, S-10691 Stockholm, Sweden.							ABERG A, 1993, BIOCHEMISTRY-US, V26, P5541; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BAUGHER JF, 1977, J PHYS CHEM-US, V81, P1349, DOI 10.1021/j100529a002; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRUDVIG GW, 1995, METHOD ENZYMOL, V246, P536; Davydov A, 1996, BIOCHEM BIOPH RES CO, V219, P213, DOI 10.1006/bbrc.1996.0207; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; GESSNER C, 1997, THESIS TU BERLIN; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Katterle B, 1997, J BIOL CHEM, V272, P10414; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LUBITZ W, 1995, ADV PHOTOSYNTHESIS, V3, P255; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NELSON DJ, 1977, J CHEM SOC PERK T 2, P2005, DOI 10.1039/p29770002005; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; Persson AL, 1998, J BIOL CHEM, V273, P31016, DOI 10.1074/jbc.273.47.31016; PRUTZ WA, 1979, INT J RADIAT BIOL, V36, P513, DOI 10.1080/09553007914551301; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; Sjoberg BM, 1997, STRUCT BOND, V88, P139; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tong W, 1998, BIOCHEMISTRY-US, V37, P5840, DOI 10.1021/bi9728811; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Wertz J.E., 1986, ELECT SPIN RESONANCE; ZWEYGART W, 1994, J MAGN RESON SER A, V109, P172, DOI 10.1006/jmra.1994.1151	49	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17696	17704		10.1074/jbc.274.25.17696	http://dx.doi.org/10.1074/jbc.274.25.17696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364210	hybrid			2022-12-27	WOS:000080974300046
J	Nath, A; Conant, K; Chen, PQ; Scott, C; Major, EO				Nath, A; Conant, K; Chen, PQ; Scott, C; Major, EO			Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes - A hit and run phenomenon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; GENE-EXPRESSION; GLIAL-CELLS; T-CELLS; INDUCTION; DISEASE; INTERLEUKIN-6; DEMENTIA	The pathological correlates of dementia due to human immunodeficiency virus (HIV) infection are glial cell activation and cytokine dysregulation, These findings occur in the setting of small numbers of productively infected cells within the brain. We determined whether exposure of susceptible cells to Tat protein of HIV could result in the production of select proinflammatory cytokines. In a dose-responsive manner, Tat induced interleukin (IL)-1 beta production in monocytic cells, while astrocytic cells showed an increase in mRNA for IL-1 beta, but had a translation block for IL-1 beta protein production. Conversely, IL-6 protein and mRNA productions were strongly induced in astrocytic cells and minimally in monocytic cells. IL-IP and IL-6 production were independent of tumor necrosis factor-alpha production. An exposure to Tat for a few minutes was sufficient for sustained releases of cytokines for several hours. This prolonged cytokine production is likely maintained by a positive feed back loop of Tat-induced nuclear factor kappa B activation and cytokine production that is independent of extracellular calcium. Thus a transient exposure may be sufficient to initiate a cascade of events resulting in cerebral dysfunction and a "hit and run" approach may be in effect. Hence cross-sectional measurement of viral load in the brain may not be a useful indicator of the role of viral products in the neuropathogenesis of HIV dementia.	Univ Kentucky, Dept Neurol, Kentucky Clin, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Immunol, Lexington, KY 40536 USA; NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E OW3, Canada	University of Kentucky; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Manitoba	Nath, A (corresponding author), Univ Kentucky, Dept Neurol, Kentucky Clin, Rm L-445, Lexington, KY 40536 USA.							AKIRA S, 1992, IMMUNOL REV, V313, P47; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; DACUNHA A, 1993, BRAIN RES, V631, P39, DOI 10.1016/0006-8993(93)91183-S; DINARELLO CA, 1987, IMMUNOL LETT, V16, P227, DOI 10.1016/0165-2478(87)90151-9; Dollard SC, 1995, NEUROPATH APPL NEURO, V21, P518, DOI 10.1111/j.1365-2990.1995.tb01098.x; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FURER M, 1993, CELL ADHES COMMUN, V1, P223, DOI 10.3109/15419069309097256; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; Haughey N. J., 1998, Journal of Neurovirology, V4, P353; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; Hull M, 1996, NEUROBIOL AGING, V17, P795; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; Navia BA, 1998, NEUROLOGY, V51, P221, DOI 10.1212/WNL.51.1.221; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; NORRIS JG, 1994, J IMMUNOL, V152, P841; NUMEROF RP, 1990, CELL IMMUNOL, V130, P118, DOI 10.1016/0008-8749(90)90166-O; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POLI G, 1992, PATHOBIOLOGY, V60, P246, DOI 10.1159/000163729; RAUTONEN N, 1994, AIDS, V8, P1504, DOI 10.1097/00002030-199410000-00023; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; VITKOVIC L, 1991, AIDS RES HUM RETROV, V7, P723, DOI 10.1089/aid.1991.7.723; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wiley CA, 1996, AIDS, V10, P943; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	40	297	306	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17098	17102		10.1074/jbc.274.24.17098	http://dx.doi.org/10.1074/jbc.274.24.17098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358063	hybrid			2022-12-27	WOS:000080780400062
J	White, PC; Cordeiro, MC; Arnold, D; Brodelius, PE; Kay, J				White, PC; Cordeiro, MC; Arnold, D; Brodelius, PE; Kay, J			Processing, activity, and inhibition of recombinant cyprosin, an aspartic proteinase from cardoon (Cynara cardunculus)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-D; SUBSTRATE-SPECIFICITY; ARABIDOPSIS-THALIANA; DRUG DESIGN; PROTEASE; PURIFICATION; ACTIVATION; EXPRESSION; FLOWERS; GENES	The cDNA encoding the precursor of an aspartic proteinase from the flowers of the cardoon, Cynara cardunculus, was expressed in Pichia pastoris, and the recombinant, mature cyprosin that accumulated in the culture medium was purified and characterized. The resultant mixture of microheterogeneous forms was shown to consist of glycosylated heavy chains (34 or 32 kDa) plus associated light chains with molecular weights in the region of 14,000-18,000, resulting from excision of most, but not all, of the 104 residues contributed by the unique region known as the plant specific insert. SDS-polyacrylamide gel electrophoresis under non-reducing conditions indicated that disulfide bonding held the heavy and light chains together in the heterodimeric enzyme forms. In contrast, when a construct was expressed in which the nucleotides encoding the 104 residues of the plant specific insert were deleted, the inactive, unprocessed precursor form (procyprosin) accumulated, indicating that the plant-specific insert has a role in ensuring that the nascent polypeptide is folded properly and rendered capable of being activated to generate mature, active proteinase. Kinetic parameters were derived for the hydrolysis of a synthetic peptide substrate by wildtype, recombinant cyprosin at a variety of pH and temperature values and the subsite requirements of the enzyme were mapped using a systematic series of synthetic inhibitors. The significance is discussed of the susceptibility of cyprosin to inhibitors of human immunodeficiency virus proteinase and particularly of renin, some of which were found to have subnanomolar potencies against the plant enzyme.	Cardiff Univ, Sch Biosci, Cardiff CF1 3US, S Glam, Wales; Kalmar Univ, Dept Nat Sci, S-39129 Kalmar, Sweden; Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany	Cardiff University; Linnaeus University; University of Kalmar; Eberhard Karls University of Tubingen	Kay, J (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF1 3US, S Glam, Wales.	smbjk@cardiff.ac.uk						Arnold D, 1997, BIOL CHEM, V378, P883, DOI 10.1515/bchm.1997.378.8.883; ASAKURA T, 1995, EUR J BIOCHEM, V232, P77, DOI 10.1111/j.1432-1033.1995.tb20783.x; Asakura T, 1997, J AGR FOOD CHEM, V45, P1070, DOI 10.1021/jf960582x; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; Brodelius PE, 1998, ADV EXP MED BIOL, V436, P435; BUDT KH, 1995, BIOORGAN MED CHEM, V3, P559, DOI 10.1016/0968-0896(95)00069-S; CORDEIRO MC, 1994, PLANT MOL BIOL, V24, P733, DOI 10.1007/BF00029855; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; DHondt K, 1997, PLANT MOL BIOL, V33, P187, DOI 10.1023/A:1005794917200; DREYER T, 1985, BIOCHEM J, V231, P777, DOI 10.1042/bj2310777; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HEIMGARTNER U, 1990, PHYTOCHEMISTRY, V29, P1405, DOI 10.1016/0031-9422(90)80090-4; HILL J, 1993, FEBS LETT, V326, P101, DOI 10.1016/0014-5793(93)81770-Z; Hiraiwa N, 1997, EUR J BIOCHEM, V246, P133, DOI 10.1111/j.1432-1033.1997.00133.x; JUPP RA, 1990, BIOCHEM J, V265, P871, DOI 10.1042/bj2650871; KAY J, 1992, SCAND J CLIN LAB INV, V52, P23, DOI 10.3109/00365519209104651; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; Khan AR, 1998, PROTEIN SCI, V7, P815; Kreft S, 1997, PHYTOCHEMISTRY, V44, P1001, DOI 10.1016/S0031-9422(96)00668-1; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MONOD M, 1994, MOL MICROBIOL, V13, P357, DOI 10.1111/j.1365-2958.1994.tb00429.x; Mutlu A, 1998, PHYTOCHEMISTRY, V47, P1453, DOI 10.1016/S0031-9422(97)00834-0; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; Powell DJ, 1996, EUR J BIOCHEM, V241, P664, DOI 10.1111/j.1432-1033.1996.00664.x; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SARKKINEN P, 1992, PLANTA, V186, P317, DOI 10.1007/BF00195311; SCARBOROUGH PE, 1994, PROTEIN ENG, V7, P495, DOI 10.1093/protein/7.4.495; Schaller A, 1996, PLANT MOL BIOL, V31, P1073, DOI 10.1007/BF00040725; Tigue NJ, 1998, J BIOL CHEM, V273, P26441, DOI 10.1074/jbc.273.41.26441; Valler M J, 1985, J Enzyme Inhib, V1, P77, DOI 10.3109/14756368509031284; VandenHazel HB, 1997, BIOCHEM J, V326, P339, DOI 10.1042/bj3260339; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; WIKLUND A, 1992, BOT J LINN SOC, V109, P75, DOI 10.1111/j.1095-8339.1992.tb00260.x; Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249; YAMADA M, 1994, BBA-PROTEIN STRUCT M, V1206, P279, DOI 10.1016/0167-4838(94)90219-4	40	50	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16685	16693		10.1074/jbc.274.24.16685	http://dx.doi.org/10.1074/jbc.274.24.16685			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358007	hybrid			2022-12-27	WOS:000080780400006
J	Blanpain, C; Lee, B; Vakili, J; Doranz, BJ; Govaerts, C; Migeotte, I; Sharron, M; Dupriez, V; Vassart, G; Doms, RW; Parmentier, M				Blanpain, C; Lee, B; Vakili, J; Doranz, BJ; Govaerts, C; Migeotte, I; Sharron, M; Dupriez, V; Vassart, G; Doms, RW; Parmentier, M			Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-DIRECTED MUTAGENESIS; LINE-TROPIC HIV-1; RECEPTOR GENE; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; DIVERSE HUMAN; INFECTION; ENTRY	CCR5 is the major coreceptor for macrophage-tropic human immunodeficiency virus type I (HIV-1). For most G-protein-coupled receptors that have been tested so far, the disulfide bonds linking together the extracellular loops (ECL) are required for maintaining the structural integrity necessary for ligand binding and receptor activation, A natural mutation affecting Cys(20), which is thought to form a disulfide bond with Cys(269), has been described in various human populations, although the consequences of this mutation for CCR5 function are not known. Using site-directed mutagenesis, we mutated the four extracellular cysteines of CCR5 singly or in combination to investigate their role in maintaining the structural conformation of the receptor, its ligand binding and signal transduction properties, and its ability 60 function as a viral coreceptor. Alanine substitution of any single Cys residue reduced surface expression levels by 40-70%. However, mutation of Cys(101) or Cys(178), predicted to link ECL1 and ECL2 of the receptor, abolished recognition of CCR5 by a panel of conformation sensitive anti-CCR5 antibodies. The effects of the mutations on receptor expression and conformation were partially temperature-sensitive, with partial restoration of receptor expression and conformation achieved by incubating cells at 32 degrees C. All cysteine mutants were unable 60 bind detectable levels of MIP-1 beta, and did not respond functionally to CCR5 agonists. Surprisingly, all cysteine mutants did support infection by R5 strains of HIV, though at reduced levels. These results indicate that both disulfide bonds of CCR5 are necessary for maintaining the structural integrity of the receptor necessary for ligand binding and signaling. Env binding and the mechanisms of HIV entry appear much less sensitive to alterations of CCR5 conformation.	Free Univ Brussels, Inst Rech Interdisciplinaire, IRIBHN, B-1070 Brussels, Belgium; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Euroscreen, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania	Parmentier, M (corresponding author), Free Univ Brussels, Inst Rech Interdisciplinaire, IRIBHN, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709; Migeotte, Isabelle/0000-0002-8972-8211; Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [R01 AI40880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Carrington M, 1997, AM J HUM GENET, V61, P1261, DOI 10.1086/301645; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; FRASER CM, 1989, J BIOL CHEM, V264, P9266; Genoud S, 1999, J VIROL, V73, P1645, DOI 10.1128/JVI.73.2.1645-1648.1999; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; NODA K, 1994, J BIOL CHEM, V269, P6743; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	59	105	112	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18902	18908		10.1074/jbc.274.27.18902	http://dx.doi.org/10.1074/jbc.274.27.18902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383387	hybrid			2022-12-27	WOS:000081196300010
J	Blom, AM; Webb, J; Villoutreix, BO; Dahlback, B				Blom, AM; Webb, J; Villoutreix, BO; Dahlback, B			A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN C4-BINDING PROTEIN; HUMAN-COMPLEMENT SYSTEM; AMYLOID-P COMPONENT; HUMAN FACTOR-H; MOLECULAR-CLONING; REGULATORY COMPONENT; STREPTOCOCCUS-PYOGENES; CLASSICAL PATHWAY; C3B INACTIVATOR	C4b-binding protein (C4BP) is a regulator of the classical complement pathway, acting as a cofactor to factor I in the degradation of C4b. Computer modeling and structural analysis predicted a cluster of positively charged amino acids at the interface between complement control protein modules 1 and 2 of the C4BP cu-chain to be involved in C4b binding. Three C4BP mutants, R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q, were ex pressed and assayed for their ability to bind Gib and to function as factor I cofactors. The apparent affinities of R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q for immobilized Gib were 15-, 50-, and 140-fold lower, respectively, than that of recombinant wild type C4BP. The Gib binding site demonstrated herein was also found to be a specific heparin binding site. In C4b degradation, the mutants demonstrated decreased ability to serve as factor I cofactors. In particular, the R39Q/R64Q/R66Q mutant was inefficient as cofactor for cleavage of the Arg(937)-Thr(938) peptide bond in Gib. In contrast, the factor I mediated cleavage of Arg(1317)-Asn(1318) bond was less affected by the C4BP mutations. In conclusion, we identify a cluster of amino acids that is part of a C4b binding site involved in the regulation of the complement system.	Univ Lund, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				Accardo P, 1996, J IMMUNOL, V157, P4935; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blom AM, 1998, BBA-PROTEIN STRUCT M, V1388, P181, DOI 10.1016/S0167-4838(98)00178-2; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; BUDZKO DB, 1970, IMMUNOCHEMISTRY, V7, P227, DOI 10.1016/0019-2791(70)90158-8; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; CHUNG LP, 1985, BIOSCIENCE REP, V5, P855, DOI 10.1007/BF01119897; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DE FRUTOS PG, 1995, BBA-GENE STRUCT EXPR, V1261, P285, DOI 10.1016/0167-4781(95)00019-D; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1985, J IMMUNOL, V134, P3320; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GIGLI I, 1977, BIOCHEM J, V165, P439, DOI 10.1042/bj1650439; Hardig Y, 1997, BIOCHEM J, V323, P469; HARDIG Y, 1995, BIOCHEM J, V308, P795; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HESSING M, 1990, J IMMUNOL, V144, P204; HESSING M, 1990, FEBS LETT, V271, P131, DOI 10.1016/0014-5793(90)80389-Z; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; Hillarp A, 1997, J IMMUNOL, V158, P1315; HILLARP A, 1988, J BIOL CHEM, V263, P12759; HILLARP A, 1994, J IMMUNOL, V153, P4190; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; KUHN S, 1995, J IMMUNOL, V155, P5663; LAW SK, 1980, J IMMUNOL, V125, P634; Mackay D.H.J., 1989, PREDICTION PROTEIN S, P317; Makrides SC, 1998, PHARMACOL REV, V50, P59; MATSUGUCHI T, 1989, BIOCHEM BIOPH RES CO, V165, P138, DOI 10.1016/0006-291X(89)91045-0; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Mikata S, 1998, MOL IMMUNOL, V35, P537, DOI 10.1016/S0161-5890(98)00046-7; NAGASAWA S, 1982, J BIOCHEM-TOKYO, V92, P1329, DOI 10.1093/oxfordjournals.jbchem.a134052; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGATA RT, 1993, J IMMUNOL, V150, P2273; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PATRICK RA, 1970, IMMUNOCHEMISTRY, V7, P217, DOI 10.1016/0019-2791(70)90157-6; PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Prodinger WM, 1998, J IMMUNOL, V161, P4604; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHREIBER RD, 1974, J EXP MED, V140, P1324, DOI 10.1084/jem.140.5.1324; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEYA T, 1995, MOL IMMUNOL, V32, P355, DOI 10.1016/0161-5890(94)00157-V; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; THERN A, 1995, J IMMUNOL, V154, P375; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; Villoutreix BO, 1999, IMMUNOPHARMACOLOGY, V42, P121, DOI 10.1016/S0162-3109(99)00022-3; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; ZABERN I, 1982, J IMMUNOL, V128, P1433; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	61	97	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19237	19245		10.1074/jbc.274.27.19237	http://dx.doi.org/10.1074/jbc.274.27.19237			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383431	hybrid			2022-12-27	WOS:000081196300054
J	McVey, M; Hill, J; Howlett, A; Klein, C				McVey, M; Hill, J; Howlett, A; Klein, C			Adenylyl cyclase, a coincidence detector for nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; NEUROBLASTOMA-CELLS; INHIBITION; STIMULATION; CALMODULIN; ACTIVATION; DISCOIDEUM; DIVERSITY; BINDING; CGMP	Nitric oxide (NO) donors inhibit hormone- and forskolin-stimulated adenylyl cyclase activity in purified plasma membrane preparations from N18TG2 neuroblastoma cells. Northern blot analyses indicate that the predominant isoform of adenylyl cyclase in N18TG2 cells is the type VI. Our experiments eliminate all the known regulatory proteins for this isoform as possible targets of NO. NO decreases the V-max of the enzyme without altering the K-m for ATP. Occupancy of the substrate-binding site protects the enzyme from the inhibitory effects of NO, suggesting that the conformation of the enzyme determines its sensitivity. The inhibition is reversed by reducing agents, implicating a Cys residue(s) as the target for nitric oxide and an S-nitrosylation as the underlying modification. These findings implicate NO as a novel cellular regulator of the type VI isoform of adenylyl cyclase.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Klein, C (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	KleinC@slu.edu		Howlett, Allyn/0000-0002-2810-0164				BIDAUTRUSSELL M, 1987, NEUROCHEM INT, V11, P287, DOI 10.1016/0197-0186(87)90048-9; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HOWLETT AC, 1982, MOL PHARMACOL, V21, P664; IYENGAR R, 1981, J BIOL CHEM, V256, P1036; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MATSUZAWA H, 1975, P NATL ACAD SCI USA, V72, P3472, DOI 10.1073/pnas.72.9.3472; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SIEGEL LI, 1986, ANAL BIOCHEM, V159, P82, DOI 10.1016/0003-2697(86)90310-6; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Tao YP, 1998, J PHARMACOL EXP THER, V286, P298; TAO YP, 1992, FEBS LETT, V314, P49, DOI 10.1016/0014-5793(92)81459-Y; Tao YP, 1996, CELL SIGNAL, V8, P27, DOI 10.1016/0898-6568(95)02011-X; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALZ MA, 1987, J NEUROSCI RES, V17, P291, DOI 10.1002/jnr.490170314; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	30	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18887	18892		10.1074/jbc.274.27.18887	http://dx.doi.org/10.1074/jbc.274.27.18887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383385	hybrid			2022-12-27	WOS:000081196300008
J	Chen, Y; Schindler, M; Simon, SM				Chen, Y; Schindler, M; Simon, SM			A mechanism for tamoxifen-mediated inhibition of acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; DEFECTIVE ACIDIFICATION; PHOSPHOLIPID-VESICLES; CHLORIDE CHANNELS; LOCAL-ANESTHETICS; PROTON TRANSPORT; CYSTIC-FIBROSIS; RESISTANT CELLS; BONE-RESORPTION; H+-ATPASE	Tamoxifen has been reported to inhibit acidification of cytoplasmic organelles in mammalian cells. Here, the mechanism of this inhibition is investigated using in vitro assays on isolated organelles and liposomes. Tamoxifen inhibited ATP-dependent acidification in organelles from a variety of sources, including isolated microsomes from mammalian cells, vacuoles from Saccharomyces cerevisiae, and inverted membrane vesicles from Escherichia coli. Tamoxifen increased the ATPase activity of the vacuolar proton ATPase but decreased the membrane potential (V-m) generated by this proton pump, suggesting that tamoxifen may act by increasing proton permeability. In liposomes, tamoxifen increased the rate of pH dissipation. Studies comparing the effect of tamoxifen on pH gradients using different salt conditions and with other known ionophores suggest that tamoxifen affects transmembrane pH through two independent mechanisms. First, as a lipophilic weak base, it partitions into acidic vesicles, resulting in rapid neutralization. Second, it mediates coupled, electroneutral transport of proton or hydroxide with chloride. An understanding of the biochemical mechanism(s) for the effects of tamoxifen that are independent of the estrogen receptor could contribute to predicting side effects of tamoxifen and in designing screens to select for estrogen-receptor antagonists without these side effects.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Rockefeller University; Michigan State University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10021 USA.	simon@rockvax.rockefeller.edu		Simon, Sanford/0000-0002-8615-4224	NATIONAL CANCER INSTITUTE [R01CA081257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81257] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Altan N, 1999, P NATL ACAD SCI USA, V96, P4432, DOI 10.1073/pnas.96.8.4432; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BERMAN E, 1995, LEUKEMIA, V9, P1631; BERMAN E, 1991, BLOOD, V77, P818; BIWERSI J, 1994, ANAL BIOCHEM, V219, P139, DOI 10.1006/abio.1994.1242; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CALLAGHAN R, 1995, BRIT J CANCER, V71, P294, DOI 10.1038/bjc.1995.59; CHATTERJEE M, 1990, BRIT J CANCER, V62, P712, DOI 10.1038/bjc.1990.365; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; Goulian M, 1998, BIOPHYS J, V74, P328, DOI 10.1016/S0006-3495(98)77790-2; GREENBERG DA, 1987, CANCER RES, V47, P70; GRUNER SM, 1991, ANN NY ACAD SCI, V625, P685, DOI 10.1111/j.1749-6632.1991.tb33902.x; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; JORDAN VC, 1995, P SOC EXP BIOL MED, V208, P144; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; Kellen J. A., 1996, TAMOXIFEN ANTIESTROG; Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rostovtseva TK, 1998, BIOPHYS J, V75, P1783, DOI 10.1016/S0006-3495(98)77620-9; SATO K, 1977, TOHOKU J EXP MED, V123, P185, DOI 10.1620/tjem.123.185; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V599, P150, DOI 10.1016/0005-2736(80)90064-4; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; SEELIG A, 1988, BIOCHIM BIOPHYS ACTA, V939, P267, DOI 10.1016/0005-2736(88)90070-3; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Song JB, 1996, J PHARMACOL EXP THER, V277, P1444; SUN XC, 1992, J BIOL CHEM, V267, P19147; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Weinlander G, 1997, J CANCER RES CLIN, V123, P452, DOI 10.1007/BF01372550; Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488; Williams JP, 1997, J CELL BIOCHEM, V66, P358, DOI 10.1002/(SICI)1097-4644(19970901)66:3<358::AID-JCB8>3.3.CO;2-K; WISEMAN H, 1993, FEBS LETT, V330, P53, DOI 10.1016/0014-5793(93)80918-K; WISEMAN H, 1994, TRENDS PHARMACOL SCI, V15, P83, DOI 10.1016/0165-6147(94)90283-6; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	48	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18364	18373		10.1074/jbc.274.26.18364	http://dx.doi.org/10.1074/jbc.274.26.18364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373441	hybrid			2022-12-27	WOS:000081056700033
J	Dharmawardana, KR; Olson, ST; Bock, PE				Dharmawardana, KR; Olson, ST; Bock, PE			Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; PEPTIDE CHLOROMETHYL KETONES; MACROMOLECULAR SUBSTRATE RECOGNITION; AMINO-ACID SEQUENCE; CLOTTING FACTOR-V; ACTIVE-SITE; ALPHA-THROMBIN; FACTOR-XA; CATALYZED ACTIVATION; HEAVY-CHAIN	The blood coagulation proteinase, thrombin, converts factor V into factor Va through a multistep activation pathway that is regulated by interactions with thrombin exosites, Thrombin exosite interactions with human factor V and its activation products were quantitatively characterized in equilibrium binding studies based on fluorescence changes of thrombin covalently labeled with 2-anilinonaphthalene-6-sulfonic acid (ANS) linked to the catalytic site histidine residue by N-alpha-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl ([ANS]FPR-thrombin). Exosite I was shown to play a predominant role in the binding of factor V and factor Va from the effect of the exosite I-specific ligand, hirudin(54-65), on the interactions. Factor V and factor Va bound to exosite I of [ANS]FPR-thrombin with similar dissociation constants of 3.4 +/- 1.3 and 1.1 +/- 0.4 mu M and fluorescence enhancements of 182 +/- 41 and 127 +/- 17%, respectively. Native thrombin and labeled thrombin bound with similar affinity to factor Va. Among factor V activation products, the factor Va heavy chain was shown to contain the site of exosite I binding, whereas exosite I-independent, lower affinity interactions were observed for activation fragments E and C1, and no detectable binding was observed for the factor Va light chain. The results support the conclusion that the factor V activation pathway is initiated by exosite I-mediated binding of thrombin to a site in the heavy chain region of factor V that facilitates the initial cleavage at Arg(709) to generate the heavy chain of factor Va. The results further suggest that binding of thrombin through exosite I to factor V activation intermediates may regulate their conversion to factor Va and that similar binding of thrombin to the factor Va produced may reflect a mode of interaction involved in the regulation of prothrombin activation.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL039888, R37HL039888, R29HL038779, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02832, HL-38779, HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1998, THROMB HAEMOSTASIS, V79, P1157, DOI 10.1055/s-0037-1615033; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, V481, P297, DOI 10.1016/0005-2744(77)90264-9; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KANE WH, 1981, J BIOL CHEM, V256, P1002; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; MIHALYI E, 1968, J CHEM ENG DATA, V13, P179, DOI 10.1021/je60037a011; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	52	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18635	18643		10.1074/jbc.274.26.18635	http://dx.doi.org/10.1074/jbc.274.26.18635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373475	hybrid			2022-12-27	WOS:000081056700067
J	Enkemann, SA; Pavur, KS; Ryazanov, AG; Berger, SL				Enkemann, SA; Pavur, KS; Ryazanov, AG; Berger, SL			Does prothymosin alpha affect the phosphorylation of elongation factor 2?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; HL-60 CELLS; HISTONE H1; IN-VITRO; C-MYC; GENE; EXPRESSION; PROTEIN; PROLIFERATION; THYMOSIN-ALPHA-1	Prothymosin alpha is a small, acidic, essential nuclear protein that plays a poorly defined role in the proliferation and survival of mammalian cells. Recently, Vega et al. proposed that exogenous prothymosin alpha can specifically increase the phosphorylation of eukaryotic elongation factor 2 (eEF-2) in extracts of NIH3T3 cells (Vega, F. V., Vidal, A., Hellman, U., Wernstedt, C., and Dominguez, F. (1998) J. Biol. Chem. 273, 10147-10152). Using similar lysates prepared by four methods (detergent lysis, Dounce homogenization, digitonin permeabilization, and sonication) and three preparations of prothymosin alpha, one of which was purified by gentle means (the native protein, and a histidine-tagged recombinant prothymosin alpha expressed either in bacteria or in COS cells), we failed to find a response. A reconstituted system composed of eEF-2, recombinant eEF-2 kinase, calmodulin, and calcium was also unaffected by prothymosin alpha. However, unlike our optimized buffer, Vega's system included a phosphatase inhibitor, 50 mM fluoride, which when evaluated in our laboratories severely reduced phosphorylation of all species. Under these conditions, any procedure that decreases the effective fluoride concentration will relieve the inhibition and appear to activate. Our data do not support a direct relationship between the function of prothymosin a and the phosphorylation of eEF-2.	NCI, Sect Genes & Genes Prod, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, Dept Pharmacol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Med & Canc Inst, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Berger, SL (corresponding author), NCI, Sect Genes & Genes Prod, Natl Inst Hlth, Bldg 37,Rm 5D-10,37 Convent Dr, Bethesda, MD 20892 USA.	bergers@pop.nci.nih.gov	ryazanov, alexey/J-8081-2017					BARCIA MG, 1992, FEBS LETT, V312, P152, DOI 10.1016/0014-5793(92)80924-6; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CASTRO A, 1995, APPL OPTICS, V34, P3218, DOI 10.1364/AO.34.003218; CELIS JE, 1990, P NATL ACAD SCI USA, V87, P4231, DOI 10.1073/pnas.87.11.4231; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; CORDERO OJ, 1992, BIOCHEM INT, V28, P1117; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOSIL M, 1990, FEBS LETT, V269, P373, DOI 10.1016/0014-5793(90)81196-U; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FRILLINGOS S, 1991, MOL CELL BIOCHEM, V108, P85; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOLDEMBERG AL, 1973, BIOCHIM BIOPHYS ACTA, V291, P489, DOI 10.1016/0005-2736(73)90500-2; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1987, FEBS LETT, V218, P107, DOI 10.1016/0014-5793(87)81028-1; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1008, DOI 10.1073/pnas.81.4.1008; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; HARWOOD JP, 1973, J BIOL CHEM, V248, P4901; HELLUNGLARSEN P, 1969, BIOCHIM BIOPHYS ACTA, V190, P434, DOI 10.1016/0005-2787(69)90092-6; JOHNSON RA, 1973, J BIOL CHEM, V248, P5114; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MORI M, 1993, ONCOGENE, V8, P2821; NAIRN AC, 1996, TRANSLATIONAL CONTRO, P295; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Rodriguez P, 1998, BIOCHEM J, V331, P753, DOI 10.1042/bj3310753; ROSON E, 1993, HISTOCHEM J, V25, P497, DOI 10.1007/BF00159285; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; RYAZANOV AG, 1993, TRANSLATIONAL REGULA, V2, P433; Sburlati A R, 1990, Protein Expr Purif, V1, P184, DOI 10.1016/1046-5928(90)90014-P; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SMITH MR, 1993, BLOOD, V82, P1127; SZABO P, 1992, CLIN IMMUNOL IMMUNOP, V65, P195, DOI 10.1016/0090-1229(92)90146-F; Tao L, 1999, J CELL PHYSIOL, V178, P154, DOI 10.1002/(SICI)1097-4652(199902)178:2<154::AID-JCP4>3.0.CO;2-V; Trumbore MW, 1998, PROTEIN EXPRES PURIF, V13, P383, DOI 10.1006/prep.1998.0909; Trumbore MW, 1997, J BIOL CHEM, V272, P26394, DOI 10.1074/jbc.272.42.26394; Vega FV, 1998, J BIOL CHEM, V273, P10147, DOI 10.1074/jbc.273.17.10147; Wang RH, 1997, J BIOL CHEM, V272, P26405, DOI 10.1074/jbc.272.42.26405; Warburg O., 1942, BIOCHEM Z, V310, P384; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6	52	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18644	18650		10.1074/jbc.274.26.18644	http://dx.doi.org/10.1074/jbc.274.26.18644			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373476	hybrid			2022-12-27	WOS:000081056700068
J	Ramos, CHI				Ramos, CHI			Mapping subdomains in the C-terminal region of troponin I involved in its binding to troponin C and to thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SMALL-ANGLE SCATTERING; SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; PHOSPHORYLASE-KINASE; REGULATORY DOMAIN; CROSS-LINKING; CATALYTIC SUBUNIT; RABBIT	Troponin I (TnI) is the inhibitory component of troponin, the ternary complex that regulates skeletal and cardiac muscle contraction. Previous work showed that the C-terminal region of TnI, when linked to the "inhibitory region" (residues 98-116), possesses the major regulatory functions of the molecule (Farah, C. S., Miyamoto, C. A., Ramos, C. H. I., Silva, A. C. R., Quaggio, R. B., Fujimori, K., Smillie, L. B., and Reinach, F. C. (1994) J. Biol. Chem. 269, 5230-5240). To investigate these functions in more detail, serial deletion mutants of the C-terminal region of TnI were constructed. These experiments showed that longer C-terminal deletions result in lower inhibition of the actomyosin ATPase activity and weaken the interaction with the N-terminal domain of troponin C (TnC), consistent with the antiparallel model for the interaction between these two proteins. The conclusion is that the whole C-terminal region of TnI is necessary for its full regulatory activity. The region between residues 137 and 144, which was shown to have homology with residues 108-115 in the inhibitory region (Farah, C. S., and Reinach, F. C. (1995) FASEB J. 9, 755-767), is involved in the binding to TnC. The region between residues 98 and 129 is involved in modulating the affinity of TnC for calcium. The C-terminal residues 166-182 are involved in the binding of TnI to thin filament. A model for the function of TnI is discussed.	Ctr Biol Mol Estructural, Lab Nacl Luz Sincroton, BR-13083970 Campinas, SP, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil	Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade de Sao Paulo	Ramos, CHI (corresponding author), Ctr Biol Mol Estructural, Lab Nacl Luz Sincroton, CP 6192, BR-13083970 Campinas, SP, Brazil.		Ramos, CH/C-1571-2012	Ramos, CH/0000-0002-7246-9081				ALDELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEDMAN JR, 1977, J BIOL CHEM, V252, P2437; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEINOHEN JK, 1987, ANAL BIOCHEM, V113, P313; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KOBAYASHI T, 1995, BIOCHEMISTRY-US, V34, P10946, DOI 10.1021/bi00034a029; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEVIT S, 1976, J BIOL CHEM, V251, P1333; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; NGAI SM, 1992, J BIOL CHEM, V267, P15715; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PAUDEL HK, 1990, P NATL ACAD SCI USA, V87, P7285, DOI 10.1073/pnas.87.18.7285; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Stone DB, 1998, J MOL BIOL, V281, P689, DOI 10.1006/jmbi.1998.1965; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	53	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18189	18195		10.1074/jbc.274.26.18189	http://dx.doi.org/10.1074/jbc.274.26.18189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373418	hybrid			2022-12-27	WOS:000081056700010
J	Hendriks, J; Hoff, WD; Crielaard, W; Hellingwerf, KJ				Hendriks, J; Hoff, WD; Crielaard, W; Hellingwerf, KJ			Protonation deprotonation reactions triggered by photoactivation of photoactive yellow protein from Ectothiorhodospira halophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-COUMARIC ACID; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; PURPLE PHOTOTROPHIC BACTERIUM; PHOTOCYCLE INTERMEDIATE; ACTIVE-SITE; FLUORESCENCE; SPECTROSCOPY; DENATURATION; DEPENDENCE; RHODOPSIN	Light-dependent pH changes were measured in unbuffered solutions of wild type photoactive yellow protein (PYP) and its H108F and E46Q variants, using two independent techniques: transient absorption changes of added pH indicator dyes and direct readings with a combination pH electrode. Depending on the absolute pH of the sample, a reversible protonation as well as a deprotonation can be observed upon formation of the transient, blue-shifted photocycle intermediate (pB) of this photoreceptor protein. The latter is observed at very alkaline pH, the former at acidic pH values. At neutral pH, however, the formation of the pB state is not paralleled by significant protonation/deprotonation of PYP, as expected for concomitant protonation of the chromophore and deprotonation of Glu-46 during pB formation. We interpret these results as further evidence that a proton is transferred from Glu-46 to the coumaric acid chromophore of PYP, during pB formation. One cannot exclude the possibility, however, that this transfer proceeds through the bulk aqueous phase. Simultaneously, an amino acid side chain(s) (e.g. His108) changes from a buried to an exposed position. These results, therefore, further support the idea that PYP significantly unfolds in the pB state and resolve the controversy regarding proton transfer during the PYP photocycle.	Univ Amsterdam, Microbiol Lab, EC Slater Inst, Bioctr, NL-1018 WS Amsterdam, Netherlands	University of Amsterdam	Hellingwerf, KJ (corresponding author), Nieuwe Achtergracht 127, NL-1018 WS Amsterdam, Netherlands.	K.Hellingwerf@chem.uva.nl						BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BOOTH IR, 1985, MICROBIOL REV, V49, P359, DOI 10.1128/MMBR.49.4.359-378.1985; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Changenet P, 1998, CHEM PHYS LETT, V282, P276, DOI 10.1016/S0009-2614(97)01334-1; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hoff WD, 1996, BIOCHEMISTRY-US, V35, P1274, DOI 10.1021/bi951755z; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hoff WD, 1997, BBA-BIOENERGETICS, V1322, P151, DOI 10.1016/S0005-2728(97)00082-0; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; KRAAYENHOF R, 1982, ANAL BIOCHEM, V127, P93, DOI 10.1016/0003-2697(82)90149-X; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1993, ARCH BIOCHEM BIOPHYS, V306, P515, DOI 10.1006/abbi.1993.1545; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; MILLER A, 1993, BIOCHIM BIOPHYS ACTA, V1141, P190, DOI 10.1016/0005-2728(93)90042-E; OESTERHELT D, 1973, EUR J BIOCHEM, V37, P316, DOI 10.1111/j.1432-1033.1973.tb02990.x; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; RENTHAL R, 1977, BIOCHEM BIOPH RES CO, V77, P155, DOI 10.1016/S0006-291X(77)80177-0; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; XE A, 1996, BIOCHEMISTRY-US, V35, P14671	38	62	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17655	17660		10.1074/jbc.274.25.17655	http://dx.doi.org/10.1074/jbc.274.25.17655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364204	hybrid			2022-12-27	WOS:000080974300040
J	Layton, JE; Shimamoto, G; Osslund, T; Hammacher, A; Smith, DK; Treutlein, HR; Boone, T				Layton, JE; Shimamoto, G; Osslund, T; Hammacher, A; Smith, DK; Treutlein, HR; Boone, T			Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor - evidence that Glu(19) of G-CSF interacts with Arg(288) of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; GROWTH-HORMONE RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; HUMAN INTERLEUKIN-6; CONFORMATIONAL-CHANGES; SIGNAL TRANSDUCER; CRYSTAL-STRUCTURE; ALPHA-CHAIN; COMPLEX	Granulocyte colony-stimulating factor (G-CSF) forms a tetrameric complex with its receptor, comprising two G-CSF and two receptor molecules. The structure of the complex is unknown, and it is unclear whether there are one or two binding sites on G-CSF and the receptor. The immunoglobulin-like domain and the cytokine receptor homologous module of the receptor are involved in G-CSF binding, and Arg(288) in the cytokine receptor homologous module is particularly important. To identify residues in G-CSF that interact with Arg(288), selected charged residues in G-CSF were mutated to Ale. To clarify whether there are two binding sites, a chimeric receptor was created in which the Ig domain was replaced with that of the related receptor gp130, This chimera bound G-CSF but could not transduce a signal, consistent with failure of dimerization and loss of one binding site, The G-CSF mutants had reduced mitogenic activity on cells expressing wild-type receptor. When tested with the chimeric receptor, all G-CSF mutants except one (E46A) showed reduced binding, suggesting that Glu(46) is important for interaction with the Ig domain, On cells expressing R288A receptor, all the G-CSF mutants except E19A showed reduced mitogenic activity, indicating that Glu(19) of G-CSF interacts with Arg(288) of the receptor.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Amgen Inc, Thousand Oaks, CA 91320 USA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Amgen	Layton, JE (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, POB 2008, Parkville, Vic 3050, Australia.		Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Smith, David/0000-0003-3608-0586				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CAMPBELL IK, 1991, J IMMUNOL, V147, P1238; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1997, J BIOCHEM-TOKYO, V121, P370; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LAYTON JE, 1997, GROWTH FACTORS CYTOK, P557; Li TS, 1997, BIOCHEMISTRY-US, V36, P8849, DOI 10.1021/bi962713t; LOVEJOY B, 1993, J MOL BIOL, V234, P640, DOI 10.1006/jmbi.1993.1617; Mellado M, 1997, J BIOL CHEM, V272, P9189; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLA NA, 1990, COLONY STIMULATING F, P77; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Rowlinson SW, 1998, J BIOL CHEM, V273, P5307, DOI 10.1074/jbc.273.9.5307; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; WERNER JM, 1994, BIOCHEMISTRY-US, V33, P7184, DOI 10.1021/bi00189a022; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Young DC, 1997, PROTEIN SCI, V6, P1228, DOI 10.1002/pro.5560060611; ZINK T, 1994, BIOCHEMISTRY-US, V33, P8453, DOI 10.1021/bi00194a009; ZSEBO KM, 1986, IMMUNOBIOLOGY, V172, P175, DOI 10.1016/S0171-2985(86)80097-3	43	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17445	17451		10.1074/jbc.274.25.17445	http://dx.doi.org/10.1074/jbc.274.25.17445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364174	hybrid			2022-12-27	WOS:000080974300010
J	McCollum, D; Feoktistova, A; Gould, KL				McCollum, D; Feoktistova, A; Gould, KL			Phosphorylation of the myosin-II light chain does not regulate the timing of cytokinesis in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; HEAVY-CHAIN; CONTRACTILE RING; CULTURED-CELLS; GENE; DICTYOSTELIUM; EXPRESSION; IDENTIFICATION; LOCALIZATION; EFFICIENCY	Proper coordination of cytokinesis with chromosome separation during mitosis is crucial to ensure that each daughter cell inherits an equivalent set of chromosomes. It has been proposed that one mechanism by which this is achieved is through temporally regulated myosin regulatory light chain (RLC) phosphorylation (Satterwhite, L. L., and Pollard, T. D. (1992) Curr. Opin. Cell Biol, 4, 43-52), A variety of evidence is consistent with this model. A direct test of the importance of RLC phosphorylation in vivo has been done only in Dictyostelium and Drosophila; phosphorylation of the RLC is essential in Drosophila (Jordan, P., and Karess, R. (1997) J. Cell Biol, 139, 1805-1819) but not essential in Dictyostelium (Ostrow, B, D,, Chen, P,, and Chisholm, R, L, (1994) J, Cell Biol, 127, 1945-1955), The Schizosaccharomyces pombe myosin light chain Cdc4p is essential for cytokinesis, but it was unknown whether phosphorylation played a role in its regulation. Here we show that the S, pombe myosin light chain Cdc4p is phosphorylated in vivo on either serine 2 or 6 but not both. Mutation of either or both of these sites to alanine did not effect the ability of Cdc4p to bind the type II myosin Myo2p, and cells expressing only these mutated versions of Cdc4p grew and divided normally. Similarly, mutation of Ser-2, Ser-6, or both residues to aspartic acid did not affect growth or division of cells. Thus we conclude that phosphorylation of Cdc4p is not essential in vivo for the function of the protein.	Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Sch Med, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Gould, KL (corresponding author), Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	kathy.gould@mcmail.vanderbilt.edu		Gould, Kathleen/0000-0002-3810-4070	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016145] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16145] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1998, GENETICS, V149, P1265; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHEN TLL, 1995, J CELL SCI, V108, P3207; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HAMMER JA, 1994, J CELL BIOL, V127, P1779, DOI 10.1083/jcb.127.6.1779; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; Jordan P, 1997, J CELL BIOL, V139, P1805, DOI 10.1083/jcb.139.7.1805; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; MARKS J, 1985, EUR J CELL BIOL, V39, P27; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; May KM, 1997, CELL MOTIL CYTOSKEL, V38, P385, DOI 10.1002/(SICI)1097-0169(1997)38:4<385::AID-CM8>3.0.CO;2-2; May KM, 1998, CELL MOTIL CYTOSKEL, V39, P195, DOI 10.1002/(SICI)1097-0169(1998)39:3<195::AID-CM2>3.0.CO;2-4; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Motegi F, 1997, FEBS LETT, V420, P161, DOI 10.1016/S0014-5793(97)01510-X; Naqvi NI, 1999, EMBO J, V18, P854, DOI 10.1093/emboj/18.4.854; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17691	17695		10.1074/jbc.274.25.17691	http://dx.doi.org/10.1074/jbc.274.25.17691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364209	hybrid			2022-12-27	WOS:000080974300045
J	Sakurai, T; Moriguchi, T; Furuya, K; Kajiwara, N; Nakamura, T; Yanagisawa, M; Goto, K				Sakurai, T; Moriguchi, T; Furuya, K; Kajiwara, N; Nakamura, T; Yanagisawa, M; Goto, K			Structure and function of human prepro-orexin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATERAL HYPOTHALAMIC AREA; TRANSGENIC MICE; EXPRESSION; PEPTIDES; BEHAVIOR; PROTEIN; NEURONS	Orexin-A and -B are recently identified potent orexigenic peptides that are derived from the same precursor peptide and are highly specifically localized in neurons located in the lateral hypothalamic area, a region classically implicated in feeding behavior. We cloned the whole length of the human prepro-orexin gene and corresponding cDNA. The human prepro-orexin mRNA was predicted to encode a 131-residue precursor peptide (prepro-orexin). The human prepro-orexin gene consists of two exons and one intron distributed over 1432 base pairs. The 143-base pair first exon includes the 5'-untranslated region and a small part of the coding region that encodes the first seven residues of the secretory signal sequence. The second exon contains the remaining portion of the open reading frame and 3'-untranslated region. The 3.2 kilobase pairs of the 5'-upstream region from a cloned human prepro-orexin gene promoter is sufficient to direct the expression of the Escherichia coli beta-galactosidase (lacZ) gene in transgenic mice to neurons in the lateral hypothalamic area and adjacent regions. The lacZ-positive neurons were positively stained with anti-orexin antibody but not with anti-melanin-concentrating hormone antibody. These findings suggest that this genomic fragment contains all the necessary elements for appropriate expression of the gene and will be useful for the targeted expression of the exogenous gene in orexin-containing neurons. These mice might also be useful for examining the molecular mechanisms by which orexin gene expression is regulated.	Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Res Ctr, Tsukuba, Ibaraki 3058575, Japan; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Tsukuba; University of Tsukuba; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sakurai, T (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan.							[Anonymous], [No title captured]; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MACGOWEN R, 1989, GENE DEV, V3, P1669; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Peyron C, 1998, J NEUROSCI, V18, P9996; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	20	151	158	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17771	17776		10.1074/jbc.274.25.17771	http://dx.doi.org/10.1074/jbc.274.25.17771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364220	hybrid			2022-12-27	WOS:000080974300056
J	Yeh, SR; Rousseau, DL				Yeh, SR; Rousseau, DL			Ligand exchange during unfolding of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING KINETICS; CIRCULAR-DICHROISM; PATHWAYS; SPECTROSCOPY; NUCLEATION; LEVINTHAL; SECONDARY; EVENTS; STATE; VIEW	The productive folding pathway of cytochrome c passes through an obligatory HW intermediate in which the heme is coordinated by a solvent water molecule and a native ligand, His-18, prior to the formation of the folded HM state with both the native His-18 and Met-80 heme coordination. Two off pathway intermediates, a five-coordinated state (5C) and a bis-histidine state (HH), were also identified during the folding reaction, In the present work, the thermodynamics and the kinetics of the unfolding reaction of cytochrome c were investigated with resonance Raman scattering, tryptophan fluorescence spectroscopy, and circular dichroism, The objective of these experiments was to determine if the protein opens up and diverges into the differing heme ligation states through a many pathway mechanism or if it passes through intermediate states analogous to those observed during the folding reaction. Equilibrium unfolding results indicate that, in contrast to 5C, the stability of HH with respect to HW decreases as the concentration of GdnHCl increases. The difference in their response to the denaturant indicates that the polypeptide structure of 5C is relatively loose as compared with HH in which the polypeptide is misfolded. Time-resolved resonance Raman measurements show that strikingly similar ligand exchange reactions occur during unfolding as were observed during folding Combined with fluorescence data, a kinetic model is proposed in which local structural rearrangements controlled by heme ligand exchange reactions appear prior to the global relaxation of the polypeptide chain.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Yeh, SR (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	SYEH@AECOM.YU.EDU		Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54812, GM-54806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; Bhuyan AK, 1998, BIOCHEMISTRY-US, V37, P9147, DOI 10.1021/bi980470u; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; Colon W, 1997, BIOCHEMISTRY-US, V36, P12535, DOI 10.1021/bi971697c; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; Englander SW, 1998, ACCOUNTS CHEM RES, V31, P737, DOI 10.1021/ar970085h; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; JORDAN T, 1995, PROTEIN SCI, V4, P716; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Laurents DV, 1998, BIOPHYS J, V75, P428, DOI 10.1016/S0006-3495(98)77530-7; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ptitsyn OB, 1998, BIOCHEMISTRY-MOSCOW+, V63, P367; Shakhnovich EI, 1996, FOLD DES, V1, pR50, DOI 10.1016/S1359-0278(96)00027-2; Shakhnovich EI, 1998, FOLD DES, V3, pR108, DOI 10.1016/S1359-0278(98)00056-X; Shastry MCR, 1998, ACCOUNTS CHEM RES, V31, P717; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Sosnick TR, 1996, PROTEINS, V24, P413; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; Telford JR, 1998, ACCOUNTS CHEM RES, V31, P755, DOI 10.1021/ar970078t; TSONG TY, 1976, BIOCHEMISTRY-US, V15, P5467, DOI 10.1021/bi00670a007; VEERARAGHAVAN S, 1995, BIOCHEMISTRY-US, V34, P12892, DOI 10.1021/bi00039a052; Xu YJ, 1998, NAT STRUCT BIOL, V5, P774, DOI 10.1038/1810; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yeh SR, 1998, ACCOUNTS CHEM RES, V31, P727, DOI 10.1021/ar970084p; Yeh SR, 1998, NAT STRUCT BIOL, V5, P222, DOI 10.1038/nsb0398-222	36	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17853	17859		10.1074/jbc.274.25.17853	http://dx.doi.org/10.1074/jbc.274.25.17853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364230	hybrid			2022-12-27	WOS:000080974300066
J	Gao, J; Serrero, G				Gao, J; Serrero, G			Adipose differentiation related protein (ADRP) expressed in transfected COS-7 cells selectively stimulates long chain fatty acid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; RAT HEART MYOCYTES; BINDING-PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; OLEATE; TRANSPORT; METABOLISM; PERMEATION	Adipose differentiation related protein (ADRP) is a 50-kDa novel protein cloned from a mouse 1246 adipocyte cDNA library, rapidly induced during adipocyte differentiation. We have examined ADRP function, and we show here that ADRP facilitates fatty acid uptake in COS cells transfected with ADRP cDNA We demonstrate that uptake of long chain fatty acids was significantly stimulated in a time-dependent fashion in ADRP-expressing COS-7 cells compared with empty vector-transfected control cells. Oleic acid uptake velocity increased significantly in a dose-dependent manner in ADRP-expressing COS-7 cells compared with control cells. The transport K-m was 0.051 mu M, and V-max was 57.97 pmol/10(5) cells/min in ADRP-expressing cells, and K-m was 0.093 mu M and V-max was 20.13 pmol/10(5) cells/min in control cells. The oleate uptake measured at 4 degrees C was only 10% that at 37 degrees C, ADRP also stimulated uptake of palmitate and arachidonate but had no effect on uptake of medium chain fatty acid such as octanoic acid and glucose. These data suggest that ADRP specifically enhances uptake of long chain fatty acids by increasing the initial rate of uptake and provide novel information about ADRP function as a saturable transport component for long chain fatty acids.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Program Oncol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Serrero, G (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.				NIDDK NIH HHS [R01DK 51463] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051463] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AMRI EZ, 1994, J LIPID RES, V35, P930; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 1997, J LIPID RES, V38, P2249; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9731; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9739; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; FUJII S, 1987, LIPIDS, V22, P544, DOI 10.1007/BF02540374; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HEIMBERG M, 1978, P251; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; RUDNEY H, 1986, ANNU REV NUTR, V6, P245, DOI 10.1146/annurev.nu.06.070186.001333; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SPECTOR A A, 1978, P229; Spiegelman B M, 1986, Prog Clin Biol Res, V226, P445; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUMP DD, 1992, J HEPATOL, V16, P304, DOI 10.1016/S0168-8278(05)80661-0; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Ye H, 1998, BIOCHEM J, V330, P803, DOI 10.1042/bj3300803; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	35	189	195	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16825	16830		10.1074/jbc.274.24.16825	http://dx.doi.org/10.1074/jbc.274.24.16825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358026	hybrid			2022-12-27	WOS:000080780400025
J	Hermolin, J; Dmitriev, OY; Zhang, Y; Fillingame, RH				Hermolin, J; Dmitriev, OY; Zhang, Y; Fillingame, RH			Defining the domain of binding of F-1 subunit epsilon with the polar loop of F-0 subunit c in the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; ALPHA-SUBUNIT; CROSS-LINKING; PROTON TRANSLOCATION; ENERGY TRANSDUCTION; F0F1-ATP SYNTHASE; GAMMA-SUBUNIT; 2ND STALK; F-ATPASE; ROTATION	We have previously shown that the E31C-substituted epsilon subunit of F-1 can be cross-linked by disulfide bond formation to the Q42C-substituted c subunit of F-0 in the Escherichia coli F1F0-ATP synthase complex (Zhang, Y., and Fillingame, R. H. (1995) J. Biol. Chem. 270, 24609-24614). The interactions of subunits epsilon and c are thought to be central to the coupling of H+ transport through F-1 to ATP synthesis in F-1, To further define the domains of interaction, we have introduced additional Cys into subunit epsilon and subunit c and tested for cross-link formation following sulfhydryl oxidation, The results show that Cys, in a continuous stretch of residues 26-33 in subunit epsilon, can be cross-linked to Cys at positions 40, 42, and 44 in the polar loop region of subunit c. The results are interpreted, and the subunit interaction is modeled using the NMR and x-ray diffraction structures of the monomeric subunits together with information on the packing arrangement of subunit c in a ring of 12 subunits, In the model, residues 26-33 form a turn of antiparallel beta-sheet which packs between the polar loop regions of adjacent subunit c at the cytoplasmic surface of the c(12) oligomer.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.		Dmitriev, Oleg/AAB-7830-2019; Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1997, J EXP BIOL, V200, P217; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAROE DJ, 1992, J BACTERIOL, V174, P633, DOI 10.1128/jb.174.2.633-637.1992; Licher T, 1998, FEBS LETT, V431, P419, DOI 10.1016/S0014-5793(98)00807-2; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	53	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17011	17016		10.1074/jbc.274.24.17011	http://dx.doi.org/10.1074/jbc.274.24.17011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358051	hybrid			2022-12-27	WOS:000080780400050
J	Matskevitch, I; Wagner, CA; Stegen, C; Broer, S; Noll, B; Risler, T; Kwon, HM; Handler, JS; Waldegger, S; Busch, AE; Lang, F				Matskevitch, I; Wagner, CA; Stegen, C; Broer, S; Noll, B; Risler, T; Kwon, HM; Handler, JS; Waldegger, S; Busch, AE; Lang, F			Functional characterization of the betaine/gamma-aminobutyric acid transporter BGT-1 expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLUME REGULATORY MECHANISMS; BRAIN GABA TRANSPORTER; RAT-BRAIN; MOLECULAR-CLONING; MOUSE-BRAIN; CDNA; HETEROGENEITY; CHANNELS; CELLS	Betaine is an osmolyte accumulated in cells during osmotic cell shrinkage. The canine transporter mediating cellular accumulation of the osmolyte betaine and the neurotransmitter gamma-aminobutyric acid (BGT-1) was expressed in Xenopus oocytes and analyzed by two-electrode voltage clamp and tracer flux studies. Exposure of oocytes expressing BGT-1 to betaine or gamma-aminobutyric acid (GABA) depolarized the cell membrane in the current clamp mode and induced an inward current under voltage clamp conditions. At 1 mM substrate the induced currents decreased in the following order: betaine GABA > diaminobutyric acid = beta-alanine > proline quinidine > dimethylglycine > glycine > sarcosine. Both the V-max and K-m of GABA- and betaine-induced currents were voltage-dependent, and GABA- and betaine-induced currents and radioactive tracer uptake were strictly Na+-dependent but only partially dependent on the presence of Cl-. The apparent affinity of GABA decreased with decreasing Naf concentrations. The K-m of Na+ also depended on the GABA and Cl- concentration. A decrease of the Cl- concentration reduced the apparent affinity for Na+ and GABA, and a decrease of the Na+ concentration reduced the apparent affinity for Cl- and GABA. A comparison of Na-22(+)-, Cl-36(-)-, and C-14-labeled GABA and C-14-labeled betaine fluxes and GABA- and betaine-induced currents yielded a coupling ratio of Na+/Cl-/organic substrate of 3:1:1 or 3:2:1, Based on the data, a transport model of ordered binding is proposed in which GABA binds first, Na+ second, and Cl- third. In conclusion, BGT-1 displays significant functional differences from the other members of the GABA transporter family.	Univ Tubingen, Inst Physiol 1, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Biochem, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med, D-72076 Tubingen, Germany; Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD 21205 USA; IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Johns Hopkins University; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry	Lang, F (corresponding author), Univ Tubingen, Inst Physiol 1, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.		Lee-Kwon, Whaseon/D-6021-2011; Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634				BORDEN LA, 1992, J BIOL CHEM, V267, P21098; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; BORDEN LA, 1995, J NEUROCHEM, V64, P977; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; BURG MB, 1994, J EXP ZOOL, V268, P171, DOI 10.1002/jez.1402680216; Busch AE, 1996, J PHYSIOL-LONDON, V491, P735, DOI 10.1113/jphysiol.1996.sp021253; Cammack JN, 1996, P NATL ACAD SCI USA, V93, P723, DOI 10.1073/pnas.93.2.723; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KWON HM, 1992, J BIOL CHEM, V267, P6297; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Quick MW, 1997, J NEUROSCI, V17, P2967; RASOLA A, 1995, FEBS LETT, V373, P229, DOI 10.1016/0014-5793(95)01052-G; Risso S, 1996, J PHYSIOL-LONDON, V490, P691, DOI 10.1113/jphysiol.1996.sp021178; SMITH KE, 1992, MOL PHARMACOL, V42, P563; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	28	57	60	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16709	16716		10.1074/jbc.274.24.16709	http://dx.doi.org/10.1074/jbc.274.24.16709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358010	hybrid			2022-12-27	WOS:000080780400009
J	Bird, TH; Du, SY; Bauer, CE				Bird, TH; Du, SY; Bauer, CE			Autophosphorylation, phosphotransfer, and DNA-binding properties of the RegB RegA two-component regulatory system in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; SIGNAL-TRANSDUCTION SYSTEM; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATOR; RESPONSE REGULATORS; BACILLUS-SUBTILIS; OXYGEN REGULATION; PHOSPHORYLATION; DOMAIN; PROTEINS	In the purple, photosynthetic bacterium, Rhodobacter capsulatus, the RegB/RegA two-component system is required for activation of several anaerobic processes, such as synthesis of the photosynthetic apparatus and assimilation of CO2 and N-2. It is believed that RegB is an integral membrane histidine kinase that monitors the external environment. Under anaerobic growth conditions, it transduces a signal through phosphorylation of the response regulator, RegA, which then induces target gene expression. We used an in vitro assay to characterize the phosphorylation of wild-type RegA and a mutant variant (RegA*) that is responsible for abnormally high photosynthesis gene expression under both aerobic and anaerobic growth conditions. Phosphorylation assays indicate that phosphorylated RegA* (RegA*similar to P) is much more stable than RegA similar to P, indicating that it may be locked in a conformation that is resistant to dephosphorylation, DNase I footprint assays also indicate that unphosphorylated RegA* has a much higher affinity for specific DNA binding sites than the wild-type protein. Phosphorylation of RegA* increases DNA binding 2,5-fold, whereas phosphorylation of RegA increases DNA binding more than 16-fold. Collectively, these results support the hypothesis that RegA* is a constitutively active variant that does not require phosphorylation to assume a structural conformation required to bind DNA.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.				NIGMS NIH HHS [GM40941, GM00618, R01 GM040941, R37 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, K04GM000618, R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILALOV I, 1996, BIOCHEMISTRY-US, V35, P11053; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; Elsen S, 1998, J BIOL CHEM, V273, P30762, DOI 10.1074/jbc.273.46.30762; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MAKINO K, 1994, PHOSPHATE MICROORGAN; MASUDA S, 1998, IN PRESS P 11 INT C; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STUDIER RW, 1990, METHOD ENZYMOL, V53, P450; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; Tiwari RP, 1996, MICROBIOL-UK, V142, P1693, DOI 10.1099/13500872-142-7-1693; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEGLENSKI P, 1989, J BACTERIOL, V264, P4479; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	37	55	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16343	16348		10.1074/jbc.274.23.16343	http://dx.doi.org/10.1074/jbc.274.23.16343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347192	hybrid			2022-12-27	WOS:000080668600052
J	Deacon, K; Blank, JL				Deacon, K; Blank, JL			MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; PROTEIN-KINASE; MAP KINASE; MOLECULAR-CLONING; DIFFERENTIAL ACTIVATION; SELECTIVE ACTIVATION; CELLULAR STRESSES; JNK; PHOSPHORYLATION	Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase kinase 3 (MEKK3) activates the c-Jun NH2-terminal kinase (JNK) pathway, although no substrates for MEKK3 have been identified. We have examined the regulation by MEKK3 of MAPK kinase 7 (MKK7) and MKK6, two novel MAPK kinases specific for JNK and p38, respectively. Coexpression of MKK7 with MEKK3 in COS-7 cells enhanced MKK7 autophosphorylation and its ability to activate recombinant JNK1 in vitro. MKK6 autophosphorylation and in vitro activation of p38 alpha were also observed following coexpression of MKK6 with MEKK3. MEKK2, a closely related homologue of MEKK3, also activated MKK7 and MKK6 in COS-7 cells. Importantly, immunoprecipitates of either MEKK3 or MEKK2 directly activated recombinant MKK7 and MKK6 in vitro. These data identify MEKK3 as a MAPK kinase kinase specific for MKK7 and MKK6 in the JNK and p38 pathways. We have also examined whether MEKK3 or MEKK2 activates p38 in intact cells using MAPK-activated protein kinase-2 (MAPKAPK2) as an affinity ligand and substrate. Anisomycin, sorbitol, or the expression of MEKK3 in HEK293 cells enhanced MAPKAPK2 phosphorylation, whereas MEKK2 was less effective. Furthermore, MAPKAPK2 phosphorylation induced by MEKK3 or cellular stress was abolished by the p38 inhibitor SB-203580, suggesting that MEKK3 is coupled to p38 activation in intact cells.	Univ Leicester, Sch Med, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Blank, JL (corresponding author), Univ Leicester, Sch Med, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DUAM G, 1994, TRENDS BIOCHEM SCI, V19, P474; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GAUN Z, 1998, J BIOL CHEM, V273, P28670; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu X, 1996, ONCOGENE, V13, P135; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	62	78	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16604	16610		10.1074/jbc.274.23.16604	http://dx.doi.org/10.1074/jbc.274.23.16604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347227	hybrid			2022-12-27	WOS:000080668600087
J	Deshpande, T; Takagi, T; Hao, LN; Buratowski, S; Charbonneau, H				Deshpande, T; Takagi, T; Hao, LN; Buratowski, S; Charbonneau, H			Human PIR1 of the protein-tyrosine phosphatase superfamily has RNA 5 '-triphosphatase and diphosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; CAPPING ENZYME BINDS; MESSENGER-RNA; NUCLEOSIDE TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR; TERMINAL DOMAIN; LEF-4 SUBUNIT; POLYMERASE-II; BACULOVIRUS	A human cDNA was isolated encoding a protein with significant sequence similarity (41% identity) to the BVP RNA 5'-phosphatase from the Autographa californica nuclear polyhedrosis virus. This protein is a member of the protein-tyrosine phosphatase (PTP) superfamily and is identical to PIR1, shown by Yuan et al. (Yuan, Y., Da-Ming, L., and Sun, H. (1998) J. Biol. Chem. 272, 20347-20353) to be a nuclear protein that can associate with RNA or ribonucleoprotein complexes, We demonstrate that PIR1 removes two phosphates from the 5'-triphosphate end of RNA, but not from mononucleotide triphosphates, The specific activity of PIR1 with RNA is several orders of magnitude greater than that with the best protein substrates examined, suggesting that RNA is its physiological substrate. A 120-amino acid segment C-terminal to the PTP domain is not required for RNA phosphatase activity. We propose that PIR1 and its closest homologs, which include the metazoan mRNA capping enzymes, constitute a subgroup of the PTP family that use RNA as a substrate.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Charbonneau, H (corresponding author), Purdue Univ, Dept Biochem, 1153 Biochem, W Lafayette, IN 47907 USA.	charb@biochem.purdue.edu			NATIONAL CANCER INSTITUTE [R01CA059935, R29CA059935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM G, 1975, CELL, V5, P51, DOI 10.1016/0092-8674(75)90091-4; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Guarino LA, 1998, J VIROL, V72, P10003, DOI 10.1128/JVI.72.12.10003-10010.1998; GUPTA KC, 1980, J VIROL, V33, P292, DOI 10.1128/JVI.33.1.292-303.1980; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; ITOH N, 1984, J BIOL CHEM, V259, P3930; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; KIM D, 1993, VIROLOGY, V195, P587, DOI 10.1006/viro.1993.1410; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; Shuman S, 1997, VIROLOGY, V227, P1, DOI 10.1006/viro.1996.8305; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; TONKS NK, 1988, J BIOL CHEM, V263, P6731; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yuan Y, 1998, J BIOL CHEM, V273, P20347, DOI 10.1074/jbc.273.32.20347; YUE Z, 1997, P NATL ACAD SCI USA, V94, P12758	39	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16590	16594		10.1074/jbc.274.23.16590	http://dx.doi.org/10.1074/jbc.274.23.16590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347225	hybrid			2022-12-27	WOS:000080668600085
J	Takasuga, S; Katada, T; Ui, M; Hazeki, O				Takasuga, S; Katada, T; Ui, M; Hazeki, O			Enhancement by adenosine of insulin-induced activation of phosphoinositide 3-kinase and protein kinase B in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; POTENTIAL ROLE; ADIPOSE-CELLS; CYCLIC-AMP; SENSITIVITY; SUFFICIENT	The role of adenosine receptor in regulation of insulin-induced activation of phosphoinositide S-kinase (PI 3-kinase) and protein kinase B was studied in isolated rat adipocytes. Rat adipocytes are known to spontaneously release adenosine, which in turn binds and stimulates the adenosine A, receptors on the cells. In the present study, we observed that degradation of this adenosine by adenosine deaminase attenuated markedly the insulin-induced accumulation of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), a product of PI 3-kinase. p-Aminophenylacetyl xanthine amine congener (PAPA-XAC), an inhibitor of the adenosine A(1) receptor, also inhibited the insulin-induced PtdIns(3,4,5)P-3 accumulation, When extracellular adenosine was inactivated by adenosine deaminase, phenylisopropyladenosine, an adenosine A(1) receptor agonist, potentiated the insulin-induced accumulation of PtdIns(3,4,5)P-3, Insulin-induced activation of protein kinase B, the activity of which is controlled by the lipid products of PI 3-kinase, was also potentiated by adenosine. Prostaglandin E-2, another activator of a pertussis toxin-sensitive GTP-binding protein in these cells, potentiated the insulin actions. Thus, the receptors coupling to the GTP-binding protein were found to positively regulate the production of PtdIns(3,4,5)P-3, a putative second messenger for insulin actions, in physiological target cells of insulin.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Dept Physiol Chem,Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan	Hiroshima University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Hazeki, O (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Dept Physiol Chem,Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GAWLER D, 1987, NATURE, V327, P224; GREEN A, 1987, J BIOL CHEM, V262, P15702; GREEN A, 1979, BIOCHEM J, V180, P365, DOI 10.1042/bj1800365; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; HONNOR RC, 1992, CELL SIGNAL, V4, P87, DOI 10.1016/0898-6568(92)90010-6; JOOST HG, 1982, MOL PHARMACOL, V22, P614; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KURODA M, 1987, J BIOL CHEM, V262, P245; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LANOUE KF, 1994, FASEB J, V8, P72, DOI 10.1096/fasebj.8.1.8299893; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOXAM CM, 1996, NATURE, V379, P840; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1977, BIOCHEM BIOPH RES CO, V75, P271, DOI 10.1016/0006-291X(77)91039-7; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520	29	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19545	19550		10.1074/jbc.274.28.19545	http://dx.doi.org/10.1074/jbc.274.28.19545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391887	hybrid			2022-12-27	WOS:000081377300007
J	Ahlgren, R; Suske, G; Waterman, MR; Lund, J				Ahlgren, R; Suske, G; Waterman, MR; Lund, J			Role of Sp1 in cAMP-dependent transcriptional regulation of the bovine CYP11A gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; ACTIVATION DOMAINS; PROMOTER ACTIVITY; RESPONSE ELEMENT; GRANULOSA-CELLS; P-450SCC GENE; LUTEAL CELLS; EXPRESSION	The pituitary peptide hormone ACTH regulates transcription of the cholesterol side chain cleavage cytochrome P450 (CYP11A) gene via cAMP and activation of cAMP-dependent protein kinase. A G-rich sequence element conferring cAMP-dependent regulation has been found to reside within region -118 to -100 of the bovine CYP11A promoter. Previous studies have suggested that it binds a protein antigenically related to the transcription factor Sp1. We now report that the -118/-100 element binds both Sp1 and Sp3, members of the Sp family of transcription factors. me have made use of Drosophila SL2 cells, which lack endogenous Sp factors, to dissect the possible functional roles of Sp1, Sp3, and Sp4. All factors stimulated the activity of cotransfected reporter constructs in which the promoter of the bovine CYP11A gene regulates luciferase expression. Sp3 did not repress Sp1-dependent activation, as has previously been shown for other G-rich promoters. Mutation of the -118/-100 element of CYP11A abolished Sp1-mediated activation of a CYP11A reporter gene in SL2 cells as well as cAMP responsiveness in human H295R cells. Furthermore, cotransfection of SL2 cells with the catalytic subunit of cAMP-dependent protein kinase together with Sp1 and a CYP11A reporter construct enhanced Sp1-dependent activation of the reporter 4.2-fold, demonstrating that Sp1 confers cAMP responsiveness in these cells. Thus, we show that introduction of Sp1 alone in an Sp-negative cell such as SL2 is sufficient to achieve the cAMP-dependent regulation observed using the -118/ -100 element of CYP11A in adrenocortical cells.	Univ Bergen, Sch Med, Dept Anat & Cell Biol, N-5009 Bergen, Norway; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	University of Bergen; Philipps University Marburg; Vanderbilt University	Lund, J (corresponding author), Univ Bergen, Sch Med, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.			Suske, Guntram/0000-0002-4807-0513	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; Grimaldi P, 1996, MOL CELL ENDOCRINOL, V117, P167, DOI 10.1016/0303-7207(95)03744-6; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jacob AL, 1998, J BIOL CHEM, V273, P13391, DOI 10.1074/jbc.273.22.13391; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KAGAWA N, 1992, J BIOL CHEM, V267, P25213; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUND J, 1990, J BIOL CHEM, V265, P3304; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; OONK RB, 1990, J BIOL CHEM, V265, P22392; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RICE DA, 1990, J BIOL CHEM, V265, P11713; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	50	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19422	19428		10.1074/jbc.274.27.19422	http://dx.doi.org/10.1074/jbc.274.27.19422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383457	hybrid			2022-12-27	WOS:000081196300080
J	Rouard, M; Bass, J; Grigorescu, F; Garrett, TPJ; Ward, CW; Lipkind, G; Jaffiole, C; Steiner, DF; Bell, GI				Rouard, M; Bass, J; Grigorescu, F; Garrett, TPJ; Ward, CW; Lipkind, G; Jaffiole, C; Steiner, DF; Bell, GI			Congenital insulin resistance associated with a conformational alteration in a conserved beta-sheet in the insulin receptor L1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; LIGAND-BINDING DOMAIN; FACTOR-I RECEPTOR; FIRST 3 DOMAINS; GROWTH-FACTOR; ALPHA-SUBUNIT; CROSS-LINKING; IDENTIFICATION; DETERMINANTS; SPECIFICITY	The hormone binding site of members of the insulin receptor family is contained within a highly conserved extracellular region of the receptor. Recent crystallization of the N-terminal region of the binding site revealed two large domains (L1, L2), each organized as a single-stranded right-handed beta-helix, connected by a rod-shaped cysteine-rich domain. Here, we analyze two new naturally occurring mutations in a single p-sheet within L1, D59G and L62P, that we previously identified in a young woman with classic congenital insulin resistance (type A). Substitution of D59G, a beta-sheet connecting loop residue, caused decreased hormone binding but did not disrupt overall folding, assembly, or movement to the cell surface. In contrast, replacement of the adjacent residue L62P, which is located within the beta-sheet, and positioned in a hormone binding surface, completely disrupted intracellular folding, oligomerization, and trafficking and resulted in aberrant proteolytic degradation. Immunohistochemistry in combination with biosynthetic studies showed that misfolded receptors were retained in an incorrect cellular location and that they colocalized with the resident endoplasmic reticulum chaperone calnexin, This study, together with other mutagenesis data, shows that formation of beta-sheet elements within the L1 beta-helix are critical for the folding of the entire extracellular domain of the receptor and that the hormone contact site is composed in part by residues in this domain.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Inst Univ Rech, Mol Endocrinol Lab, F-34093 Montpellier, France; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Bass, J (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.		Grigorescu, Florin/Q-3728-2019; GRIGORESCU, FLORIN/C-2238-2013	Grigorescu, Florin/0000-0002-3095-5639; GRIGORESCU, FLORIN/0000-0002-3095-5639				ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P110; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; KRAULIS P, 1991, J APP CRYST A, V47, P110; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; KUROSE T, 1994, J BIOL CHEM, V269, P29190; McKern NM, 1997, PROTEIN SCI, V6, P2663; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; OLSON TS, 1988, J BIOL CHEM, V263, P7342; Rouard M, 1997, BIOCHEM BIOPH RES CO, V234, P764, DOI 10.1006/bbrc.1997.6695; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR S, 1994, ENDOCR REV, V2, P58; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WERTHEIMER E, 1994, J BIOL CHEM, V269, P7587; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	27	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18487	18491		10.1074/jbc.274.26.18487	http://dx.doi.org/10.1074/jbc.274.26.18487			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373457	hybrid			2022-12-27	WOS:000081056700049
J	Chaudhuri, J; Chowdhury, D; Maitra, U				Chaudhuri, J; Chowdhury, D; Maitra, U			Distinct functions of eukaryotic translation initiation factors eIF1A and eIF3 in the formation of the 40 S ribosomal preinitiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; RABBIT RETICULOCYTES; DISSOCIATION FACTOR; MOLECULAR-CLONING; CALF LIVER; FACTOR-III; PURIFICATION; SUBUNIT; ASSOCIATION; MECHANISM	We have used an in vitro translation initiation assay to investigate the requirements for the efficient transfer of Met-tRNA(f) (as Met-tRNA(f).eIF2.GTP ternary complex) to 40 S ribosomal subunits in the absence of mRNA (or an AUG codon) to form the 40 S preinitiation complex. We observed that the 17-kDa initiation factor eIF1A is necessary and sufficient to mediate nearly quantitative transfer of Met-tRNA(f) to isolated 40 S ribosomal subunits. However, the addition of 60 S ribosomal subunits to the 40 S preinitiation complex formed under these conditions disrupted the 40 S complex resulting in dissociation of Met-tRNA(f) from the 40 S subunit. When the eIF1A-dependent preinitiation reaction was carried out with 40 S ribosomal subunits that had been preincubated with eIF3, the 40 S preinitiation complex formed included bound eIF3 (40 S.eIF3.Met-tRNA(f).eIF2.GTP). In contrast to the complex lacking eIF3, this complex was not disrupted by the addition of 60 S ribosomal subunits, These results suggest that in vivo, both eIF1A and eIF3 are required to form a stable 40 S preinitiation complex, eIF1A catalyzing the transfer of Met-tRNA(f).eIF2.GTP to 40 S subunits, and eIF3 stabilizing the resulting complex and preventing its disruption by 60 IS ribosomal subunits.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; RAYCHAUDHURI P, 1986, J BIOL CHEM, V261, P7723; RUSSELL DW, 1979, J BIOL CHEM, V254, P8796; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; SMITH KE, 1975, J BIOL CHEM, V250, P6880; SRIVASTAVA S, 1992, J MOL BIOL, V226, P301, DOI 10.1016/0022-2836(92)90946-H; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712	27	78	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17975	17980		10.1074/jbc.274.25.17975	http://dx.doi.org/10.1074/jbc.274.25.17975			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364246	hybrid			2022-12-27	WOS:000080974300082
J	Inoue, T; Nishio, N; Suzuki, S; Kataoka, K; Kohzuma, T; Kai, Y				Inoue, T; Nishio, N; Suzuki, S; Kataoka, K; Kohzuma, T; Kai, Y			Crystal structure determinations of oxidized and reduced pseudoazurins from Achromobacter cycloclastes - Concerted movement of copper site in redox forms with the rearrangement of hydrogen bond at a remote histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS S-6; AMINO-ACID-SEQUENCE; NITRITE REDUCTASE; X-RAY; THIOSPHAERA-PANTOTROPHA; PH VALUES; PROTEIN; REFINEMENT; RESOLUTION; AMICYANIN	The crystal structures of oxidized and reduced pseudoazurins from a denitrifying bacterium, Achromobacter cycloclastes IAM1013, have been determined at 1.35- and 1.6-Angstrom resolutions, respectively. The copper site in the oxidized state exhibits a distorted tetrahedral structure like those of other pseudoazurins. However, not only a small change of the copper geometry, but concerted peptide bond flips are identified. The imidazole ring of remote His(6) has a hydrogen bonding distance of 2.73 Angstrom between N-delta 1(His(6)) and O-gamma 1(Thr(36)) in the oxidized protein. When the protein is reduced at pH 6.0, the imidazole ring rotates by 30.3 degrees and moves 1.00 Angstrom away from the position of the oxidized state. A new hydrogen bond between N-epsilon 2(His(6)) and O-epsilon 1(Glu(4)) is formed with a distance of 3.03 Angstrom, while the hydrogen bond between N-delta 1(His(6))-O-gamma 1(Thr(36)) is maintained with an interatomic distance of 2.81 Angstrom. A concomitant peptide bond flip of main chain between Ile(34) and Thr(36) occurs.	Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Ibaraki Univ, Fac Sci, Dept Chem, Ibaraki 3108512, Japan	Osaka University; Osaka University; Ibaraki University	Kai, Y (corresponding author), Osaka Univ, Grad Sch Engn, Dept Chem Mat, Osaka 5650871, Japan.		Kohzuma, Takamitsu/U-2966-2019; KATAOKA, Kunishige/J-8457-2015					Adman E., 1985, METALLOPROTEINS, V1, P1; ADMAN ET, 1989, J BIOL CHEM, V264, P87; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; AMBLER RP, 1985, BIOCHEM J, V232, P451, DOI 10.1042/bj2320451; AMBLER RP, 1997, EVOLUTION METALLOENZ, P100; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAN C, 1995, BIOCHEM J, V308, P585, DOI 10.1042/bj3080585; Chen JY, 1996, BIOCHEM BIOPH RES CO, V219, P423, DOI 10.1006/bbrc.1996.0249; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DENNISON C, 1994, J CHEM SOC DALTON, P437, DOI 10.1039/dt9940000437; DENNISON C, 1994, J CHEM SOC CHEM COMM, P581, DOI 10.1039/c39940000581; DENNISON C, 1994, INORG CHEM, V33, P3299, DOI 10.1021/ic00093a017; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HORMEL S, 1986, FEBS LETT, V197, P301, DOI 10.1016/0014-5793(86)80346-5; INOUE T, 1994, ACTA CRYSTALLOGR D, V50, P317, DOI 10.1107/S0907444994000260; INOUE T, 1993, J BIOCHEM-TOKYO, V114, P761, DOI 10.1093/oxfordjournals.jbchem.a124251; IWASAKI H, 1973, J BIOCHEM, V73, P659, DOI 10.1093/oxfordjournals.jbchem.a130125; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; Kohzuma T, 1997, J ELECTROANAL CHEM, V438, P49, DOI 10.1016/S0022-0728(97)00056-9; KOHZUMA T, 1993, CHEM LETT, P149, DOI 10.1246/cl.1993.149; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1995, PROTEIN ENG, V8, P153, DOI 10.1093/protein/8.2.153; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Libeu CAP, 1997, BIOCHEMISTRY-US, V36, P13160, DOI 10.1021/bi9704111; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETRATOS K, 1988, ACTA CRYSTALLOGR B, V44, P628, DOI 10.1107/S0108768188008912; PETRATOS K, 1987, FEBS LETT, V218, P209, DOI 10.1016/0014-5793(87)81048-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SYKES AG, 1993, BIOINORGANIC CHEM CO, V1, P78; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; VAKOUFARI E, 1994, FEBS LETT, V347, P203, DOI 10.1016/0014-5793(94)00544-3; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975	45	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17845	17852		10.1074/jbc.274.25.17845	http://dx.doi.org/10.1074/jbc.274.25.17845			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364229	hybrid			2022-12-27	WOS:000080974300065
J	Liu, JY; Jiang, T; Zhang, JP; Liang, DC				Liu, JY; Jiang, T; Zhang, JP; Liang, DC			Crystal structure of allophycocyanin from red algae Porphyra yezoensis at 2.2-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM MASTIGOCLADUS-LAMINOSUS; AMINO-ACID-SEQUENCES; ANGSTROM RESOLUTION; C-PHYCOCYANIN; FREMYELLA-DIPLOSIPHON; BETA-SUBUNIT; X-RAY; CRYSTALLIZATION; REFINEMENT; PHYCOERYTHRIN	The crystal structure of allophycocyanin from red algae Porphyra yezoensis (APC-PY) at 2.2-Angstrom resolution has been determined by the molecular replacement method. The crystal belongs to space group R32 with cell parameters a = b = 105.3 Angstrom, c = 189.4 Angstrom, alpha = beta = 90 degrees, gamma = 120 degrees, After several cycles of refinement using program X-PLOR and model building based on the electron density map, the crystallographic R-factor converged to 19.3% (R-free factor is 26.9%) in the range of 10.0 to 2.2 Angstrom The r.m.s. deviations of bond length and angles are 0.015 Angstrom and 2.9 degrees, respectively. In the crystal, two APC-PY trimers associate face to face into a hexamer, The assembly of two trimers within the hexamer is similar to that of C-phycocyanin (C-PC) and R-phycoerythrin (R-PE) hexamers, but the assembly tightness of the two trimers to the hexamer is not so high as that in C-PC and R-PE hexamers, The chromophore-protein interactions and possible pathway of energy transfer were discussed. Phycocyanobilin 1 alpha 84 of APC-PY forms 5 hydrogen bonds with 3 residues in subunit 2 beta of another monomer, In R-PE and C-PC, chromophore 1 alpha 84 only forms 1 hydrogen bond with 2 beta 77 residue in subunit 2 beta. This result may support and explain great spectrum difference exists between APC trimer and monomer.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Chaoyang Dist, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Liang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Chaoyang Dist, Peoples R China.	dcliang@sun5.ibp.ac.cn						APT KE, 1993, PLANT MOL BIOL, V21, P27, DOI 10.1007/BF00039615; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; BRUNGER AT, 1990, XPLOR VERSION 2 1; Chang WR, 1996, J MOL BIOL, V262, P721, DOI 10.1006/jmbi.1996.0547; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; FICNER R, 1993, EUR J BIOCHEM, V218, P103, DOI 10.1111/j.1432-1033.1993.tb18356.x; FICNER R, 1992, J MOL BIOL, V228, P935, DOI 10.1016/0022-2836(92)90876-L; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; HOUMARD J, 1988, J BACTERIOL, V170, P5512, DOI 10.1128/jb.170.12.5512-5521.1988; HOUMARD J, 1986, MOL GEN GENET, V205, P404, DOI 10.1007/BF00338074; Jiang T, 1999, PROTEINS, V34, P224; KARSHIKOV A, 1991, PROTEIN ENG, V4, P681, DOI 10.1093/protein/4.6.681; Liu JY, 1998, ACTA CRYSTALLOGR D, V54, P662, DOI 10.1107/S0907444997017824; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MACCOLL R, 1983, ARCH BIOCHEM BIOPHYS, V223, P24, DOI 10.1016/0003-9861(83)90567-2; MINAMI Y, 1985, FEBS LETT, V191, P216, DOI 10.1016/0014-5793(85)80011-9; NAVAZA J, 1984, ACTA CRYSTALLOGR A, V50, P157; OFFNER GD, 1983, J BIOL CHEM, V258, P9931; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SIDLER W, 1981, H-S Z PHYSIOL CHEM, V362, P611, DOI 10.1515/bchm2.1981.362.1.611	27	61	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16945	16952		10.1074/jbc.274.24.16945	http://dx.doi.org/10.1074/jbc.274.24.16945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358042	hybrid			2022-12-27	WOS:000080780400041
J	Wright, K; Kolios, G; Westwick, J; Ward, SG				Wright, K; Kolios, G; Westwick, J; Ward, SG			Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation - Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE AKT; HUMAN B-CELLS; SIGNAL-TRANSDUCTION; KAPPA-B; MEDIATED APOPTOSIS; ULCERATIVE-COLITIS; SYNTHASE ACTIVITY; IGE SYNTHESIS	A combination of the pro-inflammatory cytokines interleukin (IL)-1 alpha, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha induces nitric oxide synthase mRNA expression and nitric oxide (NO) generation in the human colon carcinoma cell line HT-29, This can be inhibited by pretreatment with IL-13 via a phosphatidylinositol (PI) 3-kinase-dependent mechanism (Wright, K., Ward, S. G., Kolios, G., and Westwick, J. (1997) J. Biol. Chem. 272, 12626-12633), Since NO has been implicated in regulating mechanisms leading to cell death, while activation of PI 3-kinase-dependent signaling cascades are thought to be involved with promoting cell survival events, we have investigated the outcome of these cytokine treatments on apoptosis and cell survival of HT-29 cells. Initiation of apoptosis can be achieved by the combinations of IFN-gamma/TNF-alpha, IFN-gamma/CD95, IL-1 alpha/IFN-gamma, and IL-1 alpha/IFN-gamma/TNF-alpha to varying extents. Induction of apoptotic markers by HT-29 cells in response to cytokine treatment is not dependent on NO production. Pretreatment with IL-13 protects against IL-1 alpha/IFN-gamma/TNF-alpha- and IFN-gamma/TNF-alpha- as well as IFN-gamma/CD95-induced (but not IL-1 alpha/IFN-gamma-induced) cell death. In addition, IFN-gamma/TNF-alpha and IL-1 alpha/IFN-gamma/TNF-alpha stimulate activation of caspase-8 and caspase-3, which IL-13 pretreatment was able to partially inhibit and delay. IL-13 also stimulates activation of the major PI 3-kinase effector, protein kinase B, The PI 3-kinase inhibitors wortmannin and LY294002 inhibit IL-13 stimulation of protein kinase B as well as the cell survival effects of IL-13, These data demonstrate that cytokine-induced apoptosis of HT-29 cells is NO-independent and that the activation of a PI 8-kinase-dependent signaling cascade by IL-13 is a key signal responsible for the inhibition of apoptosis.	Univ Bath, Dept Pharm& Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Ward, SG (corresponding author), Univ Bath, Dept Pharm& Pharmacol, Bath BA2 7AY, Avon, England.		Wright, Karen Leslie/C-7959-2011; Kolios, George/N-6641-2013; Ward, Stephen/AAE-4341-2020	Wright, Karen Leslie/0000-0003-0040-9247; Kolios, George/0000-0002-2066-4782; Ward, Stephen G./0000-0002-6795-6002				ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Aggarwal S, 1999, J IMMUNOL, V162, P2154; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; delPeso L, 1997, SCIENCE, V278, P687; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FEHSEL K, 1995, J IMMUNOL, V155, P2858; GARDINER KR, 1995, GUT, V37, P530, DOI 10.1136/gut.37.4.530; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Iwamoto M, 1996, J PATHOL, V180, P152; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kolios G, 1999, EUR J IMMUNOL, V29, P530, DOI 10.1002/(SICI)1521-4141(199902)29:02<530::AID-IMMU530>3.0.CO;2-Y; Kolios G, 1998, GUT, V43, P56, DOI 10.1136/gut.43.1.56; Kolios G, 1996, BRIT J PHARMACOL, V119, P351, DOI 10.1111/j.1476-5381.1996.tb15993.x; KOLIOS G, 1995, BRIT J PHARMACOL, V116, P2866, DOI 10.1111/j.1476-5381.1995.tb15938.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JH, 1994, J BIOL CHEM, V269, P30077; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; Lomo J, 1997, BLOOD, V89, P4415; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; Manna SK, 1998, J IMMUNOL, V161, P2863; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obiri NI, 1997, J IMMUNOL, V158, P756; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Veldman RJ, 1998, BIOCHEM BIOPH RES CO, V247, P802, DOI 10.1006/bbrc.1998.8896; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926	67	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17193	17201		10.1074/jbc.274.24.17193	http://dx.doi.org/10.1074/jbc.274.24.17193			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358077	hybrid			2022-12-27	WOS:000080780400076
J	Posch, M; Sutterluety, H; Skern, T; Seiser, C				Posch, M; Sutterluety, H; Skern, T; Seiser, C			Characterization of the translation-dependent step during iron-regulated decay of transferrin receptor mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; ELEMENT-BINDING-PROTEIN; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; MOUSE THYMIDINE KINASE; RESPONSIVE-ELEMENT; C-FOS; ACONITASE ACTIVITY; NITRIC-OXIDE; AUTOREGULATED INSTABILITY	Iron regulates the stability of the mRNA encoding the transferrin receptor (TfR). When iron is scarce, iron regulatory proteins (IRPs) stabilize TfR mRNA by binding to the 3'-untranslated region. High levels of iron induce degradation of TfR mRNA; the translation inhibitor cycloheximide prevents this. To distinguish between cotranslational mRNA decay and a trans effect of translation inhibitors, we designed a reporter system exploiting the properties of the selectable marker gene thymidine kinase (TK), The 3'-untranslated region of human transferrin receptor, which contains all elements necessary for iron-dependent regulation of mRNA stability, was fused to the TK cDNA. In stably transfected mouse fibroblasts, the expression of the reporter gene was perfectly regulated by iron. Introduction of stop codons in the TK coding sequence or insertion of stable stem-loop structures in the leader sequence did not affect on the iron-dependent regulation of the reporter mRNA This implies that global translation inhibitors stabilize TfR mRNA in trans. Cycloheximide prevented the destabilization of TfR mRNA only in the presence of active IRPs. Inhibition of IRP inactivation by cycloheximide or by the specific proteasome inhibitor MG132 correlated with the stabilization of TfR mRNA These observations suggest that inhibition of translation by cycloheximide interferes with the rate-limiting step of iron-induced TfR mRNA decay in a transacting mechanism by blocking IRP inactivation.	Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Fac Med, Inst Biochem, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna	Seiser, C (corresponding author), Univ Vienna, Vienna Bioctr, Inst Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.		Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500; Sutterluty-Fall, Hedwig/0000-0001-9249-9299; Seiser, Christian/0000-0002-7046-9352				AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BHONSALE SS, 1992, GENE DEV, V6, P1927; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1994, ADV EXP MED BIOL, V356, P141; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOESSLING LS, 1994, J BIOL CHEM, V269, P4343; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LANG V, 1994, J BIOL CHEM, V269, P6117; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PANTOPOULOS K, 1995, RNA, V1, P155; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1994, J BIOL CHEM, V269, P18630; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schlegl J, 1997, RNA, V3, P1159; SEISER C, 1993, J BIOL CHEM, V268, P13074; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEARNE PA, 1985, J IMMUNOL, V134, P3474; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WARD JH, 1982, J BIOL CHEM, V257, P317; WARD JH, 1984, J BIOL CHEM, V259, P3235; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	83	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16611	16618		10.1074/jbc.274.23.16611	http://dx.doi.org/10.1074/jbc.274.23.16611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347228	hybrid			2022-12-27	WOS:000080668600088
J	Pastorino, JG; Tafani, M; Farber, JL				Pastorino, JG; Tafani, M; Farber, JL			Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; PROTEIN-KINASE; APOPTOSIS; ACTIVATION; AKT; SURVIVAL; 3-KINASE; TNF; INHIBITOR	Tumor necrosis factor (TNF) induced the phosphorylation of BAD at serine 136 in HeLa cells under conditions that are not cytotoxic. BAD phosphorylation by TNF was dependent on phosphatidylinositide-3-OH kinase (PI3K) and was accompanied by the translocation of BAD from the mitochondria to the cytosol. Blocking the phosphorylation of BAD and its translocation to the cytosol with the PI3K inhibitor wortmannin activated caspase-3 and markedly potentiated the cytotoxicity of TNF. Transient transfection with a PI3K dominant negative mutant or a dominant negative mutant of the serine threonine kinase Akt, the downstream target of PI3K and the enzyme that phosphorylates BAD, similarly potentiated the cytotoxicity of TNF. By contrast, transfection with a constitutively active Akt mutant protected against the cytotoxicity of TNF in the presence of wortmannin. Phosphorylation of BAD prevents its interaction with the antiapoptotic protein Bcl-X-L. Transfection with a Bcl-X-L expression vector protected against the cytotoxicity of TNF in the presence of wortmannin. The mechanism by which the inhibition of the phosphorylation of BAD is likely linked to the induction of lethal mitochondrial damage in TNF-intoxicated cells is discussed.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA	Jefferson University	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 251,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	farber1@jeflin.tju.edu	Tafani, Marco/U-7230-2019; Tafani, Marco/C-3275-2017	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NIDDK NIH HHS [DK38305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Durandy A, 1997, J IMMUNOL, V158, P2576; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Fujita E, 1998, CELL DEATH DIFFER, V5, P289, DOI 10.1038/sj.cdd.4400355; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jackson TR, 1996, J CELL SCI, V109, P289; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	24	121	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19411	19416		10.1074/jbc.274.27.19411	http://dx.doi.org/10.1074/jbc.274.27.19411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383455	hybrid			2022-12-27	WOS:000081196300078
J	Valentin, E; Koduri, RS; Scimeca, JC; Carle, G; Gelb, MH; Lazdunski, M; Lambeau, G				Valentin, E; Koduri, RS; Scimeca, JC; Carle, G; Gelb, MH; Lazdunski, M; Lambeau, G			Cloning and recombinant expression of a novel mouse-secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; AMINO-ACID-SEQUENCE; INTERFACIAL CATALYSIS; SCOOTING MODE; PORCINE PANCREAS; CELL-MEMBRANES; MESSENGER-RNA; BETA-CELLS; BINDING; GENE	Secreted phospholipases A(2) (sPLA(2)s) form a class of structurally related enzymes that are involved in a variety of physiological and pathological effects including inflammation and associated diseases, cell proliferation, cell adhesion, and cancer, and are now known to bind to specific membrane receptors. Here, we report the cloning and expression of a novel sPLA(2) isolated from mouse thymus, Based on its structural features, this sPLA(2) is most similar to the previously cloned mouse group ILA sPLA(2) (mGIIA sPLA(2)). As for mGIIA sPLA(2), the novel sPLA(2) is made up of 125 amino acids with 14 cysteines, is basic (pI = 8.71) and its gene has been mapped to mouse chromosome 4, However, the novel sPLA(2) has only 48% identity with mGIIA and displays similar levels of identity with the other mouse group IIC and V sPLA(2)s, indicating that the novel sPLA(2) is not an isoform of mGIIA sPLA(2). This novel sPLA(2) has thus been called mouse group IID (mGIID) sPLA(2). In further contrast with mGIIA, which is found mainly in intestine, transcripts coding for mGIID sPLA(2) are found in several tissues including pancreas, spleen, thymus, skin, lung, and ovary, suggesting distinct functions for the two enzymes. Recombinant expression of mGIID sPLA(2) in Escherichia coli indicates that the cloned sPLA(2) is an active enzyme that has much lower specific activity than mGIIA and displays a distinct specificity for binding to various phospholipid vesicles. Finally, recombinant mGIID sPLA(2) did not bind to the mouse M-type sPLA(2) receptor, while mGIIA was previously found to bind to this receptor with high affinity.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fac Med, Lab Etud Genome Murin, IAG, CNRS,UMR 6549, F-06107 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411,660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Carle, Georges/GWC-5240-2022; Lambeau, Gerard/GRJ-5624-2022; Scimeca, Jean-Claude/P-3830-2016	Scimeca, Jean-Claude/0000-0003-3773-6110; Carle, Georges/0000-0002-3901-1052; Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235, R01HL036235, R23HL036235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hara N, 1997, ADV EXP MED BIOL, V407, P109; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Kadam Shilpa, 1998, Indian Journal of Experimental Biology, V36, P553; Kennedy BP, 1998, CANCER RES, V58, P500; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kinkaid Adrian R., 1997, Biochemical Society Transactions, V25, p497S; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Kundu GC, 1997, J BIOL CHEM, V272, P2346; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; METZ S, 1991, FEBS LETT, V295, P110, DOI 10.1016/0014-5793(91)81397-Q; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; OGAWA M, 1991, RES COMMUN CHEM PATH, V74, P241; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Ohmachi H, 1996, INT J ONCOL, V9, P511; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIGGINS GJ, 1995, CANCER RES, V55, P5184; SCHMITT JD, 1995, CHEM PHYS LIPIDS, V77, P131, DOI 10.1016/0009-3084(95)02461-Q; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WILLIAMSON P, 1995, MAMM GENOME, V6, P429, DOI 10.1007/BF00355646; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P3870, DOI 10.1021/bi961541x	64	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19152	19160		10.1074/jbc.274.27.19152	http://dx.doi.org/10.1074/jbc.274.27.19152			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383420	Green Published, hybrid			2022-12-27	WOS:000081196300043
J	Meacci, E; Vasta, V; Moorman, JP; Bobak, DA; Bruni, P; Moss, J; Vaughan, M				Meacci, E; Vasta, V; Moorman, JP; Bobak, DA; Bruni, P; Moss, J; Vaughan, M			Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; DIFFICILE TOXIN-B; BREFELDIN-A; GUANINE-NUCLEOTIDE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEPENDENT ACTIVATION; SELECTIVE-INHIBITION; HUMAN NEUTROPHILS; GOLGI-APPARATUS	Phospholipase D (PLD) has been implicated as a crucial signaling enzyme in secretory pathways. Two 20-kDa guanine nucleotide-binding proteins, Rho and ADP-ribosylation factor (ARF), are involved in the regulation of secretion and can activate PLD in vitro. We investigated in intact (human adenocarcinoma A549 cells) the role of RhoA and ARF in activation of PLD by phorbol 12-myristate 13-acetate, bradykinin, and/or sphingosine 1-phosphate, To express recombinant Clostridium botulinum C3 exoenzyme (using double subgenomic recombinant Sindbis virus C3), an ADP-ribosyltransferase that inactivates Rho, or dominant-negative Rho containing asparagine at position 19 (using double subgenomic recombinant Sindbis virus Rho19N), cells were infected with Sindbis virus, a novel vector that allows rapid, high level expression of heterologous proteins. Expression of C3 toxin or Rho19N increased basal and decreased phorbol 12-myristate 13-acetate-stimulated PLD activity. Bradykinin or sphingosine 1-phosphate increased PLD activity with additive effects that were abolished in cells expressing C3 exoenzyme or Rho19N, In cells expressing C3, modification of Rho appeared to be incomplete, suggesting the existence of pools that differed in their accessibility to the enzyme. Similar results were obtained with cells scrape-loaded in the presence of C3; however, results with virus infection were more reproducible. To assess the role of ARF, cells were incubated with brefeldin A (BFA), a fungal metabolite that disrupts Golgi structure and inhibits enzymes that catalyze ARF activation by accelerating guanine nucleotide exchange. BFA disrupted Golgi structure, but did not affect basal or agonist-stimulated PLD activity, i.e. it did not alter a rate limiting step in PLD activation, It also had no effect on Rho-stimulated PLD activity, indicating that RhoA action did not involve a BFA-sensitive pathway, A novel PLD activation mechanism, not sensitive to BFA and involving RhoA, was identified in human airway epithelial cells by use of a viral infection technique that preserves cell responsiveness.	NHLBI, Pulmonary Crit Care Med Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Florence; University of Virginia	Moss, J (corresponding author), NHLBI, Pulmonary Crit Care Med Branch, Natl Inst Hlth, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Bruni, Paola/A-1151-2008	Bruni, Paola/0000-0002-1151-3413	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000627, Z01HL000656, Z01HL000638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 54572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUADRADO A, 1993, ONCOGENE, V8, P2959; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6409; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Guillemain I, 1997, EUR J BIOCHEM, V249, P812, DOI 10.1111/j.1432-1033.1997.00812.x; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Huang HV, 1996, CURR OPIN BIOTECH, V7, P531, DOI 10.1016/S0958-1669(96)80057-7; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JinsiParimoo A, 1997, J BIOL CHEM, V272, P14556, DOI 10.1074/jbc.272.23.14556; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LI GP, 1995, ARCH BIOCHEM BIOPHYS, V316, P529, DOI 10.1006/abbi.1995.1070; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Moorman JP, 1996, J IMMUNOL, V156, P4146; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Ojio K, 1996, BIOCHEM BIOPH RES CO, V224, P591, DOI 10.1006/bbrc.1996.1069; Pan ZXK, 1998, J IMMUNOL, V160, P3038; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Singer WD, 1996, J BIOL CHEM, V271, P4504; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsai SC, 1998, J BIOL CHEM, V273, P20697, DOI 10.1074/jbc.273.33.20697; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; YAN JP, 1994, J CELL BIOL, V126, P65, DOI 10.1083/jcb.126.1.65; YEO EJ, 1994, J BIOL CHEM, V269, P27823	50	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18605	18612		10.1074/jbc.274.26.18605	http://dx.doi.org/10.1074/jbc.274.26.18605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373471	hybrid			2022-12-27	WOS:000081056700063
J	Barroso, I; Santisteban, P				Barroso, I; Santisteban, P			Insulin-induced early growth response gene (Egr-1) mediates a short term repression of rat melic enzyme gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; STIMULATED H-35 CELLS; RETINOID-X-RECEPTOR; MALIC ENZYME; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; 3T3 CELLS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FUNCTIONAL-ANALYSIS; UPSTREAM SEQUENCES	In this report we have studied insulin regulation of malic enzyme (ME) gene transcription in rat H-35 hepatoma cells and localized the insulin-responsive region of the ME promoter between positions -177 and -102. This region contains a putative insulin response element (IRE-II), When nuclear extracts from untreated or insulin-treated H-35 cells were incubated with IRE-II!, transcription factors Spl and Sp3 were observed to, bind constitutively to this element, whereas insulin induces the quick and transient binding of an insulin response factor. This induction requires de novo protein synthesis, Competition and supershift assays demonstrated that the insulin response factor is the immediate-early gene Egr-1. In vitro assays revealed that Egr-1 displaces Spl from its binding site in IRE-II. Insulin induces Egr-1 mRNA,with a time course pattern that corresponds perfectly to the Egr-1 binding to IRE-II. This induction depends on the activation of mitogen-activated protein (MAP) kinase, and it is phosphatidylinositol 3-kinase-independent, as demonstrated with specific inhibitors for both pathways. By cotransfecting the wild-type or a dominant negative Ras, an upstream regulator of MAP kinase, we show that Ras inhibits ME promoter activity. Furthermore, overexpression of Egr-1 in H-35 cells represses the ME gene promoter in a dose-dependent manner. These results suggest that insulin induces a quick, transient, and Ras/MAP kinase-dependent activation of Egr-1 which leads to a transient repression of ME gene transcription. On a late phase, insulin would activate a different, Egr-1-independent pathway, which would result in activation of the ME gene.	Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Consejo Super Invest Cient, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Consejo Super Invest Cient, Arturo Duperier 4, E-28029 Madrid, Spain.		Santisteban, Pilar/E-7829-2016	Santisteban, Pilar/0000-0002-2758-796X				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GARCIAJIMENEZ C, 1994, MOL ENDOCRINOL, V8, P1361, DOI 10.1210/me.8.10.1361; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KICKENS M, 1998, J BIOL CHEM, V273, P20144; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; MANIATIS T, 1982, MOL CLONING LABORATO, P324; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REUBER MD, 1961, J NATL CANCER I, V26, P891; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Slieker LJ, 1998, BIOCHEM BIOPH RES CO, V251, P225, DOI 10.1006/bbrc.1998.9433; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Svaren J, 1996, MOL CELL BIOL, V16, P3545; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG ZY, 1992, J BIOL CHEM, V267, P21999	66	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17997	18004		10.1074/jbc.274.25.17997	http://dx.doi.org/10.1074/jbc.274.25.17997			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364249	hybrid			2022-12-27	WOS:000080974300085
J	Spanfo, S; Silletta, MG; Colanzi, A; Alberti, S; Fiucci, G; Valente, C; Fusella, A; Salmona, M; Mironov, A; Luini, A; Corda, D				Spanfo, S; Silletta, MG; Colanzi, A; Alberti, S; Fiucci, G; Valente, C; Fusella, A; Salmona, M; Mironov, A; Luini, A; Corda, D			Molecular cloning and functional characterization of brefeldin A-ADP-ribosylated substrate - A novel protein involved in the maintenance of the Golgi structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; GUANINE-NUCLEOTIDE; BINDING-PROTEIN; DROSOPHILA CTBP; E1A PROTEIN; TRANSFORMATION; EXCHANGE; DOMAIN; GTP	Brefeldin A (BFA) is a fungal metabolite that disassembles the Golgi apparatus into tubular networks and causes the dissociation of coatomer proteins from Golgi membranes. We have previously shown that an additional effect of BFA is to stimulate the ADP-ribosylation of two cytosolic proteins of 38 and 50 kDa (brefeldin A-ADP-riboslyated substrate (BARS)) and that this effect greatly facilitates the Golgi-disassembling activity of the toxin, In this study, BARS has been purified from rat brain cytosol and microsequenced, and the EARS cDNA has been cloned. BARS shares high homology with two known proteins, C-terminal-binding protein 1 (CtBP1) and CtBPS, It is therefore a third member of the CtBP family. The role of BARS in Golgi disassembly by BFA was verified in permeabilized cells. In the presence of dialyzed cytosol that had been previously depleted of BARS or treated with an anti-BARS antibody, BFA potently disassembled the Golgi, However, in cytosol complemented with purified BARS, or even in control cytosols containing physiological levels of BARS, the action of BFA on Golgi disassembly was strongly inhibited. These results suggest that BARS exerts a negative control on Golgi tubulation, with important consequences for the structure and function of the Golgi complex.	Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Ist Ric Farmacol Mario Negri, I-66030 Chieti, Italy; Dept Biochem & Mol Pharmacol, I-20157 Milan, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Corda, D (corresponding author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Ist Ric Farmacol Mario Negri, I-66030 Chieti, Italy.		salmona, mario/AAA-7116-2020; Valente, Carmen/AAH-5261-2019; Colanzi, Antonino/D-6821-2012; Corda, Daniela/K-6385-2016; Alberti, Saverio/M-4511-2014; salmona, mario/ABI-4066-2020; Luini, Alberto/L-1372-2013; Spanò, Stefania/F-4951-2011	salmona, mario/0000-0002-9098-9873; Valente, Carmen/0000-0002-6244-9108; Colanzi, Antonino/0000-0002-5643-0216; Corda, Daniela/0000-0002-3614-751X; Alberti, Saverio/0000-0002-4647-6042; Luini, Alberto/0000-0002-8729-2549; Spanò, Stefania/0000-0001-9154-7463	Telethon [E.0982] Funding Source: Medline	Telethon(Fondazione Telethon)		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAVO R, 1984, 2 DIMENSIONAL GEL EL; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P114; DIGIROLAMO M, 1995, P NATL ACAD SCI USA, V92, P7065, DOI 10.1073/pnas.92.15.7065; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mironov A, 1997, J CELL BIOL, V139, P1109, DOI 10.1083/jcb.139.5.1109; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200	22	81	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17705	17710		10.1074/jbc.274.25.17705	http://dx.doi.org/10.1074/jbc.274.25.17705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364211	hybrid			2022-12-27	WOS:000080974300047
J	Gaponenko, V; Abusamhadneh, E; Abbott, MB; Finley, N; Gasmi-Seabrook, G; Solaro, RJ; Rance, M; Rosevear, PR				Gaponenko, V; Abusamhadneh, E; Abbott, MB; Finley, N; Gasmi-Seabrook, G; Solaro, RJ; Rance, M; Rosevear, PR			Effects of troponin I phosphorylation on conformational exchange in the regulatory domain of cardiac troponil C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL-SHIFT ANISOTROPY; N-15 NMR RELAXATION; BACKBONE DYNAMICS; SITE; INTERFERENCE; COMPLEX	Conformational exchange has been demonstrated within the regulatory domain of calcium-saturated cardiac troponin C when bound to the NH2-terminal domain of cardiac troponin I-(1-80), and cardiac troponin I-(1-80)DD, having serine residues 23 and 24 mutated to aspartate to mimic the phosphorylated form of the protein. Binding of cardiac troponin I-(1-80) decreases conformational exchange for residues 29, 32, and 34. Comparison of average transverse cross correlation rates show that both the NH2- and COOH-terminal domains of cardiac troponin C tumble with similar correlation times when bound to cardiac troponin I-(1-80). In contrast, the NH2- and COOH-terminal domains in free cardiac troponin C and cardiac troponin C bound cardiac troponin I-(1-80)DD tumble independently. These results suggest that the nonphosphorylated cardiac specific NH2 terminus of cardiac troponin I interacts with the NH2-terminal domain of cardiac troponin C.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rance, M (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		Gaponenko, Vadim/K-9729-2019	Gaponenko, Vadim/0000-0002-7891-9223	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040089] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49934] Funding Source: Medline; NIAMS NIH HHS [AR 44324] Funding Source: Medline; NIGMS NIH HHS [GM 40089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; Dohet C, 1995, FEBS LETT, V377, P131, DOI 10.1016/0014-5793(95)01319-9; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Kroenke CD, 1998, J AM CHEM SOC, V120, P7905, DOI 10.1021/ja980832l; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; Reiffert SU, 1998, BIOCHEMISTRY-US, V37, P13516, DOI 10.1021/bi980280j; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SIA KS, 1997, J BIOL CHEM, V272, P18216; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; VANEERD JP, 1976, CALCIUM TRANSPORT CO, P427; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847	19	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16681	16684		10.1074/jbc.274.24.16681	http://dx.doi.org/10.1074/jbc.274.24.16681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358006	hybrid			2022-12-27	WOS:000080780400005
J	Rund, S; Lindner, B; Brade, H; Holst, O				Rund, S; Lindner, B; Brade, H; Holst, O			Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENUS-SPECIFIC EPITOPE; ESCHERICHIA-COLI; KDO; ENDOTOXIN; STRAIN; ACID; TWAR	The lipopolysaccharide (LPS) of Chlamydia trachomatis L2 was isolated from tissue culture-grown elementary bodies using a modified phenol/water procedure followed by extraction with phenol/chloroform/light petroleum. From a total of 5 x 10(4) cm(2) of infected monolayers, 22.3 mg of LPS were obtained. Compositional analysis indicated the presence of 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo), GlcN, phosphorus, and fatty acids in a molar ratio of 2.8:2:2.1:4.5. Matrix-assisted laser-desorption ionization mass spectrometry performed on the de-O-acylated LPS gave a major molecular ion peak at mit 1781.1 corresponding to a molecule of 3 Kdo, 2 GlcN, 2 phosphates, and two 3-hydroxyeicosanoic acid residues. The structure of deacylated LPS obtained after successive treatment with hydrazine and potassium hydroxide was determined by 600 MHz NMR spectroscopy as Kdo alpha 2 --> 8Kdo alpha 2 --> 4Kdo alpha 2 --> 6D --> GlcpN beta 1 --> 6D-GlcpN alpha 1, 4-bisphosphate. These data, together with those published recently on the acylation pattern of chlamydial lipid A (Qureshi, N,, Kaltashov, I., Walker, K,, Doroshenko, V,, Cotter, R, J,, Takayama, K, Sievert, T, R,, Rice, P, A., Lin, J,-S, L,, and Golenbock, D, T, (1997) J, Biol, Chem, 272, 10594-10600) allow us to present for the first time the complete structure of a major molecular species of a chlamydial LPS.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Res Ctr Borstel, Ctr Med & Biosci, Div Biophys, D-23845 Borstel, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel	Brade, H (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany.		Lindner, Buko/G-9731-2014					BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; BRADE H, 1987, P NATL ACAD SCI USA, V84, P2508, DOI 10.1073/pnas.84.8.2508; Brade H., 1999, ENDOTOXIN HLTH DIS; BRADE L, 1986, INFECT IMMUN, V54, P568, DOI 10.1128/IAI.54.2.568-574.1986; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NANO FE, 1985, SCIENCE, V228, P742, DOI 10.1126/science.2581315; NURMINEN M, 1983, SCIENCE, V220, P1279, DOI 10.1126/science.6344216; NURMINEN M, 1985, INFECT IMMUN, V48, P573, DOI 10.1128/IAI.48.2.573-575.1985; PRYTULLA S, 1991, CARBOHYD RES, V215, P345, DOI 10.1016/0008-6215(91)84033-B; Qureshi N, 1997, J BIOL CHEM, V272, P10594; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; Storz J, 1971, CHLAMYDIA CHLAMYDIA; WENMAN WM, 1982, NATURE, V269, P68; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C	23	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16819	16824		10.1074/jbc.274.24.16819	http://dx.doi.org/10.1074/jbc.274.24.16819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358025	hybrid			2022-12-27	WOS:000080780400024
J	Ferguson, PL; Flintoff, WF				Ferguson, PL; Flintoff, WF			Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GREEN FLUORESCENT PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-ASSOCIATED PROTEIN; GENE FUSION APPROACH; METHOTREXATE UPTAKE; MEMBRANE TOPOLOGY; BINDING-PROTEIN; TRANSPORT-DEFICIENT; N-GLYCOSYLATION	The membrane topology of the human reduced folate carrier protein (591 amino acids) was assessed by single insertions of the hemagglutinin epitope into nine sites of the protein. Reduced folate carrier-deficient Chinese hamster ovary cells expressing each of these constructs were probed with anti-hemagglutinin epitope monoclonal antibodies to assess whether the insertion was exposed to the external environment or to the cytoplasm. The results are consistent with the 12-transmembrane topology predicted for this protein. The hemagglutinin epitope insertion mutants were also tested for their effects on the function of the reduced folate carrier. For these studies, each of the constructs had a carboxyl-terminal fusion of the enhanced green fluorescent protein to monitor and quantitate expression. Insertions into the external loop between transmembrane regions 7 and 8 (Pro-297), the cytoplasmic loop between transmembrane regions 6 and 7 (Ser-225), and near the cytoplasmic amino and carboxyl termini (Pro-SO and Gly-492, respectively) had minor effects on methotrexate binding and uptake. The insertion into the cytoplasmic loop between transmembrane regions 10 and 11 (Gln-385) greatly reduced both binding and uptake of methotrexate, whereas the insertion into the external loop between transmembrane regions 11 and 12 (Pro-427) selectively interfered with uptake but not binding.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Flintoff, WF (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.							Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; DIXON KH, 1994, J BIOL CHEM, V269, P17; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; Girotti M, 1996, J CELL SCI, V109, P2915; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Hampton RY, 1996, P NATL ACAD SCI USA, V93, P828, DOI 10.1073/pnas.93.2.828; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; Howard M, 1995, AM J PHYSIOL-CELL PH, V269, pC1565, DOI 10.1152/ajpcell.1995.269.6.C1565; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1998, BIOCHEMISTRY-US, V37, P2305, DOI 10.1021/bi972332v; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATHERLY LH, 1994, BIOCHEM PHARMACOL, V47, P1094, DOI 10.1016/0006-2952(94)90423-5; MATHERLY LH, 1991, CANCER RES, V51, P3420; MCCORMICK JI, 1979, EUR J CANCER, V15, P1377, DOI 10.1016/0014-2964(79)90115-4; MOSCOW JA, 1995, CANCER RES, V55, P3790; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Nikiforovich GV, 1998, PROTEIN ENG, V11, P279, DOI 10.1093/protein/11.4.279; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAMBROOK J, 1989, MOL CLONING, V9, P14; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Wong SC, 1998, BBA-BIOMEMBRANES, V1375, P6, DOI 10.1016/S0005-2736(98)00118-7; YANG CH, 1988, J BIOL CHEM, V263, P9703; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; [No title captured]	56	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16269	16278		10.1074/jbc.274.23.16269	http://dx.doi.org/10.1074/jbc.274.23.16269			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347183	hybrid			2022-12-27	WOS:000080668600043
J	Middlemas, DS; Kihl, BK; Zhou, JF; Zhu, XY				Middlemas, DS; Kihl, BK; Zhou, JF; Zhu, XY			Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; TRK PROTOONCOGENE PRODUCT; NGF-DEPENDENT SURVIVAL; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; IN-VITRO; PHOSPHATIDYLINOSITOL-3 KINASE; NEURONAL DIFFERENTIATION	Brain-derived neurotrophic factor (BDNF) promotes neuronal survival and protection against neuronal damage. We addressed whether BDNF might promote survival and chemoprotection in neuroblastoma (NB) using a drug-sensitive human NE cell line. All-trans-retinoic acid (ATRA) induces a striking phenotypic differentiation of NB1643 cells, and exogenous BDNF treatment promotes survival of these differentiated cells. ATRA induces TRKB expression, and exogenous BDNF stimulates both autophosphorylation of TRKB and induction of the immediate early gene, FOS, in these cells. BDNF mRNA is expressed in NB1643 cells, Because the time course of TRKB induction closely parallels phenotypic differentiation of these cells, it seems probable that ATRA induces differentiation of NB1643 cells by establishing an autocrine loop involving BDNF and TRKB, Exogenous BDNF treatment resulted in a further increase in neurite outgrowth, which again suggests that an autocrine loop is involved in differentiation of NB1643 cells in response to ATRA, We then tested whether BDNF might afford drug resistance in NE and found that BDNF does indeed protect in this NE model against cisplatin, a DNA-damaging agent actually used in the treatment of NE.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Middlemas, DS (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [R29CA071628, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [1 R29 CA 71628, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Alcantara S, 1997, J NEUROSCI, V17, P3623; Baxter GT, 1997, J NEUROSCI, V17, P2683; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BOZYCZKOCOYNE D, 1993, J NEUROSCI METH, V50, P205, DOI 10.1016/0165-0270(93)90009-G; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; CROM WR, 1981, CANCER CHEMOTH PHARM, V6, P95; DUGICHDJORDJEVIC MM, 1995, NEUROSCIENCE, V66, P861, DOI 10.1016/0306-4522(94)00631-E; Easton JB, 1999, J BIOL CHEM, V274, P11321, DOI 10.1074/jbc.274.16.11321; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GURWELL JA, 1993, DEV BRAIN RES, V76, P293, DOI 10.1016/0165-3806(93)90222-V; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Harlow E., 1988, ANTIBODIES LAB MANUA; IRELAND CM, 1994, ANTICANCER RES, V14, P2397; Israel MA, 1994, ATLAS HUMAN TUMOR CE, P42; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; LOEB DM, 1994, J BIOL CHEM, V269, P8901; Lucarelli E, 1994, Prog Clin Biol Res, V385, P185; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MIDDLEMAS DS, 1993, METHODS NEUROSCI, V12, P139; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PAPADOPOULOS NG, 1994, J IMMUNOL METHODS, V177, P101, DOI 10.1016/0022-1759(94)90147-3; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; POLUHA W, 1995, ONCOGENE, V10, P185; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REECE PA, 1987, CLIN PHARMACOL THER, V42, P320, DOI 10.1038/clpt.1987.155; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; Scala S, 1996, CANCER RES, V56, P3737; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; Thompson J, 1997, CLIN CANCER RES, V3, P423; TRICHE TJ, 1983, HUM PATHOL, V14, P569; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VONHOLST A, 1995, MOL CELL NEUROSCI, V6, P185; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZAR JH, 1984, BIOSTAT ANAL, P292	80	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16451	16460		10.1074/jbc.274.23.16451	http://dx.doi.org/10.1074/jbc.274.23.16451			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347207	hybrid			2022-12-27	WOS:000080668600067
J	Ravandi, A; Kuksis, A; Shaikh, NA				Ravandi, A; Kuksis, A; Shaikh, NA			Glycated phosphatidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; DIABETIC-PATIENTS; ADVANCED GLYCOSYLATION; ANIONIC PHOSPHOLIPIDS; SCAVENGER RECEPTORS; FLUOROMETRIC ASSAY; MASS-SPECTROMETRY; CORE ALDEHYDES; LDL-RECEPTOR; IN-VIVO	Non-enzymatic glycation of low density lipoprotein (LDL) has been suggested to be responsible for the increase in susceptibility to atherogenesis of diabetic individuals. Although the association of lipid glycation with this process has been investigated, the effect of specific lipid glycation products on LDL metabolism has not been addressed. This study reports that glucosylated phosphatidylethanolamine (Glc-PtdEtn), the major LDL lipid glycation product, promotes LDL uptake and cholesteryl ester (CE) and triacylglycerol (TG) accumulation by THP-1 macrophages. Incubation of THP-1 macrophages at a concentration of 100 mu g/ml protein LDL specifically enriched (10 nmol/mg LDL protein) with synthetically prepared Glc-PtdEtn resulted in a significant increase in CE and TG accumulation when compared with LDL enriched in non-glucosylated PtdEtn, After a 24-h incubation with LDL containing Glc-PtdEtn, the macrophages contained 2-fold higher CE (10.11 +/- 1.54 mu g/mg cell protein) and TG (285.32 +/- 4.38 mu g/mg cell protein) compared with LDL specifically enriched in non-glucosylated PtdEtn (CE, 3.97 +/- 0.95, p < 0.01 and TG, 185.57 +/- 3.58 mu g/mg cell protein, p < 0.01), The corresponding values obtained with LDL containing glycated protein and lipid were similar to those of LDL containing Glc-PtdEtn (CE, 11.9 +/- 1.35 and TG, 280.78 +/- 3.98 mu g/mg cell protein). The accumulation of both neutral lipids was further significantly increased by incubating the macrophages with Glc-PtdEtn LDL exposed to copper oxidation, By utilizing the fluorescent probe, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI), a 1.6-fold increase was seen in Glc-PtdEtn + LDL uptake when compared with control LDL, Competition studies revealed that acetylated LDL is not a good competitor for DiI Glc-PtdEtn LDL (5-6% inhibition), whereas glycated LDL gave an 80% inhibition, and LDL + Glc-PtdEtn gave 93% inhibition of uptake by macrophages, These results indicate that glucosylation of PtdEtn in LDL accounts for the entire effect of LDL glycation on macrophage uptake and CE and TG accumulation and, therefore, the increased atherogenic potential of LDL in hyperglycemia.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L6, Canada; Special Diagnost Inc, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Kuksis, A (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Ravandi, Amir/O-7552-2019					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AVIRAM M, 1992, BIOCHEM BIOPH RES CO, V185, P465, DOI 10.1016/S0006-291X(05)81008-3; AVIRAM M, 1993, J CLIN INVEST, V91, P1942, DOI 10.1172/JCI116413; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; FOLCH J, 1957, J BIOL CHEM, V226, P497; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; GREENSPAN P, 1995, BBA-LIPID LIPID MET, V1257, P257, DOI 10.1016/0005-2760(95)00088-T; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KLEIN RL, 1990, DIABETOLOGIA, V33, P299, DOI 10.1007/BF00403324; KLEIN RL, 1992, DIABETES, V41, P1301, DOI 10.2337/diabetes.41.10.1301; KOBAYASHI K, 1995, HORM METAB RES, V27, P356, DOI 10.1055/s-2007-979978; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KUKSIS A, 1981, J CHROMATOGR, V224, P1, DOI 10.1016/S0378-4347(00)80133-4; KUKSIS A, 1980, J CHROMATOGR, V2, P1; LOPESVIRELLA MF, 1988, DIABETES, V37, P550, DOI 10.2337/diabetes.37.5.550; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyons TJ, 1997, CURR OPIN LIPIDOL, V8, P174, DOI 10.1097/00041433-199706000-00008; LYONS TJ, 1987, DIABETOLOGIA, V30, P916, DOI 10.1007/BF00295874; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; RABINI RA, 1994, CLIN BIOCHEM, V27, P381, DOI 10.1016/0009-9120(94)90042-6; Ravandi A, 1998, CLIN CHEM, V44, pA73; RAVANDI A, 1995, J BIOCHEM BIOPH METH, V30, P271, DOI 10.1016/0165-022X(95)00015-7; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; RAVANDI A, 1995, LIPIDS, V30, P885, DOI 10.1007/BF02537478; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V177, P433, DOI 10.1016/0006-291X(91)92002-2; Sambrano GR, 1997, ARTERIOSCL THROM VAS, V17, P3442, DOI 10.1161/01.ATV.17.12.3442; SASAKI J, 1982, BIOCHIM BIOPHYS ACTA, V713, P199, DOI 10.1016/0005-2760(82)90237-5; SOBENIN IA, 1993, ATHEROSCLEROSIS, V100, P41, DOI 10.1016/0021-9150(93)90066-4; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Teupser D, 1996, BBA-LIPID LIPID MET, V1303, P193, DOI 10.1016/0005-2760(96)00094-X; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	41	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16494	16500		10.1074/jbc.274.23.16494	http://dx.doi.org/10.1074/jbc.274.23.16494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347212	hybrid			2022-12-27	WOS:000080668600072
J	Saha, N; Schwer, B; Shuman, S				Saha, N; Schwer, B; Shuman, S			Characterization of human, Schizosaccharomyces pombe, and Candida albicans mRNA cap methyltransferases and complete replacement of the yeast capping apparatus by mammalian enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; GUANYLYLTRANSFERASE ACTIVITIES; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; 5'-CAPPING ENZYME; ESCHERICHIA-COLI; ACTIVE-SITE	Human and fission yeast cDNAs encoding mRNA (guanine-N7) methyltransferase were identified based on similarity of the human (Hcm1p; 476 amino acids) and Schizosaccharomyces pombe (Pcm1p; 389 amino acids) polypeptides to the cap methyltransferase of Saccharomyces cerevisiae (Abd1p), Expression of PCM1 or HCM1 in S. cerevisiae complemented the lethal phenotype resulting from deletion of the ABD1 gene, as did expression of the NH2-terminal deletion mutants PCM1(94-389) and HCM1(121-476), The CCM1 gene encoding Candida albicans cap methyltransferase (Ccm1p; 474 amino acids) was isolated from a C, albicans genomic library by selection for complementation of the conditional growth phenotype of S, cerevisiae abd1-ts mutants. Human cap methyltransferase was expressed in bacteria, purified, and characterized. Recombinant Hcm1p catalyzed quantitative S-adenosylmethionine-dependent conversion of GpppA-capped poly(A) to m7GpppA-capped poly(A), We identified by alanine-scanning mutagenesis eight amino acids (Asp-203, Gly-207, Asp-211, Asp-227, Arg-239, Tyr-289, Phe-291, and Phe-354) that are essential for human cap methyltransferase function in vivo, All eight residues are conserved in other cellular cap methyltransferases. Five of the mutant human proteins (D203A, R239A, Y289A, F291A, and F354A) were expressed in bacteria and found to be defective in cap methylation in vitro. Concordance of mutational effects on Hcm1p, Abd1p, and vaccinia capping enzyme underscores a conserved structural basis for cap methylation in DNA viruses, yeast, and metazoans, This is in contrast to the structural and mechanistic divergence of the RNA triphosphatase components of the yeast and metazoan capping systems. Nevertheless, we demonstrate that the entire three-component yeast capping apparatus, consisting of RNA 5'-triphosphatase (Cet1p), RNA guanylyltransferase (Ceg1p), and Abd1p could be replaced in vivo by the two-component mammalian apparatus consisting of a bifunctional triphosphatase-guanylyltransferase Mce1p and the methyltransferase Hcm1(121-476)p. Isogenic yeast strains with fungal versus mammalian capping systems should facilitate rational screens for antifungal drugs that target cap formation in vivo.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Janbon G, 1997, YEAST, V13, P985, DOI 10.1002/(SICI)1097-0061(199708)13:10<985::AID-YEA153>3.0.CO;2-T; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1979, P NATL ACAD SCI USA, V76, P4961, DOI 10.1073/pnas.76.10.4961; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; SHIBAGAKI Y, 1995, J BIOCHEM, V118, P1303, DOI 10.1093/oxfordjournals.jbchem.a125023; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; VENKATESAN S, 1980, J BIOL CHEM, V255, P2829; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	37	67	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16553	16562		10.1074/jbc.274.23.16553	http://dx.doi.org/10.1074/jbc.274.23.16553			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347220	hybrid			2022-12-27	WOS:000080668600080
J	Ma, LL; Xu, JY; Coulombe, PA; Wirtz, D				Ma, LL; Xu, JY; Coulombe, PA; Wirtz, D			Keratin filament suspensions show unique micromechanical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE SPONGE NEVUS; INTERMEDIATE FILAMENTS; MECHANICAL-PROPERTIES; TRANSGENIC MICE; ROD DOMAIN; ACTIN GELS; F-ACTIN; NETWORKS; VIMENTIN; EXPRESSION	All epithelial cells feature a prominent keratin intermediate filament (IF) network in their cytoplasm. Studies in transgenic mice and in patients with inherited epithelial fragility syndromes showed that a major function of keratin Ifs is to provide mechanical support to epithelial cell sheets. Yet the micromechanical properties of keratin Ifs themselves remain unknown. We used rheological methods to assess the properties of suspensions of epidermal type I and type II keratin Ifs and of vimentin, a type III LF polymer. We find that both types of Ifs form gels with properties akin to visco elastic solids. With increasing deformation they display strain hardening and yield relatively rapidly. Remarkably, both types of gels recover their preshear properties upon cessation of the deformation. Repeated imposition of small deformations gives rise to a progressively stiffer gel for keratin but not vimentin Ifs. The visco-elastic moduli of both gels show a weak dependence upon the frequency of the input shear stress and the concentration of the polymer, suggesting that both steric and nonsteric interactions between individual polymers contribute to the observed mechanical properties. In support of this, the length of individual polymers contributes only modestly to the properties of IF gels. Collectively these properties render Ifs unique among cytoskeletal polymers and have strong implications for their function in vivo.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Coulombe, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Wirtz, Denis/A-3257-2010		NIAMS NIH HHS [AR42047] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042047, R55AR042047] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1980, VISCOELASTIC PROPERT; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bousquet O, 1996, CURR BIOL, V6, P1563, DOI 10.1016/S0960-9822(02)70772-0; COULOMBE P.A., 1994, MOL B INT U, P259; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; Doi M., 1989, THEORY POLYM DYNAMIC; Eckes B, 1998, J CELL SCI, V111, P1897; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; IRVINE AD, 1997, NAT GENET, V12; ISHIKAWA H, 1968, J CELL BIOL, V38, P538, DOI 10.1083/jcb.38.3.538; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Morse DC, 1998, MACROMOLECULES, V31, P7030, DOI 10.1021/ma9803032; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; RICHARD G, 1995, NAT GENET, V11, P453, DOI 10.1038/ng1295-453; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; RUGG EL, 1995, NAT GENET, V11, P450, DOI 10.1038/ng1295-450; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VENETIANER A, 1983, NATURE, V305, P730, DOI 10.1038/305730a0; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; Wiche G, 1998, J CELL SCI, V111, P2477; WITTEN TA, 1988, J PHYS-PARIS, V49, P1055, DOI 10.1051/jphys:019880049060105500; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570	55	116	116	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19145	19151		10.1074/jbc.274.27.19145	http://dx.doi.org/10.1074/jbc.274.27.19145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383419	hybrid			2022-12-27	WOS:000081196300042
J	Soutourina, J; Plateau, P; Delort, F; Peirotes, A; Blanquet, S				Soutourina, J; Plateau, P; Delort, F; Peirotes, A; Blanquet, S			Functional characterization of the D-Tyr-tRNA(Tyr) deacylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; D-AMINO ACIDS; METHIONYL; CLEAVAGE; MUTANTS; GENES; SITE; IDENTIFICATION; HYDROLASE; PROTEINS	The yihZ gene of Escherichia coli is shown to produce a deacylase activity capable of recycling misaminoacylated D-Tyr-tRNA(Tyr). The reaction is specific and, under optimal in vitro conditions, proceeds at a rate of 6 s(-1) with a K-m value for the substrate equal to 1 mu M. Cell growth is sensitive to interruption of the yihZ gene if D-tyrosine is added to minimal culture medium. Toxicity of exogenous D-tyrosine is exacerbated if, in addition to the disruption of yihZ, the gene of D-amino acid dehydrogenase (dadA) is also inactivated. Orthologs of the yihZ gene occur in many, but not all, bacteria. In support of the idea of a general role of the D-Tyr-tRNA(Tyr) deacylase function in the detoxification of cells, similar genes can be recognized in Saccharomyces cerevisiae, Caenorhabditis elegans, Arabidopsis thaliana, mouse, and man.	Ecole Polytech, CNRS, Unite Mixte Rech 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Plateau, P (corresponding author), Ecole Polytech, CNRS, Unite Mixte Rech 7654, Biochim Lab, F-91128 Palaiseau, France.	plateau@coli.polytechnique.fr	Soutourina, Julie/F-8305-2014	Soutourina, Julie/0000-0001-5218-2350				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARKER DG, 1982, EUR J BIOCHEM, V125, P357, DOI 10.1111/j.1432-1033.1982.tb06691.x; BERG P, 1958, J BIOL CHEM, V233, P601; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BONNET J, 1972, EUR J BIOCHEM, V31, P335, DOI 10.1111/j.1432-1033.1972.tb02538.x; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BRUNI CB, 1977, J BACTERIOL, V130, P4, DOI 10.1128/JB.130.1.4-10.1977; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Callahan C, 1996, J BACTERIOL, V178, P7329, DOI 10.1128/jb.178.24.7329-7332.1996; CAPARROS M, 1991, RES MICROBIOL, V142, P345, DOI 10.1016/0923-2508(91)90050-K; CAPARROS M, 1992, J BACTERIOL, V174, P5549; CHAMPNEY WS, 1970, J BACTERIOL, V104, P107, DOI 10.1128/JB.104.1.107-116.1970; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; DAVIE JW, 1956, ARCH BIOCHEM BIOPHYS, V65, P21; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; JENSEN RA, 1972, ARCH MIKROBIOL, V87, P173, DOI 10.1007/BF00424998; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KUHN J, 1974, BIOCHIM BIOPHYS ACTA, V332, P298, DOI 10.1016/0005-2736(74)90382-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MARSH L, 1987, J BACTERIOL, V169, P1818, DOI 10.1128/jb.169.5.1818-1823.1987; MCFALL E, 1996, ESCHERICHIA COLI SAL, P358; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MELLOT P, 1989, J MOL BIOL, V208, P429, DOI 10.1016/0022-2836(89)90507-X; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; NORTON SJ, 1963, J BIOL CHEM, V238, P269; OHNISHI E, 1962, J BIOL CHEM, V237, P138; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SOURGOUTCHOV A, 1974, EUR J BIOCHEM, V46, P431, DOI 10.1111/j.1432-1033.1974.tb03636.x; UZAN M, 1978, MOL GEN GENET, V165, P21, DOI 10.1007/BF00270372; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILD J, 1981, MOL GEN GENET, V181, P373, DOI 10.1007/BF00425614; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001	40	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19109	19114		10.1074/jbc.274.27.19109	http://dx.doi.org/10.1074/jbc.274.27.19109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383414	hybrid			2022-12-27	WOS:000081196300037
J	Taylor, CT; Fueki, N; Agah, A; Hershberg, RM; Colgan, SP				Taylor, CT; Fueki, N; Agah, A; Hershberg, RM; Colgan, SP			Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION; E-SELECTIN; CELL-LINE; BARRIER FUNCTION; LIPOPOLYSACCHARIDE; PROMOTER; CREB; PERMEABILITY	Tissue hypoxia is intimately associated with a number of chronic inflammatory conditions of the intestine. In this study, we investigated the impact of hypoxia on the expression of a panel of inflammatory mediators by intestinal epithelia, Initial experiments revealed that epithelial (T84 cell) exposure to ambient hypoxia evoked a time-dependent induction of the proinflammatory markers tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), and major histocompatibility complex (MHC) class II (37 +/- 6.1-, 7 +/- 0.8-, and 9 +/- 0.9-fold increase over normoxia, respectively, each p < 0.01). Since the gene regulatory elements for each of these molecules contains an NF-kappa B binding domain, we investigated the influence of hypoxia on NF-kappa B activation. Cellular hypoxia induced a time dependent increase in nuclear p65, suggesting a dominant role for NF-kappa B in hypoxia-elicited induction of proinflammatory gene products. Further work, however, revealed that hypoxia does not influence epithelial intercellular adhesion molecule 1 (ICAM-1) or MHC class I, the promoters of which also contain NF-kappa B binding domains, suggesting differential responses to hypoxia, Importantly, the genes for TNF-alpha, IL-8, and MHC class II, but not ICAM-1 or MHC class I, contain cyclic AMP response element (CRE) consensus motifs, Thus, we examined the role of cAMP in the hypoxia-elicited phenotype, Hypoxia diminished CRE binding protein (CREB) expression. In parallel, T84 cell cAMP was diminished by hypoxia (83 +/- 13.2% decrease, p < 0.001), and pharmacologic inhibition of protein kinase A induced TNF-alpha and protein release (9 +/- 3.9-fold increase). Addback of cAMP resulted in reversal of hypoxia-elicited TNF-alpha release (86 +/- 3.2% inhibition with 3 mM 8-bromo-cAMP). Furthermore, overexpression of CREB but not mutated CREB by retroviral-mediated gene transfer reversed hypoxia-elicited induction of TNF-alpha defining a causal relationship between hypoxia-elicited CREB reduction and TNF-alpha induction. Such data indicate a prominent role for CREB in the hypoxia-elicited epithelial phenotype and implicate intracellular cAMP as an important second messenger in differential induction of proinflammatory mediators.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Virginia Mason Medical Center	Colgan, SP (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn 7,Rm 704,75 Francis St, Boston, MA 02115 USA.		Colgan, Sean P./B-4573-2009		NHLBI NIH HHS [HL60569] Funding Source: Medline; NIDDK NIH HHS [DK50189, DK09699] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009699, R37DK050189, R29DK050189, R01DK050189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; CIACCI C, 1993, J CLIN INVEST, V92, P527, DOI 10.1172/JCI116598; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; COLGAN SP, 1993, J CELL BIOL, V120, P785, DOI 10.1083/jcb.120.3.785; COLGAN SP, 1994, J IMMUNOL, V153, P2122; COLGAN SP, 1994, AM J PHYSIOL, V267, P402; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Crosson SM, 1996, BIOCHEM BIOPH RES CO, V227, P915, DOI 10.1006/bbrc.1996.1605; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, P204; DITTEL BN, 1993, BLOOD, V81, P2272; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; MADARA JL, 1990, AM J PATHOL, V137, P1273; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; OGAWA S, 1990, ADV EXP MED BIOL, V281, P303; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; POWELL DW, 1987, PHYSL GASTROINTESTIN, P1267; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; SPENGLER RN, 1989, INFECT IMMUN, V57, P2837, DOI 10.1128/IAI.57.9.2837-2841.1989; Stevens T, 1995, ENDOTHELIUM-J ENDOTH, V3, P1, DOI [10.3109/10623329509024653, DOI 10.3109/10623329509024653]; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; Taylor CT, 1998, J PHARMACOL EXP THER, V284, P568; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WIDNELL KL, 1994, P NATL ACAD SCI USA, V91, P10947, DOI 10.1073/pnas.91.23.10947; Widnell KL, 1996, J NEUROCHEM, V66, P1770; ZHONG WW, 1995, IMMUNOLOGY, V84, P446; Zund G, 1996, P NATL ACAD SCI USA, V93, P7075, DOI 10.1073/pnas.93.14.7075; Zund G, 1996, J BIOL CHEM, V271, P7460; Zund G, 1997, AM J PHYSIOL-CELL PH, V273, pC1571, DOI 10.1152/ajpcell.1997.273.5.C1571	45	79	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19447	19454		10.1074/jbc.274.27.19447	http://dx.doi.org/10.1074/jbc.274.27.19447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383461	hybrid			2022-12-27	WOS:000081196300084
J	Dery, O; Thoma, MS; Wong, H; Grady, EF; Bunnett, NW				Dery, O; Thoma, MS; Wong, H; Grady, EF; Bunnett, NW			Trafficking of proteinase-activated receptor-2 and beta-arrestin-1 tagged with green fluorescent protein - beta-arrestin-dependent endocytosis of a proteinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; COUPLED RECEPTOR; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; THROMBIN RECEPTOR; MOLECULAR-CLONING; CHOLECYSTOKININ RECEPTOR; MEDIATED ENDOCYTOSIS; PLATELET ACTIVATION; SUBSTANCE-P	Proteases cleave proteinase-activated receptors (PARs) to expose N-terminal tethered ligands that bind and activate the cleaved receptors. The tethered ligand, once exposed, is always available to interact with its binding site. Thus, efficient mechanisms must prevent continuous activation, including receptor phosphorylation and uncoupling from G-proteins, receptor endocytosis, and lysosomal degradation. beta-Arrestins mediate uncoupling and endocytosis of certain neurotransmitter receptors, which are activated in a reversible manner. However, the role of beta-arrestins in trafficking of PARs, which are irreversibly activated, and the effects of proteases on the subcellular distribution of beta-arrestins have not been examined. We studied trafficking of PARS and beta-arrestin1 coupled to green fluorescent protein. Trypsin induced the following: (a) redistribution of beta-arrestin1 from the cytosol to the plasma membrane, where it co-localized with PAR2; (b) internalization of beta-arrestin1 and PARS into the same early endosomes; (c) redistribution of beta-arrestin1 to the cytosol concurrent with PARS translocation to lysosomes; and (d) mobilization of PARS from the Gels apparatus to the plasma membrane. Overexpression of a C-terminal fragment of beta-arrestin-(319-418), which interacts constitutively with clathrin but does not bind receptors, inhibited agonist-induced endocytosis of PARS. Our results show that p-arrestins mediate endocytosis of PARS and support a role for beta-arrestins in uncoupling of PARs.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; W Los Angeles Vet Affairs Med Ctr, CURE, Digest Dis Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.			Thoma, Mark/0000-0003-0332-7044; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK42307, DK39957] Funding Source: Medline; NINDS NIH HHS [NS21710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R01DK039957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1997, BIOCHEM J, V322, P1; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Caughey GH, 1995, MAST CELL PROTEASES, P305; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORVERA C, 1999, IN PRESS J PHYSL LON; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HEIN L, 1994, J BIOL CHEM, V269, P27719; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	54	143	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18524	18535		10.1074/jbc.274.26.18524	http://dx.doi.org/10.1074/jbc.274.26.18524			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373461	hybrid			2022-12-27	WOS:000081056700053
J	Hernandez-Sanchez, C; Ito, Y; Ferrer, J; Reitman, M; LeRoith, D				Hernandez-Sanchez, C; Ito, Y; Ferrer, J; Reitman, M; LeRoith, D			Characterization of the mouse sulfonylurea receptor 1 promoter and its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SENSITIVE K+ CHANNELS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC BETA-CELLS; INSULIN-SECRETION; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; ATP; TRANSCRIPTION; KIR6.2	The ATP-sensitive potassium channels (K-ATP(+) channels) are heteromultimeric structures formed by a member of the sulfonylurea receptor (SUR) family and a member of the inwardly rectifying potassium channel family (Kir6.x), The K+,, channels play an essential role in nutrient-induced insulin secretion from the pancreatic beta-cell, We have cloned and characterized the promoter region of the mouse SUR1 gene, and have shown that it lacks CAAT and TATA boxes or an initiator element. Studies of transcription initiation in several tissues showed that there is a common SUR1 promoter in brain, heart, and pancreas and in the pancreatic beta-cell line, PTC3, The SUR1 gene uses multiple transcription start sites with the major site located 54 base pairs 5'-upstream of the translation initiation site. Transient transfection experiments in pancreatic p-cell lines showed that the proximal promoter fragment -84/+54 is sufficient for significant transcriptional activity. The proximal promoter region contains multiple SP1-binding sites, and cotransfection experiments of the SUR1 promoter-luciferase vector with SP1 expression Vector in Drosophila SL2 cells demonstrated a stimulatory effect of SP1 on SUR1 transcriptional activity. The mobility shift assays confirmed the interaction of the SP1 transcription factor with the proximal promoter region of the SUR1 gene. Together, these results indicate that SP1 may mediate transcription initiation of the SUR1 gene. In addition, we have described the coordinate regulation of the gene expression of both K-ATP(+),, channel subunits by glucocorticoids. SUR1 and Kir6,2 mRNA levels are down-regulated by similar to 40-50% in response to glucocorticoid treatment. Interestingly, the extent of the inhibitory effect as well as the kinetics and sensitivity are very similar for both mRNAs, Studies of mRNA turnover demonstrate that glucocorticoids most likely decrease the transcriptional activity of both SUR1 and Kir6,2 genes since glucocorticoids failed to affect the stability of each mRNA, Likewise, the reduction in mRNA levels was correlated with a decrease in SUR1 and Kir6,2 protein levels.	NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA; Hosp Clin Barcelona, Dept Endocrinol, E-08036 Barcelona, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Barcelona; Hospital Clinic de Barcelona	Hernandez-Sanchez, C (corresponding author), NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Rm 8D12,Bldg 10,10 Ctr Dr,MSC 1758, Bethesda, MD 20892 USA.	catalinah@bdg10.niddk.nih.gov	Hernández-Sánchez, Catalina/N-1737-2014; Ferrer, Jorge/A-3176-2012; Reitman, Marc/B-4448-2013	Hernández-Sánchez, Catalina/0000-0002-0846-5019; Ferrer, Jorge/0000-0002-5959-5729; Reitman, Marc/0000-0002-0426-9475				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHEROFT FM, 1988, ANNU REV NEUROSCI, V11, P97; Ashfield R, 1998, DIABETES, V47, P1274, DOI 10.2337/diabetes.47.8.1274; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; CONN JW, 1956, METABOLISM, V5, P114; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P773; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FISCHER B, 1990, ENDOCRINOLOGY, V126, P2635, DOI 10.1210/endo-126-5-2635; HernandezSanchez C, 1997, ENDOCRINOLOGY, V138, P705, DOI 10.1210/en.138.2.705; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LANS MS, 1994, J BIOL CHEM, V269, P14170; MATTHES H, 1994, ENDOCRINOLOGY, V135, P476, DOI 10.1210/en.135.1.476; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18261	18270		10.1074/jbc.274.26.18261	http://dx.doi.org/10.1074/jbc.274.26.18261			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373428	hybrid			2022-12-27	WOS:000081056700020
J	Zhou, ZM; Lin, SH; Cotter, RJ; Raetz, CRH				Zhou, ZM; Lin, SH; Cotter, RJ; Raetz, CRH			Lipid a modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12 - Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; TEMPERATURE REQUIREMENT GENE; RESISTANT PMRA-MUTANTS; ABC FAMILY TRANSPORTER; ACID-DEFICIENT MUTANT; POLYMYXIN-RESISTANT; BACTERIAL-ENDOTOXINS; MULTICOPY SUPPRESSOR; CHEMICAL-STRUCTURE; OUTER-MEMBRANE	Two-thirds of the lipid A in wild-type Escherichia coli K12 is a hexa-acylated disaccharide of glucosamine in which monophosphate groups are attached at positions 1 and 4', The remaining lipid A contains a monophosphate substituent at position 4' and a pyrophosphate moiety at position 1, The biosynthesis of the l-pyrophosphate unit is unknown, Its presence is associated with lipid A translocation to the outer membrane (Zhou, Z,,White, K, A, Polissi, A., Georgopoulos, C,, and Raetz, C. R, H, (1998) J, Biol. Chem. 273, 12466-12475), To determine if a phosphatase regulates the amount of the lipid A 1-pyrophosphate, we grew cells in broth containing nonspecific phosphatase inhibitors. Na2WO4 and sodium fluoride increased the relative amount of the 1-pyrophosphate slightly. Remarkably, NH4VO3-treated cells generated almost no 1-pyrophosphate, but made six major new lipid A derivatives (EV1 to EV6). Matrix-assisted laser desorption ionization/time of flight mass spectrometry of purified EV1 to EV6 indicated that these compounds were lipid A species substituted singly or in combination with palmitoyl, phosphoethanolamine, and/or aminodeoxypentose residues. The aminodeoxypentose residue was released by incubation in chloroform/methanol (4:1, v/v) at 25 degrees C, and was characterized by H-1 NMR spectroscopy. The chemical shifts and vicinal coupling constants of the two anomers of the aminodeoxypentose released from EV3 closely resembled those of synthetic 4-amino-4-deoxy-L-arabinose. NH4VO3-induced lipid A modification did not require the PhoP/PhoQ two-component regulatory system, and also occurred in E. coli msbB or htrB mutants, The lipid A variants that accumulate in NH4VO3 treated E. coli K12 are the same as many of those normally found in untreated Salmonella typhimurium and Salmonella minnesota, demonstrating that E, coli K12 has latent enzyme systems for synthesizing these important derivatives.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM54882-01, GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babinski KJ, 1998, FASEB J, V12, pA1288; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BISHOP RE, 1999, IN PRESS FASEB J, V13; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COTTER RJ, 1987, BIOMED ENVIRON MASS, V14, P591, DOI 10.1002/bms.1200141103; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GEBB C, 1975, EUR J BIOCHEM, V54, P493, DOI 10.1111/j.1432-1033.1975.tb04161.x; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HASE S, 1977, EUR J BIOCHEM, V75, P23, DOI 10.1111/j.1432-1033.1977.tb11500.x; HASIN M, 1982, J BIOL CHEM, V257, P2475; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KYOSSEV ZN, 1995, EUR J BIOCHEM, V228, P109, DOI 10.1111/j.1432-1033.1995.0109o.x; MEYERS E, 1974, ANN NY ACAD SCI, V235, P493, DOI 10.1111/j.1749-6632.1974.tb43286.x; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PETERSON AA, 1987, ANTIMICROB AGENTS CH, V31, P230, DOI 10.1128/AAC.31.2.230; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1984, HDB ENDOTOXIN, V1; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; STANKIEWICZ PJ, 1995, MET IONS BIOL SYST, V31, P287; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VOLK WA, 1970, EUR J BIOCHEM, V17, P223; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WANG R, 1992, J MICROBIOL METH, V15, P151, DOI 10.1016/0167-7012(92)90037-5; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	63	192	197	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18503	18514		10.1074/jbc.274.26.18503	http://dx.doi.org/10.1074/jbc.274.26.18503			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373459	hybrid			2022-12-27	WOS:000081056700051
J	Chan, JM; Ryle, MJ; Seefeldt, LC				Chan, JM; Ryle, MJ; Seefeldt, LC			Evidence that MgATP accelerates primary electron transfer in a Clostridium pasteurianum Fe protein-Azotobacter vinelandii MoFe protein nitrogenase tight complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; PARAMAGNETIC-RESONANCE; KLEBSIELLA-PNEUMONIAE; ADENOSINE 5'-TRIPHOSPHATE; NUCLEOTIDE-BINDING; SODIUM DITHIONITE; EPR SPECTROSCOPY; REDOX PROPERTIES; METAL CENTERS; P-CLUSTERS	The nitrogenase catalytic cycle involves binding of the iron (Fe) protein to the molybdenum-iron (MoFe) protein, transfer of a single electron from the Fe protein to the MoFe protein concomitant with the hydrollysis of at least two MgATP molecules, followed by dissociation of the two proteins. Earlier studies found that combining the Fe protein isolated from the bacterium Clostridium pasteurianum with the MoFe protein isolated from the bacterium Azotobacter vinelandii resulted in an inactive, nondissociating Fe protein-MoFe protein complex. In the present work, it is demonstrated that primary electron transfer occurs within this nitrogenase tight complex in the absence of MgATP (apparent first-order rate constant k = 0.007 s(-1)) and that MgATP accelerates this electron transfer reaction by more than 10,000-fold to rates comparable to those observed within homologous nitrogenase complexes (k = 100 s(-1)). Electron transfer reactions were confirmed by EPR spectroscopy. Finally, the midpoint potentials (E-m) for the Fe protein [4Fe-4S](2+/+) cluster and the MoFe protein p(2+/N) cluster were determined for both the uncomplexed and complexed proteins and with or without MgADP. Calculations from electron transfer theory indicate that the measured changes in E-m are not likely to be sufficient to account for the observed nucleotide-dependent rate accelerations for electron transfer.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Seefeldt, LC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	seefeldt@cc.usu.edu		Seefeldt, Lance/0000-0002-6457-9504				ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BUI PT, 1969, BIOCHEMISTRY-US, V8, P2462, DOI 10.1021/bi00834a031; Burgess B. K., 1985, MOLYBDENUM ENZYMES, P161; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CARNAHAN JE, 1958, J BACTERIOL, V75, P121, DOI 10.1128/JB.75.2.121-124.1958; CHRISTIANSEN J, 1995, J AM CHEM SOC, V117, P10017, DOI 10.1021/ja00145a012; CHROMY V, 1974, CLIN CHEM, V20, P1362; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Dutton P L, 1978, Methods Enzymol, V54, P411; EMERICH DW, 1976, P NATL ACAD SCI USA, V73, P4369, DOI 10.1073/pnas.73.12.4369; EMERICH DW, 1978, BIOCHIM BIOPHYS ACTA, V527, P359, DOI 10.1016/0005-2744(78)90350-9; EMERICH DW, 1978, J BACTERIOL, V134, P936, DOI 10.1128/JB.134.3.936-943.1978; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; JACOBS BA, 1991, J AM CHEM SOC, V113, P4390, DOI 10.1021/ja00012a003; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P399, DOI 10.1021/bi971681m; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P16770, DOI 10.1021/bi962286j; LARSEN C, 1995, ARCH BIOCHEM BIOPHYS, V323, P215, DOI 10.1006/abbi.1995.9972; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MENSINK RE, 1992, EUR J BIOCHEM, V208, P289, DOI 10.1111/j.1432-1033.1992.tb17185.x; MORGAN TV, 1988, J INORG BIOCHEM, V33, P111, DOI 10.1016/0162-0134(88)80039-4; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PALMER G, 1972, ARCH BIOCHEM BIOPHYS, V153, P325, DOI 10.1016/0003-9861(72)90452-3; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; REES DC, 1998, BIOL NITROGEN FIXATI, P11; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; Spee JH, 1998, FEBS LETT, V432, P55, DOI 10.1016/S0014-5793(98)00827-8; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1975, BIOCHEM J, V145, P391, DOI 10.1042/bj1450391; THORNELEY RNF, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P103; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; WATT GD, 1989, BIOCHEMISTRY-US, V28, P1844, DOI 10.1021/bi00430a062; WATT GD, 1980, BIOCHEMISTRY-US, V19, P4926, DOI 10.1021/bi00562a035; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x; ZUMFT WG, 1972, BIOCHEM BIOPH RES CO, V48, P1525, DOI 10.1016/0006-291X(72)90887-X	56	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17593	17598		10.1074/jbc.274.25.17593	http://dx.doi.org/10.1074/jbc.274.25.17593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364195	hybrid			2022-12-27	WOS:000080974300031
J	Naim, HY; Joberty, G; Alfalah, M; Jacob, R				Naim, HY; Joberty, G; Alfalah, M; Jacob, R			Temporal association of the N- and O-linked glycosylation events and their implication in the polarized sorting of intestinal brush border sucrase-isomaltase, aminopeptidase N, and dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; PHLORIZIN HYDROLASE; GLYCAN INITIATION; MDCK CELLS; BIOSYNTHESIS; LOCALIZATION; OLIGOSACCHARIDES; PROTEIN	The temporal association between O-glycosylation and processing of N-linked glycans in the Golgi apparatus as well as the implication of these events in the polarized sorting of three brush border proteins has been the subject of the current investigation. O-Glycosylation of pro-sucrase-isomaltase (pro-SI), aminopeptidase N (ApN), and dipeptidyl peptidase IV (DPPIV) is drastically reduced when processing of the mannose-rich N-linked glycans is blocked by deoxymannojirimycin, an inhibitor of the Golgi-located mannosidase I. By contrast, O-glycosylation is not affected in the presence of swainsonine, an inhibitor of Golgi mannosidase II. The results indicate that removal of the outermost mannose residues by mannosidase I from the mannose-rich N-linked glycans is required before O-glycosylation can ensue. On the other hand, subsequent mannose residues in the core chain impose no sterical constraints on the progression of O-glycosylation. Reduction or modification of N- and O-glycosylation do not affect the transport of pro-SI, ApN, or DPPIV to the cell surface per se. However, the polarized sorting of two of these proteins, pro-SI and DPPIV, to the apical membrane is substantially altered when O-glycans are not completely processed, while the sorting of ApN is not affected. The processing of N-linked glycans, on the other hand, has no influence on sorting of all three proteins. The results indicate that O-linked carbohydrates are at least a part of the sorting mechanism of pro-SI and DPPIV, The sorting of ApN implicates neither O-linked nor N-linked glycans and is driven most likely by carbohydrate-independent mechanisms.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Al Falah, Dr. Marwan/C-6281-2011; Jacob, Ralf/B-8163-2011					DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, GASTROENTEROLOGY, V109, P1039, DOI 10.1016/0016-5085(95)90561-8; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ELBEIN AD, 1983, METHOD ENZYMOL, V98, P135; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JACOB R, 1994, J BIOL CHEM, V269, P2712; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JOKINEN M, 1985, J BIOL CHEM, V260, P1314; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW SH, 1991, J BIOL CHEM, V266, P19710; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1994, FEBS LETT, V342, P302; NAIM HY, 1993, BIOCHEM J, V296, P607, DOI 10.1042/bj2960607; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; PILLER V, 1990, J BIOL CHEM, V265, P9264; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROUSSET M, 1979, CANCER RES, V39, P531; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	47	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17961	17967		10.1074/jbc.274.25.17961	http://dx.doi.org/10.1074/jbc.274.25.17961			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364244	hybrid			2022-12-27	WOS:000080974300080
J	Kwok, Y; Zeng, QP; Hurley, LH				Kwok, Y; Zeng, QP; Hurley, LH			Structural insight into a quinolone-topoisomerase II-DNA complex - Further evidence for a 2 : 2 quinobenzoxazine-Mg2+ self-assembly model formed in the presence of topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED ALKYLATION; ANTINEOPLASTIC AGENTS; ANTITUMOR ACTIVITIES; MECHANISM; CLEAVAGE; BINDING; DRUGS; PSOROSPERMIN; GYRASE; ANTIBACTERIALS	Quinobenzoxazine A-62176, developed from the antibacterial fluoroquinolones, is active in vitro and in vivo against murine and human tumors. It has been previously claimed that A-62176 is a catalytic inhibitor of mammalian topoisomerase II that does not stabilize the cleaved complex. However, at low drug concentrations and pH 6-7, we have found that A-62176 can enhance the formation of the cleaved complex at certain sites. Using a photocleavage assay, mismatched sequences, and competition experiments between psorospermin and A-62176, we pinpointed the drug binding site on the DNA base pairs between positions +1 and +2 relative to the cleaved phosphodiester bonds. A 2:2 quinobenzoxazine-Mg2+ self-assembly model was previously proposed, in which one drug molecule intercalates into the DNA helix and the second drug molecule is externally bound, held to the first molecule and DNA by two Mg2+ bridges, The results of competition experiments between psorospermin and A-62176, as well as between psorospermin and A-62176 and norfloxacin, are consistent with this model and provide the first evidence that this 2:2 quinobenzoxazine-Mg2+ complex is assembled in the presence of topoisomerase II. These results also have parallel implications for the mode of binding of the quinolone antibiotics to the bacterial gyrase-DNA complex.	Univ Texas, Coll Pharm, Drugs Dynam Inst, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Hurley, LH (corresponding author), Univ Texas, Coll Pharm, Drugs Dynam Inst, Austin, TX 78712 USA.				NCI NIH HHS [CA-49751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049751, R35CA049751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOTT S, 1980, NATURE, V287, P561, DOI 10.1038/287561a0; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BOND PJ, 1975, P NATL ACAD SCI USA, V72, P4825, DOI 10.1073/pnas.72.12.4825; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHU DTW, 1987, J HETEROCYCLIC CHEM, V24, P453, DOI 10.1002/jhet.5570240228; CHU DTW, 1992, DRUG EXP CLIN RES, V18, P275; CHU DTW, 1994, DRUG EXP CLIN RES, V20, P177; CLEMENT JJ, 1995, CANCER RES, V55, P830; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; FAN JY, 1995, J MED CHEM, V38, P408, DOI 10.1021/jm00003a003; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; Hansen M, 1996, J AM CHEM SOC, V118, P5553; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; Kwok Y, 1998, J BIOL CHEM, V273, P33020, DOI 10.1074/jbc.273.49.33020; Kwok Y, 1998, P NATL ACAD SCI USA, V95, P13531, DOI 10.1073/pnas.95.23.13531; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Maxam A M, 1980, Methods Enzymol, V65, P499; Osheroff N, 1994, Adv Pharmacol, V29B, P105; PALU G, 1992, P NATL ACAD SCI USA, V89, P9671, DOI 10.1073/pnas.89.20.9671; Palumbo M, 1993, Trends Microbiol, V1, P232, DOI 10.1016/0966-842X(93)90138-H; PERMANA PA, 1994, BIOCHEMISTRY-US, V33, P11333, DOI 10.1021/bi00203a031; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; Pommier Yves, 1997, P153; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3879, DOI 10.1021/bi00435a038; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	31	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17226	17235		10.1074/jbc.274.24.17226	http://dx.doi.org/10.1074/jbc.274.24.17226			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358081	hybrid			2022-12-27	WOS:000080780400080
J	Lehtonen, JYA; Horiuchi, M; Daviet, L; Akishita, M; Dzau, VJ				Lehtonen, JYA; Horiuchi, M; Daviet, L; Akishita, M; Dzau, VJ			Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED NEURONS; SERINE PALMITOYLTRANSFERASE; CERAMIDE BIOSYNTHESIS; TYROSINE-PHOSPHATASE; FUSARIUM-MONILIFORME; CELL-PROLIFERATION; SPHINGOID BASES; WEHI-231 CELLS; INHIBITION; DEATH	This study examines the role of sphingolipids in mediating the apoptosis of PC12W cells induced by the angiotensin II type 2 (AT(2)) receptor. PC12W cells express abundant AT(2) receptor but not angiotensin II type 1 receptor and undergo apoptosis when stimulated by angiotensin II. AT(2) receptor-induced ceramide accumulation preceded the onset of caspase 3 activation and DNA fragmentation. AT(2) receptor-induced ceramide accumulation did not result from the degradation of complex sphingolipids (SL) such as sphingomyelin or glycosphingolipids, as no changes in neutral or acidic sphingomyelinase activities, sphingomyelin level, nor in cellular glycolipid composition were observed. AT(2) receptor activated serine palmitoyltransferase with a maximum time of 24 h after angiotensin II stimulation. The AT(2) receptor-induced accumulation of ceramide was blocked by inhibitors of the de novo pathway of SL synthesis, beta-chloro-L-alanine and fumonisin B-1. Inhibition of the de novo biosynthesis of SLs by fumonisin B-1 and beta-chloro-L-alanine completely abrogated the AT(2) receptor-mediated apoptosis, Pertussis toxin and orthovanadate blocked AT(2) receptor-mediated ceramide production. Taken together our data demonstrate that in PC12W cells the stimulation of AT(2) receptor induces the activation of de novo pathway, and a metabolite of this pathway, possibly ceramide, mediates AT(2) receptor-induced apoptosis.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dzau, VJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL035610, R01HL046631, R01HL035252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Booz GW, 1996, HYPERTENSION, V28, P635, DOI 10.1161/01.HYP.28.4.635; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; DOSTAL DE, 1992, AM J PHYSIOL, V263, pC851, DOI 10.1152/ajpcell.1992.263.4.C851; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; Smith ER, 1997, J BIOL CHEM, V272, P5640, DOI 10.1074/jbc.272.9.5640; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Tsuzuki S, 1996, BIOCHEM BIOPH RES CO, V228, P825, DOI 10.1006/bbrc.1996.1739; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; WANG E, 1991, J BIOL CHEM, V266, P14486; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	36	88	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16901	16906		10.1074/jbc.274.24.16901	http://dx.doi.org/10.1074/jbc.274.24.16901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358036	hybrid			2022-12-27	WOS:000080780400035
J	Li, JR; Bombeck, CA; Yang, SF; Kim, YM; Billiar, TR				Li, JR; Bombeck, CA; Yang, SF; Kim, YM; Billiar, TR			Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; RAT HEPATOCYTES; IN-VIVO; INHIBITS APOPTOSIS; PROTEASES; NECROSIS; FAMILY; MECHANISMS	Nitric oxide (NO) is a potent inhibitor of apoptosis in many cell types, including hepatocytes. We and others have described NO-dependent decreases in caspase activity in cells undergoing apoptosis. However, previous work has not determined whether NO disrupts the proteolytic processing and thus the activation of pro-caspases, Here we report that NO suppresses proteolytic processing and activation of multiple pro-caspases in intact cells, including caspase-3 and caspase-8. We found that both exogenous NO as well as endogenously produced NO via adenoviral inducible NO synthase gene transfer protected hepatocytes from tumor necrosid factor (TNF) alpha plus actinomycin D (TNF alpha/ActD)-induced apoptosis. Affinity labeling with biotin-VAD-fmk of all active caspase species in TNF alpha-mediated apoptosis identified four newly labeled spots (activated caspases) present exclusively in TNF alpha/ActD-treated cells. Both NO and the caspase inhibitor, Ac-DEVD-CHO, prevented the appearance of the four newly labeled spots or active caspases. Immunoanalysis of affinity labeled caspases demonstrated that caspase-3 was the major effector caspase. Western blot analysis also identified the activation of caspase-8 in the TNF alpha/ActD-treated cells, and the activation was suppressed by NO. Furthermore, NO inhibited several other events associated with caspase activation in cells, including release of cytochrome c from mitochondria, decrease in mitochondrial transmembrane potential, and cleavage of poly(ADP-ribose) polymerase in TNF alpha/ActD-treated cells. These findings indicate the involvement of multiple caspases in TNF alpha-mediated apoptosis in hepatocytes and establish the capacity of NO to inhibit not only active caspases but also caspase activation.	Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA; Kangweon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kangwon National University	Billiar, TR (corresponding author), Univ Pittsburgh, Dept Surg, Sch Med, A1010 PUH, Pittsburgh, PA 15213 USA.		Li, Jianrong/C-4126-2011	Li, Jianrong/0000-0002-8232-9322	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044100, R29GM044100, R01GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19866, GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, CANCER RES, V58, P5201; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Estevez AG, 1998, J NEUROSCI, V18, P3708; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; *HOEF SCI INSTR, 1994, PROT EL APPL GUID, P65; Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEIST M, 1994, J IMMUNOL, V153, P1778; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Sweeney EA, 1998, FEBS LETT, V425, P61, DOI 10.1016/S0014-5793(98)00198-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	51	235	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17325	17333		10.1074/jbc.274.24.17325	http://dx.doi.org/10.1074/jbc.274.24.17325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358093	hybrid			2022-12-27	WOS:000080780400092
J	Olayioye, MA; Beuvink, I; Horsch, K; Daly, JM; Hynes, NE				Olayioye, MA; Beuvink, I; Horsch, K; Daly, JM; Hynes, NE			ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; FAMILY KINASES; V-SRC; SIGNAL-TRANSDUCTION; INTERFERON RECEPTOR; BREAST-CANCER	Epidermal growth factor (EGF) binding to its receptor, ErbB1, triggers various signal transduction pathways, one of which leads to the activation of signal transducer and activator of transcription (Stat) factors. The mechanism underlying ErbB1-induced Stat activation and whether Stats are downstream targets of other ErbB receptors have not been explored. In this report we show that ErbB2, ErbB3, and ErbB4 do not potentiate Stat5 phosphorylation by EGF, However, neu differentiation factor-induced heterodimers of ErbB2 and ErbB4 activated Stat5. In A431 cells, Stat1, Stat3, and Stat5, were constitutively complexed with ErbB1 and rapidly phosphorylated on tyrosine in response to EGF. Neither mutation of the conserved tyrosine residue (Tyr(694)) nor inactivation of the Stat5a SH2 domain disrupted this association. However, an intact SH2 domain was necessary for EGF-induced Stat5a phosphorylation, In contrast to prolactin, which induced only Tyr(694) phosphorylation of Stat5a, EGF promoted phosphorylation on Tyr(694) and additional tyrosine residue(s). Janus kinases (Jaks) were also constitutively associated with ErbB receptors and were phosphorylated in response to EGF-related ligands, However, we provide evidence that EGF- and neu differentiation factor-induced Stat activation are dependent on Src but not Jak kinases. Upon EGF stimulation, c-Src was rapidly recruited to Stat/ ErbB receptor complexes. Pharmacological Src kinase inhibitors and a dominant negative c-Src ablated both Stat and Jak tyrosine phosphorylation, However, dominant negative Jaks did not affect EGF-induced Stat phosphorylation, Taken together, the experiments establish two independent roles for Src kinases: (i) key molecules in ErbB receptor-mediated Stat signaling and (ii) potential upstream regulators of Jak kinases.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	hynes@fmi.ch						BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; DALY JM, 1999, IN PRESS ONCOGENE; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MISSBACH M, 1999, IN PRESS BONE NY; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	296	305	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17209	17218		10.1074/jbc.274.24.17209	http://dx.doi.org/10.1074/jbc.274.24.17209			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358079	hybrid			2022-12-27	WOS:000080780400078
J	Ouchane, S; Kaplan, S				Ouchane, S; Kaplan, S			Topological analysis of the membrane-localized redox-responsive sensor kinase PrrB from Rhodobacter sphaeroides 2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; ESCHERICHIA-COLI; HISTIDINE KINASE; PROTEIN; FUSIONS; RHODOBACTER-SPHAEROIDES-2.4.1; CONSTRUCTION; CAPSULATUS; PERMEASE; COMPLEX	Photosynthesis gene expression in Rhodobacter sphaeroides is controlled in part by the two-component (Prr) regulatory system composed of a membrane-bound sensor kinase (PrrB) and a response regulator (PrrA). Hydropathy profile-based computer analysis predicted that the PrrB polypeptide could contain six membrane-spanning domains at its amino terminus and a hydrophilic, cytoplasmic carboxyl terminus. Both the localization and the topology of the PrrB sensor kinase have been studied by generating a series of gene fusions with the Escherichia coli periplasmically localized alkaline phosphatase and the cytoplasmic beta-galactosidase. Eighteen prrB-phoA and five prrB-lacZ fusions were constructed and expressed in both E. coli and R. sphaeroides. Enzymatic activity assays and immunoblot analyses were performed to identify and to localize the different segments of PrrB in the membrane. The data obtained in E. coli generally correlated with the data obtained in R. sphaeroides and support the computer predictions. On the basis of the theoretical model and the results provided by these studies, a topological model for the membrane localization of the PrrB polypeptide is proposed.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System	Kaplan, S (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.		OUCHANE, Soufian/HHM-5430-2022; Ouchane, Soufian/ABE-2609-2020	Ouchane, Soufian/0000-0002-8161-3866	NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DANIELSEN S, 1995, MICROBIOL-SGM, V141, P2905, DOI 10.1099/13500872-141-11-2905; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; Eraso JM, 1996, J BACTERIOL, V178, P7037, DOI 10.1128/jb.178.24.7037-7046.1996; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LeBlanc HN, 1996, J BACTERIOL, V178, P4801, DOI 10.1128/jb.178.16.4801-4806.1996; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MILLER JH, 1972, EXPT MOL GENETICS, P54; MOORE MD, 1989, J BACTERIOL, V171, P4385, DOI 10.1128/JB.171.8.4385-4394.1989; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; MUNOA FJ, 1991, J BIOL CHEM, V266, P17667; O'Gara JP, 1998, J BACTERIOL, V180, P4044; OGara JP, 1997, J BACTERIOL, V179, P1951, DOI 10.1128/jb.179.6.1951-1961.1997; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Park Y, 1999, J BACTERIOL, V181, P1039, DOI 10.1128/JB.181.3.1039-1042.1999; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pemberton JM, 1998, MICROBIOL-UK, V144, P267, DOI 10.1099/00221287-144-2-267; Sambrook J., 2002, MOL CLONING LAB MANU; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; TAI TN, 1988, PLASMID, V19, P175, DOI 10.1016/0147-619X(88)90037-6; VARGA AR, 1989, J BACTERIOL, V171, P5830, DOI 10.1128/jb.171.11.5830-5839.1989; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YUN CH, 1991, J BIOL CHEM, V266, P10967; Zeilstra-Ryalls J, 1998, J BACTERIOL, V180, P2801, DOI 10.1128/JB.180.11.2801-2809.1998; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	40	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17290	17296		10.1074/jbc.274.24.17290	http://dx.doi.org/10.1074/jbc.274.24.17290			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358089	hybrid			2022-12-27	WOS:000080780400088
J	Voice, JK; Klemke, RL; Le, A; Jackson, JH				Voice, JK; Klemke, RL; Le, A; Jackson, JH			Four human Ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-RAS; EXCHANGE FACTOR; INCREASING COMPLEXITY; KINASE ACTIVATION; PLASMA-MEMBRANE; TYROSINE KINASE; PROTEIN-KINASE; ONCOGENIC RAS; IN-VIVO; N-RAS	Human cells contain four homologous Ras proteins, but it is unknown whether each of these Ras proteins participates in distinct signal transduction cascades or has different biological functions. To directly address these issues, we assessed the relative ability of constitutively active (G12V) versions of each of the four Ras homologs to activate the effector protein Raf-l in vivo. In addition, we compared their relative abilities to induce transformed foci, enable anchorage-independent growth, and stimulate cell migration. We found a distinct hierarchy between the four Ras homologs in each of the parameters studied. The hierarchies were as follows: for Raf-l activation, Ki-Ras 4B > Ki-Ras 4A >>> N-Ras > Ha-Ras; for focus formation, Ha-Ras greater than or equal to Ki-Ras 4A >>> N-Ras = Ki-Ras 4B; for anchorage-independent growth, Ki-Ras 4A greater than or equal to N-Ras >>> Ki-Ras 4B = Ha-Ras = no growth; and for cell migration, Ki-Ras 4B >>> Ha-Ras > N-Ras = Ki-Ras 4A = no migration. Our results indicate that the four Ras homologs significantly differ in their abilities to activate Raf-l and induce distinctly different biological responses. These studies, in conjunction with our previous report that demonstrated that the Ras homologs can be differentially activated by upstream guanine nucleotide exchange factors (Jones, M. K., and Jackson, J. H. (1998) J. Biol. Chem. 273, 1782-1787), indicate that each of the four Ras proteins may qualitatively or quantitatively participate in distinct signaling cascades and have significantly different biological roles in vivo. Importantly, these studies also suggest for the first time that the distinct and likely cooperative biological functions of the Ki-ras-encoded Ki-ras 4A and Ki-Ras 4B proteins may help explain why constitutively activating mutations of Ki-ras, but not N-ras or Ha-ras, are frequently detected in human carcinomas.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Jackson, JH (corresponding author), Scripps Res Inst, Dept Immunol, IMM-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jjackson@scripps.edu			NCI NIH HHS [CA 54298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1990, BLOOD, V75, P1684; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee T, 1996, DEVELOPMENT, V122, P409; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Pells S, 1997, ONCOGENE, V15, P1781, DOI 10.1038/sj.onc.1201354; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	40	226	231	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17164	17170		10.1074/jbc.274.24.17164	http://dx.doi.org/10.1074/jbc.274.24.17164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358073	hybrid			2022-12-27	WOS:000080780400072
J	Miura, D; Manabe, K; Ozono, K; Saito, M; Gao, QZ; Norman, AW; Ishizuka, S				Miura, D; Manabe, K; Ozono, K; Saito, M; Gao, QZ; Norman, AW; Ishizuka, S			Antagonistic action of novel 1 alpha,25-dihydroxyvitamin D-3-26,23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; BIOLOGICAL-ACTIVITY ASSESSMENT; 1,25-DIHYDROXYVITAMIN D-3; 24-HYDROXYLASE GENE; RAT; IDENTIFICATION; METABOLITES; RESPONSES; GROWTH; LINE	We examined the effects of two novel 1 alpha,25-dihydroxyvitamin D-3-26,23-lactone (1 alpha,25-lactone) analogues on human promyelocytic leukemia cell (HL-60) differentiation using the evaluation system of the vitamin D nuclear receptor (VDR)/vitamin D-responsive element (DRE)-mediated genomic action stimulated by 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) and its analogues. We found that the 1 alpha,25-lactone analogues (23S)-25-dehydro-1 alpha-hydroxyvitamin-D-3-26,23-lactone (TEI-9647), and (23R)-25-dehydro-1 alpha-hydroxyvitamin-D3-26,23-lactone (TEI-9648) bound much more strongly to the VDR than the natural (23S,25R)-1 alpha,25(OH)(2)D-3-26,23-lactone, but did not induce cell differentiation even at high concentrations (10(-6) M). Intriguingly, the differentiation of HL-60 cells induced by 1 alpha,25(OH)(2)D-3 was inhibited by either TEI-9647 or TEI-9648 but not by the natural lactone. In contrast, retinoic acid or 12-O-tetradecanoylphorbol-13- acetate-induced HL-60 cell differentiation was not blocked by TEI-9647 or TEI-9648. In separate studies, TEI-9647 (10(-7) M) was found to be an effective antagonist of both 1 alpha,25(OH)(2)D-3 (10(-8) M) mediated induction of p21(WAF1,CIP1) in HL-60 cells and activation of the luciferase reporter assay in COS-7 cells transfected with cDNA containing the DRE of the rat 25(OH)D-3-24-hydroxylase gene and cDNA of the human VDR. Collectively the results strongly suggest that our novel 1 alpha,25-1actone analogues, TEI-9647 and TEI-9648, are specific antagonists of 1 alpha,25(OH)(2)D-3 action, specifically VDR/DRE-mediated genomic action. As such, they represent the first examples of antagonists, which act on the nuclear VDR.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Osaka Med Ctr Maternal & Child Hlth, Dept Environm Med Res Inst, Osaka 5941101, Japan; Teijin Inst Biomed Res, Dept Bone & Calcium Metab, Tokyo 1918512, Japan; Teijin Inst Biomed Res, Safety Res Dept, Tokyo 1918512, Japan	University of California System; University of California Riverside; University of California System; University of California Riverside	Norman, AW (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.							ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CADE C, 1987, ENDOCRINOLOGY, V120, P1490, DOI 10.1210/endo-120-4-1490; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; COLLINS SJ, 1987, BLOOD, V70, P1233; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HONDA A, 1993, BIOCHEM J, V295, P509, DOI 10.1042/bj2950509; HONDA A, 1992, J STEROID BIOCHEM, V41, P109, DOI 10.1016/0960-0760(92)90231-7; INABA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P20, DOI 10.1016/0167-4889(89)90179-1; INABA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P257, DOI 10.1016/0003-9861(91)90293-R; ISHIZUKA S, 1984, BIOCHEMISTRY-US, V23, P1473, DOI 10.1021/bi00302a021; ISHIZUKA S, 1984, J STEROID BIOCHEM, V20, P611; ISHIZUKA S, 1987, J BIOL CHEM, V262, P7165; ISHIZUKA S, 1981, FEBS LETT, V134, P207, DOI 10.1016/0014-5793(81)80603-5; ISHIZUKA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P82, DOI 10.1016/0003-9861(85)90482-5; ISHIZUKA S, 1990, ENDOCRINOLOGY, V127, P695, DOI 10.1210/endo-127-2-695; ISHIZUKA S, 1988, ENDOCRINOLOGY, V123, P781, DOI 10.1210/endo-123-2-781; ISHIZUKA S, 1988, MOL CELL ENDOCRINOL, V55, P7; ISHIZUKA S, 1997, VITAMIN D CHEM BIOL, P683; ISHIZUKA S, 1988, VITAMIN D MOL CELLUL, P143; KIYOKI M, 1985, BIOCHEM BIOPH RES CO, V127, P693, DOI 10.1016/S0006-291X(85)80217-5; LEE YS, 1989, J BIOL CHEM, V264, P13701; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; MANABE K, 1997, VITAMIN D CHEM BIOL, P79; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEMERE I, 1991, HDB PHYSL; NEVEU I, 1994, J NEUROSCI RES, V38, P214, DOI 10.1002/jnr.490380212; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; ONISKO BL, 1980, BIOCHEMISTRY-US, V19, P4124, DOI 10.1021/bi00558a034; Pike J. W., 1997, Vitamin D., P105; REDDY GS, 1987, J BONE MINER RES S, V2, P36; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SONG X, 1997, ENDOCRINOLOGY, V139, P457; WION D, 1991, J NEUROSCI RES, V28, P110, DOI 10.1002/jnr.490280111; YOSHIDA M, 1984, J PHARMACOBIO-DYNAM, V7, P962; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617; ZHOU JY, 1989, BLOOD, V74, P82; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	51	105	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16392	16399		10.1074/jbc.274.23.16392	http://dx.doi.org/10.1074/jbc.274.23.16392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347199	hybrid			2022-12-27	WOS:000080668600059
J	Quiram, PA; Jones, JJ; Sine, SM				Quiram, PA; Jones, JJ; Sine, SM			Pairwise Interactions between neuronal alpha(7) acetylcholine receptors and alpha-conotoxin ImI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; MOLECULAR DISSECTION; CURARIFORM ANTAGONISTS; CONSERVED TYROSINES; CONFER SELECTIVITY; MUTANT CYCLES; CHANNEL PORE; K+ CHANNEL; IDENTIFICATION; RESIDUES	The present work uses alpha-conotoxin ImI (CTx ImI) to probe the neurotransmitter binding site of neuronal alpha(7) acetylcholine receptors. We identify key residues in alpha(7) that contribute to CTx ImI affinity, and use mutant cycles analysis to identify pairs of residues that stabilize the receptor-conotoxin complex. We first mutated key residues in the seven known loops of alpha(7) that converge at the subunit interface to form the ligand binding site. The mutant subunits were expressed in 293 HEK cells, and CTx ImI binding was measured by competition against the initial rate of I-125-alpha-bungarotoxin binding. The results reveal a predominant contribution by Tyr-195 in alpha(7), accompanied by smaller contributions by Thr-77, Tyr-93, Asn-111, Gln-117, and Trp-149, Based upon our previous identification of bioactive residues in CTx ImI, we measured binding of receptor and toxin mutations and analyzed the results using thermodynamic mutant cycles. The results reveal a single dominant interaction between Arg-7 of CTx ImI and Tyr-195 of alpha(7) that anchors the toxin to the binding site. We also find multiple weak interactions between Asp-5 of CTx ImI and Trp-149, Tyr-151, and Gly-153 of alpha(7), and between Trp-10 of CTx ImI and Thr-77 and Asn-111 of alpha(7). The overall results establish the orientation of CTx ImI as it bridges the subunit interface and demonstrate close approach of residues on opposing faces of the alpha(7) binding site.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu			NINDS NIH HHS [NS-31744] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; ANDRUE D, 1994, METHODS MOL BIOL PEP, V35, P139; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; FU DX, 1994, J BIOL CHEM, V269, P26152; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; PRINCE RJ, 1997, NICOTINIC ACETYLCHOL, P31; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	29	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19517	19524		10.1074/jbc.274.28.19517	http://dx.doi.org/10.1074/jbc.274.28.19517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391883	hybrid			2022-12-27	WOS:000081377300003
J	Hashimoto, T; Fujita, T; Usuda, N; Cook, W; Qi, C; Peters, JM; Gonzalez, FJ; Yeldandi, AV; Rao, MS; Reddy, JK				Hashimoto, T; Fujita, T; Usuda, N; Cook, W; Qi, C; Peters, JM; Gonzalez, FJ; Yeldandi, AV; Rao, MS; Reddy, JK			Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty Acyl-CoA oxidase - Genotype correlation with fatty liver phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; RAT-LIVER; CARNITINE PALMITOYLTRANSFERASE; 3-KETOACYL-COA THIOLASE; MOLECULAR-CLONING; PTS2 RECEPTOR; HUMAN PEX7; GENE; PURIFICATION; EXPRESSION	Fatty acid beta-oxidation occurs in both mitochondria and peroxisomes. Long chain fatty acids are also metabolized by the cytochrome P450 CYP4A omega-oxidation enzymes to toxic dicarboxylic acids (DCAs) that serve as substrates for peroxisomal beta-oxidation. Synthetic peroxisome proliferators interact with peroxisome proliferator activated receptor alpha (PPAR alpha) to transcriptionally activate genes that participate in peroxisomal, microsomal, and mitochondrial fatty acid oxidation. Mice lacking PPAR alpha (PPAR alpha(-/-)) fail to respond to the inductive effects of peroxisome proliferators, whereas those lacking fatty acyl-CoA oxidase (AOX(-/-)), the first enzyme of the peroxisomal beta-oxidation system, exhibit extensive microvesicular steatohepatitis, leading to hepatocellular regeneration and massive peroxisome proliferation, implying sustained activation of PPAR alpha by natural ligands. We now report that mice nullizygous for both PPAR alpha and AOX (PPAR alpha(-/-) AOX(-/-)) failed to exhibit spontaneous peroxisome proliferation and induction of PPAR alpha-regulated genes by biological ligands unmetabolized in the absence of AOX. In AOX-/- mice, the hyperactivity of PPAR alpha enhances the severity of steatosis by inducing CYP4A family proteins that generate DCAs and since they are not metabolized in the absence of peroxisomal beta-oxidation, they damage mitochondria leading to steatosis. Blunting of microvesicular steatosis, which is restricted to few liver cells in periportal regions in PPAR alpha(-/-) AOX(-/-) mice, suggests a role for PPAR alpha-induced genes, especially members of CYP4A family, in determining the severity of steatosis in livers with defective peroxisomal beta-oxidation. In age-matched PPAR alpha(-/-) mice, a decrease in constitutive mitochondrial beta-oxidation with intact constitutive peroxisomal beta-oxidation system contributes to large droplet fatty change that is restricted to centrilobular hepatocytes. These data define a critical role for both PPAR alpha and AOX in hepatic lipid metabolism and in the pathogenesis of specific fatty liver phenotype.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Peters, Jeffrey/D-8847-2011	Peters, Jeffrey/0000-0003-2782-2998	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; FORMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZAI K, 1992, J BIOL CHEM, V267, P1027; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kurtz DM, 1998, P NATL ACAD SCI USA, V95, P15592, DOI 10.1073/pnas.95.26.15592; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANNAERTS GP, 1982, ANN NY ACAD SCI, V386, P30, DOI 10.1111/j.1749-6632.1982.tb21405.x; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OCKNER RK, 1993, HEPATOLOGY, V18, P669, DOI 10.1002/hep.1840180327; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; OZASA H, 1983, J BIOCHEM-TOKYO, V94, P543, DOI 10.1093/oxfordjournals.jbchem.a134385; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1985, HDB CARCINOGEN TESTI, P482; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SHERLOCK S, 1995, LANCET, V345, P227; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TONSGARD JH, 1985, J CLIN INVEST, V76, P816, DOI 10.1172/JCI112039; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; USUDA N, 1988, LAB INVEST, V58, P100; YOKOTA S, 1985, HISTOCHEMISTRY, V82, P25, DOI 10.1007/BF00502087	49	203	212	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19228	19236		10.1074/jbc.274.27.19228	http://dx.doi.org/10.1074/jbc.274.27.19228			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383430	hybrid			2022-12-27	WOS:000081196300053
J	Linton, MF; Babaev, VR; Gleaves, LA; Fazio, S				Linton, MF; Babaev, VR; Gleaves, LA; Fazio, S			A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER ACCUMULATION; MOUSE PERITONEAL-MACROPHAGES; BONE-MARROW TRANSPLANTATION; ISOLATED HUMAN LYMPHOCYTES; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-E; KNOCKOUT MICE; CANINE BETA; LDL; SUSCEPTIBILITY	To evaluate the contribution of the macrophage low density lipoprotein receptor (LDLR) to atherosclerotic lesion formation, we performed bone marrow transplantation studies in different mouse strains. First, LDLR(-/-) mice were transplanted with either LDLR(+/+) marrow or LDLR(-/-) marrow and were challenged with an atherogenic Western type diet. The diet caused severe hypercholesterolemia of a similar degree in the two groups, and no differences in the aortic lesion area were detected. Thus, macrophage LDLR expression does not influence foam cell lesion formation in the setting of extreme LDL accumulation. To determine whether macrophage LDLR expression affects foam cell formation under conditions of moderate, non-LDL by. perlipidemia, we transplanted C57BL/6 mice with either LDLR(-/-) marrow (experimental group) or LDLR(+/+) marrow (controls). Cholesterol levels were not significantly different between the two groups at baseline or after 6 weeks on a butterfat diet, but were 40% higher in the experimental mice after 13 weeks, mostly due to accumulation of beta-very low density lipoprotein (beta-VLDL). Despite the increase in cholesterol levels, mice receiving LDLR(-/-) marrow developed 63% smaller lesions than controls, demonstrating that macrophage LDLR affects the rate of foam cell formation when the atherogenic stimulus is beta-VLDL. We conclude that the macrophage LDLR is responsible for a significant portion of lipid accumulation in foam cells under conditions of dietary stress.	Vanderbilt Univ, Sch Med, Div Endocrinol, Med Ctr,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Linton, MF (corresponding author), Vanderbilt Univ, Sch Med, Div Endocrinol, Med Ctr,Dept Med, 715 Med Res Bldg 2, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53989-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boisvert WA, 1997, ARTERIOSCL THROM VAS, V17, P340, DOI 10.1161/01.ATV.17.2.340; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; ELLSWORTH JL, 1987, J BIOL CHEM, V262, P2316; Fazio S, 1997, J LIPID RES, V38, P391; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; Herijgers N, 1997, ARTERIOSCL THROM VAS, V17, P1995, DOI 10.1161/01.ATV.17.10.1995; HO YK, 1976, J CLIN INVEST, V58, P1465, DOI 10.1172/JCI108603; HO YK, 1977, J EXP MED, V145, P1531, DOI 10.1084/jem.145.6.1531; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; KNIGHT BL, 1986, EUR J BIOCHEM, V156, P205, DOI 10.1111/j.1432-1033.1986.tb09569.x; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KOO C, 1986, J BIOL CHEM, V261, P1194; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; MAHLEY RW, 1980, J LIPID RES, V21, P970; NAGELKERKE JF, 1986, J BIOL CHEM, V261, P8909; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Weintraub MS, 1996, BRIT MED J, V312, P936; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	35	79	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19204	19210		10.1074/jbc.274.27.19204	http://dx.doi.org/10.1074/jbc.274.27.19204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383427	hybrid			2022-12-27	WOS:000081196300050
J	Poukka, H; Aarnisalo, P; Karvonen, U; Palvimo, JJ; Janne, OA				Poukka, H; Aarnisalo, P; Karvonen, U; Palvimo, JJ; Janne, OA			Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; RAT GLUCOCORTICOID RECEPTOR; STEROID-HORMONE RECEPTORS; CREB-BINDING-PROTEIN; NUCLEAR-PORE COMPLEX; SUMO-1 MODIFICATION; DNA-BINDING; DEOXYRIBONUCLEIC-ACID; TARGETING SIGNAL; DOMAIN	Ubc9, a homologue of the class E2 ubiquitin-conjugating enzymes, has recently been shown to catalyze conjugation of a small ubiquitin-like molecule-1 (SUMO-1) to a variety of target proteins. SUMO-1 modifications have been implicated in the targeting of proteins to the nuclear envelope and certain intranuclear structures and in converting proteins resistant to ubiquitin-mediated degradation, In the present work, we find that Ubc9 interacts with the androgen receptor (AR), a member of the steroid receptor family of ligand-activated transcription factors. In transiently transfected COS-1 cells, AR dependent but not basal transcription is enhanced by the coexpression of Ubc9. The N-terminal half of the AR hinge region containing the C-terminal part of the bipartite nuclear localization signal is essential for the interaction with Ubc9, Deletion of this part of the nuclear localization signal, which does not completely prevent the transfer of AR to the nucleus, abolishes the AR-Ubc9 interaction and attenuates the transcriptional response to cotransfected Ubc9, The C93S substitution of Ubc9, which prevents SUMO-1 conjugation by abrogating the formation of a thiolester bond between SUMO-1 and Ubc9, does not influence the capability of Ubc9 to stimulate AR-dependent transactivation, implying that Ubc9 is able to act as an AR coregulator in a fashion independent of its ability to catalyze SUMO-1 conjugation.	Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Janne, OA (corresponding author), Univ Helsinki, Inst Biomed, Dept Physiol, POB 9,Siltavuorenpenger 20 J, FIN-00014 Helsinki, Finland.			Palvimo, Jorma/0000-0003-2373-0578				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	48	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19441	19446		10.1074/jbc.274.27.19441	http://dx.doi.org/10.1074/jbc.274.27.19441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383460	hybrid			2022-12-27	WOS:000081196300083
J	Sun, J; Xu, W; Hervas, M; Navarro, JK; De La Rosa, MA; Chitnis, PR				Sun, J; Xu, W; Hervas, M; Navarro, JK; De La Rosa, MA; Chitnis, PR			Oxidizing side of the cyanobacterial photosystem I - Evidence for interaction between the electron donor proteins and a luminal surface helix of the PsaB subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; PHOTOSYNTHETIC REACTION-CENTER; FLASH ABSORPTION-SPECTROSCOPY; SP PCC 6803; CYTOCHROME C(6); SYNECHOCOCCUS-ELONGATUS; TARGETED INACTIVATION; MUTATIONAL ANALYSIS; PLASTOCYANIN; POLYPEPTIDES	Photosystem I (PSI) interacts with plastocyanin or cytochrome c(6) on the luminal side. To identify sites of interaction between plastocyanin/cytochrome c(6) and the PSI core, site-directed mutations were generated in the luminal J loop of the PsaB protein from Synechocystis sp, PCC 6803. The eight mutant strains differed in their photoautotrophic growth. Western blotting with subunit-specific antibodies indicated that the mutations affected the PSI level in the thylakoid membranes. PSI proteins could not be detected in the S600R/G601C/ N602I, N609K/S610C/T611I, and M614I/G615C/W616A mutant membranes. The other mutant strains contained different levels of PSI proteins. Among the mutant strains that contained PSI proteins, the H595C/L596I, Q627H/L628C/I629S, and N638C/N639S mutants showed similar levels of PSI-mediated electron transfer activity when either cytochrome c(6) or an artificial electron donor was used. In contrast, cytochrome c(6) could not function as an electron donor to the W622C/A623R mutant, even though the PSI activity mediated by an artificial electron donor was detected in this mutant. Thus, the W622C/A623R mutation affected the interaction of the PSI complex with cytochrome c(6). Biotin-maleimide modification of the mutant PSI complexes indicated that His-595, Trp-622, Leu-628, Tyr-632, and Asn-638 in wildtype PsaB may be exposed on the surface of the PSI complex. The results presented here demonstrate the role of an extramembrane loop of a PSI core protein in the interaction with soluble electron donor proteins.	Iowa State Univ, Dept Biochem & Biophys, Ames, IA 50011 USA; Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Iowa State University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	Chitnis, PR (corresponding author), Iowa State Univ, Dept Biochem & Biophys, Ames, IA 50011 USA.	chitnis@iastate.edu	navarro, jose a/B-6354-2015; Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014	navarro, jose a/0000-0002-0536-6074; Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; Xu, Wu/0000-0002-2982-3276				ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; BOUSSIBA S, 1992, RES PHOTOSYNTHESIS, V3, P429; Chitnis PR, 1996, PLANT PHYSIOL, V111, P661, DOI 10.1104/pp.111.3.661; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DEISENHOFER J, 1991, ANNU REV CELL BIOL, V7, P1; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Furr HC, 1992, MODERN CHROMATOGRAPH, P1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAEHNEL W, 1980, BIOCHIM BIOPHYS ACTA, V593, P384, DOI 10.1016/0005-2728(80)90075-4; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HATANAKA H, 1993, BIOCHIM BIOPHYS ACTA, V1141, P45, DOI 10.1016/0005-2728(93)90187-K; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V34, P339, DOI 10.1016/0003-9861(51)90012-4; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; SANDMANN G, 1986, ARCH MICROBIOL, V145, P76, DOI 10.1007/BF00413030; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; Sun J, 1998, METHOD ENZYMOL, V297, P124; Sun J, 1997, J BIOL CHEM, V272, P21793, DOI 10.1074/jbc.272.35.21793; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1994, J BIOL CHEM, V269, P21512; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU QA, 1994, J BIOL CHEM, V269, P3205; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	46	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19048	19054		10.1074/jbc.274.27.19048	http://dx.doi.org/10.1074/jbc.274.27.19048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383406	Green Published, hybrid			2022-12-27	WOS:000081196300029
J	Unkles, SE; Heck, IS; Appleyard, MVCL; Kinghorn, JR				Unkles, SE; Heck, IS; Appleyard, MVCL; Kinghorn, JR			Eukaryotic molybdopterin synthase - Biochemical and molecular studies of Aspergillus nidulans cnxG and cnxH mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI; NITRATE REDUCTASE; CHLORATE TOXICITY; CONVERTING FACTOR; GENE; CLONING; LOCUS; INVOLVEMENT; DEFICIENCY	We describe the primary structure of eukaryotic molybdopterin synthase small and large subunits and compare the sequences of the lower eukaryote, Aspergillus nidulans, and a higher eukaryote, Homo sapiens. Mutants in the A. nidulans cnxG (encoding small subunit) and cnxH (large subunit) genes have been analyzed at the biochemical and molecular level. Chlorate-sensitive mutants, all the result of amino acid substitutions, were shown to produce low levels of molybdopterin, and growth tests suggest that they have low levels of molybdoenzymes. In contrast, chlorate-resistant cnx strains have undetectable levels of molybdopterin, lack the ability to utilize nitrate or hypoxanthine as sole nitrogen sources, and are probably null mutations. Thus on the basis of chlorate toxicity, it is possible to distinguish between amino acid substitutions that permit a low level of molybdopterin production and those mutations that completely abolish molybdopterin synthesis, most likely reflecting molybdopterin synthase activity per se. Residues have been identified that are essential for function including the C-terminal Gly of the small subunit (CnxG), which is thought to be crucial for the sulfur transfer process during the formation of molybdopterin. Two independent alterations at residue Gly-148 in the large subunit, CnxH, result in temperature sensitivity suggesting that this residue resides in a region important for correct folding of the fungal protein. Many years ago it was proposed, from data showing that temperature-sensitive cnxH mutants had thermolabile nitrate reductase, that CnxH is an integral part of the molybdoenzyme nitrate reductase (MacDonald, D. W., and Cove, D. J. (1974) fur. J. Biochem. 47, 107-110). Studies of temperature-sensitive cnxH mutants isolated in the course of this study do not support this hypothesis. Homologues of both molybdopterin synthase subunits are evident in diverse eukaryotic sources such as worm, rat, mouse, rice, and fruit fly as well as humans as discussed in this article. In contrast, molybdopterin synthase homologues are absent in the yeast Saccharomyces cerevisiae. Precursor Z and molybdopterin are undetectable in this organism nor do there appear to be homologues of molybdoenzymes.	Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Univ St Andrews, Sch Biol, Div Environm & Evolut Biol, St Andrews KY16 9TH, Fife, Scotland; Inst Plant Biochem, D-72076 Tubingen, Germany	Monash University; University of St Andrews	Unkles, SE (corresponding author), Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia.							ABERG B, 1947, KUNGL LANTBRUKSHOGSK, V15, P37; ADELBERG EA, 1965, BIOCHEM BIOPH RES CO, V18, P788, DOI 10.1016/0006-291X(65)90855-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; ARST HN, 1997, MICROBIOLOGY, V143, P1437; BAL J, 1977, MUTAT RES, V56, P153, DOI 10.1016/0027-5107(77)90203-2; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COOLEY RN, 1985, BIOCHIM BIOPHYS ACTA, V831, P89, DOI 10.1016/0167-4838(85)90153-0; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1976, HEREDITY, V36, P191, DOI 10.1038/hdy.1976.24; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; COVE DJ, 1976, MOL GEN GENET, V146, P147, DOI 10.1007/BF00268083; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GARRETT RG, 1976, MOL GEN GENET, V147, P179; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; HECK IS, 1995, PHOTOCHEM PHOTOBIOL, V61, P54, DOI 10.1111/j.1751-1097.1995.tb09242.x; Herman C., 1966, ASPERGILLUS NEWS LET, V7, P13; Hughes EF, 1998, DEV MED CHILD NEUROL, V40, P57; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KETCHUM PA, 1970, P NATL ACAD SCI USA, V66, P1016, DOI 10.1073/pnas.66.3.1016; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; MACDONALD DW, 1974, EUR J BIOCHEM, V47, P107, DOI 10.1111/j.1432-1033.1974.tb03673.x; MACDONALD DW, 1974, EUR J BIOCHEM, V46, P169; MINAGAWA N, 1982, J BIOCHEM, V91, P761, DOI 10.1093/oxfordjournals.jbchem.a133763; MIZE C, 1995, J INHERIT METAB DIS, V18, P283, DOI 10.1007/BF00710416; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Sloan J, 1999, NUCLEIC ACIDS RES, V27, P854, DOI 10.1093/nar/27.3.854; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; UNKLES SE, 1992, APPL MOL GENETICS FI, P28; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	40	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19286	19293		10.1074/jbc.274.27.19286	http://dx.doi.org/10.1074/jbc.274.27.19286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383438	hybrid			2022-12-27	WOS:000081196300061
J	Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A				Ziouzenkova, O; Asatryan, L; Akmal, M; Tetta, C; Wratten, ML; Loseto-Wich, G; Jurgens, G; Heinecke, J; Sevanian, A			Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood - Relevance to atherogenesis caused by hemodialysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; ACCELERATED ATHEROSCLEROSIS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; LDL SUBFRACTION; GENERATION; PROTEINS; HYDROPEROXIDES; ERYTHROCYTES; SPECIFICITY	Human blood contains a form of minimally modified low density lipoprotein (LDL), termed LDL-, whose origin remains unknown. Exploring the mechanism of formation, we found that LDL- can be produced in plasma in the absence of oxygen following LDL incubation with oxidized hemoglobin species. A high degree of apolipoprotein B100 modification results from covalent association of hemoglobin with LDL involving dityrosine formation but not due to the malonaldehyde epitope formation. This was evidenced by the cross-reactivity of oxidized LDL with antibodies against hemoglobin that was accompanied by a 60-fold increase in dityrosine levels. In this study we found significantly higher LDL- levels in the blood of hemodialysis patients, perhaps contributing 60 their greatly increased risk of atherosclerosis. The mechanism of LDL- formation was studied during ex vivo blood circulation using a model system resembling clinical hemodialysis in terms of the induction of inflammatory responses. This circulation increased free hemoglobin and LDL- levels compared with non-circulated blood without appreciable lipid peroxidation, Pronounced increases in LDL- were found also during circulation of plasma supplemented with nanomolar hemoglobin levels. The increase in dityrosine content and presence of heme in LDL after blood circulation suggest that LDL is modified, in part, by hemoglobin-LDL conjugates containing heme, Thus, hemoglobin-mediated reactions leading to LDL oxidation in plasma can account for high LDL- levels in hemodialysis patients.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Div Nephrol, Los Angeles, CA 90033 USA; Bellco SPA, Clin & Lab Res Dept, I-41037 Mirandola, Italy; Washington Univ, Sch Med, St Louis, MO 63110 USA; Karl Franzens Univ Graz, A-8010 Graz, Austria	University of Southern California; University of Southern California; Washington University (WUSTL); University of Graz	Sevanian, A (corresponding author), 1985 Zonal Ave,PSC 612, Los Angeles, CA 90033 USA.	asevan@thevine.net	Ziouzenkova, Ouliana/B-3690-2012; Ziouzenkova, Ouliana/AAM-1971-2020; Jürgens, Günther/B-8818-2011	Ziouzenkova, Ouliana/0000-0003-2449-2591; 	FOGARTY INTERNATIONAL CENTER [F05TW005340] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050350] Funding Source: NIH RePORTER; FIC NIH HHS [1 F05 TW05340-01] Funding Source: Medline; NHLBI NIH HHS [HL50350] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Balagopalakrishna C, 1997, ADV EXP MED BIOL, V411, P337; Banni S, 1996, NEPHRON, V72, P177, DOI 10.1159/000188838; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bonomini M, 1997, NEPHRON, V75, P402, DOI 10.1159/000189577; CAZZOLATO G, 1991, FREE RADICAL BIO MED, V11, P247, DOI 10.1016/0891-5849(91)90120-R; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; DAUL AE, 1994, DEUT MED WOCHENSCHR, V119, P1263, DOI 10.1055/s-2008-1058831; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DELMASBEAUVIEUX MC, 1995, NEPHRON, V69, P404, DOI 10.1159/000188510; Demuth K, 1996, ARTERIOSCL THROM VAS, V16, P773, DOI 10.1161/01.ATV.16.6.773; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FORTIER N, 1988, BLOOD, V71, P1427; GIULIVI C, 1994, METHOD ENZYMOL, V231, P490; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Greilberger J, 1997, ARTERIOSCL THROM VAS, V17, P2721, DOI 10.1161/01.ATV.17.11.2721; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HATTORI A, 1978, ARCH HISTOL JAPON, V41, P205, DOI 10.1679/aohc1950.41.205; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HODIS HN, 1994, J LIPID RES, V35, P669; Kim JG, 1997, FREE RADICAL BIO MED, V23, P251, DOI 10.1016/S0891-5849(96)00615-6; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MAGGI E, 1994, KIDNEY INT, V45, P876, DOI 10.1038/ki.1994.115; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MAPLES KR, 1990, ARCH BIOCHEM BIOPHYS, V277, P402, DOI 10.1016/0003-9861(90)90596-Q; MARESCA M, 1992, CELL BIOCHEM FUNCT, V10, P79, DOI 10.1002/cbf.290100203; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PAGANGA G, 1992, FEBS LETT, V303, P154, DOI 10.1016/0014-5793(92)80508-E; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RiceEvans C, 1996, FREE RADICAL RES, V25, P285, DOI 10.3109/10715769609149053; Sevanian A, 1997, J LIPID RES, V38, P419; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; Taccone-Galluci M, 1994, ASAIO J, V40, pM663, DOI 10.1097/00002480-199407000-00081; TETTA C, 1991, NEPHROL DIAL TRANSPL, V6, P24; VANDENBERG JJM, 1992, FREE RADICAL BIO MED, V12, P487, DOI 10.1016/0891-5849(92)90102-M; WINTERBOURN CC, 1985, HDB METHODS OXYGEN R; WONG SHY, 1987, CLIN CHEM, V33, P214; Yang CY, 1997, FREE RADICAL BIO MED, V23, P82, DOI 10.1016/S0891-5849(96)00624-7; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUKAWA S, 1995, NEPHROL DIAL TRANSPL, V10, P1	48	113	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18916	18924		10.1074/jbc.274.27.18916	http://dx.doi.org/10.1074/jbc.274.27.18916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383389	hybrid			2022-12-27	WOS:000081196300012
J	Chen, KD; Li, YS; Kim, M; Li, S; Yuan, S; Chien, S; Shyy, JYJ				Chen, KD; Li, YS; Kim, M; Li, S; Yuan, S; Chien, S; Shyy, JYJ			Mechanotransduction in response to shear stress - Roles of receptor tyrosine kinases, integrins, and Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; PROTEIN-1 GENE-EXPRESSION; GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; VASCULAR ENDOTHELIUM; MECHANICAL-STRESS; RAS PATHWAY; ACTIVATION; FLOW	Shear stress, the tangential component of hemodynamic forces, activates many signal transduction pathways in vascular endothelial cells. The conversion of mechanical stimulation into chemical signals is still unclear. We report here that shear stress (12 dynes/cm(2)) induced a rapid and transient tyrosine phosphorylation of Flk-1 and its concomitant association with the adaptor protein Shc; these are accompanied by a concurrent clustering of Flk-1, as demonstrated by confocal microscopy. Our results also show that shear stress induced an association of alpha(v)beta(3) and beta 1 integrins with Shc, and an attendant association of Shc with Grb2. These associations are sustained, in contrast to the transient Flk-1 Shc association in response to shear stress and the transient association between alpha(v)beta(3) integrin and Shc caused by cell attachment to substratum. Shc-SH2, an expression plasmid encoding the SH2 domain of Shc, attenuated shear stress activation of extracellular signal-regulated kinases and c-Jun N-terminal kinases, and the gene transcription mediated by the activator protein- 1/12-O-tetradecanoylphorbol-13-acetate-responsive element complex. Our results indicate that receptor tyrosine kinases and integrins can serve as mechanosensors to transduce mechanical stimuli into chemical signals via their association with Shc.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Biomed Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Shyy, JYJ (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Li, Song/0000-0002-4760-8828	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019454, R37HL044147, P01HL043026] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44147, HL43026, HL19454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CALALB MB, 1995, MOL CELL BIOL, V15, P954; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; Gotoh N, 1995, ONCOGENE, V11, P2525; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Hu YL, 1997, J HISTOCHEM CYTOCHEM, V45, P237, DOI 10.1177/002215549704500209; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRASAD ARS, 1993, CIRC RES, V72, P827, DOI 10.1161/01.RES.72.4.827; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEISS FU, 1997, CURR OPIN GENE DEV, V7, P880; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	60	451	473	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18393	18400		10.1074/jbc.274.26.18393	http://dx.doi.org/10.1074/jbc.274.26.18393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373445	hybrid			2022-12-27	WOS:000081056700037
J	Merry, CLR; Lyon, M; Deakin, JA; Hopwood, JJ; Gallagher, JT				Merry, CLR; Lyon, M; Deakin, JA; Hopwood, JJ; Gallagher, JT			Highly sensitive sequencing of the sulfated domains of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; IDURONATE 2-SULFATE RESIDUES; BINDING DOMAIN; PURIFIED ENZYME; BASIC FGF; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; PROTEOGLYCANS; POLYSACCHARIDES; BIOSYNTHESIS	The heparan sulfates (HS) are hypervariable linear polysaccharides that act as membrane co-receptors for growth factors, chemokines, and extracellular matrix proteins. In most instances, the molecular basis of protein recognition by HS is poorly understood. We have sequenced 75% of the sulfated domains (S-domains) of fibroblast HS, including all of the major ones. This analysis revealed tight coupling of N- and 2-O-sulfation and a low frequency but precise positioning of 6-O-sulfates, which are required functional groups for MS-mediated activation of the fibroblast growth factors. S-domain sequencing was conducted using a novel and highly sensitive method based on a new way of reading the sequence from high performance liquid chromatography separation profiles of metabolically labeled HS-saccharides following specific chemical and enzymatic scis-sion. The implications of the patterns seen in the sulfated domains for better understanding of the synthesis and function of HS are discussed.	Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England; Univ Manchester, Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Dis Res Unit, N Adelaide, SA 5006, Australia	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Gallagher, JT (corresponding author), Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England.			merry, catherine/0000-0002-3490-2809; Lyon, Malcolm/0000-0001-9575-6879				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIELICKI J, 1993, BIOCHEM J, V289, P241, DOI 10.1042/bj2890241; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIES J, 1995, DEVELOPMENT, V121, P1507; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; DWEK RA, 1995, J ANAT, V187, P2790; EDGE CJ, 1992, P NATL ACAD SCI USA, V89, P6338, DOI 10.1073/pnas.89.14.6338; FRANSSON LA, 1989, HEPARIN, P115; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gallagher JT, 1998, TRENDS GLYCOSCI GLYC, V10, P137, DOI 10.4052/tigg.10.137; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hacker U, 1997, DEVELOPMENT, V124, P3565; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINKER A, 1979, BIOCHEM J, V183, P711, DOI 10.1042/bj1830711; Litjens T, 1997, BIOCHEM J, V327, P89, DOI 10.1042/bj3270089; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RADOFF S, 1984, J BIOL CHEM, V259, P166; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; Rudd PM, 1997, NATURE, V388, P205, DOI 10.1038/40677; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1997, BIOMETHODS, V9, P261; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621	47	114	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18455	18462		10.1074/jbc.274.26.18455	http://dx.doi.org/10.1074/jbc.274.26.18455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373453	hybrid			2022-12-27	WOS:000081056700045
J	Stolz, J; Hoja, U; Meier, S; Sauer, N; Schweizer, E				Stolz, J; Hoja, U; Meier, S; Sauer, N; Schweizer, E			Identification of the plasma membrane H+-biotin symporter of Saccharomyces cerevisiae by rescue of a fatty acid-auxotrophic mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-CARBOXYLASE; ESCHERICHIA-COLI; ACETYL-COENZYME; YEAST-CELLS; TRANSCRIPTION; PANTOTHENATE; EXPRESSION; STRAINS; TRANSFORMATION; BIOSYNTHESIS	Bakers' yeast is auxotrophic for biotin (vitamin H) and depends on the efficient uptake of this compound from the environment. A mutant strain with strongly reduced biotin uptake and with reduced levels of protein biotinylation was identified. The strain was auxotrophic for long-chain fatty acids, and this auxotrophy could be suppressed with high levels of biotin in the medium. After transformation of this mutant with a yeast genomic library, the unassigned open reading frame YGR065C was identified to complement this mutation. This gene codes for a protein with 593 amino acids and 12 putative transmembrane helices, Northern blot analysis revealed that, in wild-type cells, the corresponding mRNA levels were increased at low biotin concentrations. Likewise, cellular biotin uptake was increased with decreasing biotin availability. Expression of YGR065C under the control of the constitutive ADH1 promoter resulted in very high biotin transport rates across the plasma membrane that were no longer regulated by the biotin concentration in the growth medium. We conclude that YGR065C encodes the first biotin transporter identified for a non-mammalian organism and designate this gene VHT1 for vitamin H transporter 1.	Univ Erlangen Nurnberg, Lehrstuhl Bot 1, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Lehrstuhl Biochem, D-91058 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Bot 1, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; Bayer E A, 1979, Methods Enzymol, V62, P371; BECKER JM, 1971, P NATL ACAD SCI USA, V68, P2604, DOI 10.1073/pnas.68.10.2604; BONJOUR JP, 1985, ANN NY ACAD SCI, V447, P97, DOI 10.1111/j.1749-6632.1985.tb18428.x; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V311, P62, DOI 10.1006/abbi.1994.1209; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; DAKSHINAMURTI K, 1985, ANN NY ACAD SCI, V447, P38, DOI 10.1111/j.1749-6632.1985.tb18424.x; Dyer DL, 1997, METHOD ENZYMOL, V279, P393; EISENBERG M, 1987, CELLULAR MOL BIOL, V1, P544; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRASSL SM, 1992, J BIOL CHEM, V267, P22902; GRASSL SM, 1992, J BIOL CHEM, V267, P17760; Hablacher M, 1993, J BIOL CHEM, V268, P10946; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HERTZ R, 1943, P SOC EXP BIOL MED, V52, P14; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Leonian LH, 1942, AM J BOT, V29, P459, DOI 10.2307/2437311; MALONE EA, 1993, MOL GEN GENET, V237, P449, DOI 10.1007/BF00279450; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Menendez J, 1998, YEAST, V14, P647; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MORTIMER RK, 1986, GENETICS, V113, P35; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; PIFFETEAU A, 1985, BIOCHIM BIOPHYS ACTA, V816, P77, DOI 10.1016/0005-2736(85)90395-5; PRAKASH O, 1974, J BACTERIOL, V120, P785, DOI 10.1128/JB.120.2.785-791.1974; Prasad PD, 1997, PLACENTA, V18, P527, DOI 10.1016/0143-4004(77)90006-6; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SWANSON MS, 1992, GENETICS, V132, P325; TUROSCY V, 1987, J BACTERIOL, V169, P2598, DOI 10.1128/jb.169.6.2598-2600.1987; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1998, METHOD MICROBIOL, V26, P67; [No title captured]	48	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18741	18746		10.1074/jbc.274.26.18741	http://dx.doi.org/10.1074/jbc.274.26.18741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373489	hybrid			2022-12-27	WOS:000081056700081
J	Gohla, A; Offermanns, S; Wilkie, TM; Schultz, G				Gohla, A; Offermanns, S; Wilkie, TM; Schultz, G			Differential involvement of G alpha(12) and G alpha(13) in receptor-mediated stress fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; G-PROTEINS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; P115 RHOGEF; ACTIVATION; EXCHANGE; EXPRESSION; DIVERSITY	The ubiquitously expressed heterotrimeric guanine nucleotide-binding proteins (G-proteins) G(12) and G(13) have been shown to activate the small GTPase Rho. Rho stimulation leads to a rapid remodeling of the actin cytoskeleton and subsequent stress fiber formation. We investigated the involvement of G(12) or G(13) in stress fiber formation induced through a variety of G(q)/G(11)-coupled receptors. Using fibroblast cell lines derived from wildtype and G alpha(q)/G alpha(11)-deficient mice, we show that agonist-dependent activation of the endogenous receptors for thrombin or lysophosphatidic acid and of the heterologously expressed bradykinin B-2, vasopressin V-1A, endothelin ETA, and serotonin 5-HT2C receptors induced stress fiber formation in either the presence or absence of G alpha(q)/G alpha(11). Stress fiber assembly induced through the muscarinic M-1 and the metabotropic glutamate subtype 1 alpha receptors was dependent on G(q)/G(11) proteins. The activation of the G(q)/G(11)-coupled endothelin ETB and angiotensin AT,A receptors failed to induce stress fiber formation. Lysophosphatidic acid, B-2, and 5-HT2C receptor-mediated stress fiber formation was dependent on G alpha(13) and involved epidermal growth factor (EGF) receptors, whereas thrombin, ETA, and V-1A receptors induced stress fiber accumulation via G alpha(12) in an EGF receptor-independent manner. Our data demonstrate that many G(q)/G(11)-coupled receptors induce stress fiber assembly in the absence of G alpha(q) and G alpha(11) and that this involves either a G alpha(12) or a G alpha(13)/EGF receptor-mediated pathway.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Free University of Berlin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805; Gohla, Antje/0000-0002-7442-1487				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE E, 1992, J BIOL CHEM, V267, P1212; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAH V, 1996, J BIOL CHEM, V49, P31185; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WONG YH, 1994, METHOD ENZYMOL, V238, P81; YANG JT, 1993, DEVELOPMENT, V119, P1093	38	191	196	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17901	17907		10.1074/jbc.274.25.17901	http://dx.doi.org/10.1074/jbc.274.25.17901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364236	hybrid			2022-12-27	WOS:000080974300072
J	Grenert, JP; Johnson, BD; Toft, DO				Grenert, JP; Johnson, BD; Toft, DO			The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; N-TERMINAL FRAGMENT; RABBIT RETICULOCYTE LYSATE; STEADY-STATE ANALYSIS; DNA TOPOISOMERASE-II; GYRASE-B-PROTEIN; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; IN-VIVO; MOLECULAR CHAPERONE	The chaperone hsp90 is capable of binding and hydrolyzing ATP. Using information on a related ATPase, DNA gyrase B, we selected three conserved residues in hsp90's ATP-binding domain for mutation. Two off these mutations eliminate nucleotide binding, while the third retains nucleotide binding but is apparently deficient in ATP hydrolysis. We first analyzed how these mutations affect hsp90's binding to the co-chaperones p23 and Hop, and to the hydrophobic resin, phenyl-Sepharose. These experiments showed that ATP's effects, specifically, increased affinity for p23 and decreased affinity for Hop and phenyl-Sepharose, are brought on by ATP binding alone. We also tested the ability of hsp90 mutants to assist hsp70, hsp40, and Hop in the refolding of denatured firefly luciferase. While hsp90 is capable of participating in this process in a nucleotide-independent manner, the ability to hydrolyze ATP markedly potentiates hsp90's effect. Finally, we assembled progesterone receptor heterocomplexes with hsp70, hsp40, Hop, pas, and wild type or mutant hsp90. While neither ATP binding nor hydrolysis was necessary to bind hsp90 to the receptor, mature complexes containing p23 and capable of hormone binding were only obtained with wild type hsp90.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55906 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK46249] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Bartha BB, 1998, BIOPHYS CHEM, V72, P313, DOI 10.1016/S0301-4622(98)00114-8; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Csermely P, 1997, LIFE SCI, V61, P411, DOI 10.1016/S0024-3205(97)00398-6; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DITMAR KD, 1997, J BIOL CHEM, V272, P13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gerloff DL, 1997, PROTEINS, V27, P450, DOI 10.1002/(SICI)1097-0134(199703)27:3<450::AID-PROT12>3.3.CO;2-9; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; GRODY WW, 1980, J STEROID BIOCHEM, V12, P115, DOI 10.1016/0022-4731(80)90260-5; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; TOFT D, 1979, J STEROID BIOCHEM, V11, P413, DOI 10.1016/0022-4731(79)90060-8; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	66	191	198	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17525	17533		10.1074/jbc.274.25.17525	http://dx.doi.org/10.1074/jbc.274.25.17525			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364185	hybrid			2022-12-27	WOS:000080974300021
J	Juang, YT; Au, WC; Lowther, W; Hiscott, J; Pitha, PM				Juang, YT; Au, WC; Lowther, W; Hiscott, J; Pitha, PM			Lipopolysaccharide inhibits virus-mediated induction of interferon genes by disruption of nuclear transport of interferon regulatory factors 3 and 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED RESPONSE ELEMENT; ALPHA PROMOTER REGION; PROTEIN-KINASE-C; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; HUMAN-MONOCYTES; IFN-GAMMA; PERITONEAL-MACROPHAGES; ENDOGENOUS INTERFERON	We have studied the effects of lipopolysaccharide (LPS) on the Newcastle disease virus (NDV)-mediated induction of cytokine genes expression. Raw cells treated with LPS before or after virus infection showed down-regulation in the expression of interferon A and, to a lesser extent, interferon B genes. In contrast, induction of the interleukin (IL)-6 gene was enhanced. The effects of LPS were not a result of the suppression of virus replication, because the transcription of viral nucleocapsid gene was not affected. Consistent with these findings, LPS also suppressed the NDV-mediated induction of chloramphenicol acetyltransferase reporter gene driven by murine interferon A4 promoter in a transient transfection assay. Furthermore, LPS-inhibited virus-mediated phosphorylation of interferon regulatory factor (IRF)-3 and the consequent translocation of IRF-3 from cytoplasm to nucleus. The LPS-mediated inhibition of IFNA gene expression was much weaker in infected Raw cells that constitutively overexpressed IRF-5. The nuclear translocation of IRF-7 in infected cells was also inhibited by LPS. These data suggest that LPS down-regulates the virus-mediated induction of IFNA genes by post-translationally targeting the IRF-3 and IRF-7 proteins.	Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; McGill Univ, Dept Microbiol & Med, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Lady Davis Institute; McGill University	Pitha, PM (corresponding author), Johns Hopkins Univ, Ctr Oncol, 418 N Bond St, Baltimore, MD 21231 USA.				NIAID NIH HHS [AI19737] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An MR, 1996, MOL CELL BIOL, V16, P2295; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BAKOUCHE O, 1992, J IMMUNOL, V148, P84; BARBER SA, 1995, J IMMUNOL, V155, P1404; BELARDELLI F, 1987, J GEN VIROL, V68, P2203, DOI 10.1099/0022-1317-68-8-2203; BISAT F, 1988, NUCLEIC ACIDS RES, V16, P6067, DOI 10.1093/nar/16.13.6067; CAMUSSI G, 1995, J IMMUNOL, V155, P316; CAVAILLON JM, 1985, IMMUNOL LETT, V10, P35, DOI 10.1016/0165-2478(85)90047-1; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FEIST W, 1989, IMMUNOBIOLOGY, V179, P293, DOI 10.1016/S0171-2985(89)80036-1; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GESSANI S, 1987, J IMMUNOL, V139, P1991; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; JAKWAY JP, 1986, SCIENCE, V234, P743, DOI 10.1126/science.3095921; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KIELIAN TL, 1995, IMMUNOPHARMACOLOGY, V29, P187, DOI 10.1016/0162-3109(95)00003-C; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LIU MK, 1994, J IMMUNOL, V153, P2642; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; Nickolaus P, 1998, J INTERF CYTOK RES, V18, P187, DOI 10.1089/jir.1998.18.187; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OHMORI Y, 1995, J IMMUNOL, V155, P3593; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PITHA PM, 1988, J IMMUNOL, V141, P3611; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; REIMANN T, 1994, J IMMUNOL, V153, P5740; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TEBO JM, 1992, J IMMUNOL, V149, P2352; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; VEALS SA, 1991, BRIT J HAEMATOL, V79, P9, DOI 10.1111/j.1365-2141.1991.tb08110.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	55	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18060	18066		10.1074/jbc.274.25.18060	http://dx.doi.org/10.1074/jbc.274.25.18060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364258	hybrid			2022-12-27	WOS:000080974300094
J	Morinaga, N; Adamik, R; Moss, J; Vaughan, M				Morinaga, N; Adamik, R; Moss, J; Vaughan, M			Brefeldin A inhibited activity of the Sec7 domain of p200, a mammalian guanine nucleotide-exchange protein for ADP-ribosylation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GOLGI-APPARATUS; PHOSPHOLIPASE-D; HOMOLOGY DOMAINS; CHOLERA-TOXIN; ARF; COMPARTMENTS; CYTOHESIN-1; PLECKSTRIN; ACTIVATION; TRANSPORT	A brefeldin A (BFA)-inhibited guanine nucleotide-exchange protein (GEP) for ADP-ribosylation factors (ARF) was purified earlier from bovine brain cytosol. Cloning and expression of the cDNA confirmed that the recombinant protein (p200) is a PEA-sensitive ARF GEP. p200 contains a domain that is 50% identical in amino acid sequence to a region in yeast Sec7, termed the Sec7 domain. Sec7 domains have been identified also in other proteins with ARF GEP activity, some of which are not inhibited by BFA. To identify structural elements that influence GEP activity and its BFA sensitivity, several truncated mutants of p200 were made. Deletion of sequence C-terminal to the Sec7 domain did not affect GEP activity. A protein lacking 594 amino acids at the N terminus, as well as sequence following the Sec7 domain, also had high activity, The mutant lacking 630 N-terminal amino acids was, however, only 1% as active, as was the Sec7 domain itself (mutant lacking 697 N-terminal residues). It appears that the Sec7 domain of p200 contains the catalytic site but additional sequence (perhaps especially that between positions 595 and 630) modifies activity dramatically. Myristoylated recombinant ARFs were better than non-myristoylated as substrates; ARFs 1 and 3 were better than ARF5, and no activity was detected with ARF6. Physical interaction of the Sec7 domain with an ARF1 mutant was demonstrated, but it was much weaker than that of the cytohesin-1 Sec7 domain with the same ARF protein. Effects of BFA on p200 and all mutants with high activity were similar with similar to 50% inhibition at less than or equal to 50 mu M. The inactive BFA analogue B36 did not inhibit the Sec7 domain or p200. Thus, the Sec7 domain of p200, like that of Sec7 itself (Sata, M., Donaldson, J. G., Moss, J., and Vaughan, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4204-4208), plays a role in BFA inhibition as well as in GEP activity, although the latter is markedly modified by other structural elements.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Morinaga, N (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000627, Z01HL000638, ZIAHL000627, Z01HL000656] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305	30	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17417	17423		10.1074/jbc.274.25.17417	http://dx.doi.org/10.1074/jbc.274.25.17417			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364170	hybrid			2022-12-27	WOS:000080974300006
J	Subramaniam, N; Treuter, E; Okret, S				Subramaniam, N; Treuter, E; Okret, S			Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; BOVINE PROLACTIN GENE; CREB-BINDING-PROTEIN; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSCRIPTION; MEDIATED REPRESSION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CROSS-TALK	Recent development in the field of gene regulation by nuclear receptors (NRs) have identified a role for cofactors in transcriptional control. While some of the NR-associated proteins serve as coactivators, the effect of the receptor interacting protein 140 (RIP140) on NR transcriptional responses is complex. In this report we have studied the effect of RIP140 on gene regulation by the glucocorticoid receptor (GR). We demonstrate that RIP140 antagonized all GR-mediated responses tested, which included activation through classical GRE, the synergistic effects of glucocorticoids on AP-1 and Pbx1/HOXB1 responsive elements, as well as gene repression through a negative GRE and cross-talk with NF-kappa B (RelA). This involved the ligand-binding domain of the GR and did not occur when the GR was bound to the antagonist RU486, The strong repressive effect of RIP140 was restricted to glucocorticoid-mediated responses in as much as it slightly increased signaling through the RelA and the Pit-1/Pbx proteins and only slightly repressed signaling through the Pbx1/HOXB1 and AP-1 proteins, excluding general squelching as a mechanism. Instead, this suggests that RIP140 acts as a direct inhibitor of GR function. In line with a direct effect of RIP140 on the GR, we demonstrate a GR-RIP140 interaction in vitro by a glutathione S-transferase-pull down assay. Furthermore, the repressive effect of RIP140 could partially be overcome by overexpression of the coactivator TIF2, which involved a competition between TIF2 and RIP140 for binding to the GR.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, SE-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Ctr Biotechnol, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, F60 Novum, SE-14186 Huddinge, Sweden.	Sam.Okret@mednut.ki.se		Treuter, Eckardt/0000-0002-4147-8989				Akerblom I.W., 1991, NUCLEAR HORMONE RECE, P175; Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Delaunay F, 1996, EUR J BIOCHEM, V242, P839, DOI 10.1111/j.1432-1033.1996.0839r.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; DROUIN J, 1998, NUCL HORMONE RECEPTO, P118; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; LIU W, 1995, MOL CELL BIOL, V15, P1005; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	54	86	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18121	18127		10.1074/jbc.274.25.18121	http://dx.doi.org/10.1074/jbc.274.25.18121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364267	hybrid			2022-12-27	WOS:000080974300103
J	Van Ryk, DI; Venkatesan, S				Van Ryk, DI; Venkatesan, S			Real-time kinetics of HIV-1 Rev-Rev response element interactions - Definition of minimal, binding sites on RNA and protein and stoichiometric analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE-PLASMON RESONANCE; STRUCTURAL GENE-EXPRESSION; NUCLEAR EXPORT SIGNAL; VIRAL MESSENGER-RNA; TYPE-1 REV; TRANS-ACTIVATOR; TARGET SEQUENCE; REGULATORY PROTEINS; FUNCTIONAL-ANALYSIS	The kinetics of interaction between the human immunodeficiency virus-1 Rev protein and its RNA target, Rev response element (RRE) RNA was determined in vitro using a biosensor technique. Our results showed that the primary Rev binding site is a core stem-loop RNA molecule of 30 nucleotides that bound Rev at a 1:1 ratio, whereas the 244-nucleotide full-length RRE bound four Rev monomers. At high Rev concentrations, additional binding of Rev to RRE was observed with ratios of more than 10:1. Because RRE mutants that lacked the core binding site and were inactive in vivo bound Rev nonspecifically at these concentrations, the real stoichiometric ratio of Rev-RRE is probably closer to 4:1. Binding affinity of Rev for RRE was approximately 10(-10) M, whereas the affinity for the core RNA was about 10(-11) M, the difference being due to the contribution of low affinity binding sites on the RRE. Mathematical analysis suggested cooperativity of Rev binding, probably mediated by the Rev oligomerization domains. C-terminal deletions of Rev had no effect on RRE binding, but truncation of the N terminus by as few as 11 residues significantly reduced binding specificity. This method was also useful to rapidly evaluate the potential of aminoglycoside antibiotics, to inhibit the Rev-RRE interaction.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Venkatesan, S (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 10,Rm 6A05,9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000528, Z01AI000528] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1989, P NATL ACAD SCI USA, V86, P6111, DOI 10.1073/pnas.86.16.6111; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BOHNLEIN E, 1991, J VIROL, V65, P7051; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COCHRANE AW, 1989, J VIROL, V63, P4438, DOI 10.1128/JVI.63.10.4438-4440.1989; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DALY TJ, 1993, BIOCHEMISTRY-US, V32, P8945, DOI 10.1021/bi00085a028; DALY TJ, 1995, J MOL BIOL, V253, P243, DOI 10.1006/jmbi.1995.0549; DAYTON ET, 1992, J VIROL, V66, P1139, DOI 10.1128/JVI.66.2.1139-1151.1992; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1990, J VIROL, V64, P3734, DOI 10.1128/JVI.64.8.3734-3741.1990; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAMMERSCHMID M, 1994, J VIROL, V68, P7329, DOI 10.1128/JVI.68.11.7329-7335.1994; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOLLAND SM, 1990, J VIROL, V64, P5966, DOI 10.1128/JVI.64.12.5966-5975.1990; HOLLAND SM, 1992, J VIROL, V66, P3699, DOI 10.1128/JVI.66.6.3699-3706.1992; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; *PHARM BIOS AB, 1994, BIAT HDB; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WINGFIELD PT, 1991, BIOCHEMISTRY-US, V30, P7527, DOI 10.1021/bi00244a023; WOOD SJ, 1993, MICROCHEM J, V47, P330, DOI 10.1006/mchj.1993.1051; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	82	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17452	17463		10.1074/jbc.274.25.17452	http://dx.doi.org/10.1074/jbc.274.25.17452			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364175	hybrid			2022-12-27	WOS:000080974300011
J	Espanel, X; Sudol, M				Espanel, X; Sudol, M			A single point mutation in a Group IWW domain shifts its specificity to that of Group IIWW domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; EPITHELIAL SODIUM-CHANNEL; WW DOMAIN; MISSENSE MUTATION; LIDDLES-SYNDROME; SOLID SUPPORTS; BETA-SUBUNIT; SH3 DOMAINS; PY MOTIF; IDENTIFICATION	WW domains can be divided into three groups based on their binding specificity. By random mutagenesis, we switched the specificity of the Yes-associated protein (YAP) WW1 domain, a Group I WW domain, to that of the FE65 WW domain, which belongs to Group II. We showed that a single mutation, leucine 190 (beta B5) to tryptophan, is required to switch from Group I to Group II. Although this single substitution in YAP WW1 domain is sufficient to precipitate the two protein isoforms of Mena, an in vivo ligand of FE65, we showed that an additional substitution, histidine 192 (beta B7) to glycine, significantly increased the ability of YAP to mimic FE65. This double mutant (L190W/H192G) precipitates eight of the nine protein bands that FE65 pulls down from rat brain protein lysates. Based on both our data and a sequence comparison between Group I and Group II WW domains, we propose that a block of three consecutive aromatic amino acids within the second beta-sheet of the domain is required, but not always sufficient, for a WW domain to belong to Group II. These data deepen our understanding of WW domain binding specificity and provide a basis for the rational design of modified WW domains with potential therapeutic applications.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.				NCI NIH HHS [CA45757, CA01605] Funding Source: Medline; NIDDK NIH HHS [DK50795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050795] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; GERTLER GB, 1996, CELL, V87, P1; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HASSON JH, 1995, P NATL ACAD SCI USA, V92, P11495; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; WENG ZG, 1995, MOL CELL BIOL, V15, P5627	32	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17284	17289		10.1074/jbc.274.24.17284	http://dx.doi.org/10.1074/jbc.274.24.17284			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358088	hybrid			2022-12-27	WOS:000080780400087
J	Jayaraman, G; Srinivas, R; Duggan, C; Ferreira, E; Swaminathan, S; Somasundaram, K; Williams, J; Hauser, C; Kurkinen, M; Dhar, R; Weitzman, S; Buttice, G; Thimmapaya, B				Jayaraman, G; Srinivas, R; Duggan, C; Ferreira, E; Swaminathan, S; Somasundaram, K; Williams, J; Hauser, C; Kurkinen, M; Dhar, R; Weitzman, S; Buttice, G; Thimmapaya, B			p300/cAMP-responsive element-binding protein interactions with Ets-1 and Ets-2 in the transcriptional activation of the human stromelysin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; ONCOGENIC ACTIVITY; ADENOVIRUS E1A; FAMILY MEMBER; C-JUN; P300; CBP; CREB; COACTIVATOR	In this paper we show that transcription factors Ets-1 and Ets-2 recruit transcription adapter proteins p300 and CBP (cAMP-responsive element-binding protein) during the transcriptional activation of the human stromelysin promoter, which contains palindromic Ets-binding sites. Ets-2 and p300/CBP exist as a complex in vivo. Two regions of p300/CBP between amino acids (a.a.) 328 and 596 and a.a. 1678 and 2370 independently can interact with Ets-1 and Ets-2 in vitro and in vivo. Both these regions of p300/CBP bind to the transactivation domain of Ets-2, whereas the C-terminal region binds only to the DNA binding domain of Ets-2. The N- and the C-terminal regions of CBP (a.a. 1-1097 and 1678-2442, respectively) which lack histone acetylation activity independently are capable of coactivating Ets-2. Other Ets family transcription factors failed to cooperate with p300/CBP in stimulating the stromelysin promoter. The LXXLL sequence, reported to be important in receptor-coactivator interactions, does not appear to play a role in the interaction of Ets-2 with p300/CBP. Previous studies have shown that the stimulation of transcriptional activation activity of Ets-2 requires phosphorylation of threonine 72 by the Ras/mitogen-activated protein kinase signaling pathway. We show that mutation of this site does not affect its capacity to bind to and to cooperate with p300/CBP.	Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; CNRS, Inst Biol Lille, F-59021 Lille, France; Burnham Inst, La Jolla, CA 92037 USA; Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Centre National de la Recherche Scientifique (CNRS); Sanford Burnham Prebys Medical Discovery Institute; Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thimmapaya, B (corresponding author), Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol Oncol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Duggan, Catherine/AAE-9777-2020; Duggan, Catherine/F-9414-2015	Duggan, Catherine/0000-0001-7369-4021; Buttice', Giovanna/0000-0001-6550-5585; Swaminathan, Sathyamangalam/0000-0002-4388-2248	NATIONAL CANCER INSTITUTE [P20CA065764, R01CA074403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011536] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 1P20CA65764, CA74403] Funding Source: Medline; NIA NIH HHS [AG11536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BIRKENDELHANSON H, 1996, CRIT REV ORAL BIOL M, V4, P197; BIRNKERHOFF CE, 1991, ARTHRITIS RHEUM, V34, P1073; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURELY SK, 1996, ANNU REV BIOCHEM, V65, P769; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATRISIAN LM, 1992, MOL REPROD DEV, V32, P111, DOI 10.1002/mrd.1080320206; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NERLOV C, 1991, ONCOGENE, V6, P1583; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	76	117	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17342	17352		10.1074/jbc.274.24.17342	http://dx.doi.org/10.1074/jbc.274.24.17342			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358095	hybrid			2022-12-27	WOS:000080780400094
J	Stanley, TB; Jin, DY; Lin, PJ; Stafford, DW				Stanley, TB; Jin, DY; Lin, PJ; Stafford, DW			The propeptides of the vitamin K-dependent proteins possess different affinities for the vitamin K-dependent carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MATRIX GLA PROTEIN; IN-VITRO CARBOXYLATION; FACTOR-IX; RECOGNITION SITE; SUBSTRATE CARBOXYLATION; BOVINE LIVER; BONE; PROTHROMBIN; MUTATIONS	The vitamin K-dependent gamma-glutamyl carboxylase catalyzes the modification of specific glutamates in a number of proteins required for blood coagulation and associated with bone and calcium homeostasis. All known vitamin K-dependent proteins possess a conserved eighteen-amino acid propeptide sequence that is the primary binding site for the carboxylase, We compared the relative affinities of synthetic propeptides of nine human vitamin R-dependent proteins by determining the inhibition constants (K-i) toward a factor IX propeptide/gamma-carboxyglutamic acid domain substrate. The Ki values for six of the propeptides (factor X, matrix Gla protein, factor VII, factor IX, PRGP1, and protein S) were between 2-35 nM, with the factor X propeptide having the tightest affinity. In contrast, the inhibition constants for the propeptides of prothrombin and protein C are similar to 100-fold weaker than the factor X propeptide, The propeptide of bone Gla protein demonstrates severely impaired carboxylase binding with an inhibition constant of at least 200,000-fold weaker than the factor X propeptide, This study demonstrates that the affinities of the propeptides of the vitamin K-dependent proteins vary over a considerable range; this may have important physiological consequences in the levels of vitamin K-dependent proteins and the biochemical mechanism by which these substrates are modified by the carboxylase.	Univ N Carolina, Dept Biol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, Ctr Thrombosis & Hemostasis, CB 3280, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL06350] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENTON ME, 1995, BIOCHEMISTRY-US, V34, P9541, DOI 10.1021/bi00029a031; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; CROSSEN RC, 1997, BACULOVIRUS EXPRESSI, P35; DEMETZ M, 1981, FEBS LETT, V123, P215, DOI 10.1016/0014-5793(81)80290-6; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FURIE B, 1990, BLOOD, V75, P1753; Furie BC, 1997, J BIOL CHEM, V272, P28258, DOI 10.1074/jbc.272.45.28258; HANDFORD PA, 1991, PROTEIN ENG, V4, P319, DOI 10.1093/protein/4.3.319; HUBER P, 1990, J BIOL CHEM, V265, P12467; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; Oldenburg J, 1997, BRIT J HAEMATOL, V98, P240, DOI 10.1046/j.1365-2141.1997.2213036.x; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; RICH DH, 1981, J MED CHEM, V24, P706, DOI 10.1021/jm00138a013; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; SHAH DV, 1983, P SOC EXP BIOL MED, V173, P148; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; SOUTE BAM, 1981, BIOCHIM BIOPHYS ACTA, V676, P101, DOI 10.1016/0304-4165(81)90013-1; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; STANTON C, 1995, THROMB RES, V80, P63, DOI 10.1016/0049-3848(95)00151-G; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE J W, 1988, Biofactors, V1, P55; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VERMEER C, 1984, FEBS LETT, V165, P16, DOI 10.1016/0014-5793(84)80005-8; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, METHOD ENZYMOL, V282, P346	33	71	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16940	16944		10.1074/jbc.274.24.16940	http://dx.doi.org/10.1074/jbc.274.24.16940			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358041	hybrid, Green Published			2022-12-27	WOS:000080780400040
J	Masse, E; Drolet, M				Masse, E; Drolet, M			Relaxation of transcription-induced negative supercoiling is an essential function of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-LOOP FORMATION; GYRASE GENES; MUTANTS; TEMPLATE; MUTATIONS; VITRO	It has been suggested that the essential function of DNA topoisomerase I in Escherichia coli is to prevent chromosomal DNA from reaching an unacceptably high level of global negative supercoliing. However, other in vivo studies have shown that DNA topoisomerase I is very effective in removing local negative supercoliing generated during transcription elongation. To determine whether topoisomerase I is essential for controlling global or local DNA supercoliing, we have prepared a set of topA null mutant strains in combination with different plasmid DNAs. Although we found a correlation between the severity of the growth defect with both transcription-induced and global supercoliing, near to complete growth inhibition correlated only with transcription-induced supercoliing. This result strongly suggests that the major function of DNA topoisomerase I is to relax local negative supercoliing generated during transcription elongation.	Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Drolet, M (corresponding author), Univ Montreal, Dept Microbiol & Immunol, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	Marc.Drolet@umontreal.ca	Drolet, Marc/M-1328-2019					COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RECORD MT, 1996, CELLULAR MOL BIOL, V1, P792; Sambrook J., 2002, MOL CLONING LAB MANU; SINGER M, 1989, MICROBIOL REV, V53, P1; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	17	61	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16654	16658		10.1074/jbc.274.23.16654	http://dx.doi.org/10.1074/jbc.274.23.16654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347233	hybrid			2022-12-27	WOS:000080668600093
J	Shulga, N; James, P; Craig, EA; Goldfarb, DS				Shulga, N; James, P; Craig, EA; Goldfarb, DS			A nuclear export signal prevents Saccharomyces cerevisiae Hsp70 Ssb1p from stimulating nuclear localization signal-directed nuclear transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; HEAT-SHOCK; KARYOPHILIC PROTEINS; YEAST; IMPORT; BINDING; COMPLEX; PATHWAY; TRANSLOCATION; DEGRADATION	Hsp70 has been implicated in nuclear localization signal (NLS)-directed nuclear transport. Saccharomyces cerevisiae contains distinct SSA and SSB gene families of cytosolic Hsp70s. The nucleocytoplasmic localization of Ssa1p and Ssb1p was investigated using green fluorescent protein (GFP) fusions. Whereas GFP-Ssa1p localized both to the nucleus and cytoplasm, GFP-Ssb1p appeared only in the cytosol. The C-terminal domain of Ssb1p contains a leucine-rich nuclear export signal (NES) that is necessary and sufficient to direct nuclear export. The accumulation of GFP-Ssb1p in the nuclei of xpo1-1 cells suggests that Ssb1p shuttles across the nuclear envelope. Elevated levels of SSA1 but not SSB1 suppressed the NLS-GFP nuclear localization defects of nup188-Delta cells. Studies with Ssa1p/Ssb1p chimeras revealed that the Ssb1p NES is sufficient and necessary to inhibit the function of Ssa- or Ssb-type Hsp70s in nuclear transport. Thus, NES-less Ssb1p stimulates nuclear transport in nup188-Delta cells and NES-containing Ssa1p does not. We conclude that the differential function of Ssa1p and Ssb1p in nuclear transport is due to the NES-directed export of the Ssb1p and not to functional differences in their ATPase or peptide binding domains.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Goldfarb, DS (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	dasg@uhura.cc.rochester.edu						Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brodsky JL, 1998, FEBS LETT, V435, P183, DOI 10.1016/S0014-5793(98)01065-5; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; JEOUNG DI, 1991, GENE DEV, V5, P2235, DOI 10.1101/gad.5.12a.2235; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; MANDELL RB, 1992, EXP CELL RES, V198, P164, DOI 10.1016/0014-4827(92)90163-3; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OHBA M, 1994, FEBS LETT, V351, P263; Ohba M, 1997, FEBS LETT, V409, P307, DOI 10.1016/S0014-5793(97)00535-8; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	50	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16501	16507		10.1074/jbc.274.23.16501	http://dx.doi.org/10.1074/jbc.274.23.16501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347213	hybrid			2022-12-27	WOS:000080668600073
J	Uriarte, M; Marina, A; Ramon-Maiques, S; Fita, I; Rubio, V				Uriarte, M; Marina, A; Ramon-Maiques, S; Fita, I; Rubio, V			The carbamoyl-phosphate synthetase of Pyrococcus furiosus is enzymologically and structurally a carbamate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; ARGININE-DEIMINASE; ARCHAEON; BINDING; EXPRESSION; SUBUNIT; ENZYME; ARCHAEBACTERIA; BIOSYNTHESIS	The hyperthermophiles Pyrococcus furiosus and Pyrococcus abyssi make pyrimidines and arginine from carbamoyl phosphate (CP) synthesized by an enzyme that differs from other carbamoyl-phosphate synthetases and that resembles carbamate kinase (CK) in polypeptide mass, amino acid sequence, and oligomeric organization, This enzyme was reported to use ammonia, bicarbonate, and two ATP molecules as carbamoyl-phosphate synthetases to make CP and to exhibit bicarbonate-dependent ATPase activity. We have reexamined these findings using the enzyme of P, furiosus expressed in Escherichia coli from the corresponding gene cloned in a plasmid, We show that the enzyme uses chemically made carbamate rather than ammonia and bicarbonate and catalyzes a reaction with the stoichiometry and equilibrium that are typical for CK, Furthermore, the enzyme catalyzes actively full reversion of the CK reaction and exhibits little bicarbonate-dependent ATPase, In addition, it cross-reacts with antibodies raised against CK from Enterococcus faecium, and its three-dimensional structure, judged by x-ray crystallography of enzyme crystals, is very similar to that of CK, Thus, the enzyme is, in all respects other than its function in vivo, a CK, Because in other organisms the function of CK is to make ATP from ADP and CP derived from arginine catabolism, this is the first example of using CK for making rather than using CP, The reasons for this use and the adaptation of the enzyme to this new function are discussed.	CSIC, Inst biomed Valencia, Valencia 46010, Spain; CSIC, Ctr Invest & Desarrollo, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC)	Rubio, V (corresponding author), CSIC, Inst biomed Valencia, C Jaime Roig 11, Valencia 46010, Spain.	rubio@ibv.csic.es	Marina, Alberto/H-6264-2011; Ramon-Maiques, Santiago/R-2533-2019; Rubio, Vicente/K-7919-2014	Marina, Alberto/0000-0002-1334-5273; Rubio, Vicente/0000-0001-8124-1196; Ramon-Maiques, Santiago/0000-0001-9674-8088				ABDELAL AT, 1979, ANNU REV MICROBIOL, V33, P139, DOI 10.1146/annurev.mi.33.100179.001035; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BERGMEYER HU, 1986, METHOD ENZYMAT AN, V7, P346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAPLOW M, 1968, J AM CHEM SOC, V90, P6795, DOI 10.1021/ja01026a041; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Gaastra W, 1984, Methods Mol Biol, V1, P349, DOI 10.1385/0-89603-062-8:349; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUTHOHRL.G, 1969, EUR J BIOCHEM, V8, P207, DOI 10.1111/j.1432-1033.1969.tb00516.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; Legrain C, 1997, EUR J BIOCHEM, V247, P1046, DOI 10.1111/j.1432-1033.1997.01046.x; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LILLEY MD, 1993, NATURE, V364, P45, DOI 10.1038/364045a0; Marina A, 1999, PROTEIN SCI, V8, P934; Marina A, 1998, EUR J BIOCHEM, V253, P280, DOI 10.1046/j.1432-1327.1998.2530280.x; Marshall M, 1970, METHOD ENZYMOL, V17, P229; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1958, J BIOL CHEM, V233, P1560; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NUZUM CT, 1975, UREA CYCLE, P325; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; PURCAREA C, 1995, THESIS U PARIS SUD P; ROSSMAN MG, 1972, MOL REPLACEMENT METH; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; Rubio V, 1998, EUR J BIOCHEM, V255, P262, DOI 10.1046/j.1432-1327.1998.2550262.x; RUBIO V, 1994, CARBON DIOXIDE FIXAT, P249; SANDLER SJ, 1994, J BACTERIOL, V176, P3661, DOI 10.1128/JB.176.12.3661-3672.1994; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; THORNE KJI, 1963, J BIOL CHEM, V238, P2992; VANDECASTEELE M, 1990, J GEN MICROBIOL, V136, P1177, DOI 10.1099/00221287-136-7-1177; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004	51	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16295	16303		10.1074/jbc.274.23.16295	http://dx.doi.org/10.1074/jbc.274.23.16295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347186	hybrid			2022-12-27	WOS:000080668600046
J	Adam-Stitah, S; Penna, L; Chambon, P; Rochette-Egly, C				Adam-Stitah, S; Penna, L; Chambon, P; Rochette-Egly, C			Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LIGAND-BINDING DOMAIN; N-TERMINAL KINASE; HA-RAS MUTATION; PROTEIN-KINASE; ACID RECEPTOR; TRANSCRIPTION FACTORS; NUCLEAR RECEPTORS; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION	The nuclear receptor mouse retinoid X receptor alpha (mRXR alpha) was shown to be constitutively phosphorylated in its NH2-terminal A/B region, which contains potential phosphorylation sites for proline-directed Ser/Thr kinases, Mutants for each putative site were generated and overexpressed in transfected COS-1 cells. Constitutively phosphorylated residues identified by tryptic phosphopeptide mapping included serine 22 located in the A1 region that is specific to the RXR alpha 1 isoform, Overexpression and UV activation of the stress-activated kinases, c-Jun NH2-terminal kinases 1 and 2 (JNK1 and JNK2), hyperphosphorylated RXR alpha, resulting in a marked decrease in its electrophoretic mobility. This inducible hyperphosphorylation involved three residues (serines 61 and 75 and threonine 87) in the B region of RXR alpha and one residue (serine 265) in the ligand binding domain (E region). Binding assays performed in vitro with purified recombinant proteins demonstrated that JNKs did not interact with RXR alpha but bound to its heterodimeric partners, retinoic acid receptors alpha and gamma (RAR alpha and RAR gamma). Hyperphosphorylation by JNKs did not affect the transactivation properties of either RXR alpha homodimers or RXR alpha/RAR alpha heterodimers in transfected cultured cells.	Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163,CU Strasbourg, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						BLOMHOFF R, 1994, NUTR REV, V52, P13; Bocco JL, 1996, ONCOGENE, V12, P1971; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brocard J, 1996, BIOCHEM BIOPH RES CO, V229, P211, DOI 10.1006/bbrc.1996.1782; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; DEGRAEVE F, 1999, IN PRESS ONCOGENE; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P., 1994, Vitamin A in health and disease., P189; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Maden M, 1998, DEVELOPMENT, V125, P4133; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mascrez B, 1998, DEVELOPMENT, V125, P4691; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	60	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18932	18941		10.1074/jbc.274.27.18932	http://dx.doi.org/10.1074/jbc.274.27.18932			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383391	hybrid			2022-12-27	WOS:000081196300014
J	Mordoch, SS; Granot, D; Lebendiker, M; Schuldiner, S				Mordoch, SS; Granot, D; Lebendiker, M; Schuldiner, S			Scanning cysteine accessibility of EmrE, an H+-coupled multidrug transporter from Escherichia coli, reveals a hydrophobic pathway for solutes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; TRANSLOCATION PATHWAY; PROTEIN; RESIDUES; CHANNEL; SEGMENT; IDENTIFICATION; MUTAGENESIS; CLONING; EFFLUX	EmrE is a 12-kDa Escherichia coli multidrug transporter that confers resistance to a wide variety of toxic reagents by actively removing them in exchange for hydrogen ions, The three native Cys residues in EmrE are inaccessible to N-ethylmaleimide (NEM) and a series of other sulfhydryls. In addition, each of the three residues can be replaced with Ser without significant loss of activity, A protein without all the three Cys residues (Cys-less) has been generated and shown to be functional. Using this Cys-less protein, we have now generated a series of 48 single Cys replacements throughout the protein. The majority of them (43) show transport activity as judged from the ability of the mutant proteins to confer resistance against toxic compounds and from in vitro analysis of their activity in proteoliposomes. Here we describe the use of these mutants to study the accessibility to NEM, a membrane permeant sulfhydryl reagent. The study has been done systematically so that in one transmembrane segment (TMS2) each single residue was replaced. In each of the other three transmembrane segments, at least four residues covering one turn of the helix were replaced. The results show that although the residues in putative hydrophilic loops readily react with NEM, none of the residues in putative transmembrane domains are accessible to the reagent, The results imply very tight packing of the protein without any continuous aqueous domain. Based on the findings described in this work, we conclude that in EmrE the substrates are translocated through a hydrophobic pathway.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	shimons@leonardo.ls.huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED M, 1994, J BIOL CHEM, V269, P28506; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kimura-Someya T, 1998, J BIOL CHEM, V273, P32806, DOI 10.1074/jbc.273.49.32806; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; Means G.E., 1971, CHEM MODIFICATION PR; MORIMYO M, 1992, NUCLEIC ACIDS RES, V20, P3159, DOI 10.1093/nar/20.12.3159; Mulholland SE, 1998, J AM CHEM SOC, V120, P10296, DOI 10.1021/ja981279a; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PUREWAL AS, 1990, FEMS MICROBIOL LETT, V68, P73; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuldiner S, 1997, J EXP BIOL, V200, P335; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Tang XB, 1998, J BIOL CHEM, V273, P22545, DOI 10.1074/jbc.273.35.22545; XU M, 1993, J BIOL CHEM, V268, P21505; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	28	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19480	19486		10.1074/jbc.274.27.19480	http://dx.doi.org/10.1074/jbc.274.27.19480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383465	hybrid			2022-12-27	WOS:000081196300088
J	Nakamura, T; Iwakura, M				Nakamura, T; Iwakura, M			Circular permutation analysis as a method for distinction of functional elements in the M20 loop of Escherichia coli dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE TRANSCARBAMOYLASE; BACILLUS-STEAROTHERMOPHILUS; POLYPEPTIDE-CHAINS; CRYSTAL-STRUCTURE; TRANSITION-STATE; PROTEIN; CONSTRUCTION; MECHANISM; BINDING; ENZYME	A functional element of an enzyme can be defined as the smallest unit of the local peptide backbone of which the connectivity is crucial for the catalytic activity. In order to elucidate the distribution of functional elements in an active site flexible loop (the M20 loop) of Escherichia coli dihydrofolate reductase, systematic cleavage of main chain connectivity was performed using circular permutation. Our analysis is based on the assumption that a permutation within a functional element would significantly reduce enzyme function, whereas ones outside or at the boundaries of the elements would affect the function only slightly. Thus, a functional element would be assigned as the minimum peptide chain between the identified boundaries. Comparison of the activities of the circularly permuted variants revealed that the peptide chain around the M20 loop could be divided into four regions (regions 1-4). Region 1 was found to play an important role in overall tertiary fold because most variants permuted at region 1 did not accumulate in E, coli cells stably, A distinction between region 2 and region 3 was in agreement with the extent of movements calculated from the coordinates of a carbons, supporting the idea that the movement of peptide backbone is a key feature of enzyme function, The boundary between region 3 and region 4 coincided with that between the M20 loop and the following a helix. From equilibrium binding studies, region 2 was found to be involved in the binding of nicotinamide substrates, whereas region 4 appeared to be very important for the binding of pterin substrates.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Osaka Natl Res Inst, Osaka 5638577, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Iwakura, M (corresponding author), Natl Inst Biosci & Human Technol, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.	iwakura@nibh.go.jpl	Nakamura, Tsutomu/M-3412-2018	Nakamura, Tsutomu/0000-0002-5511-8087				BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; EDER J, 1992, BIOCHEMISTRY-US, V31, P3617, DOI 10.1021/bi00129a010; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P439, DOI 10.1021/bi00168a007; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; HAHN M, 1994, P NATL ACAD SCI USA, V91, P10417, DOI 10.1073/pnas.91.22.10417; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; Iwakura M, 1998, PROTEIN ENG, V11, P707, DOI 10.1093/protein/11.8.707; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; IWAKURA M, 1998, PROTEIN SCI S1, V7, P85; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; KOMMAR AA, 1995, FEBS LETT, V376, P195; KREITMAN RJ, 1994, P NATL ACAD SCI USA, V91, P6889, DOI 10.1073/pnas.91.15.6889; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; Miller GP, 1998, BIOCHEMISTRY-US, V37, P6327, DOI 10.1021/bi972922t; Miller GP, 1998, BIOCHEMISTRY-US, V37, P6336, DOI 10.1021/bi973065w; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; MULLINS LS, 1994, J AM CHEM SOC, V116, P5529, DOI 10.1021/ja00092a001; Ohmae E, 1998, J BIOCHEM, V123, P839; PROTASOVA NY, 1994, PROTEIN ENG, V7, P1373, DOI 10.1093/protein/7.11.1373; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; STONE SR, 1982, BIOCHEMISTRY-US, V21, P3757, DOI 10.1021/bi00259a006; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; TOYAMA H, 1991, J BIOL CHEM, V266, P13634; VIGNAIS ML, 1995, PROTEIN SCI, V4, P994; VIGUERA AR, 1995, J MOL BIOL, V247, P670, DOI 10.1016/S0022-2836(05)80146-9; VOLTZ KW, 1982, J BIOL CHEM, V257, P2528; YANG YR, 1993, P NATL ACAD SCI USA, V90, P11980, DOI 10.1073/pnas.90.24.11980; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006	41	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19041	19047		10.1074/jbc.274.27.19041	http://dx.doi.org/10.1074/jbc.274.27.19041			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383405	hybrid			2022-12-27	WOS:000081196300028
J	Schmid, JA; Mach, L; Paschke, E; Glossl, J				Schmid, JA; Mach, L; Paschke, E; Glossl, J			Accumulation of sialic acid in endocytic compartments interferes with the formation of mature lysosomes - Impaired proteolytic processing of cathepsin B in fibroblasts of patients with lysosomal sialic acid storage disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; MANNOSE 6-PHOSPHATE RECEPTOR; N-ACETYLNEURAMINIC ACID; LATE ENDOSOMES; BETA-HEXOSAMINIDASE; PROCATHEPSIN-B; SALLA DISEASE; MULTIVESICULAR ENDOSOMES; PROTEIN-DEGRADATION; TERMINAL LYSOSOMES	The impact of an altered endocytic environment on the biogenesis of lysosomes was studied in fibroblasts of patients suffering from sialic acid storage disease (SASD). This inherited disorder is characterized by the accumulation of acidic monosaccharides in lysosomal compartments and a concomitant decrease of their buoyant density. We demonstrate that C-terminal trimming of the lysosomal cysteine proteinase cathepsin B is inhibited in SASD fibroblasts. This late event in the biosynthesis of cathepsin B normally takes place in mature lysosomes, suggesting an impaired biogenesis of these organelles in SASD cells. When normal fibroblasts are loaded with sucrose, which inhibits transport from late endosomes to lysosomes, C-terminal cathepsin B processing is prevented to the same extent. Further characterization of the terminal endocytic compartments of SASD cells revealed properties usually associated with late endosomes/prelysosomes. In addition to a decreased buoyant density, SASD "lysosomes" show a reduced acidification capacity and appear smaller than their normal counterparts. We conclude that the accumulation of small non-diffusible compounds within endocytic compartments interferes with the formation of mature lysosomes and that the acidic environment of the latter organelles is a prerequisite for C-terminal processing of lysosomal hydrolases.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Univ Agr Sci, Ctr Appl Genet, A-1190 Vienna, Austria; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Childrens Hosp, A-8036 Graz, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna; University of Western Australia	Glossl, J (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	Johannes.Schmid@univie.ac.at	Schmid, Johannes A./C-7659-2009; Glössl, Josef/H-8208-2013	Schmid, Johannes A./0000-0002-6586-3507; Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				ANBARI M, 1994, HEPATOLOGY, V19, P1034, DOI 10.1002/hep.1840190432; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BRAULKE T, 1988, BIOL CHEM H-S, V369, P441, DOI 10.1515/bchm3.1988.369.1.441; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Bright NA, 1997, J CELL SCI, V110, P2027; BUCKMASTER MJ, 1988, BIOCHEM J, V249, P921, DOI 10.1042/bj2490921; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; FIGURA KV, 1978, EXP CELL RES, V111, P15, DOI 10.1016/0014-4827(78)90231-8; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HANCOCK LW, 1988, BIOCHEM BIOPH RES CO, V152, P83, DOI 10.1016/S0006-291X(88)80683-1; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; Hirst J, 1998, MOL BIOL CELL, V9, P809, DOI 10.1091/mbc.9.4.809; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; JAHRAUS A, 1994, J CELL SCI, V107, P145; JOHNSON KF, 1991, BIOCHIM BIOPHYS ACTA, V1073, P120, DOI 10.1016/0304-4165(91)90191-I; Karageorgos LE, 1997, EXP CELL RES, V234, P85, DOI 10.1006/excr.1997.3581; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MCVEYWARD DM, 1995, J CELL BIOL, V129, P1229; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; POHL J, 1987, ANAL BIOCHEM, V165, P96, DOI 10.1016/0003-2697(87)90205-3; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; RENLUND M, 1986, J CLIN INVEST, V77, P568, DOI 10.1172/JCI112338; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; ROWAN AD, 1993, BIOCHEM J, V294, P923, DOI 10.1042/bj2940923; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Storrie Brian, 1996, Bioessays, V18, P895, DOI 10.1002/bies.950181108; TIETZE F, 1989, J BIOL CHEM, V264, P15316; Tjelle TE, 1996, J CELL SCI, V109, P2905; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	65	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19063	19071		10.1074/jbc.274.27.19063	http://dx.doi.org/10.1074/jbc.274.27.19063			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383408	hybrid			2022-12-27	WOS:000081196300031
J	Tanaka, N; Kaneko, K; Asao, H; Kasai, H; Endo, Y; Fujita, T; Takeshita, T; Sugamura, H				Tanaka, N; Kaneko, K; Asao, H; Kasai, H; Endo, Y; Fujita, T; Takeshita, T; Sugamura, H			Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; DNA-BINDING ACTIVITY; JAK-3 JANUS KINASE; C-MYC INDUCTION; IL-2 RECEPTOR; CELL-GROWTH; JAK-STAT5 PATHWAY; ADAPTER MOLECULE; TYROSINE KINASE	STAM containing an SH3 (Src homology 3) domain and an immunoreceptor tyrosine-based activation motif was previously revealed to be implicated in signaling pathways immediately downstream of Jak2 and Jak3 tyrosine kinases associated with cytokine receptors. We molecularly cloned a novel molecule interacting with the SH3 domain of STAM, which was named AMSH (associated molecule with the SH3 domain of STAM). AMSH contains a putative bipartite nuclear localization signal and a homologous region of a c-Jun activation domain-binding protein 1 (JAB1) subdomain in addition to a binding site for the SH3 domain of STAM. AMSH mutant deleted of the C-terminal half conferred dominant negative effects on signaling for DNA synthesis and c-myc induction mediated by interleukin 2 and granulocyte macrophage-colony-stimulating factor. These results suggest that AMSH plays a critical role in the cytokine-mediated intracellular signal transduction downstream of the Jak2/Jak3.STAM complex.	Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Fukushima Med Coll, Dept Biochem, Fukushima 96012, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	Tohoku University; Fukushima Medical University; Japan Science & Technology Agency (JST)	Sugamura, H (corresponding author), Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	sugamura@mail.cc.tohoku.ac.jp	Kasai, Hirotake/L-9668-2017; Takeshita, Toshikazu/AAL-1382-2021	Kasai, Hirotake/0000-0002-5808-0803; 				Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cooper CL, 1998, J CELL BIOCHEM, V71, P277, DOI 10.1002/(SICI)1097-4644(19981101)71:2<277::AID-JCB12>3.0.CO;2-I; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502	40	110	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19129	19135		10.1074/jbc.274.27.19129	http://dx.doi.org/10.1074/jbc.274.27.19129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383417	hybrid			2022-12-27	WOS:000081196300040
J	Wang, D; Zheng, F; Holmberg, S; Kohlhaw, GB				Wang, D; Zheng, F; Holmberg, S; Kohlhaw, GB			Yeast transcriptional regulator Leu3p - Self-masking, specificity of masking, and evidence for regulation by the intracellular level of Leu3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ISOPROPYLMALATE SYNTHASE; SACCHAROMYCES-CEREVISIAE; LEUCINE BIOSYNTHESIS; S-ADENOSYLMETHIONINE; ACTIVATION DOMAIN; DNA-BINDING; GENE LEU3; PROTEIN; MULTIPLE; IDENTIFICATION	Recent work suggests that the masking of the activation domain (AD) of yeast transactivator Leu3p, observed in the absence of the metabolic signal alpha-isopropylmalate, is an intramolecular event. Much of the evidence came from the construction and analysis of a mutant form of Leu3p (Leu3-dd) whose AD is permanently masked (Wang, D,, Hu, Y,, Zheng, F,, Zhou, K,, and Kohlhaw, G, B, (1997) J, Biol, Chem, 272, 19383-19392). In a modified two-hybrid experiment, the ADs of both wild type Leu3p and Leu3-dd were shown to interact with the remainder of the Leu3 protein, in an alpha-isopropylmalate-dependent manner. The finding that masking and unmasking proceed apparently normally when full-length Leu3p is expressed in mammalian cells is also consistent with the notion of intramolecular masking. Here we report on the identification of nine missense mutations tall of them suppressors of the Leu3-dd phenotype) that cause permanent unmasking of Leu3p, The nine mutations map to three short segments located within a 140-residue-long region of the C-terminal part of the middle region of Leu3p, These segments may be part of a spatial trap for the AD. We also performed "domain swaps'" between Leu3p and Cha4p, a serine/threonine-responsive activator that, like Leu3p, belongs to the family of Zn(II),Cys, proteins, We show that AD masking and response to the appropriate metabolic signal only occur when a given AD remains attached to its own middle region; middle region swapping results in constitutively active proteins. Finally, we show that the extent to which Leu3p regulates reporter gene expression depends on the intracellular concentration of Leu3p, The possible physiological significance of this observation is discussed in light of the known regulation of Leu3p by Gcn4p.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Univ Copenhagen, Inst Mol Biol, Dept Genet, DK-1353 Copenhagen K, Denmark	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Copenhagen	Kohlhaw, GB (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Holmberg, Steen/N-1128-2014	Holmberg, Steen/0000-0002-0262-3207	NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BORNAES C, 1993, MOL CELL BIOL, V13, P7604, DOI 10.1128/MCB.13.12.7604; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; DRAIN P, 1988, GENETICS, V119, P13; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Guo H, 1996, FEBS LETT, V390, P191, DOI 10.1016/0014-5793(96)00653-9; HAMPSEY DM, 1981, J BIOL CHEM, V256, P3791; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; Holmberg S, 1996, GENETICS, V144, P467; HU Y, 1996, THESIS PURDUE U W LA; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; HU YM, 1995, J BIOL CHEM, V270, P5270, DOI 10.1074/jbc.270.10.5270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SZE JY, 1993, J BIOL CHEM, V268, P2505; SZE JY, 1993, MOL CELL BIOL, V13, P5702, DOI 10.1128/MCB.13.9.5702; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Voss H, 1997, YEAST, V13, P655, DOI 10.1002/(SICI)1097-0061(19970615)13:7<655::AID-YEA120>3.0.CO;2-I; Wade PA, 1996, MOL CELL BIOL, V16, P1641; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU K, 1991, THESIS PURDUE U W LA; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	36	38	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19017	19024		10.1074/jbc.274.27.19017	http://dx.doi.org/10.1074/jbc.274.27.19017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383402	hybrid			2022-12-27	WOS:000081196300025
J	Wesche, H; Gao, X; Li, XX; Kirschning, CJ; Stark, GR; Cao, ZD				Wesche, H; Gao, X; Li, XX; Kirschning, CJ; Stark, GR; Cao, ZD			IRAK-M is a novel member of the pelle/interleukin-1 receptor-associated kinase (IRAK) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASES; INTERLEUKIN-1 RECEPTOR; ACCESSORY PROTEIN; DROSOPHILA TOLL; SIGNALING PATHWAYS; MOLECULAR-CLONING; MYD88; COMPLEX	The interleukin-1 receptor-associated kinase (IRAK) was first described as a signal transducer for interleukin-1 (IL-1) and has later been implicated in signal transduction of other members of the Toll/IL-1 receptor family. We now report the identification and characterization of a novel IRAK-like molecule. In contrast to the ubiquitously expressed IRAK and IRAK-2, this new IRAK-like molecule is found mainly in cells of monomyeloic origin and is, therefore, designated IRAK-M. Although IRAK-M and IRAK-2 exhibit only a negligible autophosphorylation activity, they can reconstitute the IL-1 response in a 293 mutant cell line lacking IRAK. In addition, we show for the first time that members of the IRAK family are indispensable elements of lipopolysaccharide signal transduction, The discovery of IRAK-M adds another level of complexity to our understanding of signaling by members of the Toll/IL-1 receptor family.	Tularik Inc, San Francisco, CA 94080 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cao, ZD (corresponding author), Tularik Inc, 2 Corporate Dr, San Francisco, CA 94080 USA.							Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LI X, 1999, IN RPESS MOL CELL BI; LORD KA, 1990, ONCOGENE, V5, P1095; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; THOMA JA, 1999, IN PRESS J IMMUNOL; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	42	333	378	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19403	19410		10.1074/jbc.274.27.19403	http://dx.doi.org/10.1074/jbc.274.27.19403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383454	hybrid			2022-12-27	WOS:000081196300077
J	de Haard, HJ; van Neer, N; Reurs, A; Hufton, SE; Roovers, RC; Henderikx, P; de Bruine, AP; Arends, JW; Hoogenboom, HR				de Haard, HJ; van Neer, N; Reurs, A; Hufton, SE; Roovers, RC; Henderikx, P; de Bruine, AP; Arends, JW; Hoogenboom, HR			A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; POLYMERASE CHAIN-REACTION; BY-PASSING IMMUNIZATION; DISPLAY LIBRARIES; ESCHERICHIA-COLI; SYNTHETIC REPERTOIRES; LUTEINIZING-HORMONE; BETA-SUBUNITS; SELECTION; CELLS	We report the design, construction, and use of the first very large non-immunized phage antibody library in Fab format, which allows the rapid isolation and affinity analysis of antigen-specific human antibody fragments. Individually cloned heavy and light chain variable region libraries were combined in an efficient two-step cloning procedure, permitting the cloning of a total of 3.7 x 10(10) independent Fab clones. The performance of the library was determined by the successful selection of on average 14 different Fabs against 6 antigens tested. These include tetanus toroid, the hapten phenyl-oxazolone, the breast cancer-associated MUC1 antigen, and three highly related glycoprotein hormones: human chorionic gonadotropin, human luteinizing hormone, and human follicle-stimulating hormone. In the latter category, a panel of either homone-specific or crossreactive antibodies were identified. The design of the library permits the monitoring of selections with polyclonal phage preparations and to carry out large scale screening of antibody off-rates with unpurified Fab fragments on BIAcore. Antibodies with off-rates in the order of 10(-2) to 10(-4) s(-1) and affinities up to 2.7 nM were recovered. The kinetics of these phage antibodies are of the same order of magnitude as antibodies associated with a secondary immune response. This new phage antibody library is set to become a valuable source of antibodies to many different targets, and to play a vital role in target discovery and validation in the area of functional genomics.	Target Quest BV, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, NL-6202 AZ Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Hoogenboom, HR (corresponding author), Target Quest BV, POB 5800, NL-6202 AZ Maastricht, Netherlands.	hho@lpat.azm.nl	Hufton, Simon E/E-3949-2013; hufton, simon/AAA-8245-2019	hufton, simon/0000-0003-1756-0306; Roovers, Rob/0000-0002-9715-2136				BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; CAI XH, 1995, P NATL ACAD SCI USA, V92, P6537, DOI 10.1073/pnas.92.14.6537; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; Cole LA, 1997, CLIN CHEM, V43, P2233; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; de Haard HJW, 1998, CLIN DIAGN LAB IMMUN, V5, P636, DOI 10.1128/CDLI.5.5.636-644.1998; de Haard HJW, 1998, PROTEIN ENG, V11, P1267, DOI 10.1093/protein/11.12.1267; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Gargano N, 1996, J VIROL, V70, P7706, DOI 10.1128/JVI.70.11.7706-7712.1996; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Henderikx P, 1998, CANCER RES, V58, P4324; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Holliger P, 1998, NAT BIOTECHNOL, V16, P1015, DOI 10.1038/3460; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; Kazemier B, 1996, J IMMUNOL METHODS, V194, P201, DOI 10.1016/0022-1759(96)00086-5; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kortt AA, 1997, PROTEIN ENG, V10, P423, DOI 10.1093/protein/10.4.423; LARRICK JW, 1989, BIOCHEM BIOPH RES CO, V160, P1250, DOI 10.1016/S0006-291X(89)80138-X; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MARKS JD, 1993, BIO-TECHNOL, V11, P1145, DOI 10.1038/nbt1093-1145; MASURE HR, 1981, J CLIN ENDOCR METAB, V53, P1014, DOI 10.1210/jcem-53-5-1014; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; ORUM H, 1993, NUCLEIC ACIDS RES, V21, P4491, DOI 10.1093/nar/21.19.4491; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; PAPAPETROU PD, 1980, CANCER-AM CANCER SOC, V45, P2583, DOI 10.1002/1097-0142(19800515)45:10<2583::AID-CNCR2820451018>3.0.CO;2-W; Persic L, 1997, GENE, V187, P9, DOI 10.1016/S0378-1119(96)00628-2; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; ROIT IM, 1985, IMMUNOLOGY; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	52	405	566	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18218	18230		10.1074/jbc.274.26.18218	http://dx.doi.org/10.1074/jbc.274.26.18218			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373423	hybrid			2022-12-27	WOS:000081056700015
J	Mou, HM; Grazio, HJ; Cook, TA; Beavo, JA; Cote, RH				Mou, HM; Grazio, HJ; Cook, TA; Beavo, JA; Cote, RH			cGMP binding to noncatalytic sites on mammalian rod photoreceptor phosphodiesterase is regulated by binding of its gamma and delta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; OUTER SEGMENTS; G-PROTEIN; GMP PHOSPHODIESTERASE; VISUAL TRANSDUCTION; LIGHT ADAPTATION; TARGET ENZYME; PHOTORESPONSE; PURIFICATION; ACTIVATION	The binding of cGMP to the noncatalytic sites on two isoforms of the phosphodiesterase (PDE) from mammalian rod outer segments has been characterized to evaluate their role in regulating PDE during phototransduction. Nonactivated, membrane-associated PDE (PDE-M, alpha beta gamma(2)) has one exchangeable site for cGMP binding; endogenous cGMP remains nonexchangeable at the second site, Non-activated, soluble PDE (PDE-S, alpha beta gamma(2)delta) can release and bind cGMP at both noncatalytic sites; the delta subunit is likely responsible for this difference in cGMP exchange rates. Removal of the delta and/or gamma subunits yields a catalytic cup dimer with identical catalytic and binding properties for both PDE-M and PDE-S as follows: high affinity cGMP binding is abolished at one site (K-D > mu M); cGMP binding affinity at the second site (K-D similar to 60 nM) is reduced 3-4-fold compared with the nonactivated enzyme; the kinetics of cGMP exchange to activated PDE-M and PDE-S are accelerated to similar extents. The properties of nonactivated PDE can be restored upon addition of gamma subunit. Occupancy of the noncatalytic sites by cGMP may modulate the interaction of the gamma subunit with the alpha beta dimer and thereby regulate cytoplasmic cGMP concentration and the lifetime of activated PDE during visual transduction in photoreceptor cells.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University System Of New Hampshire; University of New Hampshire; University of Washington; University of Washington Seattle	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick/G-3363-2013	Cote, Rick/0000-0002-1573-6526	NEI NIH HHS [R01 EY005798, EY-08197, EY-05798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798, R01EY008197] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CERVETTO L, 1984, PHOTORECEPTORS, P159; COLES JA, 1975, J PHYSL, V247, P180; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; COTE RH, 1989, J BIOL CHEM, V264, P15384; COTE RH, 1999, IN PRESS METHODS ENZ, V316; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Gallagher S., 1998, CURRENT PROTOCOLS PR; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MIKI N, 1975, J BIOL CHEM, V250, P6320; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495	41	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18813	18820		10.1074/jbc.274.26.18813	http://dx.doi.org/10.1074/jbc.274.26.18813			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373499	Green Published, hybrid			2022-12-27	WOS:000081056700091
J	Sakamoto, H; Omata, Y; Palmer, G; Noguchi, M				Sakamoto, H; Omata, Y; Palmer, G; Noguchi, M			Ferric alpha-hydroxyheme bound to heme oxygenase can be converted to verdoheme by dioxygen in the absence of added reducing equivalents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IX-ALPHA; COMPLEX; LIGAND; HISTIDINE-25; REQUIREMENT; DEGRADATION; CONVERSION; RADICALS; FORM; EPR	Whether or not reducing equivalents are indispensable for the conversion of ferric alpha-hydroxyheme bound to heme oxygenase-l to verdoheme remains controversial (Matera, R. M., Takahashi, S., Fujii, H., Zhou, H., Ishikawa, K., Yoshimura, T., Rousseau, D. L., Yoshida, T., and Ikeda-Saito, M. (1996) J. Biol. Chem. 271, 6618-6624; Liu, Y., Moenne-Loccoz, P., Loehr, T. M., and Ortiz de Montellano, P. R. (1997) J. Biol. Chem. 272, 6906-6917), To resolve this controversy, we have prepared a ferric alpha-hydroxyheme-heme oxygenase-l complex and titrated the complex with O-2, under strictly anaerobic conditions. The formation of verdoheme was monitored by optical and electron spin resonance spectroscopies. Electron spin resonance spectra of the complex showed that alpha-hydroxyheme exists as a mixture of resonance structures composed of the iron(III) porphyrin and the iron(II) porphyrin rr neutral radical. Upon addition of CO the latter species becomes dominant. The results obtained from these titration experiments indicate that alpha-hydroxyheme can be converted to verdoheme by an approximately equimolar amount of O-2, without any requirement for exogenous electrons. The verdoheme formed from alpha-hydroxyheme was shown to be in the ferrous oxidation state by the addition of CO or potassium ferricyanide to the resultant verdoheme-heme oxygenase-l complex.	Kurume Univ, Sch Med, Dept Med Biochem, Kurume, Fukuoka 8300011, Japan; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77351 USA	Kurume University; Rice University	Noguchi, M (corresponding author), Kurume Univ, Sch Med, Dept Med Biochem, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	mnoguchi@med.kurume-u.ac.jp	Sakamoto, Hiroshi/A-3181-2011		NIGMS NIH HHS [GM 21337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG WE, 1971, ADV CHEM, V100, P271; Fajer J., 1979, PORPHYRINS, V4, P197; FUHRHOP JH, 1975, J AM CHEM SOC, V97, P7141, DOI 10.1021/ja00857a029; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; Liu Y, 1997, J BIOL CHEM, V272, P6909, DOI 10.1074/jbc.272.11.6909; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MORISHIMA I, 1995, INORG CHEM, V34, P1528, DOI 10.1021/ic00110a035; MORISHIMA I, 1986, J AM CHEM SOC, V108, P3858, DOI 10.1021/ja00273a067; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; Omata Y, 1998, ACTA CRYSTALLOGR D, V54, P1017, DOI 10.1107/S0907444998003448; PALMER G, 1977, ANAL BIOCHEM, V83, P597, DOI 10.1016/0003-2697(77)90063-X; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	25	42	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18196	18200		10.1074/jbc.274.26.18196	http://dx.doi.org/10.1074/jbc.274.26.18196			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373419	hybrid			2022-12-27	WOS:000081056700011
J	Zabel, U; Hausler, C; Weeger, M; Schmidt, HHHW				Zabel, U; Hausler, C; Weeger, M; Schmidt, HHHW			Homodimerization of soluble guanylyl cyclase subunits - Dimerization analysis using a glutathione S-transferase affinity tag	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LUNG; RAT LUNG; MOLECULAR-CLONING; PURIFICATION; IDENTIFICATION; EXPRESSION; BINDING	Soluble guanylyl cyclase (sGC) is an alpha/beta-heterodimeric hemoprotein that, upon interaction with the intercellular messenger molecule NO, generates cGMP. Although the related family of particulate guanylyl cyclases (pGCs) forms active homodimeric complexes, it is not known whether homodimerization of sGC subunits occurs. We report here the expression in Sf9 cells of glutathione S-transferase-tagged recombinant human sGC alpha 1 and pi subunits, applying a novel and rapid purification method based on GSH-Sepharose affinity chromatography, Surprisingly, in intact Sf9 cells, both homodimeric GST alpha/alpha: and GST beta/beta complexes were formed that were catalytically inactive, Upon coexpression of the respective complementary subunits, GST alpha/beta or GST beta/alpha heterodimers were preferentially formed, whereas homodimers were still detectable, When subunits were mixed after expression, e,g, GST beta and beta or;GST alpha and beta, no dimerization was observed, In conclusion, our data suggest the previously unrecognized possibility of a physiological equilibrium between homo- and heterodimeric sGC complexes.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Zabel, U (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Schmidt, Harald HHW/B-1549-2008	Schmidt, Harald HHW/0000-0003-0419-5549				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KIM TD, 1994, J BIOL CHEM, V269, P15540; Koesling Doris, 1995, P43, DOI 10.1016/B978-012721985-1/50005-8; Lincoln T., 1996, BIOCH SMOOTH MUSCLE, P257; NAKANE M, 1990, J BIOL CHEM, V265, P16841; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2692; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	25	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18149	18152		10.1074/jbc.274.26.18149	http://dx.doi.org/10.1074/jbc.274.26.18149			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373411	hybrid			2022-12-27	WOS:000081056700003
J	Arneson, LS; Kunz, J; Anderson, RA; Traub, LM				Arneson, LS; Kunz, J; Anderson, RA; Traub, LM			Coupled inositide phosphorylation and phospholipase D activation initiates clathrin-coat assembly on lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; I PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASES; TRANS-GOLGI NETWORK; PLECKSTRIN HOMOLOGY DOMAINS; LIPID KINASE FAMILY; PHOSPHATIDIC-ACID; VESICLE FORMATION; PIT FORMATION; BREFELDIN-A; MEDIATED ENDOCYTOSIS	Adaptors appear to control clathrin-coat assembly by determining the site of lattice polymerization but the nucleating events that target soluble adaptors to an appropriate membrane are poorly understood. Using an in vitro model system that allows AP-2-containing clathrin coats to assemble on lysosomes, we show that adaptor recruitment and Goat initiation requires phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) synthesis. PtdIns(4,5)P-2 is generated on lysosomes by the sequential action of a lysosome-associated type II phosphalidylinositol 4-kinase and a soluble type I phosphatidylinositol I-phosphate B-kinase. Phosphatidic acid, which potently stimulates type I phosphatidylinositol 4-phosphate B-kinase activity, is generated on the bilayer by a phospholipase D1-like enzyme located on the lysosomal surface. Quenching phosphatidic acid function with primary alcohols prevents the synthesis of PtdIns(4,5)P-2 and blocks coat assembly. Generating phosphatidic acid directly on lysosomes with exogenous bacterial phospholipase D in the absence of ATP still drives adaptor recruitment and limited coat assembly, indicating that PtdIns(4,5)P-2 functions, at least in part, to activate the PtdIns(4,5)P-2-dependent phospholipase D1, These results provide the first direct evidence for the involvement of anionic phospholipids in clathrin-coat assembly on membranes and define the enzymes responsible for the production of these important lipid mediators.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison	Traub, LM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.			Traub, Linton/0000-0002-1303-0298; Anderson, Richard/0000-0001-6265-8359	NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; NIDDK NIH HHS [R01 DK53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; COLLINS CA, 1983, J BIOL CHEM, V258, P2130; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NTURE, V347, P173; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Katayama K, 1998, BIOCHEM J, V329, P647, DOI 10.1042/bj3290647; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Ktistakis NT, 1998, BIOESSAYS, V20, P495; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHMID SL, 1991, J CELL BIOL, V114, P896; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Warren RA, 1997, J BIOL CHEM, V272, P2116; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	74	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17794	17805		10.1074/jbc.274.25.17794	http://dx.doi.org/10.1074/jbc.274.25.17794			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364223	hybrid, Green Submitted			2022-12-27	WOS:000080974300059
J	Iost, I; Dreyfus, M; Linder, P				Iost, I; Dreyfus, M; Linder, P			Ded1p, a DEAD-box protein required for translation initiation in Saccharomyces cerevisiae, is an RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' NONCODING REGION; 23S RIBOSOMAL-RNA; COLI REP HELICASE; MESSENGER-RNA; ESCHERICHIA-COLI; SECONDARY STRUCTURE; MUTATIONAL ANALYSIS; DNA HELICASE; ATP HYDROLYSIS; HELA-CELLS	The Ded1 protein (Ded1p), a member of the DEAD-box family, has recently been shown to be essential for translation initiation in Saccharomyces cerevisiae. Here, we show that Ded1p purified from Escherichia coli has an ATPase activity, which is stimulated by various RNA substrates. Using an RNA strand-displacement assay, we show that Ded1p has also an ATP-dependent RNA unwinding activity. Hydrolysis of ATP is required for this activity: the replacement of ATP by a nonhydrolyzable analog or a mutation in the DEAD motif abolishing ATPase activity results in loss of RNA unwinding We find that cells harboring a Ded1 protein with this mutated DEAD motif are nonviable, suggesting that the ATPase and RNA helicase activities of this protein are essential to the cell. Finally, RNA binding measurements indicate that the presence of ATP, but not ADP, increases the affinity of Ded1p for duplex versus single-stranded RNA; we discuss how this differential effect might drive the unwinding reaction.	Univ Geneva, Ctr Med, Dept Biochim Med, CH-1211 Geneva 4, Switzerland; Ecole Normale Super, CNRS, UMR 8541, Genet Mol Lab, F-75230 Paris, France	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Iost, I (corresponding author), Univ Geneva, Ctr Med, Dept Biochim Med, CH-1211 Geneva 4, Switzerland.		Iost, Isabelle/M-7149-2014	Iost, Isabelle/0000-0001-9061-4177				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; Boddeker N, 1997, NUCLEIC ACIDS RES, V25, P537, DOI 10.1093/nar/25.3.537; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; CZAPLINSKI K, 1995, RNA, V1, P610; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Gururajan R, 1997, BBA-GENE STRUCT EXPR, V1350, P169, DOI 10.1016/S0167-4781(96)00155-8; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kaiser C., 1994, METHODS YEAST GENETI; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LANKER S, 1992, J BIOL CHEM, V267, P21167; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE CG, 1992, J BIOL CHEM, V267, P4398; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PANUSKA JR, 1980, J BIOL CHEM, V255, P5208; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Tsu CA, 1998, BIOCHEMISTRY-US, V37, P16989, DOI 10.1021/bi981837y; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WENG Y, 1993, RNA, V4, P205; Weng YM, 1996, MOL CELL BIOL, V16, P5477; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	58	164	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17677	17683		10.1074/jbc.274.25.17677	http://dx.doi.org/10.1074/jbc.274.25.17677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364207	hybrid			2022-12-27	WOS:000080974300043
J	Kwon, YT; Levy, F; Varshavsky, A				Kwon, YT; Levy, F; Varshavsky, A			Bivalent inhibitor of the N-end rule pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; RECOGNITION COMPONENT; SACCHAROMYCES-CEREVISIAE; UBIQUITIN SYSTEM; BINDING-SITES; G-ALPHA; YEAST; ASPARAGINE; SEQUENCE; RESIDUE	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. Ubr1p, the recognition (E3) component of the Saccharomyces cerevisiae N-end rule pathway, contains at least two substrate-binding sites. The type 1 site is specific for N-terminal basic residues Arg, Lys, and His. The type 2 site is specific for N-terminal bulky hydrophobic residues Phe, Leu, Trp, Tyr, and Ile. Previous work has shown that dipeptides bearing either type 1 or type 2 N-terminal residues act as weak but specific inhibitors of the N-end rule pathway. We took advantage of the two-site architecture of Ubr1p to explore the feasibility of bivalent N-end rule inhibitors, whose expected higher efficacy would result from higher affinity of the cooperative (bivalent) binding to Ubr1p. The inhibitor comprised mixed tetramers of beta-galactosidase that bore both N-terminal Arg (type 1 residue) and N-terminal Leu (type 2 residue) but that were resistant to proteolysis in vivo. Expression of these constructs in S. cerevisiae inhibited the N-end rule pathway much more strongly than the expression of otherwise identical beta-galactosidase tetramers whose N-terminal residues were exclusively Arg or exclusively Leu. In addition to demonstrating spatial proximity between the type 1 and type 2 substrate-binding sites of Ubr1p, these results provide a route to high affinity inhibitors of the N-end rule pathway.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	California Institute of Technology; Ludwig Institute for Cancer Research	Varshavsky, A (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd,147-75, Pasadena, CA 91125 USA.	avarsh@its.caltech.edu			NIDDK NIH HHS [DK39520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAGRAMAM K, 1995, MOL MICROBIOL, V15, P225, DOI 10.1111/j.1365-2958.1995.tb02237.x; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V87, P2374; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Grigoryev S, 1996, J BIOL CHEM, V271, P28521, DOI 10.1074/jbc.271.45.28521; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MADURA K, 1993, J BIOL CHEM, V268, P12046; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Ptashne M., 1992, A GENETIC SWITCH; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; REISS Y, 1988, J BIOL CHEM, V263, P2693; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sijts AJAM, 1997, J BIOL CHEM, V272, P19261, DOI 10.1074/jbc.272.31.19261; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; STEWART AE, 1995, J BIOL CHEM, V270, P25, DOI 10.1074/jbc.270.1.25; Taban CH, 1996, EXPERIENTIA, V52, P865, DOI 10.1007/BF01938871; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Varshavsky A., 1998, UBIQUITIN BIOL CELL, P223	41	29	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18135	18139		10.1074/jbc.274.25.18135	http://dx.doi.org/10.1074/jbc.274.25.18135			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364269	hybrid, Green Accepted			2022-12-27	WOS:000080974300105
J	Rakovic, S; Cui, Y; Iino, S; Galione, A; Ashamu, GA; Potter, BVL; Terrar, DA				Rakovic, S; Cui, Y; Iino, S; Galione, A; Ashamu, GA; Potter, BVL; Terrar, DA			An antagonist of cADP-ribose inhibits arrhythmogenic oscillations of intracellular Ca2+ in heart cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; PIG VENTRICULAR MYOCYTES; CARDIAC PURKINJE-FIBERS; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; CONTRACTION; RAT; CHANNELS; NEURONS; MUSCLE	Oscillations of Ca2+ in heart cells are a major underlying cause of important cardiac arrhythmias, and it is known that Ca2+-induced release of Ca2+ from intracellular stores (the sarcoplasmic reticulum) is fundamental to the generation of such oscillations. There is now evidence that cADP-ribose may be an endogenous regulator of the Ca2+ release channel of the sarcoplasmic reticulum (the ryanodine receptor), raising the possibility that cADP-ribose may influence arrhythmogenic mechanisms in the heart. 8-Amino-cADP-ribose an antagonist of cADP-ribose, suppressed oscillatory activity associated with overloading of intracellular Ca2+ stores in cardiac myocytes exposed to high doses of the p-adrenoreceptor agonist isoproterenol or the Na+/K+-ATPase inhibitor ouabain, The oscillations suppressed by 8-amino-cADP-ribose included intracellular Ca2+ waves, spontaneous action potentials, after-depolarizations, and transient inward currents. Another antagonist of cADP-ribose, 8-bromo-cADP-ribose, was also effective in suppressing isoproterenol-induced oscillatory activity. Furthermore, in the presence of ouabain under conditions in which there was no arrhythmogenesis, exogenous cADP-ribose was found to be capable of triggering spontaneous contractile and electrical activity, Because enzymatic machinery for regulating the cytosolic cADP-ribose concentration is present within the cell, we propose that 8-amino-cADP-ribose and 8-bromo-cADP-ribose suppress cytosolic Ca2+ oscillations by antagonism of endogenous cADP-ribose, which sensitizes the Ca2+ release channels of the sarcoplasmic reticulum to Ca2+.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Bath, Sch Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Oxford; University of Bath	Terrar, DA (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Potter, Barry/AAX-4781-2020; Galione, Antony/E-5884-2011; Potter, Barry VL/A-1845-2012	Galione, Antony/0000-0002-4132-7646; Terrar, Derek/0000-0001-9408-6594				ARONSON RS, 1988, J PHYSIOL-LONDON, V400, P113, DOI 10.1113/jphysiol.1988.sp017114; BERS DM, 1991, EXCITATION CONTRACTI, P119; Chidambaram N, 1998, BIOCHEM MOL BIOL INT, V44, P1225; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; EISNER DA, 1984, J PHYSIOL-LONDON, V355, P251, DOI 10.1113/jphysiol.1984.sp015417; EISNER DA, 1986, J PHYSIOL-LONDON, V372, P539, DOI 10.1113/jphysiol.1986.sp016024; Empson RM, 1997, J BIOL CHEM, V272, P20967, DOI 10.1074/jbc.272.34.20967; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; FOZZARD HA, 1985, J AM COLL CARDIOL, V5, pA10, DOI 10.1016/S0735-1097(85)80458-7; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1996, RYANODINE RECEPTORS, P52; Guo XQ, 1997, J BIOL CHEM, V272, P16984, DOI 10.1074/jbc.272.27.16984; GUSE AH, 1995, J IMMUNOL, V155, P3353; HARRISON SM, 1992, J PHYSIOL-LONDON, V449, P517, DOI 10.1113/jphysiol.1992.sp019100; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; Iino S, 1997, CIRC RES, V81, P879; KIMURA J, 1988, J PHYSIOL-LONDON, V407, pP79; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEVI AJ, 1994, PROG BIOPHYS MOL BIO, V62, P1, DOI 10.1016/0079-6107(94)90005-1; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; MCGARRY SJ, 1993, BRIT J PHARMACOL, V108, P1043, DOI 10.1111/j.1476-5381.1993.tb13503.x; Meszaros LG, 1997, BIOCHEM BIOPH RES CO, V234, P252, DOI 10.1006/bbrc.1997.6620; MESZAROS V, 1995, BIOCHEM BIOPH RES CO, V210, P452, DOI 10.1006/bbrc.1995.1681; MITCHELL MR, 1984, BRIT J PHARMACOL, V81, P543, DOI 10.1111/j.1476-5381.1984.tb10107.x; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; SITSAPESAN R, 1994, J MEMBRANE BIOL, V137, P215; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WIER WG, 1984, J GEN PHYSIOL, V83, P395, DOI 10.1085/jgp.83.3.395	37	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17820	17827		10.1074/jbc.274.25.17820	http://dx.doi.org/10.1074/jbc.274.25.17820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364226	hybrid			2022-12-27	WOS:000080974300062
J	Srinivasula, SM; Ahmad, M; Lin, J; Poyet, JL; Fernandes-Alnemri, T; Tsichlis, PN; Alnemri, ES				Srinivasula, SM; Ahmad, M; Lin, J; Poyet, JL; Fernandes-Alnemri, T; Tsichlis, PN; Alnemri, ES			CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappa B activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; CYTOCHROME-C; CELL-DEATH; SIGNAL-TRANSDUCTION; KINASE COMPLEX; INTERACTING PROTEIN; MOLECULAR-CLONING; ADAPTER MOLECULE; TNF; MITOCHONDRIA	Molecules that regulate NF-kappa B activation play critical roles in apoptosis and inflammation. We describe the cloning of the cellular homolog of the equine herpesvirus-2 protein E10 and show that both proteins regulate apoptosis and NF-kappa B activation. These proteins were found to contain N-terminal caspase-recruitment domains (CARDs) and novel C-terminal domains (CTDs) and were therefore named CLAPs (CARD-like apoptotic proteins). The cellular and viral CLAPs induce apoptosis downstream of caspase-8 by activating the Apaf-1-caspase-9 pathway and activate NF-kappa B by acting upstream of the NF-kappa B-inducing kinase, NIK, and the IkB kinase, IKK alpha. Deletion of either the CARD or the CTD domain inhibits both activities, The CARD domain was found to be important for homo- and heterodimerization of CLAPs, Substitution of the CARD domain with an inducible FKBP12 oligomerization domain produced a molecule that can induce NF-kappa B activation, suggesting that the CARD domain functions as an oligomerization domain, whereas the CTD domain functions as the effector domain in the NF-kappa B activation pathway. Expression of the CARD domain of human CLAP abrogates tumor necrosis factor-cw-induced NF-kappa B activation, suggesting that cellular CLAP plays an essential role in this pathway of NF-kappa B activation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NIA NIH HHS [AG13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Meinl E, 1998, IMMUNOL TODAY, V19, P474, DOI 10.1016/S0167-5699(98)01309-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robertson NM, 1997, CANCER RES, V57, P43; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P13706; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	95	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17946	17954		10.1074/jbc.274.25.17946	http://dx.doi.org/10.1074/jbc.274.25.17946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364242	hybrid			2022-12-27	WOS:000080974300078
J	Kane, PM; Tarsio, M; Liu, JZ				Kane, PM; Tarsio, M; Liu, JZ			Early steps in assembly of the yeast vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ENDOPLASMIC-RETICULUM PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; SECRETORY PATHWAY; ADENOSINE TRIPHOSPHATASE; MEMBRANE GLYCOPROTEIN; CARBOXYPEPTIDASE-Y; 14-KDA SUBUNIT; IN-VITRO	Vacuolar proton-translocating ATPases are composed of a complex of integral membrane proteins, the V-0 sector, attached to a complex of peripheral membrane proteins, the V-1 sector. We have examined the early steps in biosynthesis of the yeast vacuolar ATPase by biosynthetically labeling wild-type and mutant cells for varied pulse and chase times and immunoprecipitating fully and partially assembled complexes under nondenaturing conditions. In wild-type cells, several V-1 subunits and the 100-bDa V-0 subunit associate within 3-5 min, followed by addition of other V-0 subunits with time. Deletion mutants lacking single subunits of the enzyme show a variety of partial complexes, including both com plexes that resemble intermediates in the assembly pathway of wild-type cells and independent V-1 and V-0, sectors that form without any apparent V1V0 subunit interaction. Two yeast sec mutants that show a temperature-conditional block. in export from the endoplasmic reticulum accumulate a complex containing several V-1 subunits and the 100-kDa V-0 subunit during incubation at elevated temperature. This complex can assemble with the 17-KDa V-0 subunit when the temperature block is reversed. We propose that assembly of the yeast V-ATPase can occur by two different pathways: a concerted assembly pathway involving early interactions between V-1 and V-0 subunits and an independent assembly pathway requiring full assembly of V-1 and V-0 sectors before combination of the two sectors. The data suggest that in wild-type cells, assembly occurs predominantly by the concerted assembly pathway, and V-ATPase complexes acquire the full complement of V-0 subunits during or after exit from the endoplasmic reticulum.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1993, J BIOL CHEM, V268, P12749; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P221; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Li XH, 1998, PLANT CELL, V10, P119, DOI 10.1105/tpc.10.1.119; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1982, METHODS YEAST GENETI, P177; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; XIE XS, 1994, J BIOL CHEM, V269, P25809; Xie XS, 1996, J BIOL CHEM, V271, P30980; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	53	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17275	17283		10.1074/jbc.274.24.17275	http://dx.doi.org/10.1074/jbc.274.24.17275			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358087	hybrid			2022-12-27	WOS:000080780400086
J	Leuschner, WD; Hoch, W				Leuschner, WD; Hoch, W			Subtype-specific assembly of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is mediated by their N-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; INHIBITORY GLYCINE RECEPTOR; D-ASPARTATE RECEPTOR; GLUTAMATE-RECEPTOR; BINDING-PROTEINS; CA2+ PERMEABILITY; AMPA RECEPTORS; TRANSMEMBRANE SEGMENT; FUNCTIONAL EXPRESSION; TETRAMERIC STRUCTURE	Glutamate receptors (GluR) are oligomeric protein complexes formed by the assembly of four or perhaps five subunits, The rules that govern the selectivity of this process are not well understood. Here, we expressed combinations of subunits from two related GluR subfamilies in COS7 cells, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate receptors. By co-immunoprecipitation experiments, we assessed the ability of AMPA receptor subunits to assemble into multimeric complexes. Subunits GluR1-4 associated with indistinguishable efficiency with each other, whereas the kainate receptor subunits GluR6 and 7 showed a much lower degree of association with GluR1, Using chimeric receptors and truncation fragments of subunits, we show that this assembly specificity is determined by N-terminal regions of these subunits and that the most N-terminal domain of GluR2 together with a membrane anchor efficiently associates with GLuR1.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Hoch, W (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	werner.hoch@tuebingen.mpg.de						ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Angulo MC, 1997, J NEUROSCI, V17, P6685; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BROSE N, 1994, J BIOL CHEM, V269, P16780; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hackam AS, 1998, J NEUROCHEM, V70, P40; Hall RA, 1997, J NEUROCHEM, V68, P625; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hopf C, 1998, EUR J BIOCHEM, V253, P382, DOI 10.1046/j.1432-1327.1998.2530382.x; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Laube B, 1998, J NEUROSCI, V18, P2954; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LERMA J, 1994, EUR J NEUROSCI, V6, P1080, DOI 10.1111/j.1460-9568.1994.tb00605.x; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; PUCHALSKI RB, 1994, NEURON, V13, P131, DOI 10.1016/0896-6273(94)90464-2; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Sahara Y, 1997, J NEUROSCI, V17, P6611; SHEN NV, 1993, NEURON, V11, P67; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Tsang TC, 1996, BIOTECHNIQUES, V20, P51; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; Wood MW, 1997, J BIOL CHEM, V272, P3532, DOI 10.1074/jbc.272.6.3532; Wu TY, 1996, BIOCHEM J, V319, P731, DOI 10.1042/bj3190731; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; ZHANG D, 1995, NEUROSCIENCE, V67, P177, DOI 10.1016/0306-4522(94)00627-H	70	93	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16907	16916		10.1074/jbc.274.24.16907	http://dx.doi.org/10.1074/jbc.274.24.16907			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358037	hybrid			2022-12-27	WOS:000080780400036
J	Rena, G; Guo, SD; Cichy, SC; Unterman, TG; Cohen, P				Rena, G; Guo, SD; Cichy, SC; Unterman, TG; Cohen, P			Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; P70 S6 KINASE; CAENORHABDITIS-ELEGANS; MAPKAP KINASE-1; ACTIVATION; INSULIN; INHIBITION; GENE; PATHWAY; SIGNALS	Protein kinase B lies "downstream" of phosphatidylinositide (PtdIns) 3-kinase and is thought to mediate many of the intracellular actions of insulin and other growth factors. Here we show that FKHR, a human homologue of the DAF16 transcription factor in Caenorhabditis elegans, is rapidly phosphorylated by human protein kinase B alpha (PKB alpha) at Thr-24, Ser-256, and Ser-319 in vitro and at a much faster rate than BAD, which is thought to be a physiological substrate for PKB, The same three sites, which all lie in the canonical PKB consensus sequences (Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr)), became phosphorylated when FKHR was cotransfected with either PKB or PDK1 (an upstream activator of PKB), All three residues became phosphorylated when 293 cells were stimulated with insulin-like growth factor 1 (IGF-1), The IGF-1-induced phosphorylation was abolished by the PtdIns 3-kinase inhibitor wortmannin but not by PD 98059 (an inhibitor of the mitogen-activated protein kinase cascade) or by rapamycin, These results indicate that FKHR is a physiological substrate of PKB and that it may mediate some of the physiological effects of PKB on gene expression. DAF16 is known to be a component of a signaling pathway that has been partially dissected genetically and includes homologues of the insulin/IGF-1 receptor, PtdIns 8-kinase and PKB, The conservation of Thr-24, Ser-256, and Ser-319 and the sequences surrounding them in DAF16 therefore suggests that DAF16 is also a direct substrate for PKB in C, elegans.	Univ Dundee, Dept Biochem, Med Res Council Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	University of Dundee; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rena, G (corresponding author), Univ Dundee, Dept Biochem, Med Res Council Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.		Rena, Graham/AAV-7985-2021	Rena, Graham/0000-0002-9121-1350				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barthel A, 1997, ENDOCRINOLOGY, V138, P3559, DOI 10.1210/en.138.8.3559; BIGGS WH, 1999, IN PRESS P NATL ACAD; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; Rena G, 1998, NUCLEIC ACIDS RES, V26, P3867, DOI 10.1093/nar/26.16.3867; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wood WB, 1998, CELL, V95, P147, DOI 10.1016/S0092-8674(00)81744-4	38	586	608	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17179	17183		10.1074/jbc.274.24.17179	http://dx.doi.org/10.1074/jbc.274.24.17179			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358075	hybrid			2022-12-27	WOS:000080780400074
J	Roussel, A; Canaan, S; Egloff, MP; Riviere, M; Dupuis, L; Verger, R; Cambillau, C				Roussel, A; Canaan, S; Egloff, MP; Riviere, M; Dupuis, L; Verger, R; Cambillau, C			Crystal structure of human gastric lipase and model of lysosomal acid lipase, two lipolytic enzymes of medical interest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER STORAGE-DISEASE; CANDIDA-RUGOSA LIPASE; INTERFACIAL ACTIVATION; ENZYMATIC-ACTIVITY; MOLECULAR-CLONING; WOLMAN-DISEASE; INSECT CELLS; HYDROLASE; PURIFICATION; EXPRESSION	Fat digestion in humans requires not only the classical pancreatic lipase but also gastric lipase, which is stable and active despite the highly acidic stomach environment. We report here the structure of recombinant human gastric lipase at 3.0-Angstrom resolution, the first structure to be described within the mammalian acid lipase family. This globular enzyme (379 residues) consists of a core domain belonging to the alpha/beta hydrolase-fold family and a "cap" domain, which is analogous to that present in serine carboxypeptidases. It possesses a classical catalytic triad (Ser-153, His-353, Asp-324) and an oxyanion hole (NH groups of G1n-154 and Leu-67), Four N-glycosylation sites were identified on the electron density maps. The catalytic serine is deeply buried under a segment consisting of 30 residues, which can be defined as a lid and belonging to the cap domain. The displacement of the lid is necessary for the substrates to have access to Ser-153, A phosphonate inhibitor was positioned in the active site that clearly suggests the location of the hydrophobic substrate binding site. The lysosomal acid lipase was modeled by homology, and possible explanations for some previously reported mutations leading to the cholesterol ester storage disease are given based on the present model.	CNRS IFR1 UPR 9025, Lab Lipolyse Enzymat, F-13402 Marseille 20, France; CNRS IFR1 UPR 9039, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Cambillau, C (corresponding author), CNRS IFR1 UPR 9025, Lab Lipolyse Enzymat, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr	berti, liliane/F-5878-2011					AMEIS D, 1994, EUR J BIOCHEM, V219, P905, DOI 10.1111/j.1432-1033.1994.tb18572.x; AMEIS D, 1995, J LIPID RES, V36, P241; ANDERSON RA, 1991, J BIOL CHEM, V266, P22479; ANDERSON RA, 1994, P NATL ACAD SCI USA, V91, P2718, DOI 10.1073/pnas.91.7.2718; AOUBALA M, 1994, BBA-LIPID LIPID MET, V1213, P319, DOI 10.1016/0005-2760(94)00058-1; ASLANIDIS C, 1994, GENOMICS, V20, P329, DOI 10.1006/geno.1994.1180; Aslanidis C, 1996, GENOMICS, V33, P85, DOI 10.1006/geno.1996.0162; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODMER MW, 1987, BIOCHIM BIOPHYS ACTA, V909, P237, DOI 10.1016/0167-4781(87)90083-2; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURKE JA, 1972, SCIENCE, V176, P309, DOI 10.1126/science.176.4032.309; Canaan S, 1998, PROTEIN EXPRES PURIF, V14, P23, DOI 10.1006/prep.1998.0946; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CARRIERE F, 1994, LIPASES THEIR STRUCT, P181; De Caro J, 1998, BBA-PROTEIN STRUCT M, V1386, P39, DOI 10.1016/S0167-4838(98)00058-2; DEREWENDA ZS, 1992, J MOL BIOL, V227, P818, DOI 10.1016/0022-2836(92)90225-9; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; GARGOURI Y, 1986, GASTROENTEROLOGY, V91, P919, DOI 10.1016/0016-5085(86)90695-5; GARGOURI Y, 1988, J BIOL CHEM, V263, P2159; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; Hamosh, 1990, LINGUAL GASTRIC LIPA; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KLIMA H, 1993, J CLIN INVEST, V92, P2713, DOI 10.1172/JCI116888; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Lang DA, 1998, EUR J BIOCHEM, V254, P333, DOI 10.1046/j.1432-1327.1998.2540333.x; LAPEY A, 1974, J PEDIATR-US, V84, P328, DOI 10.1016/S0022-3476(74)80712-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; Lohse P, 1997, J LIPID RES, V38, P1896; Lohse P, 1997, J LIPID RES, V38, P892; Longhi S, 1997, PROTEIN SCI, V6, P275; MARTINEZ C, 1994, BIOCHEMISTRY-US, V33, P83, DOI 10.1021/bi00167a011; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOREAU H, 1992, J MOL BIOL, V225, P147, DOI 10.1016/0022-2836(92)91032-K; MOREAU H, 1989, HISTOCHEMISTRY, V91, P419, DOI 10.1007/BF00493829; MULLER DPR, 1975, GUT, V16, P838; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas A, 1996, BIOCHEMISTRY-US, V35, P398, DOI 10.1021/bi9515578; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pagani F, 1996, HUM MOL GENET, V5, P1611, DOI 10.1093/hmg/5.10.1611; PAGANO NJ, 1994, MECH COMPOS MATER, V1, P3; Pariyarath R, 1996, FEBS LETT, V397, P79, DOI 10.1016/S0014-5793(96)01134-9; PATRICK AD, 1969, NATURE, V222, P1087; PETERSEN SB, 1994, LIPASES THEIR STRUCT, P23; Roussel A, 1998, PROTEINS, V32, P523; Roussel A, 1991, SILICON GRAPHICS GEO, P86; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SEEDORF U, 1995, ARTERIOSCL THROM VAS, V15, P773, DOI 10.1161/01.ATV.15.6.773; Suzuki A, 1997, GASTROENTEROLOGY, V112, P2048, DOI 10.1053/gast.1997.v112.pm9178698; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uppenberg J, 1995, BIOCHEMISTRY-US, V34, P16838, DOI 10.1021/bi00051a035; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WickerPlanquart C, 1996, PROTEIN ENG, V9, P1225, DOI 10.1093/protein/9.12.1225	61	132	145	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16995	17002		10.1074/jbc.274.24.16995	http://dx.doi.org/10.1074/jbc.274.24.16995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358049	hybrid			2022-12-27	WOS:000080780400048
J	Ujita, M; McAuliffe, J; Hindsgaul, O; Sasaki, K; Fukuda, MN; Fukuda, M				Ujita, M; McAuliffe, J; Hindsgaul, O; Sasaki, K; Fukuda, MN; Fukuda, M			Poly-N-acetyllactosamine synthesis in branched N-glycans is controlled by complemental branch specificity of i-extension enzyme and beta 1,4-galactosyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BLOOD-GROUP-I; ASPARAGINE-LINKED OLIGOSACCHARIDES; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN-ERYTHROCYTE-MEMBRANE; L-SELECTIN; CARBOHYDRATE STRUCTURE; SUGAR CHAINS; KIDNEY CELLS; HL-60 CELLS	Poly-N-acetyllactosamine is a unique carbohydrate that can carry various functional oligosaccharides, such as sialyl Lewis X. It has been shown that the amount of poly-N-acetyllactosamine is increased in N-glycans, when they contain Gal beta 1 --> 4GlcNAc beta 1 --> 6(Gal beta 1 --> 4GlcNAc beta 1 --> 2)Man alpha 1 --> branched structure. To determine how this increased synthesis of poly-N-acetyllactosamines takes place, the branched acceptor was incubated with a mixture of i-extension enzyme (iGnT) and beta 1,4-galactosyltransferase I(beta 4Gal-TI), First, N-acetyllactosamine repeats were more readily added to the branched acceptor than the summation of poly-N-acetyllactosamines formed individually on each unbranched acceptor. Surprisingly, poly-N-acetyllactosamine was more efficiently formed on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man alpha --> R side chain than in Gal beta 1 --> 4GlcNAc beta 1 --> 6Man alpha --> R, due to preferential action of iGnT on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man alpha --> R side chain. On the other hand, galactosylation was much more efficient on pl,G-linked GlcNAc than beta 1,a-linked GlcNAc, preferentially forming Gal beta 1 --> 4GlcNAc beta 1 --> 6(GlcNA beta 1 --> 2)Man alpha 1 --> 6Man beta --> R. Starting with this preformed acceptor, N-acetyllactosamine repeats were added almost equally to Gal beta 1 --> 4GlcNAc beta 1 --> 6Man alpha --> R and Gal beta 1 --> 4GlcNA beta 1 --> 2Man alpha --> R side chains. Taken together, these results indicate that the complemental branch specificity of iGnT and beta 4Gal-TI leads to efficient and equal addition of N-acetyllactosamine repeats on both side chains of GlcNAc beta 1 --> 6(GlcNAc beta 1 --> 2)Man alpha 1 --> 6Man beta --> R structure, which is consistent with the structures found in nature. The results also suggest that the addition of Gal beta 1 --> 4GlcNA beta 1 --> 6 side chain on Gal beta 1 --> 4GlcNAc beta 1 --> 2Man --> R side chain converts the acceptor to one that is much more favorable for iGnT and beta 4Gal-TI.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan	Sanford Burnham Prebys Medical Discovery Institute; Kyowa Kirin Ltd	Ujita, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLANKEN WM, 1982, EUR J BIOCHEM, V127, P547, DOI 10.1111/j.1432-1033.1982.tb06906.x; BOCK K, 1992, CARBOHYD RES, V228, P1, DOI 10.1016/S0008-6215(00)90544-5; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; FUKUDA MN, 1992, CRC HDB ENDOGLYCOSID, P55; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; HOKKE CH, 1991, FEBS LETT, V286, P18, DOI 10.1016/0014-5793(91)80931-R; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; IMAI Y, 1993, NATURE, V361, P555; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; PIERCE M, 1986, J BIOL CHEM, V261, P772; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SRIVASTAVA G, 1992, CARBOHYD RES, V224, P83, DOI 10.1016/0008-6215(92)84095-A; Taguchi T, 1997, GLYCOBIOLOGY, V7, P31, DOI 10.1093/glycob/7.1.31; TAKEUCHI M, 1988, J BIOL CHEM, V263, P3657; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WATSON E, 1994, GLYCOBIOLOGY, V4, P227, DOI 10.1093/glycob/4.2.227; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	57	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16717	16726		10.1074/jbc.274.24.16717	http://dx.doi.org/10.1074/jbc.274.24.16717			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358011	hybrid			2022-12-27	WOS:000080780400010
J	Yao, XL; Cowan, MJ; Gladwin, MT; Lawrence, MM; Angus, CW; Shelhamer, JH				Yao, XL; Cowan, MJ; Gladwin, MT; Lawrence, MM; Angus, CW; Shelhamer, JH			Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; LIPID 2ND MESSENGERS; RAT MESANGIAL CELLS; BINDING PROTEINS; GENE-EXPRESSION; SUBSTRATE; CLONING; FAMILY; RNA	The effect of the glucocorticosteroid, dexamethasone, on arachidonic acid (AA) release and on protein levels of p11 and cytosolic phospholipase A(2) (cPLA(2)) was studied in two epithelial cell lines, HeLa cells and BEAS-2B cells. Dexamethasone treatment of HeLa cells and BEAS-2B cells increased cellular pll protein and mRNA levels in a time- and dose-dependent manner. It had little effect on levels of cPLA(2) protein. In order to determine if increased pll protein expression resulted in increased interaction between p11 and cPLA(2), anti-cPLA(2) antibodies were used to immunoprecipitate p11.cPLA(2) complexes and Western blots of the immunoprecipitate were used to detect p11, In cells treated with dexamethasone, more p11 was detected in the anti-cPLA(2) immunoprecipitate compared with control cells. Dexamethasone treatment of HeLa cells prelabeled with [H-3]AA decreased the release of [H-3]AA under basal conditions and after stimulation with the calcium ionophore A23187 (10(-6) M). In order to determine if altering the p11 protein levels in HeLa cells independent of glucocorticosteroid treatment could also produce an effect on [H-3]AA release, cells were stably transfected with plasmids expressing either p11 antisense mRNA or p11 mRNA Cloned HeLa cells expressing p11 antisense mRNA exhibited less cellular p11 protein compared with control cells and greater [H-3]AA release compared with cells transfected with a control vector. Cloned HeLa cells stably transfected with a p11 expression vector exhibited increased p11 cellular protein and diminished [H-3]AA release under basal conditions and in response to A23187, Therefore, dexamethasone alteration of epithelial cell AA release may be due in part to induction of p11 protein expression.	NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Shelhamer, JH (corresponding author), NIH, Ctr Clin, Dept Crit Care Med, Bldg 10,Rm 7-D-43, Bethesda, MD 20892 USA.							BLACKWELL GJ, 1978, BRIT J PHARMACOL, V62, P79, DOI 10.1111/j.1476-5381.1978.tb07009.x; BUHL WJ, 1992, EICOSANOIDS, V5, pS26; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V48, P1729, DOI 10.1016/0006-2952(94)90458-8; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; FLOWER R, 1989, BIOCHEM SOC T, V17, P276, DOI 10.1042/bst0170276; FULLER PJ, 1989, J IMMUNOL, V143, P1015; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Mahajan DK, 1997, FERTIL STERIL, V68, P967, DOI 10.1016/S0015-0282(97)00189-1; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 1996, LIFE SCI, V60, P67, DOI 10.1016/S0024-3205(96)00590-5; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Vervoordeldonk MJBM, 1996, BIOCHEM J, V315, P435, DOI 10.1042/bj3150435; VERVOORDELDONK MJBM, 1994, BBA-MOL CELL RES, V1224, P541, DOI 10.1016/0167-4889(94)90292-5; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; Wijkander J, 1997, BIOCHEM J, V325, P405, DOI 10.1042/bj3250405; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; YANG J, 1994, P NATL ACAD SCI USA, V91, P529, DOI 10.1073/pnas.91.2.529	44	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17202	17208		10.1074/jbc.274.24.17202	http://dx.doi.org/10.1074/jbc.274.24.17202			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358078	hybrid			2022-12-27	WOS:000080780400077
J	Liu, YF; Ghahremani, MH; Rasenick, MM; Jakobs, KH; Albert, PR				Liu, YF; Ghahremani, MH; Rasenick, MM; Jakobs, KH; Albert, PR			Stimulation of cAMP synthesis by G(i)-coupled receptors upon ablation of distinct G alpha(i) protein expression - G(i) subtype specificity of the 5-HT1A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MAMMALIAN ADENYLYL CYCLASES; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CELL-LINES; MOLECULAR-CLONING; RAT HIPPOCAMPUS; PHOSPHOLIPASE-C; GI-PROTEIN; INHIBITION	The three G alpha(i) subunits were independently depleted from rat pituitary GH4C1 cells by stable transfection of each G alpha(i) antisense rat cDNA construct. Depletion of any G alpha(i) subunit eliminated receptor-induced inhibition of basal cAMP production, indicating that all Ga, subunits are required for this response. By contrast, receptor-mediated inhibition of vasoactive intestinal peptide (VIP)-stimulated cAMP production was blocked by selective depletions for responses induced by the transfected serotonin 1A (5-HT1A) (G alpha(i2) or G alpha(i3)) or endogenous muscarinic-M4 (G alpha(i1) or G alpha(i2)) receptors. Strikingly, receptor activation in G alpha(i1)-depleted clones (for the 5-HT1A receptor) or G alpha(i3)-depleted clones (for the muscarinic receptor) induced a pertussis toxin-sensitive increase in basal cAMP production, whereas the inhibitory action on VIP-stimulated cAMP synthesis remained. Finally, in G alpha(i2)-depleted clones, activation of 5-HT1A receptors increased VIP-stimulated cAMP synthesis. Thus, 5-HT1A and muscarinic M4 receptor may couple dominantly to G alpha(i1) and G alpha(i3), respectively, to inhibit cAMP production. Upon removal of these G alpha(i) subunits to reduce inhibitory coupling, stimulatory receptor coupling is revealed that may involve G beta gamma-induced activation of adenylyl cyclase II, a G(i)-stimulated cyclase that is predominantly expressed in GH4C1 cells. Thus G(i)-coupled receptor activation involves integration of both inhibitory and stimulatory outputs that can be modulated by specific changes in alpha(i) subunit expression level.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Illinois, Dept Physiol, Chicago, IL 60612 USA; Univ Illinois, Dept Biophys, Chicago, IL 60612 USA; Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; Univ Essen Gesamthsch, Inst Pharmakol, D-45122 Essen, Germany; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Duisburg Essen; University of Ottawa	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Ghahremani, Mohammad H/F-1615-2013; Albert, Paul/E-4804-2010	Ghahremani, Mohammad H/0000-0001-5051-6214; Albert, Paul/0000-0002-1809-3554				ALBERT PR, 1994, TRENDS PHARMACOL SCI, V15, P250, DOI 10.1016/0165-6147(94)90320-4; ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ALBERT PR, 1997, P SOC NEUROSCI, V23, P289; Baker LP, 1999, J NEUROSCI, V19, P180, DOI 10.1523/JNEUROSCI.19-01-00180.1999; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CADOGAN AK, 1994, J NEUROCHEM, V62, P1816; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUMUIS A, 1988, MOL PHARMACOL, V33, P178; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOETZL EJ, 1994, J BIOL CHEM, V269, P809; GREEN A, 1990, J BIOL CHEM, V265, P5206; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIU YF, 1991, J BIOL CHEM, V266, P23689; LIU YF, 1994, J BIOL CHEM, V269, P13880; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MARKSTEIN R, 1986, N-S ARCH PHARMACOL, V333, P335, DOI 10.1007/BF00500006; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093	46	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16444	16450		10.1074/jbc.274.23.16444	http://dx.doi.org/10.1074/jbc.274.23.16444			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347206	hybrid			2022-12-27	WOS:000080668600066
J	O'Rourke, JP; Newbound, GC; Hutt, JA; DeWille, J				O'Rourke, JP; Newbound, GC; Hutt, JA; DeWille, J			CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G(0) growth arrest and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP FAMILY MEMBERS; BREAST-CANCER CELLS; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; TUMOR-SUPPRESSOR; CYCLIN D1; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; CDK INHIBITOR; EXPRESSION	CCAAT/enhancer-binding proteins (C/EBPs) are a highly conserved family of DNA-binding proteins that regulate cell-specific growth, differentiation, and apoptosis. Here, we show that induction of C/EBP delta gene expression during G(0) growth arrest is a general property of mammary-derived cell lines. C/EBP delta is not induced during G(0) growth arrest in 3T3 or IEC18 cells. C/EBP delta induction is G(0)-specific in mouse mammary epithelial cells; C/EBP delta gene expression is not induced by growth arrest in the G(1), S, or G(2) phase of the cell cycle. C/EBP delta antisense-expressing cells (AS1 cells) maintain elevated cyclin D1 and phosphorylated retinoblastoma protein levels and exhibit delayed G(0) growth arrest and apoptosis in response to serum and growth factor withdrawal. Conversely, C/EBP delta-overexpressing cells exhibited a rapid decline in cyclin D1 and phosphorylated retinoblastoma protein levels, a rapid increase in the cyclin-dependent kinase inhibitor p27, and accelerated G(0) growth arrest and apoptosis in response to serum and growth factor withdrawal. When C/EBP delta levels were rescued in AS1 cells by transfection with a C/EBP delta "sense" construct, normal G(0) growth arrest and apoptosis were restored. These results demonstrate that C/EBP delta plays a key role in the regulation of G(0) growth arrest and apoptosis in mammary epithelial cells.	Ohio State Univ, Ohio State Comprehens Canc Ctr, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Comprehens Canc Ctr, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Comprehens Canc Ctr, Div Mol Biol & Canc Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	DeWille, J (corresponding author), Ohio State Univ, Ohio State Comprehens Canc Ctr, Dept Vet Biosci, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, R29CA057607, R01CA057607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000136] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058, CA 57607] Funding Source: Medline; NCRR NIH HHS [RR00136CA] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Boudreau F, 1996, EXP CELL RES, V222, P1, DOI 10.1006/excr.1996.0001; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; CANTWELL CA, 1998, GENE DEV, V18, P2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; COOPER G, 1997, CELL MOL APPROACH, P561; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Helbing CC, 1997, CANCER RES, V57, P1255; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Katayose Y, 1997, CANCER RES, V57, P5441; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MERLO GR, 1993, ANN NY ACAD SCI, V698, P108, DOI 10.1111/j.1749-6632.1993.tb17195.x; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOTT LM, 1992, BLOOD, V80, P1725; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1998, CANCER RES, V58, P3448; Shao NS, 1996, ONCOGENE, V13, P1; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16582	16589		10.1074/jbc.274.23.16582	http://dx.doi.org/10.1074/jbc.274.23.16582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347224	hybrid			2022-12-27	WOS:000080668600084
J	Sharma, DK; Vidugiriene, J; Bangs, JD; Menon, AK				Sharma, DK; Vidugiriene, J; Bangs, JD; Menon, AK			A cell-free assay for glycosylphosphatidylinositol anchoring in African trypanosomes - Demonstration of a transamidation reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; TERMINAL SIGNAL PEPTIDE; SURFACE GLYCOPROTEIN; MEMBRANE-PROTEINS; GPI ANCHOR; DEVELOPMENTAL VARIATION; BRUCEI; BIOSYNTHESIS; PURIFICATION; ATTACHMENT	We established an in vitro assay for the addition of glycosyl-phosphatidylinositol (GPI) anchors to proteins using procyclic trypanosomes engineered to express GPI-anchored variant surface glycoprotein (VSG), The assay is based on the premise that small nucleophiles, such as hydrazine, can substitute for the GPI moiety and effect displacement of the membrane anchor of a GPI-anchored protein or pro-protein causing release of the protein into the aqueous medium. Cell membranes containing pulse-radiolabeled VSG were incubated with hydrazine, and the VSG released from the membranes was measured by carbonate extraction, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis/fluorography, Release of VSG was time- and temperature-dependent, was stimulated by hydrazine, and occurred only for VSG molecules situated in early compartments of the secretory pathway. No nucleophile-induced VSG release was seen in membranes prepared from cells expressing a VSG variant with a conventional transmembrane anchor (i.e. a nonfunctional GPI signal sequence). Pro-VSG was shown to be a substrate in the reaction by assaying membranes prepared from cells treated with mannosamine, a GPI biosynthesis inhibitor. When a biotinylated derivative of hydrazine was used instead of hydrazine, the released VSG could be precipitated with streptavidin-agarose, indicating that the biotin moiety was covalently incorporated into the protein. Hydrazine was shown to block the C terminus of the released VSG hydrazide because the released material, unlike a truncated form of VSG lacking a GPI signal sequence, was not susceptible to proteolysis by carboxypeptidases, These results firmly establish that the released material in our assay is VSG hydrazide and strengthen the proof that CPI anchoring proceeds via a transamidation reaction mechanism. The reaction could be inhibited with sulfhydryl alkylating reagents, suggesting that the transamidase enzyme contains a functionally important sulfhydryl residue.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Vilnius State Univ, Dept Biochem, Vilnius, Lithuania; Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Vilnius University; University of Wisconsin System; University of Wisconsin Madison	Sharma, DK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI35739, R01 AI035739] Funding Source: Medline; NIGMS NIH HHS [R01 GM055427, GM55427] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035739, R29AI035739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE Y, 1993, J BIOL CHEM, V268, P3525; AMTHAUER R, 1993, P NATL ACAD SCI USA, V90, P3973, DOI 10.1073/pnas.90.9.3973; AMTHAUER R, 1992, P NATL ACAD SCI USA, V89, P6124, DOI 10.1073/pnas.89.13.6124; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; Doering TL, 1997, BIOCHEM J, V328, P669; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Field M. C., 1992, LIPID MODIFICATION P, P155; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HERELD D, 1988, POST TRANSLATIONAL M, P9; HOWELL S, 1994, J BIOL CHEM, V269, P16993; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; RALTON JE, 1993, J BIOL CHEM, V268, P24183; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Sambrook J., 2002, MOL CLONING LAB MANU; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATE SS, 1974, P NATL ACAD SCI USA, V71, P3329, DOI 10.1073/pnas.71.9.3329; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	40	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16479	16486		10.1074/jbc.274.23.16479	http://dx.doi.org/10.1074/jbc.274.23.16479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347210	hybrid			2022-12-27	WOS:000080668600070
J	Ames, JB; Dizhoor, AM; Ikura, M; Palczewski, K; Stryer, L				Ames, JB; Dizhoor, AM; Ikura, M; Palczewski, K; Stryer, L			Three-dimensional structure of guanylyl cyclase activating protein-2, a calcium-sensitive modulator of photoreceptor guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONE DYSTROPHY; MYRISTOYLATED RECOVERIN; MOLECULAR-CLONING; RHODOPSIN KINASE; OUTER SEGMENTS; VERTEBRATE; NMR; SWITCH; GCAP-2; RETINA	Guanylyl cyclase activating protein-2 (GCAP-2) is a Ca2+-sensitive regulator of phototransduction in retinal photoreceptor cells. GCAP-2 activates retinal guanylyl cyclases at low Ca2+ concentration (<100 nM) and inhibits them at high Ca2+ (>500 nM). The light-induced lowering of the Ca2+ level from similar to 500 nM in the dark to similar to 50 nM following illumination is known to play a key role in visual recovery and adaptation. We report here the three-dimensional structure of unmyristoylated GCAP-2 with three bound Ca2+ ions as determined by nuclear magnetic resonance spectroscopy of recombinant, isotopically labeled protein. GCAP-2 contains four EF-hand motifs arranged in a compact tandem array like that seen previously in recoverin. The root mean square deviation of the main chain atoms in the EF-hand regions is 2.2 Angstrom in comparing the Ca2+-bound structures of GCAP-2 and recoverin. EF-1, as in recoverin, does not bind calcium because it contains a disabling Cys-Pro sequence. GCAP-2 differs from recoverin in that the calcium ion binds to EF-4 in addition to EF-2 and EF-3. A prominent exposed patch of hydrophobic residues formed by EF-1 and EF-2 (Leu(24), Trp(27), Phe(31), Phe(45) Phe(48), Phe(49), Tyr(81), Val(82), Leu(85), and Leu(89)) may serve as a target-binding site for the transmission of calcium signals to guanylyl cyclase.	Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, Rockville, MD 20850 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	University System of Maryland; University of Maryland Baltimore; Wayne State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University	Ames, JB (corresponding author), Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	james@carb.nist.gov		Dizhoor, Alexander/0000-0001-6770-9186; Ikura, Mitsuhiko/0000-0002-9524-1303	NEI NIH HHS [EY08061, EY12347, EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522, R01EY008061, R01EY012347, R29EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames BN, 1996, HUM ECOL RISK ASSESS, V2, P6, DOI 10.1080/10807039.1996.10387453; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Hughes RE, 1998, PROTEIN SCI, V7, P2675, DOI 10.1002/pro.5560071222; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; RATTO GM, 1988, J NEUROSCI, V8, P3240; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YAP K, 1999, IN PRESS TRENDS BIOC; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19329	19337		10.1074/jbc.274.27.19329	http://dx.doi.org/10.1074/jbc.274.27.19329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383444	hybrid			2022-12-27	WOS:000081196300067
J	Hurt-Camejo, E; Rosengren, B; Sartipy, P; Elfsberg, K; Camejo, G; Svensson, L				Hurt-Camejo, E; Rosengren, B; Sartipy, P; Elfsberg, K; Camejo, G; Svensson, L			CD44, a cell surface chondroitin sulfate proteoglycan, mediates binding of interferon-gamma and some of its biological effects on human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HIGH-AFFINITY RECEPTOR; IFN-GAMMA; HEPARAN-SULFATE; IMMUNE INTERFERON; EXTRACELLULAR-MATRIX; TERMINAL SEQUENCE; ENDOTHELIAL-CELLS; ACCESSORY FACTOR; GENE-EXPRESSION	Several cytokines and growth factors act on cells after their association with the glycosaminoglycan (GAG) moiety of cell surface proteoglycans (PGs). Interferon-gamma (IFN-gamma) binds to GAG; however, the relevance of this interaction for the biological activity of IFN-gamma on human cells remains to be established. Human arterial smooth muscle cells (HASMC), the main cells synthesizing PG in the vascular wall, respond markedly to IFN-gamma. We found that treatment of HASMC with chondroitinase ABC, an enzyme that degrades chondroitin sulfate GAG, reduced IFN-gamma binding by more than 50%. This treatment increased the affinity of I-125-IFN-gamma for cells from a K-d value of about 93 nM to a K-d value of about 33 nM. However, the total binding was reduced from 9.3 +/- 0.77 pmol/mu g to 3.0 +/- 0.23 pmol/mg (n = 4). Interestingly, pretreatment with chondroitinase ABC reduced significantly the cellular response toward IFN-gamma. The interaction of IFN-gamma with chondroitin sulfate GAG was confirmed by affinity chromatography of isolated cell-associated S-35-, H-3-labeled PG on a column with immobilized IFN-gamma. The cell-associated PG that binds to IFN-gamma was a chondroitin sulfate PG (CSPG). This CSPG had a core protein of approximately 110 kDa that was recognized by anti-CD44 antibodies on Western blots. High molecular weight complexes between IFN-gamma and chondroitin 6-sulfate were observed in gel exclusion chromatography. Additions of chondroitin 6-sulfate to cultured HASMC antagonized the antiproliferative effect and expression of major histocompatibility complex II antigens induced by IFN-gamma. These results indicate that IFN-gamma binds with low affinity to the chondroitin sulfate GAG moiety of the cell surface CSPG receptor CD44. This interaction may increase the local concentration of IFN-gamma at the cell surface, thus facilitating its binding to high affinity receptors and modulating the ability of IFN-gamma to signal a cellular response.	Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Astra Hassle AB, S-43183 Molndal, Sweden	University of Gothenburg	Hurt-Camejo, E (corresponding author), Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden.	Eva.Hurt@wlab.wall.gu.se						AIYER RA, 1986, J IMMUNOL, V136, P3329; AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; Batra RK, 1997, J BIOL CHEM, V272, P11736, DOI 10.1074/jbc.272.18.11736; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EPPS DE, 1995, ANAL BIOCHEM, V227, P342, DOI 10.1006/abio.1995.1290; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FAGER G, 1988, EXP CELL RES, V176, P319, DOI 10.1016/0014-4827(88)90334-5; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINBLOOM DS, 1989, J IMMUNOL, V142, P2314; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Henke CA, 1996, J CLIN INVEST, V97, P2541, DOI 10.1172/JCI118702; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; HURTCAMEJO E, 1995, ARTERIOSCLER THROMB, V15, P1456; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONASSON L, 1985, J CLIN INVEST, V76, P125, DOI 10.1172/JCI111934; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, CELL MOL BIOL, V37, P253; Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; Lustig F, 1996, BIOCHEMISTRY-US, V35, P12077, DOI 10.1021/bi960118l; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN C, 1988, INFLAMMATION BASIC P, P229; Olsson U, 1997, ARTERIOSCL THROM VAS, V17, P149, DOI 10.1161/01.ATV.17.1.149; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEELIG GF, 1988, BIOCHEMISTRY-US, V27, P1981, DOI 10.1021/bi00406a026; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; THYBERG J, 1991, CELL CULTURE TECHNIQ, P315; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; VANLOON APGM, 1991, J LEUKOCYTE BIOL, V49, P462, DOI 10.1002/jlb.49.5.462; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216	71	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18957	18964		10.1074/jbc.274.27.18957	http://dx.doi.org/10.1074/jbc.274.27.18957			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383394	hybrid			2022-12-27	WOS:000081196300017
J	Jeong, SY; Ahn, SG; Lee, JH; Kim, HS; Kim, JW; Rhim, H; Jeong, SW; Kim, IK				Jeong, SY; Ahn, SG; Lee, JH; Kim, HS; Kim, JW; Rhim, H; Jeong, SW; Kim, IK			3-deazaadenosine, a S-adenosylhomocysteine hydrolase inhibitor, has dual effects on NF-kappa B regulation - Inhibition of NF-kappa B transcriptional activity and promotion of I kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; HL-60 CELLS; LEUKOCYTE ADHESION; C-MYC; ACTIVATION; APOPTOSIS; ANALOGS; KINASE; GENE	Previously we reported that 3 deazaadenosine (DZA), a potent inhibitor and substrate for 3-adenosylhomocysteine hydrolase inhibits bacterial lipopolysaccharide-induced transcription of tumor necrosis factor-alpha and interleukin-1 beta in mouse macrophage RAW 264.7 cells. In this study, we demonstrate the effects of DZA on nuclear factor-kappa B (NF-kappa B) regulation. DZA inhibits the transcriptional activity of NF-kappa B through the hindrance of p65 (Rel-A) phosphorylation without reduction of its nuclear translocation and DNA binding activity. The inhibitory effect of DZA on NF-kappa B transcriptional activity is potentiated by the addition of homocysteine. Taken together, DZA promotes the proteolytic degradation of I kappa B alpha, but not I kappa B beta, resulting in an increase of DNA binding activity of NF-kappa B in the nucleus in the absence of its transcriptional activity in RAW 264.7 cells. The reduction of I kappa B alpha by DZA is neither involved in I kappa B kinase complex activation nor modulated by the addition of homocysteine. This study strongly suggests that DZA may be a potent drug for the treatment of diseases in which NF-kappa B plays a central pathogenic role, as well as a useful tool for studying the regulation and physiological functions of NF-kappa B.	Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Res Inst Mol Genet, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Kim, IK (corresponding author), Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea.							AKSAMIT RR, 1982, J BIOL CHEM, V257, P621; ANTWERP DJV, 1996, SCIENCE, V274, P787; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BACKLUND PS, 1986, EUR J BIOCHEM, V160, P245, DOI 10.1111/j.1432-1033.1986.tb09963.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; CHIANG PK, 1977, MOL PHARMACOL, V13, P939; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUERRE JA, 1992, BIOCHEM CELL BIOL, V70, P703, DOI 10.1139/o92-107; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ENDRESEN PC, 1993, BIOCHEM PHARMACOL, V46, P1893, DOI 10.1016/0006-2952(93)90629-B; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Jeong SY, 1996, IMMUNOLOGY, V89, P558, DOI 10.1046/j.1365-2567.1996.d01-781.x; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; Kim IK, 1997, J BIOMED SCI, V4, P83, DOI 10.1007/BF02255598; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KRENITSKY TA, 1986, J MED CHEM, V29, P138, DOI 10.1021/jm00151a022; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Loennechen T, 1997, PHARMACOL TOXICOL, V81, P199, DOI 10.1111/j.1600-0773.1997.tb00046.x; MAYERS DL, 1995, P NATL ACAD SCI USA, V92, P215, DOI 10.1073/pnas.92.1.215; MEDZIHRADSKY JL, 1982, J IMMUNOPHARMACOL, V4, P29, DOI 10.3109/08923978209031073; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZIMMERMAN TP, 1978, P NATL ACAD SCI USA, V75, P6220, DOI 10.1073/pnas.75.12.6220	46	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18981	18988		10.1074/jbc.274.27.18981	http://dx.doi.org/10.1074/jbc.274.27.18981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383397	hybrid			2022-12-27	WOS:000081196300020
J	Rogalla, T; Ehrnsperger, M; Preville, X; Kotlyarov, A; Lutsch, G; Ducasse, C; Paul, C; Wieske, M; Arrigo, AP; Buchner, J; Gaestel, M				Rogalla, T; Ehrnsperger, M; Preville, X; Kotlyarov, A; Lutsch, G; Ducasse, C; Paul, C; Wieske, M; Arrigo, AP; Buchner, J; Gaestel, M			Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress tumor necrosis factor alpha by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; INDUCED CELL-DEATH; MAP KINASE KINASE; NIH 3T3 CELLS; TNF-ALPHA; IN-VIVO; ACTIN POLYMERIZATION; MOLECULAR CHAPERONE; DYNAMIC CHANGES; B-CRYSTALLIN	The small heat shock proteins (sHsps) from human (Hsp27) and mouse (Hsp25) form large oligomers which can act as molecular chaperones in vitro and protect cells from heat shock and oxidative stress when overexpressed. In addition, mammalian sHsps are rapidly phosphorylated by MAPKAP kinase 2/3 at two or three serine residues in response to various extracellular stresses. Here we analyze the effect of sHsp phosphorylation on its quaternary structure, chaperone function, and protection against oxidative stress. We show that in vitro phosphorylation of recombinant sHsp as well as molecular mimicry of Hsp27 phosphorylation lead to a significant decrease of the oligomeric size. We demonstrate that both phosphorylated sHsps and the triple mutant Hsp27-S15D,S78D,S82D show significantly decreased abilities to act as molecular chaperones suppressing thermal denaturation and facilitating refolding of citrate synthase in vitro. In parallel, Hsp27 and its mutants were analyzed for their ability to confer resistance against oxidative stress when overexpressed in L929 and 13.S.1.24 cells. While wild type Hsp27 confers resistance, the triple mutant S15D,S78D,S82D cannot protect against oxidative stress effectively. These data indicate that large oligomers of sHsps are necessary for chaperone action and resistance against oxidative stress whereas phosphorylation down-regulates these activities by dissociation of sHsp complexes to tetramers.	Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, D-06120 Halle, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, F-69622 Villeurbanne, France	Martin Luther University Halle Wittenberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Regensburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gaestel, M (corresponding author), Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, Hoher Weg 8, D-06120 Halle, Germany.		Paul, Catherine/F-8376-2019; Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Preville, Xavier/0000-0002-1416-7405; Buchner, Johannes/0000-0003-1282-7737; Paul, Catherine/0000-0002-7657-5535				Arata S, 1997, J CELL PHYSIOL, V170, P19, DOI 10.1002/(SICI)1097-4652(199701)170:1<19::AID-JCP3>3.0.CO;2-O; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CAIRNS J, 1994, J BIOL CHEM, V269, P9176; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; Coronas V, 1997, J NEUROCHEM, V69, P1870; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1998, MOL CHAPERONES LIFE, P533; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; LIM K, 1989, BIOTECHNIQUES, V7, P576; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NOVER L, 1983, MOL CELL BIOL, V3, P1648, DOI 10.1128/MCB.3.9.1648; Preville X, 1998, CELL STRESS CHAPERON, V3, P177, DOI 10.1379/1466-1268(1998)003<0177:PINEFP>2.3.CO;2; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; ROSSI JM, 1989, J CELL BIOL, V108, P425, DOI 10.1083/jcb.108.2.425; SANGER F, 1949, BIOCHEM J, V45, P563, DOI 10.1042/bj0450563; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Suzuki TC, 1998, PLANT PHYSIOL, V116, P1151, DOI 10.1104/pp.116.3.1151; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	57	611	635	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18947	18956		10.1074/jbc.274.27.18947	http://dx.doi.org/10.1074/jbc.274.27.18947			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383393	hybrid			2022-12-27	WOS:000081196300016
J	Xie, ZJ; Kometiani, P; Liu, J; Li, J; Shapiro, JI; Askari, A				Xie, ZJ; Kometiani, P; Liu, J; Li, J; Shapiro, JI; Askari, A			Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; FREE-RADICALS; RESPONSE GENES; REDOX STRESS; CELLS; TRANSCRIPTION; OUABAIN; CARDIOMYOCYTES; INHIBITION	We showed before that in cardiac myocytes partial inhibition of Na+/K+-ATPase by nontoxic concentrations of ouabain causes hypertrophy and transcriptional regulations of growth-related marker genes through multiple Ca2+-dependent signal pathways many of which involve Ras and p42/44 mitogen-activated protein kinases, The aim of this work was to explore the roles of intracellular reactive oxygen species (ROS) in these ouabain-initiated pathways. Ouabain caused a rapid generation of ROS within the myocytes that was prevented by preexposure of cells to N-acetyl-cysteine (NAC) or vitamin E, These antioxidants also blocked or attenuated the following actions of ouabain: inductions of the genes of skeletal alpha-actin and atrial natriuretic factor, repression of the gene of the alpha(3)-subunit of Na+/K+-ATPase, activation of mitogen-activated protein kinases, activation of Ras-dependent protein synthesis, and activation of transcription factor NF-kappa B. Induction of c-fos and activation of AP-I by ouabain were not sensitive to NAG. Ouabain-induced inhibition of active Rb+ uptake through Na+/K+-ATPase and the resulting rise in intracellular Ca2+ were also not prevented by NAG. A phorbol ester that also causes myocyte hypertrophy did not increase ROS generation, and its effects on marker genes and protein synthesis were not affected by NAG. We conclude the following: (a) ROS are essential second messengers within some but not all signal pathways that are activated by the effect of ouabain on Na+/K+-ATPase; (b) the ROS-dependent pathways are involved in ouabain-induced hypertrophy; (c) increased ROS generation is not a common response of the myocyte to all hypertrophic stimuli; and (d) it may be possible to dissociate the positive inotropic effect of ouabain from its growth-related effects by alteration of the redox state of the cardiac myocyte.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43614 USA		Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MohazzabH KM, 1997, CIRCULATION, V96, P614; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Perry G, 1997, NEW ENGL J MED, V336, P525; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEN P, 1993, J STEROID BIOCHEM, V47, P55, DOI 10.1016/0960-0760(93)90057-4; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; STEMMER P, 1988, BIOCHIM BIOPHYS ACTA, V940, P188, DOI 10.1016/0005-2736(88)90194-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497	35	263	271	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19323	19328		10.1074/jbc.274.27.19323	http://dx.doi.org/10.1074/jbc.274.27.19323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383443	hybrid			2022-12-27	WOS:000081196300066
J	Brauner-Osborne, H; Jensen, AA; Sheppard, PO; O'Hara, P; Krogsgaard-Larsen, P				Brauner-Osborne, H; Jensen, AA; Sheppard, PO; O'Hara, P; Krogsgaard-Larsen, P			The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA2+-SENSING RECEPTOR; EXTRACELLULAR DOMAIN; EXPRESSION; CLONING; PROTEINS; RAT; SELECTIVITY; CA2+	The calcium-sensing receptor (CaR) is a G-protein-coupled receptor that displays 19-25% sequence identity to the gamma-aminobutyric acid type B (GABA,) and metabotropic glutamate (mGlu) receptors, All three groups of receptors have a large amino-terminal domain (ATD), which for the mGlu receptors has been shown to bind the endogenous agonist, To investigate whether the agonist-binding domain of the CaR also is located in the ATD, we constructed a chimeric receptor named Ca/1a consisting of the ATD of CaR and the seven transmembrane region and C terminus of mGlu(1a). The Ca/1a receptor stimulated inositol phosphate production when exposed to the cationic agonists Ca2+, Mg2+, and Ba2+ in transiently transfected tsA cells (a transformed HEK 293 cell line). The pharmacological profile of Ca/1a (EC50 values of 3.3, 2.6, and 3.9 mM for these cations, respectively) was very similar to that of the wild-type CaR (EC50 values of 3.2, 4.7, and 4.1 mM, respectively). For the mGlu(1a) receptor, it has been shown that Ser-165 and Thr-188, which are located in the ATD, are involved in the agonist binding. An alignment of CaR with the mGlu receptors showed that these two amino acid residues have been conserved in CaR as Ser-147 and Ser-170, respectively. Each of these residues was mutated to alanines and tested pharmacologically using the endogenous agonist Ca2+. CaR-S147A showed an impaired function as compared with wild-type CaR both with respect to potency of Ca2+ (4-fold increase in EC50) and maximal response (79% of wild-type response). CaR-S170A showed no significant response to Ca2+ even at 50 mM concentration. In contrast, each of the two adjacent mutations, S169A and S171A, resulted in pharmacological profiles almost identical to that of the wild-type receptor. These data demonstrate that Ser-170 and to some extent Ser-147 are involved in the Ca2+ activation of the CaR, and taken together, our results reveal a close resemblance of the activation mechanism between the CaR and the mGlu receptors.	Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; Zymogenet Inc, Seattle, WA 98105 USA	Royal Danish School of Pharmacy; Zymogenet Inc.	Brauner-Osborne, H (corresponding author), Royal Danish Sch Pharm, Dept Med Chem, NeuroSci PharmaBiotec Res Ctr, 2 Univ Pk, DK-2100 Copenhagen, Denmark.		Bräuner-Osborne, Hans/D-7260-2011; Jensen, Anders/AAJ-3335-2020	Bräuner-Osborne, Hans/0000-0001-9495-7388; Jensen, Anders/0000-0002-7927-5052				BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	24	141	148	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18382	18386		10.1074/jbc.274.26.18382	http://dx.doi.org/10.1074/jbc.274.26.18382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373443	hybrid			2022-12-27	WOS:000081056700035
J	Goodwin, RL; Pabon-Pena, LM; Foster, GC; Bader, D				Goodwin, RL; Pabon-Pena, LM; Foster, GC; Bader, D			The cloning and analysis of LEK1 identifies variations in the LEK centromere protein F mitosin gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DIFFERENTIATION; CENP-F; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; LEUCINE ZIPPERS; EXPRESSION; CYCLINS; MARKER	We report the cloning of a novel murine cDNA, LEK1, that is related to human CENP-F and mitosin and more distantly to chicken CMF1, The proteins from these three organisms have significant homology, yet differ in their temporal, spatial, and subcellular localizations. The human proteins bind the kinetochore in mitotic cells, whereas the chicken protein is found only in skeletal and cardiac muscle and is developmentally regulated. Mouse LEK1 is a single copy gene that codes for two developmentally regulated transcripts. The LEK1 protein is expressed early and ubiquitously in mouse development and is generally down-regulated as development proceeds in a manner that correlates to a cessation of mitosis, In adult tissues, the LEK1 protein is detected exclusively in the pronucleus of the oocyte and was not observed in other actively dividing tissues. Subcellular localization revealed that the LEK1 protein in mitotic cells does not bind the kinetochore, From these data, we hypothesize that chicken CMF1, human CENP-F, mitosin, and mouse LEK1 are members of an emerging family of genes that have important and functionally distinct roles in development and cell division.	Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA	Vanderbilt University	Bader, D (corresponding author), Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA.		Goodwin, Richard L./AAN-5007-2020; Goodwin, Richard/R-6169-2019	Goodwin, Richard/0000-0002-2537-2535	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL09916, HL37675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009916, R01HL037675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Ausubel FM., 1994, CURRENT PROTOCOLS; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHA GKT, 1998, J CELL BIOL, V143, P49; Clark GM, 1997, CANCER RES, V57, P5505; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; HOGAN B, 1921, MANIPULATING MOUSE E; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; Landberg G, 1996, CYTOMETRY, V25, P90, DOI 10.1002/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu SC, 1998, CANCER EPIDEM BIOMAR, V7, P597; Muro Y, 1997, BONE MARROW TRANSPL, V19, P951, DOI 10.1038/sj.bmt.1700764; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; Rattner JB, 1997, CLIN INVEST MED, V20, P308; SLIBESTEIN L, CELL, V1075, P86; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; WANG J, 1995, BIOCHEM BIOPH RES CO, V206, P82, DOI 10.1006/bbrc.1995.1012; Wei Y, 1996, DEVELOPMENT, V122, P2779; ZHU XL, 1995, J BIOL CHEM, V270, P19545, DOI 10.1074/jbc.270.33.19545; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zhu XL, 1997, J CELL BIOCHEM, V66, P441, DOI 10.1002/(SICI)1097-4644(19970915)66:4<441::AID-JCB3>3.0.CO;2-L	28	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18597	18604		10.1074/jbc.274.26.18597	http://dx.doi.org/10.1074/jbc.274.26.18597			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373470	hybrid			2022-12-27	WOS:000081056700062
J	Liu, PQ; Liu, CE; Ames, GFL				Liu, PQ; Liu, CE; Ames, GFL			Modulation of ATPase activity by physical disengagement of the ATP-binding domains of an ABC transporter, the histidine permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; COMPLETE GENOME SEQUENCE; CYSTIC-FIBROSIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRAFFIC ATPASE; PERIPLASMIC PERMEASES; MULTIDRUG-RESISTANCE; CASSETTE TRANSPORTER; MEMBRANE	The membrane-bound complex of the prokaryotic histidine permease, a periplasmic protein-dependent ABC transporter, is composed of two hydrophobic subunits, HisQ and HisM, and two identical ATP-binding subunits, HisP, and is energized by ATP hydrolysis. The soluble periplasmic binding protein, HisJ, creates a signal that induces ATP hydrolysis by HisP. The crystal structure of HisP has been resolved and shown to have an "L" shape, with one of its arms (arm I) being involved in ATP binding and the other one (arm II) being proposed to interact with the hydrophobic subunits (Hung, L.-W., Wang, I. X., Nikaido, K., Liu, P.-Q., Ames, G. F.-L., and Kim, S.-H. (1998) Nature 396, 703-707). Here we study the basis for the defect of several HisP mutants that have an altered signaling pathway and hydrolyze ATP constitutively. We use biochemical approaches to show that they produce a loosely assembled membrane complex, in which the mutant HisP subunits are disengaged from HisQ and HisM, suggesting that the residues involved are important in the interaction between HisP and the hydrophobic subunits. In addition, the mutant HisPs are shown to have lower affinity for ADP and to display no cooperativity for ATP. All of the residues affected in these HisP mutants are located in arm II of the crystal structure of HisP, thus supporting the proposed function of arm II of HisP as interacting with HisQ and HisM, A revised model involving a cycle of disengagement and reengagement of HisP is proposed as a general mechanism of action for ABC transporters.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, GFL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	giovanna@uclink4.berkeley.edu			NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1977, J BACTERIOL, V129, P1289, DOI 10.1128/JB.129.3.1289-1297.1977; AMES GFL, 1985, CURR TOP MEMBR TRANS, V23, P103; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bliss JM, 1997, J BACTERIOL, V179, P1400, DOI 10.1128/jb.179.4.1400-1403.1997; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; Gruis DB, 1997, BIOCHEMISTRY-US, V36, P7739, DOI 10.1021/bi9701585; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM YJ, 1994, CELL, V78, P845; Ko YH, 1997, BIOCHEMISTRY-US, V36, P5053, DOI 10.1021/bi9630265; Liu CE, 1999, J BIOL CHEM, V274, P739, DOI 10.1074/jbc.274.2.739; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; LIU CE, 1996, THESIS U CALIFORNIA; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; MCDONNELL PA, 1993, J MOL BIOL, V233, P447, DOI 10.1006/jmbi.1993.1523; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; OPELLA SJ, 1994, METHOD ENZYMOL, V239, P536; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; Qu BH, 1997, J BIOENERG BIOMEMBR, V29, P483, DOI 10.1023/A:1022439108101; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHNEIDER E, 1995, J BACTERIOL, V177, P5364, DOI 10.1128/jb.177.18.5364-5367.1995; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YIN Y, 1995, FEBS LETT, V366, P1, DOI 10.1016/0014-5793(95)00454-H; ZHANG F, 1995, BIOCHEMISTRY-US, V34, P4193, DOI 10.1021/bi00013a007	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18310	18318		10.1074/jbc.274.26.18310	http://dx.doi.org/10.1074/jbc.274.26.18310			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373434	hybrid			2022-12-27	WOS:000081056700026
J	Edwards, JS; Palsson, BO				Edwards, JS; Palsson, BO			Systems properties of the Haemophilus influenzae Rd metabolic genotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; LINEAR OPTIMIZATION; NETWORK ANALYSIS; GENOME SEQUENCE; GENES; FLUX; IDENTIFICATION; BIOINFORMATICS	Haemophilus influenzae Rd was the first free-living organism for which the complete genomic sequence was established. The annotated sequence and known biochemical information was used to define the H. influenzae Rd metabolic genotype. This genotype contains 488 metabolic reactions operating on 343 metabolites. The stoichiometric matrix was used to determine the systems characteristics of the metabolic genotype and to assess the metabolic capabilities of H. influenzae. The need to balance cofactor and biosynthetic precursor production during growth on mixed substrates led to the definition of six different optimal metabolic phenotypes arising from the same metabolic genotype, each with different constraining features. The effects of variations in the metabolic genotype were also studied, and it was shown that the H. influenzae Rd metabolic genotype contains redundant functions under defined conditions. We thus show that the synthesis of in silico metabolic genotypes from annotated genome sequences is possible and that systems analysis methods are available that can be used to analyze and interpret phenotypic behavior of such genotypes.	Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, BO (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785	CSR NIH HHS [1RGM57089-01A1] Funding Source: Medline	CSR NIH HHS		Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Ash C, 1997, TRENDS MICROBIOL, V5, P135, DOI 10.1016/S0966-842X(97)01031-7; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; BUTLER LO, 1962, J GEN MICROBIOL, V27, P51, DOI 10.1099/00221287-27-1-51; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Casari G, 1996, TRENDS GENET, V12, P244, DOI 10.1016/0168-9525(96)30057-7; Chvatal V., 1983, LINEAR PROGRAMMING; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Edwards JS, 1998, BIOTECHNOL BIOENG, V58, P162, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<162::AID-BIT8>3.0.CO;2-J; EDWARDS JS, 1998, METABOLIC ENG; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endy D, 1997, BIOTECHNOL BIOENG, V55, P375, DOI 10.1002/(SICI)1097-0290(19970720)55:2<375::AID-BIT15>3.0.CO;2-G; FELL D, 1996, UNDERSTANDING CONTRO; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLEISCHMANN RD, 1995, SCIENCE, V269, P507; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Heinrich R., 1996, REGULATION CELLULAR; HERRIOTT RM, 1970, J BACTERIOL, V101, P513, DOI 10.1128/JB.101.2.513-516.1970; Huerta AM, 1998, NUCLEIC ACIDS RES, V26, P55, DOI 10.1093/nar/26.1.55; *I GEN RES, 1998, TIGR; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KLEIN RD, 1979, J GEN MICROBIOL, V113, P409, DOI 10.1099/00221287-113-2-409; Lee Y, 1996, NAT BIOTECHNOL, V14, P491, DOI 10.1038/nbt0496-491; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Macfadyen LP, 1996, RES MICROBIOL, V147, P541, DOI 10.1016/0923-2508(96)84010-1; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; PENFOUND T, 1996, ESCHERICHIA COLI SAL, V1, P721; Pennisi E, 1998, SCIENCE, V281, P148, DOI 10.1126/science.281.5374.148; PRAMANIK J, 1997, BIOTECHNOL BIOENG, V56, P399; REICH JG, 1981, ENERGY METABOLISM CE; Robison K, 1996, SCIENCE, V271, P1302; SAVINELL JM, 1992, J THEOR BIOL, V154, P421, DOI 10.1016/S0022-5193(05)80161-4; SAVINELL JM, 1992, J THEOR BIOL, V154, P455, DOI 10.1016/S0022-5193(05)80162-6; Schilling CH, 1998, P NATL ACAD SCI USA, V95, P4193, DOI 10.1073/pnas.95.8.4193; SCHUTZ EA, 1994, SPORTS MED ARTHROSC, V2, P165; SHULER ML, 1983, FDN BIOCH ENG, P101; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Strang G, 1988, LINEAR ALGEBRA ITS A; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; TALMADGE MB, 1960, BIOCHEM BIOPH RES CO, V2, P203, DOI 10.1016/0006-291X(60)90013-9; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trivedi B, 1998, NAT BIOTECHNOL, V16, P1316, DOI 10.1038/4280; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; VARMA A, 1995, BIOTECHNOL BIOENG, V45, P69, DOI 10.1002/bit.260450110; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1993, J THEOR BIOL, V165, P477, DOI 10.1006/jtbi.1993.1202; VARMA A, 1993, BIOTECHNOL BIOENG, V42, P59, DOI 10.1002/bit.260420109; Yada T, 1998, BIOINFORMATICS, V14, P317, DOI 10.1093/bioinformatics/14.4.317	57	263	335	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17410	17416		10.1074/jbc.274.25.17410	http://dx.doi.org/10.1074/jbc.274.25.17410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364169	hybrid			2022-12-27	WOS:000080974300005
J	Shaked, GM; Fridlander, G; Meiner, Z; Taraboulos, A; Gabizon, R				Shaked, GM; Fridlander, G; Meiner, Z; Taraboulos, A; Gabizon, R			Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE AGENT; PHYSICAL-PROPERTIES; TRANSGENIC MICE; CONGO RED; PRP; HAMSTERS; REPLICATION; STRAINS; ACCUMULATION	PrPSc, an abnormal isoform of PrPC, is the only known component of the prion, an agent causing fatal neurodegenerative disorders such as bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD). It has been postulated that prion diseases propagate by the conversion of detergent-soluble and protease-sensitive PrPC molecules into protease-resistant and insoluble PrPSc molecules by a mechanism in which PrPSc serves as a template. We show here that the chemical chaperone dimethyl sulfoxide (Me2SO) can partially inhibit the aggregation of either PrPSc or that of its protease-resistant core PrP27-30. Following; Me2SO removal by methanol precipitation, solubilized PrP27-30 molecules aggregated into small and amorphous structures that did not resemble the rod configuration observed when scrapie brain membranes were extracted with Sarkosyl and digested with proteinase K. Interestingly, aggregates derived from Me2SO-solubilized PrP27-30 presented less than 1% of the prion infectivity obtained when the same amount of PrP27-30 in rods was inoculated into hamsters. These results suggest that the conversion of PrPC into protease-resistant and detergent-insoluble PrP molecules is not the only crucial step in prion replication. Whether an additional requirement is the aggregation of newly formed proteinase K-resistant PrP molecules into uniquely structured aggregates remains to be established.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.	gabizonr@hadassah.org.il						Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1961, J COMP PATHOL THERAP, V71, P101, DOI 10.1016/S0368-1742(61)80013-1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, BRAIN PATHOL, V8, P499; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; RAVID M, 1977, LANCET, V1, P730; SAFAR J, 1990, NEUROLOGY, V40, P503, DOI 10.1212/WNL.40.3_Part_1.503; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	44	57	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17981	17986		10.1074/jbc.274.25.17981	http://dx.doi.org/10.1074/jbc.274.25.17981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364247	hybrid			2022-12-27	WOS:000080974300083
J	Jones, DR; Pettitt, TR; Sanjuan, MA; Merida, I; Wakelam, MJO				Jones, DR; Pettitt, TR; Sanjuan, MA; Merida, I; Wakelam, MJO			Interleukin-2 causes an increase in saturated monounsaturated phosphatidic acid derived from 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ETHER-LINKED DIGLYCERIDES; PHOSPHOLIPASE-D; LYMPHOCYTE-PROLIFERATION; MESANGIAL CELLS; T-CELLS; ACTIVATION; DIACYLGLYCEROL; GENERATION; ZETA	Phosphatidic acid generation through activation of diacylglycerol kinase cu has been implicated in interleukin-2-dependent T-lymphocyte proliferation. To investigate this lipid signaling in more detail, we characterized the molecular structures of the diradylglycerols and phosphatidic acids in the murine CTLL-2 T-cell line under both basal and stimulated conditions. In resting cells, 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol subtypes represented 44 and 55% of total diradylglycerol, respectively, and both showed a highly saturated profile containing primarily 16:0 and 18:1 fatty acids. 1-O-Alk-1'-enyl-2-acylglycerol represented 1-2% of total diradylglycerol, Interleukin-2 stimulation did not alter the molecular species profiles, however, it did selectively reduce total 1-O-alkyl-2-acylglycerol by over 50% at 15 min while only causing a 10% drop in 1,2-diacylglycerol, When radiolabeled CTLL-2 cells were challenged with interleukin-a, no change in the cellular content of phosphatidylcholine nor phosphatidylethanolamine was observed thereby ruling out phospholipase C activity as the source of diradylglycerol, In addition, interleukin-a failed to stimulate de novo synthesis of diradylglycerol, Structural analysis revealed approximately equal amounts of 1,2-diacyl phosphatidic acid and 1-O-alkyl-2-acyl phosphatidic acid under resting conditions, both containing only saturated and monounsaturated fatty acids. After acute (2 and 15 min) interleukin-a stimulation the total phosphatidic acid mass increased, almost entirely through the formation of 1-O-alkyl-2-acyl species. In vitro assays revealed that both 1,2-diacylglycerol and 1-O-alkyl-2-acylglycerol were substrates for 1,2-diacylglycerol kinase cu, the major isoform in CTLL-2 cells, and that the lipid kinase activity was almost totally inhibited by R59949, In conclusion, this investigation shows that, in CTLL-2 cells, 1,2-diacylglycerol kinase ct specifically phosphorylates a pre-existing pool of 1-O-alkyl-2-acylglycerol to form the intracellular messenger 1-O-alkyl-2-acyl phosphatidic acid.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain; Univ Birmingham, CRC, Inst Canc Studies, Birmingham, W Midlands, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Birmingham	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain.	imerida@cnb.uam.es	Sanjuán, Miguel Ángel/I-6896-2019; Merida, Isabel/A-9713-2014	Sanjuán, Miguel Ángel/0000-0001-6694-0634; Merida, Isabel/0000-0003-2762-6241; Wakelam, Michael/0000-0003-4059-9276				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FERGUSON MAJ, 1994, PRACTICAL APPROACH G, V125, P349; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FORD DA, 1989, J BIOL CHEM, V264, P13818; FORD DA, 1990, AM J PHYSIOL, V25, pC30; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; Hermans SWG, 1996, EUR J BIOCHEM, V235, P73, DOI 10.1111/j.1432-1033.1996.00073.x; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; MILLS GB, 1986, J IMMUNOL, V136, P3019; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Pettitt TR, 1998, FEBS LETT, V427, P371, DOI 10.1016/S0014-5793(98)00471-2; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X	34	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16846	16852		10.1074/jbc.274.24.16846	http://dx.doi.org/10.1074/jbc.274.24.16846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358029	hybrid			2022-12-27	WOS:000080780400028
J	Park, SG; Jung, KH; Lee, JS; Jo, YJ; Motegi, H; Kim, S; Shiba, K				Park, SG; Jung, KH; Lee, JS; Jo, YJ; Motegi, H; Kim, S; Shiba, K			Precursor of pro-apoptotic cytokine modulates aminoacylation activity of tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ACTIVATING POLYPEPTIDE-II; PROTEIN-PROTEIN INTERACTIONS; ELONGATION-FACTOR 1-ALPHA; MULTISYNTHETASE COMPLEX; TERMINAL PEPTIDE; COMPONENT; MECHANISMS; EUKARYOTES; CLONING	Endothelial monocyte activating polypeptide II (EMAPII) is a cytokine that is specifically induced by apoptosis, Its precursor (pro-EMAPII) has been suggested to be identical to p43, which is associated with the multi-tRNA synthetase complex. Herein, we have demonstrated that the N-terminal domain of pro-EMAPII interacts with the N-terminal extension of human cytoplasmic arginyl-tRNA synthetase (RRS) using genetic and immunoprecipitation analyses. Aminoacylation activity of RRS was enhanced about 2.5-fold by the interaction with pro-EMAPII but not with its N- or C-terminal domains alone. The N-terminal extension of RRS was not required for enzyme activity but did mediate activity stimulation by pro-EMAPII. Pro-EMAPII reduced the apparent K-m of RRS to tRNA, whereas the k(cat) value remained unchanged. Therefore, the precursor of EMAPII is a multi-functional protein that assists aminoacylation in normal cells and releases the functional cytokine upon apoptosis.	Sungkyunkwan Univ, Dept Biol Sci, Natl Creat Res Initiat Ctr ARS Network, Suwon 440746, Kyunggido, South Korea; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan	Sungkyunkwan University (SKKU); Japanese Foundation for Cancer Research	Kim, S (corresponding author), Sungkyunkwan Univ, Dept Biol Sci, Natl Creat Res Initiat Ctr ARS Network, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	shkim@yurim.skku.ac.kr	Shiba, Kiyotaka/I-9588-2014; Kim, Sunghoon/AAE-8314-2020	Shiba, Kiyotaka/0000-0001-6459-0204; 				FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; GIRJES AA, 1995, GENE, V164, P347, DOI 10.1016/0378-1119(95)00502-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM S, 1993, BIOCHEMISTRY-US, V32, P13026, DOI 10.1021/bi00211a011; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; LAZARD M, 1993, GENE, V132, P237, DOI 10.1016/0378-1119(93)90201-D; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; REED VS, 1994, J BIOL CHEM, V269, P32932; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5	28	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16673	16676		10.1074/jbc.274.24.16673	http://dx.doi.org/10.1074/jbc.274.24.16673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358004	hybrid			2022-12-27	WOS:000080780400003
J	Perez-Mato, I; Castro, C; Ruiz, FA; Corrales, FJ; Mato, JM				Perez-Mato, I; Castro, C; Ruiz, FA; Corrales, FJ; Mato, JM			Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; NITRIC-OXIDE; GENE-EXPRESSION; MESSENGER-RNA; INJURY; PEROXYNITRITE; CIRRHOSIS	S-Adenosylmethionine serves as the methyl donor for many biological methylation reactions and provides the propylamine group for the synthesis of polyamines. S-Adenosylmethionine is synthesized from methionine and ATP by the enzyme methionine adenosyltransferase. The cellular factors regulating S-adenosylmethionine synthesis have not been well defined. Here we show that in rat hepatocytes S-nitrosoglutathione monoethyl ester, a cell-permeable nitric oxide donor, markedly reduces cellular S-adenosylmethionine content via inactivation of methionine adenosyltransferase by S-nitrosylation. Removal of the nitric oxide donor from the incubation medium leads to the denitrosylation and reactivation of methionine adenosyltransferase and to the rapid recovery of cellular S-adenosylmethionine levels. Nitric oxide inactivates methionine adenosyltransferase via S-nitrosylation of cysteine 121. Replacement of the acidic (aspartate 355) or basic (arginine 357 and arginine 363) amino acids located in the vicinity of cysteine 121 by serine leads to a marked reduction in the ability of nitric oxide to S-nitrosylate and inactivate hepatic methionine adenosyltransferase. These results indicate that protein S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target cysteine.	Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain	University of Navarra	Mato, JM (corresponding author), Univ Navarra, Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain.		MATO, JOSE/A-5187-2011; Carmen, Castro/C-7813-2009; Ruiz, Felix A./B-1032-2008	MATO, JOSE/0000-0003-1264-3153; Carmen, Castro/0000-0002-6802-0572; Ruiz, Felix A./0000-0003-0748-5015; Corrales, Fernando/0000-0002-0231-5159				ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Avila MA, 1997, HEPATOLOGY, V25, P391; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; FELL D, 1985, J CHROMATOGR, V345, P150, DOI 10.1016/0378-4347(85)80146-8; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Freeswick Paul D., 1994, P1031; GUARNER C, 1993, HEPATOLOGY, V18, P1139; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; LIEBER CS, 1990, HEPATOLOGY, V11, P165, DOI 10.1002/hep.1840110203; MARTINDUCE A, 1998, HEPATOLOGY, V8, P65; Mato Jose M., 1994, P461; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; Pannala A, 1997, BIOCHEM BIOPH RES CO, V232, P164, DOI 10.1006/bbrc.1997.6254; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SanchezGongora E, 1997, FASEB J, V11, P1013, DOI 10.1096/fasebj.11.12.9337154; SAYLE R, 1993, RAS WIN MOL GRAPHICS; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; VARELAMOREIRAS G, 1995, HEPATOLOGY, V22, P1310, DOI 10.1016/0270-9139(95)90644-4	32	118	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17075	17079		10.1074/jbc.274.24.17075	http://dx.doi.org/10.1074/jbc.274.24.17075			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358060	Green Published, hybrid			2022-12-27	WOS:000080780400059
J	Simonsson, T; Sjoback, R				Simonsson, T; Sjoback, R			DNA tetraplex formation studied with fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED POLYMORPHIC REGION; C-MYC GENE; TELOMERIC DNA; CHROMATIN STRUCTURE; QUARTET STRUCTURES; CRYSTAL-STRUCTURE; GUANINE TETRADS; FORM; HAIRPIN; THERMODYNAMICS	It is emerging that DNA tetraplexes are pivotal for many major cellular processes, and techniques that assess their structure and nature to the point are under development. Here we show how the structural conversion of largely unstructured single-stranded DNA molecules into compact intrastrand DNA tetraplexes can be monitored by fluorescence resonance energy transfer. We recently reported that intrastrand tetraplex formation takes place in a nuclease hypersensitive element upstream of the human c-myc proto-oncogene. Despite the highly repetitive guanine-rich sequence of the hypersensitive element, fluorescence resonance energy transfer measurements indicate that only one well defined tetraplex structure forms therein. The proposed structure, which is specifically stabilized by potassium ions in vitro, has a core of three stacked guanine tetrads that is capped by two intrastrand A-T base pairs.	Chalmers Univ Technol, Lundberg Inst, Dept Biochem, SE-40530 Gothenburg, Sweden	Chalmers University of Technology	Simonsson, T (corresponding author), Chalmers Univ Technol, Lundberg Inst, Dept Biochem, Box 462, SE-40530 Gothenburg, Sweden.	Tomas@bcbp.chalmers.se						AGRAWAL S, 1986, NUCLEIC ACIDS RES, V14, P6227, DOI 10.1093/nar/14.15.6227; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; Catasti P, 1996, J MOL BIOL, V264, P534, DOI 10.1006/jmbi.1996.0659; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GHOSH SS, 1994, NUCLEIC ACIDS RES, V22, P3155, DOI 10.1093/nar/22.15.3155; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; Hardin CC, 1997, BIOCHEMISTRY-US, V36, P15428, DOI 10.1021/bi970488p; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; Howell R, 1997, MOL BIOL EVOL, V14, P144, DOI 10.1093/oxfordjournals.molbev.a025747; Howell RM, 1996, J BIOL CHEM, V271, P5208; JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KENIRY MA, 1995, EUR J BIOCHEM, V233, P631, DOI 10.1111/j.1432-1033.1995.631_2.x; Kettani A, 1997, NAT STRUCT BIOL, V4, P382, DOI 10.1038/nsb0597-382; KUBISTA M, 1994, ANALYST, V119, P417, DOI 10.1039/an9941900417; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Pauling L., 1960, NATURE CHEM BOND; PILCH DS, 1995, CURR OPIN STRUC BIOL, V5, P334, DOI 10.1016/0959-440X(95)80095-6; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shiber MC, 1996, NUCLEIC ACIDS RES, V24, P5004, DOI 10.1093/nar/24.24.5004; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; Simonsson T, 1998, NUCLEIC ACIDS RES, V26, P1167, DOI 10.1093/nar/26.5.1167; Sjoback R, 1998, BIOPOLYMERS, V46, P445; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; Vorlickova M, 1998, NUCLEIC ACIDS RES, V26, P2679, DOI 10.1093/nar/26.11.2679; WANG Y, 1994, STRUCTURE, V2, P1141, DOI 10.1016/S0969-2126(94)00117-0; WANG Y, 1995, J MOL BIOL, V251, P76, DOI 10.1006/jmbi.1995.0417; YANG MS, 1994, BIOCHEMISTRY-US, V33, P15329, DOI 10.1021/bi00255a014	46	70	73	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17379	17383		10.1074/jbc.274.24.17379	http://dx.doi.org/10.1074/jbc.274.24.17379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358100	hybrid			2022-12-27	WOS:000080780400099
J	Orlov, SN; Thorin-Trescases, N; Kotelevtsev, SV; Tremblay, J; Hamet, P				Orlov, SN; Thorin-Trescases, N; Kotelevtsev, SV; Tremblay, J; Hamet, P			Inversion of the intracellular Na+/K+ ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DNA FRAGMENTATION; HUMAN-LYMPHOCYTES; CELL SHRINKAGE; ACTIVATION; FAS; PROLIFERATION; INHIBITION; MECHANISM; POTASSIUM	Long term elevation of the intracellular Na+/K+ ratio inhibits macromolecule synthesis and proliferation in the majority of cell types studied so far, including vascular smooth muscle cells (VSMC). We report here that inhibition of the Na+,K+ pump in VSMC by ouabain or a 1-h preincubation in K+-depleted medium attenuated apoptosis triggered by serum withdrawal, staurosporine, or okadaic acid. In the absence of ouabain, both DNA degradation and Caspase-3 activation in VSMC undergoing apoptosis were insensitive to modification of the extracellular Na+/K+ ratio as well as to hyperosmotic cell shrinkage. In contrast, protection of VSMC from apoptosis by ouabain was abolished under equimolar substitution of Na-o(+) with K-o(+), showing that the antiapoptotic action of Na+,K+ pump inhibition was caused by inversion of the intracellular Na+/K+ ratio. Unlike VSMC, the same level of increment of the [Na+](i)/ [K+](i) ratio caused by a 2-h preincubation of Jurkat cells with ouabain did not affect chromatin cleavage and Caspase-3 activity triggered by treatment with Fas ligand, staurosporine, or hyperosmotic shrinkage, Thus, our results show for the first time that similar to cell proliferation, maintenance of a physiologically low intracellular Na+/K+ ratio is required for progression of VSMC apoptosis.	Univ Montreal, CHU Montreal, Ctr Rech, Mol Med Lab, Montreal, PQ H2W 1T8, Canada; Moscow MV Lomonosov State Univ, Fac Biol, Lab Biomembranes, Moscow, Russia	Universite de Montreal; Lomonosov Moscow State University	Hamet, P (corresponding author), Univ Montreal, CHU Montreal, Ctr Rech, Mol Med Lab, Campus Hotel Dieu,3850 Rue St Urbain, Montreal, PQ H2W 1T8, Canada.	hamet@ere.umontreal.ca	ORLOV, SERGEI/I-4071-2013; Cossette, Suzanne/I-8008-2016					Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; BALASUBRAMANYAM M, 1994, J CLIN INVEST, V94, P2002, DOI 10.1172/JCI117553; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BERTHE P, 1991, CELL SIGNAL, V3, P453, DOI 10.1016/0898-6568(91)90075-6; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOBIK A, 1988, J HYPERTENS, V6, pS219, DOI 10.1097/00004872-198812040-00065; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRODIE C, 1995, J CELL PHYSIOL, V165, P246, DOI 10.1002/jcp.1041650205; Champagne MJ, 1999, HYPERTENSION, V33, P906, DOI 10.1161/01.HYP.33.3.906; COTTER TG, 1990, ANTICANCER RES, V10, P1153; FRANKS DJ, 1984, J CELL PHYSIOL, V119, P41, DOI 10.1002/jcp.1041190108; GARNER R, 1994, J IMMUNOL, V153, P5413; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HAMET P, 1995, HYPERTENSION, V26, P642, DOI 10.1161/01.HYP.26.4.642; HENNINGSEN NC, 1984, SCAND J CLIN LAB INV, V44, P197, DOI 10.3109/00365518409083796; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLASSEN NV, 1993, INT J RADIAT BIOL, V64, P571, DOI 10.1080/09553009314551791; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 1998, CONTRIB NEPHROL, V123, P158, DOI 10.1159/000059911; LUBIN M, 1980, BIOCHEM BIOPH RES CO, V97, P1060, DOI 10.1016/0006-291X(80)91483-7; LUBIN M, 1967, NATURE, V213, P451, DOI 10.1038/213451a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHYAMA H, 1981, RADIAT RES, V85, P333, DOI 10.2307/3575566; Olej B, 1998, BIOSCIENCE REP, V18, P1, DOI 10.1023/A:1022259832207; Orlov SN, 1996, BIOCHEM BIOPH RES CO, V221, P708, DOI 10.1006/bbrc.1996.0661; Orlov SN, 1996, J MEMBRANE BIOL, V153, P125, DOI 10.1007/s002329900116; ORLOV SN, 1999, IN PRESS CARDIOVASC; OSHIMI Y, 1995, J IMMUNOL, V154, P599; PRASAD KVS, 1987, CANCER RES, V47, P5397; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WEBB GD, 1995, CLIN SCI, V88, P695, DOI 10.1042/cs0880695; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9	45	106	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16545	16552		10.1074/jbc.274.23.16545	http://dx.doi.org/10.1074/jbc.274.23.16545			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347219	hybrid			2022-12-27	WOS:000080668600079
J	Galustian, C; Lubineau, A; le Narvor, C; Kiso, M; Brown, G; Feizi, T				Galustian, C; Lubineau, A; le Narvor, C; Kiso, M; Brown, G; Feizi, T			L-selectin interactions with novel mono- and multisulfated Lewis(x) sequences in comparison with the potent ligand 3 '-sulfated Lewis(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE; O-LINKED OLIGOSACCHARIDES; MAJOR CAPPING GROUP; SULFATED OLIGOSACCHARIDES; SIALIC-ACID; BINDING; NEOGLYCOLIPIDS; GLYCOPROTEINS; GLYCAM-1	The cell adhesion molecule L-selectin binds to 3'-sialyl-lewis (Le)(x) and -Le(a) and to 3'-sulfo-Le(x) and -Le(a) sequences, The binding to 3'-sialyl-Le(x) is strongly affected by the presence of 6-O-sulfate as found on oligosaccharides of the counter receptor, GlyCAM-1; 6-O-sulfate on the N-acetylglucosamine (6-sulfation) enhances, whereas 6-O-sulfate on the galactose (6'-sulfation) virtually abolishes binding. To extend knowledge on the specificity of L-selectin, we have investigated interactions with novel sulfo-oligosaccharides based on the Le(x) pentasaccharide sequence. We observe that, also with 3'-sulfo-Le(x), the B-sulfation enhances and 6'-sulfation suppresses L-selectin binding, The 6'-sulfation without 3'-sialyl or 3'-sulfate gives no binding signal with L-selectin, Where the 6-sulfo,3'-sialyl-Le(x) is on an extended di-N-acetyllactosamine backbone, additional 6-O-sulfates on the inner galactose and inner N-acetylglucosamine do not influence the binding. Although binding to the 6,3'-sulfo-Le(x) and 6-sulfo,3'-sialyl-Le(x) sequences is comparable, the former is a more effective inhibitor of L-selectin binding. This difference is most apparent when L-selectin is in paucivalent form (predominantly di- and tetramer) rather than multivalent, Indeed, as inhibitors of the paucivalent L-selectin, the 3'-sulfo-Le(x) series are more potent than the corresponding 3'-sialyl-Le(x) series. Thus, for synthetic strategies to design therapeutic oligosaccharide analogs as antagonists of L-selectin binding, those based on the simpler 3'-sulfo-Le(x) (and also the 3'-sulfo-Le(x)) would seem most appropriate.	Univ London Imperial Coll Sci Technol & Med, Northwick Pk Hosp, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Univ Paris Sud, Lab Chim Organ Multifunct, F-91405 Orsay, France; Gifu Univ, Dept Appl Bioorgan Chem, Gifu 50111, Japan; Univ Lancaster, Dept Biol Sci, Inst Environm & Nat Sci, Lancaster LA1 4YQ, England	Imperial College London; UDICE-French Research Universities; Universite Paris Saclay; Gifu University; Lancaster University	Feizi, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Northwick Pk Hosp, Glycosci Lab, Watford Rd, Harrow HA1 3UJ, Middx, England.			Feizi, Ten/0000-0001-6495-0329				AUGE C, 1997, CARBOHYDRATE MIMICS, P365; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GREEN PJ, 1995, GLYCOBIOLOGY, V5, P29, DOI 10.1093/glycob/5.1.29; HASEGAWA A, 1992, J CARBOHYD CHEM, V11, P645, DOI 10.1080/07328309208016154; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; Komba S, 1996, BIOORGAN MED CHEM, V4, P1833, DOI 10.1016/S0968-0896(96)00165-4; Komba S, 1999, ANGEW CHEM INT EDIT, V38, P1131, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1131::AID-ANIE1131>3.0.CO;2-B; Lubineau A, 1994, Bioorg Med Chem, V2, P1143, DOI 10.1016/S0968-0896(00)82066-0; MANNING DD, 1995, J ORG CHEM, V60, P6254, DOI 10.1021/jo00125a005; ROSEN SD, 1993, HISTOCHEMISTRY, V100, P185, DOI 10.1007/BF00269091; ROY R, 1997, CARBOHYDR LETT, V2, P259; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	24	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18213	18217		10.1074/jbc.274.26.18213	http://dx.doi.org/10.1074/jbc.274.26.18213			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373422	hybrid			2022-12-27	WOS:000081056700014
J	Jiang, B; Cyert, MS				Jiang, B; Cyert, MS			Identification of a novel region critical for calcineurin function in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; 1,3-BETA-D-GLUCAN SYNTHASE; AUTOINHIBITORY DOMAIN; CATALYTIC SUBUNIT; MEMBRANE-PROTEIN; ESCHERICHIA-COLI; SHUTTLE VECTORS	Calcineurin is a Ca2+/calmodulin-regulated protein phosphatase that plays critical functional roles in T cell activation and other Ca2+-mediated signal transduction pathways in mammalian cells. In Saccharomyces cerevisiae, calcineurin regulates the transcription of several genes involved in maintaining ion homeostasis (PMC1, PMR1, and PMR2) and cell wall synthesis (FKS2). In this paper, we report the identification and characterization of 11 single amino acid substitutions in the yeast calcineurin catalytic subunit Cna1p. We show that six substitutions (R177G, F211S, S232F, D258V, L259P, and A262P) affect the stability of calcineurin and that two substitutions (V385D and M400R) disrupt the interaction between Cna1p and the calcineurin regulatory subunit Cnb1p. We also identify three mutations (S373P, H375L, and L379S) that are clustered between the catalytic and the calcineurin B subunit-binding domains. These mutations do not significantly affect the ability of Cna1p to interact with Cnb1p, calmodulin, or Fkb1p (FK506-binding protein). However, these residue substitutions dramatically affect calcineurin activity both in vitro and in vivo. Thus, by using a random mutagenesis approach, we have shown for the first time that the linker region of the calcineurin catalytic subunit, as defined by the Ser(373), His(375), and Leu(379) residues, is crucial for its function as a phosphatase.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Cyert, MS (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Cyert, Martha/0000-0003-3825-7437				Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1989, ADV EXP MED BIOL, V155, P347; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU XQ, 1993, ACTA PHARM SINIC, V14, P200; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MENDOZA I, 1994, J BIOL CHEM, V269, P2792; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NAKAMURA T, 1992, FEBS LETT, V309, P103, DOI 10.1016/0014-5793(92)80749-7; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Sherman F., 1986, METHODS YEAST GENETI; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; SIKORSKI RS, 1989, GENETICS, V122, P19; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Withee JL, 1998, GENETICS, V149, P865; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18543	18551		10.1074/jbc.274.26.18543	http://dx.doi.org/10.1074/jbc.274.26.18543			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373463	hybrid			2022-12-27	WOS:000081056700055
J	Mochizuki, T; Kitanaka, C; Noguchi, K; Muramatsu, T; Asai, A; Kuchino, Y				Mochizuki, T; Kitanaka, C; Noguchi, K; Muramatsu, T; Asai, A; Kuchino, Y			Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase - Implications for the Pim-1-mediated activation of the c-Myc signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAGENESIS; TRANSGENIC MICE; INHIBITS APOPTOSIS; MESSENGER-RNA; MYELOID CELLS; BONE-MARROW; EXPRESSION; PROTEIN; INDUCTION	The pim-1 oncogene encodes a serine/threonine kinase (Pim-1) involved in the transduction of cytokine-triggered mitogenic signals. Pim-1 is unique in that it closely cooperates with c-Myc not only in oncogenesis, but also in apoptosis induction. However, the molecular basis of Pim-1 function remains poorly understood, largely because the downstream effector molecule(s) for Pim-1 kinase has not been identified. Here we provide several lines of evidence that Cdc25A cell cycle phosphatase, a direct transcriptional target for c-Myc, is a substrate for Pim-1 kinase and functions as an effector for Pim-1, We found that Pim-1 physically interacts with Cdc25A both in vitro and in vivo and phosphorylates Cdc25A. We also observed that Pim-1-mediated phosphorylation of Cdc25A increases its phosphatase activity. In addition, wild-type Pim-1, but not kinase-inactive Pim-1, enhanced Cdc25A-mediated cellular transformation and apoptosis, Our results indicate that Cdc25A might be a key molecule that links Pim-1 and c-Myc and that also ties Pim-1-mediated mitogenic signals to cell cycle machinery.	Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; University of Tokyo; Japan Science & Technology Agency (JST)	Kuchino, Y (corresponding author), Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.							ACTON D, 1992, MECH B CELL NEOPLASI, P293; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; ASKEW DS, 1991, ONCOGENE, V6, P1915; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hernandez S, 1998, CANCER RES, V58, P1762; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOOVER D, 1991, J BIOL CHEM, V266, P14018; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PADMA R, 1991, CANCER RES, V51, P2486; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SHINTO Y, 1995, ONCOGENE, V11, P1729; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKAHASHI C, 1995, BIOCHEM BIOPH RES CO, V215, P538, DOI 10.1006/bbrc.1995.2498; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIPSCHNEIDER MT, 1995, BLOOD, V85, P3494, DOI 10.1182/blood.V85.12.3494.bloodjournal85123494; Zornig M, 1996, ONCOGENE, V12, P1789	49	198	217	4	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18659	18666		10.1074/jbc.274.26.18659	http://dx.doi.org/10.1074/jbc.274.26.18659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373478	hybrid			2022-12-27	WOS:000081056700070
J	Muramatsu, M; Sankaranand, VS; Anant, S; Sugai, M; Kinoshita, K; Davidson, NO; Honjo, T				Muramatsu, M; Sankaranand, VS; Anant, S; Sugai, M; Kinoshita, K; Davidson, NO; Honjo, T			Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; PRIMARY IMMUNE-RESPONSE; CATALYTIC SUBUNIT; CHROMOSOMAL LOCALIZATION; SOMATIC HYPERMUTATION; MOLECULAR-CLONING; PROTEIN; ENZYME; MATURATION; BINDING	We have identified a novel gene referred to as activation-induced deaminase (AID) by subtraction of cDNAs derived from switch-induced and uninduced murine B lymphoma CH12F3-2 cells, more than 80% of which switch exclusively to IgA upon stimulation. The amino acid sequence encoded by ALD cDNA is homologous to that of apolipoprotein B (apoB) mRNA-editing enzyme, catalytic polypeptide 1 (APOBEC-1), a type of cytidine deaminase that constitutes a catalytic subunit for the apoB mRNA-editing complex. In vitro experiments using a glutathione S-transferase AID fusion protein revealed significant cytidine deaminase activity that is blocked by tetrahydrouridine and by zinc chelation. However, AID alone did neither demonstrate activity in C to U editing of apoB mRNA nor bind to AU-rich RNA targets, AID mRNA expression is induced in splenic B cells that were activated in vitro or by immunizations with sheep red blood cells. In situ hybridization of immunized spleen sections revealed the restricted expression of AID mRNA in developing germinal centers in which modulation of immunoglobulin gene information through somatic hypermutation and class switch recombination takes place. Taken together, these findings suggest that AID is a new member of the RNA-editing deaminase family and may play a role in genetic events in the germinal center B cell.	Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan; Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA	Kyoto University; Kyoto University; Washington University (WUSTL)	Honjo, T (corresponding author), Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Muramatsu, Masamichi/C-4339-2015; Honjo, Tasuku/N-4470-2016; Anant, Shrikant/AAF-8020-2020	Muramatsu, Masamichi/0000-0002-0153-3533; Sugai, Manabu/0000-0003-1668-7647	NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; George J, 1992, Semin Immunol, V4, P11; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; Kinoshita K, 1998, IMMUNITY, V9, P849, DOI 10.1016/S1074-7613(00)80650-0; KOCKS C, 1988, P NATL ACAD SCI USA, V85, P8206, DOI 10.1073/pnas.85.21.8206; KRAAL G, 1985, ADV EXP MED BIOL, V186, P145; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; Lorenz M, 1996, CURR TOP MICROBIOL, V217, P151; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Nakamura T, 1998, GENOMICS, V54, P89, DOI 10.1006/geno.1998.5571; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; REDIES C, 1993, J COMP NEUROL, V333, P398, DOI 10.1002/cne.903330307; SABLITZKY F, 1985, EMBO J, V4, P345, DOI 10.1002/j.1460-2075.1985.tb03635.x; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; Smith HC, 1996, TRENDS GENET, V12, P418, DOI 10.1016/0168-9525(96)10042-1; Smith KGC, 1997, EMBO J, V16, P2996, DOI 10.1093/emboj/16.11.2996; Sugai M, 1998, NUCLEIC ACIDS RES, V26, P911, DOI 10.1093/nar/26.4.911; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	34	885	928	4	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18470	18476		10.1074/jbc.274.26.18470	http://dx.doi.org/10.1074/jbc.274.26.18470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373455	Green Submitted, hybrid			2022-12-27	WOS:000081056700047
J	Shimada, Y; Nakamura, M; Naito, Y; Nomura, K; Ohno-Iwashita, Y				Shimada, Y; Nakamura, M; Naito, Y; Nomura, K; Ohno-Iwashita, Y			C-terminal amino acid residues are required for the folding and cholesterol binding property of perfringolysin O, a pore-forming cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-ACTIVATED CYTOLYSIN; THETA-TOXIN; CLOSTRIDIUM-PERFRINGENS; STREPTOLYSIN-O; NUCLEOTIDE-SEQUENCE; LISTERIOLYSIN-O; TRYPTOPHAN RESIDUES; LIPOSOMAL MEMBRANES; ESCHERICHIA-COLI; PNEUMOLYSIN	Perfringolysin O (theta-toxin) is a pore-forming cytolysin whose activity is triggered by binding to cholesterol in the plasma membrane. The cholesterol binding activity is predominantly localized in the beta-sheet-rich C-terminal half. In order to determine the roles of the C-terminal amino acids in theta-toxin conformation and activity, mutants were constructed by truncation of the C terminus. While the mutant with a two-amino acid C-terminal truncation retains full activity and has similar structural features to native theta-toxin, truncation of three amino acids causes a 40% decrease in hemolytic activity due to the reduction in cholesterol binding activity with a slight change in its higher order structure. Furthermore, both mutants were found to be poor at in vitro refolding after denaturation in 6 M guanidine hydrochloride, resulting in a dramatic reduction in cholesterol binding and hemolytic activities. These activity losses were accompanied by a slight decrease in beta-sheet content. A mutant toxin with a five-amino acid truncation expressed in Escherichia coli is recovered as a further truncated form lacking the C-terminal 21 amino residues. The product retains neither cholesterol binding nor hemolytic activities and shows a highly disordered structure as detected by alterations in the circular dichroism and tryptophan fluorescence spectra. These results show that the C-terminal region of theta-toxin has two distinct roles; the last 21 amino acids are involved to maintain an ordered overall structure, and in addition, the last two amino acids at the C-terminal end are needed for protein folding in vitro, in order to produce the necessary conformation for optimal cholesterol binding and hemolytic activities.	Tokyo Metropolitan Inst Gerontol, Dept Prot Biochem, Itabashi Ku, Tokyo 1730015, Japan; Inst Phys & Chem Res, Div Biomol Characterizat, Wako, Saitama 5310198, Japan	Tokyo Metropolitan Institute of Gerontology; RIKEN	Shimada, Y (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Prot Biochem, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	yshimada@tmig.or.jp; iwashita@tmig.or.jp						Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen YJ, 1996, PROTEINS, V26, P465; COOK RA, 1988, CRIT REV BIOTECHNOL, V8, P159, DOI 10.3109/07388558809147554; delosToyos JR, 1996, INFECT IMMUN, V64, P480, DOI 10.1128/IAI.64.2.480-484.1996; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Feil SC, 1996, FEBS LETT, V397, P290, DOI 10.1016/S0014-5793(96)01200-8; GEOFFROY C, 1990, J BACTERIOL, V172, P7301, DOI 10.1128/jb.172.12.7301-7305.1990; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; IWAMOTO M, 1990, EUR J BIOCHEM, V194, P25, DOI 10.1111/j.1432-1033.1990.tb19422.x; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; KEHOE MA, 1987, INFECT IMMUN, V55, P3228, DOI 10.1128/IAI.55.12.3228-3232.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER MM, 1961, KABAT MAYERS EXPT IM, P133; MENGAUD J, 1987, INFECT IMMUN, V55, P3225, DOI 10.1128/IAI.55.12.3225-3227.1987; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MITCHELL TJ, 1992, BACTERIAL PROTEIN TO, P429; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V554, P68, DOI 10.1016/0005-2736(79)90007-5; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; Nakayama H, 1996, J CHROMATOGR A, V730, P279, DOI 10.1016/0021-9673(95)00974-4; OHNOIWASHITA Y, 1986, BIOCHEMISTRY-US, V25, P6048, DOI 10.1021/bi00368a032; OHNOIWASHITA Y, 1988, EUR J BIOCHEM, V176, P95, DOI 10.1111/j.1432-1033.1988.tb14255.x; OWEN RHG, 1994, FEMS MICROBIOL LETT, V121, P217, DOI 10.1016/0378-1097(94)90129-5; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SAITO M, 1982, MECH AGEING DEV, V20, P53, DOI 10.1016/0047-6374(82)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SekinoSuzuki N, 1996, EUR J BIOCHEM, V241, P941, DOI 10.1111/j.1432-1033.1996.00941.x; SHIMIZU T, 1991, INFECT IMMUN, V59, P137, DOI 10.1128/IAI.59.1.137-142.1991; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sugahara M, 1996, J CRYST GROWTH, V168, P288, DOI 10.1016/0022-0248(96)00334-X; TWETEN RK, 1988, INFECT IMMUN, V56, P3235, DOI 10.1128/IAI.56.12.3235-3240.1988; Voziyan PA, 1996, BIOCHEMISTRY-US, V35, P12526, DOI 10.1021/bi960562o; WALKER JA, 1987, INFECT IMMUN, V55, P1184, DOI 10.1128/IAI.55.5.1184-1189.1987	37	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18536	18542		10.1074/jbc.274.26.18536	http://dx.doi.org/10.1074/jbc.274.26.18536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373462	hybrid			2022-12-27	WOS:000081056700054
J	Herring, BP; Hoggatt, AM; Smith, AF; Gallagher, PJ				Herring, BP; Hoggatt, AM; Smith, AF; Gallagher, PJ			Targeted expression of SV40 large T-antigen to visceral smooth muscle induces proliferation of contractile smooth muscle cells and results megacolon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; NONMUSCLE MYOSIN; MOUSE EMBRYOGENESIS; ACTIN EXPRESSION; PROTEIN; RAT; PHENOTYPE; CALDESMON; KINASE; CYTOSKELETAL	Many pathological conditions result from the proliferation and de-differentiation of smooth muscle cells leading to impaired contractility of the muscle. Here we show that targeted expression of SV40 large T-antigen to visceral smooth muscle cells in vivo results in increased smooth muscle cell proliferation without de-differentiation or decreased contractility. These data suggest that the de-differentiation and proliferation of smooth muscle cells, seen in many pathological states, may be independently regulated. In the T-antigen transgenic mice the increased smooth muscle cell proliferation results in thickening of the distal colon. Consequently the distal colon becomes hyper-contractile and impedes the flow of digesta through the colon resulting in enlargement of the colon oral to the obstruction. These transgenic mice thus represent a novel model of megacolon that results from increased smooth muscle cell proliferation rather than altered neuronal innervation.	Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Physiol & Biophys, 635 Barnhill Dr, Indianapolis, IN 46202 USA.				NHLBI NIH HHS [R01 HL054118-03, R01 HL058571, R01 HL054118, HL 58571, HL 54118] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118, R01HL058571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1993, CIRC RES, V73, P1002; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; CHIAVEGATO A, 1993, EXP CELL RES, V207, P310, DOI 10.1006/excr.1993.1198; DeLeon H, 1997, CIRC RES, V80, P514, DOI 10.1161/01.RES.80.4.514; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GABELLA G, 1990, ANAT EMBRYOL, V182, P409; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gattuso JM, 1997, GUT, V41, P252, DOI 10.1136/gut.41.2.252; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; HAEBERLE JR, 1992, J MUSCLE RES CELL M, V13, P81, DOI 10.1007/BF01738431; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; KIM YS, 1994, MOL CELL BIOCHEM, V131, P115, DOI 10.1007/BF00925947; LECLERC G, 1992, CIRCULATION, V85, P543, DOI 10.1161/01.CIR.85.2.543; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MALMQVIST U, 1991, AM J PHYSIOL, V260, pC1085, DOI 10.1152/ajpcell.1991.260.5.C1085; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sartore S, 1997, ARTERIOSCL THROM VAS, V17, P1210, DOI 10.1161/01.ATV.17.7.1210; Siegman MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1571, DOI 10.1152/ajpgi.1997.272.6.G1571; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; SOBUE K, 1991, J BIOL CHEM, V266, P12115; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; Wartiovaara K, 1998, ANN MED, V30, P66, DOI 10.3109/07853899808999386; WOODCOCKMITCHELL J, 1993, AM J RESP CELL MOL, V8, P617, DOI 10.1165/ajrcmb/8.6.617	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17725	17732		10.1074/jbc.274.25.17725	http://dx.doi.org/10.1074/jbc.274.25.17725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364214	Green Accepted, hybrid			2022-12-27	WOS:000080974300050
J	Maher, P				Maher, P			p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; FACTOR RECEPTOR; FGF-RECEPTOR; NEURONAL DIFFERENTIATION; FUNCTIONAL SPECIFICITY; TYROSINE-PHOSPHATASE; MESODERM INDUCTION; NEURITE OUTGROWTH	Basic fibroblast growth factor (FGF-2) is a member of a family of polypeptides that have roles in a wide range of biological processes. To determine why different cell types show distinct responses to treatment with FGF-2, the array of FGF receptors present on the surface of a cell which differentiates in response to FGF-2 (PC12 cells) was compared with that present on the surface of a cell that proliferates in response to FGF-S (Swiss 3T3 fibroblasts). Both cell types express exclusively FGFR1, suggesting that there are cell type-specific FGFR1 signaling pathways. Since mitogen-activated protein kinases function as mediators of cellular responses to a variety of stimuli, the roles of these proteins in FGF-mediated responses were examined. FGF-2 activates extracellular signal-regulated kinases with similar kinetics in both fibroblasts and PC12 cells, and a specific inhibitor of extracellular signal-regulated kinase activation blocks differentiation but has little effect on proliferation. In contrast, while p38 mitogen-activated protein kinase is activated weakly and transiently in PC12 cells treated with FGF-2, a much stronger and sustained activation of this kinase is seen in FGF-2-treated fibroblasts. Furthermore, specific inhibitors of this kinase block proliferation but have no effect on differentiation. This effect on proliferation is specific for FGF-2 since the same concentrations of inhibitors have little or no effect on proliferation induced by serum.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Maher, P (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; EISEMANN A, 1991, ONCOGENE, V6, P1195; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Guay J, 1997, J CELL SCI, V110, P357; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin HY, 1996, J NEUROSCI, V16, P4579; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagarkatti DS, 1998, J MOL CELL CARDIOL, V30, P1651, DOI 10.1006/jmcc.1998.0733; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SHAOUL E, 1995, ONCOGENE, V10, P1553; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	69	124	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17491	17498		10.1074/jbc.274.25.17491	http://dx.doi.org/10.1074/jbc.274.25.17491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364180	hybrid			2022-12-27	WOS:000080974300016
J	Quinto, I; Mallardo, M; Baldassarre, F; Scala, G; Englund, G; Jeang, KT				Quinto, I; Mallardo, M; Baldassarre, F; Scala, G; Englund, G; Jeang, KT			Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappa B (I kappa B-alpha S32/36A) and the implications for vaccine development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; DYNAMICS IN-VIVO; EFFICIENT REPLICATION; CHEMOKINE RECEPTORS; INDUCED APOPTOSIS; SIV VACCINE; T-CELLS; ALPHA; TYPE-1; LIVE	Live-attenuated human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine. Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV. Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to prevent the emergence off virulent mutants. New strategies that attenuate via mechanisms distinct from loss-of-function are needed for enhancing the safety phenotype of viral genome. Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for attenuating HIV-1, We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-resistant nuclear factor-kappa B inhibitor (I kappa B-alpha S32/36A) in the nef region. HIV-1 expressing 1 kappa B-alpha S32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. We provide formal proof that the phenotypic and attenuating characteristics of I kappa B-alpha S32/36A permit its stable maintenance in a live, replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture. As compared with other open-reading frames embedded into HIV/SIV genome, this degree of stability is unprecedented. Thus, I kappa B-alpha S32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of live HIV-1, can be stable. These findings illustrate gain-of-function as a feasible strategy for developing safer live-attenuated HIVs to be tested as candidates for AIDS vaccine.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Magna Graecia University of Catanzaro	Quinto, I (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via Sergio Pansini 5, I-80131 Naples, Italy.	quinto@dbbm.unina.it	SCALA, GIUSEPPE/A-3280-2009; Jeang, Kuan-Teh/A-2424-2008	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; Beer B, 1997, P NATL ACAD SCI USA, V94, P4062, DOI 10.1073/pnas.94.8.4062; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 1999, J VIROL, V73, P1138, DOI 10.1128/JVI.73.2.1138-1145.1999; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giavedoni LD, 1996, J VIROL, V70, P2247, DOI 10.1128/JVI.70.4.2247-2251.1996; Gundlach BR, 1997, J VIROL, V71, P2225, DOI 10.1128/JVI.71.3.2225-2232.1997; Ilyinskii PO, 1997, J VIROL, V71, P1880, DOI 10.1128/JVI.71.3.1880-1887.1997; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KESTLER HW, 1995, SCIENCE, V270, P1219; Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marx PA, 1998, SEMIN IMMUNOL, V10, P215, DOI 10.1006/smim.1998.0135; MYERS G, 1996, HUMAN RETROVIRUSES A, P3; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pohlmann S, 1998, J VIROL, V72, P5589; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; Shibata R, 1997, J VIROL, V71, P8141, DOI 10.1128/JVI.71.11.8141-8148.1997; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WRIGHT SC, 1988, J IMMUNOL, V141, P99; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Zhang JB, 1997, VIRUS RES, V49, P205, DOI 10.1016/S0168-1702(97)01462-7	45	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17567	17572		10.1074/jbc.274.25.17567	http://dx.doi.org/10.1074/jbc.274.25.17567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364191	hybrid			2022-12-27	WOS:000080974300027
J	Brugna, M; Nitschke, W; Asso, M; Guigliarelli, B; Lemesle-Meunier, D; Schmidt, C				Brugna, M; Nitschke, W; Asso, M; Guigliarelli, B; Lemesle-Meunier, D; Schmidt, C			Redox components of cytochrome bc-type enzymes in acidophilic prokaryotes II. The Rieske protein of phylogenetically distant acidophilic organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-PARAMAGNETIC-RESONANCE; FORMING HYDROGEN-BONDS; LUMEN-SIDE DOMAIN; 2FE-2S CLUSTER; BC(1) COMPLEX; THIOBACILLUS-FERROOXIDANS; BOVINE HEART; SULFOLOBUS-ACIDOCALDARIUS; CRYSTAL-STRUCTURE	The Rieske proteins of two phylogenetically distant acidophilic organisms, i.e. the proteobacterium Thiobacillus ferrooxidans and the crenarchaeon Sulfolobus acidocaldarius, were studied by EPR. Redox titrations at a range of pH values showed that the Rieske centers of both organisms are characterized by redox midpoint potential-versus-pH curves featuring a common pK value of 6.2. This pK value is significantly more acidic (by almost 2 pH units) than that of Rieske proteins in neutrophilic species. The orientations of the Rieske center's g tensors with respect to the plane of the membrane were studied between pH 4 and 8 using partially ordered samples. At pH 4, the Sulfolobus Rieske cluster was found in the "typical" orientation of chemically reduced Rieske centers, whereas this orientation changed significantly on going toward high pH values. The Thiobacillus protein, by contrast, appeared to be in the "standard" orientation at both low and high pH values. The results are discussed with respect to the molecular parameters conveying acid resistance and in light of the recently demonstrated long-range conformational movement of the Rieske protein during enzyme turnover in cytochrome bc(1) complexes.	CNRS, Inst Biol Struct & Microbiol, UPR 9036, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Lubeck	Lemesle-Meunier, D (corresponding author), CNRS, Inst Biol Struct & Microbiol, UPR 9036, Lab Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	lemesle@ibsm.cnrs-mrs.fr	Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032				ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANEMULLER S, 1994, BIOCHEM BIOPH RES CO, V202, P252, DOI 10.1006/bbrc.1994.1920; Botuyan MV, 1996, J MOL BIOL, V263, P752, DOI 10.1006/jmbi.1996.0613; Brugna M, 1998, J BACTERIOL, V180, P3719, DOI 10.1128/JB.180.14.3719-3723.1998; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CASTRESANA J, 1995, J MOL BIOL, V250, P202, DOI 10.1006/jmbi.1995.0371; CROFTS AR, 1999, IN PRESS PHOTOTROPHI; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; Elbehti A, 1996, FEMS MICROBIOL LETT, V136, P51; Elbehti A, 1999, J BIOL CHEM, V274, P16760, DOI 10.1074/jbc.274.24.16760; ERECINSKA M, 1978, BIOCHIM BIOPHYS ACTA, V501, P63, DOI 10.1016/0005-2728(78)90095-6; FEE JA, 1984, J BIOL CHEM, V259, P124; GUSS JM, 1986, J MOL BIOL, V192, P361, DOI 10.1016/0022-2836(86)90371-2; Holton B, 1996, BIOCHEMISTRY-US, V35, P15485, DOI 10.1021/bi961367c; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P244, DOI 10.1016/0005-2728(76)90082-7; Kramer DM, 1997, BIOCHEMISTRY-US, V36, P4203, DOI 10.1021/bi962241i; KUILA D, 1986, J BIOL CHEM, V261, P2768; KUTOH E, 1988, J BIOL CHEM, V263, P9020; LANE DJ, 1992, J BACTERIOL, V174, P269, DOI 10.1128/jb.174.1.269-278.1992; LIEBL U, 1992, J BIOL CHEM, V267, P14068; LIEBL U, 1990, FEBS LETT, V261, P427, DOI 10.1016/0014-5793(90)80608-L; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MATIN A, 1990, FEMS MICROBIOL LETT, V75, P307, DOI 10.1111/j.1574-6968.1990.tb04104.x; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; PRINCE RC, 1983, BIOCHIM BIOPHYS ACTA, V723, P133, DOI 10.1016/0005-2728(83)90112-3; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; RIEDEL A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P263, DOI 10.1016/0005-2728(93)90227-7; Riedel A, 1995, J BIOL CHEM, V270, P30869, DOI 10.1074/jbc.270.52.30869; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; Schafer G, 1996, BBA-BIOENERGETICS, V1277, P163, DOI 10.1016/S0005-2728(96)00104-1; Schmidt CL, 1996, FEBS LETT, V388, P43, DOI 10.1016/0014-5793(96)00511-X; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; SCHUTZ M, 1994, PHOTOSYNTH RES, V39, P163, DOI 10.1007/BF00029383; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; ZANNONI D, 1985, FEBS LETT, V193, P93, DOI 10.1016/0014-5793(85)80086-7; Zhang JM, 1996, J BIOL CHEM, V271, P31360, DOI 10.1074/jbc.271.49.31360; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	48	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16766	16772		10.1074/jbc.274.24.16766	http://dx.doi.org/10.1074/jbc.274.24.16766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358018	hybrid			2022-12-27	WOS:000080780400017
J	Corradin, S; Mauel, J; Ransijn, A; Sturzinger, C; Vergeres, G				Corradin, S; Mauel, J; Ransijn, A; Sturzinger, C; Vergeres, G			Down-regulation of MARCKS-related protein (MRP) in macrophages infected with Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMAL BRAIN-DEVELOPMENT; NECROSIS-FACTOR-ALPHA; KINASE-C; DONOVANI LIPOPHOSPHOGLYCAN; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; INTERFERON-GAMMA; MAJOR SUBSTRATE; GROWTH-FACTOR; IFN-GAMMA	Leishmania, a protozoan parasite of macrophages, has been shown to interfere with host cell signal transduction pathways including protein kinase C (PKC)-dependent signaling. Myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP, MacMARCKS) are PKC substrates in diverse cell types, MARCKS and MRP are thought to regulate the actin network and thereby participate in cellular responses involving cytoskeletal rearrangement. Because MRP is a major PKC substrate in macrophages, we examined its expression in response to infection by Leishmania, Activation of murine macrophages by cytokines increased MRP expression as determined by Western blot analysis. Infection with Leishmania promastigotes at the time of activation or up to 48 h postactivation strongly decreased MRP levels. Leishmania-dependent MRP depletion was confirmed by [H-3]myristate labeling and by immunofluorescence microscopy. All species or strains of Leishmania parasites tested, including lipophosphoglycan-deficient Leishmania major L119, decreased MRP levels. MRP depletion was not obtained with other phagocytic stimuli including zymosan, latex beads, or heat-killed Streptococcus mitis, a Gram-positive bacterium. Experiments with [H-3]myristate labeled proteins revealed the appearance of lower molecular weight fragments in Leishmania-infected cells suggesting that MRP depletion may be due to proteolytic degradation.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	University of Lausanne; University of Basel	Corradin, S (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Aderem A, 1992, Curr Top Microbiol Immunol, V181, P189; ADEREM AA, 1988, P NATL ACAD SCI USA, V85, P6310, DOI 10.1073/pnas.85.17.6310; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BEHIN R, 1979, EXP PARASITOL, V48, P81, DOI 10.1016/0014-4894(79)90057-2; BERENS RL, 1978, J PARASITOL, V64, P160, DOI 10.2307/3279633; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CORRADIN SB, 1991, J IMMUNOL, V146, P279; CORRADIN SB, 1991, EUR J IMMUNOL, V21, P2553, DOI 10.1002/eji.1830211036; DESCOTEAUX A, 1992, J IMMUNOL, V149, P3008; DING AH, 1988, J IMMUNOL, V141, P2407; FRANKENBURG S, 1990, J IMMUNOL, V145, P4284; GREEN SJ, 1990, J IMMUNOL, V145, P4290; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; LAUMAS S, 1989, P NATL ACAD SCI USA, V86, P3021, DOI 10.1073/pnas.86.9.3021; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; MCNEELY TB, 1987, BIOCHEM BIOPH RES CO, V148, P653, DOI 10.1016/0006-291X(87)90926-0; MEERPOHL HG, 1976, EUR J IMMUNOL, V6, P213, DOI 10.1002/eji.1830060313; MOORE KJ, 1993, J IMMUNOL, V150, P4457; MURRAY PJ, 1990, EXP PARASITOL, V71, P294, DOI 10.1016/0014-4894(90)90034-A; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481; OLIVIER M, 1992, J IMMUNOL, V148, P1188; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; Rittig MG, 1998, INFECT IMMUN, V66, P4331; Rose SD, 1996, J NEUROSCI RES, V44, P235; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; VALMORI D, 1992, J IMMUNOL, V149, P717; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	46	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16782	16787		10.1074/jbc.274.24.16782	http://dx.doi.org/10.1074/jbc.274.24.16782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358020	hybrid			2022-12-27	WOS:000080780400019
J	Deltour, L; Foglio, MH; Duester, G				Deltour, L; Foglio, MH; Duester, G			Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice - Overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-III ALCOHOL; DEPENDENT FORMALDEHYDE DEHYDROGENASE; CLASS-I; ALCOHOL/RETINOL DEHYDROGENASES; MOLECULAR-PROPERTIES; EXPRESSION PATTERNS; NUCLEOTIDE-SEQUENCE; MOUSE; GENE; INHIBITION	Targeting of mouse alcohol dehydrogenase genes Adh1, Adh3, and Adh4 resulted in null mutant mice that all developed and reproduced apparently normally but differed markedly in clearance of ethanol and formaldehyde plus metabolism of retinol to the signaling molecule retinoic acid. Following administration of an intoxicating dose of ethanol, Adh1 -/- mice, and to a lesser extent Adh4 -/- mice, but not Adh3 -/- mice, displayed significant reductions in blood ethanol clearance. Ethanol-induced sleep was significantly longer only in Adh1 -/- mice. The incidence of embryonic resorption following ethanol administration was increased S-fold in Adh1 -/- mice and 1.5-fold in Adh4 -/- mice but was unchanged in Adh3 -/- mice. Formaldehyde toxicity studies revealed that only Adh3 -/- mice had a significantly reduced LD,, value. Retinoic acid production following retinol administration was reduced 4.8-fold in Adh1 -/- mice and 8.5-fold in Adh4 -/- mice. Thus, Adh1 and Adh4 demonstrate overlapping functions in ethanol and retinol metabolism in vivo, whereas Adh3 plays no role with these substrates but instead functions in formaldehyde metabolism. Redundant roles for Adh1 and Adh4 in retinoic acid production may explain the apparent normal development of mutant mice.	Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Gene Regulat Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Duester, Gregg/0000-0003-4335-3650	NIAAA NIH HHS [AA09731] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BURNETT KG, 1980, BIOCHEM PHARMACOL, V29, P125, DOI 10.1016/0006-2952(80)90318-4; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Deltour L, 1997, BIOL REPROD, V56, P102, DOI 10.1095/biolreprod56.1.102; DELTOUR L, 1999, IN PRESS DEV GENET; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; DUESTER G, 1999, IN PRESS BIOCH PHARM; Ferguson RA, 1997, CLIN CHIM ACTA, V257, P199, DOI 10.1016/S0009-8981(96)06444-3; Foglio MH, 1996, EUR J BIOCHEM, V237, P496, DOI 10.1111/j.1432-1033.1996.0496k.x; Goate AM, 1998, CURR OPIN GENET DEV, V8, P282, DOI 10.1016/S0959-437X(98)80082-8; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1998, ALCOHOL CLIN EXP RES, V22, P1607, DOI 10.1111/j.1530-0277.1998.tb03955.x; Haselbeck RJ, 1997, ENDOCRINOLOGY, V138, P3035, DOI 10.1210/en.138.7.3035; Haselbeck RJ, 1997, DEV DYNAM, V208, P447, DOI 10.1002/(SICI)1097-0177(199704)208:4<447::AID-AJA1>3.0.CO;2-I; Haselbeck RJ, 1998, DEV DYNAM, V213, P114, DOI 10.1002/(SICI)1097-0177(199809)213:1<114::AID-AJA11>3.0.CO;2-2; Hogan B, 1994, MANIPULATING MOUSE E; HOLMES RS, 1981, J EXP ZOOL, V217, P151, DOI 10.1002/jez.1402170202; HOLMES RS, 1977, GENETICS, V87, P709; HOLMQUIST B, 1991, BIOCHEM BIOPH RES CO, V178, P1371, DOI 10.1016/0006-291X(91)91045-E; JORNVALL H, 1995, ADV EXP MED BIOL, V372, P281; Joyner AL, 1993, GENE TARGETING PRACT; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; Martinez MC, 1996, EUR J BIOCHEM, V241, P849, DOI 10.1111/j.1432-1033.1996.00849.x; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; VOELKER RA, 1980, P NATL ACAD SCI-BIOL, V77, P1091, DOI 10.1073/pnas.77.2.1091; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; Yamamoto M, 1998, DEV BRAIN RES, V107, P103, DOI 10.1016/S0165-3806(98)00003-0; ZgombicKnight M, 1997, GENOMICS, V41, P105, DOI 10.1006/geno.1997.4637; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	46	143	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16796	16801		10.1074/jbc.274.24.16796	http://dx.doi.org/10.1074/jbc.274.24.16796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358022	hybrid			2022-12-27	WOS:000080780400021
J	Konczalik, P; Moss, J				Konczalik, P; Moss, J			Identification of critical, conserved vicinal aspartate residues in mammalian and bacterial ADP-ribosylarginine hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; RHODOSPIRILLUM-RUBRUM; NITROGENASE ACTIVITY; RIBOSYLATION; RIBOSYLTRANSFERASE; INTEGRIN; PROTEIN; BINDING; SUBSTRATE; LAMININ	NAD:arginine ADP-ribosyltransferases and ADP-ribosylarginine hydrolases catalyze opposing arms of a putative ADP-ribosylation cycle. ADP-ribosylarsnine hydrolases from mammalian tissues and Rhodospirillum rubrum exhibit three regions of similarity in deduced amino acid sequence. We postulated that amino acids in these consensus regions could be critical for hydrolase function. To test this hypothesis, hydrolase, cloned from rat brain, was expressed as a glutathione S-transferase fusion protein in Escherichia coli and purified by glutathione-Sepharose affinity chromatography. Conserved amino acids in each of these regions were altered by site-directed mutagenesis. Replacement of Asp-60 or Asp-61 with Ala, Gin, or Asn, but not Glu, significantly reduced enzyme activity. The double Asp-60 --> Glu/Asp-61 --> Glu mutant was inactive, as were Asp-60 --> Gln/Asp-61 --> Gln or Asp-60 --> Asn/Asp-61 --> Asn. The catalytically inactive single and double mutants appeared to retain conformation, since they bound ADP-ribose, a substrate analogue and an inhibitor of enzyme activity, with affinity similar to that of the wild-type hydrolase and with the expected stoichiometry of one. Replacing His-65, Arg-139, Asp-285, which are also located in the conserved regions, with alanine did not change specific activity. These data clearly show that the conserved vicinal aspartates 60 and 61 in rat ADP-ribosylarginine hydrolase are critical for catalytic activity, but not for high affinity binding of the substrate analogue, ADP-ribose.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Konczalik, P (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N307,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1997, BACTERIAL TOXINS TOO; Aktories K, 1990, ADP RIBOSYLATING TOX, P79; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; DUMAN RS, 1991, J NEUROCHEM, V57, P2124, DOI 10.1111/j.1471-4159.1991.tb06431.x; Fishman P.H., 1990, ADP RIBOSYLATING TOX, P127; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; HARTMANN A, 1986, J BACTERIOL, V165, P864, DOI 10.1128/jb.165.3.864-870.1986; KANEMOTO RH, 1984, J BACTERIOL, V158, P713, DOI 10.1128/JB.158.2.713-720.1984; KATADA T, 1982, J BIOL CHEM, V257, P7210; KHARADIA SV, 1992, EXP CELL RES, V201, P33, DOI 10.1016/0014-4827(92)90345-9; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1992, J BIOL CHEM, V267, P10481; NELSON M, 1992, METHOD ENZYMOL, V216, P279; OKAZAKI IJ, 1995, BIOCHIMIE, V77, P319, DOI 10.1016/0300-9084(96)88141-7; Okazaki IJ, 1998, J BIOL CHEM, V273, P23617, DOI 10.1074/jbc.273.37.23617; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; TAKADA T, 1994, MOL CELL BIOCHEM, V138, P119, DOI 10.1007/BF00928452; TAKADA T, 1993, J BIOL CHEM, V268, P17837; UI M, 1990, ADP RIBOSYLATING TOX, P45; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Wang J, 1996, J IMMUNOL, V156, P2819; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273	26	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16736	16740		10.1074/jbc.274.24.16736	http://dx.doi.org/10.1074/jbc.274.24.16736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358013	hybrid			2022-12-27	WOS:000080780400012
J	Vie, A; Cigna, M; Toci, R; Birman, S				Vie, A; Cigna, M; Toci, R; Birman, S			Differential regulation of Drosophila tyrosine hydroxylase isoforms by dopamine binding and cAMP-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; TARGETED DISRUPTION; METAL-IONS; PURIFICATION; MELANOGASTER; IRON; EXPRESSION; ENZYME; GENE; SERINE-40	Tyrosine hydroxylase (TH) catalyzes the first step in dopamine biosynthesis in Drosophila as in vertebrates. We have previously reported that tissue-specific alternative splicing of the TH primary transcript generates two distinct TH isoforms in Drosophila, DTH I and DTH II (Birman, S,, Morgan, B,, Anzivino, M,, and Hirsh, J, (1994) J. Biol. Chem. 269, 26559-26567), Expression of DTH I is restricted to the central nervous system, whereas DTH II is expressed in non-nervous tissues like the epidermis, The two enzymes present a single structural difference; DTH II specifically contains a very acidic segment of 71 amino acids inserted in the regulatory domain. We show here that the enzymatic and regulatory properties of vertebrate TH are generally conserved in insect TH and that the isoform DTH II presents unique characteristics. The two DTH isoforms were expressed as apoenzymes in Escherichia coli and purified by fast protein liquid chromatography, The recombinant DTH isoforms are enzymatically active in the presence of ferrous iron and a tetrahydropteridine co-substrate, However, the two enzymes differ in many of their properties. DTH II has a lower K-m value for the cosubstrate (6R)-tetrahydrobiopterin and requires a lower level of ferrous ion than DTH I to be activated, The two isoforms also have a different pH profile. As for mammalian TH, enzymatic activity of the Drosophila enzymes is decreased by dopamine binding, and this effect is dependent on ferrous iron levels. However, DTH II appears comparatively less sensitive than DTH I to dopamine inhibition. The central nervous system isoform DTH I is activated through phosphorylation by cAMP-dependent protein kinase (PKA) in the absence of dopamine. In contrast, activation of DTH II by PKA is only manifest in the presence of dopamine. Site-directed mutagenesis of Ser(32), a serine residue occurring in a PKA site conserved in all known TH proteins, abolishes phosphorylation of both isoforms and activation by PKA. We propose that tissue-specific alternative splicing of TH has a functional role for differential regulation of dopamine biosynthesis in the nervous and non-nervous tissues of insects.	CNRS, Lab Neurobiol Cellulaire & Fonct, F-13402 Marseille 9, France; CNRS, Chim Bacterienne Lab, F-13009 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Birman, S (corresponding author), CNRS, Lab Neurobiol Cellulaire & Fonct, 31 Chemin Joseph Aiguier, F-13402 Marseille 9, France.							ABATE C, 1988, BIOCHEM BIOPH RES CO, V151, P1446, DOI 10.1016/S0006-291X(88)80524-2; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; Alterio J, 1998, J BIOL CHEM, V273, P10196, DOI 10.1074/jbc.273.17.10196; ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; BERTRAM G, 1994, J COMP PHYSIOL B, V164, P238, DOI 10.1007/BF00354085; BIRMAN S, 1994, J BIOL CHEM, V269, P26559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDNIK V, 1987, J NEUROGENET, V4, P309, DOI 10.3109/01677068709102351; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; DAUBNER SC, 1995, PROTEIN SCI, V4, P538; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FITZPATRICK PF, 1989, BIOCHEM BIOPH RES CO, V161, P211, DOI 10.1016/0006-291X(89)91582-9; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; FONTECAVE M, 1993, BIOCHIMIE, V75, P767, DOI 10.1016/0300-9084(93)90126-D; GAHN LG, 1993, BIOCHEM J, V295, P189, DOI 10.1042/bj2950189; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HOELDTKE R, 1977, J BIOL CHEM, V252, P3160; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KATZ IR, 1976, BIOCHIM BIOPHYS ACTA, V429, P84, DOI 10.1016/0005-2744(76)90032-2; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; Kumer SC, 1996, J NEUROCHEM, V67, P443; LEBOURDELLES B, 1991, J BIOL CHEM, V266, P17124; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LUNDELL MJ, 1994, DEV BIOL, V165, P385, DOI 10.1006/dbio.1994.1261; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAGATSU T, 1971, J NEUROCHEM, V18, P2179, DOI 10.1111/j.1471-4159.1971.tb05076.x; NECKAMEYER WS, 1993, J NEUROGENET, V8, P189, DOI 10.3109/01677069309083448; NECKAMEYER WS, 1989, NEURON, V2, P1167, DOI 10.1016/0896-6273(89)90183-9; OKUNO S, 1991, J NEUROCHEM, V57, P53, DOI 10.1111/j.1471-4159.1991.tb02098.x; Ota A, 1997, NEUROSCI LETT, V229, P57, DOI 10.1016/S0304-3940(97)00418-7; POLLOCK RJ, 1981, J NEUROCHEM, V37, P855, DOI 10.1111/j.1471-4159.1981.tb04471.x; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; RAUSCH WD, 1988, J NEUROCHEM, V50, P202, DOI 10.1111/j.1471-4159.1988.tb13250.x; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RESTIFO LL, 1990, ADV INSECT PHYSL, V22, P116; RIBEIRO P, 1993, J MOL NEUROSCI, V4, P125, DOI 10.1007/BF02782125; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; Schneider S, 1996, MOL CELL ENDOCRINOL, V116, P73, DOI 10.1016/0303-7207(95)03699-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIGNY A, 1981, J NEUROCHEM, V36, P483, DOI 10.1111/j.1471-4159.1981.tb01618.x; WALKER SJ, 1994, BBA-PROTEIN STRUCT M, V1206, P113, DOI 10.1016/0167-4838(94)90079-5; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983; WU J, 1992, J BIOL CHEM, V267, P25754; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	59	48	49	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16788	16795		10.1074/jbc.274.24.16788	http://dx.doi.org/10.1074/jbc.274.24.16788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358021	hybrid			2022-12-27	WOS:000080780400020
J	Espinas, ML; Jimenez-Garcia, E; Vaquero, A; Canudas, S; Bernues, J; Azorin, F				Espinas, ML; Jimenez-Garcia, E; Vaquero, A; Canudas, S; Bernues, J; Azorin, F			The N-terminal POZ domain of GAGA mediates the formation of oligomers that bind DNA with high affinity and specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME REMODELING FACTOR; PROTEIN INTERACTION MOTIF; TRIPLE-STRANDED DNA; TRANSCRIPTION FACTOR; BTB DOMAIN; IN-VITRO; CELL-CYCLE; DROSOPHILA; CHROMATIN; GENE	The Drosophila GAGA factor self-oligomerizes both in vivo and in vitro. GAGA oligomerization depends on the presence of the N-terminal POZ domain and the formation of dimers, tetramers, and oligomers of high stoichiometry is observed in vitro. GAGA oligomers bind DNA with high affinity and specificity, As a consequence of its multimeric character, the interaction of GAGA with DNA fragments carrying several GAGA binding sites is multivalent and of higher affinity than its interaction with fragments containing single short sites. A single GAGA oligomer is capable of binding adjacent GAGA binding sites spaced by as many as 20 base pairs. GAGA oligomers are functionally active, being transcriptionally competent in vitro. GAG;A-dependent transcription activation depends strongly on the number of GAGA binding sites present in the promoter. The POZ domain is not necessary for in vitro transcription but, in its absence, no synergism is observed on increasing the number of binding sites contained within the promoter. These results are discussed in view of the distribution of GAGA binding sites that, most frequently, form clusters of relatively short sites spaced by small variable distances.	CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Azorin, F (corresponding author), CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, Jordi Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Canudas, Silvia/K-4184-2014; Bernues, Jordi/ABE-8360-2021; Canudas, Silvia/AAC-3163-2022; Azorin, Fernando/N-4388-2014; Vaquero, Alejandro/ABG-8634-2020	Canudas, Silvia/0000-0002-5630-1588; Bernues, Jordi/0000-0001-6218-8254; Canudas, Silvia/0000-0002-5630-1588; Azorin, Fernando/0000-0002-8426-7858; Espinas, M Lluisa/0000-0003-3914-2228				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GODT D, 1993, DEVELOPMENT, V119, P799; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Lehmann M, 1998, J BIOL CHEM, V273, P28504, DOI 10.1074/jbc.273.43.28504; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Platero JS, 1998, J CELL BIOL, V140, P1297; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WEBER JA, 1995, NUCLEIC ACIDS RES, V23, P3327, DOI 10.1093/nar/23.16.3327; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	34	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16461	16469		10.1074/jbc.274.23.16461	http://dx.doi.org/10.1074/jbc.274.23.16461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347208	hybrid			2022-12-27	WOS:000080668600068
J	Maki, CG				Maki, CG			Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DAMAGE; IN-VIVO; PROTEIN; DEGRADATION; GENE; EXPRESSION; E6; ACCUMULATION; LOCALIZATION; INHIBITION	Wild-type p53 is degraded in part through the ubiquitin proteolysis pathway. Recent studies indicate that MDM2 can bind p53 and promote its rapid degradation although the molecular basis for this degradation has not been clarified. This report demonstrates that MDM2 can promote the ubiquitination of wild-type p53 and cancer-derived p53 mutants in transiently transfected cells. Deletion mutants that disrupted the oligomerization domain of p53 displayed low binding affinity for MDM2 and were poor substrates for ubiquitination. However, efficient MDM2 binding and ubiquitination were restored when an olgomerization-deficient p53 mutant was fused to the dimerization domain from another protein. These results indicate that oligomerization is required for p53 to efficiently bind and be ubiquitinated by MDM2. p53 ubiquitination was inhibited in cells exposed to UV radiation, and this inhibition coincided with a decrease in MDM2 protein levels and p53 MDM2 complex formation. In contrast, p53 dimerization was unaffected following UV treatment. These results suggest that UV radiation may stabilize p53 by blocking the ubiquitination and degradation of p53 mediated by MDM2.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.							Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Perego P, 1996, CANCER RES, V56, P556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1988; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X	32	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16531	16535		10.1074/jbc.274.23.16531	http://dx.doi.org/10.1074/jbc.274.23.16531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347217	hybrid			2022-12-27	WOS:000080668600077
J	Riley, JK; Takeda, K; Akira, S; Schreiber, RD				Riley, JK; Takeda, K; Akira, S; Schreiber, RD			Interleukin-10 receptor signaling through the JAK-STAT pathway - Requirement for two distinct receptor-derived signals for anti-inflammatory action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA RECEPTOR; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; T-CELLS; CYTOKINE; IL-10; ACTIVATION; GROWTH; GENE	Interleukin-10 (IL-IO) is a cytokine that has pleiotropic effects on a variety of different cell types. Although many of the biologic responses induced by IL-10 are also induced by other cytokines, such as IL-6, IL-10 is relatively unique in its ability to potently inhibit production of pro-inflammatory cytokines in macrophages. In this study, we have used gain-of-function and loss-of-function genetic approaches to define the intracellular components involved in the different biologic actions of IL-10. Herein, we demonstrate that the ability of IL-10 to inhibit tumor necrosis factor alpha (TNF alpha) production in lipopolysaccharide stimulated macrophages requires the presence of Stat3, Jak1, and two distinct regions of the IL-10 receptor intracellular domain. Macrophages deficient in Stat3 or Jak1 were unable to inhibit lipopolysaccharide-induced TNF alpha production following treatment with murine IL-10. Structure-function analysis of the intracellular domain of the IL-10 receptor cu chain showed that whereas two redundant Stat3 recruitment sites ((427)YQKQ(430) and (477)YLKQ(480)) were required for all IL-10-dependent effects on either B cells or macrophages, expression of IL-10-dependent anti-inflammatory function required the presence on the intracellular domain of the IL-10 receptor of a carboxyl-terminal sequence containing at least one functionally critical serine, These results thus demonstrate that IL-10-induced inhibition of TNF alpha production requires two distinct regions of the IL-10 receptor intracellular domain and thereby establish a distinctive molecular basis for the developmental versus the anti-inflammatory actions of IL-10.	Washington Univ, Sch Med, Dept Pathol, Ctr Immunol, St Louis, MO 63110 USA; Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan	Washington University (WUSTL); Hyogo College of Medicine	Schreiber, RD (corresponding author), Washington Univ, Sch Med, Dept Pathol, Ctr Immunol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	schreiber@immunology.wustl.edu	Takeda, Kiyoshi/C-9331-2009; Akira, Shizuo/C-3134-2009; Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIRANO T, 1994, CYTOKINE HDB, P145; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LIU Y, 1994, J IMMUNOL, V152, P1821; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; Spencer SD, 1998, J EXP MED, V187, P571, DOI 10.1084/jem.187.4.571; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA K, 1993, BLOOD, V81, P2964; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8	44	283	305	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16513	16521		10.1074/jbc.274.23.16513	http://dx.doi.org/10.1074/jbc.274.23.16513			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347215	hybrid			2022-12-27	WOS:000080668600075
J	Matsui, E; Kawasaki, S; Ishida, H; Ishikawa, K; Kosugi, Y; Kikuchi, H; Kawarabayashi, Y; Matsui, I				Matsui, E; Kawasaki, S; Ishida, H; Ishikawa, K; Kosugi, Y; Kikuchi, H; Kawarabayashi, Y; Matsui, I			Thermostable flap endonuclease from the archaeon, Pyrococcus horikoshii, cleaves the replication fork-like structure endo exonucleolytically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING RECBCD ENZYME; NUCLEOTIDE EXCISION-REPAIR; HOT-SPOT-CHI; ESCHERICHIA-COLI; DNA-REPLICATION; MAMMALIAN 5'-EXONUCLEASE; NUCLEIC-ACIDS; RECOMBINATION; STRAND; 3'-EXONUCLEASE	The flap endonuclease gene homologue from the hyperthermophilic archaeon, Pyrococcus horikoshii, was overexpressed in Escherichia coli and purified, The results of gel filtration indicated that this protein was a 41-kDa monomer. P. horikoshii flap endonuclease (phFEN) cleaves replication fork-like substrates (RF) and 5' double strand flap structures (DF) using both flap endonuclease and 5'-3'-exonuclease activities. The mammalian flap endonuclease (mFEN) is a single-strand flap-specific endonuclease (Harrington, J. J,, and Lieber, M, R, (1994) EMBO J, 13, 1235-1246), but the action patterns of phFEN appear to be quite different from those of mFEN at this point, The DF specific flap endonuclease ase and 5'-exonuclease activities have not yet been reported. Therefore, this is the first report of the specific endo/exonuclease activities of phFEN. The DF-specific 5'-exonuclease activity degraded the downstream primer of 3' single-flap structure and was 15 times higher than the activities against nicked substrates without 3' flap strand. DF-specific flap endonuclease cleaved the 5' double-flap strand in DF and the lagging strand in RF at the junction portion. Because the RF appears to be the intermediate structure, due to the arrest of the replication fork, the double strand breaks after the arrests of the replication forks are probably caused by phFEN.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; AIST, Natl Inst Technol & Evaluat, Tokyo 150, Japan; New Energy & Ind Technol Dev Org, Tokyo 170, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Biosci & Human Technol, Higashi 1-1, Tsukuba, Ibaraki 305, Japan.	imatsui@ccmail.nibh.go.jp						Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; COX SL, 1998, JIKKENIGAKU, V16, P1031; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; ROBB FT, 1996, ABSTR THERM 96, P85; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tracy RB, 1997, CELL, V90, P205, DOI 10.1016/S0092-8674(00)80328-1; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	35	25	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18297	18309		10.1074/jbc.274.26.18297	http://dx.doi.org/10.1074/jbc.274.26.18297			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373433	hybrid			2022-12-27	WOS:000081056700025
J	Niviere, V; Fieschi, F; Decout, JL; Fontecave, M				Niviere, V; Fieschi, F; Decout, JL; Fontecave, M			The NAD(P)H : Flavin oxidoreductase from Escherichia coli - Evidence for a new mode of binding for reduced pyridine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHTHALATE DIOXYGENASE REDUCTASE; VIBRIO-FISCHERI ATCC-7744; FERREDOXIN-NADP(+) REDUCTASE; RIBONUCLEOTIDE REDUCTASE; BIOLUMINESCENT BACTERIUM; SUBSTRATE-SPECIFICITY; SULFITE REDUCTASE; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; NADPH	The NAD(P)H:flavin oxidoreductase from Escherichia coli, named Fre, is a monomer of 26.2 kDa that catalyzes the reduction of free flavins using NADPH or NADH as electron donor. The enzyme does not contain any prosthetic group but accommodates both the reduced pyridine nucleotide and the flavin in a ternary complex prior to oxidoreduction. The specificity of the flavin reductase for the pyridine nucleotide was studied by steady-state kinetics using a variety of NADP analogs. Both the nicotinamide ring and the adenosine part of the substrate molecule have been found to be important for binding to the polypeptide chain. However, in the case of NADPH, the 2'-phosphate group destabilized almost completely the interaction with the adenosine moiety. Moreover, NADPH and NMNH are very good substrates for the flavin reductase, and we have shown that both these molecules bind to the enzyme almost exclusively by the nicotinamide ring. This provides evidence that the flavin reductase exhibits a unique mode for recognition of the reduced pyridine nucleotide. In addition, we have shown that the flavin reductase selectively transfers the pro-R hydrogen from the C-4 position of the nicotinamide ring and is therefore classified as an A-side-specific enzyme.	Univ J Fourier, CNRS, CEA,Ctr Redox Biol, DBMS,Lab Chim & Biochim, F-38054 Grenoble 9, France; Univ J Fourier, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Niviere, V (corresponding author), Univ J Fourier, CNRS, CEA,Ctr Redox Biol, DBMS,Lab Chim & Biochim, Batiment K,17 Ave Martyrs, F-38054 Grenoble 9, France.		Fieschi, Franck/W-2748-2019	Niviere, Vincent/0000-0002-5132-457X; FIESCHI, Franck/0000-0003-1194-8107				Adolph HW, 1997, BIOCHEMISTRY-US, V36, P8743, DOI 10.1021/bi970398k; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DALZIEL K, 1973, ENZYMES, V11, P2; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; FONTECAVE M, 1992, ADV ENZYMOL, V65, P145; Fromm H J, 1979, Methods Enzymol, V63, P467; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; GAUDU P, 1994, J BIOL CHEM, V269, P8182; Gray KA, 1996, NAT BIOTECHNOL, V14, P1705, DOI 10.1038/nbt1296-1705; HULTQUIST DE, 1993, AM J HEMATOL, V42, P13, DOI 10.1002/ajh.2830420105; INOUYE S, 1994, BIOCHEM BIOPH RES CO, V205, P275, DOI 10.1006/bbrc.1994.2661; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; MOSTAD SB, 1993, J CHEM EDUC, V70, P504, DOI 10.1021/ed070p504; Niviere V, 1996, J BIOL CHEM, V271, P16656, DOI 10.1074/jbc.271.28.16656; Niviere V, 1998, BIOCHEMISTRY-US, V37, P11879, DOI 10.1021/bi980396f; Parry RJ, 1997, J BIOL CHEM, V272, P23303, DOI 10.1074/jbc.272.37.23303; RUDOLPH FB, 1979, METHOD ENZYMOL, V63, P139; Segel I.H., 1975, ENZYME KINETICS; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; TRIMBOLI AJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P48, DOI 10.1006/abbi.1994.1469; YUBISUI T, 1979, J BIOCHEM, V85, P719; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	39	36	38	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18252	18260		10.1074/jbc.274.26.18252	http://dx.doi.org/10.1074/jbc.274.26.18252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373427	Green Submitted, hybrid			2022-12-27	WOS:000081056700019
J	Rabbani, A; Iskandar, M; Ausio, J				Rabbani, A; Iskandar, M; Ausio, J			Daunomycin-induced unfolding and aggregation of chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRACYCLINE ANTIBIOTICS; DEOXYRIBONUCLEIC-ACID; EQUILIBRIUM BINDING; MOLECULAR-STRUCTURE; HISTONE TAILS; DNA-BINDING; NUCLEOSOMES; ADRIAMYCIN; DAUNORUBICIN; D(CPGPTPAPCPG)	Using equilibrium dialysis and sedimentation velocity analysis, we have characterized the binding of the antitumor drug daunomycin to chicken erythrocyte chromatin before and after depletion of linker histones and to its constitutive DNA under several ionic strengths (5, 25, and 75 mM NaCl), The equilibrium dialysis experiments reveal that the drug binds cooperatively to both the chromatin fractions and to the DNA counterpart within the range of ionic strength used in this study. A significant decrease in the binding affinity was observed at 75 mM NaCl, At any given salt concentration, daunomycin exhibits higher binding affinity for DNA than for linker histone-depleted chromatin or chromatin (in decreasing order). Binding of daunomycin to DNA does not significantly affect the sedimentation coefficient of the molecule. This is in contrast to binding to chromatin and to its linker histone depleted counterpart. In these instances, preferential binding of the drug to the linker DNA regions induces an unfolding of the chromatin fiber that is followed by aggregation, presumably because of histone-DNA interfiber interactions.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Tehran, Inst Biochem & Biophys, Tehran 14174, Iran	University of Victoria; University of Tehran	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						Arcamone F., 1981, DOXORUBICIN ANTICANC; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; BARCELO F, 1991, INT J BIOL MACROMOL, V13, P235; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CERA C, 1991, NUCLEIC ACIDS RES, V19, P2309, DOI 10.1093/nar/19.9.2309; Chaires J. B., 1996, ADV DNA SEQUENCE SPE, V2, P141; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P284, DOI 10.1021/bi00271a009; DIMARCO A, 1974, ANTIBIOTICS; DORIGOTTI L., 1964, TUMORI, V50, P117; DORR RT, 1982, CURRENT CONCEPTS USE, P1; FRITZSCHE H, 1987, BIOCHEMISTRY-US, V26, P1996, DOI 10.1021/bi00381a032; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GELVAN D, 1986, BIOCHEM PHARMACOL, V35, P3267, DOI 10.1016/0006-2952(86)90423-5; GRAVES DE, 1983, BIOCHEMISTRY-US, V22, P3941, DOI 10.1021/bi00285a033; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Krajewski WA, 1997, J BIOMOL STRUCT DYN, V14, P641, DOI 10.1080/07391102.1997.10508164; KRIEBARDIS T, 1987, J BIOL CHEM, V262, P12632; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Maniatis T., 1982, MOL CLONING; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; NEIDLE S, 1979, FEBS LETT, V107, P348, DOI 10.1016/0014-5793(79)80405-6; Neidle S, 1979, Prog Med Chem, V16, P151, DOI 10.1016/S0079-6468(08)70188-7; PEARLMAN LF, 1986, CANCER RES, V46, P341; PHILLIPS DR, 1989, FEBS LETT, V246, P233, DOI 10.1016/0014-5793(89)80289-3; QUIGLEY GJ, 1980, P NATL ACAD SCI-BIOL, V77, P7204, DOI 10.1073/pnas.77.12.7204; RABBANI A, 1994, GEN PHARMACOL-VASC S, V25, P787, DOI 10.1016/0306-3623(94)90261-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID CW, 1971, BIOPOLYMERS, V10, P883, DOI 10.1002/bip.360100511; SEN D, 1986, BIOCHEMISTRY-US, V25, P1503, DOI 10.1021/bi00355a005; TATCHELL K, 1979, BIOCHEMISTRY-US, V18, P2870, DOI 10.1021/bi00580a031; THOMAS JO, 1980, J MOL BIOL, V144, P89, DOI 10.1016/0022-2836(80)90215-6; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; YAGER TD, 1984, J BIOL CHEM, V259, P4212; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561; ZUNINO F, 1980, BIOCHIM BIOPHYS ACTA, V607, P206, DOI 10.1016/0005-2787(80)90073-8	44	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18401	18406		10.1074/jbc.274.26.18401	http://dx.doi.org/10.1074/jbc.274.26.18401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373446	hybrid			2022-12-27	WOS:000081056700038
J	Ame, JC; Rolli, V; Schreiber, V; Niedergang, C; Apiou, F; Decker, P; Muller, S; Hoger, T; Murcia, JMD; de Murcia, G				Ame, JC; Rolli, V; Schreiber, V; Niedergang, C; Apiou, F; Decker, P; Muller, S; Hoger, T; Murcia, JMD; de Murcia, G			PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSE); CATALYTIC DOMAIN; CDNA SEQUENCE; PROTEIN; REPAIR; PURIFICATION; BINDING; CELLS; OVERPRODUCTION; NUCLEAR	Poly(ADP-ribosylation) is a post-translational modification of nuclear proteins in response to DNA damage that activates the base excision repair machinery. Poly(ADP-ribose) polymerase which we will now call PARP-1, has been the only known enzyme of this type for over 30 years. Here, we describe a cDNA encoding a 62-kDa protein that shares considerable homology with the catalytic domain of PARP-1 and also contains a basic DNA-binding domain. We propose to call this enzyme poly(ADP-ribose) polymerase 2 (PARP-2). The PARP-2 gene maps to chromosome 14C1 and 14q11.2 in mouse and human, respectively, Purified recombinant mouse PARP-2 is a damaged DNA-binding protein in vitro and catalyzes the formation of poly(ADP-ribose) polymers in a DNA-dependent manner. PARP-2 displays automodification properties similar to PARP-1. The protein is localized in the nucleus in vivo and may account for the residual poly(ADP-ribose) synthesis observed in PARP-1-deficient cells, treated with alkylating agents or hydrogen peroxide.	Ecole Super Biotechnol Strasbourg, Lab Conventionne Commissariat Energie Atom, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France; Inst Curie Rech, UMR 147, F-75248 Paris, France; BASF AG, Pharmaceut Res, D-67056 Ludwigshafen, Germany; CNRS, UPR 9021, Inst Biol Mol & Cellulaire, F-67000 Strasbourg, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; BASF; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de Murcia, G (corresponding author), Ecole Super Biotechnol Strasbourg, Lab Conventionne Commissariat Energie Atom, CNRS, UPR 9003, Blvd Sebastien Brant, F-67400 Illkirch Graffenstaden, France.	demurcia@esbs.u-strasbg.fr	Schreiber, Valérie/M-5007-2016; Decker, Patrice/AAD-8624-2022; Muller, Sylviane/J-5319-2014	Schreiber, Valérie/0000-0003-0507-639X; Decker, Patrice/0000-0002-8155-2792				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN YM, 1994, EUR J BIOCHEM, V224, P135, DOI 10.1111/j.1432-1033.1994.tb20004.x; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; DANG CV, 1989, J BIOL CHEM, V264, P18019; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DURKACZ BW, 1981, EUR J BIOCHEM, V121, P65, DOI 10.1111/j.1432-1033.1981.tb06430.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Griesenbeck J, 1997, BIOCHEMISTRY-US, V36, P7297, DOI 10.1021/bi962710g; JUNG S, 1994, J MOL BIOL, V244, P114, DOI 10.1006/jmbi.1994.1709; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; KEITH G, 1990, ANAL BIOCHEM, V191, P309, DOI 10.1016/0003-2697(90)90224-W; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; Mahajan PB, 1998, PLANT PHYSIOL, V118, P895, DOI 10.1104/pp.118.3.895; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; Miranda EA, 1997, BRAZ J MED BIOL RES, V30, P923, DOI 10.1590/S0100-879X1997000800002; Miwa M, 1982, Princess Takamatsu Symp, V12, P205; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; OFARRELL M, 1995, BIOCHIMIE, V77, P486, DOI 10.1016/0300-9084(96)88165-X; Ruf A, 1998, J MOL BIOL, V278, P57, DOI 10.1006/jmbi.1998.1673; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879	46	578	620	1	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17860	17868		10.1074/jbc.274.25.17860	http://dx.doi.org/10.1074/jbc.274.25.17860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364231	hybrid			2022-12-27	WOS:000080974300067
J	Bauer, B; Mirey, G; Vetter, IR; Garcia-Ranea, JA; Valencia, A; Wittinghofer, A; Camonis, JH; Cool, RH				Bauer, B; Mirey, G; Vetter, IR; Garcia-Ranea, JA; Valencia, A; Wittinghofer, A; Camonis, JH; Cool, RH			Effector recognition by the small GTP-binding proteins Ras and Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PLATELET GN-PROTEINS; C-FOS PROMOTER; PUTATIVE EFFECTOR; ACTIVATING PROTEIN; EXCHANGE FACTOR; PHOSPHOLIPASE-D; INTERACTING DOMAIN; SYNAPTIC VESICLES; ESCHERICHIA-COLI	The Ral effector protein RLIP76 (also called RIP/RalBP1) binds to Ral GTP via a region that shares no sequence homology with the Ras-binding domains of the Ser/Thr kinase c-Raf-1 and the Ral-specific guanine nucleotide exchange factors. Whereas the Res-binding domains have a similar ubiquitin-like structure, the Ral-binding domain of RLIP was predicted to comprise a coiled-coil region. In order to obtain more information about the specificity and the structural mode of the interaction between Ral and RLIP, we have performed a sequence space and a mutational analysis. The sequence space analysis of a comprehensive nonredundant assembly of Ras-like proteins strongly indicated that positions 36 and 37 in the core of the effector region are tree-determinant positions for all subfamilies off Ras-like proteins and dictate the specificity of the interaction of these GTPases with their effector proteins. Indeed, we could convert the specific interaction with Ras effecters and RLIP by mutating these residues in Res and Ral. We therefore conclude that positions 36 and 37 are critical for the discrimination between Ras and Ral effecters and that, despite the absence of sequence homology between the Ral-binding and the Ras-binding domains, their mode of interaction is most probably similar.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany; Inst Curie, INSERM, U248, F-75248 Paris 05, France; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Prot Design Grp, M-28049 Madrid, Spain	Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Cool, RH (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	robbert.cool@mpi-dortmund.mpg.de	Valencia, Alfonso/I-3127-2015; Mirey, Gladys/H-5676-2019	Valencia, Alfonso/0000-0002-8937-6789; Mirey, Gladys/0000-0002-0095-1864; Cool, Robbert/0000-0002-9845-2202; Garcia Ranea, Juan Antonio/0000-0003-0327-1837				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDRADE MA, 1999, GENOME SEQUENCE ANAL; Atrian S, 1998, J MOL EVOL, V47, P211, DOI 10.1007/PL00006378; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; CASARI G, 1995, PROTEIN FOLD DISTANC, P124; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4830; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; FRECH M, 1990, J BIOL CHEM, V265, P6353; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Herberg JA, 1998, J MOL BIOL, V277, P839, DOI 10.1006/jmbi.1998.1637; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Murai H, 1997, J BIOL CHEM, V272, P10483; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; OLOFSSON B, 1988, ONCOGENE, V3, P231; Park SH, 1995, ONCOGENE, V11, P2349; Pazos F., 1997, BIOCOMPUTING EMERGEN, P132; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romero F, 1996, MOL CELL BIOL, V16, P37; Rose MD., 1990, METHODS YEAST GENETI; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schwartz MA, 1998, ONCOGENE, V17, P625, DOI 10.1038/sj.onc.1201977; Shirouzu M, 1998, J BIOL CHEM, V273, P7737, DOI 10.1074/jbc.273.13.7737; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	71	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17763	17770		10.1074/jbc.274.25.17763	http://dx.doi.org/10.1074/jbc.274.25.17763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364219	Green Published, hybrid			2022-12-27	WOS:000080974300055
J	Carballo, M; Conde, M; El Bekay, R; Martin-Nieto, J; Camacho, MJ; Monteseirin, J; Conde, J; Bedoya, FJ; Sobrino, F				Carballo, M; Conde, M; El Bekay, R; Martin-Nieto, J; Camacho, MJ; Monteseirin, J; Conde, J; Bedoya, FJ; Sobrino, F			Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; T-LYMPHOCYTES; CYTOKINE RECEPTORS; PHOSPHATASE INHIBITORS; DEPENDENT ACTIVATION; TRANSCRIPTION FACTOR; PHENYLARSINE OXIDE; HYDROGEN-PEROXIDE; INTERFERON-GAMMA	Oxidizing agents are powerful activators of factors responsible for the transcriptional activation of cytokine-encoding genes involved in tissue injury. In this study we show evidence that STAT3 is a transcription factor whose activity is modulated by H2O2 in human lymphocytes, in which endogenous catalase had previously been inhibited. H2O2-induced nuclear translocation of STAT3 to form sequence-specific DNA-bound complexes was evidenced by immunoblotting of nuclear fractions and electrophoretic mobility shift assays, and vanadate was found to strongly synergize with H2O2. Moreover, anti-STAT3 antibodies specifically precipitated a protein of 92 kDa that becomes phosphorylated on tyrosine upon lymphocyte treatment with H2O2. Phenylarsine oxide, a tyrosine phosphatase inhibitor, and genistein, a tyrosine kinase inhibitor, cooperated and cancelled, respectively, the H2O2-promoted STAT3 nuclear translocation, Evidence is also presented, using Fe2+/Cu2+ ions, that 'OH generated from H2O2 through Fenton reactions could be a candidate oxygen reactive species to directly activate STAT3, Present data suggest that H2O2 and vanadate are likely to inhibit the activity of intracellular tyrosine phosphatase(s), leading to enhanced STAT3 tyrosine phosphorylation and hence its translocation to the nucleus, These results demonstrate that the DNA binding activity of STAT3 can be modulated by oxidizing agents and provide a framework to understand the effects of oxidative stress on the JAK-STAT signaling pathway.	Univ Seville, Hosp Virgen Macarena, Dept Bioquim Med & Biol Mol, Fac Med, E-41009 Seville, Spain; Univ Seville, Hosp Virgen Macarena, Dept Med, Serv Reg Inmunol & Alergia, E-41009 Seville, Spain; Univ Alicante, Div Genet, E-03080 Alicante, Spain	Hospital Universitario Virgen Macarena; University of Sevilla; Hospital Universitario Virgen Macarena; University of Sevilla; Universitat d'Alacant	Sobrino, F (corresponding author), Fac Med, Dept Bioquim Med & Biol Mol, Avda Sanchex Pizjuan 4, Seville 41009, Spain.	fsobrino@cica.es	Bedoya, Francisco J/R-4871-2018; Bedoya, Francisco/AAX-8812-2021; Bekay, Rajaa El/AAZ-3959-2020; MARTÍN-NIETO, JOSÉ/R-5428-2018; El Bekay, RAJAA/AGN-6069-2022	Bedoya, Francisco J/0000-0003-0262-7029; Bedoya, Francisco/0000-0003-0262-7029; MARTÍN-NIETO, JOSÉ/0000-0002-7815-6887; El Bekay, RAJAA/0000-0003-3332-3431; Sobrino, Francisco/0000-0002-4503-5739				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Coligan J.E., 1993, CURRENT PROTOCOLS IM; CROSS AR, 1989, NEUTROPHIL CELLULAR, P97; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLESCHER E, 1994, J IMMUNOL, V153, P4880; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GUNTHER MR, 1995, ARCH BIOCHEM BIOPHYS, V316, P515, DOI 10.1006/abbi.1995.1068; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Jornot L, 1998, BIOCHEM J, V335, P85, DOI 10.1042/bj3350085; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; Liu BQ, 1996, J IMMUNOL, V157, P160; NAKAMURA K, 1993, ONCOGENE, V8, P3133; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STONE RL, 1994, J BIOL CHEM, V269, P31323; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	57	218	224	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17580	17586		10.1074/jbc.274.25.17580	http://dx.doi.org/10.1074/jbc.274.25.17580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364193	hybrid, Green Published			2022-12-27	WOS:000080974300029
J	Hecht, A; Litterst, CM; Huber, O; Kemler, R				Hecht, A; Litterst, CM; Huber, O; Kemler, R			Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; ACIDIC ACTIVATION DOMAINS; RNA-POLYMERASE-II; XENOPUS EMBRYOS; AXIS SPECIFICATION; FACTOR-TFIIB; IN-VITRO; DROSOPHILA; ARMADILLO; PLAKOGLOBIN	beta-Catenin, a member of the family of Armadillo repeat proteins, plays a dual role in cadherin-mediated cell adhesion and in signaling by Wnt growth factors, Upon Wnt stimulation beta-catenin undergoes nuclear translocation and serves as transcriptional coactivator of T cell factor DNA-binding proteins. Previously the transactivation potential of different portions of beta-catenin has been demonstrated, but the precise location of transactivating elements has not been established. Also, the mechanism of transactivation by beta-catenin and the molecular basis for functional differences between beta-catenin and the closely related proteins Armadillo and Plakoglobin are poorly understood. Here we have used a yeast system for the detailed characterization of the transactivation properties of beta-catenin. We show that its transactivation domains possess a modular structure, consist of multiple subelements that cover broad regions at its N and C termini, and extend considerably into the Armadillo repeat region. Compared with beta-catenin the N termini of Plakoglobin and Armadillo have different transactivation capacities that may explain their distinct signaling properties. Furthermore, transactivating elements of beta-catenin interact specifically and directly with the TATA-binding protein in vitro providing further evidence that a major function of beta-catenin during Wnt signaling is to recruit the basal transcription machinery to promoter regions of Wnt target genes.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Max Planck Society	Hecht, A (corresponding author), Max Planck Inst Immunobiol, Stuebeweg 51, D-79108 Freiburg, Germany.	hecht@immunbio.mpg.de	Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747; Hecht, Andreas/0000-0003-2262-2575				ABERLE H, 1994, J CELL SCI, V107, P3655; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bierkamp C, 1999, DEVELOPMENT, V126, P371; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLEY JR, 1995, DNA CLONING PRACTICA, P169; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; Kobayashi N, 1998, MOL CELL BIOL, V18, P4023, DOI 10.1128/MCB.18.7.4023; Kofron M, 1997, DEVELOPMENT, V124, P1553; Laurent MN, 1997, DEVELOPMENT, V124, P4905; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	66	154	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18017	18025		10.1074/jbc.274.25.18017	http://dx.doi.org/10.1074/jbc.274.25.18017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364252	hybrid			2022-12-27	WOS:000080974300088
J	Kaliman, P; Canicio, J; Testar, X; Palacin, M; Zorzano, A				Kaliman, P; Canicio, J; Testar, X; Palacin, M; Zorzano, A			Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappa B and inducible nitric-oxide synthase define a common myogenic signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; TRANSCRIPTION FACTOR; DNA-BINDING; MYOBLAST DIFFERENTIATION; S6 KINASE; IGF-I; EXPRESSION; ACTIVATION; ALPHA	Insulin-like growth factors (IGFs) are potent inducers of skeletal muscle differentiation and plnosphatidylinositol (PI) 3-kinase activity is essential for this process. Here we show that IGF-II induces nuclear factor-kappa B (NF-kappa B) and nitric-oxide synthase (NOS) activities downstream from PI 3-kinase and that these events are critical for myogenesis. Differentiation of rat L6E9 myoblasts with IGF-II transiently induced NF-kappa B DNA binding activity, inducible nitric-oxide synthase (iNOS) expression, and nitric oxide (NO) production. IGF-II-induced iNOS expression and NO production were blocked by NF-kappa B inhibition. Both NF-kappa B and NOS activities were essential for IGF-II-induced terminal differentiation (myotube formation and expression of skeletal muscle proteins: myosin heavy chain, GLUT 4, and caveolin 3), which was totally blocked by NF-kappa B or NOS inhibitors in rat and human myoblasts. Moreover, the NOS substrate L-Arg induced myogenesis in the absence of IGFs in both rat and human myoblasts, and this effect was blocked by NOS inhibition. Regarding the mechanisms involved in IGF-II activation of NF-kappa B, PI S-kinase inhibition prevented NF-kappa B activation, iNOS expression, and NO production. Moreover, IGF-II induced, through a PI 3-kinase-dependent pathway, a decrease in I kappa B-alpha protein content that correlated with a decrease in the amount of I kappa B-alpha associated with p65 NF-kappa B.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Kaliman, P (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avinguda Diagonal 645, E-08028 Barcelona, Spain.		Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015	Palacin, Manuel/0000-0002-8670-293X				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BRENMAN JE, 1995, CELL, V82, P742; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; Canicio J, 1998, ENDOCRINOLOGY, V139, P5042, DOI 10.1210/en.139.12.5042; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GUO K, 1995, MOL CELL BIOL, V15, P3823; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LEE KH, 1994, J BIOL CHEM, V269, P14371; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PUJADES C, 1992, J CELL SCI, V102, P815; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	105	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17437	17444		10.1074/jbc.274.25.17437	http://dx.doi.org/10.1074/jbc.274.25.17437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364173	hybrid			2022-12-27	WOS:000080974300009
J	Monick, MM; Carter, AB; Hunninghake, GW				Monick, MM; Carter, AB; Hunninghake, GW			Human alveolar macrophages are markedly deficient in REF-1 and AP-1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-2; INTERSTITIAL LUNG-DISEASE; BLOOD MONOCYTES; ARACHIDONATE METABOLISM; TRANSCRIPTION FACTOR; MESSENGER-RNA; PROTEIN; EXPRESSION; FOS; JUN	Although many functions of human alveolar macrophages are altered compared with their precursor cell, the blood monocyte (monocyte), the reason(s) for these functional changes have not been determined. We recently reported that human alveolar macrophages do not express AP-1 DNA binding activity (Monick, M. RI., Carter, A B., Gudmundsson, G;., Geist, L, J,, and Hunninghake, G;. W, (1998) Am, J, Physiol, 275, L389-L397). To determine why alveolar macrophages do not express AP-1 DNA binding activity, we first showed that there was not a decrease in expression of the FOS and JUN proteins that make up the AP-1 complex. There was, however, a significant difference in the amounts of the nuclear protein, REF-1 (which regulates AP-1 DNA: binding by altering the redox status of FOS and JUN proteins), in alveolar macrophages compared with monocytes, In addition, in vitro differentiation of monocytes to a macrophage-like cell resulted in decreased amounts of REF-1, Finally, addition of REF-1 from activated monocytes to alveolar macrophage nuclear proteins resulted in a marked increase in AP-1 DNA binding, These studies strongly suggest that the process of differentiation of monocytes into alveolar macrophages is associated with a loss of REF-1 and AP-1 activity. This observation may explain, in part, some of the functional differences observed for alveolar macrophages compared with monocytes.	Univ Iowa, Coll Med, Dept Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Hunninghake, GW (corresponding author), Univ Iowa Hosp & Clin, Div Pulm, Rm 100 EMRB,200 Hawkins Dr, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL-03860, HL-37121] Funding Source: Medline; NIAID NIH HHS [AI-35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; BALTER MS, 1989, J IMMUNOL, V142, P602; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Bingisser P, 1996, AM J RESP CELL MOL, V15, P64, DOI 10.1165/ajrcmb.15.1.8679223; BROWN GP, 1988, AM J PHYSIOL, V254, pC809, DOI 10.1152/ajpcell.1988.254.6.C809; CAMPBELL DA, 1986, THORAX, V41, P429, DOI 10.1136/thx.41.6.429; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; ELIAS JA, 1985, J IMMUNOL, V135, P3198; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fung H, 1998, CANCER RES, V58, P189; Geist LJ, 1997, AM J RESP CELL MOL, V16, P31, DOI 10.1165/ajrcmb.16.1.8998076; Gillardon F, 1997, MOL BRAIN RES, V52, P194, DOI 10.1016/S0169-328X(97)00237-4; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HEMPEL SL, 1994, J BIOL CHEM, V269, P32979; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOOGSTEDEN HC, 1989, CHEST, V95, P574, DOI 10.1378/chest.95.3.574; Hopkins HA, 1995, AM J PHYSIOL-LUNG C, V269, pL849, DOI 10.1152/ajplung.1995.269.6.L849; Hopkins HA, 1996, J INFECT DIS, V174, P69, DOI 10.1093/infdis/174.1.69; HUNNINGHAKE GW, 1986, ANN NY ACAD SCI, V465, P82, DOI 10.1111/j.1749-6632.1986.tb18483.x; HUNNINGHAKE GW, 1980, METHOD CELL BIOL, P95; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLINE JN, 1993, CHEST, V104, P47, DOI 10.1378/chest.104.1.47; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; MONICK M, 1987, AM REV RESPIR DIS, V135, P72; Monick MM, 1998, AM J PHYSIOL-LUNG C, V275, pL389, DOI 10.1152/ajplung.1998.275.2.L389; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P4320; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Rothwell DG, 1997, ONCOL RES, V9, P275; STRIETER RM, 1990, AM J RESP CELL MOL, V2, P321, DOI 10.1165/ajrcmb/2.4.321; Suzuki S, 1998, BIOCHEM MOL BIOL INT, V44, P217; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	38	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18075	18080		10.1074/jbc.274.25.18075	http://dx.doi.org/10.1074/jbc.274.25.18075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364260	hybrid			2022-12-27	WOS:000080974300096
J	Ireton, K; Payrastre, B; Cossart, P				Ireton, K; Payrastre, B; Cossart, P			The Listeria monocytogenes protein InlB is an agonist of mammalian phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FOCAL ADHESION KINASE; ACTIN-BASED MOVEMENT; PHOSPHATIDYLINOSITOL 3-KINASE; EGF-RECEPTOR; SURFACE PROTEIN; CELLS; ENTRY; ACTIVATION; INTERNALIN	The Gram-positive pathogen Listeria monocytogenes induces its own internalization into some non-phagocytic mammalian cells by stimulating host tyrosine phosphorylation, phosphoinositide (PI) 3-kinase activity, and rearrangements in the actin cytoskeleton, Entry into many cultured cell lines is mediated by the bacterial protein In1B, Here we investigate the role of In1B in regulating mammalian signal transduction and cytoskeletal structure. Treatment of Vero cells with purified In1B caused rapid and transient increases in the lipid products of the PI 3-kinase p85-p110, tyrosine phosphorylation of the mammalian adaptor proteins Gab1, Chi, and Shc, and association of these proteins with p85. In1B also stimulated large scale changes in the actin cytoskeleton(membrane ruffling), which were PIS-kinase-dependent. These results identify In1B as the first reported non-mammalian agonist of PI 3-kinase and demonstrate similarities in the signal transduction events elicited by this bacterial protein and known agonists such as epidermal growth factor.	Unite Interact Bacteries Cellules, F-75724 Paris 15, France; Hop Purpan, INSERM U326, F-31059 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cossart, P (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.			, Bernard/0000-0002-8693-0190				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Braun L, 1998, MOL MICROBIOL, V27, P1077, DOI 10.1046/j.1365-2958.1998.00750.x; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DRAMSI S, 1997, INFECT IMMUN, V65, P1616; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; Gaillard JL, 1996, J EXP MED, V183, P359, DOI 10.1084/jem.183.2.359; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERZOG M, 1994, CELL BIOL LAB HDB, P355; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ireton K, 1997, ANNU REV GENET, V31, P113, DOI 10.1146/annurev.genet.31.1.113; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINGNAU A, 1995, INFECT IMMUN, V63, P3896, DOI 10.1128/IAI.63.10.3896-3903.1995; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; NOBES CD, 1995, J CELL SCI, V108, P225; Parida SK, 1998, MOL MICROBIOL, V28, P81, DOI 10.1046/j.1365-2958.1998.00776.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; Sheehan B, 1996, MOL MICROBIOL, V20, P785, DOI 10.1111/j.1365-2958.1996.tb02517.x; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	38	143	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17025	17032		10.1074/jbc.274.24.17025	http://dx.doi.org/10.1074/jbc.274.24.17025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358053	hybrid			2022-12-27	WOS:000080780400052
J	Brix, J; Rudiger, S; Bukau, B; Schneider-Mergener, J; Pfanner, N				Brix, J; Rudiger, S; Bukau, B; Schneider-Mergener, J; Pfanner, N			Distribution of binding sequences for the mitochondrial import receptors Tom20, Tom22, and Tom70 in a presequence-carrying preprotein and a non-cleavable preprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC DIHYDROFOLATE-REDUCTASE; OUTER-MEMBRANE PROTEIN; ADP-ATP CARRIER; 12 AMINO-ACIDS; INNER MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; TARGETING SIGNAL; ADP/ATP CARRIER	Preproteins destined for mitochondria either are synthesized with amino-terminal signal sequences, termed presequences, or possess internal targeting information within the protein. The preprotein translocase of the outer mitochondrial membrane (designated Tom) contains specific import receptors. The cytosolic domains of three import receptors, Tom20, Tom22, and Tom70, have been shown to interact with preproteins. Little is known about the internal targeting information in preproteins and the distribution of binding sequences for the three import receptors, We have studied the binding of the purified cytosolic domains of Tom20, Tom22, and Tom70 to cellulose-bound peptide scans derived from a presequence-carrying cleavable preprotein, cytochrome c oxidase subunit IV, and a non-cleavable preprotein with internal targeting information, the phosphate carrier. All three receptor domains are able to bind efficiently to linear 13-mer peptides, yet with different specificity. Tom20 preferentially binds to presequence segments of subunit IV. Tom22 binds to segments corresponding to the carboxyl-terminal part of the presequence and the amino-terminal part of the mature protein. Tom70 does not bind efficiently to any region of subunit IV. In contrast, Tom70 and Tom20 bind to multiple segments within the phosphate carrier, yet the amino-terminal region is excluded. Both charged and uncharged peptides derived from the phosphate carrier show specific binding properties for Tom70 and Tom20, indicating that charge is not a critical determinant of internal targeting sequences. This feature contrasts with the crucial role of positively charged amino acids in presequences. Our results demonstrate that linear peptide segments of preproteins can serve as binding sites for all three receptors with differential specificity and imply different mechanisms for translocation of cleavable and non-cleavable preproteins.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany	University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Rüdiger, Stefan GD/G-4906-2012; Pfanner, Nikolaus/AAV-7878-2021	Rüdiger, Stefan GD/0000-0002-1807-2972; Bukau, Bernd/0000-0003-0521-7199				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELMOUALIJ B, 1997, YEAST, V13, P578; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; Kramer A, 1998, METH MOL B, V87, P25; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Ryan MT, 1998, BIOL CHEM, V379, P289; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13052, DOI 10.1021/bi980746y; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x	68	187	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16522	16530		10.1074/jbc.274.23.16522	http://dx.doi.org/10.1074/jbc.274.23.16522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347216	hybrid			2022-12-27	WOS:000080668600076
J	Alvarez, M; Wouters, J; Maes, D; Mainfroid, V; Rentier-Delrue, F; Wyns, L; Depiereux, E; Martial, JA				Alvarez, M; Wouters, J; Maes, D; Mainfroid, V; Rentier-Delrue, F; Wyns, L; Depiereux, E; Martial, JA			Lys(13) plays a crucial role in the functional adaptation of the thermophilic triose-phosphate isomerase from Bacillus stearothermophilus to high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THERMOTOGA-MARITIMA; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; PHOSPHOGLYCERATE KINASE; ASPARAGINE RESIDUES; ANGSTROM RESOLUTION; PROTEIN STABILITY; ESCHERICHIA-COLI	The thermophilic triose-phosphate isomerases (TIMs) of Bacillus stearothermophilus (bTIM) and Thermotoga maritima (tTIM) have been found to possess a His(12)- Lys(13) pair instead of the Asn(12)-Gly(13) pair normally present in mesophilic TIMs. His(12) in bTIM was proposed to prevent deamidation at high temperature, while the precise role of Lys(13) is unknown. To investigate the role of the His(12) and Lys(13) pair in the enzyme's thermoadaptation, we reintroduced the "mesophilic residues" Asn and Gly into both thermophilic TIMs. Neither double mutant displayed diminished structural stability, but the bTIM double mutant showed drastically reduced catalytic activity. No similar behavior was observed with the tTIM double mutant, suggesting that the presence of the His(12) and Lys(13) cannot be systematically correlated to thermoadaptation in TIMs, We determined the crystal structure of the bTIM double mutant complexed with 2-phosphoglycolate to 2,4-Angstrom resolution. A molecular dynamics simulation showed that upon substitution of Lys(13) to, Gly an increase of the flexibility of loop 1 is observed, causing an incorrect orientation of the catalytic Lys(10). This suggests that Lys(13) in bTIM plays a crucial role in the functional adaptation of this enzyme to high temperature. Analysis of bTIM single mutants supports this assumption.	Univ Liege, Lab Biol Mol & Genie Genet, B-4000 Liege, Belgium; Fac Univ Notre Dame Paix, Lab Biol Mol Struct, B-5000 Namur, Belgium; Free Univ Brussels VIB, Ultrastruct Unit, B-1640 Rhode St Genese, Belgium	University of Liege; University of Namur; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Martial, JA (corresponding author), Univ Liege, Lab Biol Mol & Genie Genet, B6, B-4000 Liege, Belgium.	jmartial@ulg.ac.be		Wouters, Johan/0000-0002-4920-6857				AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; Alvarez M, 1998, J BIOL CHEM, V273, P2199, DOI 10.1074/jbc.273.4.2199; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASAL JI, 1987, BIOCHEMISTRY-US, V26, P1258, DOI 10.1021/bi00379a009; CHEN HM, 1994, BIOCHEM J, V301, P275, DOI 10.1042/bj3010275; DELBONI LF, 1995, PROTEIN SCI, V4, P2594, DOI 10.1002/pro.5560041217; FAHEY RC, 1971, BIOCHEM J, V124, pP77, DOI 10.1042/bj1240077P; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Gebbia JA, 1997, GENE, V188, P221, DOI 10.1016/S0378-1119(96)00811-6; GRACY RW, 1983, ALTERED PROTEINS AGI, P27; Grattinger M, 1998, J MOL BIOL, V280, P525, DOI 10.1006/jmbi.1998.1861; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMAL M, 1995, FEBS LETT, V374, P363, DOI 10.1016/0014-5793(95)01145-5; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; LEYVAVAZQUEZ MA, 1994, J BACTERIOL, V176, P3903, DOI 10.1128/JB.176.13.3903-3910.1994; LHOIR C, 1990, GENE, V89, P47, DOI 10.1016/0378-1119(90)90204-5; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; Maldonado E, 1998, J MOL BIOL, V283, P193, DOI 10.1006/jmbi.1998.2094; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MCCARTHY DJ, 1994, BIOCHEMISTRY-US, V33, P2815; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; NOBLE MEM, 1993, ACTA CRYSTALLOGR D, V49, P403, DOI 10.1107/S0907444993002628; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; Pfeil W, 1997, J MOL BIOL, V272, P591, DOI 10.1006/jmbi.1997.1278; Pfeil W., 1998, PROTEIN STABILITY FO; RENTIERDELRUE F, 1993, J MOL BIOL, V229, P85, DOI 10.1006/jmbi.1993.1010; Rice DW, 1996, FEMS MICROBIOL REV, V18, P105; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL RJM, 1995, CURR OPIN BIOTECH, V6, P370, DOI 10.1016/0958-1669(95)80064-6; SCHURIG H, 1995, EMBO J, V14, P442, DOI 10.1002/j.1460-2075.1995.tb07020.x; Shimizu T, 1997, INT J BIOCHEM CELL B, V29, P303, DOI 10.1016/S1357-2725(96)00088-X; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Tomizawa H, 1995, PROTEIN ENG, V8, P1023, DOI 10.1093/protein/8.10.1023; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Velanker SS, 1997, STRUCTURE, V5, P751, DOI 10.1016/S0969-2126(97)00230-X; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; Williams JC, 1999, PROTEIN ENG, V12, P243, DOI 10.1093/protein/12.3.243; Wouters J, 1998, PROTEIN SCI, V7, P2472, DOI 10.1002/pro.5560071127; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	60	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19181	19187		10.1074/jbc.274.27.19181	http://dx.doi.org/10.1074/jbc.274.27.19181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383424	hybrid			2022-12-27	WOS:000081196300047
J	Kawauchi, S; Takahashi, S; Nakajima, O; Ogino, H; Morita, M; Nishizawa, M; Yasuda, K; Yamamoto, M				Kawauchi, S; Takahashi, S; Nakajima, O; Ogino, H; Morita, M; Nishizawa, M; Yasuda, K; Yamamoto, M			Regulation of lens fiber cell differentiation by transcription factor c-Maf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CRYSTALLIN GENE; TISSUE-SPECIFIC EXPRESSION; ENHANCER ELEMENT; ENCODES; BINDING; MOUSE; RAT; DELTA-1-CRYSTALLIN; SEQUENCES; PROMOTER	To elucidate the regulatory mechanisms underlying lens development, we searched for members of the large Maf family, which are expressed in the mouse lens, and found three, c-Maf, MafB, and Nrl. Of these, the earliest factor expressed in the lens was c-Maf. The expression of c-Maf was most prominent in lens fiber cells and persisted throughout lens development. To examine the functional contribution of c-Maf to lens development, we isolated genomic clones encompassing the murine c-maf gene and carried out its targeted disruption. Insertion of the beta-galactosidase (lacZ) gene into the c-maf locus allowed visualization of c-Maf accumulation in heterozygous mutant mice by staining for LacZ activity. Homozygous mutant embryos and newborns lacked normal lenses. Histological examination of these mice revealed defective differentiation of lens fiber cells. The expression of crystallin genes was severely impaired in the c-maf-null mutant mouse lens. These results demonstrate that c-Maf is an indispensable regulator of lens differentiation during murine development.	Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Bunkyo Ku, Tokyo 1138549, Japan; Scripps Res Inst, La Jolla, CA 92037 USA; Nara Inst Sci & Technol, Ikoma 6300101, Japan	University of Tsukuba; University of Tsukuba; Tokyo Medical & Dental University (TMDU); Scripps Research Institute; Nara Institute of Science & Technology	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr TARA, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.		Ogino, Hajime/G-5279-2019; Yamamoto, Masayuki/A-4873-2010; Warfield, Simon/B-3352-2009	Ogino, Hajime/0000-0003-2707-2330; Yamamoto, Masayuki/0000-0002-9073-9436; Warfield, Simon/0000-0002-7659-3880				CARTIER M, 1992, NAT GENET, V2, P42, DOI 10.1038/ng0992-42; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Eichmann A, 1997, MECH DEVELOP, V65, P111, DOI 10.1016/S0925-4773(97)00063-4; FUNAHASHI J, 1991, NUCLEIC ACIDS RES, V19, P3543, DOI 10.1093/nar/19.13.3543; GINO H, 1998, SCIENCE, V280, P115; Graw J, 1997, BIOL CHEM, V378, P1331; HERIQUE D, 1995, NATURE, V375, P787; HOGAN B, 1994, MANIPULATING MOUSE E, P277; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Liu Q, 1996, ONCOGENE, V12, P207; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murata T, 1998, GENES CELLS, V3, P443, DOI 10.1046/j.1365-2443.1998.00204.x; MUTHUKKARUPPAN V, 1965, J EXP ZOOL, V159, P269, DOI 10.1002/jez.1401590210; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; ODA SI, 1980, EXP EYE RES, V31, P673, DOI 10.1016/S0014-4835(80)80051-0; OsumiYamashita N, 1997, DEV GROWTH DIFFER, V39, P53; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; SAX CM, 1993, NUCLEIC ACIDS RES, V21, P2633, DOI 10.1093/nar/21.11.2633; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; YAMAMOTO M, 1991, J BIOL CHEM, V266, P3317; YASUDA K, 1986, STRUCTURE EXPRESSION, P183; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	31	196	199	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19254	19260		10.1074/jbc.274.27.19254	http://dx.doi.org/10.1074/jbc.274.27.19254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383433	Green Submitted, hybrid			2022-12-27	WOS:000081196300056
J	Lin, S; Na, CL; Akinbi, HT; Apsley, KS; Whitsett, JA; Weaver, TE				Lin, S; Na, CL; Akinbi, HT; Apsley, KS; Whitsett, JA; Weaver, TE			Surfactant protein B (SP-B) -/- mice are rescued by restoration of SP-B expression in alveolar type II cells but not Clara cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; SECRETORY PROTEIN; STRUCTURAL REQUIREMENTS; NATURAL SURFACTANT; HUMAN-LUNG; IN-VIVO; GENE; LOCALIZATION; BRONCHIOLAR; DEFICIENCY	Surfactant protein B (SP-B) mRNA and protein are restricted to alveolar Type II and Clara cells in the respiratory epithelium. In order to investigate the function of SP-B in these distinct cell types, transgenic mice were generated in which SP-B expression was selectively restored in Type II cells or Clara cells of SP-B -/- mice. The 4.8-kilobase murine SP-C promoter was used to generate 3 transgenic lines which expressed human SP-B in Type II cells (mSP-C/hSP-B). Likewise, the 2.3-kilobase murine CCSP promoter was used to generate two transgenic lines which expressed human SP-B in Clara cells (mCCSP/hSP-B). mSP-C/hSP-B and mCCSP/hSP-B transgenic mice were subsequently bred to SP-B +/- mice in order to selectively express SP-B in Type II cells or Clara cells of SP-B -/- mice. Selective restoration of SP-B expression in Type II cells completely rescued the neonatal lethal phenotype in SP-B -/- mice. Expression of SP-B in some, but not all Type II cells of SP-B -/- mice, allowed postnatal survival, but resulted in significantly altered lung architecture and function. Selective restoration of SP-B expression in Clara cells of SP-B -/- mice resulted in respiratory dysfunction and invariable neonatal death, related to the complete absence of mature SP-B peptide in these mice. These results indicate that expression and processing of the SP-B proprotein to the mature peptide in Type II cells is absolutely required for lung function in vivo and that SP-B expression in Clara cells cannot substitute for this function.	Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Weaver, TE (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL056285, R01HL036055, R01HL056285] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56285, HL56285-S, HL36055] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V12, pL381; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DEMELLO DE, 1994, AM J RESP CELL MOL, V11, P230, DOI 10.1165/ajrcmb.11.2.8049084; ENHORNING G, 1995, AM J RESP CRIT CARE, V151, P554, DOI 10.1164/ajrccm.151.2.7842219; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; HAMVAS A, 1994, J PEDIATR-US, V125, P356, DOI 10.1016/S0022-3476(05)83276-7; HAWGOOD S, 1993, AM J PHYSIOL, V264, pL290, DOI 10.1152/ajplung.1993.264.3.L290; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MIZUNO K, 1995, PEDIATR RES, V37, P271, DOI 10.1203/00006450-199503000-00004; NOGEE LM, 1991, AM J RESP CELL MOL, V4, P102, DOI 10.1165/ajrcmb/4.2.102; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1987, J HISTOCHEM CYTOCHEM, V35, P1339, DOI 10.1177/35.11.3309049; PINKERTON KE, 1994, J APPL PHYSIOL, V77, P1953, DOI 10.1152/jappl.1994.77.4.1953; PLOPPER CG, 1983, AM REV RESPIR DIS, V128, pS37; PLOPPER CG, 1980, EXP LUNG RES, V1, P139, DOI 10.3109/01902148009069644; REVAK SD, 1988, J CLIN INVEST, V81, P826, DOI 10.1172/JCI113391; RIDER ED, 1993, AM REV RESPIR DIS, V147, P669, DOI 10.1164/ajrccm/147.3.669; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; STRIPP BR, 1994, GENOMICS, V20, P27, DOI 10.1006/geno.1994.1123; TOKIEDA K, 1999, IN PRESS AM J RESP C; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	36	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19168	19174		10.1074/jbc.274.27.19168	http://dx.doi.org/10.1074/jbc.274.27.19168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383422	hybrid			2022-12-27	WOS:000081196300045
J	Chapman, SC; Ayala, JE; Streeper, RS; Culbert, AA; Eaton, EM; Svitek, CA; Goldman, JK; Tavare, JM; O'Brien, RM				Chapman, SC; Ayala, JE; Streeper, RS; Culbert, AA; Eaton, EM; Svitek, CA; Goldman, JK; Tavare, JM; O'Brien, RM			Multiple promoter elements are required for the stimulatory effect of insulin on human collagenase-1 gene transcription - Selective effects on activator protein-1 expression may explain the quantitative difference in insulin and phorbol ester action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; MATRIX METALLOPROTEINASES; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PROLACTIN GENE; KINASE-C; 5'-FLANKING REGION; TISSUE INHIBITORS; DIABETES-MELLITUS; RESPONSE ELEMENT; MESANGIAL CELLS	Several of the complications seen in patients with both type I and type II diabetes mellitus are associated with alterations in the expression of matrix metalloproteinases. To identify the cis-acting elements that mediate the stimulatory effect of insulin on collagenase-1 (matrix metalloproteinase-1) gene transcription a series of collagenase-chloramphenicol acetyltransferase (CAT) fusion genes were transiently transfected into HeLa cells, Multiple promoter elements, including an Ets and activator protein-1 (AP-1) motif, were required for the effect of insulin. The AP-1 motif appears to be a target for insulin signaling because it is sufficient to mediate an effect of insulin on the expression of a heterologous fusion gene, whereas the data suggest that the Ets motif acts to enhance the effect of insulin mediated through the AP-1 motif. Multiple promoter elements were also required for the stimulatory effect of phorbol esters on collagenase-CAT gene transcription, and the AP-1 motif was also a target for phorbol ester signaling. However, the cis-acting elements required for the effects of insulin and phorbol esters were not identical. Moreover, phorbol esters were a much more potent inducer of collagenase-CAT gene transcription than insulin, a difference that may be explained by selective effects of insulin and phorbol esters on AP-1 expression.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Vanderbilt University; University of Bristol	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 761 MRB 2, Nashville, TN 37232 USA.			Tobin, Stacey/0000-0003-1674-9844	NIDDK NIH HHS [R01 DK52820] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052820] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1994, J AM SOC NEPHROL, V5, P1165; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARNQVIST HJ, 1988, AM J PHYSIOL, V254, pC411, DOI 10.1152/ajpcell.1988.254.3.C411; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BASAYEAUX JP, 1997, J BIOL CHEM, V272, P26188; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jiang Zhen Y., 1996, P719; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NAKAMURA T, 1994, RENAL PHYSIOL BIOCH, V17, P316; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OEMAR BS, 1991, J BIOL CHEM, V266, P2369; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Reaven GM, 1997, AM J KIDNEY DIS, V30, P928, DOI 10.1016/S0272-6386(97)90106-2; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SCHLEICHER ED, 1992, EUR J CLIN CHEM CLIN, V30, P635; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SHEHADEH A, 1995, CLIN CARDIOL, V18, P301, DOI 10.1002/clc.4960180604; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231	56	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18625	18634		10.1074/jbc.274.26.18625	http://dx.doi.org/10.1074/jbc.274.26.18625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373474	hybrid			2022-12-27	WOS:000081056700066
J	Fucini, RV; Okada, S; Pessin, JE				Fucini, RV; Okada, S; Pessin, JE			Insulin-induced desensitization of extracellular signal-regulated kinase activation results from all inhibition of Raf activity independent of Ras activation and dissociation of the Grb2-SOS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; SON-OF-SEVENLESS; PROTEIN-KINASE; ADAPTER PROTEIN; P21(RAS) DESENSITIZATION; DEPENDENT ACTIVATION; SOS-GRB2 COMPLEX; GROWTH-FACTORS; SH3 DOMAINS	Previous studies have suggested that the interaction between the small adaptor protein Grb2 with the Ras guanyl nucleotide exchange factor SOS is functionally important in the regulation of the Ras activation/inactivation cycle. To examine the relationship between the Grb2-SOS complex and Ras activation, we observed that insulin stimulation results in a rapid but transient activation of Ras and the extracellular-signal regulated kinase (ERK) followed by dissociation of the Grb2-SOS complex. Although treatment with the phorbol myristate acetate resulted in ERK activation and complete dissociation of the Grb2-SOS complex, there was no effect on subsequent insulin-stimulated Ras activation. Similarly, insulin stimulation followed by insulin removal resulted in a time-dependent restoration of the Grb2-SOS complex but which was significantly slower than the recovery of insulin-stimulated Ras activation. In addition, although insulin was able to activate Ras under these conditions, there was a complete desensitization of Raf and ERK activation. This apparent homologous desensitization of insulin action was specific for Raf and ERK as the insulin re-stimulation of insulin receptor autophosphorylation and protein kinase B activation were unaffected. Together, these data demonstrate the presence of a pathway independent of the Grb2-SOS complex that can lead to Ras activation but that the desensitization of Raf accounts for the homologous desensitization of ERK.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823, R01DK049781] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49781, DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Combettes-Souverain M, 1998, DIABETES METAB, V24, P477; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yuryev A, 1998, Cell Res, V8, P81; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18651	18658		10.1074/jbc.274.26.18651	http://dx.doi.org/10.1074/jbc.274.26.18651			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373477	hybrid			2022-12-27	WOS:000081056700069
J	Jones, DR; Gonzalez-Garcia, A; Diez, E; Martinez-A, C; Carrera, AC; Merida, I				Jones, DR; Gonzalez-Garcia, A; Diez, E; Martinez-A, C; Carrera, AC; Merida, I			The identification of phosphatidylinositol 3,5-bisphosphate in T-lymphocytes and its regulation by interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; PHOSPHOINOSITIDE 3-KINASE; CELL PROLIFERATION; KINASE ACTIVATION; PROTEIN-KINASE; OSMOTIC-STRESS; GROWTH-FACTOR; C2 DOMAIN; PATHWAY; POLYPHOSPHOINOSITIDES	In recent times 3-phosphoinositides have emerged as important regulators of cell metabolism, survival, and proliferation. During the last year, the phospholipid phosphatidylinositol 3,5-bisphosphate (PtdIns3,5P(2)) was identified in yeast, fibroblasts, SV40-transformed kidney (COS-7) cells, and platelets. The discovery of this novel phospholipid has increased the complexity of the metabolism relating to the generation of biologically active inositol-containing lipids. We describe here the identification of PtdIns3,5P(2) in the CTLL-8 mouse T-lymphocyte cell line using two in vivo radiolabeling protocols. Treatment of the cells with UV radiation led to an increase in the cellular content of PtdIns3,5P(2). In contrast, preincubation of the cells with wortmannin or treatment with hypertonic medium (high concentration sorbitol) led to the opposite effect. Herein we demonstrate that interleukin-2 (IL-2), the growth factor required for CTLL-2 cell proliferation, was able to increase the level of PtdIns3,5P(2) with similar kinetics to that of the formation of phosphatidylinositol: 3,4-bisphosphate (PtdIns3,4P(2)). An increase in this novel 3-phosphorylated lipid in response to IL-2 seems to be a general property of this cytokine because a similar result was obtained when the pre-B cell line BaF/3 ex pressing the high affinity IL-2 receptor was used. Using a constitutively active regulatory subunit of type I phosphatidylinositol 3-kinase and cells expressing a deletion of the serine-rich domain of the IL-2 receptor beta chain, which is required for IL-2-stimulated type I phosphatidylinositol 3-kinase activation, we demonstrate that IL-2-induced generation of PtdIns3,5P(2) is related to the activation of this enzyme. The results show for the first time the identification of PtdIns3,5P(2) in both T- and B-lymphocytes and indicate its positive regulation by the mitogen IL-2.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Madrid 28760, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); GlaxoSmithKline	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Merida, Isabel/A-9713-2014; Gonzalez-Garcia, Ana/D-9736-2014	Merida, Isabel/0000-0003-2762-6241; Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jones DR, 1998, FEBS LETT, V433, P23, DOI 10.1016/S0014-5793(98)00875-8; KANAZAWA T, 1994, CELL IMMUNOL, V156, P378, DOI 10.1006/cimm.1994.1183; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; Michell RH, 1997, ESSAYS BIOCHEM, V32, P31; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MILLS GB, 1986, J IMMUNOL, V136, P3019; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; VANHAESEBROCK B, 1997, TRENDS BIOCHEM SCI, V22, P355; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	39	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18407	18413		10.1074/jbc.274.26.18407	http://dx.doi.org/10.1074/jbc.274.26.18407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373447	hybrid			2022-12-27	WOS:000081056700039
J	Lee, SSK; Lehman, IR				Lee, SSK; Lehman, IR			The interaction of herpes simplex type 1 virus origin-binding protein (UL9 protein) with box I, the high affinity element of the viral origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ACTIVITY; DOMAIN	The herpes simplex type 1 (HSV-1) origin binding protein, the UL9 protein, exists in solution as a homodimer of 94-kDa monomers. It binds to Box I, the high affinity element of the HSV-I origin, Ori,, as a dimer. The UL9 protein also binds the HSV-I single strand DNA-binding protein, ICPS. Photocross-linking studies have shown that although the UL9 protein binds Box I as a dimer, only one of the two monomers contacts Box I. It is this form of the UL9 homodimer that upon interaction with ICP8, promotes the unwinding of Box I coupled to the hydrolysis of ATP to ADP and P-i. Photocross-linking studies have also shown that the amount of UL9 protein that interacts with Box I is reduced by its interaction with ICP8, Antibody directed against the C-terminal ten amino acids of the UL9 protein inhibits its Box I unwinding activity, consistent with the requirement for interaction of the C terminus of the UL9 protein with ICPS, Inhibition by the antibody is enhanced when the UL9 protein is first bound to Box I, suggesting that the C terminus of the UL9 protein undergoes a conformational change upon binding Box I.	Stanford Univ, Dept Biochem, Beckman Ctr, Stanford, CA 94305 USA	Stanford University	Lehman, IR (corresponding author), Stanford Univ, Dept Biochem, Beckman Ctr, B-400, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DODSON MS, 1993, J BIOL CHEM, V268, P1213; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; ELIAS P, 1992, J BIOL CHEM, V267, P17167; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; STABELL EC, 1993, NUCLEIC ACIDS RES, V21, P5203, DOI 10.1093/nar/21.22.5203	19	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18613	18617		10.1074/jbc.274.26.18613	http://dx.doi.org/10.1074/jbc.274.26.18613			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373472	hybrid			2022-12-27	WOS:000081056700064
J	Romaris, M; Coomans, C; Ceulemans, H; Bruystens, AM; Vekemans, S; David, G				Romaris, M; Coomans, C; Ceulemans, H; Bruystens, AM; Vekemans, S; David, G			Molecular polymorphism of the syndecans - Identification of a hypo-glycanated murine syndecan-1 splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; I COLLAGEN; SURFACE PROTEOGLYCAN; FINE-STRUCTURE; CORE PROTEINS; EXPRESSION; CLONING	We have identified a cDNA that encodes a variant form of murine syndecan-1, The variant cDNA lacks the sequence corresponding to the first 132 nucleotides of the third exon of the syndecan-1 gene. The corresponding message is rare. The alternative splice respects the reading frame and deletes 44 amino acids from the protein, joining the S(45)GS(47)GT sequence to a variant immediate downstream context. This sequence context initiates with alanine instead of glycine as residue 50, reducing the number of SGXG sequence motifs in the protein from two to one. Expression of this variant syndecan-1 in Madin-Darby canine kidney or MOLT-4 cells yielded a recombinant proteoglycan with a reduced number and clustering of the heparan sulfate chains, Both the conversions of Ala(50) and of Lys(53) into glycine enhanced the heparan sulfate substitution of the variant protein. These findings support the concept that serine glycine dipeptide signals for glycosaminoglycan/heparan sulfate synthesis depend on sequence context (Zhang, L., David, G.., and Esko, J. D. (1995) J. Biol. Chem, 270, 27127-27135) and imply that alternative splicing mechanisms may in part control the molecular polymorphism of syndecan-1 and, therefore, the efficiency and versatility of this protein in its co-receptor functions.	Univ Louvain, Lab Glycobiol & Dev Genet, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium		David, G (corresponding author), Univ Louvain, Lab Glycobiol & Dev Genet, Ctr Human Genet, Campus Gasthuisberg,0&N6,Herestr 49, B-3000 Louvain, Belgium.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HINKES MT, 1993, J BIOL CHEM, V268, P11440; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; KODA JE, 1985, J BIOL CHEM, V260, P8157; KODA JE, 1984, J BIOL CHEM, V259, P1763; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; LORIES V, 1989, J BIOL CHEM, V264, P7009; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RIDLEY RC, 1993, BLOOD, V81, P767; RODEN L, 1985, FED PROC, V44, P373; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	33	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18667	18674		10.1074/jbc.274.26.18667	http://dx.doi.org/10.1074/jbc.274.26.18667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373479	hybrid			2022-12-27	WOS:000081056700071
J	Schuler, B; Rachel, R; Seckler, R				Schuler, B; Rachel, R; Seckler, R			Formation of fibrous aggregates from a non-native intermediate: The isolated P22 tailspike beta-helix domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FOLDING MUTATIONS; INCLUSION-BODY FORMATION; HEAD-BINDING DOMAIN; TAIL-SPIKE PROTEIN; ALTERNATIVE CONFORMATIONS; AMYLOIDOGENIC PROTEINS; ELECTRON-MICROSCOPY; POLYPEPTIDE-CHAINS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS	In the assembly pathway of the trimeric P22 tailspike protein, the protein conformation critical for the partitioning between productive folding and off-pathway aggregation is a monomeric folding intermediate. The central domain of tailspike, a large right-handed parallel beta-helix, is essentially structured in this species, We used the isolated beta-helix domain (Bhx), expressed with a hexahistidine tag, to investigate the mechanism of aggregation without the two terminal domains present in the complete protein. Although Bhx has been shown to fold reversibly at low ionic strength conditions, increased ionic strength induced aggregation with a maximum at urea concentrations corresponding to the midpoint of urea-induced folding transitions. According to size exclusion chromatography, aggregation appeared to proceed via a linear polymerization mechanism. Circular dichroism indicated a secondary structure content of the aggregates similar to that of the native state, but at the same time their tryptophan fluorescence was largely quenched. Microscopic analysis of the aggregates revealed a variety of morphologies; among others, fibrils with fine structure were observed that exhibited bright green birefringence if viewed under cross-polarized light after staining with Congo red, These observations, together with the effects of folding mutations on the aggregation process, indicate the involvement of a partially structured intermediate distinct from both unfolded and native Bhx.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Regensburg, Inst Biochem Genet & Mikrobiol, D-93040 Regensburg, Germany; Univ Potsdam, D-14943 Luckenwalde, Germany	University of Regensburg; University of Regensburg; University of Potsdam	Schuler, B (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany.		Schuler, Benjamin/E-7342-2011	Schuler, Benjamin/0000-0002-5970-4251				Betts S, 1997, ADV PROTEIN CHEM, V50, P243, DOI 10.1016/S0065-3233(08)60323-X; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P1172; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; DILL KA, 1995, ADV PROTEIN CHEM, V46, P59, DOI 10.1016/S0065-3233(08)60332-0; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GLENNER GG, 1974, J HISTOCHEM CYTOCHEM, V22, P1141, DOI 10.1177/22.12.1141; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; HaasePettingell C, 1997, J MOL BIOL, V267, P88, DOI 10.1006/jmbi.1996.0841; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HEMKER DJ, 1990, MACROMOLECULES, V23, P4404, DOI 10.1021/ma00222a013; HERBST R, 1998, BIOCHEMISTRY-US, V37, P3253; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; Miller S, 1998, BIOCHEMISTRY-US, V37, P9160, DOI 10.1021/bi980190e; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; Pace C N, 1986, Methods Enzymol, V131, P266; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RACHEL R, 1986, ULTRAMICROSCOPY, V20, P305, DOI 10.1016/0304-3991(86)90194-4; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; SECKLER R, 1997, MOL CHAPERONES LIFE, P391; SMITH DH, 1980, GENETICS, V96, P331; Speed MA, 1997, PROTEIN SCI, V6, P99; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WETZEL R, 1997, ADV PROTEIN CHEM, V50, P243; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; [No title captured]	50	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18589	18596		10.1074/jbc.274.26.18589	http://dx.doi.org/10.1074/jbc.274.26.18589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373469	hybrid			2022-12-27	WOS:000081056700061
J	Haas, E; Grell, M; Wajant, H; Scheurich, P				Haas, E; Grell, M; Wajant, H; Scheurich, P			Continuous autotropic signaling by membrane-expressed tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; FACTOR TNF; FACTOR-ALPHA; CELL-DEATH; TRANSMEMBRANE FORM; FACTOR RECEPTOR; AUTOCRINE ROLE; INDUCTION; CYTOTOXICITY; PROTEIN	Tumor necrosis factor (TNF) exists in two bioactive forms, the membrane-integrated form and the proteolytically derived soluble cytokine. Cells that produce TNF are often responsive to TNF, allowing autocrine/juxtacrine feedback loops. However, whether the membrane form of TNF is involved in such regulatory circuits is unclear. Here we demonstrate that HeLa cells, expressing a permanently membrane-integrated mutant form of TNF, constitutively express TNF.TNF receptor complexes at their cell surface. These cells show a permanent activation of the transcription factor NF-kappa B, exert constitutive p38 mitogen-activated protein kinase activity, and produce high amounts of interleukin-6. In parallel, transmembrane TNF-expressing HeLa cells display high sensitivity to cycloheximide or interferon-gamma, similar to untransfected cells treated with these agents in combination with sTNF, Moreover, cycloheximide-induced apoptosis in transmembrane TNF transfectants can be blocked by the caspase inhibitor zVAD-fmk and does not necessarily need cell to cell contact, indicating a critical role of constitutive autotropic signaling of TNF . TNF receptor complexes. These data demonstrate that autotropic signaling loops of membrane TNF can exist, which may be of importance for cells that express both TNF and TNF receptors, such as T lymphocytes, macrophages, and endothelial cells.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Scheurich, P (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Decoster E, 1998, J BIOL CHEM, V273, P3271, DOI 10.1074/jbc.273.6.3271; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1997, GROWTH FACTORS CYTOK, P669; HELLER RA, 1992, CELL, V70, P47; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOPEZCEPERO M, 1994, J IMMUNOL, V152, P3333; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Moss ML, 1997, NATURE, V386, P738, DOI 10.1038/386738c0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; SCHEURICH P, 1986, INT J CANCER, V15, P127; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; SMITH DM, 1990, CANCER RES, V50, P3146; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; WALLACH D, 1988, J IMMUNOL, V140, P2994; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; WONG GHW, 1992, J IMMUNOL, V149, P3350	32	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18107	18112		10.1074/jbc.274.25.18107	http://dx.doi.org/10.1074/jbc.274.25.18107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364265	hybrid			2022-12-27	WOS:000080974300101
J	Ma, JX; Qu, W; Scarborough, PE; Tomer, KB; Moomaw, CR; Maronpot, R; Davis, LS; Breyer, MD; Zeldin, DC				Ma, JX; Qu, W; Scarborough, PE; Tomer, KB; Moomaw, CR; Maronpot, R; Davis, LS; Breyer, MD; Zeldin, DC			Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome p450 highly expressed in Kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID EPOXYGENASE; SPONTANEOUSLY HYPERTENSIVE RATS; EPOXYEICOSATRIENOIC ACIDS; HUMAN LIVER; MICROSOMAL CYTOCHROME-P450; ENANTIOFACIAL SELECTIVITY; FUNCTIONAL-SIGNIFICANCE; OMEGA-HYDROXYLATION; EPITHELIAL-CELLS; PROXIMAL TUBULE	A cDNA encoding a new cytochrome P450 was isolated from a mouse liver library. Sequence analysis reveals that this 1,886-base pair cDNA encodes a 501-amino acid polypeptide that is 69-74% identical to CYP2J subfamily P450s and is designated CYP2J5. Recombinant CYP2J5 was co-expressed with NADPH-cytochrome P450 oxidoreductase in Sf9 cells using a baculovirus system. Microsomal fractions of CYP2J5/NADPH-cytochrome P450 oxidoreductase-transfected cells metabolize arachidonic acid to 14,15-, 11,12-, and 8,9-epoxyeicosatrienoic acids and 11- and 15-hydroxyeicosatetraenoic acids (catalytic turnover, 4.5 nmol of product/nmol of cytochrome P450/min at 37 degrees C); thus CYP2J5 is enzymologically distinct. Northern analysis reveals that CYP2J5 transcripts are most abundant in mouse kidney and present at lower levels in liver. Immunoblotting using a polyclonal antibody against a CYP2J5-specific peptide detects a protein with the same electrophoretic mobility sis recombinant CYP2J5 most abundantly in mouse kidney microsomes. CYP2J5 is regulated during development in a tissue-specific fashion. In the kidney, CYP2J5 is present before birth and reaches maximal levels at 2-4 weeks of age. In the liver, CYP2J5 is absent prenatally and during the early postnatal period, first appears at 1 week, and then remains relatively constant. Immunohistochemical staining of kidney sections with anti-human CYP2J2 IBG reveals that CYP2J protein(s) are present primarily in the proximal tubules and collecting ducts, sites where the epoxyeicosatrienoic acids are known to modulate fluid/electrolyte transport and mediate hormonal action. In situ hybridization confirms abundant CYP2J5 mRNA within tubules of the renal cortex and outer medulla. Epoxyeicosatrienoic acids are endogenous constituents of mouse kidney thus providing direct evidence for the in vivo metabolism of arachidonic acid by the mouse renal epoxygenase(s). Based on these data, we conclude that CYP2J5 is an enzymologically distinct, developmentally regulated, protein that is localized to specific nephron segments and contributes to the oxidation of endogenous renal arachidonic acid pools. In light of the well documented effects of epoxyeicosatrienoic acids in modulating renal tubular transport processes, we postulate that CYP2J5 products play important functional roles in the kidney.	NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, NIH, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University	Zeldin, DC (corresponding author), NIEHS, Pulm Pathobiol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK38226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONVALET JP, 1987, AM J PHYSIOL, V253, pF377, DOI 10.1152/ajprenal.1987.253.3.F377; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; BURKE MD, 1979, PHARMACOL THERAPEUT, V7, P549, DOI 10.1016/0163-7258(79)90042-1; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1996, ADV MOL CEL, V14, P317; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; DEES JH, 1982, CANCER RES, V42, P1423; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FORCE T, 1991, J BIOL CHEM, V266, P4295; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HARDWICK JP, 1991, METHOD ENZYMOL, V206, P273; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HENRICH WL, 1990, AM J PHYSIOL, V258, pE269, DOI 10.1152/ajpendo.1990.258.2.E269; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; IMAOKA S, 1993, J PHARMACOL EXP THER, V267, P1012; IMIG JD, 1993, HYPERTENSION, V22, P357, DOI 10.1161/01.HYP.22.3.357; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR, P311; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1993, J BIOL CHEM, V268, P13565; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; Kroetz DL, 1997, MOL PHARMACOL, V52, P362, DOI 10.1124/mol.52.3.362; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; LEVERE RD, 1990, J CLIN INVEST, V86, P213, DOI 10.1172/JCI114686; Ma JX, 1998, GENOMICS, V49, P152, DOI 10.1006/geno.1998.5235; MA YH, 1994, AM J PHYSIOL, V36, pR579; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MCGIFF JC, 1993, STEROIDS, V58, P573, DOI 10.1016/0039-128X(93)90098-8; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMATA K, 1993, J LIPID MEDIATOR, V6, P369; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; OMATA K, 1992, AM J PHYSIOL, V262, pF8, DOI 10.1152/ajprenal.1992.262.1.F8; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Pascual JMS, 1998, J PHARMACOL EXP THER, V286, P772; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; ROMAN RJ, 1987, HYPERTENSION, V9, P130; ROMERO MF, 1991, RENAL PHYSIOL BIOCH, V14, P199; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schwartzman ML, 1996, NEPHRON, V73, P652; Stec DE, 1996, HYPERTENSION, V27, P564, DOI 10.1161/01.HYP.27.3.564; Stec DE, 1996, HYPERTENSION, V27, P1329, DOI 10.1161/01.HYP.27.6.1329; UMENO M, 1988, J BIOL CHEM, V263, P4956; UYEHARA CFT, 1993, AM J PHYSIOL, V34, pR943; Wang MH, 1996, ARCH BIOCHEM BIOPHYS, V336, P240, DOI 10.1006/abbi.1996.0554; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; Zeldin DC, 1997, MOL PHARMACOL, V51, P931, DOI 10.1124/mol.51.6.931; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922; Zou AP, 1996, AM J PHYSIOL-RENAL, V270, pF822, DOI 10.1152/ajprenal.1996.270.5.F822	82	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17777	17788		10.1074/jbc.274.25.17777	http://dx.doi.org/10.1074/jbc.274.25.17777			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364221	hybrid			2022-12-27	WOS:000080974300057
J	Verhamme, I; Kvassman, JO; Day, D; Debrock, S; Vleugels, N; Declerck, PJ; Shore, JD				Verhamme, I; Kvassman, JO; Day, D; Debrock, S; Vleugels, N; Declerck, PJ; Shore, JD			Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ESCHERICHIA-COLI; IDENTIFICATION; PURIFICATION; VITRONECTIN; PROTEIN; LOCALIZATION; INSERTION; COMPLEXES; MECHANISM	The serpin plasminogen activator inhibitor-1 (PAI-1) slowly converts to an inactive latent form by inserting a major part of its reactive center loop (RCL) into its beta-sheet A. A murine monoclonal antibody (MA-33B8), raised against the human plasminogen activator (tPA). PAI-1 complex, rapidly inactivates PAI-1, Results presented here indicate that MA-33B8 induces acceleration of the active-to-latent conversion. The antibody-induced inactivation of PAI-1 labeled with the fluorescent probe N,N'-dimethyl-N-(acetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylene diamine (NBD) at P9 in the RCL caused a fluorescence enhancement and shift identical to those accompanying the spontaneous conversion of the PS NBD PAI-1 to the latent form, Like latent PAI-1, antibody-inactivated PAI-1 was protected from cleavage by elastase, The rate constants for MA-33B8 binding, measured by NBD fluorescence or inactivation, were similar (1.3-1.8 x 10(4) M-1 s(-1)), resulting in a 4000-fold faster inactivation at 4.2 mu M antibody binding sites. The apparent antibody binding rate constant, at least 1000 times slower than one limited by diffusion, indicates that exposure of its epitope depends on an unfavorable equilibrium of PAI-1. Our observations are consistent with this idea and suggest that the equilibrium involves partial insertion of the RCL into sheet A: latent, RCL-cleaved, and tPA-complexed PAI-1, which are inactive loop-inserted forms, bound much faster than active PAI-1 to MA-33B8, whereas two loop-extracted forms of PAI-1, modified to prevent loop insertion, did not bind or bound much more weakly to the antibody.	Henry Ford Hlth Sci Ctr, Div Biochem Res, Detroit, MI 48202 USA; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium	Henry Ford Health System; Henry Ford Hospital; KU Leuven	Shore, JD (corresponding author), Henry Ford Hlth Sci Ctr, Div Biochem Res, 1 Ford Pl,5D, Detroit, MI 48202 USA.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45930A07] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Creighton T. E., 1993, PROTEINS STRUCTURE M, P402; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Ngo TH, 1997, FEBS LETT, V416, P373, DOI 10.1016/S0014-5793(97)01242-8; OLSON ST, 1995, J BIOL CHEM, V270, P30007; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SHORE JD, 1996, ADV EXPT MED BIOL, V425, P300; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	28	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17511	17517		10.1074/jbc.274.25.17511	http://dx.doi.org/10.1074/jbc.274.25.17511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364183	hybrid			2022-12-27	WOS:000080974300019
J	Hosaka, M; Sudhof, TC				Hosaka, M; Sudhof, TC			Homo- and heterodimerization of synapsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; FAMILY; PHOSPHOPROTEINS; ISOFORMS; SITE; CA2+; MICE	In vertebrates, synapsins constitute a family of synaptic vesicle proteins encoded by three genes. Synapsins contain a central ATP-binding domain, the C-domain, that is highly homologous between synapsins and evolutionarily conserved in invertebrates. The crystal structure of the C-domain from synapsin I revealed that it constitutes a large (>300 amino acids), independently folded domain that forms a tight dimer with or without bound ATP, We now show that the C-domains of all synapsins form homodimers, and that in addition, C-domains from different synapsins associate into heterodimers, This conclusion is based on four findings: 1) in yeast two-hybrid screens with full-length synapsin IIa as a bait, the most frequently isolated prey cDNAs encoded the C-domain of synapsins; 2) quantitative yeast two-hybrid protein-protein binding assays demonstrated pairwise strong interactions between all synapsins; 3) immunoprecipitations from transfected COS cells confirmed that synapsin II heteromultimerizes with synapsins I and III in intact cells, and similar results were obtained with bacterial expression systems; and 4) quantification of the synapsin III level in synapsin I/II double knockout mice showed that the level of synapsin III is decreased by 50%, indicating that heteromultimerization of synapsin III with synapsins I or II occurs in vivo and is required for protein stabilization. These data suggest that synapsins coat the surface of synaptic vesicles as homo- and heterodimers in which the C-domains of the various subunits have distinct regulatory properties and are flanked by variable C-terminal sequences. The data also imply that synapsin III does not compensate for the loss of synapsins I and II in the double knockout mice.	Univ Texas, SW Med Sch, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Sch, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Hosaka, Masahiro/0000-0002-1422-1774				Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HALL FL, 1990, J BIOL CHEM, V265, P6944; Hata Y, 1996, J NEUROSCI, V16, P2488; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Hosaka M, 1998, J BIOL CHEM, V273, P13371, DOI 10.1074/jbc.273.22.13371; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; Klagges BRE, 1996, J NEUROSCI, V16, P3154; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MatusLeibovitch N, 1997, MOL BRAIN RES, V45, P301, DOI 10.1016/S0169-328X(96)00265-3; Missler M, 1998, J NEUROSCI, V18, P3630; Morimoto K, 1998, SEIZURE-EUR J EPILEP, V7, P229; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rose MD., 1990, METHODS YEAST GENETI; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Staple JK, 1997, EUR J NEUROSCI, V9, P721, DOI 10.1111/j.1460-9568.1997.tb01420.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1996, P UEH MEM FDT S, P3; SUDHOF TC, 1991, NEUROSCI YEAR, V2, P146; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WOODS CM, 1985, CELL, V40, P959, DOI 10.1016/0092-8674(85)90356-3	28	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16747	16753		10.1074/jbc.274.24.16747	http://dx.doi.org/10.1074/jbc.274.24.16747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358015	hybrid			2022-12-27	WOS:000080780400014
J	Coulson, EJ; Reid, K; Barrett, GL; Bartlett, PF				Coulson, EJ; Reid, K; Barrett, GL; Bartlett, PF			p75 neurotrophin receptor-mediated neuronal death is promoted by Bcl-2 and prevented by Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LEUKEMIA INHIBITORY FACTOR; CELL-DEATH; NMR STRUCTURE; PC12 CELLS; APOPTOSIS; DOMAIN; BAX; EXPRESSION; SURVIVAL	The p75 neurotrophin receptor (p75NTR) has been shown to mediate neuronal death through an unknown pathway. We microinjected p75NTR expression plasmids into sensory neurons in the presence of growth factors and assessed the effect of the expressed proteins on cell survival. We show that, unlike other members of the TNFR family, p75NTR signals death through a unique caspase-dependent death pathway that does not involve the "death domain" and is differentially regulated by Bcl-2 family members: the anti-apoptotic molecule Bcl-2 both promoted, and was required for, p75NTR killing, whereas killing was inhibited by its homologue BcI-x(L). These results demonstrate that Bcl-2, through distinct molecular mechanisms, either promotes or inhibits neuronal death depending on the nature of the death stimulus.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne	Bartlett, PF (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.		Coulson, Elizabeth J./C-8766-2009; Bartlett, Perry/F-3813-2012	Coulson, Elizabeth J./0000-0003-3783-6197; 				ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BERNARD O, 1996, FRONTIERS SPINAL COR; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Cheema SS, 1996, J NEUROSCI RES, V46, P239, DOI 10.1002/(SICI)1097-4547(19961015)46:2<239::AID-JNR12>3.0.CO;2-Y; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Coulpier M, 1996, J NEUROSCI, V16, P5897; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Majdan M, 1997, J NEUROSCI, V17, P6988; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MERRY DE, 1994, DEVELOPMENT, V120, P301; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MURPHY M, 1993, DEVELOPMENT, V117, P1173; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	42	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16387	16391		10.1074/jbc.274.23.16387	http://dx.doi.org/10.1074/jbc.274.23.16387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347198	hybrid			2022-12-27	WOS:000080668600058
J	Jeong, EJ; Bang, S; Lee, TH; Park, YI; Sim, WS; Kim, KS				Jeong, EJ; Bang, S; Lee, TH; Park, YI; Sim, WS; Kim, KS			The solution structure of FADD death domain - Structural basis of death domain interactions of Fas and FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE DETERMINATION; SIGNALING COMPLEX DISC; NMR STRUCTURE; INDUCED APOPTOSIS; DIRECT REFINEMENT; RECEPTOR SIGNALS; EFFECTOR DOMAIN; CD95 FAS/APO-1; CELL-DEATH; RESONANCE	A signal of Pas-mediated apoptosis is transferred through an adaptor protein Pas-associated death domain protein (FADD) by interactions between the death domains of Pas and FADD. To understand the signal transduction mechanism of Pas-mediated apoptosis, we solved the solution structure of a murine FADD death domain. It consists of six helices arranged in a similar fold to the other death domains. The interactions between the death domains of Pas and FADD analyzed by site-directed mutagenesis indicate that charged residues in helices alpha 2 and alpha 3 are involved in death domain interactions, and the interacting helices appear to interact in anti-parallel pattern, alpha 2 of FADD with alpha 3 of Fas and vice versa.	KIST, Struct biol Ctr, Seoul 130650, South Korea; Korea Univ, Dept Biol, Seoul 136701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea	Korea Institute of Science & Technology (KIST); Korea University; Korea University; Yonsei University	Kim, KS (corresponding author), KIST, Struct biol Ctr, Seoul 130650, South Korea.							Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON D, 1991, CHARACTERIZATION POR, V2, P11; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	43	95	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16337	16342		10.1074/jbc.274.23.16337	http://dx.doi.org/10.1074/jbc.274.23.16337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347191	hybrid			2022-12-27	WOS:000080668600051
J	Mount, DB; Mercado, A; Song, LY; Xu, J; George, AL; Delpire, E; Gamba, G				Mount, DB; Mercado, A; Song, LY; Xu, J; George, AL; Delpire, E; Gamba, G			Cloning and characterization of KCC3 and KCC4, new members of the cation-chloride cotransporter gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; BARTTERS-SYNDROME; HYPOKALEMIC ALKALOSIS; MOLECULAR-CLONING; CHROMOSOME 15Q; ION-TRANSPORT; RABBIT; EXPRESSION; MUTATIONS; EPILEPSY	The K+-Cl- cotransporters (KCCs) belong to the gene family of electroneutral cation-chloride cotransporters, which also includes two bumetanide-sensitive Na+-K+-2Cl(-) cotransporters and a thiazide sensitive Na+-Cl- cotransporter. We have cloned cDNAs encoding mouse KCC3, human KCC3, and human KCC4, three new members of this gene family. The KCC3 and KCC4 cDNAs predict proteins of 1083 and 1150 amino acids, respectively. The KCC3 and KCC4 proteins are 65-71% identical to the previously characterized transporters KCC1 and KCC2, with which they share a predicted membrane topology, The four KCC proteins differ at amino acid residues within key transmembrane domains and in the distribution of putative phosphorylation sites within the amino- and carboxyl-terminal cytoplasmic domains. The expression of mouse KCC3 in Xenopus laevis oocytes reveals the expected functional characteristics of a K+Cl- cotransporter: Cl--dependent uptake of Rb-86(+) which is strongly activated by cell swelling and weakly sensitive to furosemide, A direct functional comparison of mouse KCC3 to rabbit KCC1 indicates that KCC3 has a much greater volume sensitivity. The human KCC3 and KCC4 genes are located on chromosomes 5p15 and 15q14, respectively. Although widely expressed, KCC3 transcripts are the most abundant in heart and kidney, and KCC4 is expressed in muscle, brain, lung, heart, and kidney, The unexpected molecular heterogeneity of K+-Cl- cotransport has implications for the physiology and pathophysiology of a number of tissues.	Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Nacl Nutr Salvador Zubiran, Mol Physiol Unit, Mexico City, DF, Mexico	Vanderbilt University; Vanderbilt University; Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Universidad Nacional Autonoma de Mexico	Mount, DB (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Dept Med, MCN S-3223, Nashville, TN 37232 USA.	david.mount@mcmail.vanderbilt.edu	Mercado, Adriana/AAR-6143-2021; Gamba, Gerardo/P-4873-2016	Mercado, Adriana/0000-0002-6881-0160; Gamba, Gerardo/0000-0002-4378-9043	NHLBI NIH HHS [R-29 HL-49251] Funding Source: Medline; NIDDK NIH HHS [K-11 DK02103] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002103] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRAGNA NC, 1994, J MEMBRANE BIOL, V142, P195; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; Andersen GO, 1998, AM J PHYSIOL-HEART C, V275, pH641, DOI 10.1152/ajpheart.1998.275.2.H641; Armour JAL, 1996, ANN HUM GENET, V60, P11, DOI 10.1111/j.1469-1809.1996.tb01167.x; AVISON MJ, 1988, J MEMBRANE BIOL, V105, P197, DOI 10.1007/BF01870997; Casaubon LK, 1996, AM J HUM GENET, V58, P28; Clayton GH, 1998, DEV BRAIN RES, V109, P281, DOI 10.1016/S0165-3806(98)00078-9; Cossins AR, 1997, J EXP BIOL, V200, P343; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; ELLISON DH, 1985, AM J PHYSIOL, V248, pF638, DOI 10.1152/ajprenal.1985.248.5.F638; Elmslie FV, 1997, HUM MOL GENET, V6, P1329, DOI 10.1093/hmg/6.8.1329; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Holtzman EJ, 1998, AM J PHYSIOL-RENAL, V275, pF550, DOI 10.1152/ajprenal.1998.275.4.F550; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Lafreniere RG, 1997, NAT GENET, V15, P298, DOI 10.1038/ng0397-298; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LAUF PK, 1992, AM J PHYSIOL, V63, pC917; Liapis H, 1998, AM J PHYSIOL-CELL PH, V275, pC1432, DOI 10.1152/ajpcell.1998.275.6.C1432; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LING BN, 1995, KIDNEY INT, V48, P1158, DOI 10.1038/ki.1995.399; LU J, 1999, IN PRESS J NEUROBIOL; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; Mount DB, 1998, J EXP BIOL, V201, P2091; Neubauer BA, 1998, NEUROLOGY, V51, P1608, DOI 10.1212/WNL.51.6.1608; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Pellegrino CM, 1998, BLOOD CELL MOL DIS, V24, P31, DOI 10.1006/bcmd.1998.0168; PIWNICAWORMS D, 1985, AM J PHYSIOL, V249, pC337, DOI 10.1152/ajpcell.1985.249.3.C337; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Randall J, 1997, AM J PHYSIOL-CELL PH, V273, pC1267, DOI 10.1152/ajpcell.1997.273.4.C1267; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; WEILMASLANSKY E, 1994, AM J PHYSIOL-CELL PH, V267, pC932, DOI 10.1152/ajpcell.1994.267.4.C932; WINGO CS, 1989, AM J PHYSIOL, V256, pF697, DOI 10.1152/ajprenal.1989.256.4.F697; Yan GX, 1996, J PHYSIOL-LONDON, V490, P215, DOI 10.1113/jphysiol.1996.sp021137	47	239	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16355	16362		10.1074/jbc.274.23.16355	http://dx.doi.org/10.1074/jbc.274.23.16355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347194	hybrid			2022-12-27	WOS:000080668600054
J	Pushkin, A; Abuladze, N; Lee, I; Newman, D; Hwang, J; Kurtz, I				Pushkin, A; Abuladze, N; Lee, I; Newman, D; Hwang, J; Kurtz, I			Cloning, tissue distribution, genomic organization, and functional characterization of NBCS, a new member of the sodium bicarbonate cotransporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-PH REGULATION; VASCULAR SMOOTH-MUSCLE; HYDROGEN EXCHANGE; PROXIMAL TUBULE; INFARCT SIZE; RABBIT HEART; ETHYLISOPROPYL-AMILORIDE; RESISTANCE ARTERIES; NA+/H+ EXCHANGE; SKELETAL-MUSCLE	Previous functional studies have demonstrated that muscle intracellular pH regulation is mediated by sodium-coupled bicarbonate transport, Na+/H+ exchange, and Cl-/bicarbonate exchange. We report the cloning, sequence analysis, tissue distribution, genomic organization, and functional analysis of a new member of the sodium bicarbonate cotransporter (NBC) family, NBC3, from human skeletal muscle. mNBC3 encodes a 1214-residue polypeptide with 12 putative membrane-spanning domains. The similar to 7.8-kilobase transcript is expressed uniquely in skeletal muscle and heart. The NBCS gene (SLC4A7) spans similar to 80 kb and is composed of 25 coding exons and 24 introns that are flanked by typical splice donor and acceptor sequences. Expression of mNBC3 cRNA in Xenopus laevis oocytes demonstrated that the protein encodes a novel stilbene-insensitive 5-(N-ethyl-N-isopropyl)-amiloride-inhibitable sodium bicarbonate cotransporter.	Univ Calif Los Angeles, Div Nephrol, Ctr Hlth Sci, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurtz, I (corresponding author), Univ Calif Los Angeles, Div Nephrol, Ctr Hlth Sci, Sch Med, 10833 Le Conte Ave,Rm 7-155 Factor Bldg, Los Angeles, CA 90095 USA.	IKurtz@med1.medsch.ucla.edu			NIDDK NIH HHS [DK46976] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046976] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALKJAER C, 1991, AM J PHYSIOL, V261, pC1010, DOI 10.1152/ajpcell.1991.261.6.C1010; AALKJAER C, 1991, J PHYSIOL-LONDON, V436, P57, DOI 10.1113/jphysiol.1991.sp018539; AALKJAER C, 1988, J PHYSIOL-LONDON, V402, P391, DOI 10.1113/jphysiol.1988.sp017211; Aalkjaer C, 1997, ACTA PHYSIOL SCAND, V161, P557, DOI 10.1046/j.1365-201X.1997.00263.x; Abuladze N, 1998, J BIOL CHEM, V273, P17689, DOI 10.1074/jbc.273.28.17689; ABULADZE N, 1998, AM J PHYSIOL, V43, pF628; AICKIN CC, 1977, J PHYSIOL-LONDON, V273, P295, DOI 10.1113/jphysiol.1977.sp012095; AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P331, DOI 10.1113/jphysiol.1994.sp020299; AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P317, DOI 10.1113/jphysiol.1994.sp020298; BLATTER LA, 1991, CIRC RES, V68, P150, DOI 10.1161/01.RES.68.1.150; BOBIK A, 1990, CLIN EXP PHARMACOL P, V17, P297, DOI 10.1111/j.1440-1681.1990.tb01324.x; BOBIK A, 1991, AM J PHYSIOL, V260, pC581, DOI 10.1152/ajpcell.1991.260.3.C581; BONANNO JA, 1992, INVEST OPHTH VIS SCI, V33, P3068; BORON WF, 1981, AM J PHYSIOL, V240, pC80, DOI 10.1152/ajpcell.1981.240.1.C80; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; BUGGE E, 1995, CARDIOVASC RES, V29, P269, DOI 10.1016/S0008-6363(96)88580-4; Bugge E, 1996, BASIC RES CARDIOL, V91, P203, DOI 10.1007/BF00788906; Burnham CE, 1998, AM J PHYSIOL-RENAL, V274, pF1119, DOI 10.1152/ajprenal.1998.274.6.F1119; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; CARR P, 1995, AM J PHYSIOL-CELL PH, V268, pC580, DOI 10.1152/ajpcell.1995.268.3.C580; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DASCAL N, 1984, J PHYSIOL-LONDON, V352, P551, DOI 10.1113/jphysiol.1984.sp015310; DEHURTADO MCC, 1995, J MOL CELL CARDIOL, V27, P231; GALLER S, 1986, J PHYSIOL-LONDON, V374, P137, DOI 10.1113/jphysiol.1986.sp016071; GERSTHEIMER FP, 1987, PFLUG ARCH EUR J PHY, V409, P60, DOI 10.1007/BF00584750; GRICHTCHENKO II, 1994, NEUROSCIENCE, V62, P1071, DOI 10.1016/0306-4522(94)90344-1; GROSSIE J, 1988, J MEMBRANE BIOL, V105, P265, DOI 10.1007/BF01871003; Henry P, 1996, CARDIOVASC RES, V32, P930; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; Juel C, 1996, ACTA PHYSIOL SCAND, V156, P369, DOI 10.1046/j.1365-201X.1996.206000.x; KAHN AM, 1986, AM J PHYSIOL, V261, pC837; KETTENMANN H, 1988, J PHYSIOL-LONDON, V406, P147, DOI 10.1113/jphysiol.1988.sp017373; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P647, DOI 10.1085/jgp.103.4.647; Komukai K, 1998, AM J PHYSIOL-HEART C, V274, pH147, DOI 10.1152/ajpheart.1998.274.1.H147; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LITTLE PJ, 1995, CARDIOVASC RES, V29, P239, DOI 10.1016/0008-6363(96)88576-2; LUCCHESI PA, 1995, CARDIOVASC RES, V29, P172, DOI 10.1016/0008-6363(96)88566-X; Munch-Ellingsen J, 1998, MOL CELL BIOCHEM, V186, P13, DOI 10.1023/A:1006820509480; NEYLON CB, 1990, CIRC RES, V67, P814, DOI 10.1161/01.RES.67.4.814; OKUBO K, 1994, J BIOL CHEM, V269, P1918; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; PEREZ NG, 1995, CAN J CARDIOL, V11, P553; Pushkin A, 1999, GENOMICS, V57, P321, DOI 10.1006/geno.1999.5781; PUTNAM RW, 1990, AM J PHYSIOL, V258, pC470, DOI 10.1152/ajpcell.1990.258.3.C470; REUSCH HP, 1995, AM J PHYSIOL-CELL PH, V268, pC147, DOI 10.1152/ajpcell.1995.268.1.C147; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; ROMERO MF, 1998, AM J PHYSIOL, V274, pF413; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; Sato H, 1997, BASIC RES CARDIOL, V92, P339, DOI 10.1007/BF00788946; STAHL F, 1992, AM J PHYSIOL, V262, pC427, DOI 10.1152/ajpcell.1992.262.2.C427; WESTERBLAD H, 1992, J PHYSIOL-LONDON, V449, P49, DOI 10.1113/jphysiol.1992.sp019074; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; Wu C, 1998, J PHYSIOL-LONDON, V508, P131, DOI 10.1111/j.1469-7793.1998.131br.x	55	156	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16569	16575		10.1074/jbc.274.23.16569	http://dx.doi.org/10.1074/jbc.274.23.16569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347222	hybrid			2022-12-27	WOS:000080668600082
J	Sturm, NR; Campbell, DK				Sturm, NR; Campbell, DK			The role of intron structures in trans-splicing and Cap 4 formation for the Leishmania spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; LEPTOMONAS-COLLOSOMA; MESSENGER-RNAS; SL RNA; TARENTOLAE; GENE; EXPRESSION; SEQUENCE; TRANSCRIPTION; REQUIREMENTS	A 39-nucleotide leader is trans-spliced onto all trypanosome nuclear mRNAs. The precursor spliced leader RNA was tested for trans-splicing function in vivo by mutating the intron. We report that in Leishmania tarentolae spliced leader RNA 5' modification is influenced by the primary sequence of stem-loop II, the Sm-binding site, and the secondary structure of stem-loop III. The sequence of stem-loop II was found to be important for cap 4 formation and splicing. As in Ascaris, mutagenesis of the bulge nucleotide in stem-loop II was detrimental to trans-splicing. Because restoration of the L. tarentolae stem-loop II structure was not sufficient to restore splicing, this result contrasts the findings in the kinetoplastid Leptomonas, where mutations that restored stem-loop II structure supported splicing. Methylation of the cap 4 structure and splicing was also dependent on both the Sm-binding site and the structure of stem-loop III and was inhibited by incomplete 3' end processing. The critical nature of the L. tarentolae Sm-binding site is consistent with its essential role in the Ascaris spliced leader RNA, whereas in Leptomonas mutation of the Sm-binding site and deletion of stem-loop III did not affect trans-splicing. A pathway for Leishmania spliced leader RNA processing and maturation is proposed.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Campbell, DK (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NIAID NIH HHS [2-T32-AI-07323, AI34536] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034536, T32AI007323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Denker JA, 1996, RNA, V2, P746; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Ferguson KC, 1999, MOL CELL BIOL, V19, P1892; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; Goncharov I, 1998, NUCLEIC ACIDS RES, V26, P2200, DOI 10.1093/nar/26.9.2200; HANNON GJ, 1992, SCIENCE, V258, P1775, DOI 10.1126/science.1465612; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARRIS KA, 1995, RNA, V1, P351; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; Sturm NR, 1998, BBA-GENE STRUCT EXPR, V1442, P347, DOI 10.1016/S0167-4781(98)00150-X; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; ULLU E, 1996, MOL BIOL PARASITIC P, P115; Xie HY, 1998, P NATL ACAD SCI USA, V95, P4235, DOI 10.1073/pnas.95.8.4235; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	33	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19361	19367		10.1074/jbc.274.27.19361	http://dx.doi.org/10.1074/jbc.274.27.19361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383448	hybrid			2022-12-27	WOS:000081196300071
J	Zou, XM; Calame, K				Zou, XM; Calame, K			Signaling pathways activated by oncogenic forms of Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; C-MYC TRANSCRIPTION; BCL-X-L; V-ABL; CELL-LINES; P53-DEPENDENT APOPTOSIS; HEMATOPOIETIC-CELLS; TUMOR-SUPPRESSOR; ADAPTER PROTEIN		Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys & Microbiol, New York, NY 10032 USA	Columbia University	Calame, K (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys & Microbiol, 630 W 168th St, New York, NY 10032 USA.	KLC1@columbia.edu						ABELSON HT, 1970, CANCER RES, V30, P2213; Banerjee A, 1998, J IMMUNOL, V161, P4611; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHUNG SW, 1995, ONCOGENE, V10, P1261; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cortes JE, 1996, AM J MED, V100, P555, DOI 10.1016/S0002-9343(96)00061-7; Cortez D, 1996, ONCOGENE, V13, P2589; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gishizky ML, 1996, CYTOKINES MOL THER, V2, P251; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOFF SP, 1985, P SOC EXP BIOL MED, V179, P403; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Guo XYD, 1998, LEUKEMIA LYMPHOMA, V30, P225, DOI 10.3109/10428199809057536; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; Liedtke M, 1998, ONCOGENE, V17, P1889, DOI 10.1038/sj.onc.1202117; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NICHOLS GL, 1994, BLOOD, V84, P2912; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROSENBERG N, 1982, CURR TOP MICROBIOL, V101, P95; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SanchezGarcia I, 1997, J MOL BIOL, V267, P225, DOI 10.1006/jmbi.1996.0779; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	77	89	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18141	18144		10.1074/jbc.274.26.18141	http://dx.doi.org/10.1074/jbc.274.26.18141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373409	hybrid			2022-12-27	WOS:000081056700001
J	Kao, AW; Noda, Y; Johnson, JH; Pessin, JE; Saltiel, AR				Kao, AW; Noda, Y; Johnson, JH; Pessin, JE; Saltiel, AR			Aldolase mediates the association of F-actin with the insulin-responsive glucose transporter GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR SEQUESTRATION; INTERNALIZATION MOTIF; CYTOPLASMIC DOMAIN; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; PLASMA-MEMBRANE; TRANSLOCATION; TERMINUS	To identify potential proteins interacting with the insulin-responsive glucose transporter(GLUT4), we generated fusion proteins of glutathione S-transferase (GST) and the final 30 amino acids from GLUT4 (GST-G4) or GLUT1 (GST-G1). Incubation of these carboxyl-terminal fusion proteins with adipocyte cell extracts revealed a specific interaction of GLUT4 with fructose 1,6-bisphosphate aldolase. In the presence of aldolase, GST-G4 but not GST-G1 was able to co-pellet with filamentous (F)-actin. This interaction was prevented by incubation with the aldolase substrates, fructose 1,6-bisphosphate or glyceraldehyde 8-phosphate. Immunofluorescence confocal microscopy demonstrated a significant co-localization of aldolase and GLUT4 in intact 3T3L1 adipocytes, which decreased following insulin stimulation. Introduction into permeabilized 3T3L1 adipocytes of fructose 1,6-bisphosphate or the metabolic inhibitor P-deoxyglucose, two agents that disrupt the interaction between aldolase and actin, inhibited insulin-stimulated GLUT4 exocytosis without affecting GLUT4 endocytosis. Furthermore, microinjection of an aldolase-specific antibody also inhibited insulin-stimulated GLUT4 translocation. These data suggest that aldolase functions as a scaffolding protein for GLUT4 and that glucose metabolism may provide a negative feedback signal for the regulation of glucose transport by insulin.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Iowa; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	alan.saltiel@wl.com	Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHENZION M, 1992, INT J BIOCHEM, V24, P821; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YANG J, 1993, J BIOL CHEM, V268, P4600	34	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17742	17747		10.1074/jbc.274.25.17742	http://dx.doi.org/10.1074/jbc.274.25.17742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364216	hybrid			2022-12-27	WOS:000080974300052
J	Millar, CA; Powell, KA; Hickson, GRX; Bader, MF; Gould, GW				Millar, CA; Powell, KA; Hickson, GRX; Bader, MF; Gould, GW			Evidence for a role for ADP-ribosylation factor 6 in insulin-stimulated glucose transporter-4 (GLUT4) trafficking in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTORS; REGULATED EXOCYTOSIS; CHROMAFFIN CELLS; SKELETAL-MUSCLE; PHOSPHOLIPASE-D; ARF PROTEINS; TRANSLOCATION; VESICLES	ADP-ribosylation factors (ARFs) play important roles in both constitutive and regulated membrane trafficking to the plasma membrane in other cells. Here we have examined their role in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. These cells express ARF5 and ARF6. ARF5 was identified in the soluble protein and intracellular membranes; in response to insulin some ARF5 was observed to re-locate to the plasma membrane. In contrast, ARF6 was predominantly localized to the plasma membrane and did not redistribute in response to insulin. We employed myristoylated peptides corresponding to the NH, termini of ARF5 and ARF6 to investigate the function of these proteins. Myr-ARF6 peptide inhibited insulin-stimulated glucose transport and GLUT4 translocation by similar to 50% in permeabilized adipocytes. In contrast, myr-BRF1 and myr-ARF5 peptides were without effect. Myr-ARF5 peptide also inhibited the insulin stimulated increase in cell surface levels of GLUT1 and transferrin receptors. Myr-ARF6 peptide significantly decreased cell surface levels of these proteins in both basal and insulin-stimulated states, but did not inhibit the fold increase in response to insulin. These data suggest an important role for ARF6 in regulating cell surface levels of GLUT4 in adipocytes, and argue for a role for both ARF5 and ARF6 in the regulation of membrane trafficking to the plasma membrane.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; INSERM, U 338, F-67084 Strasbourg, France	University of Glasgow; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gould, GW (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.W.Gould@bio.gla.ac.uk	Gould, Gwyn/AAF-6721-2019; Bader, Marie-France/O-2098-2016	Gould, Gwyn/0000-0001-6571-2875; Powell, Kate/0000-0002-1826-953X; Hickson, Gilles/0000-0001-7670-9815				Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Ralston E, 1996, J CELL SCI, V109, P2967; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Slot JW, 1997, J CELL BIOL, V137, P1243, DOI 10.1083/jcb.137.6.1243; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; YANG J, 1993, J BIOL CHEM, V268, P4600; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977; Zorzano A, 1996, DIABETES, V45, pS70, DOI 10.2337/diab.45.1.S70	47	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17619	17625		10.1074/jbc.274.25.17619	http://dx.doi.org/10.1074/jbc.274.25.17619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364199	hybrid			2022-12-27	WOS:000080974300035
J	Santalucia, T; Boheler, KR; Brand, NJ; Sahye, U; Fandos, C; Vinals, F; Ferre, J; Testar, X; Palacin, M; Zorzano, A				Santalucia, T; Boheler, KR; Brand, NJ; Sahye, U; Fandos, C; Vinals, F; Ferre, J; Testar, X; Palacin, M; Zorzano, A			Factors involved in GLUT-1 glucose transporter gene transcription in cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; POSTNATAL-DEVELOPMENT; CELL-DIFFERENTIATION; SP1-MEDIATED TRANSCRIPTION; REGULATE EXPRESSION; VESICLE POPULATIONS; BIOCHEMICAL ASPECTS; THYROID-HORMONE	Glucose constitutes a major fuel for the heart, and high glucose uptake during fetal development is coincident with the highest level of expression of the glucose transporter GLUT-1 during life. We have previously reported that GLUT-1 is repressed perinatally in rat heart, and GLUT-1, which shows a low level of expression in the fetal stage, becomes the main glucose transporter in the adult. Here, we show that the perinatal expression of GLUT-1 and GLUT-1 glucose transporters in heart is controlled directly at the level of gene transcription. Transient transfection assays show that the -99/-33 fragment of the GLUT-1 gene is sufficient to drive transcriptional activity in rat neonatal cardiomyocytes. Electrophoretic mobility shift assays demonstrate that the transcription factor Sp1, a trans-activator of GLUT-1 promoter, binds to the -102/-82 region of GLUT-2 promoter during the fetal state but not during adulthood. Mutation of the Sp1 site in this region demonstrates that Sp1 is essential for maintaining a high transcriptional activity in cardiac myocytes. Sp1 is markedly down-regulated both in heart and in skeletal muscle during neonatal life, suggesting an active role for Sp1 in the regulation of GLUT-1 transcription. In all, these results indicate that the expression of GLUT-1 and GLUT-I in heart during perinatal development is largely controlled at a transcriptional level by mechanisms that might be related to hyperplasia and that are independent from the signals that trigger cell hypertrophy in the developing heart. Furthermore, our results provide the first functional insight into the mechanisms regulating muscle GLUT-1 gene expression in a live animal.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; NIA, Gerontol Res Ctr, Mol Cardiol Unit, Cardiovasc Sci Lab,NIH, Baltimore, MD 21224 USA; Imperial Coll, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	University of Barcelona; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Imperial College London	Zorzano, A (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Diagonal 645, E-08028 Barcelona, Spain.		Vinals, Francesc/P-6278-2019; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Viñals, Francesc/F-5928-2016; Santalucia, Tomas/I-7411-2012; Santalucia, Tomas/B-6140-2012	Viñals, Francesc/0000-0002-9918-6751; Santalucia, Tomas/0000-0003-4604-9195; Santalucia, Tomas/0000-0003-4604-9195; Fandos, Cesar/0000-0001-7348-1376; Palacin, Manuel/0000-0002-8670-293X				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHALLICE CE, 1973, ULTRASTRUCTURE MAMMA, V6, P91; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHENG W, 1995, LAB INVEST, V72, P646; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CLARK CM, 1971, AM J PHYSIOL, V220, P583; CLAYCOMB WC, 1976, J BIOL CHEM, V251, P6082; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P3229; CLAYCOMB WC, 1983, ADV EXP MED BIOL, V161, P249; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gould G.W., 1997, FACILITATIVE GLUCOSE, P1; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Koban MU, 1998, CARDIOVASC RES, V37, P405, DOI 10.1016/S0008-6363(97)00276-9; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar HL, 1997, AM J CARDIOL, V80, pA90, DOI 10.1016/S0002-9149(97)00462-1; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIU ML, 1994, J BIOL CHEM, V269, P28514; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MCCULLY JD, 1988, BIOCHEM J, V256, P441, DOI 10.1042/bj2560441; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; NEWSHOLME EA, 1983, BIOCH MED SCI, P228; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; Paternostro G, 1996, J CLIN INVEST, V98, P2094, DOI 10.1172/JCI119015; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; REN JM, 1993, J BIOL CHEM, V268, P16113; RIBADEAUDUMAS A, 1999, IN PRESS CARDIOVASC; RICHARDSON JM, 1993, J BIOL CHEM, V268, P21021; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sadoshima J, 1997, CIRC RES, V80, P228, DOI 10.1161/01.RES.80.2.228; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; SHAO ZH, 1995, ONCOGENE, V10, P221; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Torrance CJ, 1997, ENDOCRINOLOGY, V138, P1215, DOI 10.1210/en.138.3.1215; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WANG C, 1985, P NATL ACAD SCI USA, V82, P3621, DOI 10.1073/pnas.82.11.3621; WHITE MK, 1995, INT J ONCOL, V7, P701; Ye JP, 1996, MOL CELL BIOL, V16, P6178; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	67	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17626	17634		10.1074/jbc.274.25.17626	http://dx.doi.org/10.1074/jbc.274.25.17626			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364200	hybrid, Green Published			2022-12-27	WOS:000080974300036
J	Sonveaux, N; Vigano, C; Shapiro, AB; Ling, V; Ruysschaert, JM				Sonveaux, N; Vigano, C; Shapiro, AB; Ling, V; Ruysschaert, JM			Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein - A tryptophan fluorescence quenching analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; ATP-DEPENDENT TRANSPORT; DRUG-TRANSPORT; SITES; NUCLEOTIDE; MECHANISM; CYSTEINE	Ligand-dependent changes in accessibility of purified P-glycoprotein, functionally reconstituted in liposomes, were investigated by fluorescence measurements.. Trp quenching experiments provided evidence that P-glyeoprotein adopts different tertiary structures upon binding of drug substrates in the absence and presence of MgATP and its nonhydrolyzable analog, MgATP gamma S, Five anthracycline derivatives were tested as drug substrates: daunorubicin, 4'-epi-doxorubicin, iododoxorubicin, 4-demethoxy-daunorubicin, and methoxy-morpholino-doxorubicin. Among them, daunorubicin and 4'-epi-doxorubicin have been shown to be rejected outside the multidrug-resistant cells, whereas the three others have been shown to accumulate in multidrug-resistant cells overexpressing P-glycoprotein and therefore retain their cytotoxic activity. A small conformational change was associated with nucleotide 'binding and amplified after nucleotide hydrolysis, Different conformational states were adopted by P-glycoprotein upon the addition of the anthracycline derivatives in the absence and presence of MgATP or MgATP gamma S. These conformational changes are shown to be related to the nature of the antitumor agents and more precisely to their capacity to accumulate in resistant cells, These data also suggest that the cytotoxicity of iododoxorubicin and 4-demethoxy-daunorubicin is related to the fact they are not transported by P-glycoprotein, On the contrary, methoxy-morpholino-doxorubicin cytotoxicity may be explained in terms of its rapid reincorporation into the:plasma membrane after being transported by P-glycoprotein.	Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	Universite Libre de Bruxelles; Vrije Universiteit Brussel; British Columbia Cancer Agency	Ruysschaert, JM (corresponding author), Free Univ Brussels, Chim Phys Macromol Interfaces Lab, CP 206-2,Bd Triomphe, B-1050 Brussels, Belgium.							BOSCH L, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF37; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Eytan GD, 1996, J BIOL CHEM, V271, P12897, DOI 10.1074/jbc.271.22.12897; FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Goldstein LJ, 1996, EUR J CANCER, V32A, P1039, DOI 10.1016/0959-8049(96)00100-1; GOTTESMAN MM, 1993, CANCER RES, V53, P747; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Praet M, 1996, BIOCHEM PHARMACOL, V51, P1341, DOI 10.1016/0006-2952(96)00042-1; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; Scala S, 1997, MOL PHARMACOL, V51, P1024, DOI 10.1124/mol.51.6.1024; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P115, DOI 10.1111/j.1432-1033.1997.00115.x; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SKACH WR, 1993, J BIOL CHEM, V268, P6903; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	35	84	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17649	17654		10.1074/jbc.274.25.17649	http://dx.doi.org/10.1074/jbc.274.25.17649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364203	hybrid			2022-12-27	WOS:000080974300039
J	Upadhyaya, AB; Lee, SH; DeJong, J				Upadhyaya, AB; Lee, SH; DeJong, J			Identification of a general transcription factor TFIIA alpha/beta homolog selectively expressed in testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TBP-DNA BINDING; ACTIVATED TRANSCRIPTION; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SMALL-SUBUNIT; 2 GENES	In this paper we describe the isolation of a cDNA that encodes a human TFIIA alpha/beta-like factor (ALF). The open reading frame of ALF predicts a protein of 478 amino acids that contains characteristic N- and C-terminal conserved domains separated by an internal nonconserved domain, In addition, a rare ALF-containing cDNA, which possesses an extended N terminus (Stoned B/TFIIA alpha/beta-like factor; SALF) has also been identified. The results of Northern and dot blot analyses show that ALF is expressed almost exclusively in testis; in contrast, TFIIA alpha/beta and TFIIA gamma are enriched in testis but are also widely expressed in other human tissues; Recombinant ALF (69 kDa) and TFIITA gamma (12 kDa) polypeptides produced in Escherichia coli form an ALF/gamma complex that can stabilize TBP-TATA interactions in an electrophoretic mobility shift assay. The ALF/gamma complex is also able to restore transcription from the adenovirus major late promoter using HeLa cell nuclear extracts that have been depleted of TFIIA, Overall, the data show that ALF is a functional homolog of human general transcription factor TFIIA alpha/beta that may be uniquely important to testis biology.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA.							Andrews J, 1996, GENETICS, V143, P1699; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BERNSTEIN R, 1994, J BIOL CHEM, V269, P24361; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Eddy EM, 1995, REPROD FERT DEVELOP, V7, P695, DOI 10.1071/RD9950695; Emami KH, 1997, GENE DEV, V11, P3007, DOI 10.1101/gad.11.22.3007; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Schmidt EE, 1997, DEV BIOL, V184, P138, DOI 10.1006/dbio.1997.8514; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50	61	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18040	18048		10.1074/jbc.274.25.18040	http://dx.doi.org/10.1074/jbc.274.25.18040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364255	hybrid			2022-12-27	WOS:000080974300091
J	Chen, HM; Wei, SQ; Engelman, A				Chen, HM; Wei, SQ; Engelman, A			Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRAL DNA INTEGRATION; PHOTO-CROSS-LINKING; HIV-1 INTEGRASE; CONCERTED INTEGRATION; PREINTEGRATION COMPLEXES; INVITRO; VITRO; PROTEIN; BINDING; MUTAGENESIS	Mu-mediated polymerase chain reaction footprinting was used to investigate the protein-DNA structure of human immunodeficiency virus type I (HIV-I) preintegration complexes. Preintegration complexes were partially purified from cells after using an established coculture infection technique as well as a novel technique using cell-free supernatant from transfected cells as the source of virus. Footprinting revealed that bound proteins protected the terminal 200-250 base pairs of each viral end from nuclease attack. Bound proteins also caused strong transpositional enhancements near each end of HIV-I. In contrast, regions of viral DNA internal to the ends did not show evidence of strong protein binding. The end regions of preintegrative HIV-I apparently form a unique nucleoprotein structure, which we term the intasome to distinguish it from the greater preintegration complex. Our novel system also allowed us to analyze the structure and function of preintegration complexes isolated from cells infected with integrase mutant viruses. Complexes were derived from viruses defective for either integrase catalysis, integrase binding to the viral DNA substrate, or an unknown function in the carboxyl-terminal domain of the integrase protein. None of these mutant complexes supported detectable integration activity. Despite the presence of the mutant integrase proteins in purified samples, none of these nucleoprotein complexes displayed the native intasome structure detected in wildtype preintegration complexes. We conclude that multiple integrase functions are required to form the native structure of the HIV-I intasome in infected cells.	Dana Farber Canc Inst, Dept Canc Immunol & Aids, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & Aids, 44 Binney St, Boston, MA 02115 USA.			Chen, Hongmin/0000-0002-8914-1875	NIAID NIH HHS [AI39394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039394, R01AI039394] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; Brown P. O., 1997, P161; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUJACZ G, 1995, J MOL BIOL, V253, P336; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Engelman A, 1997, J VIROL, V71, P3507, DOI 10.1128/JVI.71.5.3507-3514.1997; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gerton JL, 1998, J VIROL, V72, P5046, DOI 10.1128/JVI.72.6.5046-5055.1998; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Lavoie BD, 1996, CURR TOP MICROBIOL, V204, P83; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Miyoshi I., 1982, GANN MONOGR, V28, P219; Nilsen BM, 1996, J VIROL, V70, P1580, DOI 10.1128/JVI.70.3.1580-1587.1996; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; RATNER L, 1985, NATURE, V313, P227; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Sambrook J., 2002, MOL CLONING LAB MANU; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; WEISS A, 1984, J IMMUNOL, V133, P123; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	40	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17358	17364		10.1074/jbc.274.24.17358	http://dx.doi.org/10.1074/jbc.274.24.17358			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358097	hybrid, Green Submitted			2022-12-27	WOS:000080780400096
J	Coleman, DE; Sprang, SR				Coleman, DE; Sprang, SR			Structure of G(i alpha 1)center dot GppNHp, autoinhibition in a G(alpha) protein-substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ELONGATION-FACTOR TU; X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ADENYLYL-CYCLASE; TRANSITION-STATE; STEREOCHEMICAL COURSE; BINDING PROTEINS; RGS PROTEINS	The structure of the G protein G(i alpha 1) complexed with the nonhydrolyzable GTP analog guanosine-5'-(beta gamma-imino)triphosphate (GppNHp) has been determined at a resolution of 1.5 Angstrom. In the active site of G(i alpha 1). GppNHp, a water molecule is hydrogen bonded to the side chain of Glu(43) and to an oxygen atom of the gamma-phosphate group. The side chain of the essential catalytic residue Gln(204) assumes a conformation which is distinctly different from that observed in complexes with either guanosine 5'-O-3-thiotriphosphate or the transition state analog GDP . AIF(4)(-). Hydrogen bonding and steric interactions position Gln(204) such that it interacts with a presumptive nucleophilic water molecule, but cannot interact with the pentacoordinate transition state. Gln(204) must be released from this auto-inhibited state to participate in catalysis, RGS proteins may accelerate the rate of GTP hydrolysis by G protein alpha subunits, in part, by inserting an amino acid side chain into the site occupied by Gln(204), thereby destabilizing the auto-inhibited state of G alpha.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POSNER BA, 1999, IN PRESS BIOLCHEMIST; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; Raw AS, 1997, BIOCHEMISTRY-US, V36, P15660, DOI 10.1021/bi971912p; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEBB MR, 1981, J BIOL CHEM, V256, P7734; Zor T, 1998, FEBS LETT, V433, P326, DOI 10.1016/S0014-5793(98)00930-2	47	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16669	16672		10.1074/jbc.274.24.16669	http://dx.doi.org/10.1074/jbc.274.24.16669			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358003	hybrid			2022-12-27	WOS:000080780400002
J	Goretzki, L; Burg, MA; Grako, KA; Stallcup, WB				Goretzki, L; Burg, MA; Grako, KA; Stallcup, WB			High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MEMBRANE-SPANNING PROTEOGLYCAN; O2A PROGENITOR CELLS; PDGF ALPHA-RECEPTOR; RAT OPTIC-NERVE; HEPARAN-SULFATE; ENDOTHELIAL-CELLS; EXPRESSION; SURFACE; GENE	NG2 is a transmembrane chondroitin sulfate proteoglycan that is expressed by immature progenitor cells in several developmental lineages and by some types of malignant cells. In vitro studies have suggested that NG2 participates in growth factor activation of the platelet-derived growth factor-alpha receptor. In this study the ability of recombinant NG2 core protein to interact with several different growth factors (epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF)-AA, PDGF-BB, vascular endothelial growth factor (VEGF)(165) and transforming growth factor (TGF)-beta 1) was investigated using two different assay systems: enzyme-linked immunosorbent assay-type solid-phase binding and an optical biosensor (BIAcore) system. High-affinity binding of bFGF and PDGF-AA to the core protein of NG2 could be demonstrated with both types of assays. Using both the BIAcore software analysis program and nonlinear regression analysis of the solid phase binding data, K-D values in the low nanomolar range were obtained for binding of each of these growth factors to NG2. The results further indicate that NG2 contains at least two binding sites for each of these two growth factors. PDGF-BB, TGF-beta 1, VEGF, and EGF exhibited little or no binding to NG2 in either type of assay. These data suggest that NG2 can have an important role in organizing and presenting some types of mitogenic growth factors at the cell surface.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Goretzki, L (corresponding author), Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [F32CA072220] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA72220] Funding Source: Medline; NHLBI NIH HHS [F32 HL09541] Funding Source: Medline; NINDS NIH HHS [R01 NS21990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; BERTSHOLTZ C, 1986, NATURE, V320, P695; BOGLER O, 1990, P NATL ACAD SCI USA, V76, P514; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P176; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; LEGER O, 1994, INT J CANCER, V58, P700, DOI 10.1002/ijc.2910580514; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NISHIYAMA A, 1991, DEVELOPMENT, V111, P933; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1984, EMBO J, V3, P1857, DOI 10.1002/j.1460-2075.1984.tb02059.x; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REAL FX, 1985, CANCER RES, V45, P4401; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHRAPPE M, 1991, CANCER RES, V51, P4986; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tillet E, 1997, J BIOL CHEM, V272, P10769; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	173	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16831	16837		10.1074/jbc.274.24.16831	http://dx.doi.org/10.1074/jbc.274.24.16831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358027	hybrid			2022-12-27	WOS:000080780400026
J	Murayama, T; Oba, T; Katayama, E; Oyamada, H; Oguchi, K; Kobayashi, M; Otsuka, K; Ogawa, Y				Murayama, T; Oba, T; Katayama, E; Oyamada, H; Oguchi, K; Kobayashi, M; Otsuka, K; Ogawa, Y			Further characterization of the type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; BINDING-PROTEIN ISOFORMS; BULLFROG SKELETAL-MUSCLE; CA2+ RELEASE; ELECTRON-MICROSCOPY; FK506-BINDING PROTEIN; 3-DIMENSIONAL ARCHITECTURE; CRYOELECTRON MICROSCOPY; LOCALIZATION	We characterized type 3 ryanodine receptor (RyR3) purified from rabbit diaphragm by immunoaffinity chromatography using a specific antibody. The purified receptor was free from 12-kDa FK506-binding protein, although it retained the ability to bind 12-kDa FK506-binding protein. Negatively stained images of RyR3 show a characteristic rectangular structure that was indistinguishable from RyR1. The location of the D2 segment, which exists uniquely in the RyR1 isoform, was determined as the region around domain 9 close to the corner of the square-shaped assembly, with use of D2-directed antibody as a probe. The RS RS homotetramer had a single class of high affinity [H-3]ryanodine-binding sites with a stoichiometry of 1 mol/mol. In planar lipid bilayers, RyR3 displayed cation channel activity that was modulated by several ligands including Ca2+, Mg2+, caffeine, and ATP, which is consistent with [H-3]ryanodine binding activity. RyR3 showed a slightly larger unit conductance and a longer mean open time than RyR1, Whereas RyR1 showed two classes of channel activity with distinct open probabilities (P-o), RyR3 displayed a homogeneous and steeply Ca2+-dependent activity with P-o similar to 1. RyR3 was more steeply affected in the channel activity by sulfhydryl-oxidizing and -reducing reagents than RyR1, suggesting that the channel activity of RyR3 may be transformed more precipitously by the redox state. This is also a likely explanation for the difference in the Ca2+ dependence of RyR3 between [H-3]ryanodine binding and channel activity.	Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan; Nagoya City Univ, Sch Med, Dept Physiol, Nagoya 4678601, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Tokyo 1088639, Japan; Showa Univ, Sch Med, Dept Pharmacol, Tokyo 1428555, Japan; Fujisawa Pharmaceut Co Ltd, Osaka 5418541, Japan	Juntendo University; Nagoya City University; University of Tokyo; Showa University; Astellas Pharmaceuticals	Ogawa, Y (corresponding author), Juntendo Univ, Sch Med, Dept Pharmacol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 113, Japan.							AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; Copello JA, 1997, BIOPHYS J, V73, P141, DOI 10.1016/S0006-3495(97)78055-X; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KOBAYASHI M, 1993, TRANSPLANT P, V25, P655; KOSHITA M, 1989, CAN J PHYSIOL PHARM, V67, P890, DOI 10.1139/y89-139; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Oba T, 1997, AM J PHYSIOL-CELL PH, V273, pC1588, DOI 10.1152/ajpcell.1997.273.5.C1588; Oba T, 1998, AM J PHYSIOL-CELL PH, V274, pC914, DOI 10.1152/ajpcell.1998.274.4.C914; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Shirakata Y, 1995, TRANSPLANTATION, V60, P1582, DOI 10.1097/00007890-199560120-00035; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wagenknecht T, 1997, CURR OPIN STRUC BIOL, V7, P258, DOI 10.1016/S0959-440X(97)80034-6; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; YAMAMOTO K, 1985, J MOL BIOL, V183, P287, DOI 10.1016/0022-2836(85)90222-0; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069	52	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17297	17308		10.1074/jbc.274.24.17297	http://dx.doi.org/10.1074/jbc.274.24.17297			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358090	hybrid			2022-12-27	WOS:000080780400089
J	Ahmad, A; Takami, Y; Nakayama, T				Ahmad, A; Takami, Y; Nakayama, T			WD repeats of the p48 subunit of chicken chromatin assembly factor-1 required for in vitro interaction with chicken histone deacetylase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL LINE; DNA-REPLICATION INVITRO; VARIANT CAUSES CHANGES; TARGETED DISRUPTION; CRYSTAL-STRUCTURE; PROTEIN-PATTERNS; GENE-EXPRESSION; IDENTIFICATION; PROLIFERATION; ACETYLATION	Chromatin assembly factor-1 (CAF-1) is essential for chromatin assembly in eukaryotes, and comprises three subunits of 150 kDa (p150), 60 kDa (p60), and 48 kDa (p48). We cloned and sequenced cDNA encoding the small subunit of the chicken CAF-1, chCAF-1p48. It consists of 425 amino acid residues including a putative initiation Met, possesses seven WD repeat motifs, and contains only one amino acid change relative to the human and mouse CAF-1p48s. The immunoprecipitation experiment followed by Western blotting revealed that chCAF-1p48 interacts with chicken histone deacetylases (chHDAC-1 and -2) in vivo. The glutathione S-transferase pulldown affinity assay revealed the in vitro interaction of chCAF-1p48 with chHDAC-1, -2, and -3. We showed that the p48 subunit tightly binds to two regions of chHDAC-2, located between amino acid residues 82-180 and 245-314, respectively. We also established that two N-terminal, two C-terminal, or one N-terminal and one C-terminal WD repeat motif of chCAF-1p48 are required for this interaction, using deletion mutants of the respective regions. These results suggest that chCAF-1p48 is involved in many aspects of DNA-utilizing processes, through alterations in the chromatin structure based on both the acetylation and deacetylation of core histones.	Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan	University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan.							ANNUNZIATO AT, 1995, NUCLEOSOME, P31; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; Ladomery M, 1997, GENE, V198, P275, DOI 10.1016/S0378-1119(97)00325-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sambrook J., 2002, MOL CLONING LAB MANU; SEGUCHI K, 1995, J MOL BIOL, V254, P869, DOI 10.1006/jmbi.1995.0662; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; Takami Y, 1997, J MOL BIOL, V265, P394, DOI 10.1006/jmbi.1996.0733; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1995, J BIOL CHEM, V270, P30664, DOI 10.1074/jbc.270.51.30664; TAKAMI Y, 1995, J MOL BIOL, V250, P420, DOI 10.1006/jmbi.1995.0387; Takami Y, 1997, BBA-GENE STRUCT EXPR, V1354, P105, DOI 10.1016/S0167-4781(97)00077-8; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wolffe A., 1995, CHROMATIN STRUCTURE	40	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16646	16653		10.1074/jbc.274.23.16646	http://dx.doi.org/10.1074/jbc.274.23.16646			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347232	hybrid			2022-12-27	WOS:000080668600092
J	Zeng, FY; Hopp, A; Soldner, A; Wess, J				Zeng, FY; Hopp, A; Soldner, A; Wess, J			Use of a disulfide cross-linking strategy to study muscarinic receptor structure and mechanisms of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 3RD CYTOPLASMIC LOOP; SITE-DIRECTED MUTAGENESIS; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; HORMONE RECEPTOR; BOVINE RHODOPSIN; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; CHOLINERGIC RECEPTOR	To gain insight into the molecular architecture of the cytoplasmic surface of G protein-coupled receptors, we have developed a disulfide cross-linking strategy using the m3 muscarinic receptor as a model system. To facilitate the interpretation of disulfide cross-linking data, we initially generated a mutant m3 muscarinic receptor (referred to as m3'(3C)-Xa) in which most native Cys residues had been deleted or substituted with Ala or Ser (remaining Cys residues Cys-140, Cys-220, and Cys-532) and in which the central portion of the third intracellular loop had been replaced with a factor Xa cleavage site. Radioligand binding and second messenger assays showed that the m3'(3C)-Xa mutant receptor was fully functional. In the next step, pairs of Cys residues were reintroduced into the m3'(3C)-Xa construct, thus generating 10 double Cys mutant receptors, All 10 mutant receptors contained a Cys residue at position 169 at the beginning of the second intracellular loop and a second Cys within the C-terminal portion of the third intracellular loop, at positions 484-493, Radioligand binding studies and phosphatidylinositol assays indicated that all double Cys mutant receptors were properly folded. Membrane lysates prepared from COS-7 cells transfected with the different mutant receptor constructs were incubated with factor Xa protease and the oxidizing agent Cu(II)-(1,10-phenanthroline)(3), and the formation of intramolecular disulfide bonds between juxtaposed Cys residues was monitored by using a combined immunoprecipitation/immunoblotting strategy. To our surprise, efficient disulfide cross-linking was observed with 8 of the 10 double Cys mutant receptors studied (Cys-169/Cys-484 to Cys-491), suggesting that the intracellular m3 receptor surface is characterized by pronounced backbone fluctuations. Moreover, [S-35]guanosine 5'-3-O-(thio)triphosphate binding assays indicated that the formation of intramolecular disulfide cross-links prevented or strongly inhibited receptor-mediated G protein activation, suggesting that the highly dynamic character of the cytoplasmic receptor surface is a prerequisite for efficient receptor-G protein interactions. This is the first study using a disulfide mapping strategy to examine the three-dimensional structure of a hormone-activated G protein-coupled receptor.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.							Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cai KW, 1997, P NATL ACAD SCI USA, V94, P14267, DOI 10.1073/pnas.94.26.14267; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Higuchi R., 1989, PCR TECHNOLOGY, P61; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JUNG H, 1995, FEBS LETT, V358, P133, DOI 10.1016/0014-5793(94)01409-T; Jung H, 1996, BIOCHEMISTRY-US, V35, P6399, DOI 10.1021/bi952575s; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P97; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LAZARENO S, 1993, LIFE SCI, V52, P449, DOI 10.1016/0024-3205(93)90301-I; LEE GF, 1994, J BIOL CHEM, V269, P29920; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nielsen SM, 1998, EUR J BIOCHEM, V251, P217, DOI 10.1046/j.1432-1327.1998.2510217.x; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; YEAGLE PL, 1995, BIOCHEMISTRY-US, V34, P14621, DOI 10.1021/bi00045a002; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	68	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16629	16640		10.1074/jbc.274.23.16629	http://dx.doi.org/10.1074/jbc.274.23.16629			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347230	hybrid			2022-12-27	WOS:000080668600090
J	Cartier, C; Sivard, P; Tranchat, C; Decimo, D; Desgranges, C; Boyer, V				Cartier, C; Sivard, P; Tranchat, C; Decimo, D; Desgranges, C; Boyer, V			Identification of three major phosphorylation sites within HIV-1 capsid - Role of phosphorylation during the early steps of infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B VIRUS; PROTEIN-KINASE-C; VIRAL MATRIX PROTEIN; TYPE-1 VPU PROTEIN; NF-KAPPA-B; NUCLEAR IMPORT; CORE PROTEIN; REV PROTEIN; POSTTRANSLATIONAL MODIFICATIONS	We previously reported the presence of two cellular serine/threonine protein kinases incorporated in human immunodeficiency virus type 1 (HIV-1) particles. One protein kinase is MAPK ERK2 (mitogen-activated protein kinase), whereas the other one, a 53-kDa protein, still needs to be identified. Furthermore, we demonstrated that the capsid protein CAp24 is phosphorylated by one of those two virion-associated protein kinases (Cartier, C., Deckert, M., Grangeasse, C., Trauger, R., Jensen, F., Bernard, k, Cozzone, k, Desgranges, C., and Boyer, V. (1997) J. Virol. 71, 4832-4837). In this study, we showed that CAp24 is not a direct substrate of MAPK ERK2. Moreover, using site-directed mutagenesis of each of the 9 serine residues of CAp24, we demonstrated the phosphorylation of 3 serine residues (Ser-109, Ser-149, and Ser-178) in the CAp24. Substitution of each serine residue did not affect viral budding, nor viral structure. By contrast, substitution of Ser-109, Ser-149, or Ser-178 affects viral infectivity by preventing the reverse transcription process to be completely achieved. Our results suggest that CAp24 serine phosphorylation is essential for viral uncoating process.	INSERM, U271, F-69424 Lyon 03, France; Ecole Normale Super Lyon, INSERM, U412, LaboRetro,Unite Virol Humaine, F-69364 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cartier, C (corresponding author), INSERM, U271, 151 Cours A Thomas, F-69424 Lyon 03, France.		Boyer, Veronique/E-6122-2017	Decimo, Didier/0000-0002-0390-1205				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Briant L, 1997, J BIOL CHEM, V272, P19441, DOI 10.1074/jbc.272.31.19441; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; Briant L, 1998, J IMMUNOL, V160, P1875; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; Bukrinskaya AG, 1996, MOL BIOL+, V30, P303; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COATES K, 1995, J GEN VIROL, V76, P837, DOI 10.1099/0022-1317-76-4-837; Coates K, 1997, J BIOL CHEM, V272, P12289, DOI 10.1074/jbc.272.19.12289; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; Duclos-Vallee JC, 1998, J GEN VIROL, V79, P1665, DOI 10.1099/0022-1317-79-7-1665; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fouts DE, 1997, BIOCHEMISTRY-US, V36, P13256, DOI 10.1021/bi971551d; Freed EO, 1997, CELL, V88, P171, DOI 10.1016/S0092-8674(00)81836-X; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; GARNIER L, 1998, AIDS SA, V12, P5; GERLICH WH, 1982, J VIROL, V42, P761, DOI 10.1128/JVI.42.3.761-766.1982; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KANN M, 1994, J VIROL, V68, P7993, DOI 10.1128/JVI.68.12.7993-8000.1994; Kau JH, 1998, J VIROL, V72, P3796, DOI 10.1128/JVI.72.5.3796-3803.1998; LIAO W, 1995, J VIROL, V69, P1025, DOI 10.1128/JVI.69.2.1025-1029.1995; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; Luo TC, 1997, J VIROL, V71, P2535, DOI 10.1128/JVI.71.3.2535-2539.1997; MACHIDA A, 1991, J VIROL, V65, P6024, DOI 10.1128/JVI.65.11.6024-6030.1991; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; Meggio F, 1996, BIOCHEM BIOPH RES CO, V226, P547, DOI 10.1006/bbrc.1996.1392; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Paul M, 1997, VIROLOGY, V232, P207, DOI 10.1006/viro.1997.8541; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SONG WH, 1995, NUCLEIC ACIDS RES, V23, P3609, DOI 10.1093/nar/23.17.3609; Spearman P, 1996, J VIROL, V70, P8187, DOI 10.1128/JVI.70.11.8187-8194.1996; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; Tiganos E, 1997, J VIROL, V71, P4452, DOI 10.1128/JVI.71.6.4452-4460.1997; Trono D, 1997, CELL, V88, P173, DOI 10.1016/S0092-8674(00)81837-1; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; Yin L, 1998, J VIROL, V72, P6430, DOI 10.1128/JVI.72.8.6430-6436.1998	62	65	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19434	19440		10.1074/jbc.274.27.19434	http://dx.doi.org/10.1074/jbc.274.27.19434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383459	hybrid			2022-12-27	WOS:000081196300082
J	Chung, SH; Joberty, G; Gelino, EA; Macara, IG; Holz, RW				Chung, SH; Joberty, G; Gelino, EA; Macara, IG; Holz, RW			Comparison of the effects on secretion in chromaffin and PC12 cells of Rab3 family members and mutants - Evidence that inhibitory effects are independent of direct interaction with Rabphilin3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLE; CA2+-DEPENDENT EXOCYTOSIS; ENDOPLASMIC-RETICULUM; NEUROENDOCRINE CELLS; REGULATED SECRETION; TARGET PROTEIN; SMG P25A; RAS; EXPRESSION	The Rab class of low molecular weight GTPases has been implicated in the regulation of vesicular trafficking between membrane compartments in eukaryotic cells. The Rab3 family consisting of four highly homologous isoforms is associated with secretory granules and synaptic vesicles. Many different types of experiments indicate that Rab3a is a negative regulator of exocytosis and that its GTP-bound form interacts with Rabphilin3, a possible effector. Overexpression of Rabphilin3 in chromaffin cells enhances secretion. We have investigated the expression, localization, and effects on secretion of the various members of the Rab3 family in bovine chromaffin and PC12 cells. We found that Rab3a, Rab3b, Rab3c, and Rab3d are expressed to varying degrees in PC12 cells and in a fraction enriched in chromaffin granule membranes from the adrenal medulla, Immunocytochemistry revealed that all members of the family when overexpressed in PC12 cells localize to secretory granules. Binding constants for the interaction of the GTP-bound forms of Rab3a, Rab3b, Rab3c, and Rab3d with Rabphilin3 were comparable (K-d = 10-20 nM). Overexpression of each of the four members of the Rab3 family inhibited secretion. Mutations in Rab3a were identified that strongly impaired the ability of the GTP-bound form to interact with Rabphilin3, The mutated proteins inhibited secretion similarly to wild type Rab3a, Although Rab3a and Rabphilin3 are located on the same secretory granule or secretory vesicle and interact both in vitro and in situ, it is concluded that the inhibition of secretion by overexpression of Rab3a is unrelated to its ability to interact with Rabphilin3.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Michigan System; University of Michigan; University of Virginia	Holz, RW (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA056300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050127] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56300] Funding Source: Medline; NIDDK NIH HHS [R01 DK50127] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arribas M, 1997, EUR J CELL BIOL, V74, P209; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; Chung SH, 1998, J BIOL CHEM, V273, P10240, DOI 10.1074/jbc.273.17.10240; Chung SH, 1997, J NEUROCHEM, V69, P164; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DARCHEN F, 1995, J CELL SCI, V108, P1639; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; Johannes L, 1998, J NEUROCHEM, V71, P1127; Johannes L, 1996, J CELL SCI, V109, P2875; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lin CG, 1997, BIOCHEM J, V324, P85, DOI 10.1042/bj3240085; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; Nonet ML, 1997, J NEUROSCI, V17, P8061; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; Regazzi R, 1996, J CELL SCI, V109, P2265; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WICK PF, 1993, J BIOL CHEM, V268, P10983; WILSON SP, 1996, ANAL BIOCHEM, V226, P212; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	59	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18113	18120		10.1074/jbc.274.25.18113	http://dx.doi.org/10.1074/jbc.274.25.18113			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364266	hybrid			2022-12-27	WOS:000080974300102
J	Daviet, L; Lehtonen, JYA; Tamura, K; Griese, DP; Horiuchi, M; Dzau, VJ				Daviet, L; Lehtonen, JYA; Tamura, K; Griese, DP; Horiuchi, M; Dzau, VJ			Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; ADRENERGIC-RECEPTORS; KINASES; EXPRESSION; DOMAIN; AT(1); TAIL; IDENTIFICATION	The carboxyl-terminal cytoplasmic domain of the angiotensin II type 1 (AT(1)) receptor has recently been shown to interact with several classes of cytoplasmic proteins that regulate different aspects of AT(1) receptor physiology. Employing yeast two-hybrid screening of a mouse kidney cDNA library with the carboxyl-terminal cytoplasmic domain of the murine AT(1a) receptor as a bait, we have isolated a novel protein with a predicted molecular mass of 18 kDa, which we have named ATRAP (for AT(1) receptor-associated protein). ATRAP interacts specifically with the carboxyl-terminal domain of the AT(1a) receptor but not with those of ansotensin II type 2 (AT(2)), m(3) muscarinic acetylcholine, bradykinin B-2, endothelin B, and beta(2)-adrenergic receptors, The mRNA of ATRAP was abundantly expressed in kidney, heart, and testis but was poorly expressed in lung, liver, spleen, and brain. The ATRAP-AT(1a) receptor association was confirmed by affinity chromatography, by specific co-immunoprecipitation of the two proteins, and by fluorescence microscopy, showing co-localization of these proteins in intact cells. Overexpression of ATRAP in COS-7 cells caused a marked inhibition of AT(1a) receptor-mediated activation of phospholipase C without affecting m(3) receptor-mediated activation. In conclusion, we have isolated a novel protein that interacts specifically with the carboxyl-terminal cytoplasmic domain of the AT(1a) receptor and affects AT(1a) receptor signaling.	Harvard Univ, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Dzau, VJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL046631, R01HL035252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35610, HL35252, HL46631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSENG MJ, 1995, J BIOL CHEM, V270, P17884, DOI 10.1074/jbc.270.30.17884; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	30	135	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17058	17062		10.1074/jbc.274.24.17058	http://dx.doi.org/10.1074/jbc.274.24.17058			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358057	hybrid			2022-12-27	WOS:000080780400056
J	Hoshino, S; Imai, M; Kobayashi, T; Uchida, N; Katada, T				Hoshino, S; Imai, M; Kobayashi, T; Uchida, N; Katada, T			The eukaryotic polypeptide chain releasing factor (eRF3/GSPT) carrying the translation termination signal to the 3 '-poly(A) tail of mRNA - Direct association of eRF3/GSPT with polyadenylate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; SACCHAROMYCES-CEREVISIAE; POLY(A); YEAST; ERF1; COMPLEX; GENE	The mammalian GTP-binding protein GSPT, whose carboxyl-terminal sequence is homologous to the eukaryotic elongation factor EF1 alpha, binds to the polypeptide chain releasing factor eRF1 to function as eRF3 in the translation termination. The amino-terminal domain of GSPT was, however, not required for the binding. Search for other GSPT-binding proteins in yeast two-hybrid screening system resulted in the identification of a cDNA encoding polyadenylate-binding protein (PABP), whose amino terminus is associating with the poly(A) tail of mRNAs presumably for their stabilization. The interaction appeared to be mediated through the carboxyl-terminal domain of PABP and the aminoterminal region of GSPT, Interestingly, multimerization of PABP with poly(A), which is ascribed to the action of its carboxyl-terminal domain, was completely inhibited by the interaction with the amino-terminal domain of GSPT. These results indicate that GSPT/eRF3 may play important roles not only in the termination of protein synthesis but also in the regulation of mRNA stability. Thus, the present study is the first report showing that GSPT/eRF3 carries the translation termination signal to 3'-poly(A) tail ubiquitously present in eukaryotic mRNAs.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan	University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan.			Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; EUSTICE DC, 1986, J MOL BIOL, V188, P207, DOI 10.1016/0022-2836(86)90305-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN DB, 1983, MOL CELL BIOL, V3, P1625, DOI 10.1128/MCB.3.9.1625; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1986, CELL, V45, P812; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; SURGUCHOV AP, 1980, FEBS LETT, V111, P175, DOI 10.1016/0014-5793(80)80786-1; SURGUCHOV AP, 1988, TRENDS BIOCHEM SCI, V13, P120, DOI 10.1016/0968-0004(88)90062-X; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	20	220	226	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16677	16680		10.1074/jbc.274.24.16677	http://dx.doi.org/10.1074/jbc.274.24.16677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358005	hybrid			2022-12-27	WOS:000080780400004
J	Krugmann, S; Hawkins, PT; Pryer, N; Braselmann, S				Krugmann, S; Hawkins, PT; Pryer, N; Braselmann, S			Characterizing the interactions between the two subunits of the p101/p110 gamma phosphoinositide 3-kinase and their role in the activation of this enzyme by G(beta gamma) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; KINASE; P85; DOMAINS; CLONING; PI3K	Recently, we have reported the purification and cloning of a novel G protein beta gamma subunit-activated phosphoinositide S-kinase from pig neutrophils. The enzyme comprises a p110 gamma catalytic subunit and a p101 regulatory subunit. Now we have cloned the human ortholog of p101 and generated panels of p101 and p110 gamma truncations and deletions and used these in in vitro and in vivo assays to determine the protein domains responsible for subunit interaction and activation by beta gamma subunits. Our results suggest large areas of p101 including both N- and C-terminal portions interact with the N-terminal half of p110 gamma, While modifications of the N terminus of p110 gamma could modulate its intrinsic catalytic activity, binding to the N-terminal region of p101 was found to be indispensable for activation of heterodimers with G(beta gamma).	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Onyx Pharmaceut, Richmond, CA 94806 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Krugmann, S (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.		Vermeren, Sonja/AAK-7442-2020	Vermeren, Sonja/0000-0002-8460-0884; Hawkins, Phillip/0000-0002-6979-0464				CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONS S, 1995, MOL CELL BIOL, V15, P4453; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	18	72	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17152	17158		10.1074/jbc.274.24.17152	http://dx.doi.org/10.1074/jbc.274.24.17152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358071	hybrid			2022-12-27	WOS:000080780400070
J	Sathyanarayana, UG; Freeman, LA; Lee, MS; Garrard, WT				Sathyanarayana, UG; Freeman, LA; Lee, MS; Garrard, WT			RNA polymerase-specific nucleosome disruption by transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; YEAST HSP82 GENE; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; HISTONE OCTAMER; DNA-TEMPLATE; IN-VITRO; ELONGATION; EXPRESSION	The nucleosomal chromatin structure within genes is disrupted upon transcription by RNA polymerase II. To determine whether this disruption is caused by transcription per se as opposed to the RNA polymerase source, we engineered the yeast chromosomal HSP82 gene to be exclusively transcribed by bacteriophage T7 RNA polymerase in vivo. Interestingly, we found that a fraction of the T7-generated transcripts were 3' end processed and polyadenylated at or near the 3' ends of the hsp82 and the immediately downstream CIN2 genes. Surprisingly, the nucleosomal structure of the T7-transcribed hsp82 gene remained intact, in marked contrast to the disrupted structure generated by much weaker, basal level transcription of the wild type gene by RNA polymerase II under non-heat shock conditions. Therefore, disruption of chromatin structure by transcription is dependent on the RNA polymerase source. We propose that the observed RNA polymerase dependence for transcription-induced nucleosome disruption may be related either to the differential recruitment of chromatin remodeling complexes, the rates of histone octamer translocation and nucleosome reformation during polymerase traversal, and/or the degree of transient torsional stress generated by the elongating polymerase.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Sookmyung Womens Univ, Dept Biol, Seoul 140742, South Korea	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Sookmyung Women's University	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Hammon Biomed Res Bldg,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	garrard@utsw.swmed.edu			NIGMS NIH HHS [GM22201, GM29935] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022201, R01GM029935] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansari A, 1997, MOL CELL BIOL, V17, P7061, DOI 10.1128/MCB.17.12.7061; Bentley D, 1998, NATURE, V395, P21, DOI 10.1038/25616; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0; Cook PR, 1997, J CELL SCI, V110, P1033; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; Hamiche A, 1998, J BIOL CHEM, V273, P9261, DOI 10.1074/jbc.273.15.9261; HEGGELERBORDIER BT, 1995, EMBO J, V14, P2561; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; MA D, 1994, J BIOL CHEM, V269, P15362; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MCDANIEL D, 1989, MOL CELL BIOL, V9, P4789, DOI 10.1128/MCB.9.11.4789; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; ONEILL TE, 1995, NUCLEIC ACIDS RES, V23, P1075, DOI 10.1093/nar/23.6.1075; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PUERTA C, 1993, J BIOL CHEM, V268, P26663; Reeve JN, 1997, CELL, V89, P999, DOI 10.1016/S0092-8674(00)80286-X; SADHALE PP, 1992, MOL CELL BIOL, V12, P4262, DOI 10.1128/MCB.12.10.4262; SANGRAM SS, 1987, MOL CELL BIOL, V7, P3602; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shuman S, 1997, P NATL ACAD SCI USA, V94, P12758, DOI 10.1073/pnas.94.24.12758; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; SZENTGYORGYI C, 1987, J MOL BIOL, V193, P71, DOI 10.1016/0022-2836(87)90628-0; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VANHOLDE KE, 1988, CHROMATIN, P1; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	61	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16431	16436		10.1074/jbc.274.23.16431	http://dx.doi.org/10.1074/jbc.274.23.16431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347204	hybrid			2022-12-27	WOS:000080668600064
J	Sheikh, MS; Fernandez-Salas, E; Yu, MH; Hussain, A; Dinman, JD; Peltz, SW; Huang, Y; Fornace, AJ				Sheikh, MS; Fernandez-Salas, E; Yu, MH; Hussain, A; Dinman, JD; Peltz, SW; Huang, Y; Fornace, AJ			Cloning and characterization of a human genotoxic and endoplasmic reticulum stress-inducible cDNA that encodes translation initiation factor 1 (eIF(1A121/SUI1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; SACCHAROMYCES-CEREVISIAE; GENE; DNA; PROTEIN; GROWTH; YEAST; SUI1; THAPSIGARGIN; TRANSCRIPTS	We report the cloning and characterization of a DNA damage-inducible (DDI) transcript DDI A121. The full-length human DDI A121 cDNA contains an open reading frame of 113 amino acids, corresponding to a protein of 12.7 kDa. The deduced amino acid sequence of A121 shows high homology to the yeast translation initiation factor (eIF) sui1 and also exhibits perfect identity to the partial sequence of recently purified human eIF1. Expression of human A121 corrected the mutant suil phenotype in yeast, demonstrating that human A121 encodes a bona fide translation initiation factor that is equivalent to yeast sui1p. The mammalian A121/SUI1 gene exhibits two transcripts (1.35 kilobases and 0.65 kilobases) containing a common coding region but differing in their 3'-untranslated region. The long and short A121/SUI1 mRNAs are differentially regulated by genotoxic and endoplasmic reticulum stress. The genotoxic stress induction of A121/SUI1 mRNA is conserved in both humans and rodents and occurs in a p53-independent manner. Our identification of a stress-inducible cDNA that encodes eIF1 suggests that modulation of translation initiation appears to occur during cellular stress and may represent an important adaptive response to genotoxic as well as endoplasmic reticulum stress.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Programs Mol Biosci Rutgers, Piscataway, NJ 08854 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bldg 37,Rm 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Dinman, Jonathan/0000-0002-2402-9698	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESANSKY NJ, 1994, GENE, V141, P299, DOI 10.1016/0378-1119(94)90589-4; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Cui Y, 1996, EMBO J, V15, P5726, DOI 10.1002/j.1460-2075.1996.tb00956.x; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DINMAN JD, 1994, GENETICS, V136, P75; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GILL DL, 1992, ADV 2 MESSENGER PHOS, P265; HOLLANDER MC, 1996, NUCLEIC ACIDS RES, V12, P387; HOLLANDER MC, 1994, DNA REPAIR MECH IMPA, P221; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1998, CANCER RES, V58, P1593; WU SV, 1995, EUR J BIOCHEM, V230, P439, DOI 10.1111/j.1432-1033.1995.0439h.x; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; YUSPA SH, 1985, METHODS SKIN RES, P213; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	26	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16487	16493		10.1074/jbc.274.23.16487	http://dx.doi.org/10.1074/jbc.274.23.16487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347211	hybrid			2022-12-27	WOS:000080668600071
J	Koshlukova, SE; Lloyd, TL; Araujo, MWB; Edgerton, M				Koshlukova, SE; Lloyd, TL; Araujo, MWB; Edgerton, M			Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHOTERICIN-B SUSCEPTIBILITY; HISTIDINE-RICH POLYPEPTIDES; HUMAN-PAROTID SECRETION; ORAL CANDIDA; PEPTIDES; MECHANISM; YEAST; KETOCONAZOLE; IMMUNITY; PROTEINS	Salivary histatins are potent in vitro antifungal proteins and have promise as therapeutic agents against oral candidiasis. We performed pharmacological studies directed at understanding the biochemical basis of list 5 candidacidal activity. Three inhibitors of mitochondrial metabolism: carbonyl cyanide p-chlorophenylhydrazone, dinitrophenol, and azide inhibited Hst 5 killing of Candida albicans, while not inhibiting cellular ATP production. In contrast, Hst 5 caused a drastic reduction of C, albicans intracellular ATP content, which was a result of an efflux of ATP, Carbonyl cyanide p-chlorophenylhydrazone, dinitrophenol, and azide inhibited Hst 5-induced ATP efflux, thus establishing a correlation between ATP release and cell killing. Furthermore, C, albicans cells were respiring and had polarized membranes at least 80 min after ATP release, thus implying a non-lytic exit of cellular ATP in response to Hst 5. Based on evidence that transmembrane ATP efflux can occur in the absence of cytolysis through a channel-like pathway and that released ATP can act as a cytotoxic mediator by binding to membrane purinergic receptors, we evaluated whether extracellular ATP released by Hst 5 may have further functional role in cell killing. Consistent with this hypothesis, purinergic agonists BzATP and adenosine 5'O-(thiotriphosphate) induced loss of C. albicans cell viability and purinergic antagonists prevented Hst 5 killing.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Dent Med, Dept Restorat Dent, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Edgerton, M (corresponding author), SUNY Buffalo, Sch Dent Med, Dept Oral Biol, 310 Foster Hall,Main St Campus,3435 Main St, Buffalo, NY 14214 USA.				NIDCR NIH HHS [DE10641, DE12159, R01 DE010641-07, R01 DE010641] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012159, R29DE010641] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBOTT AB, 1989, J ANTIMICROB CHEMOTH, V24, P905, DOI 10.1093/jac/24.6.905; ANSEHN S, 1984, ANTIMICROB AGENTS CH, V26, P22, DOI 10.1128/AAC.26.1.22; BEGGS WH, 1994, ANTIMICROB AGENTS CH, V38, P363, DOI 10.1128/AAC.38.2.363; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Boyum R, 1997, MICROBIOL-SGM, V143, P1901, DOI 10.1099/00221287-143-6-1901; Burnstock G, 1996, CIBA F SYMP, V198, P1; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CANNON RD, 1995, J DENT RES, V74, P1152, DOI 10.1177/00220345950740050301; Chowdhury B, 1997, EUR J BIOCHEM, V247, P673, DOI 10.1111/j.1432-1033.1997.00673.x; Clark FS, 1996, ANTIMICROB AGENTS CH, V40, P419, DOI 10.1128/AAC.40.2.419; COCKAYNE A, 1984, J GEN MICROBIOL, V130, P465; COLEMAN DC, 1993, CRIT REV MICROBIOL, V19, P61, DOI 10.3109/10408419309113523; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Edgerton M, 1998, J BIOL CHEM, V273, P20438, DOI 10.1074/jbc.273.32.20438; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Guidotti G, 1996, CHEM BIOL, V3, P703, DOI 10.1016/S1074-5521(96)90244-6; Hickman SE, 1996, CIBA F SYMP, V198, P71; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1993, REV IMMUNOL, V5, P97; LOHMEIERVOGEL E, 1989, APPL ENVIRON MICROB, V55, P1974, DOI 10.1128/AEM.55.8.1974-1980.1989; MACKAY BJ, 1984, INFECT IMMUN, V44, P695, DOI 10.1128/IAI.44.3.695-701.1984; NOSHIRO A, 1987, J BIOL CHEM, V262, P14154; OLSON V, 1976, CAN J MICROBIOL, V23, P166; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; ORDONEZ JV, 1995, CYTOMETRY, V22, P154, DOI 10.1002/cyto.990220213; PERINPANAYAGAM HER, 1995, J DENT RES, V74, P345, DOI 10.1177/00220345950740011001; Peyron F, 1997, ANTIMICROB AGENTS CH, V41, P1537, DOI 10.1128/AAC.41.7.1537; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; PRASAD R, 1991, CANDIDA ALBICANS CEL, P215; RAJ PA, 1990, J BIOL CHEM, V265, P3898; Raj PA, 1998, BIOPOLYMERS, V45, P51, DOI 10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y; Raj PA, 1996, BIOCHEMISTRY-US, V35, P4314, DOI 10.1021/bi951681r; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; SABATINI LM, 1989, BIOCHEM BIOPH RES CO, V160, P495, DOI 10.1016/0006-291X(89)92460-1; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; SANTARPIA RP, 1988, ARCH ORAL BIOL, V33, P567, DOI 10.1016/0003-9969(88)90131-8; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tsai HY, 1996, INFECT IMMUN, V64, P5000, DOI 10.1128/IAI.64.12.5000-5007.1996; UNO J, 1982, ANTIMICROB AGENTS CH, V21, P912, DOI 10.1128/AAC.21.6.912; VANDENBOSSCHE H, 1987, CRIT REV MICROBIOL, V15, P57; Wang Y, 1996, J BIOL CHEM, V271, P18107, DOI 10.1074/jbc.271.30.18107; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; ZUO Y, 1995, GENE, V161, P87, DOI 10.1016/0378-1119(95)00237-Z; [No title captured]	55	161	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18872	18879		10.1074/jbc.274.27.18872	http://dx.doi.org/10.1074/jbc.274.27.18872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383383	hybrid			2022-12-27	WOS:000081196300006
J	Sieradzki, R; Pinho, MG; Tomasz, A				Sieradzki, R; Pinho, MG; Tomasz, A			Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN-4; VANCOMYCIN; TEICOPLANIN; ANTIBIOTICS; STRAIN; GENE	Both vancomycin- and teicoplanin-resistant laboratory mutants of Staphylococcus aureus produce peptidoglycans of altered composition in which the proportion of highly cross-linked muropeptide species is drastically reduced with a parallel increase in the representation of muropeptide monomers and dimers (Sieradzki, K., and Tomasz, A. (1997) J. Bacteriol. 179, 2557-2566; and Sieradzki, K,, and Tomasz, A. (1998) Microb, Drug Resist. 4, 159-168). We now report that the distorted peptidoglycan composition is related to defects in penicillin-binding protein 4 (PBP4); no PBP4 was detectable by the fluorographic assay in membrane preparations from the mutants, and comparison of the sequence of pbp4 amplified from the mutants indicated disruption of the gene by two types of abnormalities, a 17-amino acid long duplication starting at position 305 of the pbp4 gene was detected in the vancomycin-resistant mutant, and a stop codon was found to be introduced into the pbp4 KTG motif at position 261 in the mutant selected for teicoplanin resistance. Additional common patterns of disturbances in the peptidoglycan metabolism of the mutants are indicated by the increased sensitivity of mutant cell walls to the M1 muramidase and decreased sensitivity to lysostaphin, which is a reversal of the susceptibility pattern of the parental cell walls. Furthermore, the results of high performance liquid chromatography analysis of lysostaphin digests of peptidoglycan suggest an increase in the average chain length of the glycan strands in the peptidoglycan of the glycopeptide-resistant mutants. The increased molar proportion of muropeptide monomers in the cell wall of the glycopeptide-resistant mutants should provide binding sites for the "capture" of vancomycin and teicoplanin molecules, which may be part of the mechanism of glycopeptide resistance in S. aureus.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Tomasz, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Pinho, Mariana/B-9192-2008	Pinho, Mariana/0000-0002-7132-8842; Tomasz, Alexander/0000-0003-1520-1983				BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P2; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P813; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P765; CURTIS NAC, 1980, FEMS MICROBIOL LETT, V9, P263; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Domanski TL, 1997, J BACTERIOL, V179, P2651, DOI 10.1128/jb.179.8.2651-2657.1997; GROVES P, 1994, STRUCTURE, V2, P747, DOI 10.1016/S0969-2126(94)00075-1; Henze UU, 1996, ANTIMICROB AGENTS CH, V40, P2121, DOI 10.1128/AAC.40.9.2121; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; KAATZ GW, 1990, J INFECT DIS, V162, P103, DOI 10.1093/infdis/162.1.103; KOZARICH JW, 1978, J BIOL CHEM, V253, P1272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LICHENSTEIN HS, 1990, GENE, V88, P81, DOI 10.1016/0378-1119(90)90062-V; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; NIETO M, 1971, BIOCHEM J, V123, P789, DOI 10.1042/bj1230789; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563; Sieradzki K, 1998, ANTIMICROB AGENTS CH, V42, P100, DOI 10.1128/AAC.42.1.100; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Sieradzki K, 1998, MICROB DRUG RESIST, V4, P159, DOI 10.1089/mdr.1998.4.159; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; WYKE AW, 1981, EUR J BIOCHEM, V119, P389, DOI 10.1111/j.1432-1033.1981.tb05620.x; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073	26	100	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18942	18946		10.1074/jbc.274.27.18942	http://dx.doi.org/10.1074/jbc.274.27.18942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383392				2022-12-27	WOS:000081196300015
J	Wetsel, RA; Kildsgaard, J; Zsigmond, E; Liao, W; Chan, L				Wetsel, RA; Kildsgaard, J; Zsigmond, E; Liao, W; Chan, L			Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; APOLIPOPROTEIN-B; FAMILIAL HYPERCHOLESTEROLEMIA; C3A ANAPHYLATOXIN; PATHWAY; HYPERAPOB; ASP; ASSOCIATION; METABOLISM; ADIPOCYTES	The acylation stimulating protein (ASP) is a 76-amino acid peptide that has been proposed as a potent mediator of triglyceride synthesis and, when functionally impaired, as a major cause of hyperapobetalipoproteinemia (HyperapoB), Purification and sequence analysis of ASP from human sera have revealed that ASP is identical to the complement C3-derived activation peptide C3ades-Arg, Because C3 is the precursor for C3ades-Arg and therefore ASP, a deficiency in C3 would be predicted to result in a phenotype characteristic of HyperapoB. To test this hypothesis in vivo, the current study was undertaken in which ASP(C3ades-Arg)-deficient mice were used as a model system. No significant differences were found in the triglyceride, cholesterol, or free fatty acid concentrations in the plasma of fasted normal and ASP(C3ades-Arg)-deficient animals. In addition, plasma lipoprotein analyses indicated that the very low density lipoprotein, low density lipoprotein, and high density lipoprotein cholesterol and triglyceride concentrations as well as the apolipoprotein B-48 and B-100 levels were not significantly different in the plasma of ASP(C3ades-Arg)-deficient and wild type mice. Furthermore, when challenged with an oral fat load, the ASP(C3ades-Arg)-deficient mice showed no impaired ability to clear triglycerides and free fatty acids from their circulation when compared with their wild-type littermates, Collectively, these results indicate that ASP(C3ades-Arg) deficiency does not cause HyperapoB in mice and that the physiological importance of impaired ASP(C3ades-Arg) function as a cause of hyperapobetalipoproteinemia needs to be reevaluated.	Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Wetsel, RA (corresponding author), Inst Mol Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwetsel@imm2.imm.uth.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025011, R55AI025011] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51586] Funding Source: Medline; NIAID NIH HHS [AI25011] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; CABEZAS MC, 1993, J CLIN INVEST, V92, P160, DOI 10.1172/JCI116544; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Choy LN, 1996, OBES RES, V4, P521, DOI 10.1002/j.1550-8528.1996.tb00266.x; CIANFLONE K, 1988, CLIN INVEST MED, V11, P99; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; CIRCOLO A, 1999, IN RPESS IMMUNOPHARM; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; Murray I, 1997, J LIPID RES, V38, P2492; MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SINGER L, 1994, PATHOBIOLOGY, V62, P14, DOI 10.1159/000163873; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; Sniderman A., 1992, CURR OPIN LIPIDOL, V3, P137; SNIDERMAN AD, 1994, ANN MED, V26, P389, DOI 10.3109/07853899409148358; Sniderman AD, 1997, P NUTR SOC, V56, P703, DOI 10.1079/PNS19970070; Sniderman AD, 1997, DIABETOLOGIA, V40, pS152, DOI 10.1007/s001250051435; SNIDERMAN AD, 1995, INT J OBESITY, V19, pS27; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1988, CAN J PHYSIOL PHARM, V66, P239, DOI 10.1139/y88-040; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; Zhang XJ, 1998, EUR J CLIN INVEST, V28, P730	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19429	19433		10.1074/jbc.274.27.19429	http://dx.doi.org/10.1074/jbc.274.27.19429			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383458	hybrid			2022-12-27	WOS:000081196300081
J	Yang, XN; Rudolf, M; Carew, RA; Yoshida, M; Nerreter, V; Riley, AM; Chung, SK; Bruzik, KS; Potter, BVL; Schultz, C; Shears, SB				Yang, XN; Rudolf, M; Carew, RA; Yoshida, M; Nerreter, V; Riley, AM; Chung, SK; Bruzik, KS; Potter, BVL; Schultz, C; Shears, SB			Inositol 1,3,4-trisphosphate acts in vivo as a specific regulator of cellular signaling by inositol 3,4,5,6-tetrakisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ACTIVITY; RAT PANCREATOMA CELLS; D-MYO-INOSITOL; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; CHLORIDE SECRETION; AVIAN ERYTHROCYTES; POLYPHOSPHATE 4-PHOSPHATASE; MEMBRANE-PERMEANT; 1321N1 CELLS	Ca2+-activated Cl- channels are inhibited by inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4) (Xie, W. Haetzel, M. A., Bruzik, K. S., Dedman, J. R., Shears, S. B., and Nelson, D. J. (1996) J. Biol. Chem. 271, 14092-14097), a novel second messenger that is formed after stimulus-dependent activation of phospholipase C (PLC). In this study, we show that inositol 1,3,4-trisphosphate (Ins(1,3,4)P-3) is the specific signal that ties increased cellular levels of Ins(3,4,5,6)P-4 to changes in PLC activity. We first demonstrated that Ins(1,3,4)P-3 inhibited Ins(3,4,5,6)P-4 1-kinase activity that was either (i) in lysates of AR4-2J pancreatoma cells or (ii) purified 22,500-fold (yield = 13%) from bovine aorta. Next, we incubated [H-3]inositol-labeled AR4-2J cells with cell permeant and non-radiolabeled 2,5,6-tri-O-butyryl-myo-inositol 1,3,4-trisphosphate-hexakis(acetoxymethyl) ester. This treatment increased cellular levels of Ins(1,3,4)P-3 2.7-fold, while [H-3]Ins(3,4,5,6)P-4 levels increased a-fold; there were no changes to levels of other H-3-labeled inositol phosphates. This experiment provides the first direct evidence that levels of Ins(3,4,5,6)P-4 are regulated by Ins(1,3,4)P-3 in vivo, independently of Ins(1,3,4)P-3 being metabolized to Ins(3,4,5,6)P-4. In addition, we found that the Ins(1,3,4)P-3 metabolites, namely Ins(1,3)P-2 and Ins(3,4)P-2, were >100-fold weaker inhibitors of the 1-kinase compared with Ins(1,3,4)P-3 itself (IC50 = 0.17 mu M). This result shows that dephosphorylation of Ins(1,3,4)P-3 in vivo is an efficient mechanism to "switch-off" the cellular regulation of Ins(3,4,5,6)P-4 levels that comes from Ins(1,3,4)P-3-mediated inhibition of the 1-kinase. We also found that Ins(1,3,6)P-3 and Ins(1,4,6)P-3 were poor inhibitors of the 1-kinase (IC50 = 17 and >30 mu M, respectively). The non-physiological trisphosphates, D/L-Ins(1,2,4)P-3, inhibited 1-kinase relatively potently (IC50 = 0.7 mu M), thereby suggesting a new strategy for the rational design of therapeutically useful kinase inhibitors. Overall, our data provide new information to support the idea that Ins(1,3,4)P-3 acts in an important signaling cascade.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Bremen, Inst Organ Chem, D-28359 Bremen, Germany; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bremen; University of Bath; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Pohang University of Science & Technology (POSTECH)	Yang, XN (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	yang3@niehs.nih.gov	Shears, Stephen B/C-6335-2019; Potter, Barry/AAX-4781-2020; Riley, Andrew M/F-3526-2013; Potter, Barry VL/A-1845-2012	Shears, Stephen B/0000-0001-7309-8916; Riley, Andrew M/0000-0001-9003-3540; Schultz, Carsten/0000-0002-5824-2171	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANSAL VS, 1990, J BIOL CHEM, V265, P1806; BANSAL VS, 1987, J BIOL CHEM, V262, P9444; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Batty IH, 1998, BIOCHEM J, V330, P1069; BATTY IH, 1994, BIOCHEM J, V297, P529, DOI 10.1042/bj2970529; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHUNG SK, 1995, J CHEM SOC CHEM COMM, P11, DOI 10.1039/c39950000011; Chung SK, 1998, J CARBOHYD CHEM, V17, P369, DOI 10.1080/07328309808002898; Chung SK, 1996, CHEM COMMUN, P163, DOI 10.1039/cc9960000163; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; INHORN RC, 1987, J BIOL CHEM, V262, P15946; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Li WH, 1997, TETRAHEDRON, V53, P12017, DOI 10.1016/S0040-4020(97)00714-X; Maslanski J. A., 1990, METHODS INOSITIDE RE, P109; MCCONNELL FM, 1992, BIOCHEM J, V284, P447, DOI 10.1042/bj2840447; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MENNITI FS, 1991, BIOCHEM J, V274, P622, DOI 10.1042/bj2740622; Mills SJ, 1996, J ORG CHEM, V61, P8980, DOI 10.1021/jo961280x; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NOGIMORI K, 1990, BIOCHEM J, V269, P195, DOI 10.1042/bj2690195; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RILEY AM, 1994, J MED CHEM, V37, P3918, DOI 10.1021/jm00049a011; Rudolf MT, 1998, BIOORG MED CHEM LETT, V8, P1857, DOI 10.1016/S0960-894X(98)00322-9; Rudolf MT, 1997, LIEBIGS ANN-RECL, P1861; Rudolf MT, 1998, J MED CHEM, V41, P3635, DOI 10.1021/jm970781n; Schultz C, 1997, GASTROENTEROLOGY, V112, pA401; SHEARS SB, 1987, BIOCHEM J, V248, P977, DOI 10.1042/bj2480977; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shears SB, 1997, PRACT APPROACH SER, V176, P33; SHEARS SB, 1989, J BIOL CHEM, V264, P19879; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; Tan Z, 1997, J BIOL CHEM, V272, P2285; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	48	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18973	18980		10.1074/jbc.274.27.18973	http://dx.doi.org/10.1074/jbc.274.27.18973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383396	hybrid			2022-12-27	WOS:000081196300019
J	Abbott, DW; Thompson, ME; Robinson-Benion, C; Tomlinson, G; Jensen, RA; Holt, JT				Abbott, DW; Thompson, ME; Robinson-Benion, C; Tomlinson, G; Jensen, RA; Holt, JT			BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; POLYMERASE-II HOLOENZYME; V(D)J RECOMBINATION; MEIOTIC CELLS; GENE BRCA1; BREAST; MUTATION; GROWTH; MOUSE; STRAND	The breast cancer predisposition genes, BRCA1 and BRCA2, are responsible for the vast majority of hereditary breast cancer. Although BRCA2 functions to help the cell repair double-stranded DNA breaks, the function of BRCA1 remains enigmatic. Here, we develop a human genetic system to study the role of BRCA1 in oxidative DNA damage. We show that human cancer cells containing mutated BRCA1 are hypersensitive to ionizing radiation. This hypersensitivity can be reversed by the expression of forms of BRCA1 that are not growth suppressing. Reversal of hypersensitivity requires the ring finger of BRCA1, its transactivation domain, and its BRCT domain. Lastly, we show that unlike BRCA2, BRCA1 does not function in the repair of double-stranded DNA breaks. Instead, it functions in transcription-coupled DNA repair (TCR). TCR ability correlated with radioresistance as cells containing BRCA1 showed both increased TCR and radioresistance, whereas cells without BRCA1 showed decreased TCR and radiosensitivity. These findings give physiologic significance to the interaction of BRCA1 with the basal transcription machinery.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Holt, JT (corresponding author), Vanderbilt Univ, Ingram Canc Ctr, Rm 659,MRB 2,2220 Pierce Ave S, Nashville, TN 37232 USA.		Tomlinson, Gail/AAR-9776-2020; Jensen, Roy A/B-9739-2011	Jensen, Roy A/0000-0003-4430-2281; Abbott, Derek/0000-0003-4387-8094	NCI NIH HHS [R01CA5175S1, R01CA51735, R29CA62161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051735, R29CA062161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD M, 1995, NATURE, V375, P541, DOI 10.1038/375541b0; Burke TF, 1998, ONCOGENE, V16, P1031, DOI 10.1038/sj.onc.1201623; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Errami A, 1996, MOL CELL BIOL, V16, P1519; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NAMBA M, 1977, JPN J EXP MED, V47, P263; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tomlinson GE, 1998, CANCER RES, V58, P3237; WALTON DG, 1984, MUTAT RES, V129, P129, DOI 10.1016/0027-5107(84)90131-3; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YAGI T, 1982, MUTAT RES, V96, P89, DOI 10.1016/0027-5107(82)90019-7	43	201	209	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18808	18812		10.1074/jbc.274.26.18808	http://dx.doi.org/10.1074/jbc.274.26.18808			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373498	hybrid			2022-12-27	WOS:000081056700090
J	Chao, CF; Chuang, HC; Chiou, ST; Liu, TY				Chao, CF; Chuang, HC; Chiou, ST; Liu, TY			On the biosynthesis of alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid catalyzed by the sialyltransferase of Escherichia coli Bos-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; CAPSULAR POLYSACCHARIDE; NEISSERIA-MENINGITIDIS; COLOMINIC ACID; STRAIN BOS-12; POLYMERS; K92; K1	Escherichia coli Bos-la synthesizes a heteropolymer of sialic acids with alternating alpha-2,9/alpha-2,8 glycosidic linkages (1), In this study, we have shown that the polysialyltransferase of the E. coli Bos-12 recognizes an a-2,8 glycosidic linkage of sialic acid at the nonreducing end of an exogenous acceptor of either the alpha-2,8 homopolymer of sialic acid or the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid and catalyzes the transfer of Neu5Ac from CMP-Neu5Ac to this residue. When the exogenous acceptor is an alpha-a,8-linked oligomer of sialic acid, the main product synthesized is derived from the addition of a single residue of [C-14]Neu5Ac to form either an alpha-2,8 glycosidic linkage or an alpha-2,9 glycosidic linkage at the nonreducing end, at an alpha-2,8/alpha-2,9 ratio of approximately 2:1, When the acceptor is the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid, chain elongation takes place four to five times more efficiently than the alpha-2,8-linked homopolymer of sialic acid as an acceptor. It was found that the alpha-2,9-linked homopolymer of sialic acid and the alpha-2,8/alpha-2,9-linked hetero-oligomer of sialic acid with alpha-2,9 at the nonreducing end not only failed to serve as an acceptor for the E. coli Bos-la polysialyltransferase for the transfer of [C-14]Neu5Ac, but they inhibited the de novo synthesis of polysialic acid catalyzed by this enzyme. The results obtained in this study favor the proposal that the biosynthesis of the alpha-2,9/alpha-2,8 heteropolymer of sialic acid catalyzed by the E. coli Bos-la polysialyltransferase involves a successive transfer of a preformed alpha-2,8-linked dimer of sialic acid at the nonreducing terminus of the acceptor to form an alpha-2,9 glycosidic linkage between the incoming dimer and the acceptor. The glycosidic linkage at the nonreducing end of the alternating alpha-2,9/alpha-2,8 heteropolymer of sialic acid produced by E, coli Bos-la should be an alpha-2,8 glycosidic bond and not an alpha-2,9 glycosidic linkage.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Liu, TY (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	dtl@gate.sinica.edu.tw						ADA GL, 1961, J GEN MICROBIOL, V24, P409, DOI 10.1099/00221287-24-3-409; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; EGAN W, 1977, BIOCHEMISTRY-US, V16, P3687, DOI 10.1021/bi00635a028; FERRERO MA, 1991, BIOCHEM J, V280, P575, DOI 10.1042/bj2800575; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KUNDIG FD, 1971, J BIOL CHEM, V246, P2543; KWIATKOWSKI B, 1987, METHOD ENZYMOL, V138, P786; LIFELY MR, 1985, CARBOHYD RES, V143, P191; LIU TY, 1971, J BIOL CHEM, V246, P4703; LIU TY, 1977, J INFECT DIS, V136, pS71, DOI 10.1093/infdis/136.Supplement.S71; REGLERO A, 1993, INT J BIOCHEM, V25, P1517, DOI 10.1016/0020-711X(93)90507-B; REUTER G, 1994, METHOD ENZYMOL, V230, P168; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1982, METHOD ENZYMOL, V83, P540; TROY FA, 1979, J BIOL CHEM, V254, P7377; TROY FA, 1975, J BIOL CHEM, V250, P156; VANN WF, 1978, J BACTERIOL, V133, P1300, DOI 10.1128/JB.133.3.1300-1306.1978; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIMR ER, 1992, J BACTERIOL, V174, P5127, DOI 10.1128/JB.174.15.5127-5131.1992; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985	21	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18206	18212		10.1074/jbc.274.26.18206	http://dx.doi.org/10.1074/jbc.274.26.18206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373421	hybrid			2022-12-27	WOS:000081056700013
J	Fujishige, K; Kotera, J; Michibata, H; Yuasa, K; Takebayashi, S; Okumura, K; Omori, K				Fujishige, K; Kotera, J; Michibata, H; Yuasa, K; Takebayashi, S; Okumura, K; Omori, K			Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; RECESSIVE JUVENILE PARKINSONISM; SMOOTH-MUSCLE; BINDING; EXPRESSION; PHOSPHORYLATION; RELAXATION; REGION; AORTA; SITES	cDNA encoding a novel phosphodiesterase (PDE) was isolated from a human fetal lung cDNA library and designated PDE10A, The deduced amino acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other PDE families. Recombinant PDE10A transfected and expressed in COS-7 cells hydrolyzed cAMP and cGMP with K-m values of 0.26 and 7.2 mu M, respectively, and V-max with cGRIP was almost twice that with cAMP, Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 mu M for inhibition of cAMP and cGMP hydrolysis, respectively. cGMP inhibited hydrolysis of cAMP, and cAMP inhibited cGMP hydrolysis with IC50 values of 14 and 0.39 mu M, respectively. Thus, PDE10A exhibited properties of a cAMP PDE and a cAMP-inhibited cGMP PDE, PDE10A transcripts were particularly abundant in the putamen and caudate nucleus regions of brain and in thyroid and testis, and in much lower amounts in other tissues. The PDE10A gene was located on chromosome 6q26 by fluorescent in situ hybridization analysis. PDE10A represents a new member of the PDE superfamily, exhibiting unique kinetic properties and inhibitor sensitivity.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan; Mie Univ, Fac Bioresources, Biol Chem Lab, Tsu, Mie 5148507, Japan	Mitsubishi Tanabe Pharma Corporation; Mie University	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358505, Japan.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAVO J, 1990, CYCLIC NUCLEOTIDE PH, V2; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; DEGERMAN E, 1987, J BIOL CHEM, V262, P5797; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; Hayashi M, 1998, BIOCHEM BIOPH RES CO, V250, P751, DOI 10.1006/bbrc.1998.9379; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; Jones AC, 1998, AM J HUM GENET, V63, P80, DOI 10.1086/301937; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kotera J, 1998, J BIOL CHEM, V273, P26982, DOI 10.1074/jbc.273.41.26982; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P539; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MIYAHARA M, 1995, EUR J PHARMACOL, V284, P25, DOI 10.1016/0014-2999(95)00355-O; Okumura K, 1998, BIOSCI BIOTECH BIOCH, V62, P1640, DOI 10.1271/bbb.62.1640; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAEKI T, 1994, J PHARMACOL EXP THER, V284, P25; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; TAKAHASHI E, 1990, HUM GENET, V86, P4; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; Turko IV, 1998, BIOCHEM J, V329, P505; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; YAN C, 1994, J NEUROSCI, V14, P973; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x	32	338	415	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18438	18445		10.1074/jbc.274.26.18438	http://dx.doi.org/10.1074/jbc.274.26.18438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373451	hybrid			2022-12-27	WOS:000081056700043
J	Galsgaard, ED; Nielsen, JH; Moldrup, A				Galsgaard, ED; Nielsen, JH; Moldrup, A			Regulation of prolactin receptor (PRLR) gene expression in insulin-producing cells - Prolactin and growth hormone activate one of the rat PRLR gene promoters via STAT5a and STAT5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE STIMULATION THRESHOLD; BETA-CELL; PLACENTAL-LACTOGEN; HEPATIC RECEPTORS; PANCREATIC-ISLETS; INDUCTION; SECRETION; LIVER; PREGNANCY; INS-1	Expression of the prolactin receptor (PRLR) gene is increased in pancreatic islets during pregnancy and in vitro in insulin-producing cells by growth hormone (GH) and prolactin (PRL), The 5'-region of the rat PRLR gene contains at least three alternative first exons that are expressed tissue-specifically because of differential promoter usage. We show by reverse transcription-polymerase chain reaction analysis that both exon 1A- and exon 1C-containing PRLR transcripts are expressed in rat islets and that human (h)GH, ovine (o)PRL, and bovine (b)GH increase exon 1A expression 6.5 +/- 0.8-fold, 6.8 +/- 0.7-fold, and 3.9 +/- 0.7-fold and exon le expression 4.8 +/- 0.4-fold, 4.4 +/- 0.6-fold, and 2.5 +/- 0.7-fold, respectively. Expression of exon 1B was not detectable. The transcriptional activities of reporter constructs containing the 1A, 1B, or 1C promoter were found to be 22.8-fold, 2.7-fold, and 8.0-fold, respectively, above that of a promoterless reporter construct when transfected into the insulin-producing INS-1 cells. The transcriptional activity of the 1A promoter construct was increased 8.9 +/- 1.9-fold by 0.5 mu g/ml hGH. Responsiveness to hGH of the 1A promoter was localized to the region from -225 to +81 with respect to the transcription start site. This region contains the sequence TTCTAGGAA that by gel retardation experiments was shown to bind the transcription factors STAT5a and STAT5b in response to stimulation by hGH, oPRL, or bGH. Mutation of this gamma-activated sequence-like element completely abolished transcriptional induction of the 1A promoter by hGH, Our results suggest that GH and PRL increase the levels of exon 1A- and 1C-containing PRLR mRNA species and furthermore that the transcriptional activity of the 1A promoter is increased via activation of STAT5a and STAT5b.	Hagedorn Res Inst, Dept Cell Biol, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute	Galsgaard, ED (corresponding author), Hagedorn Res Inst, Dept Cell Biol, Niels Steensensvej 6, DK-2820 Gentofte, Denmark.			Nielsen, Jens Hoiriis/0000-0001-8252-3048				AMIT T, 1985, MOL CELL ENDOCRINOL, V39, P21, DOI 10.1016/0303-7207(85)90088-7; ASFARI M, 1995, MOL CELL ENDOCRINOL, V107, P209, DOI 10.1016/0303-7207(94)03445-Y; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARASH I, 1988, ENDOCRINOLOGY, V122, P1151, DOI 10.1210/endo-122-3-1151; BAXTER RC, 1984, ENDOCRINOLOGY, V115, P2009, DOI 10.1210/endo-115-5-2009; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Matsuda M, 1997, ZOOL SCI, V14, P159, DOI 10.2108/zsj.14.159; MOLDRUP A, 1990, J BIOL CHEM, V265, P8686; MOLDRUP A, 1993, ENDOCRINOLOGY, V133, P1165, DOI 10.1210/en.133.3.1165; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; Ormandy CJ, 1998, DNA CELL BIOL, V17, P761, DOI 10.1089/dna.1998.17.761; POLAK M, 1990, DIABETES, V39, P1045, DOI 10.2337/diabetes.39.9.1045; ROBERTSON JA, 1990, MOL ENDOCRINOL, V4, P1235, DOI 10.1210/mend-4-8-1235; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; SORENSON RL, 1987, PANCREAS, V2, P283, DOI 10.1097/00006676-198705000-00006; SORENSON RL, 1987, ENDOCRINOLOGY, V121, P1447, DOI 10.1210/endo-121-4-1447; Stout LE, 1997, ENDOCRINOLOGY, V138, P1592, DOI 10.1210/en.138.4.1592; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	30	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18686	18692		10.1074/jbc.274.26.18686	http://dx.doi.org/10.1074/jbc.274.26.18686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373481	hybrid			2022-12-27	WOS:000081056700073
J	Kowalczyk, AP; Hatzfeld, M; Bornslaeger, EA; Kopp, DS; Borgwardt, JE; Corcoran, CM; Settler, A; Green, KJ				Kowalczyk, AP; Hatzfeld, M; Bornslaeger, EA; Kopp, DS; Borgwardt, JE; Corcoran, CM; Settler, A; Green, KJ			The head domain of plakophilin-1 binds to desmoplakin and enhances its recruitment to desmosomes - Implications for cutaneous disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; PLAQUE PROTEIN; PEMPHIGUS-VULGARIS; MULTIGENE FAMILY; EMBRYONIC HEART; BAND-6 PROTEIN; PLAKOGLOBIN; CADHERIN; GENE; CONNECTION	The contribution of desmosomes to epidermal integrity is evident in the inherited blistering disorder associated with the absence of a functional gene for plakophilin-1. To define the function of plakophilin-1 in desmosome assembly, interactions among the desmosomal cadherins, desmoplakin, and the armadillo family members plakoglobin and plakophilin-1 were examined. In transient expression assays, plakophilin-1 formed complexes with a desmoplakin amino-terminal domain and enhanced its recruitment to cell-cell borders; this recruitment was not dependent on the equimolar expression of desmosomal cadherins. In contrast to desmoplakin-plakoglobin interactions, the interaction between desmoplakin and plakophilin-1 was not mediated by the armadillo repeat domain of plakophilin-1 but by the non-armadillo head domain, as assessed by yeast two-hybrid and recruitment assays. We propose a model whereby plakoglobin serves as a linker between the cadherins and desmoplakin, whereas plakophilin-1 enhances lateral interactions between desmoplakin molecules. This model suggests that epidermal lesions in patients lacking plakophilin-1 are a consequence of the loss of integrity resulting from a decrease in binding sites for desmoplakin and intermediate filaments at desmosomes.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Halle Wittenberg, Fac Med, Mol Biol Grp, D-06097 Halle, Germany	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Martin Luther University Halle Wittenberg	Green, KJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043380, K01AR002039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR43380, K01 AR02039] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Green KJ, 1997, SOC GEN PHY, V52, P123; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; HATZFELD M, 1994, J CELL SCI, V107, P2259; Hatzfeld M, 1996, J CELL SCI, V109, P2767; HEID HW, 1994, DIFFERENTIATION, V58, P113; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; MATHUR M, 1994, J BIOL CHEM, V269, P14075; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STANLEY JR, 1995, J EXP MED, V181, P1, DOI 10.1084/jem.181.1.1	32	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18145	18148		10.1074/jbc.274.26.18145	http://dx.doi.org/10.1074/jbc.274.26.18145			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373410	hybrid			2022-12-27	WOS:000081056700002
J	Tsai, LY; Tu, SL; Li, HM				Tsai, LY; Tu, SL; Li, HM			Insertion of atToc34 into the chloroplastic outer membrane is assisted by at least two proteinaceous components in the import system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE MEMBRANE; MACHINERY; BINDING; PATHWAY; TRANSPORT; TRANSLOCATION; PRECURSORS; APPARATUS; SIGNAL	Toc34 is a member of the outer membrane translocon complex that mediates the initial stage of protein import into chloroplasts. Toc34, like most outer membrane proteins, is synthesized in the cytosol at its mature size without a cleavable transit peptide. The majority of outer membrane proteins do not require thermolysin-sensitive components on the chloroplastic surface or ATP for their insertion into the outer membrane. However, different results have been obtained concerning the factors required for Toc34 insertion into the outer membrane, Using an Arabidopsis homologue of pea Toc34, atToc34, we show that the insertion of atToc34 was greatly reduced by thermolysin pretreatment of chloroplasts as assayed either by protease digestion or by alkaline extraction. The insertion was also dependent on the presence of ATP or GTP. A mutant of atToc34 with the GTP-binding domain deleted still required ATP for optimal insertion, indicating that ATP was used by other protein components in the import system. The ATP-supported insertion was observed even in thermolysin-pretreated chloroplasts, suggesting that the protein component responsible for ATP-stimulated insertion is a different protein from the thermolysin-sensitive component that assists atToc34 insertion.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Grad Inst Life Sci, Taipei 112, Taiwan; Natl Def Med Ctr, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Defense Medical Center	Li, HM (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbhmli@ccvax.sinica.edu.tw	Li, Hsou-min/AAZ-8011-2021; Tu, Shih-Long/ABF-5446-2021	Li, Hsou-min/0000-0002-0211-7339; Tu, Shih-Long/0000-0001-9436-278X				Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; CLINE K, 1985, J BIOL CHEM, V260, P3691; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; Fuks B, 1997, PLANT PHYSIOL, V114, P405, DOI 10.1104/pp.114.2.405; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1992, J BIOL CHEM, V267, P2986; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; Li HM, 1996, PLANT CELL, V8, P2117, DOI 10.1105/tpc.8.11.2117; Li HM, 1997, J BIOL CHEM, V272, P10968; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W	22	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18735	18740		10.1074/jbc.274.26.18735	http://dx.doi.org/10.1074/jbc.274.26.18735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373488	hybrid			2022-12-27	WOS:000081056700080
J	Liao, YF; Wieder, KG; Classen, JM; Van De Water, L				Liao, YF; Wieder, KG; Classen, JM; Van De Water, L			Identification of two amino acids within the EIIIA (ED-A) segment of fibronectin constituting the epitope for two function-blocking monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SITE-DIRECTED MUTAGENESIS; ALTERNATIVELY SPLICED EIIIB; SMOOTH-MUSCLE CELLS; CRYSTAL-STRUCTURE; MESSENGER-RNAS; TRANSFORMING GROWTH-FACTOR-BETA-1; EMBRYONIC FIBRONECTINS; CELLULAR-FIBRONECTIN; PROLIFERATIVE GLOMERULONEPHRITIS	Alternative splicing of the fibronectin gene transcript gives rise to a group of adhesive glycoproteins showing restricted spatial and temporal expression during embryonic development, tumor growth, and tissue repair, Alternative splicing occurs in three segments termed EIIIB, EIIIA, and V. The EIIIA (or ED-A) segment of fibronectin is expressed prominently but transiently in healing wounds coincident with fibroblast expression of an activation marker, smooth muscle cell cr-actin. A monoclonal antibody (IST-9) to the EIIIA segment blocks transforming growth factor-a-mediated smooth muscle cell cr-actin expression by fibroblasts in culture. A second monoclonal antibody (DH1) blocks chondrocyte condensation in chicken embryos, We find that IST-9 and DH1 react with. human, rat, and chicken but not with mouse or frog EIIIA, suggesting that His(44) may be important for antibody binding. A series of deletion mutants of rat EIIIA constructed as glutathione S-transferase fusion proteins, do not react with either IST-9, DH1, or a third monoclonal antibody (3E2). Mutations of pairs of amino acids to alanine have little effect, except for either (Val(34)Thr(35)) Or (Tyr(36)Ser(37)), which are located in a beta strand upstream from His(44). For these double mutants, the binding to all three monoclonal antibodies is markedly reduced, By contrast, single mutants at Thr(35), Tyr(36), Or Ser(37) retain full activity, suggesting that the epitope for these antibodies is determined in part by conformation. Alanine-scanning mutagenesis of rat EIIIA demonstrates the importance of Ile(43) and His44 for binding. Mutation of frog EIIIA (normally Val(43)Lys(44)) to rat (Ile(43)His(44)) is sufficient to restore fully IST-9 binding and much of the activity of DH1 and 3E2, Our findings demonstrate that the function-blocking antibodies, IST-9 and DH1, bind to the Ile(43) and His(44) residues in a conformationally dependent fashion, implicating the loop region encompassing both residues as critical for mediating EIIIA function.	Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Shriners Burns Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Van De Water, L (corresponding author), Massachusetts Gen Hosp, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA.		Liao, Yung-Feng/A-9761-2011	Van De Water, Livingston/0000-0002-3825-9224	NIGMS NIH HHS [GM56442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056442] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BARNES JL, 1995, AM J PATHOL, V147, P1361; BARNES JL, 1994, AM J PATHOL, V145, P585; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROWN LF, 1993, AM J PATHOL, V142, P793; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; Coito AJ, 1997, AM J PATHOL, V150, P1757; Copie V, 1998, J MOL BIOL, V277, P663; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESIMONE DW, 1992, DEV BIOL, V149, P357, DOI 10.1016/0012-1606(92)90291-N; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DUBIN D, 1995, ARTERIOSCL THROM VAS, V15, P1958, DOI 10.1161/01.ATV.15.11.1958; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; Gehris AL, 1997, DEV BIOL, V190, P191, DOI 10.1006/dbio.1997.8693; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GLUKHOVA MA, 1990, DEV BIOL, V141, P193, DOI 10.1016/0012-1606(90)90114-X; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; Gorski GK, 1996, GENE EXPRESSION, V6, P139; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301; Hynes RO, 1990, FIBRONECTINS; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; KNOWLTON AA, 1992, J CLIN INVEST, V89, P1060, DOI 10.1172/JCI115685; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAITINEN L, 1991, LAB INVEST, V64, P492; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; MacLeod JN, 1996, J BIOL CHEM, V271, P18954, DOI 10.1074/jbc.271.31.18954; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MAMUYA WS, 1992, J CLIN INVEST, V89, P392, DOI 10.1172/JCI115598; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MARDON HJ, 1992, J CELL SCI, V103, P423; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MATHEWS GA, 1995, J NEUROBIOL, V26, P171, DOI 10.1002/neu.480260203; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; NICKELEIT V, 1995, AM J PATHOL, V147, P965; NORTON PA, 1990, NUCLEIC ACIDS RES, V18, P4089, DOI 10.1093/nar/18.14.4089; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; Norton PA, 1998, BBA-GENE STRUCT EXPR, V1395, P145, DOI 10.1016/S0167-4781(97)00151-6; PAGANI F, 1991, J CELL BIOL, V113, P1223, DOI 10.1083/jcb.113.5.1223; Perrakis A, 1997, FOLD DES, V2, P291, DOI 10.1016/S1359-0278(97)00040-0; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; Peters JH, 1996, CELL ADHES COMMUN, V4, P103, DOI 10.3109/15419069609010766; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TAKASAKI I, 1992, HYPERTENSION, V20, P20, DOI 10.1161/01.HYP.20.1.20; VARTIO T, 1987, J CELL SCI, V88, P419; XIA P, 1995, EXP CELL RES, V217, P517, DOI 10.1006/excr.1995.1117; XIA P, 1994, EXP CELL RES, V213, P253, DOI 10.1006/excr.1994.1197; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZHANG DW, 1995, J BIOL CHEM, V270, P1817, DOI 10.1074/jbc.270.4.1817; ZHANG K, 1994, AM J PATHOL, V145, P114	84	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17876	17884		10.1074/jbc.274.25.17876	http://dx.doi.org/10.1074/jbc.274.25.17876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364233	hybrid			2022-12-27	WOS:000080974300069
J	Ronca, F; Yee, KSY; Yu, VC				Ronca, F; Yee, KSY; Yu, VC			Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; CYTOPLASMIC SEQUESTRATION; MOUSE THYMOCYTES; DRUG-RESISTANCE; GENE-MUTATIONS; N-MYC; DEATH; INDUCTION; RECEPTOR; PATHWAY	Many cell lines derived from neuroblastoma (NB) carry the wild-type p53 gene with a p53-dependent apoptotic pathway that is responsive to DNA damaging agents. A recent study has demonstrated that retinoic acid (RA) pretreatment of NE cells promotes chemoresistance to apoptosis induced by chemotherapeutic agents. We examine here the possible contribution of the p53 pathway to the chemoresistance response associated with the RA treatment in NE cells. Upon treatment with RA (1-10 mu M) for 4 days, the human NE cells, SH-SY5Y, developed resistance selectively to p53-dependent apoptotic stimuli including gamma-irradiation, etoposide, and 1-(5-isoquinolinyl sulfonyl)-2-methylpiperazine (H-7). Interestingly, RA affected the ability of H-7 to induce nuclear accumulation of the p53 protein without altering its effect on elevating the steady-state level of p53, suggesting that drug-induced up-regulation and nuclear accumulation of the wild-type p53 protein are separable processes. The modulation of nuclear import of p53 protein by RA may thus represent a potential mechanism by which certain tumor cells with the wild-type p53 gene develop resistance to chemotherapeutic agents.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Yu, VC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015	Yu, Victor/0000-0003-3270-4734				Aboseif SR, 1997, PROSTATE, V31, P161; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIEDLER JL, 1994, CANCER RES, V54, P666; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; FRITSCHE M, 1993, ONCOGENE, V8, P307; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudas Lorraine J., 1994, P443; HAMMERLING U, 1987, ONCOGENE, V2, P73; HANADA M, 1993, CANCER RES, V53, P4978; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; IMAMURA J, 1993, CANCER RES, V53, P4053; Kaba SE, 1997, J NEURO-ONCOL, V34, P145, DOI 10.1023/A:1005743707803; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOMURO H, 1993, CANCER RES, V53, P5284; LASORELLA A, 1995, CANCER RES, V55, P4711; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304, DOI 10.1074/jbc.270.47.28304; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PONZONI M, 1995, CANCER RES, V55, P853; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; VOGAN K, 1993, CANCER RES, V53, P5269; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z	42	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18128	18134		10.1074/jbc.274.25.18128	http://dx.doi.org/10.1074/jbc.274.25.18128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364268	hybrid			2022-12-27	WOS:000080974300104
J	Zhang, SH; Liu, JP; Kobayashi, R; Tonks, NK				Zhang, SH; Liu, JP; Kobayashi, R; Tonks, NK			Identification of the cell cycle regulator VCP (p97/CDC48) as a substrate of the band 4.1-related protein-tyrosine phosphatase PTPH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; MAMMALIAN HOMOLOG; PHOSPHORYLATION; ASSOCIATION; FUSION; KINASE; CDC48	The human band 4.1-related protein-tyrosine phosphatase PTPH1 was introduced into NIH3T3 cells under the control of a tetracycline-repressible promoter. Ectopic expression of wild type PTPH1 dramatically inhibited cell growth, whereas a catalytically impaired mutant showed no effect. To identify the direct target of PTPH1 in the cell, we generated a substrate-trapping mutant, in which an invariant aspartate residue was changed to alanine (D811A in PTPH1), The PTPH1-D811A mutant trapped primarily a 97-kDa tyrosine-phosphorylated protein, which was determined to be VCP (also named p97 or yeast CDC48), from various cell lysates in vitro. However, when expressed in mammalian cells, the D811A mutant was observed to contain high levels of phosphotyrosine and did not trap substrates. Mutation of tyrosine 676 to phenylalanine (Y676F) in the PTPH1-D811A mutant led to a marked reduction in phosphotyrosine content. Furthermore, this double mutant specifically trapped VCP in vivo and recognized the C-terminal tyrosinesof VCP, whose phosphorylation is important for cell cycle progression in yeast. Like wild type PTPH1, this double mutant also inhibited cell proliferation. Moreover, induction of wild type PTPH1 resulted in specific dephosphorylation of VCP without changing the overall phosphotyrosine profile of the cells, VCP has been implicated in control of a variety of membrane functions, including membrane fusions, and is a regulator of the cell cycle. Our results suggest that PTPH1 may exert its effects on cell growth through dephosphorylation of VCP, thus implicating tyrosine phosphorylation as an important regulator of VCP function.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; APTEL SK, 1998, CELL, V92, P611; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Long AR, 1998, GENE, V208, P191, DOI 10.1016/S0378-1119(97)00652-5; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pennisi E, 1998, SCIENCE, V282, P1972, DOI 10.1126/science.282.5396.1972; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	26	93	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17806	17812		10.1074/jbc.274.25.17806	http://dx.doi.org/10.1074/jbc.274.25.17806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364224	hybrid			2022-12-27	WOS:000080974300060
J	Cheng, HH; Xu, LW; Kumagai, H; Simoni, RD				Cheng, HH; Xu, LW; Kumagai, H; Simoni, RD			Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; TRANSCOBALAMIN-II RECEPTOR; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; REGULATED DEGRADATION; CHOLESTEROL HOMEOSTASIS; BETA-GALACTOSIDASE; MEMBRANE DOMAIN; UDP-GLCNAC; PROTEIN	The steady-state level of the resident endoplasmic reticulum protein, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), is regulated, in part, by accelerated degradation in response to excess sterols or mevalonate, Previous studies of a chimeric protein (HM-Gal) composed of the membrane domain of HMGR fused to Escherichia coli beta-galactosidase, as a replacement of the normal HMGR cytosolic domain, have shown that the regulated degradation of this chimeric protein, HM-Gal, is identical to that of HMGR (Chun, K. T., Bar-Nun, S., and Simoni, R. D. (1990) J. Biol. Chem. 265, 22004-22010; Skalnik, D. G., Narita, H., Kent, C., and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841), Since the cytosolic domain can be replaced with beta-galactosidase without effect on regulated degradation, it has been assumed that the cytosolic domain was not important to this process and also that the membrane domain of HMGR was both necessary and sufficient for regulated degradation. In contrast to our previous results with HM-Gal, we observed in this study that replacement of the cytosolic domain of HMGR with various heterologous proteins can have an effect on the regulated degradation, and the effect correlates with the oligomeric state of the replacement cytosolic protein. Chimeric proteins that are oligomeric in structure are relatively stable, and those that are monomeric are unstable. To test the hypothesis that the oligomeric state of the cytosolic domain of HMGR influences degradation, we use an "inducible" system for altering the oligomeric state of a protein in vivo, Using a chimeric protein that contains the membrane domain of HMGR fused to three copies of FK506-binding protein 12, we were able to induce oligomerization by addition of a "double-headed" FK506-like "dimerizer" drug (AP1510) and to monitor the degradation rate of both the monomeric form and the drug-induced oligomeric form of the protein. We show that this chimeric protein, HM-3FKBP, is unstable in the monomeric state and is stabilized by AP1510-induced oligomerization, We also examined the degradation rate of HMGR as a function of concentrations within the cell. HMGR is a functional dimer; therefore, its oligomeric state and, we predict, its degradation rate should be concentration-dependent. We observed that it is degraded more rapidly at lower concentrations.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Simoni, RD (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NHLBI NIH HHS [HL 26502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANDRA NC, 1991, ARCH BIOCHEM BIOPHYS, V290, P345, DOI 10.1016/0003-9861(91)90550-3; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FOWLER AV, 1966, SCIENCE, V154, P1027, DOI 10.1126/science.154.3752.1027; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LISCUM L, 1985, J BIOL CHEM, V260, P522; LIU SW, 1983, J BIOL CHEM, V258, P7469; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; NESS GC, 1988, BIOCHIM BIOPHYS ACTA, V953, P361, DOI 10.1016/0167-4838(88)90046-5; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PRATT D, 1983, NUCLEIC ACIDS RES, V11, P8817, DOI 10.1093/nar/11.24.8817; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107	35	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17171	17178		10.1074/jbc.274.24.17171	http://dx.doi.org/10.1074/jbc.274.24.17171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358074	hybrid			2022-12-27	WOS:000080780400073
J	Diamond, DA; Parsian, A; Hunt, CR; Lofgren, S; Spitz, DR; Goswami, PC; Gius, D				Diamond, DA; Parsian, A; Hunt, CR; Lofgren, S; Spitz, DR; Goswami, PC; Gius, D			Redox factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH 3T3 cells in response to heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CHINESE-HAMSTER FIBROBLASTS; GLUTATHIONE LEVELS; OXIDATIVE STRESS; GENE-EXPRESSION; NUCLEAR-PROTEIN; MESSENGER-RNA; REPAIR ENZYME; FREE-RADICALS; FOS	The early response genes, c-Fos and c-Jun, are induced by environmental stress and are thought to modulate injury processes via the induction of AP-l-dependent target genes. AP-I activation is thought to be regulated by changes in intracellular oxidation/reduction reactions involving the redox factor-1 (Ref-l) protein. In this study, NIH 3T3 and HeLa cells were used to determine whether heat shock induces the AP-1 transcription factor via signaling pathways involving Ref-l, Reverse transcriptase-polymerase chain reaction analysis and immunoblotting demonstrated that c-Fos and c-Jun were induced 2-10 h following heat shock, and this induction was accompanied by an increase in AP-1 DNA binding. Electrophoretic mobility shift assay extracts immunodepleted of Ref-l protein demonstrated that the increase in AP-1 DNA-binding activity following heating was dependent upon the presence of Ref-l and that Ref-l regulates inducible, but not basal, AP-1 DNA-binding activity. This was confirmed by the restoration of heat-inducible DNA binding upon addition of Ref-l to immunodepleted extracts. The ability of Ref-l from heated cells to stimulate AP-1 DNA binding was abolished by chemical oxidation and restored by chemical reduction. These results indicate that heat shock activates c-Fos/c-Jun gene expression and AP-1 DNA binding and suggests that redox-sensitive signal transduction pathways involving Ref-l may mediate heat-induced alterations in AP-1 activation.	Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA; Edward Mallinckrodt Inst Radiol, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL)	Gius, D (corresponding author), Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, 4511 Forest Pk Blvd,Suite 411, St Louis, MO 63108 USA.			Goswami, Prabhat/0000-0002-5700-2096; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [K08CA72602, CA69593, P01 CA75556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069593, P01CA075556, K08CA072602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANDREWS GK, 1994, MOL CELL BIOL, V10, P3452; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BERGELSON S, 1994, CANCER RES, V54, P36; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; Flanagan SW, 1998, FEBS LETT, V431, P285, DOI 10.1016/S0014-5793(98)00779-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FREEMAN ML, 1990, RADIAT RES, V124, P288, DOI 10.2307/3577841; FREEMAN ML, 1988, RADIAT RES, V115, P461, DOI 10.2307/3577295; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Goswami PC, 1997, CELL PROLIFERAT, V30, P271, DOI 10.1111/j.1365-2184.1997.tb00940.x; Guyton KZ, 1996, FREE RADICAL BIO MED, V20, P735, DOI 10.1016/0891-5849(95)02151-5; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; MITCHELL JB, 1983, RADIAT RES, V95, P471, DOI 10.2307/3576094; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OKUNO H, 1993, ONCOGENE, V8, P695; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; PRIVALLE CT, 1987, P NATL ACAD SCI USA, V84, P2723, DOI 10.1073/pnas.84.9.2723; RITZ MF, 1993, RECEPTOR, V3, P311; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SKIBBA JL, 1989, J BIOCHEM TOXICOL, V4, P119, DOI 10.1002/jbt.2570040208; SKIBBA JL, 1986, CANCER RES, V46, P6000; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; SPITZ DR, 1990, J CELL PHYSIOL, V142, P255, DOI 10.1002/jcp.1041420206; STEVENSON MA, 1994, CANCER RES, V54, P12; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	45	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16959	16964		10.1074/jbc.274.24.16959	http://dx.doi.org/10.1074/jbc.274.24.16959			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358044	hybrid			2022-12-27	WOS:000080780400043
J	Rodriguez, A; Martinez, I; Chung, A; Berlot, CH; Andrews, NW				Rodriguez, A; Martinez, I; Chung, A; Berlot, CH; Andrews, NW			cAMP regulates Ca2+-dependent exocytosis of lysosomes and lysosome-mediated cell invasion by trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; PERMEABILIZED CHROMAFFIN CELLS; CYCLIC-AMP; ADENYLATE-CYCLASE; EPITHELIAL-CELLS; DEPENDENT REGULATION; ACTIN-FILAMENTS; RAT-LIVER; CALCIUM; RELEASE	Ca2+-regulated exocytosis, previously believed to be restricted to specialized cells, was recently recognized as a ubiquitous process. In mammalian fibroblasts and epithelial cells, exocytic vesicles mobilized by Ca2+ were identified as lysosomes, Here we show that elevation in intracellular cAMP potentiates Ca2+-dependent exocytosis of lysosomes in normal rat kidney fibroblasts. The process can be modulated by the heterotrimeric Gr proteins G(s) and G(i), consistent with activation or inhibition of adenylyl cyclase, Normal rat kidney cell stimulation with isoproterenol, a beta-adrenergic agonist that activates adenylyl cyclase, enhances Ca2+-dependent lysosome exocytosis and cell invasion by Trypanosoma cruzi, a process that involves parasite-induced [Ca2+](i) transients and fusion of host cell lysosomes with the plasma membrane. Similarly to what is observed for T, cruzi invasion, the actin cytoskeleton acts as a barrier for Ca2+-induced lysosomal exocytosis, In addition, infective stages of T, cruzi trigger elevation in host cell cAMP levels, whereas no effect is observed with noninfective forms of the parasite, These findings demonstrate that cAMP regulates lysosomal exocytosis triggered by Ca2+ and a parasite/host cell interaction known to involve Ca2+-dependent lysosomal fusion.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol & Cellular Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University	Andrews, NW (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.			Martinez, Inigo/0000-0001-5408-9088; Andrews, Norma/0000-0002-0611-2412	NIAID NIH HHS [R01AI34867] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034867] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; DOWNEY GP, 1991, J CELL BIOL, V114, P1179, DOI 10.1083/jcb.114.6.1179; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Epple HJ, 1997, PFLUG ARCH EUR J PHY, V433, P638, DOI 10.1007/s004240050325; FORSCHER P, 1987, J NEUROSCI, V7, P3600; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; GIROD R, 1995, J NEUROSCI, V15, P2826; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; GUELLAEN G, 1977, BIOCHIM BIOPHYS ACTA, V484, P465, DOI 10.1016/0005-2744(77)90102-4; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Huang CC, 1998, J NEUROSCI, V18, P2276; Jilling T, 1996, J BIOL CHEM, V271, P4381; KEHLENBACH RH, 1994, NATURE, V372, P804; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KOTZ KJ, 1994, J CELL BIOL, V124, P463, DOI 10.1083/jcb.124.4.463; LANG J, 1995, EMBO J, V14, P3535; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; Morgan A, 1995, ESSAYS BIOCHEM, V30, P77; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NEER EJ, 1995, CELL, V80, P248; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; OSULLIVAN AJ, 1992, BIOCHEM J, V287, P403, DOI 10.1042/bj2870403; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Rovere P, 1996, J IMMUNOL, V156, P2273; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SPERELAKIS N, 1994, MOL CELL BIOCHEM, V140, P103, DOI 10.1007/BF00926749; SPIEGEL AM, 1981, ENDOCR REV, V2, P275, DOI 10.1210/edrv-2-3-275; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Tousson A, 1996, J CELL SCI, V109, P1325; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; VITALE N, 1996, EUR J NEUROSCI, V8, P1274; Zhang C, 1996, AM J PHYSIOL-RENAL, V270, pF131, DOI 10.1152/ajprenal.1996.270.1.F131	53	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16754	16759		10.1074/jbc.274.24.16754	http://dx.doi.org/10.1074/jbc.274.24.16754			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358016	hybrid			2022-12-27	WOS:000080780400015
J	Sheikh, SP; Vilardarga, JP; Baranski, TJ; Lichtarge, O; Iiri, T; Meng, EC; Nissenson, RA; Bourne, HR				Sheikh, SP; Vilardarga, JP; Baranski, TJ; Lichtarge, O; Iiri, T; Meng, EC; Nissenson, RA; Bourne, HR			Similar structures and shared switch mechanisms of the beta(2)-adrenoceptor and the parathyroid hormone receptor - Zn(II) bridges between helices III and VI block activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; METABOTROPIC GLUTAMATE RECEPTORS; BETA-ADRENERGIC RECEPTORS; TACHYKININ NK-1 RECEPTOR; ADENYLATE-CYCLASE; TRANSMEMBRANE HELICES; SYNTHETIC PEPTIDES; RHODOPSIN MUTANTS; LYMPHOMA-CELLS; ALPHA-SUBUNIT	The seven transmembrane helices of serpentine receptors comprise a conserved switch that relays signals from extracellular stimuli to heterotrimeric G proteins on the cytoplasmic face of the membrane. By substituting histidines for residues at the cytoplasmic ends of helices III and VI in retinal rhodopsin, we engineered a metal-binding site whose occupancy by Zn(II) prevented the receptor from activating a retinal G protein, G(t) (Sheikh, S. P., Zvyaga, T. A., Lichtarge, O., Sakmar, T. P., and Bourne, H. R. (1996) Nature 383, 347-350), Now we report engineering of metal-binding sites bridging the cytoplasmic ends of these two helices in two other serpentine receptors, the beta(2)-adrenoreceptor and the parathyroid hormone receptor; occupancy of the metal-binding site by Zn(II) markedly impairs the ability of each receptor to mediate ligand-dependent activation of G(s), the stimulatory regulator of adenylyl cyclase, We infer that these two receptors share with rhodopsin a common three-dimensional architecture and an activation switch that requires movement, relative to one another, of helices III and VI; these inferences are surprising in the case of the parathyroid hormone receptor, a receptor that contains seven stretches of hydrophobic sequence but whose amino acid sequence otherwise shows no apparent similarity to those of receptors in the rhodopsin family. These findings highlight the evolutionary conservation of the switch mechanism of serpentine receptors and help to constrain models of how the switch works.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Endocrine Unit, Dept Vet Affairs, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), S1212,Box 0450,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; ROSS EM, 1977, J BIOL CHEM, V252, P5761; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	41	176	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17033	17041		10.1074/jbc.274.24.17033	http://dx.doi.org/10.1074/jbc.274.24.17033			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358054	hybrid, Green Submitted			2022-12-27	WOS:000080780400053
J	Shimoda, Y; Tajima, Y; Nagase, T; Harii, K; Osumi, N; Sanai, Y				Shimoda, Y; Tajima, Y; Nagase, T; Harii, K; Osumi, N; Sanai, Y			Cloning and expression of a novel galactoside beta 1,3-glucuronyltransferase involved in the biosynthesis of HNK-1 epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; CELL-ADHESION MOLECULES; NEURAL CREST MIGRATION; CARBOHYDRATE EPITOPE; L2/HNK-1 CARBOHYDRATE; NERVOUS-SYSTEM; RAT-BRAIN; SULFOGLUCURONYL GLYCOLIPIDS; GLUCURONOSYLTRANSFERASE	We isolated a cDNA encoding a novel glucuronyltransferase, designated GlcAT-D, involved in the biosynthesis of the HNK-1 carbohydrate epitope from rat embryo cDNA by the degenerate polymerase chain reaction method. The new cDNA sequence revealed an open reading frame coding for a protein of 324 amino acids with type II transmembrane protein topology. The amino acid sequence of GlcAT-D displayed 50.0% identity to rat GlcAT-P, which is involved in the biosynthesis of the HNK-1 epitope on glycoproteins. Expression of GlcAT-D in COS-7 cells resulted in the formation of the HNK-1 epitope on the cell surface. The enzyme expressed in COS-7 cells transferred a glucuronic acid (GlcA) not only to asialo-orosomucoid, a glycoprotein bearing terminal N-acetyllactosamine structure, but also to para-globoside (lacto-N-neotetraosylceramide), a precursor of the HNK-1 epitope on glycolipids. Furthermore, substrate specificity analysis using a soluble chimeric form of GlcAT-D revealed that GlcAT-D transfers a GlcA not only to Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-pyridylamine but also to Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc-pyridylamine. Enzymatic hydrolysis and Smith degradation of the reaction product indicated that GlcAT-D transfers a GlcA through a beta 1,3-linkage to a terminal galactose, The GlcAT-D transcripts were detected in embryonic, post-natal, and adult rat brain. In situ hybridization analysis revealed that the expression pattern of GlcAT-D transcript in embryo is similar to that of GlcAT-P, but distinct expression of GlcAT-D was observed in the embryonic pallidum and retina. Regions that expressed GlcAT-D and/or GlcAT-P were always HNK-1-positive, indicating that both GlcATs are involved in the synthesis of the HNK-1 epitope in vivo.	Tokyo Metropolitan Inst Med Sci, RINSHOKEN, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Med, Dept Plast & Reconstruct Surg, Tokyo 1130033, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Cell Biol & Biophys, Tokyo 1878502, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; National Center for Neurology & Psychiatry - Japan	Sanai, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, RINSHOKEN, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1138613, Japan.		Osumi, Noriko/T-2823-2019	Osumi, Noriko/0000-0003-0548-6452				ARIGA T, 1987, J BIOL CHEM, V262, P848; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BRONNERFRASER M, 1987, DEV BIOL, V123, P321, DOI 10.1016/0012-1606(87)90390-3; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; DAS KK, 1991, J BIOL CHEM, V266, P5238; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HASE S, 1985, J BIOCHEM-TOKYO, V98, P863, DOI 10.1093/oxfordjournals.jbchem.a135366; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KAWASHIMA C, 1992, GLYCOCONJUGATE J, V9, P307, DOI 10.1007/BF00731091; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; KURATANI SC, 1991, DEV BIOL, V144, P215, DOI 10.1016/0012-1606(91)90493-M; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE YM, 1995, DEVELOPMENT, V121, P825; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OKA S, 1992, J BIOL CHEM, V267, P22711; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Osumi N, 1997, DEVELOPMENT, V124, P2961; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Watanabe Y, 1996, J BIOCHEM-TOKYO, V120, P1020; Yuen CT, 1997, J BIOL CHEM, V272, P8924	37	37	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17115	17122		10.1074/jbc.274.24.17115	http://dx.doi.org/10.1074/jbc.274.24.17115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358066	hybrid			2022-12-27	WOS:000080780400065
J	Banks, GC; Mohr, B; Reeves, R				Banks, GC; Mohr, B; Reeves, R			The HMG-I(Y) A center dot T-hook peptide motif confers DNA-binding specificity to a structured chimeric protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; 4-WAY JUNCTION DNA; HMG-I; MINOR-GROOVE; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; SATELLITE DNA; GENE; SEQUENCE	Chromosomal translocations involving genes coding for members of the HMG-I(Y) family of "high mobility group" non-histone chromatin proteins (HMG-I, HMG-Y, and HMG-IC) have been observed in numerous types of human tumors. Many of these gene rearrangements result in the creation of chimeric proteins in which the DNA-binding domains of the HMG-I(Y) proteins, the so-called A.T-hook motifs, have been fused to heterologous peptide sequences. Although little is known about either the structure or biophysical properties of these naturally occurring fusion proteins, the suggestion has been made that such chimeras have probably assumed an altered in vivo DNA-binding specificity due to the presence of the A.T-hook motifs. To investigate this possibility, we performed in vitro "domain-swap" experiments using a model protein fusion system in which a single A.T-hook peptide was exchanged for a corresponding length peptide in the well characterized "B-box" DNA-binding domain of the HMG-1 non-histone chromatin protein. Here we report that chimeric A.T-hook/B box hybrids exhibit in vitro DNA-binding characteristics resembling those of wild type HMG-I(Y) protein, rather than the HMG-1 protein. These results strongly suggest that the chimeric fusion proteins produced in human tumors as a result of HMG-I(Y) gene chromosomal translocations also retain A.T-hook-imparted DNA-binding properties in vivo.	Washington State Univ, Dept Biochem Biophys, Pullman, WA 99164 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	Washington State University; Washington State University	Reeves, R (corresponding author), Washington State Univ, Dept Biochem Biophys, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHAR HR, 1995, CELL, V82, P57; BRENOWITZ M, 1995, CURRENT PROTOCOLS MO; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; EVANS JNS, 1995, INT J PEPT PROT RES, V45, P554; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; Geurts JMW, 1997, CANCER RES, V57, P13; Geurts JMW, 1998, ONCOGENE, V16, P865, DOI 10.1038/sj.onc.1201609; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kazmierczak B, 1998, AM J PATHOL, V152, P431; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kools PFJ, 1996, CANCER GENET CYTOGEN, V91, P1, DOI 10.1016/S0165-4608(96)00109-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; REEVES R, 1993, J BIOL CHEM, V268, P21137; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; Reeves R, 1995, PROG CELL CYCLE RES, V1, P337; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Xiao S, 1997, AM J PATHOL, V150, P901; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	25	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16536	16544		10.1074/jbc.274.23.16536	http://dx.doi.org/10.1074/jbc.274.23.16536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347218	hybrid			2022-12-27	WOS:000080668600078
J	Chen, SH; Xu, M; Lin, F; Lee, D; Riek, P; Graham, RM				Chen, SH; Xu, M; Lin, F; Lee, D; Riek, P; Graham, RM			Phe(310) in transmembrane VI of the alpha(1B)-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; MEMBRANE-SPANNING SEGMENT; BINDING-SITE CREVICE; DOPAMINE D2 RECEPTOR; CONSTITUTIVE ACTIVATION; ALPHA-1B-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; AGONIST BINDING; ACTIVE STATE; SALT BRIDGE	Pharmacophore mapping of adrenergic receptors indicates that the phenyl ring of catecholamine agonists is involved in receptor binding and activation. Here we evaluated Phe(310), Phe(311), and Phe(303) in transmembrane VI (TMVI), as well as Tyr(348) in TMVII of the alpha(IB)-adrenergic receptor (alpha(1B)-AR), which have been implicated in a catechol-ring interaction. Neither catecholamine docking studies nor mutagenesis studies of Phe311, Phe303, or Tyr348 supported a role for these residues in catecholring binding. By contrast, docking studies indicated that the Phe310 side chain is well positioned to interact with the catechol-ring, and substituted cysteine accessibility method studies revealed that the side chain of the 310, but not 311 residue, is both solvent accessible and directed into the agonist-binding pocket. Also, saturation mutagenesis of both Phe310 and Phe311 revealed for the former, but not for the latter, a direct relationship between side chain volume and agonist affinity, and that aromaticity is essential for wild-type agonist binding, and for both wild-type agonist potency and efficacy. Moreover, studies of Phe310 mutants combined with a previously described constitutively active alpha(1B)-AR mutant, A293E, indicated that although not required for spontaneous receptor isomerization from the basal state, R, to a partially activated conformation R', interaction of Phe(310) with catecholamine agonists is essential for isomerization from R' to the fully activated state, R*.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Sydney, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Graham, RM (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St, Darlinghurst, NSW 2010, Australia.			Lin, Fang/0000-0003-2179-7031; chen, songhai/0000-0001-7316-7125				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GETHER U, 1995, J BIOL CHEM, V270, P28268; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; PARINI A, 1987, CIRC RES, V61, P100; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1998, MOL PHARMACOL, V53, P766, DOI 10.1124/mol.53.4.766; RIEK RP, 1995, J THEOR BIOL, V172, P245; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROTHSCHILD KJ, 1983, SCIENCE, V219, P1333, DOI 10.1126/science.6828860; SALAMON Z, 1994, BIOCHEMISTRY-US, V33, P13706, DOI 10.1021/bi00250a022; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRADER CD, 1987, P NATL ACAD SCI USA, V83, P917; SUNG SS, 1991, FASEB J, V5, pA804; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; WU DQ, 1992, J BIOL CHEM, V267, P25798	38	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16320	16330		10.1074/jbc.274.23.16320	http://dx.doi.org/10.1074/jbc.274.23.16320			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347189	hybrid			2022-12-27	WOS:000080668600049
J	Rivera-Nieves, J; Thompson, WC; Levine, RL; Moss, J				Rivera-Nieves, J; Thompson, WC; Levine, RL; Moss, J			Thiols mediate superoxide-dependent NADH modification of glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED ADP-RIBOSYLATION; NITRIC-OXIDE; S-NITROSYLATION; RELAXING FACTOR; ACID; RIBOSYLTRANSFERASE; PEROXYNITRITE; INVOLVEMENT; MECHANISM; OXIDATION	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is covalently modified by NAD in the presence of nitric oxide (NO) and dithiothreitol. Replacement of NAD with NADH in the presence of SIN-1 (3-morpholinosydnonimine) and dithiothreitol increased modification 25-fold. We now demonstrate that in contrast to NO-mediated attachment of NAD, covalent attachment of NADH to GAPDH proceeds in the presence of low molecular weight thiols, independent of NO. Removal of oxygen and transition metal ions inhibited modification, consistent with a role for reactive oxygen species; inhibition by superoxide dismutase, stimulation by xanthine oxidase/hypoxanthine, and the lack of an effect of catalase supported the hypothesis that superoxide, generated hom thiol oxidation, was involved. Electrospray mass spectrometry showed covalent Linkage of the NADH molecule to GAPDH Characterization of the product of phosphodiesterase cleavage demonstrated that linkage to GAPDH occurred through the nicotinamide of NADH. Lys-C digestion of GAPDH, followed by peptide isolation by high performance liquid chromatography, matrix-assisted laser desorption ionization time-of-flight analysis, and Ed-man sequencing, demonstrated that NADH attachment occurred at Cys-149, the active-site thiol. This thiol linkage was stable to HgCl2. Thus, linkage of GAPDH to NADH, in contrast to NAD, occurs in the presence of thiol, is independent of NO, and is mediated by superoxide.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Moss, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N-307,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.	JR3u@virginia.edu	Levine, Rodney L/D-9885-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002537] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; Babior B M, 1995, Curr Opin Hematol, V2, P55; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; BUCHANAN JD, 1978, INT J RADIAT BIOL, V33, P409, DOI 10.1080/09553007814550331; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; Halliwell B, 1996, PATHOL BIOL, V44, P6; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jocelyn P. C., 1972, BIOCH SH GROUP, P94; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LI J, 1993, J PHARMACOL EXP THER, V267, P371; MCDONALD B, 1993, P NATL ACAD SCI USA, V90, P11122, DOI 10.1073/pnas.90.23.11122; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MISRA HP, 1974, J BIOL CHEM, V249, P2151; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MORAS D, 1975, J BIOL CHEM, V250, P9137; MOSS J, 1983, J BIOL CHEM, V258, P6466; Moss J, 1997, ADV EXP MED BIOL, V419, P25; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE KL, 1993, PRACTICAL GUIDE PROT, P55; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WEST RE, 1985, J BIOL CHEM, V260, P4428; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024	38	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19525	19531		10.1074/jbc.274.28.19525	http://dx.doi.org/10.1074/jbc.274.28.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391884	hybrid			2022-12-27	WOS:000081377300004
J	Cypess, AM; Unson, CG; Wu, CR; Sakmar, TP				Cypess, AM; Unson, CG; Wu, CR; Sakmar, TP			Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HORMONE (PTH)/PTH-RELATED PEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; SITE-DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; MEMBRANE-GLYCOPROTEINS; CONSTITUTIVE ACTIVITY; CALCITONIN RECEPTORS; MUSCARINIC RECEPTOR; SEQUENCE ALIGNMENT	The glucagon receptor is a member of a distinct class of G protein-coupled receptors (GPCRs) sharing little amino acid sequence homology with the larger rhodopsin-like GPCR family. To identify the components of the glucagon receptor necessary for G-protein coupling, we replaced sequentially all or part of each intracellular loop (i1, i2, and i3) and the C-terminal tail of the glucagon receptor with the 11 amino acids comprising the first intracellular loop of the D4 dopamine receptor. When expressed in transiently transfected COS-1 cells, the mutant receptors fell into two different groups with respect to hormone-mediated signaling. The first group included the loop i1 mutants, which bound glucagon and signaled normally. The second group comprised the loop i2 and i3 chimeras, which caused no detectable adenylyl cyclase activation in COS-1 cells. However, when expressed in HEK 293T cells, the loop i2 or i3 chimeras caused very small glucagon-mediated increases in cAMP levels and intracellular calcium concentrations, with EC50 values nearly 100-fold higher than those measured for wild-type receptor. Replacement of both loops i2 and i3 simultaneously was required to completely abolish G protein signaling as measured by both cAMP accumulation and calcium flux assays. These results show that the i2 and i3 loops play a role in glucagon receptor signaling, consistent with recent models for the mechanism of activation of G proteins by rhodopsin-like GPCRs.	Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, Box 284,1230 York Ave, New York, NY 10021 USA.		Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054718, R01DK024039] Funding Source: NIH RePORTER; NCI NIH HHS [CA09673] Funding Source: Medline; NIDDK NIH HHS [DK24039, DK54718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; Buggy JJ, 1997, DIABETES, V46, P1400, DOI 10.2337/diabetes.46.9.1400; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; Cohen DP, 1997, ENDOCRINOLOGY, V138, P1400, DOI 10.1210/en.138.4.1400; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Heller RS, 1996, BIOCHEM BIOPH RES CO, V223, P624, DOI 10.1006/bbrc.1996.0945; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LO KM, 1984, P NATL ACAD SCI USA, V91, P2285; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; Tseng CC, 1997, BIOCHEM BIOPH RES CO, V232, P96, DOI 10.1006/bbrc.1997.6231; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349	68	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19455	19464		10.1074/jbc.274.27.19455	http://dx.doi.org/10.1074/jbc.274.27.19455			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383462	hybrid			2022-12-27	WOS:000081196300085
J	Diebold, SS; Kursa, P; Wagner, E; Cotten, M; Zenke, M				Diebold, SS; Kursa, P; Wagner, E; Cotten, M; Zenke, M			Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; GENE-TRANSFER; IN-VIVO; MAMMALIAN-CELLS; PLASMID DNA; HUMAN BLOOD; ADENOVIRUS; COMPLEXES	Cell surface-bound receptors represent suitable entry sites for gene delivery into cells by receptor-mediated endocytosis. Here we have taken advantage of the mannose receptor that is highly expressed on antigen-presenting dendritic cells for targeted gene transfer by employing mannosylpolyethylenimine (ManPEI) conjugates. Several ManPEI conjugates were synthesized and used for formation of ManPEI/DNA transfection complexes. Conjugates differed in the Linker between mannose and polyethylenimine (PEI) and in the size of the PEI moiety. We demonstrate that ManPEI transfection is effective in delivering DNA into mannose receptor-expressing cells. Uptake of ManPEI/DNA complexes is receptor-specific, since DNA delivery can be competed with mannosylated albumin, Additionally, incorporation of adenovirus particles into transfection complexes effectively enhances transgene expression. This is particularly important for primary immunocompetent dendritic cells. It is demonstrated here that dendritic cells transfected with ManPEI/DNA complexes containing adenovirus particles are effective in activating T cells of T cell receptor transgenic mice in an antigen-specific fashion.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Boehringer Ingelheim Austria, A-1121 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Cotten, Matthew/0000-0002-3361-3351				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Aicher A, 1997, EXP HEMATOL, V25, P39; Arthur JF, 1997, CANCER GENE THER, V4, P17; Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002; Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219; Baker A, 1997, NUCLEIC ACIDS RES, V25, P1950, DOI 10.1093/nar/25.10.1950; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1994, VIROLOGY, V205, P254, DOI 10.1006/viro.1994.1641; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; COTTEN M, 1994, GENE THER, V1, P239; COTTEN M, 1996, CURRENT PROTOCOLS HU; Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; Diebold SS, 1999, HUM GENE THER, V10, P775, DOI 10.1089/10430349950018535; Diebold SS, 1998, ADV EXP MED BIOL, V451, P449; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Erbacher P, 1996, HUM GENE THER, V7, P721, DOI 10.1089/hum.1996.7.6-721; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Ferkol T, 1996, P NATL ACAD SCI USA, V93, P101, DOI 10.1073/pnas.93.1.101; Girolomoni G, 1997, IMMUNOL TODAY, V18, P102, DOI 10.1016/S0167-5699(97)01030-X; HOQUIST KA, 1994, CELL, V76, P17; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LEMAY P, 1980, VIROLOGY, V101, P131, DOI 10.1016/0042-6822(80)90490-0; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Ribas A, 1997, CANCER RES, V57, P2865; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Westermann J, 1998, GENE THER, V5, P264, DOI 10.1038/sj.gt.3300568; WU GY, 1987, J BIOL CHEM, V262, P4429; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	54	212	251	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19087	19094		10.1074/jbc.274.27.19087	http://dx.doi.org/10.1074/jbc.274.27.19087			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383411	hybrid			2022-12-27	WOS:000081196300034
J	Lim, YP; Low, BC; Lim, J; Wong, ESM; Guy, GR				Lim, YP; Low, BC; Lim, J; Wong, ESM; Guy, GR			Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHATASE; PC12 CELLS; IN-VITRO; ACTIVATION; ZETA; RECEPTOR; SUBSTRATE; RAS; SNT	FRS2 is a docker protein that recruits signaling proteins to the plasma membrane in fibroblast growth factor signal transduction. We report here that FRS2 was associated with PKC lambda when Swiss 3T3 cells were stimulated with basic fibroblast growth factor. PKC zeta, the other member of the atypical PKC subfamily, could also bind FRS2. The association between FRS2 and PKC lambda is likely to be direct as shown by yeast two-hybrid analysis. The C-terminal fragments of FRS2 (amino acid residues 300-508) and SNT2 (amino acids 281-492), an isoform bearing 50% identity to FRS2, interacted with PKC lambda at a region (amino acids 240-562) that encompasses the catalytic domain. In vitro kinase assays revealed neither FRS2 nor SNT2 was a substrate of PKC lambda or zeta. Mutation of the alanine residue (Ala-120) to glutamate in the pseudo-substrate region of PKC lambda results in a constitutively active kinase that exhibited more than 2-fold greater binding to FRS2 in vitro than its "closed" wildtype counterpart. Tyrosine phosphorylation of FRS2 did not affect its binding to the constitutively active PRC lambda mutant, suggesting that the activation of PKC lambda is necessary and sufficient for its association with FRS2. It is likely that FRS2 serves as an anchoring protein for targeting activated atypical PKCs to the cell plasma membrane in signaling pathways.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Guy, GR (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Jormay/A-7257-2011; Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Lim, Jormay/0000-0001-7191-545X; Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; EDURNE B, 1995, EMBO J, V14, P6157; EDURNE B, 1993, CELL, V74, P555; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lim YP, 1997, J BIOL CHEM, V272, P29892, DOI 10.1074/jbc.272.47.29892; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PLUS A, 1997, P NATL ACAD SCI USA, V94, P6191; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSEN DM, 1991, P NATL ACAD SCI USA, V88, P3997; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Wang JK, 1996, ONCOGENE, V13, P721; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	34	30	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19025	19034		10.1074/jbc.274.27.19025	http://dx.doi.org/10.1074/jbc.274.27.19025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383403	hybrid			2022-12-27	WOS:000081196300026
J	Pece, S; Chiariello, M; Murga, C; Gutkind, JS				Pece, S; Chiariello, M; Murga, C; Gutkind, JS			Activation of the protein kinase Akt PKB by the formation of E-cadherin-mediated cell-cell junctions - Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TYROSINE PHOSPHORYLATION; ALPHA-CATENIN; DIMERIZATION; EXPRESSION; TRANSITION; CARCINOMA; RECEPTORS; PHENOTYPE; SURVIVAL	E-cadherins are surface adhesion molecules localized at the level of adherens junctions, which play a major role in cell adhesiveness by mediating calcium-dependent homophylic interactions at sites of cell-cell contacts. Recently, E-cadherins have been also implicated in a number of biological processes, including cell growth and differentiation, cell recognition, and sorting during developmental morphogenesis, as well as in aggregation-dependent cell survival. As phosphatidylinositol (PI) 3-kinase and Akt play a critical role in survival pathways in response to both growth factors and extracellular stimuli, these observations prompted us to explore whether E-cadherins could affect intracellular molecules regulating the activity of the PI 3-kinase/Akt signaling cascade. Using Madin-Darby canine kidney cells as a model system, we show here that engagement of E-cadherins in homophylic calcium-dependent cell cell interactions results in a rapid PI 3-kinase-dependent activation of Akt and the subsequent translocation of Akt to the nucleus. Moreover, we demonstrate that the activation of PI 3-kinase in response to cell-cell contact formation involves the phosphorylation of PI 3-kinase in tyrosine residues, and the concomitant recruitment of PI 3-kinase to E-cadherin-containing protein complexes. These findings indicate that E-cadherins can initiate outside-in signal transducing pathways that regulate the activity of PI 3-kinase and Akt, thus providing a novel molecular mechanism whereby the interaction among neighboring cells and their adhesion status may ultimately control the fate of epithelial cells.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Pece, Salvatore/B-9609-2013; Murga, Cristina/E-1965-2014	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482; Pece, Salvatore/0000-0003-1764-3929; Murga, Cristina/0000-0002-8964-4077				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; KINEH MS, 1995, J CELL BIOL, V130, P461; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Simard D, 1996, BIOCHEM BIOPH RES CO, V219, P122, DOI 10.1006/bbrc.1996.0192; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Toyoyama H, 1999, ONCOL REP, V6, P81; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	32	235	242	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19347	19351		10.1074/jbc.274.27.19347	http://dx.doi.org/10.1074/jbc.274.27.19347			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383446	hybrid			2022-12-27	WOS:000081196300069
J	Racz, A; Barsony, J				Racz, A; Barsony, J			Hormone-dependent translocation of vitamin D receptors is linked to transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; 1,25-DIHYDROXYVITAMIN D-3 RECEPTOR; TRANSCRIPTION FACTOR IIB; GLUCOCORTICOID RECEPTOR; LIVING CELLS; ACTIVATION FUNCTION-2; NUCLEAR-LOCALIZATION; BASAL TRANSCRIPTION; DNA-BINDING; DOMAIN	Vitamin D receptor (VDR) acts as a transcription factor mediating genomic actions of calcitriol. Our earlier studies suggested that calcitriol induces translocation of cytoplasmic VDR, but the physiologic relevance of this finding remained uncertain. Previous studies demonstrated that the activation function 2 domain (AF-2) plays an essential role in VDR transactivation. To elucidate hormone-dependent VDR translocation and its role, we constructed green fluorescent protein (GFP) chimeras with full-length VDR (VDR-GFP), AF-2-truncated VDR (AF-2del-VDR-GFP), and ligand-binding domain LBD)-truncated VDR (LBDdel-VDR-GFP), COS-7 cells were transiently transfected with these constructs. Western blot analysis, fluorescent microscopy, and transactivation assays showed that the generated chimeras are expressed and fluoresce and that VDR-GFP is transcriptionally active. After hormone treatment, cytoplasmic VDR-GFP translocated to the nucleus in a concentration-, time-, temperature-, and analog-specific manner. Hormone dose-response relationships for translocation and for transactivation were similar. Truncation of LED and truncation of AF-2 each abolished hormone-dependent translocation and transactivation. Our data confirm a hormone-dependent VDR translocation, demonstrate that an intact AF-2 domain is required for this translocation, and indicate that translocation is part of the receptor activation process.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Barsony, J (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 422,8 Ctr Dr, Bethesda, MD 20892 USA.	jul@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060051, Z01DK060050] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BLIZIOTES M, 1988, J CLIN ENDOCR METAB, V66, P294, DOI 10.1210/jcem-66-2-294; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DeLuca H F, 1985, Soc Gen Physiol Ser, V39, P159; DeLuca HF, 1998, NUTR REV, V56, pS4; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Georget V, 1998, J CLIN ENDOCR METAB, V83, P3597, DOI 10.1210/jc.83.10.3597; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Hager GL, 1998, J STEROID BIOCHEM, V65, P125, DOI 10.1016/S0960-0760(97)00178-7; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; HSU SC, 1995, J BIOL CHEM, V270, P3359, DOI 10.1074/jbc.270.7.3359; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Johnson JA, 1996, HISTOCHEM CELL BIOL, V105, P7, DOI 10.1007/BF01450873; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Nayeri S, 1996, NUCLEIC ACIDS RES, V24, P4513, DOI 10.1093/nar/24.22.4513; Norman AW, 1996, J STEROID BIOCHEM, V56, P13, DOI 10.1016/0960-0760(95)00219-7; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SMITH CL, 1991, MOL ENDOCRINOL, V5, P867, DOI 10.1210/mend-5-6-867; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; WIESE RJ, 1993, MOL CELL ENDOCRINOL, V90, P197, DOI 10.1016/0303-7207(93)90152-A; Zanello SB, 1997, HORM METAB RES, V29, P231, DOI 10.1055/s-2007-979027; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	43	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19352	19360		10.1074/jbc.274.27.19352	http://dx.doi.org/10.1074/jbc.274.27.19352			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383447	hybrid			2022-12-27	WOS:000081196300070
J	Sarret, P; Nouel, D; Dal Farra, C; Vincent, JP; Beaudet, A; Mazella, J				Sarret, P; Nouel, D; Dal Farra, C; Vincent, JP; Beaudet, A; Mazella, J			Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; RAT NEUROTENSIN RECEPTOR; MESSENGER-RNA; TUMOR-CELLS; SIGNAL-TRANSDUCTION; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; DESENSITIZATION; SUBTYPE; ENDOCYTOSIS	The inhibitory effect of the neuropeptide somatostatin on the expression of growth hormone was measured by quantitative polymerase chain reaction in the pituitary cell line AtT-20. We demonstrate that this effect is dependent on the internalization of somatostatin-receptor complexes and that it is totally independent from the peptide-induced inhibition of adenylate cyclase. Indeed, the inhibitory effect of the peptide on growth hormone mRNA levels was totally insensitive to pertussis toxin treatment but was totally abolished under conditions which block somatostatin receptor internalization. Comparative confocal microscopic imaging of fluorescent somatostatin sequestration and fluorescence immunolabeling of sst1, sst2A, and sst5 receptors suggests that sst2A is most probably responsible of the inhibitory effect of somatostatin on growth hormone expression.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Mazella, Jean/A-6767-2012	Sarret, Philippe/0000-0002-7627-701X				Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dournaud P, 1998, J NEUROSCI, V18, P1056; Dournaud P, 1996, J NEUROSCI, V16, P4468; DRAZNIN B, 1985, ENDOCRINOLOGY, V117, P960, DOI 10.1210/endo-117-3-960; EPELBAUM J, 1994, CRIT REV NEUROBIOL, V8, P25; Garland AM, 1996, MOL PHARMACOL, V49, P438; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Girardin SE, 1998, FEBS LETT, V431, P333, DOI 10.1016/S0014-5793(98)00787-X; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Koenig JA, 1998, BIOCHEM J, V336, P291, DOI 10.1042/bj3360291; Koenig JA, 1997, BRIT J PHARMACOL, V120, P52, DOI 10.1038/sj.bjp.0700859; LAMBERTS SWJ, 1991, INT J CANCER, V48, P938, DOI 10.1002/ijc.2910480623; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LINZER DIH, 1985, J BIOL CHEM, V260, P9574; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; LUINI A, 1986, J NEUROSCI, V6, P3128; MOREL G, 1986, ENDOCRINOLOGY, V119, P1972, DOI 10.1210/endo-119-5-1972; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PATEL YC, 1990, METABOLISM, V39, P63, DOI 10.1016/0026-0495(90)90214-W; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PATEL YC, 1994, J BIOL CHEM, V269, P1506; Patel YC, 1996, METABOLISM, V45, P31, DOI 10.1016/S0026-0495(96)90076-1; PETEN EP, 1993, KIDNEY INT, V43, pS55; Reisine T, 1995, AM J PHYSIOL-GASTR L, V269, pG813, DOI 10.1152/ajpgi.1995.269.6.G813; REISINE T, 1990, METABOLISM, V39, P70, DOI 10.1016/0026-0495(90)90215-X; REISINE T, 1985, ENDOCRINOLOGY, V116, P2259, DOI 10.1210/endo-116-6-2259; REISINE T, 1995, NEUROSCIENCE, V67, P777, DOI 10.1016/0306-4522(95)00072-Q; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; SADOUL JL, 1984, BIOCHEM BIOPH RES CO, V120, P812, DOI 10.1016/S0006-291X(84)80179-5; Sarret P, 1998, NEUROENDOCRINOLOGY, V68, P37, DOI 10.1159/000054348; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; SOTO JL, 1995, ENDOCRINOLOGY, V136, P3863, DOI 10.1210/en.136.9.3863; Souaze F, 1997, J BIOL CHEM, V272, P10087; STROH T, 1993, NEUROSCI LETT, V160, P145, DOI 10.1016/0304-3940(93)90399-6; SUGIHARA H, 1993, ENDOCRINOLOGY, V132, P1225, DOI 10.1210/en.132.3.1225; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THORNER MO, 1990, METABOLISM, V39, P40, DOI 10.1016/0026-0495(90)90207-S; WOOD DF, 1987, MOL CELL ENDOCRINOL, V52, P257, DOI 10.1016/0303-7207(87)90052-9; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; YAMADA M, 1994, MOL PHARMACOL, V46, P470; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; YU SS, 1993, J BIOL CHEM, V268, P337	58	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19294	19300		10.1074/jbc.274.27.19294	http://dx.doi.org/10.1074/jbc.274.27.19294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383439	hybrid			2022-12-27	WOS:000081196300062
J	Lind, U; Greenidge, P; Gustafsson, JA; Wright, APH; Carlstedt-Duke, J				Lind, U; Greenidge, P; Gustafsson, JA; Wright, APH; Carlstedt-Duke, J			Valine 571 functions as a regional organizer in programming the glucocorticoid receptor for differential binding of glucocorticoids and mineralocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; SINGLE AMINO-ACID; C-TERMINUS; CRYSTAL-STRUCTURE; POINT MUTATIONS; YEAST-CELLS; DOMAIN; TRANSACTIVATION; EXPRESSION; SPECIFICITY	The glucocorticoid receptor (GR) interacts specifically with glucocorticoids, whereas its closest relative, the mineralocorticoid receptor (MR), interacts with both glucocorticoids and mineralocorticoids, such as aldosterone. To investigate the mechanism underlying the glucocorticoid/mineralocorticoid specificity of the GR, we used a yeast model system to screen for GR ligand-binding domain mutants, substituted with MR residues in the segment 565-574, that can be efficiently activated by aldosterone. In all such increased activity mutants, valine 571 was replaced by methionine, even though most mutants also contained substitutions of other residues with their MR counterparts, Further analysis in yeast and COS-7 cells has revealed that the identity of residue 571 determines the behavior of other MR substituted residues in the 565-574 segment. Generally, MR substitutions in this region are only consistent with aldosterone binding if residue 571 is also replaced with methionine (MR conformation). If residue 571 is valine (GR conformation), most other MR substitution mutants drastically reduce interaction with both mineralocorticoid and glucocorticoid hormones. Eased on these functional data, we hypothesize that residue 571 functions as a regional organizer involved in discriminating between glucocorticoid and mineralocorticoid hormones, We have used a molecular model of the GR ligand-binding domain in an attempt to interpret our functional data in structural terms.	Huddinge Hosp, Karolinska Inst, Dept Med Nutr, Novum, S-14186 Huddinge, Sweden; Karo Bio AB, Novum, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Sodertorns Hogskola, S-14104 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodertorn University	Lind, U (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med Nutr, Novum, S-14186 Huddinge, Sweden.		Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHEN DG, 1994, J BIOL CHEM, V269, P7914; CHEN DG, 1994, MOL ENDOCRINOL, V8, P422, DOI 10.1210/me.8.4.422; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KAISER P, 1993, BIOTECHNIQUES, V14, P552; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lind U, 1996, MOL ENDOCRINOL, V10, P1358, DOI 10.1210/me.10.11.1358; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MILHON J, 1994, J STEROID BIOCHEM, V51, P11, DOI 10.1016/0960-0760(94)90110-4; Miller WL., 1995, ENDOCRINOL METAB, P555; Parker MG, 1996, NAT STRUCT BIOL, V3, P113, DOI 10.1038/nsb0296-113; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; VELDHUIS HD, 1982, ENDOCRINOLOGY, V110, P2044, DOI 10.1210/endo-110-6-2044; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	36	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18515	18523		10.1074/jbc.274.26.18515	http://dx.doi.org/10.1074/jbc.274.26.18515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373460	hybrid			2022-12-27	WOS:000081056700052
J	Asano, K; Hama, C; Inoue, S; Moriwaki, H; Mizobuchi, K				Asano, K; Hama, C; Inoue, S; Moriwaki, H; Mizobuchi, K			The plasmid ColI-P9 antisense inc RNA controls expression of the repZ replication protein and its positive regulator repY with different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; RIBOSOME-BINDING; GENE-EXPRESSION; COLIB-P9; TRANSLATION; INITIATION; CLONING; PSEUDOKNOT; SEQUENCES; COLLB-P9	The autonomous replication region of plasmid CoIIb-P9 contains repZ encoding the RepZ replication protein, and inc and repY as the negative and positive regulators of repZ translation, respectively, inc encodes the anti-sense Inc RNA, and repY is a short open reading frame upstream of repZ. Translation of repY enables repZ translation by inducing formation of a pseudoknot containing stem-loop I, which base pairs with the sequence preceding the repZ start codon. Inc RNA inhibits both repY translation and formation of the pseudoknot by binding to the loop I. To investigate control of repY expression by Inc RNA, we isolated a number of mutations that express repY in the presence of Inc RNA One class of mutations delete a part of another stem-loop (II), which derepresses repY expression by initiating translation at codon 10 (CUG), located within this structure, Point mutations in stern-loop II can also derepress repY translation, and the introduction of compensatory base-changes restores control of repY translation. These results not only indicate that suppressing a cryptic Start codon by secondary structure is important for maintaining the translational control of repZ but also demonstrate that the position of start site for repY translation is critical for its control by Inc RNA. Thus, Inc RNA controls repY translation by binding in the vicinity of the start codon, in contrast to the control of repZ expression at the level of loop-loop interaction.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan; Univ Electrocommun, Dept Appl Phys & Chem, Tokyo 182, Japan	University of Tokyo; University of Electro-Communications - Japan	Asano, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan.							Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1998, J BIOL CHEM, V273, P11826, DOI 10.1074/jbc.273.19.11826; ASANO K, 1991, J BIOL CHEM, V266, P3774; Asano K, 1998, EMBO J, V17, P5201, DOI 10.1093/emboj/17.17.5201; ASANO K, 1991, J BIOL CHEM, V266, P24549; Asano K, 1998, J BIOL CHEM, V273, P11815, DOI 10.1074/jbc.273.19.11815; BLOMBERG P, 1994, MOL MICROBIOL, V12, P49, DOI 10.1111/j.1365-2958.1994.tb00994.x; BLOMBERG P, 1992, EMBO J, V11, P2675, DOI 10.1002/j.1460-2075.1992.tb05333.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; GUSSIN GN, 1966, COLD SPRING HARB SYM, V31, P257, DOI 10.1101/SQB.1966.031.01.034; HAMA C, 1990, J BACTERIOL, V172, P1983, DOI 10.1128/jb.172.4.1983-1991.1990; HAMA C, 1990, J BIOL CHEM, V265, P10666; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Kato A, 1994, DNA Res, V1, P201, DOI 10.1093/dnares/1.5.201; MA CK, 1994, MOL MICROBIOL, V14, P1033, DOI 10.1111/j.1365-2958.1994.tb01337.x; Malmgren C, 1997, J BIOL CHEM, V272, P12508, DOI 10.1074/jbc.272.19.12508; Malmgren C, 1996, RNA, V2, P1022; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick WC., 1996, TRANSLATION CONTROL, P31; Miller J. H, 1972, EXPT MOL GENETICS; MORI A, 1995, MOL MICROBIOL, V17, P291, DOI 10.1111/j.1365-2958.1995.mmi_17020291.x; MURRAY NE, 1974, NATURE, V251, P476, DOI 10.1038/251476a0; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; PRASKIER J, 1991, J BACTERIOL, V161, P2393; SHIBA K, 1990, J BACTERIOL, V172, P1992, DOI 10.1128/jb.172.4.1992-1997.1990; SIEMERING KR, 1993, J BACTERIOL, V175, P2895, DOI 10.1128/JB.175.10.2895-2906.1993; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STEITZ JA, 1975, RNA PHAGES, P319; TANAKA K, 1992, NUCLEIC ACIDS RES, V20, P2705, DOI 10.1093/nar/20.11.2705; Voorma H. O., 1996, TRANSLATIONAL CONTRO, p[759, 759]; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WILSON IW, 1994, J BACTERIOL, V176, P6497, DOI 10.1128/JB.176.21.6497-6508.1994; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17924	17933		10.1074/jbc.274.25.17924	http://dx.doi.org/10.1074/jbc.274.25.17924			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364239	hybrid			2022-12-27	WOS:000080974300075
J	Costello, LC; Liu, YY; Zou, J; Franklin, RB				Costello, LC; Liu, YY; Zou, J; Franklin, RB			Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; EPITHELIAL-CELLS; CITRATE METABOLISM; GENE ENCODES; PROTEIN	The glandular epithelial cells of the human prostate gland have the unique capability and function of accumulating the highest zinc levels of any soft tissue in the body. Zinc accumulation in the prostate is regulated by prolactin and testosterone; however, little information is available concerning the mechanisms associated with zinc accumulation and its regulation in prostate epithelial cells. In the present studies the uptake and accumulation of zinc were determined in the human malignant prostate cell lines LNCaP and PC-3. The results demonstrate that LNCaP cells and PC-3 cells possess the unique capability of accumulating high levels of zinc. Zinc accumulation in both cell types is stimulated by physiological concentrations of prolactin and testosterone. The studies reveal that these cells contain a rapid zinc uptake process indicative of a plasma membrane zinc transporter. Initial kinetic studies demonstrate that the rapid uptake of zinc is effective under physiological conditions that reflect the total and mobile zinc levels in circulation. Correspondingly, genetic studies demonstrate the expression of a ZIP family zinc uptake transporter in both LNCaP and PC-3 cells. The rapid zinc uptake transport process is stimulated by treatment of cells with physiological levels of prolactin and testosterone, which possibly is the result of the regulation of the ZIP-type zinc transporter gene. These zinc-accumulating characteristics are specific for prostate cells. The studies support the concept that these prostate cells express a unique hormone-responsive, plasma membrane-associated, rapid zinc uptake transporter gene associated with their unique ability to accumulate high zinc levels.	Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Cellular & Mol Biol Sect, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Costello, LC (corresponding author), Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Cellular & Mol Biol Sect, 666 W Baltimore St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA071207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028015] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71207] Funding Source: Medline; NIDDK NIH HHS [DK 28015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; Costello LC, 1998, PROSTATE, V35, P285, DOI 10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F; COSTELLO LC, 1994, CELL MOL BIOL, V39, P515; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Franklin R. B., 1997, PROSTATE BASIC CLIN, P115; Franklin RB, 1997, MOL CELL ENDOCRINOL, V127, P19, DOI 10.1016/S0303-7207(96)03972-X; FRANKLIN RB, 1990, PROSTATE, V16, P137, DOI 10.1002/pros.2990160205; FRANKLIN RB, 1993, ENDOCR J, V3, P603; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; JUANG HH, 1995, J BIOL CHEM, V270, P12629, DOI 10.1074/jbc.270.21.12629; KAVANAGH JP, 1983, J REPROD FERTIL, V69, P359; LAO LX, 1993, PROSTATE, V22, P53, DOI 10.1002/pros.2990220108; LARUE JP, 1984, ENDOCR RES, V10, P183, DOI 10.3109/07435808409035418; LARUE JP, 1984, ENDOCR RES, V10, P171, DOI 10.3109/07435808409035417; Liu Y, 1997, PROSTATE, V30, P26, DOI 10.1002/(SICI)1097-0045(19970101)30:1<26::AID-PROS4>3.0.CO;2-J; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; ROSOFF B, 1981, PROSTATIC CELL STRUC, P447; Suhy DA, 1996, MET IONS BIOL SYST, V32, P557; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	24	186	188	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17499	17504		10.1074/jbc.274.25.17499	http://dx.doi.org/10.1074/jbc.274.25.17499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364181	hybrid			2022-12-27	WOS:000080974300017
J	Gibson, S; Tu, S; Oyer, R; Anderson, SM; Johnson, GL				Gibson, S; Tu, S; Oyer, R; Anderson, SM; Johnson, GL			Epidermal growth factor protects epithelial cells against Fas-induced apoptosis - Requirement for Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B C-AKT; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; BREAST-CANCER; KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; PRIMARY CULTURE; DEATH; PHOSPHORYLATION; EXPRESSION	Chemotherapeutic drugs that damage DNA kill tumor cells, in part, by inducing the expression of a death receptor such as Fas or its ligand, FastL. Here, we demonstrate that epidermal growth factor (EGF) stimulation of T47D breast adenocarcinoma and embryonic kidney epithelial (HEK293) cells protects these cells from Fas-induced apoptosis. EGF stimulation of epithelial cells also inhibited Fas-induced caspase activation and the proteolysis of signaling proteins downstream of the EGF receptor, Cbl and Akt/protein kinase B (Akt), EGF stimulation of Akt kinase activity blocked Fas-induced apoptosis. Expression of activated Akt in MCF-7 breast adenocarcinoma cells was sufficient to block Fas-mediated apoptosis, Inhibition of EGF-stimulated extracellular signal-regulated kinase (ERK) activity did not affect EGF protection from Fas-mediated apoptosis. The findings indicate that EGF receptor stimulation of epithelial cells has a significant survival function against death receptor-induced apoptosis mediated by Akt.	Univ Colorado, Sch Med, Program Mol Signal Transduct, Div Basic Sci,Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gibson, S (corresponding author), Univ Colorado, Sch Med, Program Mol Signal Transduct, Div Basic Sci,Natl Jewish Med & Res Ctr, Denver, CO 80206 USA.	johnsonlab@nju.org		Tu, S. Sean/0000-0003-0391-8186; Gibson, Spencer/0000-0003-0119-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48845, DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson CNG, 1999, J NEUROSCI, V19, P664; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Egert S, 1997, CARDIOVASC RES, V35, P283, DOI 10.1016/S0008-6363(97)00133-8; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GRUBER J, 1994, INT ARCH ALLERGY IMM, V105, P368, DOI 10.1159/000236785; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hodge S, 1998, VIROLOGY, V252, P354, DOI 10.1006/viro.1998.9477; Ilio KY, 1995, J ANDROL, V16, P482; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; O'Connor Rosemary, 1998, V62, P137; Porras A, 1997, FEBS LETT, V416, P324, DOI 10.1016/S0014-5793(97)01204-0; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Rusch Valerie, 1996, Cytokine and Growth Factor Reviews, V7, P133, DOI 10.1016/1359-6101(96)00016-0; Sterle M, 1997, BIOL CELL, V89, P263, DOI 10.1016/S0248-4900(97)82314-3; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Walker PR, 1998, CURR OPIN IMMUNOL, V10, P564, DOI 10.1016/S0952-7915(98)80225-2; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	42	226	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17612	17618		10.1074/jbc.274.25.17612	http://dx.doi.org/10.1074/jbc.274.25.17612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364198	hybrid			2022-12-27	WOS:000080974300034
J	Hikita, C; Takito, J; Vijayakumar, S; Al-Awqati, Q				Hikita, C; Takito, J; Vijayakumar, S; Al-Awqati, Q			Only multimeric hensin located in the extracellular matrix can induce apical endocytosis and reverse the polarity of intercalated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELL; URINARY ACIDIFICATION; FIBRONECTIN MATRIX; SRCR SUPERFAMILY; DOMAIN; RECEPTORS; PROTEINS	When an intercalated epithelial cell line was seeded at low density and allowed to reach confluence, it located the anion exchanger band 3 in the apical membrane and an H+-ATPase in the basolateral membrane, The same clonal cells seeded at high density targeted these proteins to the reverse location. Furthermore, high density cells had vigorous apical endocytosis, and low density cells had none. The extracellular matrix of high density cells was capable of inducing apical endocytosis and relocation of band 3 to the basolateral membrane in low density cells. A 230-kDa extracellular matrix (ECM) protein termed hensin, when purified to near-homogeneity, was able to reverse the phenotype of the low density cells. Antibodies to hensin prevented this effect, indicating that hensin is necessary for conversion of polarity. We show here that hensin was synthesized by both low density and high density cells. Whereas both phenotypes secreted soluble hensin into their media, only high density cells localized it in their ECM, Analysis of soluble hensin by sucrose density gradients showed that low density cells secreted monomeric hensin, and high density cells secreted higher order multimers, When S-35-labeled monomeric hensin was added to high density cells, they induced its aggregation suggesting that the multimerization was catalyzed by surface events in the high density cells. Soluble monomeric or multimeric hensin did not induce apical endocytosis in low density cells, whereas the more polymerized hensin isolated from insoluble ECM readily induced it. These multimers could be disaggregated by sulfhydryl reagents and by dimethylmaleic anhydride, and treatment of high density ECM by these reagents prevented the induction of endocytosis. These results demonstrate that hensin, like several ECM proteins, needs to be precipitated in the ECM to be functional.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Al-Awqati, Q (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NCRR NIH HHS [RR10506] Funding Source: Medline; NIDDK NIH HHS [DK-39532, DK-20999] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020999, R01DK039532, R37DK020999] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Awqati Q, 1998, AM J PHYSIOL-RENAL, V275, pF183, DOI 10.1152/ajprenal.1998.275.2.F183; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; Kadler KE, 1996, BIOCHEM J, V316, P1; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; MEANS GE, 1971, CHEM MODIFICATION PR, P76; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Sanderson IR, 1996, P NATL ACAD SCI USA, V93, P7717, DOI 10.1073/pnas.93.15.7717; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; TAKITO J, 1999, IN PRESS AM J PHYSL; TAKITO J, 1996, J CLIN INVEST, V98, P2325; VANADELSBERG J, 1994, CELL, V76, P1053, DOI 10.1016/0092-8674(94)90382-4; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; Vijayakumar S, 1999, J CELL BIOL, V144, P1057, DOI 10.1083/jcb.144.5.1057; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	27	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17671	17676		10.1074/jbc.274.25.17671	http://dx.doi.org/10.1074/jbc.274.25.17671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364206	hybrid			2022-12-27	WOS:000080974300042
J	Pond, L; Watts, C				Pond, L; Watts, C			Functional early endosomes are required for maturation of major histocompatibility complex class II molecules in human B lymphoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-II; INVARIANT CHAIN COMPLEXES; ENDOCYTIC PATHWAY; SUBCELLULAR COMPARTMENTS; LYSOSOMAL COMPARTMENTS; INTRACELLULAR PATHWAY; PEPTIDE COMPLEXES; CYTOPLASMIC TAIL; GOLGI-COMPLEX; HLA ANTIGENS	Major histocompatibility complex (MHC) class II molecules are targeted together with their invariant chain (Ii) chaperone from the secretory pathway to the endocytic pathway. Within the endosome/lysosome system, Ii must be degraded to enable peptide capture by MHC class II molecules. It remains controversial exactly which route or routes MHC class II/Ii complexes take to reach the sites of Ii processing and peptide loading. We have asked whether early endosomes are required for successful maturation of MHC class II molecules by using an in situ peroxidase/diaminobenzidine compartment ablation technique. Cells whose early endosomes were selectively ablated using transferrin-horseradish peroxidase conjugates fail to mature their newly synthesized MHC class II molecules. We show that whereas transport of secretory Ig through the secretory pathway is virtually normal in the ablated cells, newly synthesized MHC class II/Ii complexes never reach compartments capable of processing Ii. These results strongly suggest that the transport of the bulk of newly synthesized MHC class II molecules through early endosomes is obligatory and that direct input into later endosomes/lysosomes does not take place.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bldg, Dundee DD1 4HN, Scotland.			Watts, Colin/0000-0001-6183-2087				AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KOCH N, 1991, J IMMUNOL, V147, P2643; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MORTON PA, 1995, J IMMUNOL, V154, P137; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1993, J CELL SCI, V106, P831; Pond L, 1997, J IMMUNOL, V159, P543; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; QUARANTA V, 1984, J IMMUNOL, V132, P1900; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; Saudrais C, 1998, J IMMUNOL, V160, P2597; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18049	18054		10.1074/jbc.274.25.18049	http://dx.doi.org/10.1074/jbc.274.25.18049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364256	hybrid			2022-12-27	WOS:000080974300092
J	Wang, MY; Lee, Y; Unger, RH				Wang, MY; Lee, Y; Unger, RH			Novel form of lipolysis induced by leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LEPTIN; NORMAL RATS; ADIPOCYTES; EXPRESSION	Hyperleptinemia causes disappearance of body fat without a rise in free fatty acids (FFA) or ketones, suggesting that leptin can deplete adipocytes of fat without releasing FFA. To test this, we measured FFA and glycerol released from adipocytes obtained from normal lean Zucker diabetic fatty rats (+/+) and incubated for 0, 3, 6, or 24 h in either 20 ng/ml recombinant leptin or 100 nM norepinephrine (NE). Whereas NE increased both FFA and glycerol release from adipocytes of +/+ rats, leptin increased glycerol release in +/+ adipocytes without a parallel increase in FFA release. In adipocytes of obese Zucker diabetic fatty rats (fa/fa) with defective leptin receptors, NE increased both FFA and glycerol release, but leptin had no effect on either. Leptin significantly lowered the mRNA of leptin and fatty acid synthase of adipocytes (FAS) (P < 0.05), and up-regulated the mRNA of peroxisome proliferator-activated receptor (PPAR)-alpha, carnitine palmitoyl transferase-1, (CPT-P), and acyl CoA oxidase (ACO) (p < 0.05). NE (100 nM) also lowered leptin mRNA (p < 0.05) but did not affect FAS, PPAR alpha, AGO, or CPT-1 expression. We conclude that in normal adipocytes leptin directly decreases FAS expression, increases PPAR alpha and the enzymes of FFA oxidation, and stimulates a novel form of lipolysis in which glycerol is released without a proportional release of FFA.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Adm Med Ctr, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Runger@mednet.SWmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002700, R37DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; RODBELL M, 1964, J BIOL CHEM, V239, P375; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sivitz WI, 1998, METABOLISM, V47, P584, DOI 10.1016/S0026-0495(98)90244-X; SLAVIN BG, 1994, J LIPID RES, V35, P1535; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tasaka Y, 1997, ENDOCR J, V44, P671, DOI 10.1507/endocrj.44.671; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	17	282	294	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17541	17544		10.1074/jbc.274.25.17541	http://dx.doi.org/10.1074/jbc.274.25.17541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364187	hybrid			2022-12-27	WOS:000080974300023
J	Woulfe, DS; Stadel, JM				Woulfe, DS; Stadel, JM			Structural basis for the selectivity of the RGS protein, GAIP, for G alpha(i) family members - Identification of a single amino acid determinant for selective interaction of G alpha(i) subunits with GAIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; G-ALPHA PROTEINS; SIGNAL-TRANSDUCTION; IN-VITRO; TRANSITION-STATE; PHOSPHOLIPASE-C; POINT MUTATION; CORE DOMAIN; INHIBITION	GAIP is a regulator of G protein signaling (RGS) that accelerates the rate of GTP hydrolysis by some G protein alpha subunits, In the present studies, we have examined the structural basis for the ability of GAIP to discriminate among members of the G alpha(i) family. G alpha(il), G alpha(i3), and G alpha(o) interacted strongly with GAIP, whereas G alpha(i2), interacted weakly and G alpha(S) did not interact at all. A chimeric: G: protein composed of a G alpha(i2), N terminus and a G alpha(il) C terminus interacted as strongly with GAIP as native G alpha(il), whereas a chimeric N-terminal G alpha(il), with a G alpha(i2), C terminus did not interact. These results suggest that the determinants responsible for GAIP selectivity between these two G alpha(i)S reside within the C-terminal GTPase domain of the G protein. To further localize residues contributing to G protein-GAIP selectivity, a panel of 15 site-directed G alpha(il) and G alpha(i2) mutants were assayed. Of the Gcu,, mutants tested, only that containing a mutation at aspartate 229 located at the N terminus of Switch 3 did not interact with GAIP. Furthermore, the only Gar, variant that interacted strongly with GAIP contained a replacement of the corresponding G alpha(i2) Switch 3 residue (Ala(230)) with aspartate. To determine whether GAIP showed lRmetional preferences for Gac subunits that correlate with the binding data, the ability of GALP to enhance the GTPase activity of purified cu subunits was tested. GAIP catalyzed a 3-5-fold increase in the rate of GTP hydrolysis by Get,, and G alpha(i2)(A230D) but no increase in the rate of G alpha(i2) and less than a 2-fold increase in the rate of G alpha(il)(D229A) under the same conditions, Thus, GAIP was able to discriminate between G alpha(il) and G alpha(i2) in both binding and functional assays, and in both Gases residue 229/230 played a critical role in selective recognition.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	University of Pennsylvania; GlaxoSmithKline	Woulfe, DS (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd,BRB 2,Rm 913, Philadelphia, PA 19104 USA.							Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HUNT TW, 1996, NATURE, V383, P176; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miller J. H, 1972, EXPT MOL GENETICS; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; STADEL JM, 1997, TRENDS PHARMACOL SCI, V11, P190; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	37	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17718	17724		10.1074/jbc.274.25.17718	http://dx.doi.org/10.1074/jbc.274.25.17718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364213	Green Submitted, hybrid			2022-12-27	WOS:000080974300049
J	Alarcon, CM; Pedram, M; Donelson, JE				Alarcon, CM; Pedram, M; Donelson, JE			Leaky transcription of variant surface glycoprotein gene expression sites in bloodstream African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; BINDING PROTEIN COMPLEX; VSG GENE; ANTIGENIC VARIATION; BRUCEI-RHODESIENSE; T-BRUCEI; STABLE EXPRESSION; POINT MUTATIONS; METACYCLIC VSG; BLOOD-STREAM	Trypanosoma brucei undergoes antigenic variation by periodically switching the expression of its variant surface glycoprotein (VSG) genes (vsg) among an estimated 20-40 telomere-linked expression sites (ES), only one of which is fully active at a given time, We found that in bloodstream trypanosomes one ES is transcribed at a high level and other ESs are expressed at low levels, resulting in organisms containing one abundant VSG mRNA and several rare VSG RNAs. Some of the rare VSG; mRNAs come from monocistronic ESs in which the promoters are situated about 2 kilobases upstream of the vsg, in contrast to the polycistronic ESs in which the promoters are located 45-60 kilobases upstream of the vsg, The monocistronic ES containing the MVAT4 vsg does not include the ES-associated genes (esag) that occur between the promoter and the vsg in polycistronic ESs, However, bloodstream MVAT4 trypanosomes contain the mRNAs for many different ESAGs 6 and 7 (transferrin receptors), suggesting that polycistronic ESs are partially active in this clone. To explain these findings, we propose a model in which both mono- and polycistronic ESs are controlled by a similar mechanism throughout the parasite's life cycle. Certain VSGs are preferentially expressed in metacyclic versus bloodstream stages as a result of differences in ESAG expression and the proximity of the promoters to the vsg and telomere.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Human Nutr Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Pedram, Mehrdad/L-4072-2016; Donelson, John E/F-5795-2010	Pedram, Mehrdad/0000-0002-7348-3475; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032135, R01AI040591, R01AI032135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32135, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ANSORGE I, 1998, WOODS HOL MOL PAR M, P244; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; BALTZ T, 1986, NATURE, V319, P602, DOI 10.1038/319602a0; BARNES DA, 1990, MOL BIOCHEM PARASIT, V41, P101, DOI 10.1016/0166-6851(90)90101-Q; Barry JD, 1998, MOL BIOCHEM PARASIT, V91, P93, DOI 10.1016/S0166-6851(97)00193-X; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1993, COLD SPRING HARB SYM, V58, P105, DOI 10.1101/SQB.1993.058.01.014; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; Borst Piet, 1997, P109; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROWE JS, 1983, NATURE, V306, P389, DOI 10.1038/306389a0; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; ESSER KM, 1982, J IMMUNOL, V129, P1715; ESSER KM, 1985, SCIENCE, V229, P190, DOI 10.1126/science.3892689; GERRITS H, 1998, WOODS HOL MOL PAR M, P84; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; GRAHAM SV, 1991, MOL BIOCHEM PARASIT, V47, P31, DOI 10.1016/0166-6851(91)90145-V; Graham SV, 1998, MOL CELL BIOL, V18, P1137, DOI 10.1128/MCB.18.3.1137; HAJDUK SL, 1981, PARASITOLOGY, V83, P595, DOI 10.1017/S0031182000080562; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; Kim KS, 1997, J BIOL CHEM, V272, P24637, DOI 10.1074/jbc.272.39.24637; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MunozJordan JL, 1996, SCIENCE, V272, P1795, DOI 10.1126/science.272.5269.1795; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; Navarro M, 1996, MOL CELL BIOL, V16, P3615; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; Rudenko G, 1996, MOL BIOCHEM PARASIT, V80, P65, DOI 10.1016/0166-6851(96)02669-2; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 2002, MOL CLONING LAB MANU; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; Steverding D, 1996, MOL BIOCHEM PARASIT, V78, P285, DOI 10.1016/S0166-6851(96)02624-2; TETLEY L, 1987, J CELL SCI, V87, P363; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; Vanhamme L, 1998, MOL BIOCHEM PARASIT, V91, P107, DOI 10.1016/S0166-6851(97)00194-1; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	64	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16884	16893		10.1074/jbc.274.24.16884	http://dx.doi.org/10.1074/jbc.274.24.16884			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358034	hybrid			2022-12-27	WOS:000080780400033
J	Liu, Q; Jin, CW; Liao, XB; Shen, ZY; Chen, DJ; Chen, Y				Liu, Q; Jin, CW; Liao, XB; Shen, ZY; Chen, DJ; Chen, Y			The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; PROTEIN; SYSTEM; GENE; IDENTIFICATION; DEGRADATION; MODIFIER	Human UBC9 is a member of the E2 (ubiquitin conjugation enzyme) family of proteins. Instead of conjugating to ubiquitin, it conjugates with a ubiquitin homologue UBL1 (also known as SUMO-1, GMP1, SMTP3, PIC1, and sentrin). UBC9 has been shown to be involved in cell cycle regulation, DNA repair, and p53-dependent processes. The binding interfaces of the UBC9 and UBL1 complex have been determined by chemical shift perturbation using nuclear magnetic resonance spectroscopy. The binding site of UBL1 resides on the ubiquitin domain, and the binding site of UBC9 is located on a structurally conserved region of E2, Because the UBC9-UBL1 system shares many similarities with the ubiquitin system in structures and in conjugation with each other and with target proteins, the observed binding interfaces may be conserved in Ea-ubiquitin interactions in general.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Univ Calif Los Alamos Natl Lab, Div Life Sci, DNA Damage & Repair Grp, Los Alamos, NM 87545 USA	City of Hope; Beckman Research Institute of City of Hope; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Los Alamos National Laboratory	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.			Shen, Zhiyuan/0000-0003-2834-0309	NIGMS NIH HHS [GM54190] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Haas AL, 1997, FASEB J, V11, P1257; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOMOL NMR, V13, P89, DOI 10.1023/A:1008364314328; Loveys DA, 1997, GENE, V201, P169, DOI 10.1016/S0378-1119(97)00444-7; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SCHNEIDER DM, 1992, BIOCHEMISTRY-US, V31, P3645, DOI 10.1021/bi00129a013; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	31	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16979	16987		10.1074/jbc.274.24.16979	http://dx.doi.org/10.1074/jbc.274.24.16979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358047	hybrid			2022-12-27	WOS:000080780400046
J	McConalogue, K; Dery, O; Lovett, M; Wong, H; Walsh, JH; Grady, EF; Bunnett, NW				McConalogue, K; Dery, O; Lovett, M; Wong, H; Walsh, JH; Grady, EF; Bunnett, NW			Substance P-induced trafficking of beta-arrestins - The role of beta-arrestins in endocytosis of the neutrokinin-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; NEUROKININ-1 RECEPTOR; ARRESTIN/CLATHRIN INTERACTION; CHOLECYSTOKININ RECEPTOR; INDUCED INTERNALIZATION	Agonist-induced redistribution of G-protein-coupled receptors (GPCRs) and beta-arrestins determines the subsequent cellular responsiveness to agonists and is important for signal transduction. We examined substance P (SP)-induced trafficking of beta-arrestin1 and the neurokinin-1 receptor (NK1R) in KNRK cells in real time using green fluorescent protein. Green fluorescent protein did not alter function or localization of the NK1R or beta-arrestin1, SP induced (a) striking and rapid (<1 min) translocation of beta-arrestin1 from the cytosol to the plasma membrane, which preceded NK1R endocytosis; (b) redistribution of the NK1R and beta-arrestin1 into the same endosomes containing SP and the transferrin receptor (2-10 min); (c) prolonged colocalization of the NK1R and beta-arrestin1 in endosomes (>60 min); (d) gradual resumption of the steady state distribution of the NK1R at the plasma membrane and beta-arrestin1 in the cytosol (4-6 h), SP stimulated a similar redistribution of immunoreactive beta-arrestin1 and beta-arrestin2. In contrast, SP did not affect G alpha(q/11) distribution, which remained at the plasma membrane. Expression of the dominant negative beta-arrestin(319-418) inhibited SP-induced endocytosis of the NK1R, Thus, SP induces rapid translocation of beta-arrestins to the plasma membrane, where they participate in NK1R endocytosis. beta-Arrestins colocalize with the NK1R in endosomes until the NK1R recycles and beta-arrestins return to the cytosol.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Affairs Med Ctr, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.		McConalogue, Karen/AAE-6778-2019	Bunnett, Nigel W./0000-0003-3367-0644	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R01DK039957, R01DK043207, R56DK043207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207, DK39957] Funding Source: Medline; NINDS NIH HHS [NS21710] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bohm SK, 1997, BIOCHEM J, V322, P1; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Bunnett NW, 1996, HISTOCHEM J, V28, P811, DOI 10.1007/BF02272154; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Garland AM, 1996, MOL PHARMACOL, V49, P438; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Grady EF, 1996, J NEUROSCI, V16, P6975, DOI 10.1523/jneurosci.16-21-06975.1996; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; GRADY EF, 1996, NEUROSCIENCE, V16, P1239; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Macdonald SG, 1996, BIOCHEMISTRY-US, V35, P2909, DOI 10.1021/bi952351+; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Nishimura K, 1998, BIOCHEMISTRY-US, V37, P1192, DOI 10.1021/bi972302s; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SASAKAWA N, 1994, MOL PHARMACOL, V46, P380; SASAKAWA N, 1994, FEBS LETT, V347, P181, DOI 10.1016/0014-5793(94)00532-X; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VIGNA SR, 1994, J NEUROSCI, V14, P834; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	55	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16257	16268		10.1074/jbc.274.23.16257	http://dx.doi.org/10.1074/jbc.274.23.16257			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347182	hybrid			2022-12-27	WOS:000080668600042
J	Wang, CC; Schimmel, P				Wang, CC; Schimmel, P			Species barrier to RNA recognition overcome with nonspecific RNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN; SYNTHETASE; DNA; COELECTROPHORESIS; FEATURES	We show here that nonspecific RNA-protein interactions can significantly enhance the biological activity of an essential RNA protein complex. Bacterial glutaminyl-tRNA synthetase poorly aminoacylates yeast tRNA and, as a consequence, cannot rescue a knockout allele of the gene for the yeast homologue. In contrast to the bacterial protein, the yeast enzyme has an extra appended domain at the N terminus. Previously, we showed that fusion of this yeast-specific domain to the bacterial protein enabled it to function as a yeast enzyme in vivo and in vitro. We suggested that the novel yeast-specific domain contributed to RNA interactions in a way that compensated for the poor fit between the yeast tRNA and bacterial enzyme. Here we establish that the novel appended domain by itself binds nonspecifically to different RNA structures. In addition, we show that fusion of an unrelated yeast protein, Arc1p, to the bacterial enzyme also converts it into a functional yeast enzyme in vivo and in vitro. A small C-terminal segment of Arc1p is necessary and sufficient for this conversion. This segment was shown by others to have nonspecific tRNA binding properties. Thus, nonspecific RNA binding interactions in general can compensate for barriers to formation of a specific and essential RNA protein complex.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,Mail Code BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NIGMS NIH HHS [GM23532] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALZHANOVA AT, 1980, FEBS LETT, V120, P225, DOI 10.1016/0014-5793(80)80303-6; BEDOUELLE H, 1990, J BACTERIOL, V172, P3940, DOI 10.1128/jb.172.7.3940-3945.1990; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; Cilley CD, 1997, RNA, V3, P57; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FRANKEL AD, 1992, PROTEIN SCI, V1, P1539, DOI 10.1002/pro.5560011202; GALE AJ, 1995, BIOCHEMISTRY-US, V34, P8896, DOI 10.1021/bi00027a042; GARCIA A, 1993, NUCLEIC ACIDS RES, V21, P401, DOI 10.1093/nar/21.3.401; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; INOKUCHI H, 1984, P NATL ACAD SCI-BIOL, V81, P5076, DOI 10.1073/pnas.81.16.5076; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIM WA, 1991, METHOD ENZYMOL, V208, P196; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SHEN WC, 1993, J BIOL CHEM, V268, P19436; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	24	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16508	16512		10.1074/jbc.274.23.16508	http://dx.doi.org/10.1074/jbc.274.23.16508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347214	hybrid			2022-12-27	WOS:000080668600074
J	Fedi, P; Bafico, A; Soria, AN; Burgess, WH; Miki, T; Bottaro, DP; Kraus, MH; Aaronson, SA				Fedi, P; Bafico, A; Soria, AN; Burgess, WH; Miki, T; Bottaro, DP; Kraus, MH; Aaronson, SA			Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CDNA CLONING; BETA-CATENIN; TYROSINE KINASE; HEAD INDUCTION; CELL-LINE; FAMILY; PROTEIN; GROWTH; TRANSFORMATION; ACTIVATION	In an effort to isolate novel growth factors, we identified a human protein, designated Sk, that co-eluted with Neuregulin during chromatographic separation of conditioned medium from the SK-LMS-1 human leiomyosarcoma cell line. Degenerate oligonucleotides based on amino-terminal sequence analysis of the purified protein were used to isolate the corresponding cDNA from a library generated from this cell line. Sk is a novel 266-amino acid protein that contains a signal peptide sequence and two cysteine-rich domains with no similarity to other known growth factors. A single major 2-kilobase transcript was expressed in several embryonic tissues, Transfection of mammalian cells demonstrated that the protein was secreted and expressed as a doublet of approximately 35 kDa. In vitro translation and endoglycosylase analysis indicated that this doublet, which was also observed in cells expressing the endogenous protein, arises from posttranslational modification. A search of the GenBank(TM) data base revealed a match of Sk with Dkk-1, which is a novel secreted protein required for head induction in amphibian embryos and a potent Wnt inhibitor. When coexpressed with Wnt-2 in NIH3T3 cells, human Sk/Dkk-1 caused reversion of Wnt-2 induced morphological alterations and inhibited the Wnt-2 induced increase in uncomplexed beta-catenin levels. These results provide biochemical evidence that human Sk/Dkk-1 antagonizes Wnt signaling upstream of its effect on beta-catenin regulation.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA; NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS European Institute of Oncology (IEO)	Fedi, P (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	pfedi@smtplink.mssm.edu	Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	NCI NIH HHS [CA71672, CA71997] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA071672, R29CA071997, R55CA071997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Aravind L, 1998, CURR BIOL, V8, pR477, DOI 10.1016/S0960-9822(98)70309-4; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; LIN TP, 1992, CANCER RES, V52, P4413; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	38	226	271	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19465	19472		10.1074/jbc.274.27.19465	http://dx.doi.org/10.1074/jbc.274.27.19465			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383463	hybrid, Green Submitted			2022-12-27	WOS:000081196300086
J	Sanders, SL; Klebanow, ER; Weil, PA				Sanders, SL; Klebanow, ER; Weil, PA			TAF25p, a non-histone-like subunit of TFIID and SAGA complexes, is essential for total mRNA gene transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; RNA-POLYMERASE; YEAST; COMPONENT; TAF(II)S; ENCODES; MUTANT; CELLS; TAFS	We demonstrate, utilizing a temperature conditional mutant allele of the gene encoding TAF25p, that this non-histone-like TBP-associated factor, which is shared between the TFIID and SAGA complexes, is required for hulk mRNA gene transcription by RNA polymerase II in vivo. Immunoblotting experiments indicate that at the restrictive temperature, inactivation of TAF25p function results in a reduction of the levels of numerous TFIID and SAGA subunits, indicating its loss of function, like the histone-like TAFs, causes degradation of the constituents of these two multisubunit complexes. These data suggest that TAF25p plays a key structural role in maintaining TFIID and SAGA complex integrity, This is the first demonstration that a non-histone-like TAF is required for continuous, high level RNA polymerase II-mediated mRNA gene transcription in living yeast cells.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	tony.weil@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052461, R56GM052461] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07563-09] Funding Source: Medline; NIGMS NIH HHS [GM52461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; Holstege FCP, 1999, P NATL ACAD SCI USA, V96, P2, DOI 10.1073/pnas.96.1.2; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; RAY BL, 1991, CURR GENET, V20, P25, DOI 10.1007/BF00312761; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schroeder SC, 1998, NUCLEIC ACIDS RES, V26, P4186, DOI 10.1093/nar/26.18.4186; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X	25	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18847	18850		10.1074/jbc.274.27.18847	http://dx.doi.org/10.1074/jbc.274.27.18847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383379	hybrid			2022-12-27	WOS:000081196300002
J	Altstein, M; Ben-Aziz, O; Daniel, S; Schefler, I; Zeltser, I; Gilon, C				Altstein, M; Ben-Aziz, O; Daniel, S; Schefler, I; Zeltser, I; Gilon, C			Backbone cyclic peptide antagonists, derived from the insect pheromone biosynthesis activating neuropeptide, inhibit sex pheromone biosynthesis in moths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOTHIS-PELTIGERA LEPIDOPTERA; C-TERMINAL HEXAPEPTIDE; AMINO-ACID-SEQUENCE; SUBSTANCE-P; LOCUSTA-MIGRATORIA; BIOLOGICAL-ACTIVITY; BUILDING UNITS; BOMBYX-MORI; SUBESOPHAGEAL GANGLION; NEUROENDOCRINE CONTROL	We describe an application of the backbone cyclization and cycloscan concept for the design and synthesis of pheromone biosynthesis activating neuropeptide (PBAN) antagonists capable of inhibiting sex pheromone biosynthesis in Heliothis peltigera female moths. Two backbone cyclic (BBC) sub-libraries were designed and synthesized. The structure of the first sub-library ([Arg(27)]PBAN27-33NH(2), termed the Ser sub-library) was based on the active C-terminal hexapeptide sequence (Tyr-Phe-Ser-Pro-Arg-Leu-NH2) of PBAN1-33NH(2), which was found to comprise its active core. The second sub-library ([Arg(27),D-Phe30]PBAN27-33NH(2), termed the D-Phe sub-library) was based on the sequence of the lead antagonist Arg-Tyr-Phe-(D)Phe-Pro-Arg-Leu-NH,. In both sub-libraries the Pro residue was replaced by an N-alpha(omega-amino-alkyl)Gly building unit having various lengths of the alkyl chain. All the cyclic peptides in each sub-library had the same primary sequence and the same location of the ring. The members of each library differed from each other by the bridge size and bridge chemistry. Screening of the two libraries for pheromonotropic antagonists resulted in the disclosure of four compounds that fully inhibited sex pheromone biosynthesis at 1 nmol and were devoid of agonistic activity. All antagonistic peptides originated from the D-Phe sub-library. Substitution of the D-Phe30 amino acid, with a Ser resulted in a loss of antagonistic activity, Agonistic activities were exhibited by peptides from both sub-libraries.	Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel; Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Hebrew University of Jerusalem	Altstein, M (corresponding author), Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel.							Altstein M, 1996, ARCH INSECT BIOCHEM, V31, P355, DOI 10.1002/(SICI)1520-6327(1996)31:4&lt;355::AID-ARCH1&gt;3.0.CO;2-V; ALTSTEIN M, 1993, ARCH INSECT BIOCHEM, V22, P153, DOI 10.1002/arch.940220113; ALTSTEIN M, 1996, INSECT PHEROMONE RES, P56; ALTSTEIN M, 1995, ARCH INSECT BIOCH PH, V30, P309; ALTSTEIN M, 1997, MODERN AGR ENV, P109; BAKER TC, 1989, EXPERIENTIA, V45, P248, DOI 10.1007/BF01951811; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Behrens S, 1996, INT J PEPT PROT RES, V48, P569; BITAN G, 1995, TETRAHEDRON, V51, P10513; Bitan G, 1997, J PEPT RES, V49, P421; Bitan G, 1997, J CHEM SOC PERK T 1, P1501, DOI 10.1039/a608389g; Byk G, 1996, J MED CHEM, V39, P3174, DOI 10.1021/jm960154i; DUNKELBLUM E, 1989, J CHEM ECOL, V15, P2233, DOI 10.1007/BF01014112; Friedler A, 1998, BIOCHEMISTRY-US, V37, P5616, DOI 10.1021/bi972878h; Gade G, 1997, PROG CH ORG NAT PROD, V71, P1; GAZIT Y, 1990, INSECT BIOCHEM, V20, P853, DOI 10.1016/0020-1790(90)90104-3; Gilon C, 1998, J MED CHEM, V41, P919, DOI 10.1021/jm970633x; GILON C, 1991, BIOPOLYMERS, V31, P745, DOI 10.1002/bip.360310619; GILON C, 1998, 24 EPS, P423; Gilon Chaim, 1997, Invertebrate Neuroscience, V3, P245, DOI 10.1007/BF02480381; HEINZERIAN P, 1987, AM J PHYSIOL, V252, pG439, DOI 10.1152/ajpgi.1987.252.3.G439; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V85, P219, DOI 10.1016/0742-8413(86)90077-0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HRUBY VJ, 1992, PROG BRAIN RES, V92, P215, DOI 10.1016/S0079-6123(08)61177-2; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; IMAI K, 1991, P JPN ACAD B-PHYS, V67, P98, DOI 10.2183/pjab.67.98; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KITAMURA A, 1990, AGR BIOL CHEM TOKYO, V54, P2495, DOI 10.1080/00021369.1990.10870317; KITAMURA A, 1989, BIOCHEM BIOPH RES CO, V163, P520, DOI 10.1016/0006-291X(89)92168-2; Kochansky JP, 1997, ARCH INSECT BIOCHEM, V35, P315, DOI 10.1002/(SICI)1520-6327(199705)35:3<315::AID-ARCH5>3.3.CO;2-O; KUNIYOSHI H, 1992, INSECT BIOCHEM MOLEC, V22, P399, DOI 10.1016/0965-1748(92)90078-S; KUNIYOSHI H, 1991, PEPTIDE CHEMISTRY 1990, P251; LAUFER R, 1986, J BIOL CHEM, V261, P257; LAUFER R, 1986, J MED CHEM, V29, P1284, DOI 10.1021/jm00157a029; MASLER EP, 1994, INSECT BIOCHEM MOLEC, V24, P829, DOI 10.1016/0965-1748(94)90111-2; MATSUMOTO S, 1992, BIOCHEM BIOPH RES CO, V182, P534, DOI 10.1016/0006-291X(92)91765-I; MATSUMOTO S, 1990, J INSECT PHYSIOL, V36, P427, DOI 10.1016/0022-1910(90)90060-S; Muller D, 1997, J ORG CHEM, V62, P411, DOI 10.1021/jo961580e; Nachman RJ, 1997, ANN NY ACAD SCI, V814, P73, DOI 10.1111/j.1749-6632.1997.tb46146.x; NACHMAN RJ, 1986, BIOCHEM BIOPH RES CO, V137, P936, DOI 10.1016/0006-291X(86)90315-3; NACHMAN RJ, 1993, ARCH INSECT BIOCHEM, V22, P181, DOI 10.1002/arch.940220115; NACHMAN RJ, 1991, P NATL ACAD SCI USA, V88, P4518, DOI 10.1073/pnas.88.10.4518; NAGASAWA H, 1994, ARCH INSECT BIOCHEM, V25, P261, DOI 10.1002/arch.940250403; Nakayama G R, 1998, Curr Opin Drug Discov Devel, V1, P85; PAPIRKRICHELI D, 1987, PAIN, V31, P263, DOI 10.1016/0304-3959(87)90041-8; Percy-Cunningham J.E., 1987, P27; RAINA AK, 1990, INSECT BIOCHEM, V20, P849, DOI 10.1016/0020-1790(90)90103-2; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; RAINA AK, 1993, ANNU REV ENTOMOL, V38, P329, DOI 10.1146/annurev.en.38.010193.001553; RAINA AK, 1984, SCIENCE, V225, P531, DOI 10.1126/science.225.4661.531; RAINA AK, 1992, INSECT BIOCHEM MOLEC, V22, P221, DOI 10.1016/0965-1748(92)90058-M; REVERO P, 1990, EUR J PHARMACOL, V175, P113; ROELOFS WL, 1974, PHEROMONES, P96; SCHOOFS L, 1991, GEN COMP ENDOCR, V81, P97, DOI 10.1016/0016-6480(91)90129-T; SCHOOFS L, 1990, PEPTIDES, V11, P427, DOI 10.1016/0196-9781(90)90038-7; SCHOOFS L, 1993, INSECT BIOCHEM MOLEC, V23, P859, DOI 10.1016/0965-1748(93)90104-Z; SCHOOFS L, 1993, COMP BIOCHEM PHYS C, V106, P103, DOI 10.1016/0742-8413(93)90260-R; SCHOOFS L, 1990, INSECT BIOCHEM, V20, P479, DOI 10.1016/0020-1790(90)90029-T; SCHOOFS L, 1992, INSECT BIOCHEM MOLEC, V22, P447, DOI 10.1016/0965-1748(92)90140-A; WAELBROECK M, 1985, ENDOCRINOLOGY, V116, P2643, DOI 10.1210/endo-116-6-2643; WOOL PJ, 1988, BRIT J CANCER, V57, P579; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x	62	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17573	17579		10.1074/jbc.274.25.17573	http://dx.doi.org/10.1074/jbc.274.25.17573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364192	hybrid			2022-12-27	WOS:000080974300028
J	Gerson, JH; Bobkova, E; Homsher, E; Reisler, E				Gerson, JH; Bobkova, E; Homsher, E; Reisler, E			Role of residues 311/312 in actin-tropomyosin interaction - In vitro motility study using yeast actin mutant E311A/R312A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL IMAGE-ANALYSIS; MUSCLE THIN-FILAMENTS; MYOSIN SUBFRAGMENT-1 COMPLEX; X-RAY-DIFFRACTION; SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN; ACTOMYOSIN SUBFRAGMENT-1; MUTATIONAL ANALYSIS; VERTEBRATE MUSCLE; ATP HYDROLYSIS	According to the Lorenz ct al, (Lorenz, M., Poole, K. J., Popp, D., Rosenbaum, G., and Holmes, K. C. (1995) J. Mol. Biol, 246, 108-119) atomic model of the actin-tropomyosin complex, actin residue Asp-311 (Glu-311 in yeast) is predicted to have a high binding energy contribution to actin-tropomyosin binding. Using the yeast actin mutant E311A/R312A in the in vitro motility assays, we have investigated the role of these residues in such interactions. Wild type (wt) yeast actin, like skeletal ar-actin, is fully regulated when complexed with tropomyosin (Tm) and troponin (Tn), Structure-function comparisons of the wt and E311A/R312A actins show no significant differences between them, and the unregulated F-actins slide at similar speeds in the in vitro motility assay. However, in the presence of Tm and Tn, the mutation increases both the sliding speed and the number of moving filaments at high pCa values, shifting the speed-pea curve nearly 0.5 pCa units to the left, Tm alone (no Tn) inhibits the motilities of both actins at low heavy meromyosin densities but potentiates only the motility of the mutant actin at high heavy meromyosin densities, Actin-Tm binding measurements indicate no significant difference between wt and E311A/R312A actin in Tm binding. These results implicate allosteric effects in the regulation of actomyosin function by tropomyosin.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Reisler, E (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	reisler@mbi.ucla.edu			NIAMS NIH HHS [R01 AR022031, AR30988, AR22031] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988, R01AR022031] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; CARLIER MF, 1986, J BIOL CHEM, V261, P785; COOK RK, 1993, J BIOL CHEM, V268, P2410; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gerson JH, 1997, BIOPHYS J, V72, pMP180; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HASELGROVE JC, 1973, COLD SPRING HARB SYM, V37, P341, DOI 10.1101/SQB.1973.037.01.044; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Korman V, 1998, BIOPHYS J, V74, pA347; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; POOLEWILSON P, 1996, HEART FAILURE, P4; POPP D, 1987, J MOL BIOL, V197, P679, DOI 10.1016/0022-2836(87)90474-8; SELDEN LA, 1986, J MUSCLE RES CELL M, V7, P215, DOI 10.1007/BF01753554; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P245, DOI 10.1093/oxfordjournals.jbchem.a135049; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P219, DOI 10.1093/oxfordjournals.jbchem.a135048; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WAKABAYASHI T, 1981, J BIOCHEM-TOKYO, V90, P683, DOI 10.1093/oxfordjournals.jbchem.a133523; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; WERTMAN KF, 1992, GENETICS, V132, P337; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048	47	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17545	17550		10.1074/jbc.274.25.17545	http://dx.doi.org/10.1074/jbc.274.25.17545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364188	hybrid			2022-12-27	WOS:000080974300024
J	Bracher, A; Fischer, M; Eisenreich, W; Ritz, H; Schramek, N; Boyle, P; Gentili, P; Huber, R; Nar, H; Auerbach, G; Bacher, A				Bracher, A; Fischer, M; Eisenreich, W; Ritz, H; Schramek, N; Boyle, P; Gentili, P; Huber, R; Nar, H; Auerbach, G; Bacher, A			Histidine 179 mutants of GTP cyclohydrolase I catalyze the formation of 2-amino-5-formylamino-8-ribofuranosylamino-4(3H)-pyrimidinone triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; GENE; TETRAHYDROBIOPTERIN; MOLYBDOPTERIN; MUTATIONS; SYNTHASE; COFACTOR	GTP cyclohydrolase I catalyzes the conversion of GTP to dihydroneopterin triphosphate. The replacement of histidine 179 by other amino acids affords mutant enzymes that do not catalyze the formation of dihydroneopterin triphosphate. However, some of these mutant proteins catalyze the conversion of GTP to 2-amino-5-formylamino-6-ribofuranosylamino-4(3H) -pyrimidinone 5'-triphosphate as shown by multinuclear NMR analysis. The equilibrium constant for the reversible conversion of GTP to the ring-opened derivative is approximately 0.1, The wild-type enzyme converts the formylamino pyrimidine derivative to dihydroneopterin triphosphate; the rate is similar to that observed with GTP as substrate. The data support the conclusion that the formylamino pyrimidine derivative is an intermediate in the overall reaction catalyzed by GTP cyclohydrolase I.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Dublin Trinity Coll, Chem Lab, Dublin 2, Ireland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Technical University of Munich; Trinity College Dublin; Max Planck Society	Bacher, A (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	adelbert.bacher@ch.tum.de	Fischer, Markus J./G-9477-2012; Eisenreich, Wolfgang/A-1258-2013; Fischer, Markus/AFT-1856-2022	Eisenreich, Wolfgang/0000-0002-9832-8279; Fischer, Markus/0000-0001-7243-4199; Nar, Herbert/0000-0002-3878-6964				Bandmann O, 1996, HUM MOL GENET, V5, P403, DOI 10.1093/hmg/5.3.403; Bandmann O, 1996, J NEUROL SCI, V141, P27, DOI 10.1016/0022-510X(96)00098-6; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITMAIER E, 1987, CARBON 13 NMR SPECTR, P229; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; FISCHER M, 1997, THESIS TU MUNCHEN MU; KENNE L, 1988, J CHEM SOC P1, V4, P1183; KWON NS, 1989, J BIOL CHEM, V264, P20496; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; Nagatsu T, 1997, J NEURAL TRANSM-SUPP, P203; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NEUMAN RC, 1971, BIOCHEM BIOPH RES CO, V44, P1156, DOI 10.1016/S0006-291X(71)80207-3; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PERRICAUDET M, 1973, INT J PEPT PROT RES, V5, P99; PFLEIDERER W, 1957, CHEM BER-RECL, V90, P2272, DOI 10.1002/cber.19570901022; RADOM L, 1972, AUST J CHEM, V25, P1601, DOI 10.1071/CH9721601; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; SCHMID C, 1993, ADV EXP MED BIOL, V338, P157; SHIOTA T, 1969, BIOCHIM BIOPHYS ACTA, V192, P205, DOI 10.1016/0304-4165(69)90357-2; SHIOTA T, 1967, J BIOL CHEM, V242, P1961; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Thony B, 1997, HUM MUTAT, V10, P11; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065; ZOU R, 1987, CAN J CHEM, V65, P1436, DOI 10.1139/v87-243	29	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16727	16735		10.1074/jbc.274.24.16727	http://dx.doi.org/10.1074/jbc.274.24.16727			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358012	hybrid			2022-12-27	WOS:000080780400011
J	Bustamante, C; Guthold, M; Zhu, XS; Yang, GL				Bustamante, C; Guthold, M; Zhu, XS; Yang, GL			Facilitated target location on DNA by individual Escherichia coli RNA polymerase molecules observed with the scanning force microscope operating in liquid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LAC REPRESSOR; BINDING; TRANSCRIPTION; MICA		Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		, Guthold/AAU-9371-2021	Bustamante, Carlos/0000-0002-2970-0073; Guthold, Martin/0000-0003-4177-6115				Adam G., 1968, STRUCTURAL CHEM MOL; Bausch AR, 1999, BIOPHYS J, V76, P573, DOI 10.1016/S0006-3495(99)77225-5; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; Hansma HG, 1996, BIOPHYS J, V70, P1933, DOI 10.1016/S0006-3495(96)79757-6; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KADESCH TR, 1980, J MOL BIOL, V136, P65, DOI 10.1016/0022-2836(80)90366-6; KADESCH TR, 1980, J MOL BIOL, V136, P79, DOI 10.1016/0022-2836(80)90367-8; NIYOGI SK, 1981, NUCLEIC ACIDS RES, V9, P2615, DOI 10.1093/nar/9.11.2615; RICCHETTI M, 1988, P NATL ACAD SCI USA, V85, P4610, DOI 10.1073/pnas.85.13.4610; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x	18	73	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16665	16668		10.1074/jbc.274.24.16665	http://dx.doi.org/10.1074/jbc.274.24.16665			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358002	hybrid, Green Published			2022-12-27	WOS:000080780400001
J	Guo, SD; Rena, G; Cichy, S; He, XW; Cohen, P; Unterman, T				Guo, SD; Rena, G; Cichy, S; He, XW; Cohen, P; Unterman, T			Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; MULTIHORMONAL REGULATION; TRANSCRIPTION FACTOR; HEPATOMA-CELLS; DOMINANT ROLE; LIFE-SPAN; FORK HEAD	Insulin inhibits the expression of multiple genes in the liver containing an insulin response sequence (IRS) (CAAAA(C/T)AA), and we have reported that protein kinase B (PKB) mediates this effect of insulin, Genetic studies in Caenorhabditis elegans indicate that daf-16, a forkhead/winged-helix transcription factor, is a major target of the insulin receptor-PKB signaling pathway. FKHR, a human homologue of daf-16, contains three PKB sites and is expressed in the liver. Reporter gene studies in HepG2 hepatoma cells show that FKHR stimulates insulin-like growth factor-binding protein-1 promoter activity through an IRS, and introduction of IRSs confers this effect on a heterologous promoter. Insulin disrupts IRS-dependent transactivation by FKHR, and phosphorylation of Ser-256 by PKB is necessary and sufficient to mediate this effect. Antisense studies indicate that FKHR contributes to basal promoter function and is required to mediate effects of insulin and PKB on promoter activity via an IRS, To our knowledge, these results provide the first report that FKHR stimulates promoter activity through an IRS and that phosphorylation of FKHR by PKB mediates effects of insulin on gene expression. Signaling to FKHR-related forkhead proteins via PKB may provide an evolutionarily conserved mechanism by which insulin and related factors regulate gene expression.	Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Hlth Care Syst, W Side Div, Chicago, IL 60612 USA; Univ Dundee, MRC, Prot Phosphorylat Unit, Dept Biochem, Dundee DD1 5EH, Scotland	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Dundee	Unterman, T (corresponding author), Vet Affairs W Side Med Ctr, 820 S Damen Ave,Room 5A122A Res,MP 151, Chicago, IL 60612 USA.	unterman@uic.edu	Rena, Graham/AAV-7985-2021		NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; BIGGS WH, 1999, IN PRESS P NATL ACAD; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clauson PG, 1998, SCAND J CLIN LAB INV, V58, P353, DOI 10.1080/00365519850186544; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; COTTERILL AM, 1988, J CLIN ENDOCR METAB, V67, P882, DOI 10.1210/jcem-67-5-882; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DORMAN JB, 1995, GENETICS, V141, P1399; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FABER S, 1993, J BIOL CHEM, V268, P24976; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lowe WL, 1997, ENDOCRINOLOGY, V138, P2219, DOI 10.1210/en.138.6.2219; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mithieux G, 1996, REPROD NUTR DEV, V36, P357, DOI 10.1051/rnd:19960402; NANDAN SD, 1992, LAB ANIM SCI, V42, P473; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OOI GT, 1993, J BIOL CHEM, V268, P16664; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; POWELL DR, 1991, J BIOL CHEM, V266, P18868; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VOWELS JJ, 1992, GENETICS, V130, P105; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	67	452	468	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17184	17192		10.1074/jbc.274.24.17184	http://dx.doi.org/10.1074/jbc.274.24.17184			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358076	hybrid			2022-12-27	WOS:000080780400075
J	Knauer, R; Lehle, L				Knauer, R; Lehle, L			The oligosaccharyltransferase complex from Saccharomyces cerevisiae - Isolation of the OST6 gene, its synthetic interaction with OST3, and analysis of the native complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ASPARAGINE-LINKED OLIGOSACCHARIDES; MEMBRANE-PROTEIN COMPLEXES; YEAST MUTANTS DEFICIENT; ACTIVITY IN-VIVO; ENDOPLASMIC-RETICULUM; N-GLYCOSYLATION; STRUCTURAL REQUIREMENTS; MAMMALIAN OLIGOSACCHARYLTRANSFERASE; CARBOXYPEPTIDASE-Y	The key step of N-glycosylation of proteins, an essential and highly conserved protein modification, is catalyzed by the hetero-oligomeric protein complex oligosaccharyltransferase (OST), So far, eight genes have been identified in Saccharomyces cerevisiae that are involved in this process. Enzymatically active OST preparations from yeast were shown to be composed of four (Ost1p, Wbp1p, Ost3p, Swp1p) or six subunits (Ost2p and Ost5p in addition to the four listed). Genetic studies have disclosed Stt3p and Ost4p as additional proteins needed for N-glycosylation, In this study we report the identification and functional characterization of a new OST gene, designated OST6, that has homology to OST3 and in particular a strikingly similar membrane topology. Neither gene is essential for growth of yeast. Disruption of OST6 or OST3 causes only a minor defect in N-glycosylation, but an Delta ost3 Delta ost6 double mutant displays a synthetic phenotype, leading to a severe underglycosylation of soluble and membrane-bound glycoproteins in vivo and to a reduced OST activity in vitro. Moreover, each of the two genes has also a specific func tion, since agents affecting cell wall biogenesis reveal different growth phenotypes in the respective null mutants. By blue native electrophoresis and immunodetection, a similar to 240-kDa complex was identified consisting of Ost1p, Stt3p, Wbp1p, Ost3p, Ost6p, Swp1p, Ost2p, and Ost5p, indicating that probably all so far identified OST proteins are constituents of the OST complex, It is also shown that disruption of OST3 and OST6 leads to a defect in the assembly of the complex. Hence, the function of these genes seems to be essential for recruiting a fully active complex necessary for efficient N-glycosylation,	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany	University of Regensburg	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	lehle.ludwig@biologie.uni-regensburg.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1991, Methods Enzymol, V194, P1; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HASILIK A, 1978, EUR J BIOCHEM, V91, P567, DOI 10.1111/j.1432-1033.1978.tb12710.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KANIKENNULAT C, 1995, GENETICS, V140, P933; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KOBATA A, 1996, N COMP BIOC, V30, P211; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR V, 1994, J BIOL CHEM, V269, P13451; KUMAR V, 1995, ARCH BIOCHEM BIOPHYS, V320, P217, DOI 10.1016/0003-9861(95)90003-9; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Marshall R D, 1974, Biochem Soc Symp, P17; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Pathak R, 1997, ARCH BIOCHEM BIOPHYS, V338, P1, DOI 10.1006/abbi.1996.9812; PATHAK R, 1995, FEBS LETT, V362, P229, DOI 10.1016/0014-5793(95)00253-6; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SHIMIZU J, 1994, MOL GEN GENET, V242, P641, DOI 10.1007/BF00283417; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; Spirig U, 1997, MOL GEN GENET, V256, P628, DOI 10.1007/s004380050611; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; VANREGENMORTEL MHV, 1988, LABORATORY TECHNIQUE, V19, P95; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	71	104	107	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17249	17256		10.1074/jbc.274.24.17249	http://dx.doi.org/10.1074/jbc.274.24.17249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358084	hybrid			2022-12-27	WOS:000080780400083
J	Oh, SK; Kang, H; Shin, DH; Yang, J; Chow, KS; Yeang, HY; Wagner, B; Breiteneder, H; Han, KH				Oh, SK; Kang, H; Shin, DH; Yang, J; Chow, KS; Yeang, HY; Wagner, B; Breiteneder, H; Han, KH			Isolation, characterization, and functional analysis of a novel cDNA clone encoding a small rubber particle protein from Hevea brasiliensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELONGATION-FACTOR; PARTHENIUM-ARGENTATUM; LATEX; TREE; IDENTIFICATION; EXPRESSION; ALLERGEN; BIOSYNTHESIS; LATICIFERS	Biochemical evidence reported so far suggests that rubber synthesis takes place on the surface of rubber particles suspended in the latex of Hevea brasiliensis. We have isolated and characterized a cDNA clone that encodes a protein tightly bound on a small rubber particle. We named this protein small rubber particle protein (SRPP), Prior to this study, this protein was known as a latex allergen, and only its partial amino acid sequence was reported. Sequence analysis revealed that this protein is highly homologous to the rubber elongation factor and the Phaseolus vulgaris stress-related protein. Southern and Northern analyses indicate that the protein is encoded by a single gene and highly expressed in latex. An allergenicity test using the recombinant protein confirmed that the cloned cDNA encodes the known 24-kDa latex allergen. Neither ethylene stimulation nor wounding changed the transcript level of the SRPP gene in H. brasiliensis. An in vitro rubber assay showed that the protein plays a positive role in rubber biosynthesis. Therefore, it is likely that SRPP is a part of the rubber biosynthesis machinery, if not the rubber polymerase, along with the rubber elongation factor.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Rubber Res Inst Malaysia, Biotechnol & Strateg Res Unit, Kuala Lumpur 50908, Malaysia; Univ Vienna, Inst Gen & Expt Pathol, AKH EBO 3Q, A-1090 Vienna, Austria	Institute Penyelidikan Getah Malaysia; University of Vienna	Han, KH (corresponding author), Michigan State Univ, Dept Forestry, 126 Nat Resources Bldg, E Lansing, MI 48824 USA.		Han, Kyung-Hwan/G-6141-2012; Moussa, Luciana/M-2257-2013	Han, Kyung-Hwan/0000-0001-9481-4643; 				Abeles F, 1992, ETHYLENE PLANT BIOL; Adiwilaga K, 1996, PLANT MOL BIOL, V30, P935, DOI 10.1007/BF00020805; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ARCHER BL, 1963, BIOCHEM J, V89, P565, DOI 10.1042/bj0890565; Arokiaraj P, 1998, PLANT CELL REP, V17, P621, DOI 10.1007/s002990050454; BACKHAUS RA, 1985, ISRAEL J BOT, V34, P283; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CHYE ML, 1992, PLANT MOL BIOL, V19, P473, DOI 10.1007/BF00023395; CORNISH K, 1990, PHYTOCHEMISTRY, V29, P3809, DOI 10.1016/0031-9422(90)85337-F; CORNISH K, 1993, EUR J BIOCHEM, V218, P267, DOI 10.1111/j.1432-1033.1993.tb18374.x; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GOYVAERTS E, 1991, PLANT PHYSIOL, V97, P317, DOI 10.1104/pp.97.1.317; Han KH, 1997, CAN J FOREST RES, V27, P464, DOI 10.1139/cjfr-27-4-464; John P., 1993, BIOSYNTHESIS MAJOR C, P114; KUSH A, 1990, P NATL ACAD SCI USA, V87, P1787, DOI 10.1073/pnas.87.5.1787; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT DR, 1989, J BIOL CHEM, V264, P18598; LYNEN F., 1969, Journal of the Rubber Research Institute, V21, P389; MADHAVAN S, 1989, PLANT PHYSIOL, V89, P506, DOI 10.1104/pp.89.2.506; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; Sambrook J., 1989, MOL CLONING, pA1; Siler DJ, 1997, PLANT PHYSIOL BIOCH, V35, P881; SILER DJ, 1993, PHYTOCHEMISTRY, V32, P1097, DOI 10.1016/S0031-9422(00)95072-6; SIVASUBRAMANIAM S, 1995, PLANT MOL BIOL, V29, P173, DOI 10.1007/BF00019129; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Yeang H., 1995, J NAT RUBBER RES, V10, P108; Yeang HY, 1998, ALLERGY, V53, P513, DOI 10.1111/j.1398-9995.1998.tb04089.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	35	142	189	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17132	17138		10.1074/jbc.274.24.17132	http://dx.doi.org/10.1074/jbc.274.24.17132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358068	hybrid			2022-12-27	WOS:000080780400067
J	Kaiser, A; Brembeck, FH; Nicke, B; Wiedenmann, B; Riecken, EO; Rosewicz, S				Kaiser, A; Brembeck, FH; Nicke, B; Wiedenmann, B; Riecken, EO; Rosewicz, S			All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-CARCINOMA CELLS; THYROID-HORMONE RECEPTOR; HUMAN BREAST-CANCER; NUCLEAR RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL DISPLAY; ESTROGEN-RECEPTOR; FISSION YEAST; ALPHA; MITOSIS	In this study we used differential display reverse transcription-polymerase chain reaction to search for differentially expressed all-trans-retinoic acid (ATRA)-responsive genes in pancreatic carcinoma cells. We identified the kinesin-related protein HsEg5, which plays an essential role in spindle assembly and spindle function during mitosis, as a novel molecule involved in ATRA-mediated growth inhibition. Using Northern and Western blot analysis we demonstrated that ATRA significantly inhibits HsEg5 expression in various pancreatic carcinoma cell lines as well as in HaCat keratinocytes, Inhibition of HsEg5 expression by ATRA occurs at the posttranscriptional level. As a consequence, tumor cells synchronized in S-phase revealed a retarded progression through G(2)/M phase of the cell cycle indicating that HsEg5 inhibition results in a delayed progression through mitosis, Furthermore, a significant decrease of HsEg5 protein expression achieved by antisense transfection revealed a significant growth inhibition compared with control cells. Therefore, HsEg5 represents a novel molecule involved in ATRA-mediated growth inhibition, suggesting that vitamin A derivatives can interact with the bipolar spindle apparatus during mitosis.	Charite, Med Klin, S Hepatol & Gastroenterol, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Dept Gastroenterol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rosewicz, S (corresponding author), Charite, Med Klin, S Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburgerpl 1, D-13353 Berlin, Germany.	stefan.rosewicz@charite.de		Wiedenmann, Bertram/0000-0002-7890-2552				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURGER C, 1994, J CELL SCI, V107, P2047; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clairmont A, 1997, FEBS LETT, V419, P268, DOI 10.1016/S0014-5793(97)01468-3; DE LUCA LM, 1991, FASEB J, V5, P2924; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kaiser A, 1996, DIGESTION, V57, P149, DOI 10.1159/000201329; Kaiser A, 1997, GASTROENTEROLOGY, V113, P920, DOI 10.1016/S0016-5085(97)70188-4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LOPEZBARAHONA M, 1993, J BIOL CHEM, V268, P25617; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Manji SS, 1998, J CELL PHYSIOL, V176, P1; NELSON JA, 1986, MOL CELL BIOL, V6, P452, DOI 10.1128/MCB.6.2.452; Oridate N, 1996, ONCOGENE, V12, P2019; Rosewicz S, 1997, GASTROENTEROLOGY, V112, P532, DOI 10.1053/gast.1997.v112.pm9024307; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; VONMARSCHALL Z, 1999, IN PRESS BR J CANC; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Whitehead CM, 1996, ARTHRITIS RHEUM, V39, P1635, DOI 10.1002/art.1780391005; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZHENG ZS, 1990, CANCER RES, V50, P1201; ZHOU H, 1994, J BIOL CHEM, V269, P22433	46	17	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18925	18931		10.1074/jbc.274.27.18925	http://dx.doi.org/10.1074/jbc.274.27.18925			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383390	hybrid			2022-12-27	WOS:000081196300013
J	Wang, LH; Hayashi, H; Ebina, Y				Wang, LH; Hayashi, H; Ebina, Y			Transient effect of platelet-derived growth factor on GLUT4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; AFFECTING GLUCOSE-TRANSPORT; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; SIGNALING PATHWAYS; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; FACTOR TRIGGERS; PDGF RECEPTORS	We earlier developed a novel method to detect translocation of the glucose transporter (GLUT) directly and simply using c-MYC epitope-tagged GLUT (GLUTMYC). To define the effect of platelet-derived growth factor (PDGF) on glucose transport in 3T3-L1 adipocytes, we investigated the PDGF- and insulin-induced glucose uptake, translocation of glucose transporters, and phosphatidylinositol (PI) S-kinase activity in 3T3-L1, 3T3-L1GLUT4MYC, and 3T3-L1GLUT1MYC adipocytes, Insulin and PDGF stimulated glucose uptake by 9-10- and 5.5-6.5-fold, respectively, in both 3T3-L1 and 3T3-L1GLUT4MYC adipocytes. Exogenous GLUT4MYC expression led to enhanced PDGF-induced glucose transport. In 3T3-L1GLUT4MYC adipocytes, insulin and PDGF induced an 8- and 5-fold increase in GLUT4MYC translocation, respectively, determined in a cell-surface anti-c-MYC antibody binding assay. This PDGF-induced GLUT4MYC translocation was further demonstrated with fluorescent detection. In contrast, PDGF stimulated a a-fold increase of GLUT1MYC translocation and 2.5-fold increase of glucose uptake in 3T3-L1GLUT1MYC adipocytes. The PDGF-induced GLUT4MYC translocation, glucose uptake, and PI 3-kinase activity were maximal (100%) at 5-10 min and thereafter rapidly declined to 40, 30, and 12%, respectively, within 60 min, a time when effects of insulin were maximal. Wortmannin (0.1 mu M) abolished PDGF-induced GLUT4MYC translocation and glucose uptake in 3T3-L1GLUT4MYC adipocytes. These results suggest that PDGF can transiently trigger the translocation of GLUT4 and stimulate glucose uptake by translocation of both GLUT4 and GLUT1 in a PI 3-kinase dependent signaling pathway in 3T3-L1 adipocytes.	Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 7708503, Japan	Tokushima University	Ebina, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Genet, 3-18-15 Kuramoto-cho, Tokushima 7708503, Japan.			Hayashi, Hideki/0000-0003-4585-6542				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARDY RW, 1995, ENDOCRINOLOGY, V136, P431, DOI 10.1210/en.136.2.431; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; ISHII K, 1994, BIOCHEM BIOPH RES CO, V205, P857, DOI 10.1006/bbrc.1994.2743; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUIN MJ, 1994, TRENDS ENDOCRIN MET, V5, P369; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YANG J, 1992, J BIOL CHEM, V267, P10393	45	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19246	19253		10.1074/jbc.274.27.19246	http://dx.doi.org/10.1074/jbc.274.27.19246			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383432	hybrid			2022-12-27	WOS:000081196300055
J	Das, K; Lewis, RY; Scherer, PE; Lisanti, MP				Das, K; Lewis, RY; Scherer, PE; Lisanti, MP			The membrane-spanning domains of caveolins-1 and-2 mediate the formation of gaveolin hetero-oligomers - Implications for the assembly of caveolae membranes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PRIMARY BREAST-CANCER; IN-VIVO; MUTATIONAL ANALYSIS; PLASMA-MEMBRANE; SQUAMOUS-CELL; FREQUENT LOSS; EXPRESSION; HETEROZYGOSITY; FAMILY	The mammalian caveolin gene family consists of caveolins-1, -2, and -3. The expression of caveolin-3 is muscle-specific. In contrast, caveolins-1 and -2 are co-expressed, and they form a hetero-oligomeric complex in many cell types, with particularly high levels in adipocytes, endothelial cells, and fibroblasts. These caveolin hetero-oligomers are thought to represent the functional assembly units that drive caveolae formation in vivo. Here, we investigate the mechanism by which caveolins-1 and -2 form hetero-oligomers. We reconstituted this reciprocal interaction in vivo and in vitro using a variety of complementary approaches, including the generation of glutathione S-transferase fusion proteins and synthetic peptides. Taken together, our results indicate that the membrane-spanning domains of both caveolins-1 and -2 play a critical role in mediating their ability to interact with each other. This is the first demonstration that these unusual membrane-spanning regions found in the caveolin family play a specific role in protein-protein interactions.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; LAXMAN R, 1993, CANCER, V71, P1283, DOI 10.1002/1097-0142(19930215)71:4<1283::AID-CNCR2820710419>3.0.CO;2-I; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin JC, 1996, ONCOGENE, V13, P2001; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Matsuura K, 1998, ANTICANCER RES, V18, P453; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; OAKAHASHI S, 1995, CANCER RES, V55, P4114; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; Wang XL, 1998, INT J CANCER, V75, P671, DOI 10.1002/(SICI)1097-0215(19980302)75:5<671::AID-IJC2>3.3.CO;2-6; XIU ZF, 1993, CHUNG HUA FU CHAN KO, V28, P91; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	52	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18721	18728		10.1074/jbc.274.26.18721	http://dx.doi.org/10.1074/jbc.274.26.18721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373486	hybrid			2022-12-27	WOS:000081056700078
J	Falck, J; Jensen, PB; Sehested, M				Falck, J; Jensen, PB; Sehested, M			Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase II alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; HEAT-SHOCK; CBF/NF-Y; C-MYB; NF-Y; PROMOTER; EXPRESSION; CDP/CUT; LOCALIZATION; STABILITY	Expression of DNA topoisomerase II alpha (topo II alpha) is cell cycle-regulated at both the transcriptional and the post- transcriptional levels. In order to identify cis-acting elements responsible for transcriptional regulation during the cell cycle, we investigated NIH/3T3 cells stably transfected with luciferase reporter plasmids containing various lengths of the human topo II alpha gene promoter. Serum-deprived cells expressed low levels of luciferase, and following serum-induced cell cycle reentry luciferase levels were gradually elevated 2-fold. During S phase, a steep S-fold increase in luciferase activity was seen, reaching its maximum approximately 22 h after serum addition. This pattern was observed with both a full-length (nucleotides (nt) -295 to +90] and a deletion (nt -90 to +90) promoter construct. In contrast, when testing a deletion construct (nt -51 to +90) lacking the first inverted CCAAT box (ICB1) the S phase-specific induction was absent. Mutation of ICB1 revealed that it had a repressive character, since luciferase levels rose rapidly to maximal levels immediately following serum addition. Furthermore, electrophoretic mobility shift assays demonstrated a marked decrease in ICB1 binding activity following serum addition. Together, this suggests a role of ICB1 in cell cycle-dependent repression of topo II alpha transcription.	Rigshosp, Dept Pathol, Lab Ctr, DK-2100 Copenhagen, Denmark; Rigshosp, Finsen Ctr, Dept Oncol, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Sehested, M (corresponding author), Rigshosp, Dept Pathol, Lab Ctr, RH5444,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.							Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; Brandt TL, 1997, LEUKEMIA RES, V21, P711, DOI 10.1016/S0145-2126(97)00040-4; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FRASER DJ, 1995, MOL PHARMACOL, V47, P696; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Herzog CE, 1997, BIOCHEM BIOPH RES CO, V232, P608, DOI 10.1006/bbrc.1997.6267; HICKSON ID, 1996, ANTI-CANCER DRUG, V7, P19; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HSIANG YH, 1988, CANCER RES, V48, P3230; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kramer A, 1997, CANCER RES, V57, P5117; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mo YY, 1997, CANCER RES, V57, P5004; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18753	18758		10.1074/jbc.274.26.18753	http://dx.doi.org/10.1074/jbc.274.26.18753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373491	hybrid			2022-12-27	WOS:000081056700083
J	Okamoto, M; Schoch, S; Sudhof, TC				Okamoto, M; Schoch, S; Sudhof, TC			EHSH1/intersectin, a protein that contains EH and SH3 domains and binds to dynamin and SNAP-25 - A protein connection between exocytosis and endocytosis?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUBSTRATE EPS15; ACTIN CYTOSKELETON; SYNAPTOTAGMIN-I; RECEPTOR; INTERACTS; CLATHRIN; YEAST; ORGANIZATION; SYNAPTOJANIN; ADAPTER	In yeast two-hybrid screens for proteins that bind to SNAP-25 and may be involved in exocytosis, we isolated a protein called EHSH1 (for ER domain/SH3 domain-containing protein). Cloning of full-length cDNAs revealed that EHSH1 is composed of an N-terminal region with two EH domains, a central region that is enriched in lysine, leucine, glutamate, arginine, and glutamine (KLERQ domain), and a C-terminal region comprised of five SH3 domains. The third SH3 domain is alternatively spliced, Data bank searches demonstrated that EHSH1 is very similar to Xenopus and human intersectins and to human SH3P17. In addition, we identified expressed sequence tags that encode a second isoform of EHSH1, called EHSH2. EHSH1 is abundantly expressed in brain and at lower levels in all other tissues tested. In binding studies, we found that the central KLERQ domain of EHSH1 binds to recombinant or native brain SNAP-25 and SNAP-23, The C-terminal SH3 domains, by contrast, quantitatively interact with dynamin, a protein involved in endocytosis. Dynamin strongly binds to the alternatively spliced central SH3 domain (SH3C) and the two C-terminal SH3 domains (SH3D and SH3E) but not to the N-terminal SH3 domains (SH3A and SH3B), Immunoprecipitations confirmed that both dynamin and SNAP-25 are complexed to EHSH1 in brain, Our data suggest that EHSH1/intersectin may be a novel adaptor protein that couples endocytic membrane traffic to exocytosis. The ability of multiple SH3 domains in EHSH1 to bind to dynamin suggests that EHSH1 can cluster several dynamin molecules in a manner that is regulated by alternative splicing.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	T.Sudho@mednet.SWMED.edu	Schoch, Susanne/F-7741-2012					BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; Carbone R, 1997, CANCER RES, V57, P5498; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Harlow E., 1988, ANTIBODIES LAB MANUA; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Iannolo G, 1997, CANCER RES, V57, P240; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Khvotchev M, 1998, J BIOL CHEM, V273, P2306, DOI 10.1074/jbc.273.4.2306; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Palade GE, 1995, COLD SPRING HARB SYM, V60, P821, DOI 10.1101/SQB.1995.060.01.088; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Rizo J, 1998, NAT STRUCT BIOL, V5, P839, DOI 10.1038/2280; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaife RM, 1997, CELL SIGNAL, V9, P395, DOI 10.1016/S0898-6568(97)00041-7; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang GY, 1997, J CELL SCI, V110, P505; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	55	131	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18446	18454		10.1074/jbc.274.26.18446	http://dx.doi.org/10.1074/jbc.274.26.18446			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373452	hybrid			2022-12-27	WOS:000081056700044
J	Zhou, X; Park, SI; Moustafa, ME; Carlson, BA; Crain, PF; Diamond, AM; Hatfield, DL; Lee, BJ				Zhou, X; Park, SI; Moustafa, ME; Carlson, BA; Crain, PF; Diamond, AM; Hatfield, DL; Lee, BJ			Selenium metabolism in Drosophila - Characterization of the selenocysteine tRNA population	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA POPULATION; TRANSFER RNA<SER>SEC; MASS-SPECTROMETRY; MAMMALIAN-CELLS; GENE; UGA; CHROMOSOMES; ANTICODON; SYSTEM	The selenocysteine (Sec) tRNA population in Drosophila melanogaster is aminoacylated with serine, forms selenocysteyl-tRNA, and decodes UGA. The K-m of Sec tRNA and serine tRNA for seryl-tRNA synthetase is 6.67 and 9.45 nM, respectively. Two major bands of Sec tRNA were resolved by gel electrophoresis, Both tRNAs were sequenced, and their primary structures were indistinguishable and colinear with that of the corresponding single copy gene. They are 90 nucleotides in length and contain three modified nucleosides, 5-methylcarboxymethyluridine, N-6-isopentenyladenosine, and pseudouridine, at positions 34, 37, and 55, respectively. Neither form contains 1-methyladenosine at position 58 or 5-methylcarboxymethyl-2'-O-methyluridine which are characteristically found in Sec tRNA of higher animals. We conclude that the primary structures of the two bands of Sec tRNA resolved by electrophoresis are indistinguishable by the techniques employed and that See tRNAs in Drosophila may exist in different conformational forms. The Sec tRNA gene maps to a single locus on chromosome 2 at position 47E or F, To our knowledge, Drosophila is the lowest eukaryote in which the Sec tRNA population has been characterized to date.	Seoul Natl Univ, Inst Mol Biol & Genet, Genet Mol Lab, Seoul 151742, South Korea; NCI, Sect Mol Biol Selenium, Lab Basic Res, NIH, Bethesda, MD 20892 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Illinois, Dept Human Nutr & Dietet, Chicago, IL 60612 USA	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lee, BJ (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Med Genet Lab, Seoul 151742, South Korea.	imbglmg@snu.ac.kr	Moustafa, Mohamed E/E-9002-2018; Moustafa, Mohamed/AAM-2211-2021	Moustafa, Mohamed/0000-0003-1308-6221	NATIONAL CANCER INSTITUTE [R01CA081153, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81153] Funding Source: Medline; NIGMS NIH HHS [R01 GM29812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alsina B, 1998, MOL GEN GENET, V257, P113, DOI 10.1007/s004380050630; AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Chittum HS, 1997, BIOCHEMISTRY-US, V36, P8634, DOI 10.1021/bi970608t; Chittum HS, 1997, BBA-MOL CELL RES, V1359, P25, DOI 10.1016/S0167-4889(97)00092-X; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DIAMOND AM, 1993, J BIOL CHEM, V268, P14215; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; GREEN MR, 1985, BIOCHEM BIOPH RES CO, V129, P233, DOI 10.1016/0006-291X(85)91427-5; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; HATFIELD D, 1993, TRENDS GENET, V9, P69, DOI 10.1016/0168-9525(93)90215-4; HATFIELD D, 1991, NUCLEIC ACIDS RES, V19, P939, DOI 10.1093/nar/19.4.939; HATFIELD D, 1992, BIOCHEM BIOPH RES CO, V184, P254, DOI 10.1016/0006-291X(92)91186-T; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; Pardue M L, 1975, Methods Cell Biol, V10, P1, DOI 10.1016/S0091-679X(08)60727-X; PERLAKY S, 1998, 39 ANN DROS RES C WA; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Silberklang M, 1979, Methods Enzymol, V59, P58; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	31	11	11	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18729	18734		10.1074/jbc.274.26.18729	http://dx.doi.org/10.1074/jbc.274.26.18729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373487	hybrid, Green Published			2022-12-27	WOS:000081056700079
J	Heuertz, RM; Tricomi, SM; Ezekiel, UR; Webster, RO				Heuertz, RM; Tricomi, SM; Ezekiel, UR; Webster, RO			C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; HEAT-SHOCK PROTEINS; SIGNAL-TRANSDUCTION; MAP KINASE; CELLULAR THERMORESISTANCE; HUMAN COMPLEMENT; PHOSPHORYLATION; ALVEOLITIS; RECEPTORS; FMLP	Serum levels of the acute-phase reactant, C-reactive protein (CRP), increase dramatically during acute inflammatory episodes. CRP inhibits migration of neutrophils toward the chemoattractant, f-Met-Leu-Phe (fMLP) and therefore acts as an anti-inflammatory agent, Since tyrosine kinases are involved in neutrophil migration and CRP has been shown to decrease phosphorylation of some neutrophil proteins, we hypothesized that CRP inhibits neutrophil chemotaxis via inhibition of MAP kinase activity. The importance of p38 MAP kinase in neutrophil movement was determined by use of the specific p38 MAP kinase inhibitor, SB203580. CRP and SB203580 both blocked random and fMLP-directed neutrophil movement in a concentration-dependent manner. Additionally, extracellular signal-regulated MAP kinase (ERK) was not involved in fMLP-induced neutrophil movement as determined by use of the MEK-specific inhibitor, PD98059. Blockade of ERK with PD98059 did not inhibit chemotaxis nor did it alter the ability of CRP or SB203580 to inhibit fMLP-induced chemotaxis, More importantly, CRP inhibited fMLP-induced p38 MAP kinase activity. in a concentration-dependent manner as measured by an in vitro kinase assay. Impressively, CRP-mediated inhibition of p38 MAP kinase activity correlated with CRP-mediated inhibition of fMLP-induced chemotaxis (r = -0.7144). These data show that signal transduction through p38 MAP kinase is necessary for neutrophil chemotaxis and that CRP intercedes through this pathway in inhibiting neutrophil movement.	St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Washington University (WUSTL)	Heuertz, RM (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, 3635 Vista Ave & Grand Blvd, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed N, 1996, AM J RESP CRIT CARE, V153, P1141, DOI 10.1164/ajrccm.153.3.8630558; Alvarez V, 1996, IMMUNOGENETICS, V44, P446, DOI 10.1007/BF02602806; BAN K, 1994, CARDIOVASC RES, V28, P1258, DOI 10.1093/cvr/28.8.1258; BUCHTA R, 1987, FEBS LETT, V211, P165, DOI 10.1016/0014-5793(87)81429-1; BUCHTA R, 1988, FEBS LETT, V237, P173, DOI 10.1016/0014-5793(88)80195-9; CLAUS DR, 1977, J IMMUNOL, V119, P187; Coffer PJ, 1998, BIOCHEM J, V329, P121; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DOBRINICH R, 1991, ARTHRITIS RHEUM-US, V34, P1031, DOI 10.1002/art.1780340813; Downey GP, 1998, J IMMUNOL, V160, P434; DUCLOS TW, 1981, CLIN EXP IMMUNOL, V43, P565; FOWLER AA, 1987, AM REV RESPIR DIS, V136, P1225, DOI 10.1164/ajrccm/136.5.1225; GANROT PO, 1969, SCAND J CLIN LAB INV, V24, P215, DOI 10.3109/00365516909080155; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HEUERTZ RM, 1993, AM J PATHOL, V142, P319; HEUERTZ RM, 1994, AM J PHYSIOL, V266, pL649, DOI 10.1152/ajplung.1994.266.6.L649; HOWARD T, 1994, BLOOD, V83, P231; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KEW RR, 1990, J LAB CLIN MED, V115, P339; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961; KUSHNER I, 1981, J LAB CLIN MED, V97, P739; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LI JJ, 1989, J TRAUMA, V29, P1690, DOI 10.1097/00005373-198912000-00019; MALECH HL, 1977, J CELL BIOL, V75, P666, DOI 10.1083/jcb.75.3.666; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MORLEY JJ, 1982, ANN NY ACAD SCI, V389, P406, DOI 10.1111/j.1749-6632.1982.tb22153.x; MORTENSEN RF, 1977, CELL IMMUNOL, V28, P59, DOI 10.1016/S0008-8749(77)80006-3; MORTENSEN RF, 1977, J IMMUNOL, V119, P1611; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARISH WE, 1976, CLIN ALLERGY, V6, P543, DOI 10.1111/j.1365-2222.1976.tb01939.x; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Samols David, 1995, Arthritis and Rheumatism, V38, pS233; Schnyder B, 1998, BIOCHEM J, V331, P489, DOI 10.1042/bj3310489; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; VIGO C, 1985, J BIOL CHEM, V260, P3418; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; YASUI K, 1994, J IMMUNOL, V152, P5922; Zhong WJ, 1998, J IMMUNOL, V161, P2533; ZIGMOND SH, 1983, AM REV RESPIR DIS, V127, P290; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; Zu YL, 1998, J IMMUNOL, V160, P1982	50	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17968	17974		10.1074/jbc.274.25.17968	http://dx.doi.org/10.1074/jbc.274.25.17968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364245	hybrid			2022-12-27	WOS:000080974300081
J	Bishop-Bailey, D; Hla, T				Bishop-Bailey, D; Hla, T			Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL ACTIVATION; RETINOIC ACID; CANCER CELLS; OXIDIZED LDL; GAMMA; PROSTAGLANDIN; EXPRESSION; ALPHA; GROWTH; INDUCTION	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) is a bioactive prostanoid produced by dehydration and isomerization of PGD(2), a cyclooxygenase product. It was recently shown to activate the nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma), a critical transcription factor involved in adipocyte and monocyte differentiation. In this report, we show that 15d-PGJ(2) is a potent inducer of caspase-mediated endothelial cell apoptosis. PPAR alpha, -delta, and -gamma were expressed by endothelial cells, which, when treated with 15d-PGJ(2), induced receptor translocation into the nucleus, and an increase in PPAR response element-driven reporter gene expression. Ciglitizone, a selective activator of PPAR gamma, also induced transcriptional activation and endothelial cell apoptosis. Endothelial apoptosis induced by 15d-PGJ(2) was inhibited by treatment of cells with an oligonucleotide decoy to a consensus PPAR response element sequence. Furthermore, overexpression of the PPAR gamma isotype induced endothelial cell apoptosis, which was further potentiated by 15d-PGJ(2) treatment. We conclude that 15d-PGJ(2) induces endothelial cell apoptosis via a PPAR-dependent pathway. The PPAR pathway may be a therapeutic target for numerous pathologies in which excessive angiogenesis is implicated.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Mail Code 3505,263 Farmington Ave, Farmington, CT 06030 USA.	hla@sun.uchc.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Bishop-Bailey, David/0000-0003-2455-596X	NHLBI NIH HHS [HL-54710, HL-49094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL049094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Eguchi Y, 1997, P NATL ACAD SCI USA, V94, P14689, DOI 10.1073/pnas.94.26.14689; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1989, ADV PROSTAG THROMB L, V19, P415; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOIZUMI T, 1992, PROSTAGLANDINS, V43, P121, DOI 10.1016/0090-6980(92)90081-4; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MACIAG T, 1984, METHODS PREPARATION, P195; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	36	401	412	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17042	17048		10.1074/jbc.274.24.17042	http://dx.doi.org/10.1074/jbc.274.24.17042			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358055	hybrid			2022-12-27	WOS:000080780400054
J	Henics, T; Nagy, E; Oh, HJ; Csermely, P; von Gabain, A; Subjeck, JR				Henics, T; Nagy, E; Oh, HJ; Csermely, P; von Gabain, A; Subjeck, JR			Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MESSENGER-RNA; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; IDENTIFICATION; SEQUENCE; CELLS; HEAT-SHOCK-PROTEIN-70; DEGRADATION; LYMPHOCYTES	In this study, in vitro RNA binding by members of the mammalian 70-kDa heat shock protein (Hsp) family was examined. We show that Hsp/Hsc70 and Hsp110 proteins preferentially bound AU-rich RNA in vitro. Inhibition of RNA binding by ATP suggested the involvement of the N-terminal ATP-binding domain, By using deletion mutants of Hsp110 protein, a diverged Hsp70 family member, RNA binding was localized to the N-terminal ATP-binding domain of the molecule. The C-terminal peptide-binding domain did not bind RNA, but its engagement by a peptide substrate abrogated RNA binding by the N terminus of the protein. Interestingly, removal of the C-terminal alpha-helical structure or the alpha-loop domain unique to Hsp110 immediately downstream of the peptide-binding domain, but not both, resulted in considerably increased RNA binding as compared with the wild type protein. Finally, a 70 kDa activity was immunoprecipitated from RNA-protein complexes formed in vitro between cytoplasmic proteins of human lymphocytes and AU-rich RNA. These findings support the idea that certain heat shock proteins may act as RNA-binding entities in vivo to guide the appropriate folding of RNA substrates for subsequent regulatory processes such as mRNA degradation and/or translation.	Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Pecs, Sch Med, Dept Med Microbiol & Immunol, H-7643 Pecs, Hungary; Univ Pecs, Sch Med, Dept Clin Biochem, H-7643 Pecs, Hungary; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Semmelweis Univ, Dept Med Chem, H-1444 Budapest 8, Hungary	Vienna Biocenter (VBC); University of Pecs; University of Pecs; Roswell Park Cancer Institute; Semmelweis University	Henics, T (corresponding author), Vienna Bioctr, Inst Microbiol & Genet, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	THenics@intercell.co.at	Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659; Oh, Kelly/0000-0001-8203-5247	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BRIAN CF, 1995, EMBO J, V14, P2281; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DI YP, 1995, J CELL PHYSIOL, V165, P228, DOI 10.1002/jcp.1041650203; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENICS T, 1994, J BIOL CHEM, V269, P5377; Henics T, 1997, J CELL PHYSIOL, V173, P19, DOI 10.1002/(SICI)1097-4652(199710)173:1<19::AID-JCP3>3.3.CO;2-H; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruggero D, 1998, EMBO J, V17, P3471, DOI 10.1093/emboj/17.12.3471; Scandurro AB, 1997, KIDNEY INT, V51, P579, DOI 10.1038/ki.1997.83; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Soos H, 1998, PHYSIOL CHEM PHYS ME, V30, P163; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; WELCH WJ, 1982, HEAT SHOCK BACTERIA, P257; Wells DR, 1998, GENE DEV, V12, P3236, DOI 10.1101/gad.12.20.3236; YAMAMOTO T, 1987, J BIOL CHEM, V262, P7996; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	46	99	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17318	17324		10.1074/jbc.274.24.17318	http://dx.doi.org/10.1074/jbc.274.24.17318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358092	hybrid			2022-12-27	WOS:000080780400091
J	Liu, PCC; Thiele, DJ				Liu, PCC; Thiele, DJ			Modulation of human heat shock factor trimerization by the linker domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ZN(2)CYS(6) BINUCLEAR CLUSTER; TRANSCRIPTION FACTOR CONTAINS; COILED-COIL; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; ACTIVATION DOMAIN; FACTOR-II; YEAST; PROTEIN	Heat shock transcription factors (HSFs) are stress-responsive proteins that activate the expression of heat shock genes and are highly conserved from bakers' yeast to humans. Under basal conditions, the human HSF1 protein is maintained as an inactive monomer through intramolecular interactions between two coiled-coil domains and interactions with heat shock proteins; upon environmental, pharmacological, or physiological stress, HSF1 is converted to a homotrimer that binds to its cognate DNA binding site with high affinity. To dissect regions of HSF1 that make important contributions to the stability of the monomer under unstressed conditions, we have used functional complementation in bakers' yeast as a facile assay system. Whereas wild-type human HSF1 is restrained as an inactive monomer in yeast that is unable to substitute for the essential yeast HSF protein, mutations in the linker region between the DNA binding domain and the first coiled-coil allow HSF1 to homotrimerize and rescue the viability defect of a hsf Delta strain. Fine mapping by functional analysis of HSF1-HSF2 chimeras and point mutagenesis revealed that a small region in the aminoterminal portion of the HSF1 linker is required for maintenance of HSF1 in the monomeric state in both yeast and in transfected human 293 cells. Although linker regions in transcription factors are known to modulate DNA binding specificity, our studies suggest that the human HSF1 linker plays no role in determining HSF1 binding preferences in vivo but is a critical determinant in regulating the HSF1 monomer-trimer equilibrium.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu			NIGMS NIH HHS [GM18858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto R. I., 1994, COLD SPRING HARBOR M, V26; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Nover L, 1997, CELL MOL LIFE SCI, V53, P80, DOI 10.1007/PL00000583; Orosz A, 1996, MOL CELL BIOL, V16, P7018; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zhong M, 1999, J BIOL CHEM, V274, P3135, DOI 10.1074/jbc.274.5.3135; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	51	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17219	17225		10.1074/jbc.274.24.17219	http://dx.doi.org/10.1074/jbc.274.24.17219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358080	hybrid			2022-12-27	WOS:000080780400079
J	Naray-Fejes-Toth, A; Canessa, C; Cleaveland, ES; Aldrich, G; Fejes-Toth, G				Naray-Fejes-Toth, A; Canessa, C; Cleaveland, ES; Aldrich, G; Fejes-Toth, G			sgk is an aldosterone-induced kinase in the renal collecting duct - Effects on epithelial Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THREONINE PROTEIN-KINASE; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; PROMOTER ACTIVITY; SODIUM-TRANSPORT; APICAL MEMBRANE; CELLS; GENE; CLONING; PHOSPHORYLATION	The early phase of the stimulatory effect of aldosterone on sodium reabsorption in renal epithelia is thought to involve activation of apical sodium channels. However, the genes initiating this effect are unknown. We used a combination of polymerase chain reaction-based subtractive hybridization and differential display techniques to identify aldosterone-regulated immediate early genes in renal mineralocorticoid target cells. We report here that aldosterone rapidly increases mRNA levels of a putative Ser/Thr kinase, sgk (or serum- and glucocorticoid-regulated kinase), in its native target cells, i.e. in cortical collecting duct cells. The effect occurs within 30 min of the addition of aldosterone, is mediated through mineralocorticoid receptors, and does not require de novo protein synthesis. The full-length sequences of rabbit and mouse sgk cDNAs were determined. Both cDNAs show significant homology to rat and human sgk (88-94% at the nucleotide level, and 96-99% at the amino acid level). Coexpression of the mouse sgk in Xenopus oocytes with the three subunits of the epithelial Na+ channel results in a significantly enhanced Na+ current. These results suggest that sgk is an immediate early aldosterone-induced gene, and this protein kinase plays an important role in the early phase of aldosterone-stimulated Na+ transport.	Dartmouth Med Sch, Dept Physiol, Lebanon, NH 03756 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Dartmouth College; Yale University	Naray-Fejes-Toth, A (corresponding author), Dartmouth Med Sch, Dept Physiol, Lebanon, NH 03756 USA.				NHLBI NIH HHS [HL56163] Funding Source: Medline; NIDDK NIH HHS [DK41841, DK39523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK041841] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; BENJAMIN WB, 1974, SCIENCE, V186, P269, DOI 10.1126/science.186.4160.269; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chen SY, 1998, AM J PHYSIOL-CELL PH, V274, pC39, DOI 10.1152/ajpcell.1998.274.1.C39; Denault DL, 1996, AM J PHYSIOL-CELL PH, V271, pC423, DOI 10.1152/ajpcell.1996.271.1.C423; DIATCHENKO L, 1996, P NATL ACAD SCI USA, V93, P6026; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; Escoubet B, 1997, AM J PHYSIOL-CELL PH, V272, pC1482, DOI 10.1152/ajpcell.1997.272.5.C1482; Fejes-Toth G, 1998, AM J PHYSIOL-RENAL, V274, pF596, DOI 10.1152/ajprenal.1998.274.3.F596; FEJESTOTH G, 1995, KIDNEY INT, V48, P1420, DOI 10.1038/ki.1995.431; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; FEJESTOTH G, 1995, AM J PHYSIOL-RENAL, V269, pF551, DOI 10.1152/ajprenal.1995.269.4.F551; FEJESTOTH G, 1987, AM J PHYSIOL, V253, pF1302, DOI 10.1152/ajprenal.1987.253.6.F1302; FUNDER JW, 1989, ENDOCR RES, V15, P227, DOI 10.1080/07435808909039098; GEHEB M, 1981, J BIOL CHEM, V256, P1716; Gurskaya NG, 1996, ANAL BIOCHEM, V240, P90, DOI 10.1006/abio.1996.0334; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; NARAYFEJESTOTH A, 1990, AM J PHYSIOL, V259, pF672, DOI 10.1152/ajprenal.1990.259.4.F672; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; NARAYFEJESTOTH A, 1991, J TISSUE CULT METHOD, V13, P179; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; SUTANTO W, 1987, ENDOCRINOLOGY, V121, P1405, DOI 10.1210/endo-121-4-1405; TODDTURLA KM, 1993, AM J PHYSIOL, V264, pF781, DOI 10.1152/ajprenal.1993.264.5.F781; ToddTurla KM, 1996, AM J PHYSIOL-RENAL, V270, pF237, DOI 10.1152/ajprenal.1996.270.1.F237; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; Verrey F, 1997, KIDNEY BLOOD PRESS R, V20, P148, DOI 10.1159/000174128; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Waldegger S, 1998, PFLUG ARCH EUR J PHY, V436, P575, DOI 10.1007/s004240050674; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482	46	373	379	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16973	16978		10.1074/jbc.274.24.16973	http://dx.doi.org/10.1074/jbc.274.24.16973			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358046	hybrid			2022-12-27	WOS:000080780400045
J	Wilsbacher, JL; Goldsmith, EJ; Cobb, MH				Wilsbacher, JL; Goldsmith, EJ; Cobb, MH			Phosphorylation of MAP kinases by MAP ERK involves multiple regions of MAP kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; GROWTH-FACTOR; CATALYTIC SUBUNIT; P38 GROUP; FAMILY; MEMBER; CELLS; MEK	Mitogen-activated protein (MAP) kinases are activated with great specificity by MAP/ERK kinases (MEKs). The basis for the specific activation is not understood. In this study chimeras composed of two MAP kinases, extracellular signal-regulated protein kinase 2 and p38, were assayed in vitro for phosphorylation and activation by different MEK isoforms to probe the requirements for productive interaction of MAP kinases with MEKs. Experimental results and modeling support the conclusion that the specificity of MEK/MAP kinase phosphorylation results from multiple contacts, including surfaces in both the N- and C-terminal domains.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5328 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; SEGER R, 1992, J BIOL CHEM, V267, P14373; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Sun ZY, 1998, J BIOL CHEM, V273, P4810; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	38	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16988	16994		10.1074/jbc.274.24.16988	http://dx.doi.org/10.1074/jbc.274.24.16988			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358048	hybrid			2022-12-27	WOS:000080780400047
J	Zimmermann, S; Baumann, A; Jaekel, K; Marbach, I; Engelberg, D; Frohnmeyer, H				Zimmermann, S; Baumann, A; Jaekel, K; Marbach, I; Engelberg, D; Frohnmeyer, H			UV-responsive genes of Arabidopsis revealed by similarity to the Gcn4-mediated UV response in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; AMINO-ACID TRANSPORTER; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; CHALCONE SYNTHASE; PROTEIN-KINASE; DNA-DAMAGE; SIGNALING PATHWAY; TYROSINE KINASES	A UV response that involves the Ras proteins and AP-1 transcription factors has recently been described in mammals and yeast. To test whether an equivalent response exists in plants, we monitored the expression of Arabidopsis histidinol dehydrogenase gene (HDH), a homologue of the yeast HIS4 gene, which is strongly induced by UV light and is a target of the transcriptional activator Gcn4. We show that HDH mRNA levels increase specifically in response to UV-B light. Only small increases were detected upon exposure to other wavelengths. To isolate plant genes involved in this UV response, a gcn4 mutant was transfected with an Arabidopsis thaliana cDNA library. A new type of nucleotide diphosphate kinase (NDPK Ia) with a significant homology to the human tumor suppressor protein Nm23 rescued the gcn4 phenotype. NDPK Ia specifically binds to the HIS4 promoter in vitro and induces HIS4 transcription in yeast. In Arabidopsis, the NDPK Ia protein is located in the nucleus and cytosol, Expression studies in seedlings revealed that the level of NDPK la mRNA, like that of HDH, increases in response to UV-B light. It appears that NDPK Ia and HDH are components of a novel W-responsive pathway in A. thaliana.	Univ Freiburg, Inst Biol Bot 2, D-79104 Freiburg, Germany; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	University of Freiburg; Hebrew University of Jerusalem	Frohnmeyer, H (corresponding author), Univ Freiburg, Inst Biol Bot 2, Schanzlestr 1, D-79104 Freiburg, Germany.							ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; BREWS T, 1991, GENETIC ENG, P221; Britt AB, 1996, ANNU REV PLANT PHYS, V47, P75, DOI 10.1146/annurev.arplant.47.1.75; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; Christie JM, 1996, PLANT CELL, V8, P1555, DOI 10.1105/tpc.8.9.1555; Conconi A, 1996, NATURE, V383, P826, DOI 10.1038/383826a0; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FROHNMEYER H, 1992, PLANT J, V2, P899, DOI 10.1111/j.1365-313X.1992.00899.x; Frohnmeyer H, 1997, J EXP BOT, V48, P739, DOI 10.1093/jxb/48.3.739; Frohnmeyer H, 1998, PLANT J, V13, P763, DOI 10.1046/j.1365-313X.1998.00074.x; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUYER D, 1995, P NATL ACAD SCI USA, V92, P4997, DOI 10.1073/pnas.92.11.4997; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Holdsworth MJ, 1995, PLANT MOL BIOL, V29, P711, DOI 10.1007/BF00041162; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JORDAN BR, 1996, ADV BOT RES, V22, P98; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kircher S, 1998, MOL GEN GENET, V257, P595, DOI 10.1007/s004380050687; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kraeft SK, 1996, EXP CELL RES, V227, P63, DOI 10.1006/excr.1996.0250; Lee H, 1997, INT J ONCOL, V11, P965; LIEBECK J, 1995, PLANTA, V196, P668; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAURI I, 1993, MOL GEN GENET, V241, P319, DOI 10.1007/BF00284684; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; MINET M, 1992, PLANT J, V2, P417; NAGAI A, 1991, P NATL ACAD SCI USA, V88, P4133, DOI 10.1073/pnas.88.10.4133; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; NOMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P47, DOI 10.1016/0167-4838(91)90524-4; Ouatas T, 1998, INT J DEV BIOL, V42, P43; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHAFER E, 1977, OPTISCHE STRAHLUNGSQ, P249; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TADA S, 1994, PLANT PHYSIOL, V105, P79; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x	58	69	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17017	17024		10.1074/jbc.274.24.17017	http://dx.doi.org/10.1074/jbc.274.24.17017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358052	hybrid			2022-12-27	WOS:000080780400051
J	Agata, Y; Matsuda, E; Shimizu, A				Agata, Y; Matsuda, E; Shimizu, A			Two novel Kruppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 (TIF1 beta/KRIP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR RECEPTORS; RING FINGER; DOMAIN; DROSOPHILA; FAMILY; BROMODOMAIN; EXPRESSION; TIF1-ALPHA; ACTIVATION	We have isolated two novel Kruppel-like zinc finger proteins containing the evolutionarily conserved Kruppel-associated box (KRAB), KRAZ1 and KRAZ2, and demonstrated that they repress transcription when heterologously targeted to DNA. Their repression activity appeared to be mediated by the putative corepressor RAP-1 (KRAB-associated protein-1), because KRAZ1/2 bind to KAP-1, but KRAB mutants of KRAZ1/2 that are unable to interact with KAP-1 lack repression activity, and KAP-1 has intrinsic repressor activity and potentiates KRAZ1/2-mediated repression. We dissected the KAP-1 protein into a KRAB-interacting domain and a region necessary for repression. Using a mammalian two-hybrid assay, we further demonstrated that KAP-1 deletions lacking repression activity fused to the VP16 transactivation domain strongly activated transcription when coexpressed with KRAZ1. In contrast, VP16-KAP-1 fusions retaining repression activity resulted in repression. These results provide the first evidence that KAP-1 functionally interacts with KRAB in mammalian cells and seems to exert repressor activity in the DNA-bound KRAB-KAP-1 complex, and they further support the hypothesis that KAP-1 functions as a corepressor for the large class of KRAB-containing zinc finger proteins.	Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Shimizu, A (corresponding author), Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan.	shimizu@virus.kyoto-u.ac.jp		Agata, Yasutoshi/0000-0001-9642-6994				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Agata Y, 1998, GENE, V213, P55, DOI 10.1016/S0378-1119(98)00213-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	38	72	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16412	16422		10.1074/jbc.274.23.16412	http://dx.doi.org/10.1074/jbc.274.23.16412			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347202	hybrid			2022-12-27	WOS:000080668600062
J	Sellers, LA; Feniuk, W; Humphrey, PPA; Lauder, H				Sellers, LA; Feniuk, W; Humphrey, PPA; Lauder, H			Activated g protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase - Resultant effects on cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II AT(1) RECEPTOR; SOMATOSTATIN RECEPTOR; MAP KINASE; NEURONAL DIFFERENTIATION; PC12 CELLS; GROWTH; CANCER; ANALOG; INHIBITION; PHOSPHATASE	The peptide hormone somatostatin exhibits antipro liferative activity by interacting with the G protein-coupled sst, or sst, receptor types. We show here that somatostatin at the human recombinant sst, receptor induced a concentration-dependent increase in proliferation (EC50 20 nM) with a maximal response 5-fold greater than that produced by its synthetic analog, L-362,855. Analysis of the phosphorylation status of extracellular signal-regulated kinase (ERK)1 and ERK2 showed temporal differences in the changes evoked by the agonists, Phosphorylation induced by somatostatin (100 nM) peaked 10 min after the application and produced a response that continued for at least 4 h. In contrast, L-362,855 (1 mu M) showed transient phosphorylation that had declined to basal levels by I h, However, both agonists induced rapid and sustained tyrosine phosphorylation of signal transducer and activator of transcription 3 (STAT3) which was pertussis toxin-insensitive. Serine phosphorylation of STAT3 was only apparent after somatostatin treatment and was abolished by pertussis toxin or PD 98059, together with the associated increases in proliferation. Mitogen-activated protein/ERK kinase-1 inhibition also decreased the time interval over which somatostatin-induced ERK phosphorylation was observed (<2 h), We conclude that the difference in the magnitude of the proliferative response evoked by the two agonists at the sst(4) receptor can be accounted for by their differential ability to phosphorylate STAT3 on serine residues and supports the concept that selective signaling can be achieved through pharmacological diversity.	Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Sellers, LA (corresponding author), Univ Cambridge, Dept Pharmacol, Glaxo Inst Appl Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.							AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Alderton F, 1998, BRIT J PHARMACOL, V124, P323, DOI 10.1038/sj.bjp.0701843; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; BITO H, 1994, J BIOL CHEM, V269, P12722; BREVINI TAL, 1993, J CLIN ENDOCR METAB, V77, P626, DOI 10.1210/jc.77.3.626; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DY DY, 1992, CANCER RES, V52, P917; EVERS BM, 1991, ANN SURG, V213, P190, DOI 10.1097/00000658-199103000-00002; GERICH JE, 1981, AM J MED, V70, P619, DOI 10.1016/0002-9343(81)90584-2; Hofland LJ, 1996, BAILLIERE CLIN ENDOC, V10, P163, DOI 10.1016/S0950-351X(96)80362-4; HOYER D, 1995, TRENDS PHARMACOL SCI, V16, P86, DOI 10.1016/S0165-6147(00)88988-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ISHIZUKA J, 1992, BIOCHEM BIOPH RES CO, V185, P577, DOI 10.1016/0006-291X(92)91663-B; KAMIYA Y, 1993, BIOCHEM BIOPH RES CO, V191, P302, DOI 10.1006/bbrc.1993.1217; Kerkhoff E, 1998, CANCER RES, V58, P1636; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lauder H, 1997, BRIT J PHARMACOL, V122, P663, DOI 10.1038/sj.bjp.0701443; LAUDER H, 1998, BRIT J PHARMACOL, V123, P126; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MACAULAY VM, 1991, BRIT J CANCER, V64, P451, DOI 10.1038/bjc.1991.330; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; PAGLIACCI MC, 1991, ENDOCRINOLOGY, V129, P2555, DOI 10.1210/endo-129-5-2555; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; REUBI JC, 1994, CANCER RES, V54, P3455; RUIZTORRES P, 1993, BIOCHEM BIOPH RES CO, V195, P1057, DOI 10.1006/bbrc.1993.2151; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Smalley KSM, 1998, BRIT J PHARMACOL, V125, P833, DOI 10.1038/sj.bjp.0702133; Tombes RM, 1998, BIOCHEM J, V330, P1451; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	46	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16423	16430		10.1074/jbc.274.23.16423	http://dx.doi.org/10.1074/jbc.274.23.16423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347203	hybrid			2022-12-27	WOS:000080668600063
J	Elrod-Erickson, M; Pabo, CO				Elrod-Erickson, M; Pabo, CO			Binding studies with mutants of Zif268 - Contribution of individual side chains to binding affinity and specificity in the Zif268 zinc finger-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; RECOGNITION; SELECTION; PROTEINS; DESIGN; PHAGE; RULES	The Zif268 zinc finger-DNA complex has served as a model system for understanding how Cys,His, type zinc fingers recognize DNA. Structural studies of the Zif268-DNA complex revealed that residues at four positions in the cw helix of each zinc finger play key roles in recognition, but there has been no information about the precise contributions of individual residues. Here we report the results of binding studies involving five mutants of Zif268 that have changes in the base contacting residues of finger one. These studies let us evaluate the contributions that Arg(18) (position -1 of the alpha helix), Asp(20) (position 2), Glu(21) (position 3), and Arg(24) (position 6) make to the overall energy of DNA binding. Our results confirm the important role played by these arginines. By comparing the affinities of the wild type and mutant peptides for various sites, we also prove that Asp(20) and Glu(21) play important roles in determining binding site specificity.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Pabo, CO (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Choo Y, 1998, NUCLEIC ACIDS RES, V26, P554, DOI 10.1093/nar/26.2.554; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CORMACK B, 1997, CURRENT PROTOCOLS MO; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sambrook J., 2002, MOL CLONING LAB MANU; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	22	70	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19281	19285		10.1074/jbc.274.27.19281	http://dx.doi.org/10.1074/jbc.274.27.19281			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383437	hybrid			2022-12-27	WOS:000081196300060
J	Loveland, KL; Herszfeld, D; Chu, B; Rames, E; Christy, E; Briggs, LJ; Shakri, R; de Kretser, DM; Jans, DA				Loveland, KL; Herszfeld, D; Chu, B; Rames, E; Christy, E; Briggs, LJ; Shakri, R; de Kretser, DM; Jans, DA			Novel low molecular weight microtubule-associated protein-2 isoforms contain a functional nuclear localization sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; LARGE T-ANTIGEN; CALMODULIN-BINDING PROTEINS; RAT TESTIS; IN-VITRO; BRAIN DEVELOPMENT; DNA-POLYMERASE; SITE FLANKING; IMPORT; TRANSPORT	Known high and low molecular weight (LMW) MAP2 protein isoforms result from alternative splicing of the MAP2 gene. Contrary to previous reports that MAP2 is neural-specific, we recently identified MAP2 mRNA and protein in somatic and germ cells of rat testis, and showed the predominant testicular isoform is LMW. Although cytoplasmic in neural tissue, MAP2 appeared predominantly nuclear in germ cells using immunohistochemistry. We sought to determine whether this unexpected localization was due to the inclusion of exon 10 within novel LMW MAP2 isoforms. Normally excluded from the LMW MAP2c, exon 10 harbors a putative CcN motif, comprising a nuclear localization sequence (NLS) flanked by regulatory phosphorylation sites for protein kinase CK2 and cdc2 kinase. Characterization of MAP2 mRNA in adult and immature brain and testis, by reverse transcriptase-polymerase chain reaction/Southern analysis and Northern blot, identified novel LMW forms containing exons 10 and 11, previously detected only in high molecular weight MAP2a and 2b. The MAP2 NLS targeted a large heterologous protein to the nucleus, as demonstrated using bacterially expressed MAP2-CcN-beta-galactosidase fusion protein and an in vitro nuclear import assay. Antibodies raised against the fusion protein produced a testicular immunohistochemical staining pattern correlating with MAP2 protein distribution in the nucleus of most germ cells, and precipitated both similar to 70-kDa and >220-kDa proteins recognized by the commercial MAP2-specific HMS monoclonal antibody, supporting our hypothesis of a novel LMW MAP2 isoform. These results demonstrate-the presence of a functional NLS in MAP2 and indicate that novel LMW MAP2 isoforms may be targeted to the nucleus in both neural and non-neuronal tissues.	Monash Med Ctr, Inst Reprod & Dev, Clayton, Vic 3168, Australia; John Curtin Sch Med Res, Dept Biochem & Mol Biol, Nucl Signalling Lab, Canberra, ACT 2601, Australia	Monash University; Australian National University; John Curtin School of Medical Research	Loveland, KL (corresponding author), Monash Med Ctr, Inst Reprod & Dev, 246 Clayton Rd, Clayton, Vic 3168, Australia.	kate.loveland@med.monash.edu.au	Briggs, Lyndall J/A-7549-2011; Loveland, Kate L/X-4404-2019	Loveland, Kate L/0000-0002-5750-8046; Jans, David/0000-0001-5115-4745				BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS RG, 1995, BIOCHEM SOC T, V23, P41, DOI 10.1042/bst0230041; CHARRIEREBERTRAND C, 1992, NEUROCHEM INT, V21, P535, DOI 10.1016/0197-0186(92)90085-6; Chung WJ, 1996, J NEUROCHEM, V66, P1273; DOLL T, 1993, J CELL SCI, V106, P633; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Forleo P, 1996, J MOL NEUROSCI, V7, P193, DOI 10.1007/BF02736840; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jiang MS, 1997, J BIOL CHEM, V272, P2421; KALCHEVA N, 1995, P NATL ACAD SCI USA, V92, P10894, DOI 10.1073/pnas.92.24.10894; KALCHEVA N, 1995, J NEUROCHEM, V65, P1472; KINDLER S, 1990, J BIOL CHEM, V265, P19679; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; LANGKOPF A, 1994, FEBS LETT, V354, P259, DOI 10.1016/0014-5793(94)01128-1; Loveland KL, 1996, J MOL ENDOCRINOL, V17, P61, DOI 10.1677/jme.0.0170061; Loveland KL, 1996, BIOL REPROD, V54, P896, DOI 10.1095/biolreprod54.4.896; Ludin B, 1996, J CELL SCI, V109, P91; MARECHAL D, 1988, ARCH INT PHYSIOL BIO, V96, P231, DOI 10.3109/13813458809075948; Matus Andrew, 1994, V13, P155; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; MELLO CM, 1992, J BIOMOL STRUCT DYN, V9, P791, DOI 10.1080/07391102.1992.10507956; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORIYA M, 1993, CELL TISSUE RES, V271, P441, DOI 10.1007/BF02913726; Munsie M, 1997, MOL REPROD DEV, V47, P19, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;19::AID-MRD3&gt;3.0.CO;2-T; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OHTA Y, 1989, J BIOL CHEM, V264, P16143; Pereira G, 1998, MOL BIOL CELL, V9, P775, DOI 10.1091/mbc.9.4.775; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shafit-Zagardo B, 1998, MOL NEUROBIOL, V16, P149, DOI 10.1007/BF02740642; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SURRIDGE CD, 1994, BIOCHEMISTRY-US, V33, P8051, DOI 10.1021/bi00192a009; Trejo R, 1997, MOL REPROD DEV, V48, P127, DOI 10.1002/(SICI)1098-2795(199709)48:1&lt;127::AID-MRD15&gt;3.0.CO;2-Y; TUCKER RP, 1988, DEV BIOL, V130, P423, DOI 10.1016/0012-1606(88)90338-7; VANCUROVA I, 1995, J CELL SCI, V108, P779; WANDOSELL F, 1984, CHROMOSOMA, V90, P68, DOI 10.1007/BF00352280; WANG Y, 1993, J CELL BIOL, V121, P257, DOI 10.1083/jcb.121.2.257; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	55	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19261	19268		10.1074/jbc.274.27.19261	http://dx.doi.org/10.1074/jbc.274.27.19261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383434	hybrid			2022-12-27	WOS:000081196300057
J	Lucas, LT; Gatehouse, D; Shuker, DEG				Lucas, LT; Gatehouse, D; Shuker, DEG			Efficient nitroso group transfer from N-nitrosoindoles to nucleotides and 2 '-deoxyguanosine at physiological pH - A new pathway for N-nitrosocompounds to exert genotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE TREATMENT; CHINESE CABBAGE; RAT STOMACH; DNA; 1-NITROSOINDOLE-3-ACETONITRILE; 2'-DEOXYOXANOSINE; ACID; INDOLE-3-ACETONITRILE; OLIGODEOXYNUCLEOTIDE; MUTAGENESIS	The endogenous formation of N-nitrosoindoles is of concern since humans are exposed to a variety of naturally occurring and synthetic indolic compounds. As part of a study to evaluate the genotoxicity of N-nitrosoindoles, the reactions of three model compounds with purine nucleotides and 2'-deoxyguanosine at physiological pH were investigated. The profiles of reaction products were identical for each of the N-nitrosoindoles and three distinct pathways of reaction could be discerned. These pathways were: (i) depurination to the corresponding purine bases, (ii) deamination, coupled with depurination, to give hypoxanthine and xanthine, and (iii) formation of the novel nucleotide 2'-deoxyoxanosine monophosphate and its corresponding depurination product oxanine in reactions with 2'-deoxyguanosine monophosphate, 2'-Deoxyoxanosine and oxanine were observed in reactions with S'-deoxyguanosine, Further studies showed that formation of all of these products could be rationalized by an initial transnitrosation step. These results suggest that, in contrast to many other genotoxic N-nitrosocompounds which are known to alkylate DNA, the genotoxicity of N-nitrosoindoles is likely to arise through transfer of the nitroso group to nucleophilic sites on the purine bases. All of the products resulting from transnitrosation by N-nitrosoindoles are potentially mutagenic. These findings reveal a new pathway for N-nitrosocompounds to exert genotoxicity.	Glaxo Wellcome Res & Dev Ltd, Med Safety & Evaluat Div, Ware SG12 0DP, Herts, England; Univ Leicester, MRC, Toxicol Unit, Biomonitoring & Mol Interact Sect, Leicester LE1 9HN, Leics, England	GlaxoSmithKline; University of Leicester	Shuker, DEG (corresponding author), Univ Leicester, MRC, Toxicol Unit, Biomonitoring & Mol Interact Sect, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	degs1@le.ac.uk						BARTSCH H, 1991, RELEVANCE HUMAN CANC, P1; BONNETT R, 1974, J CHEM SOC P1, V1, P962; CASTRO A, 1986, J CHEM SOC PERK T 2, P1165, DOI 10.1039/p29860001165; CROOKES MJ, 1998, J CHEM SOC CHEM COMM, P571; FURIHATA C, 1987, JPN J CANCER RES, V78, P432; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P413; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P1216; GATEHOUSE D, 1983, MUTAT RES, V124, P35, DOI 10.1016/0165-1218(83)90183-0; Glaser R, 1996, J AM CHEM SOC, V118, P10942, DOI 10.1021/ja961334k; KIRCHNER JJ, 1992, J AM CHEM SOC, V114, P4021, DOI 10.1021/ja00037a001; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MEYER TA, 1982, J CHEM SOC PERK T 2, P1383, DOI 10.1039/p29820001383; NAKAMURA H, 1981, J ANTIBIOT, V34, P1219, DOI 10.7164/antibiotics.34.1219; OCHIAI M, 1986, MUTAT RES, V172, P189, DOI 10.1016/0165-1218(86)90056-X; OHTA T, 1981, BIOCHEM BIOPH RES CO, V100, P52, DOI 10.1016/S0006-291X(81)80061-7; SHIMADA N, 1981, J ANTIBIOT, V34, P1216, DOI 10.7164/antibiotics.34.1216; Suzuki T, 1998, BIOCHEMISTRY-US, V37, P11592, DOI 10.1021/bi980971f; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P8013, DOI 10.1021/bi970166l; Suzuki T, 1996, J AM CHEM SOC, V118, P2515, DOI 10.1021/ja952550g; Suzuki T, 1997, Nucleic Acids Symp Ser, P313; VALIN N, 1985, MUTAT RES, V158, P159, DOI 10.1016/0165-1218(85)90079-5; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; WAKABAYASHI K, 1986, MUTAGENESIS, V1, P423, DOI 10.1093/mutage/1.6.423; WAKABAYASHI K, 1985, P JPN ACAD B-PHYS, V61, P190, DOI 10.2183/pjab.61.190; WAKABAYASHI K, 1989, CANCER SURV, V8, P385; WAKABAYASHI K, 1985, MUTAT RES, V143, P17, DOI 10.1016/0165-7992(85)90098-3; WAKABAYASHI K, 1987, RELEVANCE N NITROSO, P287; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YAMASHITA K, 1988, CARCINOGENESIS, V9, P1905, DOI 10.1093/carcin/9.10.1905	29	57	57	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18319	18326		10.1074/jbc.274.26.18319	http://dx.doi.org/10.1074/jbc.274.26.18319			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373435	hybrid			2022-12-27	WOS:000081056700027
J	Newton, TR; Patel, NM; Bhat-Nakshatri, P; Stauss, CR; Goulet, RJ; Nakashatri, H				Newton, TR; Patel, NM; Bhat-Nakshatri, P; Stauss, CR; Goulet, RJ; Nakashatri, H			Negative regulation of transactivation function but not DNA binding of NF-KB and AP-1 by I kappa B beta 1 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-BETA; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; ALPHA DEGRADATION; DEPENDENT TRANSCRIPTION; INDEPENDENT GROWTH; ESTROGEN-RECEPTOR; GENE-TRANSFER; P65 SUBUNIT	The transcription factor NF-kappa B regulates the expression of genes involved in cancer cell invasion, metastasis, angiogenesis, and resistance to chemotherapy, In normal cells NF-kappa B is maintained in the cytoplasm by protein-protein interaction with inhibitor I kappa Bs, In contrast, in cancer cells a substantial amount of NF-kappa B is in the nucleus and constitutively activates target genes, To understand the mechanisms of constitutive NF-kappa B activation, we have analyzed the function of I kappa B alpha and I kappa B beta in breast cancer cells, In most cases, constitutive NF-kappa B DNA binding correlated with reduced levels of either I kappa B alpha Or I kappa B beta isoforms, Overexpression of I kappa B alpha but not I kappa B beta 1 resulted in reduced constitutive DNA binding of NF-kappa B in MDA-MB-231 cells. Unexpectedly, I kappa B beta 1 overexpression moderately increased 12-O-tetradecanoylphorbol-13-acetate and interleukin-1-inducible NF-kappa B DNA binding, 12-O-Tetradecanoylphorbol-13-acetate and interleukin-1-induced transactivation by NF-kappa B, however, was lower in I kappa B beta 1-overexpressing cells. Mutants of I kappa B beta 1 lacking the C-terminal casein kinase II phosphorylation sites, which form a stable complex with DNA bound NF-kappa B without inhibiting its transactivation in other cell types, repressed the transactivation by NF-kappa B in MDA-MB-231 cells, Consistent with the results of transient transfections, the expression of urokinase plasminogen activator, an NF-kappa B target gene, was reduced in I kappa B beta 1-overexpressing cells. These results suggest that depending on the cell type, I kappa B beta 1 represses the expression of NF-kappa B-regulated genes by inhibiting either DNA binding or transactivation function of NF-kappa B.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakashatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CORNETTA K, 1994, CLIN EXP METASTAS, V12, P3, DOI 10.1007/BF01784328; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gilmore TD, 1996, ONCOGENE, V13, P1367; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERLOV C, 1991, ONCOGENE, V6, P1583; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	60	54	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18827	18835		10.1074/jbc.274.26.18827	http://dx.doi.org/10.1074/jbc.274.26.18827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373501	Green Published, hybrid			2022-12-27	WOS:000081056700093
J	Tsvetkov, PO; Protasevich, II; Gilli, R; Lafitte, D; Lobachov, VM; Haiech, J; Briand, C; Makarov, AA				Tsvetkov, PO; Protasevich, II; Gilli, R; Lafitte, D; Lobachov, VM; Haiech, J; Briand, C; Makarov, AA			Apocalmodulin finds to the myosin light chain kinase calmodulin target site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE COMPLEX; HIGH-AFFINITY; BINDING; CALCIUM; RECOGNITION; SIGNAL	The interaction of a 20-residue-long peptide derived from the calmodulin-binding domain of the smooth muscle myosin light chain kinase with calcium-free calmodulin (apocalmodulin) was studied using a combination of isothermal titration calorimetry and differential scanning calorimetry. We showed that: (i) a significant binding between apocalmodulin and the target peptide (RS20) exists in the absence of salt (K-a, = 10(6) M-1), (ii) the peptide interacts with the C-terminal lobe of calmodulin and adopts a partly helical conformation, and (iii) the presence of salt weakens the affinity of the peptide for apocalmodulin, emphasizing the importance of electrostatic interactions in the complex. Eased on these results and taking into account the work of Bayley et al. (Bayley, P. M,, Findlay, W,A,, and Martin, S. R, (1996) Protein Sci. 5, 1215-1228), we suggest a physiological role for apocalmodulin.	Univ Louis Pasteur Strasbourg 1, UMR CNRS, F-67401 Illkirch Graffenstaden, France; Univ Mediterranee, UPRESA CNRS 6032, F-13385 Marseille, France; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Aix-Marseille Universite; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Haiech, J (corresponding author), Univ Louis Pasteur Strasbourg 1, UMR CNRS, F-67401 Illkirch Graffenstaden, France.		Makarov, Alexander/P-5279-2016; haiech, jacques J/F-2890-2010	haiech, jacques/0000-0003-2908-8053				AFSHAR M, 1994, J MOL BIOL, V244, P554, DOI 10.1006/jmbi.1994.1752; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; Gilli R, 1998, BIOCHEMISTRY-US, V37, P5450, DOI 10.1021/bi972083a; GUIMARD L, 1994, ANAL BIOCHEM, V221, P118, DOI 10.1006/abio.1994.1387; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KILHOFFER MC, 1992, BIOCHIM BIOPHYS ACTA, V1160, P8, DOI 10.1016/0167-4838(92)90033-A; KILHOFFER MC, 1989, BIOCHEMISTRY-US, V28, P6086, DOI 10.1021/bi00440a053; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILOS M, 1988, J BIOL CHEM, V263, P9218; Privalov P L, 1986, Methods Enzymol, V131, P4; Protasevich I, 1997, BIOCHEMISTRY-US, V36, P2017, DOI 10.1021/bi962538g; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; Yuan T, 1999, BIOCHEMISTRY-US, V38, P1446, DOI 10.1021/bi9816453	23	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18161	18164		10.1074/jbc.274.26.18161	http://dx.doi.org/10.1074/jbc.274.26.18161			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373414	hybrid			2022-12-27	WOS:000081056700006
J	Pickering, TJ; Garforth, S; Sayers, JR; Grasby, JA				Pickering, TJ; Garforth, S; Sayers, JR; Grasby, JA			Variation in the steady state kinetic parameters of wild type and mutant T5 5 '-3 '-exonuclease with pH - Protonation of Lys-83 is critical for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; FLAP ENDONUCLEASE-1; CRYSTAL-STRUCTURE; METAL-IONS; RNASE-H; EXONUCLEASE; MECHANISM; RESIDUES; IDENTIFICATION; 5'-EXONUCLEASE	T5 5'-3'-exonuclease is a member of a family of homologous 5'-nucleases essential for DNA replication and repair. We have measured the variation of the steady state parameters of the enzyme with pH, The log of the association constant of the enzyme and substrate is pH-independent between pH 5 and 7, but art higher PH, it decreases (gradient -0.91 +/- 0.1) with increasing pH. The log of the turnover number increases (gradient 0.9 +/- 0.01) with increasing pH until a pH-independent plateau is reached. The T5 5'-3'-exonuclease-catalyzed reaction requires the protonation of a single residue for substrate binding, whereas k(cat) depends on a single deprotonation as demonstrated by the bell-shaped dependence of log (k(cat)/K-m) on pH. To investigate the role of a conserved lysine (Lys-83), the pH profile of log (k(cat)/K-m) of a K83A mutant was determined and found to increase with pH (gradient 1.01 +/- 0.01) until a pH-independent plateau is reached. We therefore conclude that protonation of Lys-83 in the wild type protein facilitates DNA binding. The origin of the pH dependence of the k(cat) parameter of the wild type enzyme is discussed.	Univ Sheffield, Dept Chem, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England; Univ Sheffield, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield	Grasby, JA (corresponding author), Univ Sheffield, Dept Chem, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England.		Sayers, Jon R/AAP-6179-2020; Garforth, Scott/B-5701-2011; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Ceska TA, 1998, TRENDS BIOCHEM SCI, V23, P331, DOI 10.1016/S0968-0004(98)01259-6; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FOTHERGILL M, 1995, J AM CHEM SOC, V117, P11619, DOI 10.1021/ja00152a001; FRENKEL GD, 1971, J BIOL CHEM, V246, P4839; Garforth SJ, 1997, NUCLEIC ACIDS RES, V25, P3801, DOI 10.1093/nar/25.19.3801; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HALE SP, 1993, BIOCHEMISTRY-US, V32, P7479, DOI 10.1021/bi00080a020; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; HUHEEY JE, 1983, INORGANIC CHEM PRINC, P295; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JENCKS WP, 1976, HDB BIOCH MOL BIOL, P305; Kim CY, 1998, BIOPHYS J, V74, pA63; Kim Y, 1997, MOL CELLS, V7, P468; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PAUL AV, 1966, J BIOL CHEM, V241, P3441; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Williams NH, 1998, COMPREHENSIVE BIOL C, V1, P543	33	6	9	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17711	17717		10.1074/jbc.274.25.17711	http://dx.doi.org/10.1074/jbc.274.25.17711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364212	hybrid			2022-12-27	WOS:000080974300048
J	Ghiselli, G; Siracusa, LD; Iozzo, RV				Ghiselli, G; Siracusa, LD; Iozzo, RV			Complete cDNA cloning, genomic organization, chromosomal assignment, functional characterization of the promoter, and expression of the murine bamacan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE PROTEOGLYCANS; NUCLEAR-LOCALIZATION SIGNALS; TUMOR STROMA; PROTEIN; FAMILY; CELLS; TRANSCRIPTION; BIOSYNTHESIS; CONDENSATION	Bamacan is a chondroitin sulfate proteoglycan that abounds in basement membranes. To gain insights into the bamacan gene regulation and transcriptional control, we examined the genomic organization and identified the promoter region of the mouse bamacan gene. Secondary structure analysis of the protein reveals a sequential organization of three globular regions interconnected by two cu-helix coiled-coils. The N- and the C-terminal ends carry a P-loop and a DA box motif that can act cooperatively to bind ATP, These features as well as the high sequence homology with members of the SMC (structural maintenance of chromosome) protein family led us to conclude that bamacan is a member of this protein family. The gene comprises 31 exons and is driven by a promoter that is highly enriched in GC sequences and lacks TATA and CAAT boxes. The promoter is highly functional in transient cell transfection assays, and step-wise 5' deletions identify a strong enhancer element between -659 and -481 base pairs that includes Jun/Fos proto-oncogene-binding elements. Using backcrossing experiments we mapped the Barn gene to distal chromosome 19, a locus syntenic to human chromosome 10q25, Bamacan is differentially expressed in mouse tissues with the highest levels in testes and brain, Notably, bamacan mRNA levels are low in normal cells and markedly reduced during quiescence but are highly increased when cells resume growth upon serum stimulation. In contrast, in all transformed cells tested, bamacan is constitutively overexpressed, and its levels do not change with cell cycle progression. These results suggest that bamacan is involved in the control of cell growth and transformation,	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, 1020 Locust St,Room 249,JAH, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, P01CA021124, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA21124, R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; ARGESON AC, 1995, GENOMICS, V25, P29, DOI 10.1016/0888-7543(95)80106-V; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brix K, 1998, J CLIN INVEST, V102, P283, DOI 10.1172/JCI1614; Chang BHJ, 1998, METHODS, V15, P41, DOI 10.1006/meth.1998.0604; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; COUCHMAN JR, 1993, KIDNEY INT, V43, P79, DOI 10.1038/ki.1993.14; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; EDELHOFF S, 1994, ONCOGENE, V9, P665; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1987, HISTOCHEMISTRY, V88, P23, DOI 10.1007/BF00490162; IOZZO RV, 1995, LAB INVEST, V73, P157; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Johnson DG, 1998, FRONT BIOSCI, V3, pd447; KANDA H, 1993, ONCOGENE, V8, P3047; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MCCARTHY KJ, 1994, J HISTOCHEM CYTOCHEM, V42, P473, DOI 10.1177/42.4.8126374; MCCARTHY KJ, 1993, J HISTOCHEM CYTOCHEM, V41, P401, DOI 10.1177/41.3.8429203; MCCARTHY KJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1479, DOI 10.1177/38.10.2401786; Poirier C, 1998, MAMM GENOME, V8, pS353, DOI 10.1007/s003359900664; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	40	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17384	17393		10.1074/jbc.274.24.17384	http://dx.doi.org/10.1074/jbc.274.24.17384			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358101	hybrid			2022-12-27	WOS:000080780400100
J	Vornlocher, HP; Hanachi, P; Ribeiro, S; Hershey, JWB				Vornlocher, HP; Hanachi, P; Ribeiro, S; Hershey, JWB			A 110-kilodalton subunit of translation initiation factor eIF3 and an associated 135-kilodalton protein are encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; GEL-ELECTROPHORESIS; CELL-PROLIFERATION; PRT1 PROTEIN; YEAST; COMPLEX; IDENTIFICATION; HOMOLOGS; DNA; SEPARATION	Translation initiation factor eIF3 is a multisubunit protein complex required for initiation of protein biosynthesis in eukaryotic cells. The complex promotes ribosome dissociation, the binding of the initiator methionyl-tRNA to the 40 S ribosomal subunit, and mRNA recruitment to the ribosome. In the yeast Saccharomyces cerevisiae eIF3 comprises up to 8 subunits. Using partial peptide sequences generated from proteins in purified eIF3, we cloned the TIF31 and TIF32 genes encoding 135- (p135) and 110-kDa (p110) proteins. Deletion/disruption of TIF31 results in no change in growth rate, whereas deletion of TIF32 is lethal. Depletion of p110 causes a severe reduction in cell growth and protein synthesis rates as well as runoff of ribosomes from polysomes, indicative of inhibition of the initiation phase. In addition, p110 depletion leads to p90 co-depletion, whereas other eIF3 subunit levels are not affected. Immunoprecipitation or nickel affinity chromatography from strains expressing (His)(6)-tagged p110 or p33 results in the co-purification of the well characterized p39 and p90 subunits of eIF3 as well as p110 and p33, This establishes p110 as an authentic subunit of eIF3. In similar experiments, p135 and other eIF3 subunits sometimes, but not always, co-purify, making assignment of p135 as an eIF3 subunit uncertain. Far Western blotting and two-hybrid analyses detect a direct interaction of p110 with p90, p135 with p33, and p33 with eIF4B. Our results, together with those from other laboratories, complete the cloning and characterization of all of the yeast eIF3 subunits.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.				NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BURKE DJ, 1991, MOL CELL BIOL, V11, P3691, DOI 10.1128/MCB.11.7.3691; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; Fields SD, 1998, J CELL SCI, V111, P1717; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; Greenberg JR, 1998, J BIOL CHEM, V273, P23485, DOI 10.1074/jbc.273.36.23485; Hanachi P, 1999, J BIOL CHEM, V274, P8546, DOI 10.1074/jbc.274.13.8546; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Kovarik P, 1998, CURR GENET, V33, P100, DOI 10.1007/s002940050314; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; Zhu QL, 1997, P NATL ACAD SCI USA, V94, P7308, DOI 10.1073/pnas.94.14.7308	43	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16802	16812		10.1074/jbc.274.24.16802	http://dx.doi.org/10.1074/jbc.274.24.16802			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358023	hybrid			2022-12-27	WOS:000080780400022
J	Wada, T; Long, JC; Zhang, D; Vik, SB				Wada, T; Long, JC; Zhang, D; Vik, SB			A novel labeling approach supports the five-transmembrane model of subunit a of the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATION; MUTAGENIC ANALYSIS; ALPHA-SUBUNIT; CROSS-LINKING; TOPOLOGY; MEMBRANE; SECTOR; F1F0-ATPASE; F1-ATPASE; MUTATIONS	Cysteine mutagenesis and surface labeling has been used to define more precisely the transmembrane spans of subunit a of the Escherichia coli ATP synthase, Regions of subunit a that are exposed to the periplasmic space have been identified by a new procedure, in which cells are incubated with polymyxin B nonapeptide (PMBN), an antibiotic derivative that partially permeabilizes the outer membrane of E. coli, along with a sulfhydryl reagent, 3-(N-maleimidylpropionyl) biocytin (MPB). This procedure permits reaction of sulfhydryl groups in the periplasmic space with MPB, but residues in the cytoplasm are not labeled, Using this procedure, residues 8, 27, 37, 127, 131, 230, 231, and 232 were labeled and so are thought to be exposed in the periplasm, Using inside-out membrane vesicles, residues near the end of transmembrane spans 1, 64, 67, 68, 69, and 70 and residues near the end of transmembrane spans 5, 260, 263, and 265 were labeled. Residues 62 and 257 were not labeled. None of these residues were labeled in PMBN-permeabilized cells. These results provide a more detailed view of the transmembrane spans of subunit a and also provide a simple and reliable technique for detection of periplasmic regions of inner membrane proteins in E, coli,	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [GM40508, R01 GM040508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CAIN BD, 1989, J BIOL CHEM, V264, P3292; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7	27	67	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17353	17357		10.1074/jbc.274.24.17353	http://dx.doi.org/10.1074/jbc.274.24.17353			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358096	hybrid			2022-12-27	WOS:000080780400095
J	Bakhtiari, N; Jie, LZ; Yao, BY; Mueller, DM				Bakhtiari, N; Jie, LZ; Yao, BY; Mueller, DM			Structure function of the beta-barrel domain of F-1-ATPase in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; ATP SYNTHASE; ALPHA-SUBUNIT; CROSS-LINKING; TERMINAL REGION; DELTA-SUBUNITS; 2ND STALK; F1	The first 90 amino acids of the alpha- and beta-subunits of mitochondrial F-1-ATPase are folded into beta-barrel dor mains and were postulated to be important for stabilizing the enzyme (Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), The role of the domains was studied by making chimeric enzymes, replacing the domains from the yeast Saccharomyces cerevisiae enzyme with the corresponding domains from the enzyme of the thermophilic bacterium Bacillus PS3, The enzymes containing the chimeric alpha-, beta-, or alpha- and beta-subunits were not functional. However, gain-of-function mutations were obtained from the strain containing the enzyme with the chimeric PS3/yeast beta-subunit, The gain-of-function mutations were all in codons encoding the beta-barrel domain of the beta-subunit, and the residues appear to map out a region of subunit-subunit interactions. Gain-of-function mutations were also obtained that provided functional expression of the chimeric PS3/ yeast alpha- and beta-subunits together. Biochemical analysis of this active chimeric enzyme indicated that it was not significantly more thermostable or labile than the wild type. The results of this study indicate that the beta-barrel domains form critical contacts (distinct from those between the alpha- and beta-subunits) that are important for the assembly of the ATP synthase.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School	Mueller, DM (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Greenbay Rd, N Chicago, IL 60064 USA.	muellerd@mis.finchcms.edu			NIGMS NIH HHS [GM44412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BURKOVSKI A, 1994, BBA-BIOENERGETICS, V1186, P243, DOI 10.1016/0005-2728(94)90184-8; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Groth G, 1996, BIOCHEM J, V318, P351, DOI 10.1042/bj3180351; Hase B, 1996, FEBS LETT, V382, P171, DOI 10.1016/0014-5793(96)00167-6; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MATTEN SR, 1995, J BIOL CHEM, V270, P1489, DOI 10.1074/jbc.270.4.1489; MIKI J, 1994, ARCH BIOCHEM BIOPHYS, V312, P317, DOI 10.1006/abbi.1994.1315; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SIKORSKI RS, 1989, GENETICS, V122, P19; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; UH M, 1990, J BIOL CHEM, V265, P19047; Vaillier J, 1999, J BIOL CHEM, V274, P543, DOI 10.1074/jbc.274.1.543; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Walker JE, 1995, METHOD ENZYMOL, V260, P163, DOI 10.1016/0076-6879(95)60136-8; Xu T, 1998, EUR J BIOCHEM, V252, P155, DOI 10.1046/j.1432-1327.1998.2520155.x	41	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16363	16369		10.1074/jbc.274.23.16363	http://dx.doi.org/10.1074/jbc.274.23.16363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347195	hybrid			2022-12-27	WOS:000080668600055
J	Floer, M; Blobel, G				Floer, M; Blobel, G			Putative reaction intermediates in Crm1-mediated nuclear protein export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; VIRAL MESSENGER-RNA; RAN-BINDING-PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; ORDER CHROMOSOME STRUCTURE; VIRUS TYPE-1 AFFECTS; REV TRANS-ACTIVATOR; PORE COMPLEX; KARYOPHERIN-BETA; IMPORTIN-ALPHA	We discovered several novel interactions between proteins involved in Crm1-mediated nuclear export of the nuclear export signal containing human immunodeficiency virus type 1 protein Rev. First, a Rev/Crm1/ RanGTP complex (where Ran is Ras-related nuclear protein) reacts with some nucleoporins (Nup42 and Nup159) but not others (NSP1, Nup116, and Nup1), forming a Nup/Crm1/RanGTP complex and concomitantly releasing Rev. Second, RanBP1 (or homologous proteins) can displace Nup and form a ternary RanBP1/RanGTP/ Crm1 complex that can be disassembled by RanGAP via GTP hydrolysis. Third, and most surprisingly, RanBP1/ RanGTP/Crm1 can be disassembled without GTP hydrolysis by the nucleotide exchange factor RanGEF. Recycling of a Ran/RanGEF complex by GTP and Mg2+ is stimulated by both Crm1 and Rev, allowing reformation of a Rev/Crm1/RanGTP complex. Based on these reactions we propose a model for Crm1-mediated export.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	79	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16279	16286		10.1074/jbc.274.23.16279	http://dx.doi.org/10.1074/jbc.274.23.16279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347184	hybrid			2022-12-27	WOS:000080668600044
J	Nakajima, K; Kato, H; Oda, J; Yamada, Y; Hashimoto, T				Nakajima, K; Kato, H; Oda, J; Yamada, Y; Hashimoto, T			Site-directed mutagenesis of putative substrate-binding residues reveals a mechanism controlling the different stereospecificities of two tropinone reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPANE ALKALOIDS; HYOSCYAMUS-NIGER; CALYSTEGINES; SOLANACEAE	Two tropinone reductases (TRs) constitute a key branch point in the biosynthetic pathway of tropane alkaloids, which are mainly produced in several solanaceous plants, The two TRs share 64% identical amino acid residues and reduce the 3-carbonyl group of a common substrate, tropinone, but they produce distinct alcohol products with different stereospecific configurations. Previous x-ray crystallographic analysis has revealed their highly conserved overall folding, and the modeling of tropinone within the putative substrate-binding sites has suggested that the different stereospecificities may be determined solely by the different binding orientations of tropinone to the enzymes, In this study, we have constructed various mutant TRs, in which putative substrate-binding residues from one TR were substituted with those found in the corresponding positions of the other TR, Substitution of five amino acid residues resulted in an almost complete reversal of stereospecificity, indicating that the different stereospecificities are indeed determined by the binding orientation of tropinone, Detailed kinetic analysis of the mutant enzymes has shown that TR stereospecificity is determined by varying the contributions from electrostatic and hydrophobic interactions and that the present TR structures represent highly evolved forms, in which strict stereospecificities and rapid turnover are accomplished together.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan; Fukui Prefectural Univ, Fac Biotechnol, Matsuoka, Fukui 9101195, Japan	Nara Institute of Science & Technology; Kyoto University; Fukui Prefectural University	Nakajima, K (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.			Nakajima, Keiji/0000-0002-1580-3354; Kato, Hiroaki/0000-0002-5993-4532				Asano N, 1997, GLYCOBIOLOGY, V7, P1085, DOI 10.1093/glycob/7.8.1085; Clackson T., 1991, PCR PRACTICAL APPROA, P207; Drager B, 1995, PLANTA MED, V61, P577, DOI 10.1055/s-2006-959381; DRAGER B, 1994, PLANT CELL TISS ORG, V38, P235, DOI 10.1007/BF00033882; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; HASHIMOTO T, 1992, PLANT PHYSIOL, V100, P836, DOI 10.1104/pp.100.2.836; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; LEETE E, 1990, PLANTA MED, V56, P339, DOI 10.1055/s-2006-960979; MOLYNEUX RJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P81, DOI 10.1006/abbi.1993.1324; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; NAKAJIMA K, 1993, P NATL ACAD SCI USA, V90, P9591, DOI 10.1073/pnas.90.20.9591; NAKAJIMA K, 1993, PLANT PHYSIOL, V103, P1465, DOI 10.1104/pp.103.4.1465; NAKAJIMA K, 1994, J BIOL CHEM, V269, P11695; PORTSTEFFEN A, 1994, PHYTOCHEMISTRY, V37, P391, DOI 10.1016/0031-9422(94)85066-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEPFER D, 1988, J BACTERIOL, V170, P1153, DOI 10.1128/jb.170.3.1153-1161.1988; Yamada Y., 1990, SECONDARY PRODUCTS P, P227	17	56	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16563	16568		10.1074/jbc.274.23.16563	http://dx.doi.org/10.1074/jbc.274.23.16563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347221	hybrid			2022-12-27	WOS:000080668600081
J	DeMali, KA; Balciunaite, E; Kazlauskas, A				DeMali, KA; Balciunaite, E; Kazlauskas, A			Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGF beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE C-GAMMA; TYROSINE-PHOSPHATASE; CELL-ADHESION; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHORYLATION SITES; DEPENDENT ACTIVATION; RAS; BINDING	Since the extracellular matrix (ECM) can promote platelet-derived growth factor (PDGF)-dependent responses, we hypothesized that the ECM mediates this effect by preventing the PDGF beta receptor (beta PDGFR) from associating with the negative regulator, RasGAP (the GTPase-activating protein of Ras). We found that binding of RasGAP to the wild-type beta PDGFR was decreased; the activation of Ras and Erk was enhanced, and [H-3]thymidine uptake was better in cells cultured on fibronectin than in cells cultured on polylysine. To investigate the mechanism by which culturing cells on fibronectin diminished the recruitment of RasGAP to the beta PDGFR, we focused on SHP-2 since it dephosphorylates the beta PDGFR at the phosphotyrosine required for binding of RasGAP. Culturing cells on fibronectin increased the amount of SHP-2 that associated with the beta PDGFR. Furthermore, cells expressing receptor mutants that failed to associate with SHP-8 were insensitive to fibronectin, The ECM enhances PDGF-dependent responses by increasing the association of SHP-2 with the beta PDGFR, which in turn decreases the time that RasGAP interacts with the receptor, Thus, fibronectin changes PDGF-dependent signaling and biological responses by altering the signal relay enzymes that are recruited to the receptor.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.			DeMali, Kris/0000-0003-0906-1371	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feldmann P, 1999, MOL CELL BIOL, V19, P1928; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1988, EMBO J, V7, P3727, DOI 10.1002/j.1460-2075.1988.tb03256.x; KAZLAUSKAS A, 1986, J CELL PHYSIOL, V126, P225, DOI 10.1002/jcp.1041260211; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WENNSTROM S, 1994, ONCOGENE, V9, P651; Woodard AS, 1998, J CELL SCI, V111, P469	43	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19551	19558		10.1074/jbc.274.28.19551	http://dx.doi.org/10.1074/jbc.274.28.19551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391888	hybrid			2022-12-27	WOS:000081377300008
J	Grundhoff, AT; Kremmer, E; Turecin, O; Glieden, A; Gindorf, C; Atz, J; Mueller-Lantzsch, N; Schubach, WH; Grasser, FA				Grundhoff, AT; Kremmer, E; Turecin, O; Glieden, A; Gindorf, C; Atz, J; Mueller-Lantzsch, N; Schubach, WH; Grasser, FA			Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT MEMBRANE-PROTEIN; RBP-J-KAPPA; RNA-DEPENDENT ATPASE; BIOCHEMICAL-CHARACTERIZATION; HODGKINS-DISEASE; HELICASE GENE; POLYMERASE-II; EXPRESSION; PROMOTER; TRANSCRIPTION	The Epstein-Barr virus-encoded nuclear antigens EBNA2 and EBNA3C both interact with the cellular transcription factor RBP-JK and modulate the expression of several shared target genes, suggesting a tight cooperation in latently infected cells. In a survey for additional cellular factors that bind to EBNA2 as well as EBNA3C, we have isolated and characterized DP1031 a novel human member of the DEAD box family of putative ATP-dependent RNA helicases, The interaction with DP103 is mediated by amino acids (aa) 121-213 of EBNA2 and aa 534-778 of EBNA3C, regions that are not involved in binding of the viral proteins to RBP-JK, The DP103-cDNA encodes a protein of 824 aa that harbors all of the common DEAD box motifs, Monoclonal antibodies raised against DP103 detect a protein of 103 kDa in mammalian cells that resides in high molecular weight complexes in vivo. We have detected an ATPase activity intrinsic to or closely associated with DP103, By subcellular fractionation, we find DP103 in both a soluble nuclear fraction as well as in the insoluble skeletal fraction. Whereas the protein and its mRNA are uniformly expressed in all tested cell lines, we observed differential expression of the mRNA. in normal human tissues.	Univ Kliniken Saarlandes, Abt Virol, Inst Med Mikrobiol & Hyg, D-66421 Homburg, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Oncol, Seattle, WA 98108 USA	Universitatsklinikum des Saarlandes; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Grasser, FA (corresponding author), Univ Kliniken Saarlandes, Abt Virol, Inst Med Mikrobiol & Hyg, D-66421 Homburg, Germany.	graesser@med-rz.uni-sb.de		Grundhoff, Adam/0000-0003-0940-7045				AKAO Y, 1992, CANCER RES, V52, P6083; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; BARTEL PL, 1993, CELLULAR INTERACTION, P53; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GRASSER FA, 1994, BLOOD, V84, P3792, DOI 10.1182/blood.V84.11.3792.bloodjournal84113792; GRASSER FA, 1991, J VIROL, V65, P3779; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HILLE A, 1993, J MED VIROL, V39, P233, DOI 10.1002/jmv.1890390311; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KNUDSON DL, 1974, J VIROL, V14, P934, DOI 10.1128/JVI.14.4.934-944.1974; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; LAUX G, 1994, J VIROL, V68, P6947, DOI 10.1128/JVI.68.11.6947-6958.1994; LEROUX A, 1994, VIROLOGY, V205, P596, DOI 10.1006/viro.1994.1687; LING PD, 1995, J VIROL, V69, P1944, DOI 10.1128/JVI.69.3.1944-1950.1995; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; RANDAHL H, 1992, EUR J BIOCHEM, V207, P55, DOI 10.1111/j.1432-1033.1992.tb17019.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rhee JY, 1998, MOL CELLS, V8, P68; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	62	91	99	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19136	19144		10.1074/jbc.274.27.19136	http://dx.doi.org/10.1074/jbc.274.27.19136			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383418	hybrid			2022-12-27	WOS:000081196300041
J	Perez, RG; Soriano, S; Hayes, JD; Ostaszewski, B; Xia, WM; Selkoe, DJ; Chen, XH; Stokin, GB; Koo, EH				Perez, RG; Soriano, S; Hayes, JD; Ostaszewski, B; Xia, WM; Selkoe, DJ; Chen, XH; Stokin, GB; Koo, EH			Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR ACCUMULATION; ENDOPLASMIC-RETICULUM; LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; SORTING SIGNALS; NT2N CELLS; SURFACE; TRAFFICKING; MUTATION	It has long been assumed that the C-terminal motif, NPXY, is the internalization signal for beta-amyloid precursor protein (APP) and that the NPXY tyrosine (Tyr(743) by APP751 numbering, Tyr(682) in APP695) is required for APP endocytosis. To evaluate this tenet and to identify the specific amino acids subserving APP endocytosis, we mutated all tyrosines in the APP cytoplasmic domain and amino acids within the sequence GYENPTY (amino acids 737-743). Stable cell lines expressing these mutations were assessed for APP endocytosis, secretion, and turnover. Normal APP endocytosis was observed for cells expressing Y709A, G737A, and Y743A mutations. However, Y738A, N740A, and P741A or the double mutation of Y738A/P741A significantly impaired APP internalization to a level similar to that observed for cells lacking nearly the entire APP cytoplasmic domain (Delta C), arguing that the dominant signal for APP endocytosis is the tetrapeptide YENP, Although not an APP internalization signal, Tyr(743) regulates rapid APP turnover because half-life increased by 50% with the Y743A mutation alone. Secretion of the APP-derived proteolytic fragment, A beta, was tightly correlated with APP internalization, such that A beta secretion was unchanged for cells having normal APP endocytosis but significantly decreased for endocytosis-deficient cell lines. Remarkably, secretion of the A beta 42 isoform was also reduced in parallel with endocytosis from internalization-deficient cell lines, suggesting an important role for APP endocytosis in the secretion of this highly pathogenic A beta species.	Allegheny Univ Hlth Sci, Dept Psychiat, Pittsburgh, PA 15212 USA; Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, Pittsburgh, PA 15212 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Perez, RG (corresponding author), 125 George St, Turtle Creek, PA 15145 USA.	perez@pitt.edu	Perez, Ruth G./AAK-9844-2020; xia, weiming/E-5465-2016; Stokin, Gorazd Bernard/D-9480-2015; Perez, Ruth/A-7388-2009	xia, weiming/0000-0002-7463-3295; Stokin, Gorazd Bernard/0000-0001-8430-8755; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012376, R01AG006173, RF1AG006173, R37AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG012376, AG06173, AG12376] Funding Source: Medline; NINDS NIH HHS [NS01812] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GUENETTE S, 1998, NEUROBIOL AGING, V19, pS72; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jung SS, 1996, J NEUROSCI RES, V46, P336, DOI 10.1002/(SICI)1097-4547(19961101)46:3<336::AID-JNR7>3.3.CO;2-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P407; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Selkoe DJ, 1996, COLD SPRING HARB SYM, V61, P587; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yamazaki T, 1996, J CELL SCI, V109, P999; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	56	344	349	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18851	18856		10.1074/jbc.274.27.18851	http://dx.doi.org/10.1074/jbc.274.27.18851			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383380	hybrid			2022-12-27	WOS:000081196300003
J	Butz, S; Fernandez-Chacon, R; Schmitz, F; Jahn, R; Sudhof, TC				Butz, S; Fernandez-Chacon, R; Schmitz, F; Jahn, R; Sudhof, TC			The subcellular localizations of atypical synaptotagmins III and VI - Synaptotagmin III is enriched in synapses and synaptic plasma membranes but not in synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; PROTEINS; DOMAIN; ISOFORM; CELLS; BRAIN; CA2+; COMPONENTS; NEUREXINS	Multiple synaptotagmins are expressed in brain, but only synaptotagmins I and II have known functions in fast, synchronous Ca2+-triggered neurotransmitter release. Synaptotagmin III was proposed to regulate other aspects of synaptic vesicle exocytosis, particularly its slow component. Such a function predicts that synaptotagmin IU. should be an obligatory synaptic vesicle protein, as would also be anticipated from its high homology to synaptotagmins I and II. To test this hypothesis, we studied the distribution, developmental expression, and localization of synaptotagmin III and its closest homolog, synaptotagmin VI. We find that synaptotagmins III and VI are present in all brain regions in heterogeneous distributions and that their levels increase during development in parallel with synaptogenesis, Furthermore, we show by immunocytochemistry that synaptotagmin III is concentrated in synapses, as expected, Surprisingly, however, we observed that synaptotagmin III is highly enriched in synaptic plasma membranes but not in synaptic vesicles. Synaptotagmin VI was also found to be relatively excluded from synaptic vesicles. Our data suggest that synaptotagmins III and VI perform roles in neurons that are not linked to synaptic vesicle exocytosis but to other Ca2+-related nerve terminal events, indicating that the functions of synaptotagmins are more diverse than originally thought.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Max Planck Inst Biophys Chem, Abt Neurobiol, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Jahn, Reinhard/0000-0003-1542-3498; Fernandez-Chacon, Rafael/0000-0002-9845-9885				Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; Daly C, 1997, J NEUROSCI, V17, P2365; Dowling J. E., 1987, RETINA; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NAGY A, 1976, BRAIN RES, V109, P285, DOI 10.1016/0006-8993(76)90531-X; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Thompson CC, 1996, J NEUROSCI, V16, P7832; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859	40	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18290	18296		10.1074/jbc.274.26.18290	http://dx.doi.org/10.1074/jbc.274.26.18290			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373432	hybrid			2022-12-27	WOS:000081056700024
J	Cunningham, SA; Tran, TM; Arrate, MP; Brock, TA				Cunningham, SA; Tran, TM; Arrate, MP; Brock, TA			Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase - A real time kinetic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; LIGAND-BINDING; CRYSTAL-STRUCTURE; FLT-1 RECEPTOR; IN-VIVO; VEGF; IDENTIFICATION; DIMERIZATION; KDR	The kinase insert domain-containing receptor (KDR) tyrosine kinase mediates calcium mobilization in endothelial cells and plays a key role during physiological and pathological angiogenesis, To provide a detailed understanding of how KDR is activated, we analyzed the kinetics of ligand-receptor interaction using BIAcore. Both predimerized (KDR-Fc) and monomeric (KDR-cbu) receptors were examined with vascular endothelial cell growth factor (VEGF) homodimers and VEGF/placental growth factor (PIGF) heterodimers. VEGF binds to KDR-Fc with k(a) = 3.6 +/- 0.07e(6), k(d) = 1.54 +/- 0.19e(-4), and K-D = 37.1 +/- 4.9 pM. These values are similar to those displayed by monomeric KDR where k(a) = 5.23 +/- 1.4e(6), k(d) = 2.74 +/- 0.76e(-4), and KD = 51.7 +/- 5.8 pM were apparent. In contrast, VEGF/PIGF bound to KDR-Fc with k(a) = 7.3 +/- 1.6e(4), k(d) = 4.4 +/- 1.2e(-4), and K-D = 6 +/- 1.2 nM. Thus, the heterodimer displays a 160-fold reduced K-D for binding to predimerized KDR, which is mainly a consequence of a 50-fold reduction in k(a). We were unable to detect association between VEGF/PIGF and monomeric KDR. However, nanomolar concentrations of VEGF/ PIGF were able to elicit weak calcium mobilization in endothelial cells. This latter observation may indicate partial predimerization of KDR on the cell surface or facilitation of binding due to accessory receptors.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Integrat Biol Physiol & Pharmacol, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, Suite 1920,7000 Fannin, Houston, TX 77030 USA.	scunningham@tbc.com						Barleon B, 1997, J BIOL CHEM, V272, P10382; BIACORE AB, 1997, BIAEVALUATION; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COA Y, 1996, J BIOL CHEM, V271, P3154; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong TAT, 1999, CANCER RES, V59, P99; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; PARK JE, 1994, J BIOL CHEM, V269, P25646; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sugihara T, 1998, J BIOL CHEM, V273, P3033, DOI 10.1074/jbc.273.5.3033; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tanaka K, 1997, JPN J CANCER RES, V88, P867, DOI 10.1111/j.1349-7006.1997.tb00463.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	41	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18421	18427		10.1074/jbc.274.26.18421	http://dx.doi.org/10.1074/jbc.274.26.18421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373449	hybrid			2022-12-27	WOS:000081056700041
J	Mathus, A; Bajaj, SP				Mathus, A; Bajaj, SP			Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa - Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	12th Symposium of the Protein-Society	JUL 25-29, 1998	SAN DIEGO, CALIFORNIA	Protein Soc			COAGULATION FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CA2+-BINDING SITE; FACTOR-X ACTIVATION; BLOOD-COAGULATION; HEMOPHILIA-B; TISSUE FACTOR; ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY	Previous studies revealed that cleavage at Arg-318-Ser-319 in the protease domain autolysis loop of factor Ma results in its diminished binding to factor VIIIa. Now, we have investigated the importance of adjacent surface-exposed helix 330-338 (162-170 in chymotrypsin numbering) of IX in its interaction with VIIIa, IXWT, eight point mutants mostly based on hemophilia B patients, and a replacement mutant (IXhelixVII in which helix 330-338 is replaced by that of factor VII) were expressed, purified, and characterized. Each mutant was activated normally by VIIa-tissue factor-Ca2+ or XIa-Ca2+, However, in both the presence and absence of phospholipid, interaction of each activated mutant with VIIIa was impaired. The role of IX EGF1 domain in binding to VIIIa was also examined, Two mutants (IXQ50P and IXPCEGF1, in which EGF1 domain is replaced by that of protein C) were used. Strikingly, interactions of the activated EGF1 mutants with VIIIa were impaired only in the presence of phospholipid. We conclude that helix 330 in Ma provides a critical binding site for VIIIa and that the EGF1 domain in this context primarily serves to correctly position the protease domain above the phospholipid surface for optimal interaction with VIIIa.	St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University	Bajaj, SP (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med, 3635 Vista Ave & Grand Blvd,POB 15250, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R55HL036365, R01HL036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED SS, 1995, BIOCHEM J, V310, P427; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BAJAJ SP, 1999, IN PRESS THROMB HAEM; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; Chang JL, 1998, J BIOL CHEM, V273, P12089, DOI 10.1074/jbc.273.20.12089; Chang JL, 1998, BLOOD, V92, p184A; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FRAZIER D, 1989, BLOOD, V74, P971; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LIN SW, 1990, J BIOL CHEM, V265, P144; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; LUDWIG M, 1992, BLOOD, V79, P1225; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mathur A, 1998, BLOOD, V92, p352A; MATHUR A, 1998, PROTEIN SCI S1, V7, P135; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SPITZER SG, 1990, BLOOD, V76, P1530; SPITZER SG, 1990, BIOCHEM J, V265, P219, DOI 10.1042/bj2650219; USHARANI P, 1985, J CLIN INVEST, V75, P76, DOI 10.1172/JCI111700; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	53	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18477	18486		10.1074/jbc.274.26.18477	http://dx.doi.org/10.1074/jbc.274.26.18477			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373456	hybrid			2022-12-27	WOS:000081056700048
J	Yohannan, J; Wienands, J; Coggeshall, KM; Justement, LB				Yohannan, J; Wienands, J; Coggeshall, KM; Justement, LB			Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ANTIGEN RECEPTOR; CD22-DEFICIENT MICE; NEGATIVE REGULATOR; PHOSPHATASE 1C; IG-BETA; ACTIVATION; KINASE; SYK; ASSOCIATION	The B cell-restricted transmembrane glycoprotein CD22 is rapidly phosphorylated on tyrosine in response to cross-linking of the B cell antigen receptor, thereby generating phosphotyrosine motifs in the cytoplasmic domain which recruit intracellular effector proteins that contain Src homology 2 domains. By virtue of its interaction with these effector proteins CD22 modulates signal transduction through the B cell antigen receptor. To define further the molecular mechanism by which CD22 mediates its co-receptor function, phosphopeptide mapping experiments were conducted to determine which of the six tyrosine residues in the cytoplasmic domain are involved in recruitment of the stimulatory effector proteins phospholipase C gamma (PLC gamma), phosphoinositide 3-kinase (PI3K), Grb2, and Syk. The results obtained indicate that the protein tyrosine kinase Syk interacts with multiple CD22-derived phosphopeptides in both immunoprecipitation and reverse Far Western assays. In contrast, the Grb2.Sos complex was observed to bind exclusively to the fourth phosphotyrosine motif ((YENV)-E-828) from CD22 and does so via a direct interaction based on Far Western and reverse Far Western blotting. Although both PLC gamma and PI3K were observed to bind to multiple phosphopeptides in precipitation experiments, subsequent studies using reverse Far Western blot analysis demonstrated that only the carboxyl-terminal phosphopeptide of CD22 ((YVTL)-V-868) binds directly to either one. This finding suggests that PLC gamma and PI3K may be recruited to CD22 either through a direct interaction with Tyr(868) Or indirectly through an association with one or more intermediate proteins.	Univ Alabama Birmingham, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Medical Branch Galveston; University System of Ohio; Ohio State University; Max Planck Society	Justement, LB (corresponding author), Univ Alabama Birmingham, Wallace Tumor Inst 378, Div Dev & Clin Immunol, Birmingham, AL 35294 USA.	louis.justement@ccc.uab.edu		Justement, Louis/0000-0001-7058-867X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Erickson LD, 1996, INT IMMUNOL, V8, P1121, DOI 10.1093/intimm/8.7.1121; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Methot N, 1996, MOL CELL BIOL, V16, P5328; Nadler MJS, 1997, J IMMUNOL, V159, P4233; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Stoddart A, 1997, INT IMMUNOL, V9, P1571, DOI 10.1093/intimm/9.10.1571; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Tuscano J, 1996, BLOOD, V87, P4723, DOI 10.1182/blood.V87.11.4723.bloodjournal87114723; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; WIENANDS J, 1995, INT IMMUNOL, V7, P1701, DOI 10.1093/intimm/7.11.1701; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	47	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18769	18776		10.1074/jbc.274.26.18769	http://dx.doi.org/10.1074/jbc.274.26.18769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373493	hybrid			2022-12-27	WOS:000081056700085
J	Luo, Y; Zhou, Y; Cooperman, BS				Luo, Y; Zhou, Y; Cooperman, BS			Antichymotrypsin interaction with chymotrypsin - Intermediates on the way to inhibited complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SERPIN-PROTEASE COMPLEXES; REACTIVE CENTER LOOP; SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; PROTEINASE COMPLEX; SERINE PROTEINASE; MICHAELIS COMPLEX; HEPARIN-BINDING; HINGE REGION	Serpins form enzymatically inactive covalent complexes (designated E*I*) with their target proteinases, corresponding most likely to the acyl enzyme that resembles the normal intermediate in substrate turnover. Formation of E*I* involves large changes in the conformation of the reactive center loop (residues P17 to P9') and of the serpin molecule in general. The "hinge" region of the reactive center loop, including residues P10-P14, shows facile movement in and out of beta-sheet A, and this movement appears to be crucial in determining whether E*I* is formed (the inhibitor pathway) or whether I is rapidly hydrolyzed to I* (the substrate pathway). Here, we report stopped-flow and rapid quench studies investigating the pH dependence of the conversion of the alpha(1)-antichymotrypsin.alpha-chymotrypsin encounter complex, E.I, to E*I*. These studies utilize fluorescent derivatives of cysteine variants of cu,antichymotrypsin at the P11 and P13 residues. Our results demonstrate three identifiable intermediates, EIa, EIb, and EIc, between E.I and E*I* and permit informed speculation regarding the nature of these intermediates. Partitioning between inhibitor and substrate pathways occurs late in the process of E*I* formation, most likely from a species occurring between EIc and E*I*.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P9487; Bjork I, 1998, BIOCHEM J, V335, P701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrell R, 1997, THROMB HAEMOSTASIS, V78, P516; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; FINK AL, 1979, P NATL ACAD SCI USA, V76, P1566, DOI 10.1073/pnas.76.4.1566; FINK AL, 1976, BIOCHEMISTRY-US, V15, P1580, DOI 10.1021/bi00652a031; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gils A, 1998, BBA-PROTEIN STRUCT M, V1387, P291, DOI 10.1016/S0167-4838(98)00139-3; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Janciauskiene S, 1998, J BIOL CHEM, V273, P28360, DOI 10.1074/jbc.273.43.28360; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KATZ DS, 1993, PROTEIN ENG, V6, P701, DOI 10.1093/protein/6.7.701; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIEBERMAN J, 1995, NEUROBIOL AGING, V16, P747, DOI 10.1016/0197-4580(95)00056-K; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCALIA R, 1995, SHOCK, V4, P251, DOI 10.1097/00024382-199510000-00004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Shrikumar A, 1998, J BIOL CHEM, V273, P17459, DOI 10.1074/jbc.273.28.17459; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, ADV EXP MED BIOL, V425, P5; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; ZHONG JQ, 1996, THESIS U PENNSYLVANI	50	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17733	17741		10.1074/jbc.274.25.17733	http://dx.doi.org/10.1074/jbc.274.25.17733			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364215	hybrid			2022-12-27	WOS:000080974300051
J	Mitchell, RA; Metz, CN; Peng, T; Bucala, R				Mitchell, RA; Metz, CN; Peng, T; Bucala, R			Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF) - Regulatory role in cell proliferation and glucocorticoid action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; N-TERMINAL KINASE; NEURITE OUTGROWTH; CYCLIC-AMP; PHOSPHORYLATION; A(2); CALCIUM; FORSKOLIN; INDUCTION	Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory mediator with the unique ability to counter-regulate the inhibitory effects of glucocorticoids on immune cell activation. MIF is released from cells in response to glucocorticoids,certain pro-inflammatory stimuli, and mitogens and acts to regulate glucocorticoid action on the ensuing inflammatory response. To gain insight into the molecular mechanism of MIF action, we have examined the role of MIF in the proliferation and intracellular signaling events of the well characterized, NIH/3T3 fibroblast cell line. Both endogenously secreted and exogenously added MIFs stimulate the proliferation of NIH/3T3 cells, and this response is associated with the activation of the p44/p42 extracellular signal-regulated (ERK) mitogen-activated protein kinases (MAP). The MIF-induced activation of these kinases was sustained for a period of at least 24 h and was dependent upon protein kinase A activity. We further show that MIF regulates cytosolic phospholipase Az activity via a protein kinase A and ERK dependent pathway and that the glucocorticoid suppression of cytokine-induced cytoplasmic phospholipase A2 activity and arachidonic acid release can be reversed by the addition of recombinant MIF. These studies indicate that the sustained activation of p44/p42 MAP kinase and subsequent arachidonate release by cytoplasmic phospholipase A2 are important features of the immunoregulatory and intracellular signaling events initiated by MIF and provide the first insight into the mechanisms that underlie the pro-proliferative and inflammatory properties of this mediator.	Picower Inst Med Res, Manhasset, NY 10030 USA; Albany Med Coll, Dept Expt Pathol, Albany, NY 12208 USA	Northwell Health; Albany Medical College	Bucala, R (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 10030 USA.	rbucala@picower.edu		Christine, Metz/0000-0002-1013-1691	NIAID NIH HHS [1R01 AI42310-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042310] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 1996, J EXP MED, V183, P277, DOI 10.1084/jem.183.1.277; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Freeman EJ, 1998, AM J PHYSIOL-CELL PH, V274, pC282, DOI 10.1152/ajpcell.1998.274.1.C282; GALLI C, 1995, J NEUROSCI, V15, P1172; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Meinhardt A, 1996, ENDOCRINOLOGY, V137, P5090, DOI 10.1210/en.137.11.5090; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Spada A, 1997, HORM RES, V47, P235, DOI 10.1159/000185469; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240	45	379	412	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18100	18106		10.1074/jbc.274.25.18100	http://dx.doi.org/10.1074/jbc.274.25.18100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364264	hybrid			2022-12-27	WOS:000080974300100
J	Steitz, TA				Steitz, TA			DNA polymerases: Structural diversity and common mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; 3'-5' EXONUCLEASE; KLENOW FRAGMENT; RNA-POLYMERASE; ACTIVE-SITE; REPLICATION; COMPLEX		Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Steitz, TA (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009					BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG WM, 1972, J BIOL CHEM, V247, P7663; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1781; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PELLETIER H, 1994, SCIENCE, V264, P1981; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6468; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2	29	659	714	5	78	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17395	17398		10.1074/jbc.274.25.17395	http://dx.doi.org/10.1074/jbc.274.25.17395			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364165	hybrid			2022-12-27	WOS:000080974300001
J	Joester, A; Faissner, A				Joester, A; Faissner, A			Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INSITU LOCALIZATION; EMBRYONIC-TISSUES; SPLICE VARIANTS; CELL-ADHESION; GROWTH-FACTOR; ADULT-MOUSE; III REPEAT; EXPRESSION; PROTEIN	The extracellular matrix glycoprotein tenascin-C (TN-C) displays a restricted and developmentally regulated distribution in the mouse central nervous system. Defined modules of the molecule have been shown to mediate specific functions, such as neuron migration, neurite outgrowth, cell adhesion, and cell proliferation. The smallest TN-C form contains a stretch of eight fibronectin type III (FNIII) domains, which are common to all TN-C isoforms, Unrestricted and independent alternative splicing of six consecutive FNIII cassettes between the fifth and sixth constitutive FNIII domain bears the potential to generate 64 different combinations that might code for TN-C proteins with subtly different functions. To explore TN-C isoform variability in mouse brain, the alternatively spliced region of TN-C mRNAs was examined by the reverse transcription-polymerase chain reaction technique. Polymerase chain reaction products of uniform size were subcloned and analyzed using domain-specific probes to reveal the expression of particular combinations of alternatively spliced FNIII domains. 27 TN-C isoforms were identified to be expressed in mouse central nervous system, of which 22 are novel. Furthermore, during development, specific TN-C isoforms were found to occur in distinct relative frequencies, as demonstrated for isoforms containing two alternatively spliced FNIII domains. We conclude that TN-C is expressed in a complex and regulated pattern in mouse central nervous system. These findings highlight the potential role of TN-C in mediating specific neuron glia interactions.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; CNRS, Ctr Neurochim, UPR 1352, Lab Neurobiol Dev & Regenerat, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Faissner, A (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				Altman J., 1982, CEREBELLUM NEW VISTA, V47, P8; BARTSCH S, 1992, J NEUROSCI, V12, P736; BARTSCH U, 1994, J NEUROSCI, V14, P4756; BARTSCH U, 1992, EUR J NEUROSCI, V4, P338, DOI 10.1111/j.1460-9568.1992.tb00881.x; Borsi L, 1996, INT J CANCER, V66, P632, DOI 10.1002/(SICI)1097-0215(19960529)66:5<632::AID-IJC9>3.0.CO;2-U; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; Derr LB, 1997, DIFFERENTIATION, V62, P71, DOI 10.1046/j.1432-0436.1997.6220071.x; DORRIES U, 1994, J NEUROSCI RES, V37, P336, DOI 10.1002/jnr.490370306; Dorries U, 1996, J NEUROSCI RES, V43, P420; Engel J, 1991, CURR OPIN CELL BIOL, V3, P779, DOI 10.1016/0955-0674(91)90050-9; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1996, TENASCIN COUNTERADHE, P47; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; KAPLONY A, 1991, DEVELOPMENT, V112, P605; MEINERS S, 1993, DEV BIOL, V160, P480, DOI 10.1006/dbio.1993.1322; Mighell AJ, 1997, INT J CANCER, V72, P236, DOI 10.1002/(SICI)1097-0215(19970717)72:2<236::AID-IJC6>3.0.CO;2-S; MIRAGALL F, 1992, MICROSC RES TECHNIQ, V23, P157, DOI 10.1002/jemt.1070230206; MITROVIC N, 1994, J NEUROCYTOL, V23, P364, DOI 10.1007/BF01666526; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NIES DE, 1991, J BIOL CHEM, V266, P2818; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RETTIG WJ, 1992, BRAIN RES, V590, P219, DOI 10.1016/0006-8993(92)91099-Z; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; SRIRAMARAO P, 1993, NUCLEIC ACIDS RES, V21, P163, DOI 10.1093/nar/21.1.163; TUCKER RP, 1993, DEVELOPMENT, V117, P347; TUCKER RP, 1993, J CELL SCI, V104, P69; VRUCINICFILIPI N, 1993, SYM SOC EXP BIOL, V47, P155; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; ZHAO Y, 1995, AM J PHYSIOL-LUNG C, V268, pL173, DOI 10.1152/ajplung.1995.268.2.L173	37	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17144	17151		10.1074/jbc.274.24.17144	http://dx.doi.org/10.1074/jbc.274.24.17144			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358070	hybrid			2022-12-27	WOS:000080780400069
J	Kumar, S; Hand, AT; Connor, JR; Dodds, RA; Ryan, PJ; Trill, JJ; Fisher, SM; Nuttall, ME; Lipshutz, DB; Zou, C; Hwang, SM; Votta, BJ; James, IE; Rieman, DJ; Gowen, M; Lee, JC				Kumar, S; Hand, AT; Connor, JR; Dodds, RA; Ryan, PJ; Trill, JJ; Fisher, SM; Nuttall, ME; Lipshutz, DB; Zou, C; Hwang, SM; Votta, BJ; James, IE; Rieman, DJ; Gowen, M; Lee, JC			Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; VEIN ENDOTHELIAL-CELLS; IN-VITRO; INDUCIBLE GENE; TUMOR-GROWTH; BONE-CELLS; EXPRESSION; CYR61; FAMILY; PRODUCT	We have identified and cloned a novel connective tissue growth factor-like (CTGF-L) cDNA from primary human osteoblast cells encoding a 250-amino acid single chain polypeptide, Murine CTGF-L cDNA, encoding a polypeptide of 251 amino acids, was obtained from a murine lung cDNA library. CTGF-L protein bears significant identity (similar to 60%) to the CCN (CTGF, Cef10/Cyr61, Nov) family of proteins. CTGF-L is composed of three distinct domains, an insulin-like growth factor binding domain, a von Willebrand Factor type C motif, and a thrombospondin type I repeat. However, unlike CTGF, CTGF-L lacks the C-terminal domain implicated in dimerization and heparin binding. CTGF-L mRNA (similar to 1.3 kilobases) is expressed in primary human osteoblasts, fibroblasts, ovary, testes, and heart, and a similar to 26-kDa protein is secreted from primary human osteoblasts and fibroblasts, In situ hybridization indicates high expression in osteoblasts forming bone, discrete alkaline phosphatase positive bone marrow cells, and chondrocytes, Specific binding of I-125-labeled insulin-like growth factors to CTGF-L was demonstrated by ligand Western blotting and cross-linking experiments, Recombinant human CTGF-L promotes the adhesion of osteoblast cells and inhibits the binding of fibrinogen to integrin receptors, In addition, recombinant human CTC;F-L inhibits osteocalcin production in rat osteoblast-like Ros 17/2.8 cells. Taken together, these results suggest that CTGF-L may play an important role in modulating bone turnover.	SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Kumar, S (corresponding author), SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, UW2109,709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Ryan, Patrick/HDO-1133-2022					ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; ASUBEL MF, 1987, CURRENT PROTOCOLS MO; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221-8747(84)90064-X; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; CANOVER CA, 1996, PRINCIPLES BONE BIOL, P607; Dodds RA, 1998, J BONE MINER RES, V13, P673, DOI 10.1359/jbmr.1998.13.4.673; DODDS RA, 1995, J BONE MINER RES, V10, P1666; DODDS RA, 1998, METHODS BONE BIOL, P198; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Marks Sandy C. Jr., 1996, P3; Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Prabhakar U, 1998, CALCIFIED TISSUE INT, V63, P214, DOI 10.1007/s002239900517; Reddi AH, 1997, CELL, V89, P159, DOI 10.1016/S0092-8674(00)80193-2; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Schutze N, 1998, ENDOCRINOLOGY, V139, P1761, DOI 10.1210/en.139.4.1761; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; Wong A, 1996, MOL PHARMACOL, V50, P529; Ying ZT, 1996, GENE, V171, P243, DOI 10.1016/0378-1119(95)00891-8; Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	40	92	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17123	17131		10.1074/jbc.274.24.17123	http://dx.doi.org/10.1074/jbc.274.24.17123			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358067	hybrid			2022-12-27	WOS:000080780400066
J	Wang, HX; Lawrence, CW; Li, GM; Hays, JB				Wang, HX; Lawrence, CW; Li, GM; Hays, JB			Specific binding of human MSH2 center dot MSH6 mismatch-repair protein heterodimers to DNA incorporating thymine- or uracil-containing UV light photoproducts opposite mismatched bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONREPLICATING PHAGE DNA; ESCHERICHIA-COLI; MUTS-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSLOCATION MECHANISM; TUMOR-CELLS; CIS-SYN; RECOMBINATION; SYSTEM; GENES	Previous studies have demonstrated recognition of DNA-containing UV light photoproducts by bacterial (Feng, W,-Y., Lee, E., and Hays, J.B. (1991) Genetics 129, 1007-1020) and human (Mu, D., Tursun, M., Duckett, D, R., Drummond, J.T., Modrich, P., and Sancar, A. (1997) Mol. Cell. Biol. 17, 760-769) long-patch mismatch-repair systems. Mismatch repair directed specifically against incorrect bases inserted during semi-conservative DNA replication might efficiently antagonize UV mutagenesis. To test this hypothesis, DNA 51-mers containing site-specific T-T cis-syn-cyclobutane pyrimidine-dimers or T-T pyrimidine-(6-4')pyrimidinone photoproducts, with all four possible bases opposite the respective 3'-thymines in the photoproducts, were analyzed for the ability to compete with radiolabeled (T/G)-mismatched DNA for binding by highly purified human MSH2 . MSHG heterodimer protein (hMutS alpha). Both (cyclobutane-dimer)/AG and ((6-4)photoproduct)/AG mismatches competed about as well as non-photoproduct T/T mismatches. The two respective pairs of photoproduct/(A(T or C)) mismatches also showed higher hMutS alpha affinity than photoproduct/AA "matches"; the apparent affinity of hMutS alpha for the ((6 - 4)photoproduct)/AA"matched" substrate was actually less than that for TT/AA homoduplexes. Surprisingly, although hMutS alpha affinities for both non-photoproduct UU/GG double mismatches and for (uracil-cyclobutane-dimer)/AG single mismatches were high, affinity for the (uracil-cyclobutane-dimer)/GG mismatch was quite low. Equilibrium binding of hMutS alpha to DNA containing (photoproduct/base) mismatches and to (T/G)-mismatched DNA was reduced similarly by ATP (in the absence of magnesium).	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Univ Rochester, Med Ctr, Dept Biophys & Biochem, Rochester, NY 14642 USA; Univ Kentucky, Med Ctr, Dept Pathol, Lexington, KY 40536 USA	Oregon State University; University of Rochester; University of Kentucky	Hays, JB (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R29CA072956] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ELLINGTON A, 1994, CURRENT PROTOCOL MOL; FANG WH, 1993, J BIOL CHEM, V268, P11838; FENG WY, 1995, GENETICS, V140, P1175; FENG WY, 1991, GENETICS, V129, P1007; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES, P545; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; KORNBERG A, 1992, DNA REPLICATION, P497; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Li GM, 1996, J BIOL CHEM, V271, P24084, DOI 10.1074/jbc.271.39.24084; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; REENAN A, 1992, GENETICS, V148, P1667; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; Umar A, 1998, GENETICS, V148, P1637	44	91	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16894	16900		10.1074/jbc.274.24.16894	http://dx.doi.org/10.1074/jbc.274.24.16894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358035	hybrid			2022-12-27	WOS:000080780400034
J	Yang, W; Freedman, LP				Yang, W; Freedman, LP			20-epi analogues of 1,25-dihydroxyvitamin D-3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; DIFFERENTIATION; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; TRANSACTIVATION; INHIBITION; INTERACTS; INDUCTION	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) plays a major role in the stimulation of bone growth, mineralization, and intestinal calcium and phosphate absorption; it also acts as a general inhibitor of cellular proliferation. Several new, clinically relevant compounds dissociate antiproliferative and calcemic activities of 1,25(OH)(2)D-3, but the molecular basis for this has not been clearly elucidated. Here, we tested whether the potency of one class of compounds, 20-epi analogues, to induce myeloid cell differentiation, is because of direct molecular effects on vitamin D receptor (VDR). We report that two 20-epi analogues, MC1627 and MC1288, induced differentiation and transcription of p21(WAf1,Cip1), a key VDR target gene involved in growth inhibition, at a concentration 100-fold lower than that of 1,25(OH)(2)D-3. We compared this sensitivity to analogue effects on VDR interacting proteins: RXR, GRIP-I, and DRIP205, a subunit of the DRIP coactivator complex. Compared with the interaction of VDR with RXR or GRIP-1, the differentiation dose-response most closely correlated to the ligand dependent recruitment of the DRIP coactivator complex to VDR and to the ability of the receptor to activate transcription in a cell-free system. These results provide compelling links between the efficiency of the 20-epi analogue in inducing VDR/DRIP interactions, transactivation in vitro, and its enhanced ability to induce cellular differentiation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Freedman, LP (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA08748] Funding Source: Medline; NIDDK NIH HHS [DK07313, DK45460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045460, R37DK045460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DELUCA HF, 1981, HARVEY LECT, V75, P333; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILWORTH FJ, 1994, BIOCHEM PHARMACOL, V47, P987; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HONMA Y, 1983, P NATL ACAD SCI-BIOL, V80, P201, DOI 10.1073/pnas.80.1.201; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MELLANY E, 1919, LANCET, V2, P407; NISHII Y, 1991, VITAMIN D, P289; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OLSSON I, 1983, CANCER RES, V43, P5862; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryhanen S, 1998, J CELL BIOCHEM, V70, P414, DOI 10.1002/(SICI)1097-4644(19980901)70:3<414::AID-JCB14>3.0.CO;2-K; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	33	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16838	16845		10.1074/jbc.274.24.16838	http://dx.doi.org/10.1074/jbc.274.24.16838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358028	hybrid			2022-12-27	WOS:000080780400027
J	Easwaran, V; Song, V; Polakis, P; Byers, S				Easwaran, V; Song, V; Polakis, P; Byers, S			The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; APC GENE-PRODUCT; NEGATIVE REGULATOR; MOLECULAR MECHANISM; COLORECTAL TUMORS; SOMATIC MUTATIONS; XENOPUS EMBRYOS; AXIS FORMATION; INTACT-CELLS	The tumor suppressor function of the adenomatous polyposis coli protein (APC) depends, in part, on its ability to bind and regulate the multifunctional protein, beta-catenin. beta-Catenin binds the high mobility group box transcription factors, lymphocyte enhancer-binding factor (LEF) and T-cell factor, to directly regulate gene transcription. Using LEF reporter assays we find that APC-mediated down-regulation of beta-catenin-LEF signaling is reversed by proteasomal inhibitors in a dose-dependent manner. APC down-regulates signaling induced by wild type beta-catenin but not by the non-ubiquitinatable S37A mutant, beta-catenin, Bisindoylmaleimide type protein kinase C inhibitors, which prevent beta-catenin ubiquitination, decrease the ability of APC to down-regulate beta-catenin-LEF signaling. All these effects on LEF signaling are paralleled by changes in beta-catenin protein levels, Lithium, an inhibitor of glycogen synthase kinase-3 beta, does not alter the ability of APC to down-regulate beta-catenin protein and beta-catenin-LEF signaling in the colon cancer cells that were tested. These results point to a role for beta-catenin ubiquitination, proteasomal degradation, and potentially a serine kinase other than glycogen synthase kinase-3 beta in the tumor-suppressive actions of APC.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20007 USA; Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	Georgetown University	Byers, S (corresponding author), E415 Res Bldg,GUMC,8970 Reservoir Rd NW, Washington, DC 20007 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Fukuchi T, 1998, CANCER RES, V58, P3526; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gumbiner B, 1997, CURR OPIN CELL BIOL, V7, P634; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; MIKI Y, 1991, JPN J CANCER RES, V82, P1003, DOI 10.1111/j.1349-7006.1991.tb01935.x; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Y, 1998, CANCER RES, V58, P2524; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Palacios J, 1998, CANCER RES, V58, P1344; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yang LM, 1997, CANCER RES, V57, P4652; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	57	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16641	16645		10.1074/jbc.274.23.16641	http://dx.doi.org/10.1074/jbc.274.23.16641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347231	hybrid			2022-12-27	WOS:000080668600091
J	Hughes, TA; La Boissiere, S; O'Hare, P				Hughes, TA; La Boissiere, S; O'Hare, P			Analysis of functional domains of the host cell factor involved in VP16 complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; OCTAMER-BINDING PROTEINS; IMMEDIATE EARLY GENE; POU-DOMAIN; TRANSCRIPTION FACTORS; CONFORMATIONAL ALTERATION; VP16-INDUCED COMPLEX; THYMIDINE KINASE; DNA-SEQUENCES; OCT-1	We present biochemical analyses of the regions of the host cell factor (HCF) involved in VP16 complex formation and in the association between the N- and C-terminal domains of HCF itself. We show that the kelch repeat region of HCF (residues 1-380) is sufficient for VP16 complex formation, but that residues C-terminal to the repeats (positions 381-450) interfere with this activity. However, these latter residues are required for the interaction between the N- and C-terminal regions of HCF. The extreme C-terminal region of HCF, corresponding to an area of strong conservation with a Caenorhabditis elegans homologue, is sufficient for interaction with the N-terminal region. These results are discussed with respect to possible differences in the roles of HCF in VP16 activity versus its normal cellular function.	The Chart, Marie Curie Res Inst, Surrey RH8 0TL, England		O'Hare, P (corresponding author), The Chart, Marie Curie Res Inst, Surrey RH8 0TL, England.		Hughes, Thomas/M-7063-2019; Hughes, Thomas A/O-8031-2015	Hughes, Thomas A/0000-0003-1169-3386				APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; Ford E, 1997, J BIOL CHEM, V272, P16048, DOI 10.1074/jbc.272.25.16048; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; Huang CC, 1996, MOL CELL BIOL, V16, P2967; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; Misra V, 1996, MOL CELL BIOL, V16, P4404; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1984, J VIROL, V50, P708, DOI 10.1128/JVI.50.3.708-716.1984; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16437	16443		10.1074/jbc.274.23.16437	http://dx.doi.org/10.1074/jbc.274.23.16437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347205	hybrid			2022-12-27	WOS:000080668600065
J	Park, HY; Perez, JM; Laursen, R; Hara, M; Gilchrest, BA				Park, HY; Perez, JM; Laursen, R; Hara, M; Gilchrest, BA			Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING HORMONE; PLATINUM C(P) MUTATION; CYCLIC-AMP; DIFFERENTIAL EXPRESSION; MAMMALIAN TYROSINASE; INDUCED PIGMENTATION; HUMAN MELANOGENESIS; CELLS; DIACYLGLYCEROL; PURIFICATION	We have previously shown that protein kinase C-beta (PKC-beta) is required for activation of tyrosinase (Park, H. Y,, Russakovsky, V., Ohno, S., and Gilchrest, B. A. (1993) J. Biol. Chem. 268, 11742-11749), the rate-limiting enzyme in melanogenesis, We now examine its mechanism of activation in human melanocytes. lit vivo phosphorylation experiments revealed that tyrosinase is phosphorylated through the PKC-dependent pathway and that introduction of PKC-beta into nonpigmented human melanoma cells lacking PKC-beta lead to the phosphorylation and activation of tyrosinase. Preincubation of intact melanosomes with purified active PKC-beta in vitro increased tyrosinase activity S-fold. By immunoelectron microscopy, PKC-beta but not PRC-alpha was closely associated with tyrosinase on the outer surface of melanosomes. Western blot analysis confirmed the association of PKC-beta with melanosomes. Only the cytoplasmic (extra-melanosomal) domain of tyrosinase, which contains two serines but no threonines, was phosphorylated by the serine/threonine kinase PKC-beta. These two serines at positions 505 and 509 both are present in the C-terminal peptide generated by trypsin digestion of tyrosinase. Go-migration experiments comparing synthetic peptide standards of all three possible phosphorylated tryptic peptides, a diphosphopeptide and two monophosphopeptides, to tyrosinase-phosphorylated in intact melanocytes by PKC-beta and then subjected to trypsin digestion revealed that both serine residues are phosphorylated by PKC-beta. We conclude that PKC-beta activates tyrosinase directly by phosphorylating serine residues at positions 505 and 509 in the cytoplasmic domain of this melanosome-associated protein.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA	Boston University; Boston University	Park, HY (corresponding author), Boston Univ, Sch Med, Dept Dermatol, J206,80 E Concord St, Boston, MA 02118 USA.	hypark@acs.bu.edu			NCI NIH HHS [R01 CA 72763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ALLAN AE, 1995, J INVEST DERMATOL, V105, P687, DOI 10.1111/1523-1747.ep12324466; Ao Y, 1998, EXP CELL RES, V244, P117, DOI 10.1006/excr.1998.4086; Atherton E., 1990, SOLID PHASE PEPTIDE; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; Hopfer U., 1992, TXB BIOCH CLIN CORRE, P1059; IMOKAWA G, 1982, CANCER RES, V42, P1994; ITO S, 1998, PIGMENTARY SYSTEM PH, P33; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; KING RA, 1993, PIGMENTATION PIGMENT, P297; KORNER A, 1977, NATURE, V267, P444, DOI 10.1038/267444a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI MS, 1990, CARCINOGENESIS, V11, P229, DOI 10.1093/carcin/11.2.229; MCLEOD SD, 1995, J ENDOCRINOL, V146, P439, DOI 10.1677/joe.0.1460439; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OETTING WS, 1998, PIGMENTARY SYSTEM PH, P231; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ORLOW SJ, 1993, J INVEST DERMATOL, V101, P137, DOI 10.1111/1523-1747.ep12363621; ORLOW SJ, 1994, J INVEST DERMATOL, V103, P196, DOI 10.1111/1523-1747.ep12392743; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; PARK HY, 1993, J BIOL CHEM, V268, P11742; Park HY, 1999, J INVEST DERMATOL, V112, P540; Park HY, 1996, EXP CELL RES, V227, P70, DOI 10.1006/excr.1996.0251; PARK HY, 1994, J INVEST DERMATOL, V102, P440; PARK HY, 1996, J CUTAN MED SURG, V1, P4; PAWELEK J, 1975, P NATL ACAD SCI USA, V72, P951, DOI 10.1073/pnas.72.3.951; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; Salopek TG, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P195; SEIJI M, 1961, J INVEST DERMATOL, V36, P243, DOI 10.1038/jid.1961.42; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; UENO Y, 1995, INT J PEPT PROT RES, V46, P106; VIJAYAN E, 1982, ARCH BIOCHEM BIOPHYS, V217, P738, DOI 10.1016/0003-9861(82)90555-0; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; WOLF M, 1984, BIOCHEM BIOPH RES CO, V122, P1268, DOI 10.1016/0006-291X(84)91229-4; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAAR M, 1991, J INVEST DERMATOL, V97, P611, DOI 10.1111/1523-1747.ep12482985; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105	54	117	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16470	16478		10.1074/jbc.274.23.16470	http://dx.doi.org/10.1074/jbc.274.23.16470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347209	hybrid			2022-12-27	WOS:000080668600069
J	Allan, BW; Garcia, R; Maegley, K; Mort, J; Wong, D; Lindstrom, W; Beechem, JM; Reich, NO				Allan, BW; Garcia, R; Maegley, K; Mort, J; Wong, D; Lindstrom, W; Beechem, JM; Reich, NO			DNA bending by EcoRI DNA methyltransferase accelerates base flipping but compromises specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; S-ADENOSYLMETHIONINE; TARGET BASE; METHYLASE; ENZYME; RECOGNITION; COFACTOR; BINDING; COMPLEX; MECHANISM	EcoRI DNA methyltransferase was previously shown to bend its cognate DNA sequence by 52 degrees and stabilize the target adenine in an extrahelical orientation. We describe the characterization of an EcoRI DNA methyltransferase mutant in which histidine 235 was selectively replaced with asparagine. Steady-state kinetic and thermodynamic parameters for the H235N mutant revealed only minor functional consequences: DNA binding affinity (K-D(DNA)) was reduced 10-fold, and k(cat) was decreased 30%. However, in direct contrast to the wild type enzyme, DNA bending within the mutant enzyme-DNA complexes was not observed by scanning force microscopy, The bending-deficient mutant showed enhanced discrimination against the methylation at nontarget sequence DNA. This enhancement of enzyme discrimination was accompanied by a change in the rate-limiting catalytic step. No presteady-state burst of product formation was observed, indicating that the chemistry step (or prior event) had become rate-limiting for methylation. Direct observation of the base flipping transition showed that the lack of burst kinetics was entirely due to slower base flipping. The combined data show that DNA bending contributes to the correct assembly of the enzyme-DNA complex to accelerate base flipping and that slowing the rate of this precatalytic isomerization can enhance specificity.	Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; Vanderbilt University; University of California System; University of California Santa Barbara	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.							Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Fersht A., 1985, ENZYME STRUCTURE MEC; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; HACKNEY DD, 1990, ENZYMES, V19, P1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sawa R., 1995, NATURE, V373, P487; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SMITH DW, 1992, NUCLEIC ACIDS RES, V20, P6091, DOI 10.1093/nar/20.22.6091; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228; WINKLER FK, 1994, STRUCTURE, V2, P79, DOI 10.1016/S0969-2126(00)00009-5; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645	33	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19269	19275		10.1074/jbc.274.27.19269	http://dx.doi.org/10.1074/jbc.274.27.19269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383435	hybrid			2022-12-27	WOS:000081196300058
J	Belting, M; Petersson, P				Belting, M; Petersson, P			Intracellular accumulation of secreted proteoglycans inhibits cationic lipid-mediated gene transfer - Co-transfer of glycosaminoglycans to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-PROMOTER SPERMINE; DNA-LIPOSOME COMPLEXES; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; ANTIPROLIFERATIVE ACTIVITY; CYSTIC-FIBROSIS; MAMMALIAN-CELLS; HUMAN-MELANOMA; IN-VITRO	Molecules secreted by potential target cells may interfere with cationic lipid-mediated gene transfer. This has been studied using human lung fibroblasts and human epidermoid lung cancer cells. Secreted cell medium components caused a substantial decrease both in the uptake of cationic lipid-DNA complexes (2-4-fold) and in reporter gene expression (100-1000-fold). Metabolic labeling of the cell medium showed that especially [S-35]sulfate-labeled macromolecules competed with DNA for binding to the cationic lipid. Release of DNA from the cationic lipid by cell medium components was demonstrated by an ethidium bromide intercalation assay. In the presence of the cationic lipid, the secreted macromolecules were internalized by the cells. By enzymatic digestions, it was shown that the competing macromolecules consist of chondroitin/dermatan sulfate and heparan sulfate proteoglycans and that the effects on transfection were mediated by the polyanionic glycosaminoglycan portion of the proteoglycan. Accordingly, pretreatment of cell medium with the polycationic peptide protamine sulfate abrogated the inhibitory effects on gene transfer. Fluorescence microscopy studies revealed that heparan sulfate, internalized as a complex with cationic lipids, accumulated in the cell nuclei. These results support the view that the lack of specificity of this type of gene transfer vehicle is a major hindrance to efficient and safe in vivo administration.	Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, S-22100 Lund, Sweden	Lund University	Belting, M (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, POB 94, S-22100 Lund, Sweden.		Petersson, Per/A-5740-2010; Petersson, Per/P-1878-2019	Petersson, Per/0000-0001-6697-0171; Petersson, Per/0000-0001-6697-0171; Belting, Mattias/0000-0003-1585-5434				Anderson WF, 1998, NATURE, V392, P25; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BELTING M, 1993, GLYCOCONJUGATE J, V10, P453, DOI 10.1007/BF00737966; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHENG F, 1992, GLYCOBIOLOGY, V2, P553, DOI 10.1093/glycob/2.6.553; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COHEN IR, 1994, CANCER RES, V54, P5771; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Escriou V, 1998, BBA-BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005-2736(97)00194-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu L, 1997, DISTRIB PARALLEL DAT, V5, P167, DOI 10.1023/A:1008641408566; LORIES V, 1987, J BIOL CHEM, V262, P854; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Nabel GJ, 1996, P NATL ACAD SCI USA, V93, P15388, DOI 10.1073/pnas.93.26.15388; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; QUAHABI AE, 1997, FEBS LETT, V414, P187; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reimer DL, 1997, J BIOL CHEM, V272, P19480, DOI 10.1074/jbc.272.31.19480; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P289, DOI 10.1042/bj2650289; SIE P, 1989, THROMB RES, V54, P63, DOI 10.1016/0049-3848(89)90337-X; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZHOU XH, 1991, BIOCHIM BIOPHYS ACTA, V1065, P8, DOI 10.1016/0005-2736(91)90003-Q	48	37	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19375	19382		10.1074/jbc.274.27.19375	http://dx.doi.org/10.1074/jbc.274.27.19375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383450	hybrid			2022-12-27	WOS:000081196300073
J	Beuret, N; Rutishauser, J; Bider, MD; Spiess, M				Beuret, N; Rutishauser, J; Bider, MD; Spiess, M			Mechanism of endoplasmic reticulum retention of mutant vasopressin precursor caused by a signal peptide truncation associated with diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPHYSIN-II GENE; CRYSTAL-STRUCTURE; INTERNAL SIGNAL; CLEAVAGE SITES; CELL-LINE; IDENTIFICATION; MUTATION; KINDREDS; SEQUENCE; SUBSTITUTION	Autosomal dominant neurohypophyseal diabetes insipidus is caused by mutations in the gene encoding the vasopressin precursor protein, prepro-vasopressin-neurophysin II. We analyzed the molecular consequences of a mutation (Delta G227) recently identified in a Swiss kindred that destroys the translation initiation codon, In COS-7 cells transfected with the mutant cDNA, translation was found to initiate at an alternative ATG, producing a truncated signal sequence that was functional for targeting and translocation but was not cleaved by signal peptidase, The mutant precursor was completely retained within the endoplasmic reticulum. The uncleaved signal did not affect folding of the neurophysin portion of the precursor, as determined by its protease resistance. However, formation of disulfide-linked aggregates indicated that it interfered with the formation of the disulfide bond in vasopressin, most likely by blocking its insertion into the hormone binding site of neurophysin. Preventing disulfide formation in the vasopressin nonapeptide by mutation of cysteine 6 to serine was shown to be sufficient to cause aggregation and retention. These results indicate that the Delta G227 mutation induces translation of a truncated signal sequence that cannot be cleaved but prevents correct folding and oxidation of vasopressin, thereby causing precursor aggregation and retention in the endoplasmic reticulum.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Kantonsspital, Dept Med, CH-6000 Luzern 16, Switzerland	University of Basel; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital	Spiess, M (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	spiess@ubaclu.unibas.ch		Spiess, Martin/0000-0001-7139-0550				BAYLIS PH, 1981, POSTGRAD MED J, V57, P36, DOI 10.1136/pgmj.57.663.36; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; Calvo B, 1998, J CLIN ENDOCR METAB, V83, P995, DOI 10.1210/jc.83.3.995; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Deeb R, 1996, BIOCHEMISTRY-US, V35, P864, DOI 10.1021/bi951947u; Ellermann M, 1939, ACTA PSYCH NEUROL, V14, P233, DOI 10.1111/j.1600-0447.1939.tb06638.x; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FORSSMAN H, 1945, ACTA MED SCANDINAV S, V159, P1; Gagliardi PC, 1997, J CLIN ENDOCR METAB, V82, P3643, DOI 10.1210/jc.82.11.3643; Gaupp R, 1941, Z GESAMTE NEUROL PSY, V171, P514, DOI 10.1007/BF02880551; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; HANHART E, 1940, HDB ERBBIOLOGIE ME 2, V4, P798; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; KAPLOWITZ PB, 1982, J PEDIATR-US, V100, P76, DOI 10.1016/S0022-3476(82)80238-2; LEVINGER EL, 1955, J CLIN ENDOCR METAB, V15, P547, DOI 10.1210/jcem-15-5-547; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Olias G, 1996, DNA CELL BIOL, V15, P929, DOI 10.1089/dna.1996.15.929; PEDERSEN EB, 1985, Q J MED, V57, P883; Rittig S, 1996, AM J HUM GENET, V58, P107; RITTIG S, 1993, VASOPRESSIN, P600; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; Ueta Y, 1996, J CLIN ENDOCR METAB, V81, P1787, DOI 10.1210/jc.81.5.1787; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WESSELS HP, 1991, METHOD CELL BIOL, V34, P287	42	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18965	18972		10.1074/jbc.274.27.18965	http://dx.doi.org/10.1074/jbc.274.27.18965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383395	hybrid			2022-12-27	WOS:000081196300018
J	Burke, JR; Witmer, MR; Zusi, FC; Gregor, KR; Davern, LB; Padmanabha, R; Swann, RT; Smith, D; Tredup, JA; Micanovic, R; Manly, SP; Villafranca, JJ; Tramposch, KM				Burke, JR; Witmer, MR; Zusi, FC; Gregor, KR; Davern, LB; Padmanabha, R; Swann, RT; Smith, D; Tredup, JA; Micanovic, R; Manly, SP; Villafranca, JJ; Tramposch, KM			Competitive, reversible inhibition of cytosolic phospholipase A(2) at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELETS; SCOOTING MODE; CELL-LINE; CATALYSIS; MEMBRANES; MECHANISM; VESICLES; BINDING; PHOSPHORYLATION; ACTIVATION	Cytosolic phospholipase A(2) (cPL(2)) catalyzes the selective release of arachidonic acid from the sn-2 position of phospholipids and is believed to play a key cellular role in the generation of arachidonic acid. When assaying the human recombinant cPLA(2) using membranes isolated from [H-3] arachidonate-labeled U937 cells as substrate, 2-(2'-benzyl-4-chlorophenoxy)ethyl-dimethyl-n-octadecyl-ammonium chloride (compound 1) was found to inhibit the enzyme in a dose-dependent manner (IC50 = 5 mu M). It was over 70 times more selective for the cPLA(2) as compared with the human nonpancreatic se creted phospholipase A(2), and it did not inhibit other phospholipases, Additionally, it inhibited arachidonate production in N-formyl-methionyl-leucyl-phenylalanine-stimulated U937 cells. To further characterize the mechanism of inhibition, an assay in which the enzyme is bound to vesicles of 1,2-dimyristoyl-sn-glycero-3-phosphomethanol containing 6-10 mol % of 1-palmitoyl-2-[1-C-14]arachidonoyl-sn-glycero-3-phosphocholine was employed. With this substrate system, the dose-dependent inhibition could be defined by kinetic equations describing competitive inhibition at the lipid-water interface. The apparent equilibrium dissociation constant for the inhibitor bound to the enzyme at the interface (K-I(*app)) was determined to be 0.097 +/- 0.032 mol % versus an apparent dissociation constant for the arachidonate-containing phospholipid of 0.3 +/- 0.1 mol %. Thus, compound 1 represents a novel structural class of inhibitor of cPLA(2) that partitions into the phospholipid bilayer and competes with the phospholipid substrate for the active site. Shorter n-alkyl-chained (C-4, C-6, C-8) derivatives of compound 1 were shown to have even smaller K-I(*app) values. However, these short-chained analogs were less potent in terms of bulk inhibitor concentration needed for inhibition when using the [H-3]arachidonate-labaled U937 membranes as substrate. This discrepancy was reconciled by showing that these shorter-chained analogs did not partition into the [H-3]arachidonate-labeled U937 membranes as effectively as compound 1. The implications for in vivo efficacy that result from these findings are discussed.	Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Buffalo, NY 14213 USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, Wallingford, CT 06492 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Burke, JR (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Drug Discovery Res, POB 4000, Princeton, NJ 08543 USA.	burkej@bms.com						Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BASSOLINOKLIMAS D, 1993, BIOCHEMISTRY-US, V32, P12624, DOI 10.1021/bi00210a010; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Burke JR, 1997, BBA-PROTEIN STRUCT M, V1341, P223, DOI 10.1016/S0167-4838(97)00085-X; Burke JR, 1997, BIOCHEMISTRY-US, V36, P6854, DOI 10.1021/bi975006o; Burke JR, 1997, ARCH BIOCHEM BIOPHYS, V341, P177, DOI 10.1006/abbi.1997.9974; BURKE JR, 1995, BIOCHEMISTRY-US, V34, P15165, DOI 10.1021/bi00046a024; BURKE JR, 1995, J BIOL CHEM, V270, P274, DOI 10.1074/jbc.270.1.274; BURKE JR, IN PRSS ARCH BIOCH B; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1992, J BIOL CHEM, V267, P18342; GELB MH, 1992, BIOORG MED CHEM LETT, V2, P1335, DOI 10.1016/S0960-894X(00)80508-9; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HERBETTE LG, 1994, NEUROPHARMACOLOGY, V33, P241, DOI 10.1016/0028-3908(94)90015-9; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11319, DOI 10.1021/bi00093a008; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; MORING J, 1994, BIOPHYS J, V67, P2376, DOI 10.1016/S0006-3495(94)80724-6; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; PARASASSI T, 1995, BIOPHYS J, V68, P1895, DOI 10.1016/S0006-3495(95)80367-X; RAGHUPATHI R, 1987, FASEB J, V46, P1945; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TRAMPOSCH KM, 1992, BIOCHEM BIOPH RES CO, V189, P272, DOI 10.1016/0006-291X(92)91554-4; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; Verger R, 1980, Methods Enzymol, V64, P340; WHEATLEY WB, 1950, J AM CHEM SOC, V72, P5575, DOI 10.1021/ja01168a059; WHEATLEY WB, 1949, J AM CHEM SOC, V71, P64, DOI 10.1021/ja01169a018; Yu Lin, 1992, Bioorganic and Medicinal Chemistry Letters, V2, P1343; 1955, Patent No. 2703324	43	7	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18864	18871		10.1074/jbc.274.27.18864	http://dx.doi.org/10.1074/jbc.274.27.18864			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383382	hybrid			2022-12-27	WOS:000081196300005
J	Iozzo, RV				Iozzo, RV			The biology of the small leucine-rich proteoglycans - Functional network of interactive proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							KERATAN SULFATE PROTEOGLYCAN; GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; CORE PROTEIN; EXTRACELLULAR-MATRIX; I COLLAGEN; EPIPHYSEAL CARTILAGE; TARGETED DISRUPTION; MOLECULAR-CLONING; GENE-EXPRESSION		Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 JAH, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Huttenlocher A, 1996, MATRIX BIOL, V15, P239, DOI 10.1016/S0945-053X(96)90115-8; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; Kadler KE, 1996, BIOCHEM J, V316, P1; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kurita K, 1996, BIOCHEM J, V318, P909, DOI 10.1042/bj3180909; NEAME PJ, 1989, PROTEOGLYCANS STRUCT; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; PLAAS AHK, 1993, J BIOL CHEM, V268, P26634; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT JE, 1995, J ANAT, V187, P259; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Tasheva ES, 1997, J BIOL CHEM, V272, P32551, DOI 10.1074/jbc.272.51.32551; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	51	529	549	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18843	18846		10.1074/jbc.274.27.18843	http://dx.doi.org/10.1074/jbc.274.27.18843			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383378	hybrid			2022-12-27	WOS:000081196300001
J	Mouz, N; Di Guilmi, AM; Gordon, E; Hakenbeck, R; Dideberg, O; Vernet, T				Mouz, N; Di Guilmi, AM; Gordon, E; Hakenbeck, R; Dideberg, O; Vernet, T			Mutations in the active site of penicillin-binding protein PBP2x from Streptococcus pneumoniae - Role in the specificity for beta-lactam antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE; GENES; 2X; TRANSPEPTIDASE; CEPHALOSPORINS; IDENTIFICATION; PURIFICATION; RELATEDNESS; BACTERIA; CLONES	Penicillin-binding protein 2x (PBP2x) isolated from clinical beta-lactam-resistant strains of Streptococcus pneumoniae (R-PBP2x) have a reduced affinity for beta-lactam antibiotics. Their transpeptidase domain carries numerous substitutions compared with homologous sequences from beta-lactam-sensitive streptococci (S-PBP2x), Comparison of R-PBP2x sequences suggested that the mutation Gln(552) --> Glu is important for resistance development. Mutants selected in the laboratory with cephalosporins frequently contain a mutation Thr(550) --> Ala, The high resolution structure of a complex between S-PBP2x* and cefuroxime revealed that Gln(552) and Thr(550), which belong to strand beta 3, are in direct contact with the cephalosporin. We have studied the effect of alterations at positions 552 and 550 in soluble S-PBP2x (S-PBP2x*) expressed in Escherichia coli. Mutation Q552E lowered the acylation efficiency for both penicillin G and cefotaxime when compared with S-PBP2x*. We propose that the introduction of a negative charge in strand beta 3 conflicts with the negative charge of the beta-lactam. Mutation T550A lowered the acylation efficiency of the protein for cefotaxime but not for penicillin G, The in vitro data presented here are in agreement with the distinct resistance profiles mediated by these mutations in vivo and underline their role as powerful resistance determinants.	CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; Univ Kaiserslautern, Dept Microbiol, D-67663 Kaiserslautern, Germany	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern	Vernet, T (corresponding author), CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	vernet@ibs.fr	Vernet, Thierry/G-1118-2012	Gordon, Elspeth Jane/0000-0002-9876-8020				COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; Di Guilmi AM, 1998, J BACTERIOL, V180, P5652, DOI 10.1128/JB.180.21.5652-5659.1998; DOWSON CG, 1989, MOL MICROBIOL, V3, P95, DOI 10.1111/j.1365-2958.1989.tb00108.x; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; Hakenbeck R, 1998, J BACTERIOL, V180, P1831, DOI 10.1128/JB.180.7.1831-1840.1998; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JAMIN M, 1993, FEBS LETT, V331, P101, DOI 10.1016/0014-5793(93)80305-E; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELL CM, 1993, FEMS MICROBIOL LETT, V106, P171; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; LAIBLE G, 1992, EUR J BIOCHEM, V207, P943, DOI 10.1111/j.1432-1033.1992.tb17128.x; MARTIN C, 1992, EMBO J, V11, P3831, DOI 10.1002/j.1460-2075.1992.tb05475.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; MUNOZ R, 1992, MOL MICROBIOL, V6, P2461; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Potgieter E, 1995, MICROB DRUG RESIST, V1, P35, DOI 10.1089/mdr.1995.1.35; Reichmann P, 1997, J INFECT DIS, V176, P1001, DOI 10.1086/516532; SIBOLD C, 1994, MOL MICROBIOL, V12, P1013, DOI 10.1111/j.1365-2958.1994.tb01089.x; Sifaoui F, 1996, ANTIMICROB AGENTS CH, V40, P152, DOI 10.1128/AAC.40.1.152; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; SOUGAKOFF W, 1989, GENE, V78, P339, DOI 10.1016/0378-1119(89)90236-9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; WISE EM, 1965, P NATL ACAD SCI USA, V54, P75, DOI 10.1073/pnas.54.1.75; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	30	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19175	19180		10.1074/jbc.274.27.19175	http://dx.doi.org/10.1074/jbc.274.27.19175			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383423	hybrid			2022-12-27	WOS:000081196300046
J	Muren, EM; Suciu, D; Topping, TB; Kumamoto, CA; Randall, LL				Muren, EM; Suciu, D; Topping, TB; Kumamoto, CA; Randall, LL			Mutational alterations in the homotetrameric chaperone SecB that implicate the structure as dimer of dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; EXPORT; LIGANDS; SPECIFICITY; PEPTIDE	Variant forms of SecB with substitutions of aminoacyl residues in the region from 74 to 80 were analyzed with respect to their ability to bind a physiological ligand, precursor galactose-binding protein, and to their oligomeric states. SecBL75Q and SecBE77K are tetramers with affinity for ligand indistinguishable from that of the wild-type SecB, and thus the export defect exhibited by strains producing these variants must result from an effect on interactions between SecB and other components. SecBF74I is tetrameric but binds ligand with a lower affinity. Substitutions at positions 76, 78, and 80 cause a shift in the equilibrium so that the SecB tetramer dissociates into dimers. We conclude that the tetramer is a dimer of dimers and that the residues Cys(76), Val(78), and Gln(80) must be involved either directly or indirectly in forming the interface between dimers. These variant species are defective in binding ligand; however, because their oligomeric state is altered no conclusion can be drawn concerning the direct role of these residues in ligand binding.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Washington State University; Tufts University	Randall, LL (corresponding author), Washington State Univ, Dept Biochem & Biophys, POB 644660, Pullman, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36415, GM29298] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLIER DN, 1993, ADV PROTEIN CHEM, V44, P151, DOI 10.1016/S0065-3233(08)60567-7; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; KIMSEY HH, 1995, J BIOL CHEM, V270, P22831, DOI 10.1074/jbc.270.39.22831; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; Miller J. H., 1972, EXPT MOL GENETICS, P431; MORGAN DG, 1993, J BACTERIOL, V175, P133, DOI 10.1128/JB.175.1.133-140.1993; Randall LL, 1998, PROTEIN SCI, V7, P2384, DOI 10.1002/pro.5560071115; Randall LL, 1998, METHOD ENZYMOL, V290, P444, DOI 10.1016/S0076-6879(98)90037-4; Randall LL, 1998, PROTEIN SCI, V7, P1195, DOI 10.1002/pro.5560070514; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Smith VF, 1996, PROTEIN SCI, V5, P488; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; Topping TB, 1997, J BIOL CHEM, V272, P19314, DOI 10.1074/jbc.272.31.19314; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	20	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19397	19402		10.1074/jbc.274.27.19397	http://dx.doi.org/10.1074/jbc.274.27.19397			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383453	hybrid			2022-12-27	WOS:000081196300076
J	Navarro, P; Valverde, AM; Benito, M; Lorenzo, M				Navarro, P; Valverde, AM; Benito, M; Lorenzo, M			Activated Ha-ras induces apoptosis by association with phosphorylated Bcl-2 in a mitogen-activated protein kinase-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; NERVE GROWTH-FACTOR; BROWN ADIPOCYTES; INDUCED DIFFERENTIATION; GENE-EXPRESSION; CELL-LINES; IN-VITRO; INHIBITION; PATHWAY; FIBROBLASTS	Serum deprivation of Ha-ras-transformed brown adipocyte cell line resulted in a dramatic apoptotic cell death, as detected either by DNA laddering or by an increase in the percentage of hypodiploid cells or by nuclei condensation and fragmentation, as compared with immortalized cell line or primary fetal brown adipocytes, Moreover, transient transfection of immortalized brown adipocytes with a constitutively active ras gene (Ha-ras(lys12)) mimics the high rate of apoptosis detected in the transformed cell line. On the other hand, transient transfection of the dominant-negative construct of raf-l rescued serum-deprived Ha-ras-transformed brown adipocytes from apoptosis, decreasing the percentage of hypodiploid cells, the external display of phosphatidylserine, and the DNA laddering. However, inhibition of mitogen-activated protein kinase with PD098059 did not preclude apoptosis and in fact increased the rate of apoptosis observed in serum-deprived Ha-ras-transformed cells, indicating that the Ras/Raf-1 pathway induced apoptosis throughout a mitogen-activated protein kinase kinase 1 (MEK-1)-independent pathway. Furthermore, apoptosis in Ha-ras-transformed brown adipocytes is concurrent with an up-regulation in the expression of the pro-apoptotic protein Bcl-xS, the expression of the anti-apoptotic protein Bcl-2 being down-regulated. Finally, an association of Ras and Raf with phosphorylated Bcl-2 protein was demonstrated in immunoprecipitates from apoptotic cells. Thus, we propose a mechanism of apoptosis in Ha-ras-transformed adipocytes under serum deprivation involving Raf-1 association with phosphorylated Bcl-2, down-regulation of Bcl-2 expression, and up-regulation of Bcl-xS expression.	Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Lorenzo, M (corresponding author), Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain.		Benito, Manuel/J-5637-2014	Benito, Manuel/0000-0002-7218-406X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BENITO M, 1993, EXP CELL RES, V209, P248, DOI 10.1006/excr.1993.1308; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN CY, 1995, BIOCHEM BIOPH RES CO, V273, P16700; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DIJESO B, 1995, BIOCHEM BIOPH RES CO, V214, P819, DOI 10.1006/bbrc.1995.2360; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; JIMENEZ B, 1995, ONCOGENE, V10, P811; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; Lorenzo M, 1996, CELL GROWTH DIFFER, V7, P1251; LYONS AB, 1992, CYTOMETRY, V13, P809; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, BIOCHEM BIOPH RES CO, V234, P616, DOI 10.1006/bbrc.1997.6641; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V201, P500, DOI 10.1006/bbrc.1994.1730; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; Valverde AM, 1998, EXP CELL RES, V243, P274, DOI 10.1006/excr.1998.4154; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; WANG CY, 1995, MAT PROCESSING COMPU, V2, P129; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	35	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18857	18863		10.1074/jbc.274.27.18857	http://dx.doi.org/10.1074/jbc.274.27.18857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383381	hybrid			2022-12-27	WOS:000081196300004
J	Nishikawa, A; Nanda, A; Gregory, W; Frenz, J; Kornfeld, S				Nishikawa, A; Nanda, A; Gregory, W; Frenz, J; Kornfeld, S			Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PROTEIN RECOGNITION DETERMINANTS; LYSINE-BASED STRUCTURE; PROCATHEPSIN-D; OLIGOSACCHARIDES; RESIDUES; VARIANTS; MEDIATE	We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A, Gregory, W,, Frenz, J,, Cacia, J,, and Kornfeld, S, (1997) J, Biol, Chem. 272, 19408-19412), We now demonstrate that murine DNase I, which contains Lys(27) and Lys(74), is phosphorylated only 20.9% when expressed in the same COS-1 cell system. This difference is mostly due to the absence of three residues present in bovine DNase I (Tyr(54), Lys(124), and Ser(190)) along with the presence of a valine at position 23 that is absent in the bovine species. We show that Val(23) inhibits phosphorylation at the Asn(18) glycosylation site, whereas Tyr(54), Lys(124), and Ser(190) enhance phosphorylation at the Asn(106) glycosylation site. Tyr(54) and Ser(190) are widely separated from each other and from Asn(106) on the surface of DNase I, indicating that residues present over a broad area influence the interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase which is responsible for the formation of mannose 6-phosphate residues on lysosomal enzymes.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Okayama Univ Sci, Dept Biochem, Okayama 700, Japan; Genentech Inc, S San Francisco, CA 94080 USA	Washington University (WUSTL); Okayama University of Science; Roche Holding; Genentech	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.		Nishikawa, Atsushi/E-6766-2013	Nishikawa, Atsushi/0000-0003-4325-1160	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CACIA J, 1995, GLYCOBIOLOGY, V4, P99; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; Pan CQ, 1998, J BIOL CHEM, V273, P18374, DOI 10.1074/jbc.273.29.18374; Pan CQ, 1998, J BIOL CHEM, V273, P11701, DOI 10.1074/jbc.273.19.11701; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; Schierau A, 1999, J BIOL CHEM, V274, P3651, DOI 10.1074/jbc.274.6.3651; SINICROPI D, 1994, ANAL BIOCHEM, V222, P351, DOI 10.1006/abio.1994.1502; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; WORRALL AF, 1990, J BIOL CHEM, V265, P21889	23	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19309	19315		10.1074/jbc.274.27.19309	http://dx.doi.org/10.1074/jbc.274.27.19309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383441	hybrid			2022-12-27	WOS:000081196300064
J	Ron, D; Napolitano, EW; Voronova, A; Vasquez, NJ; Roberts, DN; Calio, BL; Caothien, RH; Pettiford, SM; Wellik, S; Mandac, JB; Kauvar, LM				Ron, D; Napolitano, EW; Voronova, A; Vasquez, NJ; Roberts, DN; Calio, BL; Caothien, RH; Pettiford, SM; Wellik, S; Mandac, JB; Kauvar, LM			Direct interaction in T-cells between theta PKC and the tyrosine kinase p59fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; C-THETA; ANTIGEN RECEPTOR; BINDING-PROTEIN; ACTIVATION; FYN; FAMILY; PHOSPHORYLATION; LYMPHOCYTES	The protein kinase C (PKC) family has been clearly implicated in T-cell activation as have several nonreceptor protein-tyrosine kinases associated with the T-cell receptor, including p59fyn. This report demonstrates that theta PKC and p59fyn specifically interact in vitro, in the yeast two-hybrid system, and in T-cells, Further indications of direct interaction are that p59fyn potentiates theta PKC catalytic activity and that theta PKC is a substrate for tyrosine phosphorylation by p59fyn. This interaction may account for the localization of theta PKC following T-cell activation, pharmacological disruption of which results in specific cell-signaling defects. The demonstration of a physical interaction between a PKC and a protein-tyrosine kinase expands the class of PKC-anchoring proteins (receptors for activated C kinases (RACKs)) and demonstrates a direct connection between these two major T-cell-signaling pathways.	Telik Inc, S San Francisco, CA 94080 USA		Kauvar, LM (corresponding author), Telik Inc, S San Francisco, CA 94080 USA.							Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; Entschladen F, 1997, J IMMUNOL, V159, P3203; Fusaki N, 1996, J IMMUNOL, V156, P1369; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kauvar LM, 1998, J CHROMATOGR B, V715, P93, DOI 10.1016/S0378-4347(98)00045-0; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; MarieCardine A, 1995, EUR J IMMUNOL, V25, P3290, DOI 10.1002/eji.1830251214; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; Meller N, 1996, MOL CELL BIOL, V16, P5782; Mochly-Rosen D, 1998, FASEB J, V12, P35; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; RIGLEY K, 1995, J IMMUNOL, V154, P1136; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; Szamel M, 1998, J IMMUNOL, V160, P2207; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	43	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19003	19010		10.1074/jbc.274.27.19003	http://dx.doi.org/10.1074/jbc.274.27.19003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383400	hybrid			2022-12-27	WOS:000081196300023
J	Sugita, S; Janz, R; Sudhof, TC				Sugita, S; Janz, R; Sudhof, TC			Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; LONG-TERM POTENTIATION; TYROSINE KINASE INHIBITORS; NEUROTRANSMITTER RELEASE; SYNAPTOPHYSIN; RAB3A; DEFINES; SYNAPTOPORIN; HIPPOCAMPUS; PP60(C-SRC)	Synaptogyrins constitute a family of synaptic vesicle proteins of unknown function. With the full-length structure of a new brain synaptogyrin isoform, we now show that the synaptogyrin family in vertebrates includes two neuronal and one ubiquitous isoform. All of these synaptogyrins are composed of a short conserved N-terminal cytoplasmic sequence, four homologous transmembrane regions, and a variable cytoplasmic C-terminal tail that is tyrosine-phosphorylated. The localization, abundance, and conservation of synaptogyrins suggest a function in exocytosis, To test this, we employed a secretion assay in PC12 cells expressing transfected human growth hormone (hGH) as a reporter protein, When Ca2+-dependent hGH secretion from PC12 cells was triggered by high K+ or alpha-latrotoxin, co-transfection of all synaptogyrins with hGH inhibited hGH exocytosis as strongly as co-transfection of tetanus toxin light chain. Synaptophysin I, which is distantly related to synaptogyrins, was also inhibitory but less active. Inhibition was independent of the amount of hGH expressed but correlated with the amount of synaptogyrin transfected. Inhibition of exocytosis was not observed with several other synaptic proteins, suggesting specificity. Analysis of the regions of synaptogyrin required for inhibition revealed that the conserved N-terminal domain of synaptogyrin is essential for inhibition, whereas the long C-terminal cytoplasmic tail is largely dispensable. Our results suggest that synaptogyrins are conserved components of the exocytotic apparatus, which function as regulators of Ca2+-dependent exocytosis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Janz, Roger/0000-0002-9872-0596; Sugita, Shuzo/0000-0002-9182-873X	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABE K, 1993, BRAIN RES, V621, P167, DOI 10.1016/0006-8993(93)90315-E; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHUNG S, 1995, J BIOL CHEM, V269, P32717; ESHKIND LG, 1995, CELL TISSUE RES, V282, P423, DOI 10.1007/s004410050493; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Graham ME, 1997, J NEUROCHEM, V69, P2369; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MARQUEZE-POUEY B, 1991, J NEUROSCI, V11, P3388; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELLER RH, 1995, NEURON, V14, P893; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WICKPW, 1993, J BIOL CHEM, V268, P10988; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	40	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18893	18901		10.1074/jbc.274.27.18893	http://dx.doi.org/10.1074/jbc.274.27.18893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383386	hybrid			2022-12-27	WOS:000081196300009
J	Liu, Y; Emeson, RB; Samuel, CE				Liu, Y; Emeson, RB; Samuel, CE			Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-DELTA VIRUS; DSRNA BINDING DOMAIN; PROTEIN-KINASE PKR; UNWINDING ACTIVITY; MOLECULAR-CLONING; MESSENGER-RNA; HUMAN-CELLS; IN-VITRO; 2 FORMS; GLUR-B	The interferon-inducible RNA-specific adenosine deaminase (ADAR1) is an RNA editing enzyme implicated in the site-selective deamination of adenosine to inosine in cellular pre-mRNAs. The pre-mRNA for the rat serotonin-2C receptor (5-HT2CR) possesses four editing sites (A, B, C, and D), which undergo A-to-I nucleotide conversions that alter the signaling function of the encoded G-protein-coupled receptor. Measurements of 5-HT2CR pre-mRNA editing in vitro revealed site-specific deamination catalyzed by ADAR1, Three splice site variants, ADAR1-a, -b, and -c, all efficiently edited the A site of 5-HT2CR pre-mRNA, but the D site did not serve as an efficient substrate for any of the ADAR1 variants. Mutational analysis of the three double-stranded (ds) RNA binding motifs present in ADAR1 revealed a different relative importance of the individual dsRNA binding motifs for deamination of the A site of 5-HT2CR and synthetic dsRNA substrates. Quantitative reverse transcription-polymerase chain reaction analyses demonstrated that the 5-HT2CR pre-mRNA was most highly expressed in the choroid plexus of rat brain. However, ADAR1 and the related deaminase ADAR2 showed significant expression in all regions of the brain examined, including cortex, hippocampus, olfactory bulb, and striatum, where the 5-HT2CR pre-mRNA was extensively edited.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Grad Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Vanderbilt University	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.			Emeson, Ronald/0000-0002-4585-1648	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI012520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12520] Funding Source: Medline; NINDS NIH HHS [NS-35891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Belcher SM, 1997, MOL BRAIN RES, V52, P130, DOI 10.1016/S0169-328X(97)00252-0; Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Canton H, 1996, MOL PHARMACOL, V50, P799; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CATTANEO R, 1994, CURR OPIN GENET DEV, V4, P895, DOI 10.1016/0959-437X(94)90076-0; CATTANEO R, 1992, CURR TOP MICROBIOL, V176, P63; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Gerber A, 1997, RNA, V3, P453; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; HOYER D, 1994, PHARMACOL REV, V46, P157; Hurst SR, 1995, RNA, V1, P1051; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lei M, 1998, VIROLOGY, V245, P188, DOI 10.1006/viro.1998.9162; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; Liu Y, 1998, METHODS, V15, P199, DOI 10.1006/meth.1998.0624; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Lodish H., 1995, MOL CELL BIOL; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Polson AG, 1996, NATURE, V380, P454; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WEIER HUG, 1995, GENOMICS, V30, P372, DOI 10.1006/geno.1995.0034; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	58	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18351	18358		10.1074/jbc.274.26.18351	http://dx.doi.org/10.1074/jbc.274.26.18351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373439	hybrid			2022-12-27	WOS:000081056700031
J	Mason, RP; Jacob, RF; Walter, MF; Mason, PE; Avdulov, NA; Chochina, SV; Igbavboa, U; Wood, WG				Mason, RP; Jacob, RF; Walter, MF; Mason, PE; Avdulov, NA; Chochina, SV; Igbavboa, U; Wood, WG			Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ETHANOL-CONSUMPTION; ALZHEIMERS-DISEASE; PHOSPHOLIPID-MEMBRANES; APOLIPOPROTEIN-E; X-RAY; PROTEIN; BRAIN; CALCIUM; NEUROTOXICITY; CHOLESTEROL	The effects of soluble and aggregated amyloid P-peptide (AP) on cortical synaptic plasma membrane (SPM) structure were examined using small angle x-ray diffraction and fluorescence spectroscopy approaches, Electron density profiles generated from the x-ray diffraction data demonstrated that soluble and aggregated A beta(1-40) peptides associated with distinct regions of the SPM, The width of the SPM samples, including surface hydration, was 84 Angstrom at 10 degrees C, Following addition of soluble A beta(1-40), there was a broad increase in electron density in the SPM hydrocarbon core +/-0-15 Angstrom from the membrane center, and a reduction in hydrocarbon core width by 6 Angstrom. By contrast, aggregated A beta(1-40) contributed electron density to the phospholipid headgroup/hydrated surface of the SPM +/-24-37 Angstrom from the membrane center, concomitant with an increase in molecular volume in the hydrocarbon core, The SPM interactions observed for A beta(1-40) were reproduced in a brain lipid membrane system, In contrast to A beta(1-40), aggregated A beta(1-42) intercalated into the lipid bilayer hydrocarbon core +/-0-12 Angstrom from the membrane center. Fluorescence experiments showed that both soluble and aggregated A beta(1-40) significantly increased SPM bulk and protein annular fluidity, Physico chemical interactions of AP with the neuronal membrane may contribute to mechanisms of neurotoxicity, independent of specific receptor binding.	MCPHU, Sch Med, Dept Med, Membrane Biophys Lab, Pittsburgh, PA 15212 USA; MCPHU, Sch Med, Dept Biochem, Pittsburgh, PA 15212 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55417 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Mason, RP (corresponding author), Allegheny Univ Hosp, 320 E North Ave,15ST, Pittsburgh, PA 15212 USA.				NIAAA NIH HHS [AA10806] Funding Source: Medline; NIA NIH HHS [AG11056] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010806] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; AVDULOV NA, 1994, ALCOHOL CLIN EXP RES, V18, P53, DOI 10.1111/j.1530-0277.1994.tb00880.x; AVDULOV NA, 1995, ALCOHOL CLIN EXP RES, V19, P886, DOI 10.1111/j.1530-0277.1995.tb00963.x; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHEN M, 1995, BBA-MOL BASIS DIS, V1272, P101, DOI 10.1016/0925-4439(95)00073-D; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harris ME, 1996, J NEUROCHEM, V67, P277; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HERBETTE L, 1985, BIOCHIM BIOPHYS ACTA, V817, P103, DOI 10.1016/0005-2736(85)90073-2; Hertel C, 1997, P NATL ACAD SCI USA, V94, P9412, DOI 10.1073/pnas.94.17.9412; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; LUO YQ, 1995, BRAIN RES, V681, P65, DOI 10.1016/0006-8993(95)00282-U; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; MASON RP, 1989, BIOPHYS J, V55, P769, DOI 10.1016/S0006-3495(89)82875-9; Mason RP, 1996, BIOCHEM BIOPH RES CO, V222, P78, DOI 10.1006/bbrc.1996.0699; MATTSON MP, 1995, NEUROBIOL AGING, V16, P679, DOI 10.1016/0197-4580(95)00063-K; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MOODY MF, 1963, SCIENCE, V142, P1173, DOI 10.1126/science.142.3596.1173; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; OYAMA Y, 1995, JPN J PHARMACOL, V68, P77, DOI 10.1254/jjp.68.77; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PRADIER L, 1992, STRUCTURE BIOL MEMBR, P1047; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shin RW, 1997, J NEUROSCI, V17, P8187; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAHARA Y, 1992, BIOCHEMISTRY-US, V31, P8747, DOI 10.1021/bi00152a010; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; WOOD WG, 1995, BRAIN RES, V683, P36; WOOD WG, 1989, J NEUROCHEM, V52, P1925, DOI 10.1111/j.1471-4159.1989.tb07278.x; WOOD WG, 1990, BIOCHIM BIOPHYS ACTA, V1025, P243, DOI 10.1016/0005-2736(90)90103-U; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; YOUNG HS, 1992, BIOPHYS J, V61, P1244, DOI 10.1016/S0006-3495(92)81933-1	50	120	121	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18801	18807		10.1074/jbc.274.26.18801	http://dx.doi.org/10.1074/jbc.274.26.18801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373497	hybrid			2022-12-27	WOS:000081056700089
J	Wilke, RA; Mehta, RP; Lupardus, PJ; Chen, YM; Ruoho, AE; Jackson, MB				Wilke, RA; Mehta, RP; Lupardus, PJ; Chen, YM; Ruoho, AE; Jackson, MB			Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NERVE-TERMINALS; LUNG-CANCER; CLONING; EXPRESSION; CARCINOMA; K+; HALOPERIDOL; MECHANISMS; INHIBITION	Recent work has indicated that sigma receptor ligands can modulate potassium channels. However, the only sigma receptor characterized at the molecular level has a novel structure unlike any other receptor known to modulate ion channels. This 26-kDa protein has a hydropathy profile suggestive of a single membrane-spanning domain, with no apparent regions capable of G-protein activation or protein phosphorylation, In the present study patch clamp techniques and photoaffinity labeling were used in DMS-114 cells (a tumor cell line known to express sigma receptors) to investigate the role of the 26-kDa protein in ion channel modulation and probe the mechanism of signal transduction, The sigma receptor Ligands N-allylnormetazocine (SKF10047), ditolyl-guanidine, and (+/-)-2-(N-phenylethyl-N-propyl)-amino-5-hy- droxytetralin all inhibited voltage-activated potassium current (I-K). Iodoazidococaine (IAC), a high affinity sigma receptor photoprobe, produced a similar inhibition in I-K, and when cell homogenates were illuminated in the presence of IAC, a protein with a molecular mass of 26 kDa was covalently labeled. Photolabeling of this protein by IAC was inhibited by SKF10047 with half-maximal effect at 7 mu M. SKF10047 also inhibited I-K with a similar EC50 (14 mu M). Thus, physiological responses to sigma receptor ligands are mediated by a protein with the same molecular weight as the cloned sigma receptor. This indicates that ion channel modulation is indeed mediated by this novel protein. Physiological responses were the same when cells were perfused internally with either guanosine 5'-O-(2-thiodiphosphate) or GTP, indicating that signal transduction is independent of G-proteins, These results demonstrate that ion channels can be modulated by a receptor that does not have seven membrane-spanning domains and does not employ G-proteins, Sigma receptors thus modulate ion channels by a novel transduction mechanism.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [5-T32CA09614-10] Funding Source: Medline; NINDS NIH HHS [NS30016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BIELEFELDT K, 1992, J PHYSIOL-LONDON, V458, P41, DOI 10.1113/jphysiol.1992.sp019405; BOWEN WD, 1993, ASPECTS SYNAPTIC TRA, P113; Breitwieser GE, 1996, J MEMBRANE BIOL, V152, P1, DOI 10.1007/s002329900080; Brent PJ, 1996, BIOCHEM BIOPH RES CO, V219, P219, DOI 10.1006/bbrc.1996.0208; DeVita VT, 1997, CANC PRINCIPLES PRAC; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Johnson BE, 1997, AM J RESP CRIT CARE, V156, P1669, DOI 10.1164/ajrccm.156.5.96-10075; KAHOUN JR, 1992, P NATL ACAD SCI USA, V89, P1393, DOI 10.1073/pnas.89.4.1393; KAHOUN JR, 1992, MULTIPLE SIGMA PCP R, P273; Kebabian JW, 1997, DRUG DISCOV TODAY, V2, P333, DOI 10.1016/S1359-6446(97)01075-1; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; MORIO Y, 1994, BRAIN RES, V637, P190, DOI 10.1016/0006-8993(94)91232-7; MORTON ME, 1994, FASEB J, V8, P884, DOI 10.1096/fasebj.8.11.8070639; PANCRAZIO JJ, 1993, ANTICANCER RES, V13, P1231; PETTENGILL OS, 1980, CANCER-AM CANCER SOC, V45, P906, DOI 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RAMAMOORTHY JD, 1995, ENDOCRINOLOGY, V136, P924, DOI 10.1210/en.136.3.924; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SANGUINETTI MC, 1996, NATURE, V80, P384; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Seth P, 1997, BIOCHEM BIOPH RES CO, V241, P535, DOI 10.1006/bbrc.1997.7840; Seth P, 1998, J NEUROCHEM, V70, P922; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; Soriani O, 1998, J PHARMACOL EXP THER, V286, P163; SU TP, 1993, CRIT REV NEUROBIOL, V7, P187; TRUSSELL LO, 1987, J NEUROSCI, V7, P3306; WALKER JM, 1993, ASPECTS SYNAPTIC TRA, P91; Wilke RA, 1998, J PHARMACOL EXP THER, V284, P542; Wilke RA, 1999, J PHYSIOL-LONDON, V517, P391, DOI 10.1111/j.1469-7793.1999.00391.x; WU XZ, 1991, J PHARMACOL EXP THER, V257, P351	37	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18387	18392		10.1074/jbc.274.26.18387	http://dx.doi.org/10.1074/jbc.274.26.18387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373444	hybrid			2022-12-27	WOS:000081056700036
J	Brady, ME; Ozanne, DM; Gaughan, L; Waite, I; Cook, S; Neal, DE; Robson, CN				Brady, ME; Ozanne, DM; Gaughan, L; Waite, I; Cook, S; Neal, DE; Robson, CN			Tip60 is a nuclear hormone receptor coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; ANDROGEN RECEPTOR; HUMAN GENES; PROTEIN; BINDING; YEAST; DEACETYLASE; SPECIFICITY	The androgen receptor (AR) is a member of the nuclear hormone receptor superfamily, Recent work in this field has been focused upon defining the mechanisms of transcriptional control exacted by members of this superfamily. Using a COOH-terminal region of the human AR in a yeast two-hybrid screen, we have identified Tip60 as an AR-interacting protein. In this report, we show that Tip60, which was originally identified as a coactivator for the human immunodeficiency virus TAT protein, can enhance AR-mediated transactivation in a ligand-dependent manner in LNCaP and COS-1 cell lines. In addition, our experiments show that Tip60 can also enhance transactivation through the estrogen receptor and progesterone receptor in a ligand-dependent manner; thus identifying Tip60 as a nuclear hormone receptor coactivator, Our studies also demonstrate that Tip60 co-immunoprecipitates with the full-length AR in vitro and that, in our system, Tip60 enhances transactivation to levels observed with the coactivators steroid receptor coactivator 1, p300, and CREB-binding protein. The importance of such proteins in enhancing nuclear hormone receptor-mediated transcriptional activation is widely accepted, and this work suggests that Tip60 may have an equally important role to play.	Newcastle Univ, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Newcastle Univ, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	c.n.robson@newcastle.ac.uk		Neal, David/0000-0002-6033-5086				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Betts AM, 1997, FEBS LETT, V405, P328, DOI 10.1016/S0014-5793(97)00209-3; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Conneely OM, 1989, GENE REGULATION STER, V4, P220; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; ING NH, 1992, J BIOL CHEM, V267, P17617; James P, 1996, GENETICS, V144, P1425; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	47	208	210	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17599	17604		10.1074/jbc.274.25.17599	http://dx.doi.org/10.1074/jbc.274.25.17599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364196	hybrid			2022-12-27	WOS:000080974300032
J	Hoshinoso, M; Sone, M; Fukata, M; Kurodad, S; Kaibuchi, K; Nabeshima, Y; Hama, C				Hoshinoso, M; Sone, M; Fukata, M; Kurodad, S; Kaibuchi, K; Nabeshima, Y; Hama, C			Identification of the stef gene that encodes a novel guanine nucleotide exchange factor specific for Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; SIGNALING MOLECULES; SMALL GTPASES; RHO; CELL; RAS; INVASION; DOMAINS	The Rho family GTPases are involved in a variety of cellular events by changing the organization of actin cytoskeletal networks in response to extracellular signals. However, it is not clearly known how their activities are spatially and temporally regulated. Here we report the identification of a novel guanine nucleotide exchange factor for Rad, STEF, which is related in overall amino acid sequence and modular structure to mouse Tiam1 and Drosophila SIF proteins. STEF protein contains two pleckstrin homology domains, a PDZ domain and a Dbl homology domain. The in vitro assay showed that STEF protein specifically enhanced the dissociation of GDP from Rac1 but not that from either RhoA or Cdc42. Expression of a truncated STEF protein in culture cells induced membrane ruffling with altered actin localization, which implies that this protein also activates Rad in vivo. The stef transcript was observed in restricted parts of mice, including cartilaginous tissues and the cortical plate of the central nervous system during embryogenesis. These findings suggested that STEF protein participates in the control of cellular events in several developing tissues, possibly changing the actin cytoskeletal network by activating Rad.	NCNP, Natl Inst Neurosci, Dept Mol Genet, Kodaira, Tokyo 1878502, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 6068501, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Inheritance & Variat Grp, Kyoto 6190237, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 332, Japan	National Center for Neurology & Psychiatry - Japan; Kyoto University; Osaka University; Nara Institute of Science & Technology; Hiroshima University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Hoshinoso, M (corresponding author), NCNP, Natl Inst Neurosci, Dept Mol Genet, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.		Sone, Masaki/Q-9058-2019; Fukata, Masaki/AAZ-2476-2021	Fukata, Masaki/0000-0001-5200-9806				Allen WE, 1997, J CELL SCI, V110, P707; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; ANDO S, 1992, J BIOL CHEM, V267, P25709; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Gallo G, 1998, CURR BIOL, V8, pR80, DOI 10.1016/S0960-9822(98)70051-X; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KIKUCHI A, 1992, ONCOGENE, V7, P289; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; WHITEHEAD AP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	39	92	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17837	17844		10.1074/jbc.274.25.17837	http://dx.doi.org/10.1074/jbc.274.25.17837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364228	hybrid			2022-12-27	WOS:000080974300064
J	Liang, Y; Annan, RS; Carr, SK; Popp, S; Mevissen, M; Margolis, RK; Margolis, RU				Liang, Y; Annan, RS; Carr, SK; Popp, S; Mevissen, M; Margolis, RK; Margolis, RU			Mammalian homologues of the Drosophila slit protein are ligands of the heparan sulfate proteoglycan glypican-1 in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CHONDROITIN SULFATE; EXTRACELLULAR PROTEIN; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; IDENTIFICATION; CLONING; GROWTH; MOTIF; EGF	an affinity matrix in which a recombinant glypican-Fc fusion protein expressed in 293 cells was coupled to protein A-Sepharose, we have isolated from rat brain at least two proteins that were detected by SDS-polyacrylamide gel electrophoresis as a single 200-kDa silver-stained band, from which 16 partial peptide sequences were obtained by nano-electrospray tandem mass spectrometry. Mouse expressed sequence tags containing two of these peptides were employed for oligonucleotide design and synthesis of probes by polymerase chain reaction and enabled us to isolate from a rat brain cDNA library a 4.1-kilobase clone that encoded two of our peptide sequences and represented the N-terminal portion of a protein containing a signal peptide and three leucine-rich repeats. Comparisons with recently published sequences also showed that our peptides were derived from proteins that are members of the Slit/MEGF protein family, which share a number of structural features such as N-terminal leucine-rich repeats and C-terminal epidermal growth factor-like motifs, and in Drosophila Slit is necessary for the development of midline glia and commissural axon pathways. All of the five known rat and human Slit proteins contain 1523-1534 amino acids, and our peptide sequences correspond best to those present in human Slit-1 and Slit-2. Binding of these ligands to the glypican-Fc fusion protein requires the presence of the heparan sulfate chains, but the interaction appears to be relatively specific for glypican-Fc insofar as no other identified heparin-binding proteins were isolated using our affinity matrix. Northern analysis demonstrated the presence of two mRNA species of 8.6 and 7.5 kilobase pairs using probes based on both N- and C-terminal sequences, and in situ hybridization histochemistry showed that these glypican-1 ligands are synthesized by neurons, such as hippocampal pyramidal cells and cerebellar granule cells, where we have previously also demonstrated glypican-1 mRNA and immunoreactivity, Our results therefore indicate that Slit family proteins are functional ligands of glypican-1 in nervous tissue and suggest that their interactions may be critical for certain stages of central nervous system histogenesis.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	New York University; GlaxoSmithKline; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Margolis, RU (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.		Carr, Steven A./AAH-8366-2019		NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; ANNAN RS, 1996, P 44 ASMS C MASS SPE, P702; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Engel M, 1996, J COMP NEUROL, V366, P34; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GOWDA DC, 1989, J BIOL CHEM, V264, P11436; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; PILIA G, 1996, NAT GENET, V12, P225; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Ziegler J, 1997, ANAL BIOCHEM, V250, P257, DOI 10.1006/abio.1997.2248	39	102	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17885	17892		10.1074/jbc.274.25.17885	http://dx.doi.org/10.1074/jbc.274.25.17885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364234	hybrid			2022-12-27	WOS:000080974300070
J	Shang, YF; Baumrucker, CR; Green, MH				Shang, YF; Baumrucker, CR; Green, MH			Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; LUNG-CANCER; FACTOR BINDING-PROTEIN-3; NUCLEAR TRANSPORT; GENE-EXPRESSION; CARCINOMA CELLS; UP-REGULATION; INHIBITION; LINES; FIBROBLASTS	Neither retinoic acid receptor-beta (RAR beta) nor insulinlike growth factor-binding protein-3 (IGFBP-3) is expressed in breast cancer cell line MCF-7. The expression of both proteins can be induced in response to all-trans-retinoic acid (atRA). By using an RAR alpha-selective antagonist (Ro 41-5253), we demonstrated that RAR beta expression was induced by atRA through an RAR alpha-dependent signaling pathway and that RAR beta induction was correlated with IGFBP-3 induction. However, MCF-7 cells transfected with sense RAR beta cDNA expressed IGFBP-3 even in the presence of the RAR alpha-selective antagonist Ro 41-5253. On the other hand, antisense RAR beta cDNA transfection of MCF-7 cells blocked atRA-induced IGFBP-3 expression, indicating that RAR beta is directly involved in the mediation of IGFBP-3 induction by atRA. Induction of IGFBP-3 expression by atRA occurs at the transcriptional level, as measured by nuclear run-on assays. Finally, we showed that atRA-induced IGFBP-3 is functionally active in modulating the growth-promoting effect of IGF-I. These experiments indicate that RAR alpha and RAR beta, both individually and together, are important in mammary gland homeostasis and breast cancer development. By linking IGFBP-3 to RAR beta, our experiments define the signal intersection between the retinoid and IGF systems in cell growth regulation and explain why loss of RAR beta might be critical in breast cancer carcinogenesis/progression.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Dairy & Anim Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MH (corresponding author), Penn State Univ, Dept Nutr, S-126 Henderson Bldg S, University Pk, PA 16802 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032500] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD32500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; AGADIR A, 1994, CELL MOL BIOL, V40, P263; ALBISTON AL, 1995, ENDOCRINOLOGY, V136, P696, DOI 10.1210/en.136.2.696; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan K, 1997, ENDOCRINE, V7, P95, DOI 10.1007/BF02778072; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; Gebauer G, 1998, ANTICANCER RES, V18, P1191; GERBERT JF, 1991, ONCOGENE, V6, P1859; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gucev ZS, 1996, CANCER RES, V56, P1545; HIGUCHI T, 1991, CANCER RES, V51, P3958; Hong Waun Ki, 1994, P597; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HU L, 1991, CANCER RES, V51, P3972; Hung Huynh, 1995, Progress in Growth Factor Research, V6, P495, DOI 10.1016/0955-2235(95)00036-4; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; LANGENFELD J, 1997, P NATL ACAD SCI USA, V94, P12071; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Oh Y, 1998, BREAST CANCER RES TR, V47, P283, DOI 10.1023/A:1005911319432; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; ROMANS SD, 1992, CANCER RES, V56, P2235; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; WRAIGHT CJ, 1995, J INVEST DERMATOL, V105, P602, DOI 10.1111/1523-1747.ep12323716; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6	47	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18005	18010		10.1074/jbc.274.25.18005	http://dx.doi.org/10.1074/jbc.274.25.18005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364250	hybrid			2022-12-27	WOS:000080974300086
J	Shieh, RC; Chang, JC; Kuo, CC				Shieh, RC; Chang, JC; Kuo, CC			K+ binding sites and interactions between permeating K+ ions at the external pore month of an inward rectifier K+ channel (Kir2.1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PHEOCHROMOCYTOMA CELLS; POTASSIUM CHANNEL; XENOPUS OOCYTES; CA2+ CHANNEL; RECTIFICATION; IRK1; MEMBRANE; MECHANISM; STARFISH; RESIDUE	The arginine at position 148 is highly conserved in the inward rectifier K+ channel family, Increases of external pH decrease the single-channel conductance in mutant R148H of the Kir2.1 channel (arginine is mutated into histidine) but not in the wild type channel. Moreover, in 100 mM external K+, varying external pH induced biphasic changes of open channel noise, which peaks at around pH 7.4 in the R148H mutant but not in the wild type channel. The maximum single-channel conductances are higher in the wild type channel and R148H mutant at pH 6.0 than those in the B148H mutant at pH 7.4. However, the maximal conductance is achieved with much lower external [K+] for the latter. Interestingly, the single-channel conductances and open channel noise of the wild type channel at pH 6.0 and the R148H mutant at pH 6.0 and 7.4 become the same in [K+] = 10 mM, These results indicate that the residue at position 148 is accessible to the external H+ and probably is involved in the formation of two K+ binding sites in the external pore mouth, Effective repulsion between permeating K+ ions in this area requires a positive charge at position 148, and such K+-K+ interaction is the essential mechanism underlying high K+ conduction rate through the Kir2.1 channel pore.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Univ Hosp, Dept Neurol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Physiol, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Shieh, RC (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Yen Chiu Yuan Rd,Sect 2, Taipei 11529, Taiwan.			Kuo, Chung-Chin/0000-0001-8208-6829				COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kubo Y, 1996, RECEPTOR CHANNEL, V4, P73; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; Shieh RC, 1996, J PHYSIOL-LONDON, V494, P363, DOI 10.1113/jphysiol.1996.sp021498; Shieh RC, 1998, BIOPHYS J, V75, P2313, DOI 10.1016/S0006-3495(98)77675-1; Stampe P, 1998, J GEN PHYSIOL, V112, P475, DOI 10.1085/jgp.112.4.475; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	20	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17424	17430		10.1074/jbc.274.25.17424	http://dx.doi.org/10.1074/jbc.274.25.17424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364171	hybrid			2022-12-27	WOS:000080974300007
J	Gazit, E; Sauer, RT				Gazit, E; Sauer, RT			The Doc toxin and Phd antidote proteins of the bacteriophage P1 plasmid addiction system form a heterotrimeric complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELL-DEATH; PROTEASE; CLPXP; MAINTENANCE; SPECIFICITY; SUBSTRATE; PROPHAGE; OPERON; MODEL	The toxin (Doc) and antidote (Phd) proteins of the plasmid addiction system of bacteriophage P1 were purified as a complex. Cocrystals of the complex contained a 2:1 molar ratio of Phd:Doc as assayed by dye binding following SDS-polyacrylamide gel electrophoresis and as determined by amino acid analysis. Gel filtration and analytical ultracentrifugation revealed that the two addiction proteins interact in solution to form a P2D trimer composed of one Doc and two Phd molecules, These results support a model in which Phd inhibits the toxic activity of Doc by direct binding, Circular dichroism experiments showed that changes in secondary structure accompany formation of the heterotrimeric complex, raising the possibility that Phd may act by an allosteric mechanism. Studies of Phd and Doc molecules labeled with fluorescent energy donor and acceptor groups gave an equilibrium dissociation constant of about 0.8 mu M-2 and a very short, sub second half-life of complex dissociation. As a consequence, low concentrations of free Doc toxin are likely to be present both transiently and in the steady state in cells containing the Phd antidote, making mechanisms of single-hit Doe toxicity improbable.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 68-571, Cambridge, MA 02139 USA.		Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706, R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Gazit E, 1997, BIOCHEMISTRY-US, V36, P15546, DOI 10.1021/bi9707584; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; GERDES K, 1986, P NATL ACAD SCI USA, V83, P3116, DOI 10.1073/pnas.83.10.3116; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Holcik M, 1997, MICROBIOL-SGM, V143, P3403, DOI 10.1099/00221287-143-11-3403; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; LOH SM, 1988, GENE, V66, P259, DOI 10.1016/0378-1119(88)90362-9; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Magnuson R, 1998, J BACTERIOL, V180, P6342; ROSNER JL, 1972, VIROLOGY, V49, P679; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; YOUNG C, 1985, P NATL ACAD SCI USA, V82, P7374, DOI 10.1073/pnas.82.21.7374	22	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16813	16818		10.1074/jbc.274.24.16813	http://dx.doi.org/10.1074/jbc.274.24.16813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358024	hybrid			2022-12-27	WOS:000080780400023
J	Oosterom, J; Nijenhuis, WAJ; Schaaper, WMM; Slootstra, J; Meloen, RH; Gispen, WHH; Burbach, JPH; Adan, RAH				Oosterom, J; Nijenhuis, WAJ; Schaaper, WMM; Slootstra, J; Meloen, RH; Gispen, WHH; Burbach, JPH; Adan, RAH			Conformation of the core sequence in melanocortin peptides directs selectivity for the melanocortin MC3 and MC4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-STIMULATING HORMONE; ALPHA-MSH ANALOGS; MOLECULAR-CLONING; BIOLOGICAL-ACTIVITY; ADENYLATE-CYCLASE; RAT HYPOTHALAMUS; GAMMA-MSH; MELANOTROPIN; BINDING; EXPRESSION	Melanocortin peptides regulate a variety of physiological processes. Five melanocortin receptors (MC-R) have been cloned and the MC3R and MC4R are the main brain MC receptors. The aim of this study was to identify structural requirements in both ligand and receptor that determine gamma-melanocyte-stimulating hormone (MSH) selectivity for the MC3R versus the MC4R, Substitution of Asp(10) in [Nle(4)]Lys-gamma(2)-MSH for Gly(10) from [Nle(4)]alpha-MSH, increased both activity and affinity for the MC4R while the MC3R remained unaffected. Analysis of chimeric MC3R/MC4Rs and mutant MC4Rs showed that Tyr(268) Of the MC4R mainly determined the low affinity for [Nle(4)]Lys-gamma(2)-MSH. The data demonstrate that Asp(10) determines selectivity for the MC3R, however, not through direct side chain interactions, but probably by influencing how the melanocortin core sequence is presented to the receptor-binding pocket. This is supported by mutagenesis of Tyr(268) to lie in the MC4R which increased affinity and activity for [Nle(4)]Lys-gamma(2)-MSH, but decreased affinity for two peptides with constrained cyclic structure of the melanocortin core sequence, MT-II and [D-Tyr(4)]MT-II, that also displayed lower affinity for the MC3R. This study provides a general concept for peptide receptor selectivity, in which the major determinant for a selective receptor interaction is the conformational presentation of the core sequence in related peptides to the receptor-binding pocket.	Univ Utrecht, Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, NL-3508 TA Utrecht, Netherlands; Inst Anim Sci & Hlth, NL-8200 AB Lelystad, Netherlands	Utrecht University; Utrecht University Medical Center	Adan, RAH (corresponding author), Univ Utrecht, Rudolf Magnus Inst Neurosci, Fac Med, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	adan@med.uu.nl						Adan RAH, 1997, RECEPTOR CHANNEL, V5, P215; Adan RAH, 1997, PEPTIDES, V18, P1279, DOI 10.1016/S0196-9781(97)00078-8; ALOBEIDI F, 1989, J MED CHEM, V32, P174, DOI 10.1021/jm00121a032; Alvaro JD, 1997, LIFE SCI, V61, P1, DOI 10.1016/S0024-3205(97)00029-5; Arttamangkul S, 1997, J MED CHEM, V40, P1211, DOI 10.1021/jm960753p; BECKSICKINGER AG, 1994, EUR J BIOCHEM, V225, P947, DOI 10.1111/j.1432-1033.1994.0947b.x; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONTRERAS PC, 1984, J PHARMACOL EXP THER, V229, P21; EBERLE A, 1988, MELANOTROPINS; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FRANDBERG PA, 1994, BIOCHEM BIOPH RES CO, V202, P1266, DOI 10.1006/bbrc.1994.2067; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GEE CE, 1983, NATURE, V306, P374, DOI 10.1038/306374a0; GERST JE, 1986, MOL CELL ENDOCRINOL, V46, P137; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Haskell-Luevano C, 1996, Drug Des Discov, V14, P197; HaskellLuevano C, 1997, J MED CHEM, V40, P1738, DOI 10.1021/jm960845e; HaskellLuevano C, 1997, J MED CHEM, V40, P2133, DOI 10.1021/jm960840h; HaskellLuevano C, 1997, J MED CHEM, V40, P2740, DOI 10.1021/jm970018t; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huang QH, 1997, J NEUROSCI, V17, P3343; KEIGHTLEY MC, 1991, MOL CELL ENDOCRINOL, V82, P89, DOI 10.1016/0303-7207(91)90012-H; Low M.J., 1994, CURR OPIN ENDOCRINOL, V1, P79; Lung FDT, 1996, J MED CHEM, V39, P1136, DOI 10.1021/jm950369c; MELOEN RH, 1995, IMMUNOLOGICAL RECOGN, P15; MIWA H, 1995, J PHARMACOL EXP THER, V273, P367; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Oosterom J, 1998, EUR J PHARMACOL, V354, pR9, DOI 10.1016/S0014-2999(98)00491-9; Peng PJ, 1997, PEPTIDES, V18, P1001, DOI 10.1016/S0196-9781(97)00035-1; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SAHM UG, 1994, FEBS LETT, V350, P29, DOI 10.1016/0014-5793(94)00725-X; SAHM UG, 1994, PEPTIDES, V15, P1297, DOI 10.1016/0196-9781(94)90157-0; SAITO E, 1983, P NATL ACAD SCI-BIOL, V80, P3792, DOI 10.1073/pnas.80.12.3792; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAWYER TK, 1982, P NATL ACAD SCI-BIOL, V79, P1751, DOI 10.1073/pnas.79.6.1751; Schaaper WMM, 1998, LETT PEPT SCI, V5, P205, DOI 10.1023/A:1008877507882; Schioth HB, 1996, PHARMACOL TOXICOL, V79, P161, DOI 10.1111/j.1600-0773.1996.tb00261.x; Schioth HB, 1997, PEPTIDES, V18, P1009, DOI 10.1016/S0196-9781(97)00079-X; Schioth HB, 1998, EUR J PHARMACOL, V349, P359, DOI 10.1016/S0014-2999(98)00212-X; STRAND FL, 1991, PHYSIOL REV, V71, P1017, DOI 10.1152/physrev.1991.71.4.1017; TATRO JB, 1994, BRAIN RES, V635, P148, DOI 10.1016/0006-8993(94)91434-6; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; VanBergen P, 1995, EUR J PHARMACOL, V294, P795, DOI 10.1016/0014-2999(95)00657-5; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000	49	53	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16853	16860		10.1074/jbc.274.24.16853	http://dx.doi.org/10.1074/jbc.274.24.16853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358030	hybrid			2022-12-27	WOS:000080780400029
J	Oxvig, C; Thomsen, AR; Overgaard, MT; Sorensen, ES; Hojrup, P; Bjerrum, MJ; Gleich, GJ; Sottrup-Jensen, L				Oxvig, C; Thomsen, AR; Overgaard, MT; Sorensen, ES; Hojrup, P; Bjerrum, MJ; Gleich, GJ; Sottrup-Jensen, L			Biochemical evidence for heme linkage through esters with Asp-93 and Glu-241 in human eosinophil peroxidase - The ester with Asp-93 is only partially formed in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; HUMAN MYELOPEROXIDASE; MOLECULAR-CLONING; PROSTHETIC GROUP; LACTOPEROXIDASE HEME; THYROID PEROXIDASE; THIOCYANATE; RESONANCE; FAMILY; IDENTIFICATION	The covalent heme attachment has been extensively studied by spectroscopic methods in myeloperoxidase and lactoperoxidase (LPO) but not in eosinophil peroxidase (EPO). We show that heme linkage to the heavy chain is invariably present, whereas heme linkage to the light chain of EPO is present in less than one-third of EPO molecules. Mass analysis of isolated heme bispeptides supports the hypothesis of a heme b linked through two esters to the polypeptide, Mass analysis of heme monopeptides reveals that >90% have a nonderivatized methyl group at the position of the light chain linkage. Apparently, an ester had not been formed during biosynthesis, The light chain linkage could be formed by incubation with hydrogen peroxide, in accordance with a recent hypothesis of autocatalytic heme attachment based on studies with LPO (DePillis, G. D., Ozaki, S., Kuo, J. M., Maltby, D. A., and Ortiz de Montellano P. R. (1997) J. Biol. Chem. 272, 8857-8860). By sequence analysis of isolated heme peptides after aminolysis, we unambiguously identified the acidic residues, Asp-93 of the light chain and Glu-241 of the heavy chain, that form esters with the heme group. This is the first biochemical support for ester linkage to two specific residues in eosinophil peroxidase. From a parallel study with LPO, we show that Asp-125 and Glu-275 are engaged in ester linkage. The species with a nonderivatized methyl group was not found among LPO peptides.	Aarhus Univ, Dept Mol & Struct Biol, Sci Pk Div, DK-8000 Aarhus, Denmark; Odense Univ, Dept Biol Mol, DK-5230 Odense M, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg C, Denmark; Mayo Clin & Mayo Fdn, Dept Immunol & Med, Rochester, MN 55905 USA	Aarhus University; University of Southern Denmark; University of Copenhagen; Mayo Clinic	Oxvig, C (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, Sci Pk Div, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.		Højrup, Peter/ABG-8477-2020; Overgaard, Michael Toft/E-1354-2011	Overgaard, Michael Toft/0000-0002-1423-2481; Hojrup, Peter/0000-0002-7838-6180; Oxvig, Claus/0000-0002-4715-9719; Sorensen, Esben Skipper/0000-0002-7050-3354				Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BOS AJ, 1981, INFECT IMMUN, V32, P427, DOI 10.1128/IAI.32.2.427-431.1981; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; DeBolster MWG, 1997, PURE APPL CHEM, V69, P1251, DOI 10.1351/pac199769061251; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FLORIS R, 1994, EUR J BIOCHEM, V222, P677, DOI 10.1111/j.1432-1033.1994.tb18912.x; FLORIS R, 1995, J AM CHEM SOC, V117, P3907, DOI 10.1021/ja00119a003; HULTQUIST DE, 1963, J BIOL CHEM, V238, P2843; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; NICHOL AW, 1987, BIOCHEM J, V247, P147, DOI 10.1042/bj2470147; OLSEN RL, 1985, BIOCHEM J, V229, P779, DOI 10.1042/bj2290779; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; OLSEN RL, 1984, BIOCHEM J, V222, P701, DOI 10.1042/bj2220701; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; Rae TD, 1998, J BIOL CHEM, V273, P27968, DOI 10.1074/jbc.273.43.27968; SALMASO BLN, 1994, BIOPHYS J, V67, P436, DOI 10.1016/S0006-3495(94)80499-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIBBETT SS, 1985, FEBS LETT, V189, P271, DOI 10.1016/0014-5793(85)81038-3; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; THANABAL V, 1989, BIOCHEMISTRY-US, V28, P7038, DOI 10.1021/bi00443a039; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WEVER R, 1980, EUR J BIOCHEM, V108, P491, DOI 10.1111/j.1432-1033.1980.tb04746.x; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	37	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16953	16958		10.1074/jbc.274.24.16953	http://dx.doi.org/10.1074/jbc.274.24.16953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358043	hybrid			2022-12-27	WOS:000080780400042
J	Song, CZ; Chang, XJ; Bean, KM; Proia, MS; Knopf, JL; Kriz, RW				Song, CZ; Chang, XJ; Bean, KM; Proia, MS; Knopf, JL; Kriz, RW			Molecular characterization of cytosolic phospholipase A(2)-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; A(2); TRANSLOCATION	We have isolated a cDNA encoding a 1012-amino acid polypeptide cPLA(2)-beta, that has significant homology with cPLA(2)-alpha in both the calcium-dependent lipid binding domain as well as in the catalytic domain. Transient expression of cPLA(2)-beta cDNA in COS cells results in an increase in calcium-dependent phospholipase A(1) (PLA(1)) and PLA(2) activities compared with vector-transfected cells. cPLA(2)-beta is markedly less selective for cleavage at sn-2 as compared with cPLA(2)-alpha and cPLA(2)-gamma. Northern analysis reveals a cPLA(2)-beta transcript of 8 kilobase pairs that is expressed in all the human tissues examined. With the identification of cPLA(2)-beta, the newly defined cPLA(2) family now comprises three members that may have dramatically different mechanisms for regulation of expression and enzymatic activation.	Genet Inst, Small Mol Drug Discovery Grp, Cambridge, MA 02140 USA		Kriz, RW (corresponding author), Genet Inst, Small Mol Drug Discovery Grp, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.							Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	12	100	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17063	17067		10.1074/jbc.274.24.17063	http://dx.doi.org/10.1074/jbc.274.24.17063			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358058	hybrid			2022-12-27	WOS:000080780400057
J	Santagata, S; Bhattacharyya, D; Wang, FH; Singha, N; Hodtsev, A; Spanopoulou, E				Santagata, S; Bhattacharyya, D; Wang, FH; Singha, N; Hodtsev, A; Spanopoulou, E			Molecular cloning and characterization of a mouse homolog of bacterial ClpX, a novel mammalian class II member of the Hsp100/Clp chaperone family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; BACTERIOPHAGE-MU; SACCHAROMYCES-CEREVISIAE; SPECIFICITY COMPONENT; V(D)J RECOMBINATION; BACILLUS-SUBTILIS; ACTIVATED ATPASE; SERINE-PROTEASE	In this paper, we present the molecular cloning and characterization of a murine homolog of the Escherichia coli chaperone ClpX, Murine ClpX shares 38% amino acid sequence identity with the E, coli homolog and is a novel member of the Hsp100/Clp family of molecular chaperones. ClpX localizes to human chromosome 15q22.2-22.3 and in mouse is expressed tissue-specifically as one transcript of similar to 2.9 kilobases (kb) predominantly within the liver and as two isoforms of similar to 2.6 and similar to 2.9 kb within the testes. Purified recombinant ClpX displays intrinsic ATPase activity, with a K-m of similar to 25 mu M and a V-max of similar to 660 pmol min(-1) mu g(-1), which is active over a broad range of pH, temperature, ethanol, and salt parameters. Substitution of lysine 300 with alanine in the ATPase domain P-loop abolishes both ATP hydrolysis and binding. Recombinant ClpX can also interact with its putative partner protease subunit ClpP in overexpression experiments in 293T cells. Subcellular studies by confocal laser scanning microscopy localized murine ClpX green fluorescent protein fusions to the mitochondria. Deletion of the N-terminal mitochondrial targeting sequence abolished mitochondrial compartmentalization, Our results thus suggest that murine ClpX acts as a tissue-specific mammalian mitochondrial chaperone that may play a role in mitochondrial protein homeostasis.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Santagata, S (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave,E Bldg,Box 1130, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009	Santagata, Sandro/0000-0002-7528-9668	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR0 9145-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Gerth U, 1996, GENE, V181, P77, DOI 10.1016/S0378-1119(96)00467-2; Gerth U, 1998, MOL MICROBIOL, V28, P787, DOI 10.1046/j.1365-2958.1998.00840.x; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Hodges PE, 1998, NUCLEIC ACIDS RES, V26, P68, DOI 10.1093/nar/26.1.68; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Jenal U, 1998, EMBO J, V17, P5658, DOI 10.1093/emboj/17.19.5658; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Martin J, 1997, J BIOENERG BIOMEMBR, V29, P35, DOI 10.1023/A:1022407705182; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; ROISE D, 1988, J BIOL CHEM, V263, P4509; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; van Dyck L, 1998, FEBS LETT, V438, P250, DOI 10.1016/S0014-5793(98)01310-6; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WOO KM, 1992, J BIOL CHEM, V267, P20429	56	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16311	16319		10.1074/jbc.274.23.16311	http://dx.doi.org/10.1074/jbc.274.23.16311			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347188	hybrid			2022-12-27	WOS:000080668600048
J	Jeltsch, A; Christ, F; Fatemi, M; Roth, M				Jeltsch, A; Christ, F; Fatemi, M; Roth, M			On the substrate specificity of DNA methyltransferases - Adenine-N-6 DNA methyltransferases also modify cytosine residues at position N-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-MODIFICATION SYSTEM; CRYSTAL-STRUCTURE; TARGET BASE; METHYLATION; SEQUENCE; BINDING; DOMAINS; FOKI; ACID; MISMATCHES	Methylation of DNA is important in many organisms and essential in mammals, Nucleobases can be methylated at the adenine-N-6, cytosine-N-4, or cytosine-C-5 atoms by specific DNA methyltransferases. We show here that the M.EcoRV, M.EcoRI, and Escherichia coli dam methyltransferases as well as the N- and C-terminal domains of the M.KokI enzyme, which were formerly all classified as adenine-N-6 DNA methyltransferases, also methylate cytosine residues at position N-4. Kinetic analyses demonstrate that the rate of methylation of cytosine residues by M.EcoRV and the M.FokI enzymes is reduced by only 1-2 orders of magnitude in relation to methylation of adenines, This result shows that although these enzymes methylate DNA in a sequence specific manner, they have a low substrate specificity with respect to the target base, This unexpected finding has implications on the mechanism of adenine-N-6 DNA methyltransferases, Sequence comparisons suggest that adenine-N-6 and cytosine-N-4 methyltransferases have changed their reaction specificity at least twice during evolution, a model that becomes much more likely given the partial functional overlap of both enzyme types. In contrast, methylation of adenine residues by the cytosine-N-4 methyltransferase M.BamHI was not detectable. On the basis of our results, we suggest that adenine-N-6 and cytosine-N-4 methyltransferases should be grouped into one enzyme family.	Inst Biochem, Fachbereich Biol, D-35392 Giessen, Germany		Jeltsch, A (corresponding author), Inst Biochem, Fachbereich Biol, Heinrich Buff Ring 58, D-35392 Giessen, Germany.		Christ, Frauke/H-7513-2018; Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290; Christ, Frauke/0000-0001-9580-3874				Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Cal S, 1997, J BIOL CHEM, V272, P490; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Heitman J, 1993, Genet Eng (N Y), V15, P57; HELTSCH A, 1999, IN PRESS J MOL EVOL; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jeltsch A, 1999, J MOL BIOL, V285, P1121, DOI 10.1006/jmbi.1998.2389; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LANDRY D, 1989, GENE, V77, P1, DOI 10.1016/0378-1119(89)90353-3; Leismann O, 1998, EUR J BIOCHEM, V251, P899, DOI 10.1046/j.1432-1327.1998.2510899.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOONEY MC, 1989, GENE, V80, P193, DOI 10.1016/0378-1119(89)90284-9; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MASHHOON N, 1994, BIOCHEMISTRY-US, V33, P7113, DOI 10.1021/bi00189a014; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; NOYERWEIDNER M, 1993, DNA METHYLATION MOL; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roth M, 1998, J BIOL CHEM, V273, P17333, DOI 10.1074/jbc.273.28.17333; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Serva S, 1998, NUCLEIC ACIDS RES, V26, P3473, DOI 10.1093/nar/26.15.3473; SUGISAKI H, 1989, J BIOL CHEM, V264, P5757; SUGISAKI H, 1981, GENE, V16, P73; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tran PH, 1998, STRUCT FOLD DES, V6, P1563, DOI 10.1016/S0969-2126(98)00154-3; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	46	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19538	19544		10.1074/jbc.274.28.19538	http://dx.doi.org/10.1074/jbc.274.28.19538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391886	hybrid			2022-12-27	WOS:000081377300006
J	Caccuri, AM; Antonini, G; Ascenzi, P; Nicotra, M; Nuccetelli, M; Mazzetti, AP; Federici, G; Lo Bello, M; Ricci, G				Caccuri, AM; Antonini, G; Ascenzi, P; Nicotra, M; Nuccetelli, M; Mazzetti, AP; Federici, G; Lo Bello, M; Ricci, G			Temperature adaptation of glutathione S-transferase P1-1 - A case for homotropic regulation of substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POSITIVE COOPERATIVITY; MUTATION; PI; MECHANISM; ENZYME; TRANSCARBAMOYLASE; FLEXIBILITY; CYS-47; SKIN	Human glutathione S-transferase P1-1 (GST P1-1) is a homodimeric enzyme expressed in several organs as well as in the upper layers of epidermis, playing a role against carcinogenic and toxic compounds. A sophisticated mechanism of temperature adaptation has been developed by this enzyme. In fact, above 35 degrees C, glutathione (GSH) binding to GST P1-1 displays positive cooperativity, whereas negative cooperativity occurs below 25 degrees C. This binding mechanism minimizes changes of GSH affinity for GST P1-1 because of temperature fluctuation. This is a likely advantage for epithelial skin cells, which are naturally exposed to temperature variation and, incidentally, to carcinogenic compounds, always needing efficient detoxifying systems. As a whole, GST P1-1 represents the first enzyme which displays a temperature-dependent homotropic regulation of substrate (e.g. GSH) binding.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; IRCCS Bambin Gesu, Osped Pediat, I-00165 Rome, Italy; Univ Rome Tre, Dept Biol, I-00146 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Sapienza University Rome; IRCCS Bambino Gesu; Roma Tre University	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		CACCURI, ANNA MARIA/AFU-2643-2022	Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; BRAXTON BL, 1994, J BIOL CHEM, V269, P47; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; Coletta M, 1998, BIOCHEMISTRY-US, V37, P2873, DOI 10.1021/bi9713613; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; Habig W H, 1981, Methods Enzymol, V77, P398; HALPRIN KM, 1967, J INVEST DERMATOL, V48, P149, DOI 10.1038/jid.1967.24; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hochachka P. W., 1984, BIOCH ADAPTATION; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lo Bello M, 1998, J MOL BIOL, V284, P1717; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; Segel I.H., 1975, ENZYME KINETICS; SHIMIZU K, 1995, VIRCHOWS ARCH, V425, P589; Somero GN, 1996, NEWS PHYSIOL SCI, V11, P72; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; TAKETA K, 1965, J BIOL CHEM, V240, P651	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19276	19280		10.1074/jbc.274.27.19276	http://dx.doi.org/10.1074/jbc.274.27.19276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383436	hybrid			2022-12-27	WOS:000081196300059
J	O'Brien, CA; Gubrij, I; Lin, SC; Saylors, RL; Manolagas, SC				O'Brien, CA; Gubrij, I; Lin, SC; Saylors, RL; Manolagas, SC			STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-kappa B ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D-3 or parathyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; BONE-MARROW CULTURES; IN-VIVO; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; IL-6 RECEPTOR; GROWTH ARREST; GENE-TRANSFER	Interleukin (IL)-6-type cytokines stimulate osteoclastogenesis by activating gp130 in stromal/osteoblastic cells and may mediate some of the osteoclastogenic effects of other cytokines and hormones. To determine whether STAT3 is a downstream effector of gp130 in the osteoclast support function of stromal/osteoblastic cells and whether the gp130/STAT3 pathway is utilized by other osteoclastogenic agents, we conditionally expressed dominant negative (dn)-STAT3 or dn-gp130 in a stromal/osteoblastic cell line (UAMS-32) that supports osteoclast formation. Expression of either dominant negative protein abolished osteoclast formation stimulated by IL-6 + soluble IL-6 receptor, oncostatin M, or IL-1 but not by parathyroid hormone or 1,25-dihydroxyvitamin D-3. Because previous studies suggested that IL-B-type cytokines may stimulate osteoclastogenesis by inducing expression of the tumor necrosis factor-related protein, receptor activator of NF-kappa B ligand (RANKL), we conditionally expressed RANKL in UAMS-32 cells and found that this was sufficient to stimulate osteoclastogenesis, Moreover, dn-STAT3 blocked the ability of either IL-6 + soluble IL-6 receptor or oncostatin M to induce RANKL, These results establish that STAT3 is essential for gp130-mediated osteoclast formation and that the target of STAT3 during this process is induction of RANKL, In addition, this study demonstrates that activation of the gp130 STAT3 pathway in stromal/osteoblastic cells mediates the osteoclastogenic effects of IL-1, but not parathyroid hormone or 1,25-dihydroxyvitamin D-3.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Pediat Hematol Oncol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Cent Arkansas Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	O'Brien, CA (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, 4301 W Markham St,Mail Slot 587, Little Rock, AR 72205 USA.		O'Brien, Charles A./AAL-5078-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR045241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [1R29AR45241-01] Funding Source: Medline; NIA NIH HHS [P01 AG13918-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Aubin Jane E., 1993, P1; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Boyle WJ, 1998, BONE, V23, pS189; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990; Devlin RD, 1998, J BONE MINER RES, V13, P393, DOI 10.1359/jbmr.1998.13.3.393; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREY A, 1997, J BONE MINER RES  S1, V12, pS112; Grignani F, 1998, CANCER RES, V58, P14; GUBRIJ I, 1998, BONE, V23, pS216; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KAPETEIN A, 1996, J BIOL CHEM, V271, P5961; Kim GS, 1997, J BONE MINER RES, V12, P896, DOI 10.1359/jbmr.1997.12.6.896; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kumanogoh A, 1997, P NATL ACAD SCI USA, V94, P2478, DOI 10.1073/pnas.94.6.2478; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAJORS J, 1990, CURR TOP MICROBIOL, V157, P50; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Manolagas Stavros C., 1996, P701; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; OBRIEN CA, 1998, BONE, V23, pS149; Piekorz RP, 1998, BBA-MOL CELL RES, V1402, P313, DOI 10.1016/S0167-4889(98)00024-X; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Pollock JH, 1996, J BONE MINER RES, V11, P754; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; SAITO M, 1992, J IMMUNOL, V148, P4066; Saylors RL, 1998, MOL GENET METAB, V63, P198, DOI 10.1006/mgme.1997.2665; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; SUDA T, 1988, EXP HEMATOL, V16, P891; Suda Tatsuo, 1996, P87; TAKEDA S, 1997, J BONE MINER RES, V12, pS110; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	60	236	241	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19301	19308		10.1074/jbc.274.27.19301	http://dx.doi.org/10.1074/jbc.274.27.19301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383440	hybrid			2022-12-27	WOS:000081196300063
J	Pak, M; Hoskins, JR; Singh, SK; Maurizi, MR; Wickner, S				Pak, M; Hoskins, JR; Singh, SK; Maurizi, MR; Wickner, S			Concurrent chaperone and protease activities of ClpAP and the requirement for the N-terminal ClpA ATP binding site for chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; SPECIFICITY COMPONENT; MUTATIONAL ANALYSIS; DEPENDENT PROTEASE; ACTIVATED ATPASE; MU-TRANSPOSASE; HSP104; PROTEOLYSIS	ClpA, a member of the Clp/Hsp100 family of ATPases, is both an ATP-dependent molecular chaperone and the regulatory component of ClpAP protease. We demonstrate that chaperone and protease activities occur concurrently in ClpAP complexes during a single round of RepA binding to ClpAP and ATP-dependent release. This result was substantiated with a ClpA mutant, ClpA(K220V), carrying an amino acid substitution in the N-terminal ATP binding site. ClpA(K220V) is unable to activate RepA, but the presence of ClpP or chemically inactivated ClpP restores its ability to activate RepA. The presence of ClpP simultaneously facilitates degradation of RepA ClpP must remain bound to ClpA(K220V) for these effects, indicating that both chaperone and proteolytic activities of the mutant complex occur concurrently. ClpA(K220V) itself is able to form stable complexes with RepA in the presence of a poorly hydrolyzed ATP analog, adenosine 5'-O-(thiotriphosphate), and to release RepA upon exchange of adenosine 5'-O-(thiotriphosphate) with ATP. However, the released RepA is inactive in DNA binding, indicating that the N-terminal ATP binding site is essential for the chaperone activity of ClpA. Taken together, these results suggest that substrates bound to the complex of the proteolytic and ATPase components can be partitioned between release/reactivation and translocation/degradation.	NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wickner, S (corresponding author), NCI, Mol Biol Lab, NIH, Bldg 37,Rm 2D19,37 Convent Dr,MSC37-4255, Bethesda, MD 20892 USA.	wickners@dc37a.nci.nih.gov						Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WOO KM, 1992, J BIOL CHEM, V267, P20429	40	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19316	19322		10.1074/jbc.274.27.19316	http://dx.doi.org/10.1074/jbc.274.27.19316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383442	hybrid			2022-12-27	WOS:000081196300065
J	Poupon, V; Begue, B; Gagnon, J; Dautry-Varsat, A; Cerf-Bensussan, N; Benmerah, A				Poupon, V; Begue, B; Gagnon, J; Dautry-Varsat, A; Cerf-Bensussan, N; Benmerah, A			Molecular cloning and characterization of MT-ACT48, a novel mitochondrial Acyl-CoA thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; LONG-CHAIN; MEDIATED ENDOCYTOSIS; PROTEIN THIOESTERASE; TRANSPORT VESICLES; COENZYME-A; EH-DOMAIN; EPS15; PURIFICATION; EXPRESSION	While characterizing Eps15 partners, we identified a 48-kDa polypeptide (p48) which was precipitated by Eps15-derived glutathione S-transferase fusion proteins. A search in a murine expressed sequence tag data base with N-terminal microsequences of p48 led to the identification of two complete cDNA clones encoding two isoforms of a 439-amino acid protein sharing 95% nucleic and amino acid identity. Northern blot and immunoblotting studies showed that p48 was ubiquitously expressed. A significant homology (19% identity and 40% similarity) between p48 and rat brain cytosolic acyl-CoA thioesterase was observed in an 80-amino acid C-terminal domain, retrieved from proteins from human, nematode, and plants. The thioesterase function of p48 was further demonstrated against long chain acyl-CoAs in a spectrophotometric assay. Furthermore, data obtained from sequence analysis showed that p48 contained a mitochondrial targeting signal, cleaved in mature protein as assessed by microsequencing. The mitochondrial localization of both endogenous and transfected p48 was confirmed by confocal microscopy. These results indicate that p48, called MT-ACT48 (mitochondrial acyl-CoA thioesterase of 48 kDa), defines a novel family of mitochondrial long chain acyl CoA thioesterases.	Fac Necker Enfants Malad, INSERM, F-75756 Paris 15, France; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble, France; Inst Pasteur, Unite Biol Interact Cellulaires, CNRS, URA 1960, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benmerah, A (corresponding author), Fac Necker Enfants Malad, INSERM, CJF 97-10,156 Rue Vaugirard, F-75756 Paris 15, France.		Cerf-Bensussan, nadine/H-9505-2017; Gagnon, Jean/C-3136-2008; benmerah, alexandre/H-3742-2017; Begue, Bernadette/I-2744-2017	Cerf-Bensussan, nadine/0000-0003-0665-1245; Gagnon, Jean/0000-0002-0177-824X; benmerah, alexandre/0000-0003-0188-8016; Begue, Bernadette/0000-0002-1228-9978				Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; Carbone R, 1997, CANCER RES, V57, P5498; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Engberg ST, 1997, BIOCHEM J, V323, P525, DOI 10.1042/bj3230525; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Iannolo G, 1997, CANCER RES, V57, P240; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sambrook J., 2002, MOL CLONING LAB MANU; SRERE PA, 1959, BIOCHIM BIOPHYS ACTA, V33, P313, DOI 10.1016/0006-3002(59)90118-0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; Yamada J, 1997, BIOCHEM BIOPH RES CO, V232, P198, DOI 10.1006/bbrc.1997.6246	34	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19188	19194		10.1074/jbc.274.27.19188	http://dx.doi.org/10.1074/jbc.274.27.19188			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383425	hybrid			2022-12-27	WOS:000081196300048
J	Schwenzer, R; Siemienski, K; Liptay, S; Schubert, G; Peters, N; Scheurich, P; Schmid, RM; Wajant, H				Schwenzer, R; Siemienski, K; Liptay, S; Schubert, G; Peters, N; Scheurich, P; Schmid, RM; Wajant, H			The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappa B and c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; SIGNAL-TRANSDUCING PROTEINS; RING FINGER PROTEIN; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; INTERACTING PROTEIN; CONTAINS 2; T-CELLS; CD40; MEMBER	To understand how the TNF receptor-associated factor 1 (TRAF1) is transcriptionally regulated, in vitro DNA binding assays, promoter-reporter gene assays, and RNase protection assays were performed with the human TRAF1 gene. Binding of NF-kappa B to three of five putative binding sites within the human TRAF1 promoter was found in electrophoretic mobility shift assay studies, and analysis of TRAF1 gene promoter luciferase constructs confirmed the functional importance of these elements. Moreover, triggering of TNF-R1, CD40, and the interleukin-l receptor resulted in transcription of the TRAF1 gene, whereas receptors that are not activators or only poor activators of NF-kappa B in HeLa cells failed to show a significant TRAF1 induction. Because it has been shown that members of the TRAF family are involved in activation of NF-kappa B and the c-Jun N-terminal kinase (JNK) by the interleukin-1 receptor and members of the TNF receptor superfamily, a role of TRAF1 in receptor cross-talk and/or feedback regulation of activated receptor signaling complexes can be suggested. In fact, we found that TNF-induced activation of JNK is prolonged in transfectants overexpressing TRAF1, whereas overexpression of a deletion mutant of TRAF1 in which the N-terminal part had been replaced by the green fluorescent protein interfered with TNF-induced activation of NF-kappa B and JNK.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Ulm, Chirurg Klin 1, D-89081 Ulm, Germany	University of Stuttgart; Ulm University	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Aizawa S, 1997, J BIOL CHEM, V272, P2042; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siemienski K, 1997, GENE, V195, P35, DOI 10.1016/S0378-1119(97)00147-9; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	50	148	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19368	19374		10.1074/jbc.274.27.19368	http://dx.doi.org/10.1074/jbc.274.27.19368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383449	hybrid			2022-12-27	WOS:000081196300072
J	Thomas, VH; Yang, YS; Rice, KG				Thomas, VH; Yang, YS; Rice, KG			In vivo ligand specificity of E-selectin binding to multivalent sialyl Lewis(x) N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; P-SELECTIN; MYELOID CELLS; IN-VIVO; GLYCOPROTEIN LIGAND; ENZYMATIC-SYNTHESIS; ANIMAL LECTINS; O-GLYCANS; EXPRESSION; ADHESION	The in vivo specificity for E-selectin binding to a panel of N-linked oligosaccharides containing a clustered array of one to four sialyl Lewis(x) (SLe(x); NeuAc alpha 2-3Gal[Fuc alpha 1-3]beta 1-4G1cNAc) determinants was studied in mice. Following intraperitoneal dosing with lipopolysaccharide, radioiodinated tyrosinamide N-linked oligosaccharides were dosed i.v. and analyzed for their pharmacokinetics and biodistribution, Specific targeting was determined from the degree of SLe(x) oligosaccharide targeting relative to a sialyl oligosaccharide control. Oligosaccharides targeted the kidney with the greatest selectivity after a 4-h induction period following lipopolysaccharide dosing. Unique pharmacokinetic profiles were identified for SLe(x) biantennary and triantennary oligosaccharides but not for monovalent and tetraantennary SLe(x) oligosaccharides or sialyl oligosaccharide controls. Biodistribution studies established that both SLe(x) biantennary and triantennary oligosaccharides distributed to the kidney with 2-3-fold selectivity over sialyl oligosaccharide controls, whereas monovalent and tetraantennary SLe(x) oligosaccharides failed to mediate specific kidney targeting. Simultaneous dosing of SLe(x) biantennary or triantennary oligosaccharide with a mouse anti-E-selectin monoclonal antibody blocked kidney targeting, whereas co-administration with anti-P-selectin monoclonal antibody did not significantly block kidney targeting. The results suggest that SLe(x) biantennary and triantennary are N-linked oligosaccharide ligands for E-selectin and implicate E-selectin as a bivalent receptor in the murine kidney endothelium.	Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Rice, KG (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.				NIAID NIH HHS [AI33189] Funding Source: Medline; NIGMS NIH HHS [GM48049] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048049, R29GM048049] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENET LZ, 1979, J PHARM SCI, V68, P1071, DOI 10.1002/jps.2600680845; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHIU MH, 1995, J BIOL CHEM, V270, P24024, DOI 10.1074/jbc.270.41.24024; CHIU MH, 1994, J BIOL CHEM, V269, P16195; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DEFREES SA, 1995, J AM CHEM SOC, V117, P66, DOI 10.1021/ja00106a008; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; Eppihimer MJ, 1997, AM J PHYSIOL-HEART C, V273, pH1903, DOI 10.1152/ajpheart.1997.273.4.H1903; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; FRIES JWU, 1993, AM J PATHOL, V143, P725; HASEGAWA T, 1994, DRUG METAB DISPOS, V22, P8; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Henseleit U, 1996, J PATHOL, V180, P317; HEWETT JA, 1993, PHARMACOL REV, V45, P381; Konstantopoulos K, 1997, J CLIN INVEST, V100, pS19; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEE YC, 1983, J BIOL CHEM, V258, P199; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Lin CH, 1995, BIOORGAN MED CHEM, V3, P1625, DOI 10.1016/0968-0896(95)00150-6; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; RIEGELMAN S, 1980, J PHARMACOKINET BIOP, V8, P509, DOI 10.1007/BF01059549; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Thomas VH, 1998, CARBOHYD RES, V306, P387, DOI 10.1016/S0008-6215(97)10098-2; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WAGNER J. G., 1975, FUNDAMENTALS CLIN PH, Vfirst, P57; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yoshida M, 1997, ANN NY ACAD SCI, V811, P493, DOI 10.1111/j.1749-6632.1997.tb52031.x	39	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19035	19040		10.1074/jbc.274.27.19035	http://dx.doi.org/10.1074/jbc.274.27.19035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383404	hybrid			2022-12-27	WOS:000081196300027
J	Guo, CY; Wang, Y; Brautigan, DL; Larner, JM				Guo, CY; Wang, Y; Brautigan, DL; Larner, JM			Histone H1 dephosphorylation is mediated through a radiation-induced signal transduction pathway dependent on ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; CHINESE-HAMSTER CELLS; S-PHASE CHECKPOINTS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CHROMATIN STRUCTURE; POTENT INHIBITOR; GENE-PRODUCT; OVARY CELLS; PHOSPHORYLATION	Ionizing radiation is known to activate multiple signal transduction pathways, but the targets of these pathways are poorly understood. Phosphorylation of histone Ill is thought to have a role in chromatin condensation/ decondensation, and we asked whether ionizing radiation (IR) would alter H1 phosphorylation. Our data demonstrate that low doses of IR result in a dramatic, but transient, dephosphorylation of H1 isoforms, The in vivo IR-induced dephosphorylation of H1 is completely blocked by wortmannin and is abrogated in ataxia telangiectasia cells. Furthermore, we measured radiation-induced inhibition of cyclin dependent kinase activity and activation of histone H1 phosphatase activity. Both activities were affected by radiation-induced signals in an ATM dependent manner. Thus, the rapid IR-induced dephosphorylation of H1 involves a pathway including ATM and a wortmannin-sensitive step leading to both inhibition of cyclin-dependent kinase activities as well as activation of H1 phosphatase(s).	Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Dept Radiat Oncol, Box 383, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA 72622] Funding Source: Medline; NIGMS NIH HHS [GM 56362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA072622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GURLEY LR, 1971, BIOCHEMISTRY-US, V10, P1588, DOI 10.1021/bi00785a013; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; HARPER JW, 1993, CELL, V75, P805; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; Jung M, 1997, CANCER RES, V57, P24; Larner JM, 1997, CANCER SURV, V29, P25; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LIU VF, 1995, STEM CELLS, V13, P117; LU MJ, 1994, CHROMOSOMA, V103, P111; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PASCHAL B, 1998, CELL BIOL LAB HDB, V2; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18715	18720		10.1074/jbc.274.26.18715	http://dx.doi.org/10.1074/jbc.274.26.18715			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373485	hybrid			2022-12-27	WOS:000081056700077
J	Kwon, G; Xu, G; Marshall, CA; McDaniel, ML				Kwon, G; Xu, G; Marshall, CA; McDaniel, ML			Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta(12,14)-prostaglandin J(2) and aminoguanidine - A role for peroxisome proliferator-activated receptor gamma activation and iNOS expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; SIGNAL-TRANSDUCTION; GLUCOSE-TOLERANCE; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; PPAR-GAMMA; PHAS-I	Recent studies have identified a beta-cell insulin receptor that functions in the regulation of protein translation and mitogenic signaling similar to that described for insulin-sensitive cells. These findings have raised the novel possibility that beta-cells may exhibit insulin resistance similar to skeletal muscle, liver, and fat. To test this hypothesis, the effects of tumor necrosis factor-alpha (TNF alpha), a cytokine proposed to mediate insulin resistance by interfering with insulin signaling at the level of the insulin receptor and its substrates, was evaluated. TNF alpha inhibited p70(s6k) activation by glucose-stimulated beta-cells of the islets of Langerhans in a dose- and time-dependent manner, with maximal inhibition observed at similar to 20-50 ng/ml, detected after 24 and 48 h of exposure. Exogenous insulin failed to prevent TNF alpha-induced inhibition of p70(s6k), suggesting a defect in the insulin signaling pathway. To further define mechanisms responsible for this inhibition and also to exclude cytokine-induced nitric oxide (NO) as a mediator, the ability of exogenous or endogenous insulin +/- inhibitors of nitric-oxide synthase (NOS) activity, aminoguanidine or N-monomethyl-L-arginine, was evaluated. Unexpectedly, TNFa and also interleukin 1 (IL-1)-induced inhibition of p70(s6k) was completely prevented by inhibitors that block NO production. Western blot analysis verified inducible NOS (MOS) expression after TNF alpha exposure. Furthermore, the ability of IL-1 receptor antagonist protein, IRAP, to block TNF alpha-induced inhibition of p70(s6k) indicated that activation of intra-islet macrophages and the release of IL-1 that induces iNOS expression in beta-cells was responsible for the inhibitory effects of TNF alpha. This mechanism was confirmed by the ability of the peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) to attenuate TNF alpha-induced insulin resistance by down-regulating MOS expression and/or blocking IL-1 release from activated macrophages. Overall, TNF alpha-mediated insulin resistance in beta-cells is characterized by a global inhibition of metabolism mediated by NO differing from that proposed for this proinflammatory cytokine in insulin-sensitive cells.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu			NIDDK NIH HHS [DK55024, DK06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK055024, R01DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1995, DIABET ANN, V9, P265; CORBETT JA, 1996, NITRIC OXIDE PRINCIP, P177; DeFronzo RA, 1997, DIABETES REV, V5, P177; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KHAN CR, 1997, CELL, V88, P561; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LEE MK, 1994, DIABETES, V43, P1435, DOI 10.2337/diabetes.43.12.1435; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Ma ZM, 1997, J BIOL CHEM, V272, P17827, DOI 10.1074/jbc.272.28.17827; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Peraldi P, 1997, J ENDOCRINOL, V155, P219, DOI 10.1677/joe.0.1550219; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; Prigeon RL, 1998, J CLIN ENDOCR METAB, V83, P819, DOI 10.1210/jc.83.3.819; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	44	67	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18702	18708		10.1074/jbc.274.26.18702	http://dx.doi.org/10.1074/jbc.274.26.18702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373483	hybrid			2022-12-27	WOS:000081056700075
J	LaPlante, SR; Cameron, DR; Aubry, N; Lefebvre, S; Kukolj, G; Maurice, R; Thibeault, D; Lamarre, D; Llinas-Brunet, M				LaPlante, SR; Cameron, DR; Aubry, N; Lefebvre, S; Kukolj, G; Maurice, R; Thibeault, D; Lamarre, D; Llinas-Brunet, M			Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; SERINE-PROTEASE; CLEAVAGE PRODUCTS; CRYSTAL-STRUCTURE; PEPTIDE; POLYPROTEIN; PROTEINASE; INHIBITORS; CONFORMATION; PRECURSOR	The interactions of the NS3 protease domain with inhibitors that are based on N-terminal cleavage products of peptide substrates were studied by NMR methods. Transferred nuclear Overhauser effect experiments showed that these inhibitors bind the protease in a well defined, extended conformation. Protease-induced line-broadening studies helped identify the segments of inhibitors which come into contact with the protease. A comparison of the NMR data of the free and protease-bound states suggests that these ligands undergo rigidification upon complexation. This work provides the first structure of an inhibitor when bound to NS3 protease and should be valuable for designing more potent inhibitors.	Boehringer Ingelheim Canada Ltd, Dept Chem, Bio Mega Res Div, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Bio Mega Res Div, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	LaPlante, SR (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Chem, Bio Mega Res Div, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	slaplante@lav.boehringer-ingelheim.com		Cameron, Dale/0000-0001-6274-2913				BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Bodanszky M., 1993, PEPTIDE CHEM; Briand J, 1995, J BIOMOL NMR, V6, P347; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Ingallinella P, 1998, BIOCHEMISTRY-US, V37, P8906, DOI 10.1021/bi980314n; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kwong AD, 1998, ANTIVIR RES, V40, P1, DOI 10.1016/S0166-3542(98)00043-6; LaPlante SR, 1998, ANGEW CHEM INT EDIT, V37, P2729, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2729::AID-ANIE2729>3.0.CO;2-4; LaPlante SR, 1998, BIOCHEMISTRY-US, V37, P9793, DOI 10.1021/bi980555v; LaPlante SR, 1999, J AM CHEM SOC, V121, P2974, DOI 10.1021/ja983904h; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P2719, DOI 10.1016/S0960-894X(98)00480-6; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; LYERLA JR, 1974, TOP CARBON 13 NMR SP, V1, P79; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLGAR L, 1989, MECH PROTEASE ACTION; REED KE, 1998, RB8 STUD HEMATOL, V62, P1; SCHECHTER J, 1970, PHIL T R SOC LONDO B, V257, P249; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Steinkuhler C, 1996, J VIROL, V70, P6694; STEWART JM, 1984, SOLID PHASE PEPTIDE, P149; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Urbani A, 1997, J BIOL CHEM, V272, P9204; Yan YW, 1998, PROTEIN SCI, V7, P837; [No title captured]	36	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18618	18624		10.1074/jbc.274.26.18618	http://dx.doi.org/10.1074/jbc.274.26.18618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373473	hybrid			2022-12-27	WOS:000081056700065
J	Mikami, T; Kusakabe, T; Suzuki, N				Mikami, T; Kusakabe, T; Suzuki, N			Tandem organization of medaka fish soluble guanylyl cyclase alpha(1) and beta(1) subunit genes - Implications for coordinated transcription of two subunit genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE; MOLECULAR-CLONING; ORYZIAS-LATIPES; RAT LUNG; ACTIVITY REQUIRES; ENZYME SUBUNITS; BLOOD-PRESSURE; MESSENGER-RNA; 2 SUBUNITS	We determined the complete nucleotide sequences of the a, subunit gene (OIGCS-alpha(1)) and the beta(1) subunit gene (OlGCS-beta(1)) of medaka fish soluble guanylyl cyclase, In the genome, OlGCS-alpha(1) and OlGCS-beta(1) are organized in tandem. The two genes are only 986 base pairs apart and span approximately 34 kilobase pairs in the order of OlGCS-alpha(1) and OlGCS-beta(1). The nucleotide sequence of a large part of the 5'-upstream region of OlGCS-alpha(1) is complimentarily conserved in that of OlGCS-beta(1). To analyze the promoter activity of each gene, a fusion gene construct in which the 5'-upstream region was fused with the green fluorescent protein gene was injected into medaka fish 2-cell embryos. When the fusion gene containing the OlGCS-alpha(1) upstream region was injected, green fluorescent protein fluorescence was detected in the embryonic brain. The 5'-upstream region of OlGCS-beta(1) alone was insufficient for the reporter gene expression in the embryos. When the OlGCS-alpha(1) upstream region was located upstream of the OlGCS-beta(1)-green fluorescence protein fusion gene, the reporter gene was expressed in the brain and trunk region of the embryos. These results suggest that the 5'-upstream region of OlGCS-alpha(1) can affect the expression of OlGCS-beta(1). It is therefore possible that the expression of OlGCS-alpha(1) and OlGCS-beta(1) is coordinated.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Suzuki, N (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.		Kusakabe, Takehiro/H-7178-2012	Kusakabe, Takehiro/0000-0002-8325-3665				Azam M, 1998, HYPERTENSION, V32, P149, DOI 10.1161/01.HYP.32.1.149; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FAISST S, 1991, NUCLEIC ACIDS RES, V18, P6573; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GIUILI G, 1993, HUM GENET, V91, P257; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; IWAMATSU T, 1983, J EXP ZOOL, V228, P83, DOI 10.1002/jez.1402280109; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; Mikami T, 1998, EUR J BIOCHEM, V253, P42, DOI 10.1046/j.1432-1327.1998.2530042.x; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PAPAPETROPOULOS A, 1995, HYPERTENSION, V26, P696, DOI 10.1161/01.HYP.26.4.696; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Savchenko A, 1997, NATURE, V390, P694, DOI 10.1038/37803; Scholz NL, 1998, J NEUROBIOL, V34, P208, DOI 10.1002/(SICI)1097-4695(19980215)34:3<208::AID-NEU2>3.0.CO;2-6; Seimiya M, 1997, J BIOL CHEM, V272, P23407, DOI 10.1074/jbc.272.37.23407; SHIMOUCHI A, 1993, AM J PHYSIOL, V265, P6456; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Truman JW, 1996, DEVELOPMENT, V122, P3949; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; Wedel BJ, 1998, TRENDS ENDOCRIN MET, V9, P213, DOI 10.1016/S1043-2760(98)00061-7; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18567	18573		10.1074/jbc.274.26.18567	http://dx.doi.org/10.1074/jbc.274.26.18567			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373466	hybrid			2022-12-27	WOS:000081056700058
J	Bossy-Wetzel, E; Green, DR				Bossy-Wetzel, E; Green, DR			Caspases induce cytochrome c release from mitochondria by activating cytosolic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CELL-FREE SYSTEM; SIGNALING COMPLEX; FUNCTIONS DOWNSTREAM; PROTEASE ACTIVATION; NECROSIS-FACTOR; CD95 FAS/APO-1; DEATH DOMAIN; BCL-X(L); BCL-2	We investigated the ability of caspases (cysteine proteases with aspartic acid specificity) to induce cytochrome c release from mitochondria. When Jurkat cells were induced to undergo apoptosis by Fas receptor ligation, cytochrome c was released from mitochondria, an event that was prevented by the caspase inhibitor, zVAD-fmk (zVal-Ala-Asp-CR2F). Purified caspase-8 triggered rapid cytochrome c release from isolated mitochondria in vitro. The effect was indirect, as the presence of cytosol was required, suggesting that caspase-8 cleaves and activates a cytosolic substrate, which in turn is able to induce cytochrome c release from mitochondria, The cytochrome c releasing activity was not blocked by caspase inhibition, but was antagonized by Bcl-2 or Bcl-xL. Caspase-8 and caspase-3 cleaved Bid, a proapoptotic Bcl-2 family member, which gains cytochrome c releasing activity in response to caspase cleavage. However, caspase-6 and caspase-7 did not cleave Bid, although they initiated cytochrome c release from mitochondria in the presence of cytosol. Thus, effector caspases may cleave and activate another cytosolic substrate (other than Bid), which then promotes cytochrome c release from mitochondria. Mitochondria significantly amplified the caspase-8 initiated DEVD-specific cleavage activity. Our data suggest that cytochrome c release, initiated by the action of caspases on a cytosolic substrates, may act to amplify a caspase cascade during apoptosis.	La Jolla Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Green, DR (corresponding author), La Jolla Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hasegawa J, 1996, CANCER RES, V56, P1713; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZY, 1996, OPT REV, V3, P47, DOI 10.1007/s10043-996-0047-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	278	281	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17484	17490		10.1074/jbc.274.25.17484	http://dx.doi.org/10.1074/jbc.274.25.17484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364179	hybrid			2022-12-27	WOS:000080974300015
J	Jin, DY; Giordano, V; Kibler, KV; Nakano, H; Jeang, KT				Jin, DY; Giordano, V; Kibler, KV; Nakano, H; Jeang, KT			Role of adapter function in oncoprotein-mediated activation of NF-kappa B - Human T-cell leukemia virus type i tax interacts directly with I kappa B kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; IKK-ALPHA; PROTEIN; BETA; ASSOCIATION; LYMPHOCYTES; COMPLEX; P16(INK4A); REPRESSOR; INDUCTION	Mechanisms by which the human T-cell leukemia virus tyre I Tax oncoprotein activates NF-kappa B remain incompletely understood. Although others have described an interaction between Tax and a holo-I kappa B kinase (IKK) complex, the exact details of protein-protein contact are not fully defined. Here we show that Tax binds to neither IKK-alpha nor IKH-beta but instead complexes directly with IKK-gamma, a newly characterized component of the IKK complex. This direct interaction with IKK-gamma correlates with Tax-induced I kappa B-alpha phosphorylation and NF-kappa B activation, Thus, our findings establish IKK-gamma as a key molecule for adapting an oncoprotein-specific signaling to IKK-alpha and IKK-beta.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1010062, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Juntendo University; Japan Science & Technology Agency (JST)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kjeang@niaid.nih.gov	Jeang, Kuan-Teh/A-2424-2008	Nakano, Hiroyasu/0000-0003-4843-1427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, J BIOMED SCI, V6, P115, DOI 10.1007/BF02256442; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REID RL, 1993, ONCOGENE, V8, P3029; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	40	193	196	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17402	17405		10.1074/jbc.274.25.17402	http://dx.doi.org/10.1074/jbc.274.25.17402			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364167	hybrid			2022-12-27	WOS:000080974300003
J	Xu, GG; Gao, ZY; Borge, PD; Wolf, BA				Xu, GG; Gao, ZY; Borge, PD; Wolf, BA			Insulin receptor substrate 1-induced-inhibition of endoplasmic reticulum Ca2+ uptake in beta-cells - Autocrine regulation of intracellular Ca2+ homeostasis and insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC-ISLETS; TYROSINE PHOSPHORYLATION; MYOINOSITOL 1,4,5-TRISPHOSPHATE; TARGETED DISRUPTION; ISOLATED ORGANELLES; CA-2+ MOBILIZATION; PLASMA-MEMBRANE; GLUCOSE SENSOR; RAT INSULINOMA	To understand the role of the insulin receptor pathway in beta-cell function, we have generated stable beta-cells (beta IRS1-A) that overexpress by S-fold the insulin receptor substrate-1 (IRS-1) and compared them to vector-expressing controls. IRS-1 overexpression dramatically increased basal cytosolic Ca2+ levels from 81 to 278 nM, but it did not affect Ca2+ response to glucose. Overexpression of the insulin receptor also caused an increase in cytosolic Ca2+. Increased cytosolic Ca2+ was due to inhibition of Ca2+ uptake by the endoplasmic reticulum, because endoplasmic reticulum Ca2+ uptake and content were reduced in beta IRS1-A cells. Fractional insulin secretion was significantly increased 2-fold, and there was a decrease in beta IRS1-A insulin content and insulin biosynthesis. Steady-state insulin mRNA levels and glucose-stimulated ATP were unchanged. High IFS-1 levels also reduced beta-cell proliferation. These data demonstrate a direct link between the insulin receptor signaling pathway and the Ca2+-dependent pathways regulating insulin secretion of beta-cells. We postulate that during regulated insulin secretion, released insulin binds the beta-cell insulin receptor and activates IRS-1, thus further increasing cytosolic Ca2+ by reducing Ca2+ uptake. We suggest the existence of a novel pathway of autocrine regulation of intracellular Ca2+ homeostasis and insulin secretion in the beta-cell of the endocrine pancreas.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wolf, BA (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 230 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049814, P30DK019525, R01DK043354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19525, DK43354, DK49814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Avruch J, 1998, NATURE, V391, P846, DOI 10.1038/35998; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLCA JR, 1982, J BIOL CHEM, V257, P7223; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P6947, DOI 10.1073/pnas.92.15.6947; Gao ZY, 1998, EUR J NEUROSCI, V10, P2416, DOI 10.1046/j.1460-9568.1998.00252.x; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Guest PC, 1997, BIOCHEM J, V323, P445, DOI 10.1042/bj3230445; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HENQUIN JC, 1992, ENDOCRINOLOGY, V131, P127, DOI 10.1210/en.131.1.127; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEVY J, 1994, AM J MED, V96, P260, DOI 10.1016/0002-9343(94)90152-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacLennan DH, 1997, ANN NY ACAD SCI, V834, P175, DOI 10.1111/j.1749-6632.1997.tb52249.x; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PRENTKI M, 1984, J BIOL CHEM, V259, P4054; PRENTKI M, 1984, J BIOL CHEM, V259, P118; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THIES RS, 1989, J BIOL CHEM, V264, P12820; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; VARADI A, 1995, BBA-BIOMEMBRANES, V1236, P119, DOI 10.1016/0005-2736(95)00103-A; WERTHEIMER E, 1993, NAT GENET, V5, P71, DOI 10.1038/ng0993-71; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLF BA, 1988, AM J PHYSIOL, V254, pE121, DOI 10.1152/ajpendo.1988.254.2.E121; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 1998, DIABETES, V47, P1243, DOI 10.2337/diabetes.47.8.1243; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	52	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18067	18074		10.1074/jbc.274.25.18067	http://dx.doi.org/10.1074/jbc.274.25.18067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364259	hybrid			2022-12-27	WOS:000080974300095
J	Merzendorfer, H; Huss, M; Schmid, P; Harvey, WR; Wieczorek, H				Merzendorfer, H; Huss, M; Schmid, P; Harvey, WR; Wieczorek, H			A novel insect V-ATPase subunit M9.7 is glycosylated extensively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; POLYMERASE CHAIN-REACTION; MANDUCA-SEXTA MIDGUT; VACUOLAR-TYPE ATPASE; PLASMA-MEMBRANE; SECONDARY-STRUCTURE; ESCHERICHIA-COLI; PROTON PUMP; ENDOPLASMIC-RETICULUM; POLYACRYLAMIDE GELS	Plasma membrane V-ATPase isolated from midgut and Malpighian tubules of the tobacco hornworm, Manduca sexta, contains a novel prominent 20-kDa polypeptide. Based on N-terminal protein sequencing, we cloned a corresponding cDNA. The deduced hydrophobic protein consisted of 88 amino acids with a molecular mass of only 9.7 kDa. Immunoblots of the recombinant 9.7-kDa polypeptide, using a monoclonal antibody to the 20-kDa polypeptide, confirmed that the correct cDNA had been cloned. The 20-kDa polypeptide is glycosylated, as deduced from lectin staining. Treatment with N-glycosidase A resulted in the appearance of two additional protein bands of 16 and 10 kDa which both were immunoreactive to the 20-kDa polypeptide-specific monoclonal antibody. Thus, extensive N-glycosylation of the novel V-0 subunit M9.7 accounts for half of its molecular mass observed in SDS-polyacrylamide gel electrophoresis. M9.7 exhibits some similarities to the yeast protein Vma21p which resides in the endoplasmic reticulum and is required for the assembly of the V-0 complex. However, as deduced from immunoblots as well as from activities of the V-ATPase and endoplasmic reticulum marker enzymes in different membrane preparations, M9.7 is, in contrast to the yeast polypeptide, a constitutive subunit of the mature plasma membrane V-ATPase of M. sexta.	Univ Osnabruck, Dept Biol, Sect Anim Physiol, D-49069 Osnabruck, Germany; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA	University Osnabruck; State University System of Florida; University of Florida	Wieczorek, H (corresponding author), Univ Osnabruck, Dept Biol, Sect Anim Physiol, D-49069 Osnabruck, Germany.							ARAI H, 1988, J BIOL CHEM, V263, P8796; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; AZUMA M, 1995, FEBS LETT, V361, P153, DOI 10.1016/0014-5793(95)00146-Z; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEGG JCS, 1982, ANAL BIOCHEM, V127, P389, DOI 10.1016/0003-2697(82)90192-0; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FERRERAS M, 1993, ANAL BIOCHEM, V213, P206, DOI 10.1006/abio.1993.1410; FROHLICH DR, 1994, J MOL EVOL, V38, P476, DOI 10.1007/BF00178847; GRAF R, 1994, J BIOL CHEM, V269, P3767; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HAWKES R, 1982, ANAL BIOCHEM, V123, P143, DOI 10.1016/0003-2697(82)90634-0; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HSU DKW, 1995, FEBS LETT, V371, P127, DOI 10.1016/0014-5793(95)00867-9; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lepier A, 1996, J BIOL CHEM, V271, P8502, DOI 10.1074/jbc.271.14.8502; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; Ludwig J, 1998, J BIOL CHEM, V273, P10939, DOI 10.1074/jbc.273.18.10939; Merzendorfer H, 1997, J EXP BIOL, V200, P225; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROST B, 1995, PROTEIN SCI, V4, P521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; SCHNEPPE B, 1991, FEBS LETT, V292, P145, DOI 10.1016/0014-5793(91)80853-U; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	47	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17372	17378		10.1074/jbc.274.24.17372	http://dx.doi.org/10.1074/jbc.274.24.17372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358099	hybrid			2022-12-27	WOS:000080780400098
J	Pedram, M; Donelson, JE				Pedram, M; Donelson, JE			The anatomy and transcription of a monocistronic expression site for a metacyclic variant surface glycoprotein gene in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL-HYDROXYMETHYLURACIL; AFRICAN TRYPANOSOMES; VSG GENE; ANTIGENIC VARIATION; DNA MODIFICATION; POINT MUTATIONS; LIFE-CYCLE; RHODESIENSE; PROMOTER; BASE	African trypanosomes evade the immune response of their mammalian hosts by switching the expression of their variant surface glycoprotein genes (vsg). The bloodstream trypanosome clone MVAT4 of Trypanosoma brucei rhodesiense expresses a metacyclic vsg as a monocistronic RNA from a promoter located 2 kilobases (kb) upstream of its start codon. Determination of 23 kb of sequence at the metacyclic variant antigen type 4 (MVAT) vsg expression site (ES) revealed an ES-associated gene (esag) 1 preceded by an ingi retroposon and an inverted region containing an unrelated vsg, short stretches of 70-bp repeats and a pseudo esag 3. Nuclear run-on experiments indicate that the 18-kb region upstream of the MVAT4 vsg promoter is transcriptionally silent. However, multiple members of different esag families are expressed from elsewhere in the genome. The MVAT4 vsg promoter is highly repressed in the procyclic stage, in contrast to the known polycistronic vsg ESs which undergo abortive transcription. Activation of the MVAT4 vsg ES occurs in situ without nucleotide sequence changes, although this monocistronic ES undergoes a pattern of base J modifications similar to that reported for the polycistronic ESs. The relative simplicity of the MVAT4 vsg ES and the uncoupled expression of the vsg and esags provide a unique opportunity for investigating the molecular mechanisms responsible for antigenic variation in African trypanosomes.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Pedram, Mehrdad/L-4072-2016; Donelson, John E/F-5795-2010	Pedram, Mehrdad/0000-0002-7348-3475; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591, R21AI032135, R01AI032135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40591, AI32135] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; Barry JD, 1998, MOL BIOCHEM PARASIT, V91, P93, DOI 10.1016/S0166-6851(97)00193-X; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 1997, Behring Inst Mitt, P1; Borst P, 1997, MOL BIOCHEM PARASIT, V90, P1, DOI 10.1016/S0166-6851(97)00170-9; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; Borst Piet, 1997, P109; CAMPBELL DA, 1984, NUCLEIC ACIDS RES, V12, P2759, DOI 10.1093/nar/12.6.2759; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; GERRITS H, 1998, WOODS HOLE MOL PARAS, V9, P84; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; Kim KS, 1997, J BIOL CHEM, V272, P24637, DOI 10.1074/jbc.272.39.24637; KIMMEL BE, 1987, MOL CELL BIOL, V7, P1465, DOI 10.1128/MCB.7.4.1465; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LODES MJ, 1993, MOL CELL BIOL, V13, P7036, DOI 10.1128/MCB.13.11.7036; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; Morgan RW, 1996, J BIOL CHEM, V271, P9771, DOI 10.1074/jbc.271.16.9771; MURPHY NB, 1987, J MOL BIOL, V195, P855, DOI 10.1016/0022-2836(87)90490-6; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; Navarro M, 1996, MOL CELL BIOL, V16, P3615; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; Rudenko G, 1998, MOL BIOCHEM PARASIT, V95, P97, DOI 10.1016/S0166-6851(98)00099-1; Rudenko G, 1996, MOL BIOCHEM PARASIT, V80, P65, DOI 10.1016/0166-6851(96)02669-2; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 2002, MOL CLONING LAB MANU; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; TETLEY L, 1987, J CELL SCI, V87, P363; THOMPSON JS, 1994, MOL CELL BIOL, V14, P446, DOI 10.1128/MCB.14.1.446; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; Vanhamme L, 1998, MOL BIOCHEM PARASIT, V91, P107, DOI 10.1016/S0166-6851(97)00194-1; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; vanLeeuwen F, 1996, NUCLEIC ACIDS RES, V24, P2476, DOI 10.1093/nar/24.13.2476; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P131, DOI 10.1016/0166-6851(96)02726-0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VICKERMAN K, 1988, BIOL CELL, V64, P109, DOI 10.1016/0248-4900(88)90070-6; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	68	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16876	16883		10.1074/jbc.274.24.16876	http://dx.doi.org/10.1074/jbc.274.24.16876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358033	hybrid			2022-12-27	WOS:000080780400032
J	Richman, TJ; Sawyer, MM; Johnson, DI				Richman, TJ; Sawyer, MM; Johnson, DI			The Cdc42p GTPase is involved in a G(2)/M morphogenetic checkpoint regulating the apical-isotropic switch and nuclear division in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENE; PHEROMONE-RESPONSE PATHWAY; GUANINE-NUCLEOTIDE EXCHANGE; STE20P PROTEIN-KINASE; ACTIN CYTOSKELETON; CELL POLARITY; BUDDING YEAST; BINDING PROTEIN; MOLECULAR CHARACTERIZATION; ACTIVATING PROTEIN	The Cdc42p GTPase is involved in the signal transduction cascades controlling bud emergence and polarized cell growth in S. cerevisiae. Cells expressing the cdc42(V44A) effector domain mutant allele displayed morphological defects of highly elongated and multielongated budded cells indicative of a defect in the apicalisotropic switch in bud growth. In addition, these cells contained one, two, or multiple nuclei indicative of a G(2)/M delay in nuclear division and also a defect in cytokinesis and/or cell separation. Actin and chitin were delocalized, and septin ring structure was aberrant and partially delocalized to the tips of elongated Cdc42(V44A) cells; however, Cdc42(V44A)p localization was normal. Two-hybrid protein analyses showed that the V44A mutation interfered with Cdc42p's interactions with Cla4p, a p21(Cdc42/Rac)-activated kinase (PAK)-like kinase, and the novel effecters Gic1p and Gic2p, but not with the Ste20p or Skm1p PAK-like kinases, the Bni1p formin, or the Iqg1p IQGAP homolog. Furthermore, the CdC42V44A morphological defects were suppressed by deletion of the Swe1p cyclin-dependent kinase inhibitory kinase and by overexpression of Cla ip, Ste20p, the Cdc12 septin protein, or the guanine nucleotide exchange factor Cdc24p, In sum, these results suggest that proper Cdc42p function is essential for timely progression through the apical-isotropic switch and G(2)/M transition and that Cdc42(V44A)p differentially interacts with a number of effecters and regulators.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Johnson, DI (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, 202 Stafford Hall, Burlington, VT 05405 USA.				NATIONAL CANCER INSTITUTE [T32CA009286] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09286-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Akada R, 1996, GENETICS, V143, P103; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Eby JJ, 1998, CURR BIOL, V8, P967, DOI 10.1016/S0960-9822(98)00398-4; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HARTWELL LH, 1973, GENETICS, V74, P267; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Miller PJ, 1997, YEAST, V13, P561; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; REYNOLDS A, 1989, CURRENT PROTOCOLS MO, V2; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman F., 1986, METHODS YEAST GENETI; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	65	79	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16861	16870		10.1074/jbc.274.24.16861	http://dx.doi.org/10.1074/jbc.274.24.16861			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358031	hybrid			2022-12-27	WOS:000080780400030
J	Vaduva, G; Martinez-Quiles, N; Anton, IM; Martin, NC; Geha, RS; Hopper, AK; Ramesh, N				Vaduva, G; Martinez-Quiles, N; Anton, IM; Martin, NC; Geha, RS; Hopper, AK; Ramesh, N			The human WASP-interacting protein, WIP, activates the cell polarity pathway in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; SACCHAROMYCES-CEREVISIAE; ACTIN POLYMERIZATION; T-CELLS; CDC42; POLARIZATION; CYTOSKELETON; CHEMOTAXIS; VERPROLIN; GENE	WIP, the Wiskott-Aldrich syndrome protein-interacting protein, is a human protein involved in actin polymerization and redistribution in lymphoid cells. The mechanism by which WIP reorganizes actin cytoskeleton is unknown. WIP is similar to yeast verprolin, an actin- and myosin-interacting protein required for polarized morphogenesis. To determine whether WIP and verprolin are functional homologues, we analyzed the function of WIP in yeast. WIP suppresses the growth defects of VRP1 missense and null mutations as well as the defects in cytoskeletal organization and endocytosis observed in vrp1-1 cells. The ability of WIP to replace verprolin is dependent on its WH2 actin binding domain and a putative profilin binding domain. Immunofluorescence localization of WIP in yeast cells reveals a pattern consistent with its function at the cortical sites of growth. Thus, like verprolin, WIP functions in yeast to link the polarity development pathway and the actin cytoskeleton to generate cytoskeletal asymmetry. A role for WIP in cell polarity provides a framework for unifying, under a common paradigm, distinct molecular defects associated with immunodeficiencies like Wiskott-Aldrich syndrome.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, Boston, MA 02115 USA; Univ Louisville, Sch Med, Dept Biochem, Louisville, KY 40292 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Louisville	Hopper, AK (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	ahopper@psu.edu	Martinez-Quiles, Narcisa/G-8514-2013; Anton, Ines M/G-6090-2015	Anton, Ines M/0000-0002-2935-5919; Martinez Quiles, Narcisa/0000-0002-0366-6591	NHLBI NIH HHS [HL-59561, P01 HL059561] Funding Source: Medline; NIAID NIH HHS [AI-37130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS A, 1997, METHDS YEAST GENETIC, P109; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1995, MOL CELL BIOL, V15, P69, DOI 10.1128/MCB.15.1.69; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Badolato R, 1998, J IMMUNOL, V161, P1026; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; Featherstone C, 1997, SCIENCE, V275, P27, DOI 10.1126/science.275.5296.27; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; KENNEY D, 1986, BLOOD, V68, P1329; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Luton F, 1997, J IMMUNOL, V158, P3140; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; Nonoyama S, 1998, CURR OPIN IMMUNOL, V10, P407, DOI 10.1016/S0952-7915(98)80113-1; OCHS HD, 1980, BLOOD, V55, P243; Ochs HD, 1998, SPRINGER SEMIN IMMUN, V19, P435, DOI 10.1007/BF00792601; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; REMOLDODONNELL E, 1993, IMMUNODEFICIENCIES, P225; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tolerico LH, 1999, GENETICS, V151, P57; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x; ZOLADEK T, 1995, MOL CELL BIOL, V15, P6884	43	63	63	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17103	17108		10.1074/jbc.274.24.17103	http://dx.doi.org/10.1074/jbc.274.24.17103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358064	hybrid			2022-12-27	WOS:000080780400063
J	Fujio, Y; Walsh, K				Fujio, Y; Walsh, K			Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; INTEGRIN ALPHA(V)BETA(3); VESSEL DEVELOPMENT; SURVIVAL FACTOR; APOPTOSIS; ACTIVATION; EXPRESSION; ANGIOGENESIS; INSULIN	Regulation of endothelial cell apoptosis is a critical modulator of normal and pathological angiogenesis. In this study, we examined the role of the protein kinase Akt/PKB in endothelial cell survival in response to growth factor and matrix attachment signals. Vascular endothelial growth factor(VEGF)-induced cytoprotection of endothelial cell monolayers correlated with the wortmannin-sensitive induction of Akt activity. Transfection of an adenovirus expressing a dominant-negative Akt mutant decreased endothelial cell viability in the presence of VEGF. Conversely, adenoviral transduction of wild-type Akt facilitated the cell survival effects of VEGF, whereas transduction of constitutively active Akt conferred endothelial cell survival in the absence of VEGF. Constitutively active Akt also conferred survival to endothelial cells in suspension culture, whereas stimulation with VEGF did not. In suspension cultures, VEGF stimulation was unable to activate Akt, and Akt protein levels were repressed in cells undergoing anoikis. These data suggest that cross-talk between growth factor- and anchorage-dependent signaling pathways are essential for Akt activation and endothelial cell survival.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, Sackler Sch Biomed Studies, Program Cell Mol & Dev Biol, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University	Walsh, K (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.		Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930; Walsh, Kenneth/0000-0001-7580-2276	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [R37 AG015052, AG15052, R01 AG015052] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENNEDY SG, 1997, GENE DEV, V11, P710; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	472	503	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16349	16354		10.1074/jbc.274.23.16349	http://dx.doi.org/10.1074/jbc.274.23.16349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347193	Green Accepted, hybrid			2022-12-27	WOS:000080668600053
J	Xu, JH; Tse, FW				Xu, JH; Tse, FW			Brefeldin A increases the quantal size and alters the kinetics of catecholamine release from rat adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; REGULATED EXOCYTOSIS; TRANSMITTER RELEASE; ORGANELLE STRUCTURE; SYNAPTIC VESICLES; PHOSPHOLIPASE-D; IN-VITRO; FUSION; ARF; INHIBITION	The fungal metabolite, brefeldin A (BFA), is known to inhibit guanine nucleotide exchange on the ADP-ribosylating factors that are involved in vesicle membrane trafficking. Here, we investigated the action of BFA on Ca2+-regulated exocytosis in single rat adrenal chromaffin cells. Incubation of chromaffin cells with BFA (1 or 10 mu M) for 2 h effectively disrupted the Golgi membranes but did not affect the pattern of catecholamine release triggered by high extracellular K+, which was monitored with carbon fiber amperometry along with cytosolic Ca2+ measurement. The BFA treatment, however, increased the mean quantal size of catecholamine-containing vesicles and the occurrence of amperometric events with a "foot" or "stand alone" signal (which reflects sluggish or incomplete dilation of the fusion pore). To examine whether BFA altered the Ca2+-dependence of exocytosis, we employed the whole-cell recording technique in conjunction with the capacitance measurement to measure exocytosis evoked from the entire cell during voltage-gated Ca2+ entry. Our results suggested that BFA treatment did not alter either the initial rate of capacitance increase or the total amount of capacitance increase. Therefore, in chromaffin cells, BFA treatment affects Ca2+-regulated exocytosis predominantly by increasing the quantal size and by slowing the fusion kinetics of some vesicles.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Tse, FW (corresponding author), Univ Alberta, Dept Pharmacol, 9-70 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.		Tse, Frederick/C-3449-2013	Xu, Jianhua/0000-0003-0084-8856				BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow Robert H., 1995, P245; Cleves AE, 1997, NEUROCHEM RES, V22, P933, DOI 10.1023/A:1022462523315; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; Finnegan JM, 1996, J NEUROCHEM, V66, P1914; Fischer TA, 1997, AM J PHYSIOL-HEART C, V272, pH958, DOI 10.1152/ajpheart.1997.272.2.H958; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; HERRINGTON J, 1994, PULSE CONTROL, V5; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lim W, 1997, PFLUG ARCH EUR J PHY, V435, P34, DOI 10.1007/s004240050481; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Loirand G, 1997, AM J PHYSIOL-CELL PH, V273, pC816, DOI 10.1152/ajpcell.1997.273.3.C816; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; Pothos EN, 1998, J NEUROSCI, V18, P5575; Pothos EN, 1998, J NEUROSCI, V18, P4106; ROBINSON IM, 1995, P NATL ACAD SCI USA, V92, P2474, DOI 10.1073/pnas.92.7.2474; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TSE A, 1995, PFLUG ARCH EUR J PHY, V430, P645, DOI 10.1007/BF00386158; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZIZI M, 1991, J BIOL CHEM, V266, P18443	38	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19095	19102		10.1074/jbc.274.27.19095	http://dx.doi.org/10.1074/jbc.274.27.19095			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383412	hybrid			2022-12-27	WOS:000081196300035
J	Kelly, JD; Inga, A; Chen, FX; Dande, P; Shah, D; Monti, P; Aprile, A; Burns, PA; Scott, G; Abbondandolo, A; Gold, B; Fronza, G				Kelly, JD; Inga, A; Chen, FX; Dande, P; Shah, D; Monti, P; Aprile, A; Burns, PA; Scott, G; Abbondandolo, A; Gold, B; Fronza, G			Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYMERASE-BETA; NUCLEOTIDE INCORPORATION; FUNCTIONAL ASSAY; CELL-LINES; IN-VITRO; GLYCOSYLASE; MUTAGENESIS; ALKYLATION; DEFICIENT	Me-lex, a methyl sulfonate ester appended to a neutral N-methylpyrrolecarboxamide-based dipeptide, was synthesized to preferentially generate N-3-methyladenine (3-MeA) adducts which are expected to be cytotoxic rather than mutagenic DNA lesions. In the present study, the sequence specificity for DNA alkylation by Me-lex was determined in the p53 cDNA through the conversion of the adducted sites into single strand breaks and sequencing gel analysis. In order to establish the mutagenic and lethal properties of Me-lex lesions, a yeast expression vector harboring the human wild-type p53 cDNA was treated in vitro with Me-lex, and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter. The results showed that: 1) more than 99% of the lesions induced by Me-lex are 3-MeA; 2) the co-addition of distamycin quantitatively inhibited methylation at all minor groove sites; 3) Me-lex selectively methylated A's that are in, or immediately adjacent to, the lex equilibrium binding sites; 4) all but 6 of the 33 independent mutations were base pair substitutions, the majority of which (17/33; 52%) were AT-targeted; 5) AT --> TA transversions were the predominant mutations observed (13/33; 39%); 6) 13 out of 38 (39%) independent mutations involved a single lex-binding site encompassing positions A(600-602), and 9 occurred at position 602 which is a real Me-lex mutation hotspot (n = 9, p < 10(-6), Poisson's normal distribution). A hypothetical model for the interpretation of mutational events at this site is proposed. The present work is the first report on mutational properties of Me-lex. Our results suggest that 3-MeA is not only a cytotoxic but also a premutagenic lesion which exerts this unexpected property in a strict sequence-dependent manner.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 69198 USA; Natl Canc Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Leeds; University of Genoa	Gold, B (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA.	bgold@MAIL.UNMC.EDU; fronzagi@hp380.ist.unige.it	Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Inga, Alberto/AAC-3815-2022	Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Inga, Alberto/0000-0002-8767-1637	NCI NIH HHS [CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; CHAUDHURI I, 1991, CARCINOGENESIS, V12, P2283, DOI 10.1093/carcin/12.12.2283; CHURCH KM, 1990, BIOCHEMISTRY-US, V29, P6827, DOI 10.1021/bi00481a011; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; Dinglay S, 1998, MUTAT RES-DNA REPAIR, V407, P109, DOI 10.1016/S0921-8777(97)00065-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Efrati E, 1997, J BIOL CHEM, V272, P2559; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HENRYAMAR M, 1993, HEMATOL ONCOL CLIN N, V7, P369, DOI 10.1016/S0889-8588(18)30246-6; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; Kelly JD, 1998, CHEM RES TOXICOL, V11, P1481, DOI 10.1021/tx9801763; KONAKAHARA T, 1988, BIOCHEMISTRY-US, V27, P8606, DOI 10.1021/bi00423a015; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lawley P.D, 1984, ACS MONOGR SER, V182; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; MARSELOS M, 1991, CARCINOGENESIS, V12, P1751, DOI 10.1093/carcin/12.10.1751; Mehta P, 1996, CHEM RES TOXICOL, V9, P939, DOI 10.1021/tx960007n; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; ZHANG Y, 1993, BIOCHEMISTRY-US, V32, P7954, DOI 10.1021/bi00082a017	35	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18327	18334		10.1074/jbc.274.26.18327	http://dx.doi.org/10.1074/jbc.274.26.18327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373436	hybrid			2022-12-27	WOS:000081056700028
J	Muller, S; Alving, K; Peter-Katalinic, J; Zachara, N; Gooley, AA; Hanisch, FG				Muller, S; Alving, K; Peter-Katalinic, J; Zachara, N; Gooley, AA; Hanisch, FG			High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; IN-VIVO; ANTIBODIES; SPECIFICITY; CLONING; ANTIGEN; SITES; CDNA; SEQUENCE; CHAINS	The site-specific O-glycosylation of MUC1 tandem repeat peptides from secretory mucin of T47D breast cancer cells was analyzed. After affinity isolation on immobilized BC3 antibody, MUC1 was partially deglycosylated by enzymatic treatment with alpha-sialidase/beta-galactosidase and fragmented by proteolytic cleavage with the Arg-C-specific endopeptidase clostripain, The PAP20 glycopeptides were isolated by reversed phase high pressure liquid chromatography and subjected to the structural analyses by quadrupole time-of-flight electrospray ionization mass spectrometry and to the sequencing by Edman degradation. All five positions of the repeat peptide were revealed as O-glycosylation targets in the tumor cell, including the Thr within the DTR moth, The degree of substitution was estimated to average 4.8 glycans per repeat, which compares to 2.6 glycosylated sites per repeat for the mucin fi om milk (Miiller, S,, Goletz, S,, Packer, N,, Gooley, A A, Lawson, A M,, and Hanisch, F,-G, (1997) J, Biol Chem, 272, 24780-24793), In addition to a modification by glycosylation, the immunodominant DTR motif on T47D-MUC1 is altered by amino acid replacements (PAPGSTAPAAHGVTSAPESR), which were revealed in about 50% of PAP20 peptides, The high incidence of these replacements and their detection also in other cancer cell Lines imply that the conserved tandem repeat domain of MUC1 is polymorphic with respect to the peptide sequence.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Macquarie Univ, Ctr Analyt Biotechnol, Sydney, NSW 2109, Australia	University of Cologne; University of Munster; Macquarie University	Hanisch, FG (corresponding author), Univ Cologne, Fac Med, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	franz.hanisch@uni-koeln.de						Alving K, 1998, J MASS SPECTROM, V33, P1124, DOI 10.1002/(SICI)1096-9888(1998110)33:11<1124::AID-JMS734>3.0.CO;2-H; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Cao Y, 1998, TUMOR BIOL, V19, P88, DOI 10.1159/000056509; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hanisch FG, 1998, TUMOR BIOL, V19, P111, DOI 10.1159/000056511; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1992, CANCER RES, V52, P3138; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Harrison MJ, 1998, EUR J BIOCHEM, V256, P119, DOI 10.1046/j.1432-1327.1998.2560119.x; Ho S B, 1991, Semin Cancer Biol, V2, P389; Hull S R, 1989, Cancer Commun, V1, P261; Karsten U, 1998, CANCER RES, V58, P2541; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; Petrarca C, 1996, EUR J CANCER, V32A, P2155, DOI 10.1016/S0959-8049(96)00254-7; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG YC, 1992, J BIOL CHEM, V267, P2728; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; ZACHARA NE, 1998, IN PRESS MUCIN METHO	33	139	147	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18165	18172		10.1074/jbc.274.26.18165	http://dx.doi.org/10.1074/jbc.274.26.18165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373415	hybrid			2022-12-27	WOS:000081056700007
J	Shinobu, N; Maeda, T; Aso, T; Ito, T; Kondo, T; Koike, K; Hatakeyama, M				Shinobu, N; Maeda, T; Aso, T; Ito, T; Kondo, T; Koike, K; Hatakeyama, M			Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; C-TERMINAL DOMAIN; BOX-BINDING PROTEIN; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; OLIGOMERIZATION DOMAIN; RETINOBLASTOMA PROTEIN; REPRESSION FUNCTIONS	ELL was originally identified as a gene that undergoes translocation with the trithorax-like MLL gene in acute myeloid leukemia. Recent studies have shown that the gene product, ELL, functions as an RNA polymerase II elongation factor that increases the rate of transcription by RNA polymerase II by suppressing transient pausing. Using yeast two-hybrid screening with ELL as bait, we isolated the p53 tumor suppressor protein as a specific interactor of ELL. The interaction involves respectively the transcription elongation activation domain of ELL and the C-terminal tail of p53, Through this interaction, ELL inhibits both sequence-specific transactivation and sequence-independent transrepression by p53, Thus, ELL acts as a negative regulator of p53 in transcription. Conversely, p53 inhibits the transcription elongation activity of ELL, suggesting that p53 is capable of regulating general transcription by RNA polymerase II through controlling the ELL activity. Elevated levels of ELL in cells resulted in the inhibition of p53-dependent induction of endogenous p21 and substantially protected cells from p53-mediated apoptosis that is induced by genotoxic stress. Our observations indicate the existence of a mutually inhibitory interaction between p53 and a general transcription elongation factor ELL and raise the possibility that an aberrant interaction between p53 and ELL may play a role in the genesis of leukemias carrying MLL-ELL gene translocations.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	mhatakeyama@jfcr.or.jp	Maeda, Tatsuya/L-5540-2019					ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BALKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kanda Y, 1998, J BIOL CHEM, V273, P5248, DOI 10.1074/jbc.273.9.5248; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Megonigal MD, 1998, ONCOGENE, V16, P1351, DOI 10.1038/sj.onc.1201637; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; SUBLER MA, 1994, ONCOGENE, V9, P1351; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	80	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17003	17010		10.1074/jbc.274.24.17003	http://dx.doi.org/10.1074/jbc.274.24.17003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358050	hybrid			2022-12-27	WOS:000080780400049
J	Sun, LQ; Cairns, MJ; Gerlach, WL; Witherington, C; Wang, L; King, A				Sun, LQ; Cairns, MJ; Gerlach, WL; Witherington, C; Wang, L; King, A			Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; CORONARY ANGIOPLASTY; DNA ENZYME; EXPRESSION; INDUCTION	A small catalytic DNA molecule targeting c-myc RNA was found to be a potent inhibitor of smooth muscle cell (SMC) proliferation. The catalytic domain of this molecule was based on that previously derived by in vitro selection (Santoro, S, W,, and Joyce, G, F, (1997) Proc. Natl, Acad. Sci. U.S.A. 94, 4262-4266) and is known as the "10-23" general purpose RNA-cleaving deoxyribozyme, In addition to inhibiting SMC proliferation at low concentration, this molecule (targeting the translation initiation region of c-myc RNA) was found to efficiently cleave its full-length substrate in vitro and downregulate c-myc gene expression in smooth muscle cells. The serum nuclease stability of this molecule was enhanced without substantial loss of kinetic efficiency by inclusion of a 3'-3'-internucleotide inversion at the 3'-terminal. The extent of SMC suppression was found to be influenced by the length of the substrate binding arms. This correlated to some extent with catalytic activity in both the short substrate under multiple turnover conditions and the full-length substrate under single turnover conditions, with the 9 + 9 base arm molecule producing the greatest activity.	Johnson & Johnson Res Labs, Sydney, NSW 2001, Australia	Johnson & Johnson	Sun, LQ (corresponding author), Johnson & Johnson Res Labs, 74 MacLachlan Ave, Sydney, NSW 2112, Australia.			Cairns, Murray/0000-0003-2490-2538; King, Andrew/0000-0003-0481-3490				AUSUBEL FA, 1995, CURRENT PROTOCOLS MO, V2; BANSKOTA NK, 1989, MOL ENDOCRINOL, V3, P1183, DOI 10.1210/mend-3-8-1183; Bittl JA, 1996, NEW ENGL J MED, V335, P1290, DOI 10.1056/NEJM199610243351707; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Field AK, 1998, ANTIVIR RES, V37, P67; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; Libby P, 1992, J Vasc Surg, V15, P916; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; Ortigao J F, 1992, Antisense Res Dev, V2, P129; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SHI Y, 1993, CIRCULATION, V88, P1190, DOI 10.1161/01.CIR.88.3.1190; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Sun LQ, 1997, MOL BIOTECHNOL, V7, P241, DOI 10.1007/BF02740815; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641	19	98	122	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17236	17241		10.1074/jbc.274.24.17236	http://dx.doi.org/10.1074/jbc.274.24.17236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358082	hybrid			2022-12-27	WOS:000080780400081
J	Vallar, L; Melchior, C; Plancon, S; Drobecq, H; Lippens, G; Regnault, V; Kieffer, N				Vallar, L; Melchior, C; Plancon, S; Drobecq, H; Lippens, G; Regnault, V; Kieffer, N			Divalent cations differentially regulate integrin alpha(IIb) cytoplasmic tail binding to beta(3) and to calcium- and integrin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; SURFACE-PLASMON RESONANCE; SIGNAL-TRANSDUCTION; GLANZMANN THROMBASTHENIA; SELECTIVE BINDING; STRUCTURAL MODEL; LIGAND-BINDING; CELL-ADHESION; GROWTH-FACTOR; DOMAIN	We have used recombinant or synthetic alpha(IIb) and beta(3) integrin cytoplasmic peptides to study their in vitro complexation and ligand binding capacity by surface plasmon resonance. alpha(.)beta heterodimerization occurred in a 1:1 stoichiometry with a weak K-D in the micromolar range. Divalent cations were not required for this association but stabilized the alpha(.)beta complex by decreasing the dissociation rate. alpha(.)beta complexation was impaired by the R995A substitution or the KVGFFKR deletion in alpha(IIb) but not by the beta(3) S752P mutation. Recombinant calcium-and integrin-binding protein (CIB), an alpha(IIb)-specific ligand, bound to the alpha(IIb) cytoplasmic peptide in a Ca2+- or Mn2+-independent, one-to-one reaction with a K-D value of 12 mu M. In contrast, in vitro liquid phase binding of CIB to intact alpha(IIb)beta(3) occurred preferentially with Mn2+-activated alpha(IIb)beta(3) conformers, as demonstrated by enhanced coimmunoprecipitation of CIB with PAC-1-captured Mn2+-activated alpha(IIb)beta(3), suggesting that Mn2+ activation of intact alpha(IIb)beta(3) induces the exposure of a GIB-binding site, spontaneously exposed by the free alpha(IIb) peptide. Since CIB did not stimulate PAC-1 binding to inactive alpha(IIb)beta(3) nor prevented activated alpha(IIb)beta(3) occupancy by PAC-1, we conclude that CIB does not regulate alpha(IIb)beta(3) inside-out signaling, but rather is involved in an alpha(IIb)beta(3) post-receptor occupancy event.	Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CNRS, L-1511 Luxembourg, Luxembourg; Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CRP Sante, L-1511 Luxembourg, Luxembourg; Inst Biol Lille, Lab Biol RMN, F-59000 Lille, France; Fac Med, CNRS, UMR 7563, Hematol Lab, F-54500 Vandoeuvre Nancy, France	University of Luxembourg; Luxembourg Institute of Health; University of Luxembourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine	Kieffer, N (corresponding author), Ctr Univ Luxembourg, Lab FrancoLuxembourgeois Rech Biomed, CNRS, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.		Regnault, Veronique/H-9138-2016; REGNAULT, Veronique/AAY-1711-2020	REGNAULT, Veronique/0000-0001-6418-5022; Drobecq, Herve/0000-0002-4081-1575; Vallar, Laurent/0000-0002-4404-1010; Lippens, Guy/0000-0002-8236-0901				Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1997, BLOOD S1, V90, P572; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kieffer N, 1996, CELL ADHES COMMUN, V4, P25, DOI 10.3109/15419069609010761; KIEFFER N, 1986, J BIOL CHEM, V261, P5854; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOUNS WC, 1992, BLOOD, V80, P2539; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LEISNER TM, 1997, THROMB HAEMOSTASIS S, V6; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; SACKS DB, 1995, BIOCHEM J, V312, P197, DOI 10.1042/bj3120197; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SRIRAMARAO P, 1993, J BIOL CHEM, V268, P22036; STEINER B, 1989, J BIOL CHEM, V264, P13102; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Zage PE, 1998, CELL ADHES COMMUN, V5, P335, DOI 10.3109/15419069809010780	51	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17257	17266		10.1074/jbc.274.24.17257	http://dx.doi.org/10.1074/jbc.274.24.17257			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358085	hybrid			2022-12-27	WOS:000080780400084
J	Johnston, H; Kneer, J; Chackalaparampil, I; Yaciuk, P; Chrivia, J				Johnston, H; Kneer, J; Chackalaparampil, I; Yaciuk, P; Chrivia, J			Identification of a novel SNF2/SWI2 protein family member, SRCAP, which interacts with CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; DNA; CBP; COACTIVATOR; RECEPTOR; COMPLEX; P300; ONCOPROTEIN	The ability of cAMP response-element binding protein (CREB)-binding protein (CBP) to function as a co-activator for a number of transcription factors appears to be mediated by its ability to act as a histone acetyltransferase and through its interaction with a number of other proteins (general transcription factors, histone acetyltransferases, and other co-activators). Here we report that CBP also interacts with a novelATPase termed Snf2-Related CBP Activator Protein (SRCAP). Consistent with this activity, SRCAP contains the conserved ATPase domain found within members of the Snf2 family. Transfection experiments demonstrate that SRCAP is able to activate transcription when expressed as a Gal-SRCAP chimera and that SRCAP also enhances the ability of CBP to activate transcription. The adenoviral protein E1A was found to disrupt interaction between SRCAP and CBP possibly representing a mechanism for E1A-mediated transcriptional repression.	St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Chrivia, J (corresponding author), St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARKRAVARTI D, 1996, NATURE, V383, P99; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DALRYMPLE MA, 1985, NUCLEIC ACIDS RES, V13, P7865, DOI 10.1093/nar/13.21.7865; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORAN E, 1994, SEMIN VIROL, V5, P237; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Q, 1997, GENE, V202, P31, DOI 10.1016/S0378-1119(97)00446-0	33	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16370	16376		10.1074/jbc.274.23.16370	http://dx.doi.org/10.1074/jbc.274.23.16370			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347196	hybrid			2022-12-27	WOS:000080668600056
J	Kambara, T; Rhodes, TE; Ikebe, R; Yamada, M; White, HD; Ikebe, M				Kambara, T; Rhodes, TE; Ikebe, R; Yamada, M; White, HD; Ikebe, M			Functional significance of the conserved residues in the flexible hinge region of the myosin motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; ACTOMYOSIN ADENOSINE-TRIPHOSPHATASE; 3-DIMENSIONAL STRUCTURE; ENZYMATIC-PROPERTIES; 2-HEADED STRUCTURE; MOLECULAR MOTOR; LIGHT-CHAIN; HYDROLYSIS; SUBFRAGMENT-1	Analysis of the three-dimensional crystal structure of the Dictyosteliun myosin motor domain revealed that the myosin head is required to bend at residues Il-455 and Gly-457 to produce the conformation changes observed in the ternary complexes that resemble the pre- and post-hydrolysis states (Fisher, A. J., Smith, C. A., Thoden, J. B., Smith, R., Sutoh, K., Holden, H. M., and Rayment, I. (1995) Biochemistry 34, 8960-8972). Asp-454, Il-455, and Gly-457 of smooth muscle myosin were substituted by Ala, Met, and Ala, respectively, and the mechano-enzymatic activities were determined to study the role of these residues in myosin motor function. Whereas the basal steady-state Mg2+-ATPase activity of D454A was higher than that of the wild type, the rate of the hydrolytic step is reduced similar to 2,000-fold and becomes rate-limiting. M-ATP rather than M-ADP-P is the predominant steady-state intermediate, and the initial P-i burst and the ATP-induced enhancement of intrinsic tryptophan fluorescence are absent in D454A. D454A binds actin in the absence of ATP but is not dissociated from actin by ATP. Moreover, actin inhibits rather than activates the ATPase activity; consequently, D454A does not support actin translocating activity. I455M has normal actin-activated ATPase activity, P-i burst, and ATP-induced enhancement of intrinsic tryptophan fluorescence, suggesting that the enzymatic properties are normal. However, the actin translocating activity was completely inhibited. This suggests that the side chain at Ile-455 is critical for myosin motor activity but not for relatively normal enzymatic function, which indicates an apparent uncoupling between enzymatic activity and motile function. Although G457A has normal ATP-dependent actin dissociation, ATP hydrolytic step is reduced by similar to 10(5)-fold in the presence or absence of actin; consequently, G457A does not have actin translocating activity. These results indicate the importance of these conserved residues at the hinge region for normal myosin motor function.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Biochem, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NHLBI NIH HHS [HL56218, HL41776] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; DYSON RD, 1971, BIOCHEMISTRY-US, V15, P5818; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HIGASHIHARA M, 1990, FEBS LETT, V263, P241, DOI 10.1016/0014-5793(90)81383-Y; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14941; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1987, J BIOL CHEM, V262, P13828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XD, 1998, J BIOL CHEM, V273, P27404, DOI 10.1074/jbc.273.42.27404; MARUTA H, 1981, J BIOL CHEM, V256, P499; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; ORIELLY DR, 1992, BACULOVIRUS EXPRESSI; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16400	16406		10.1074/jbc.274.23.16400	http://dx.doi.org/10.1074/jbc.274.23.16400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347200	hybrid			2022-12-27	WOS:000080668600060
J	Noah, JW; Dolan, MA; Babin, P; Wollenzien, P				Noah, JW; Dolan, MA; Babin, P; Wollenzien, P			Effects of tetracycline and spectinomycin on the tertiary structure of ribosomal RNA in the Escherichia coli 30 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-SITE; PROTEIN-SYNTHESIS; P-SITE; ELONGATION; BINDING; ANTIBIOTICS; MODEL; PHOTOINCORPORATION; NUCLEOTIDES	Structural analysis of the 16 S rRNA in the 30 S subunit and 70 S ribosome in the presence of ribosome-specific antibiotics was performed to determine whether they produced rRNA structural changes that might provide further insight to their action. An UV cross-linking procedure that determines the pattern and frequency of intramolecular 16 S RNA cross-links was used to detect differences reflecting structural changes. Tetracycline and spectinomycin have specific effects detected by this assay. The presence of tetracycline inhibits the cross-link C967 x C1400 completely, increases the frequency of cross-link C1402 x 1501 twofold, and decreases the cross-link G894 x U244 by one-half without affecting other cross-links. Spectinomycin reduces the frequency of the cross-link C934 x U1345 by 60% without affecting cross-linking at other sites. The structural changes occur at concentrations at which the antibiotics exert their inhibitory effects. For spectinomycin, the apparent binding site and the affected crosslinking site are distant in the secondary structure but are close in tertiary structure in several recent models, indicating a localized effect. For tetracycline, the apparent binding sites are significantly separated in both the secondary and the three-dimensional structures, suggesting a more regional effect.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Wollenzien, P (corresponding author), N Carolina State Univ, Dept Biochem, Box 7622, Raleigh, NC 27695 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUDOWSKY EI, 1989, EUR J BIOCHEM, V159, P95; COOPERMAN BS, 1980, RIBOSOMES STRUCTURE, P531; Dragon F, 1996, J MOL BIOL, V259, P207, DOI 10.1006/jmbi.1996.0313; EPE B, 1987, FEBS LETT, V213, P443, DOI 10.1016/0014-5793(87)81539-9; Fink DL, 1996, RNA, V2, P851; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GEIGENMULLER U, 1986, EUR J BIOCHEM, V161, P723, DOI 10.1111/j.1432-1033.1986.tb10499.x; GOLDMAN RA, 1983, BIOCHEMISTRY-US, V22, P359, DOI 10.1021/bi00271a020; MAKHNO VI, 1988, MOL BIOL+, V22, P528; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mundus D, 1998, RNA, V4, P1373, DOI 10.1017/S1355838298981134; Noah JW, 1998, BIOCHEMISTRY-US, V37, P15442, DOI 10.1021/bi981148m; Oehler R, 1997, NUCLEIC ACIDS RES, V25, P1219, DOI 10.1093/nar/25.6.1219; POWERS T, 1995, RNA, V1, P194; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Ross JI, 1998, ANTIMICROB AGENTS CH, V42, P1702, DOI 10.1128/AAC.42.7.1702; SARKAR S, 1968, P NATL ACAD SCI USA, V60, P1479, DOI 10.1073/pnas.60.4.1479; Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044; Spickler C, 1997, J MOL BIOL, V273, P586, DOI 10.1006/jmbi.1997.1323; Triman KL, 1995, ADV GENET, V33, P1, DOI 10.1016/S0065-2660(08)60329-6; WILMS C, 1994, ANAL BIOCHEM, V221, P204, DOI 10.1006/abio.1994.1399; Wilms C, 1997, RNA, V3, P602; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WURMBACH P, 1983, EUR J BIOCHEM, V130, P9	29	39	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16576	16581		10.1074/jbc.274.23.16576	http://dx.doi.org/10.1074/jbc.274.23.16576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347223	hybrid			2022-12-27	WOS:000080668600083
J	Sugiyama, H; Savill, JS; Kitamura, M; Zhao, L; Stylianou, E				Sugiyama, H; Savill, JS; Kitamura, M; Zhao, L; Stylianou, E			Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappa B in primary glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-TRANSFER; ACTIVATION; PHOSPHORYLATION; EXPRESSION; INHIBITION; DISEASE; DEATH; INTERLEUKIN-1	Recent data have implicated nuclear factor kappa B (NF-kappa B) in the prevention of apoptosis in transformed cell lines exposed to tumor necrosis factor alpha (TNF-alpha). However, it is obscure whether NF-kappa B plays an anti-apoptotic role in nontransformed cells, and it is not clear whether NF-kappa B inhibits apoptosis triggered by other mediators. We investigated the effect of specific inhibition of NF-kappa B on cytokine-induced apoptosis of glomerular mesangial cells, which is important in determining the outcome of glomerulonephritis. Cultured rat mesangial cells were stably transfected with the dominant negative mutant inhibitor of NF-kappa B (I kappa B alpha M), I kappa B alpha M was resistant to stimulus-dependent degradation and suppressed NF-kappa B activation induced by TNF-alpha (10 ng/ml) or IL-1 beta (10 ng/ml), I kappa B alpha M significantly sensitized mesangial cells to TNF-alpha-induced apoptosis in a dose- and time-dependent manner but had no significant effects on the level of apoptosis in the presence of proinflammatory or apoptosis-inducing stimuli including Fas ligand, IL-1 alpha, IL-1 beta, hydrogen peroxide, lipopolysaccharide, cycloheximide, or serum deprivation, Moreover, I kappa B alpha M-mediated sensitization to TNF-alpha overcame the protective effect of mesangial cell survival factors present in serum, which usually inhibit killing of mesangial cells by the proapoptotic stimuli used. These data show that inhibition of NF-kappa B selectively sensitizes primary adult glomerular mesangial cells to TNF-induced apoptosis but not to other mediators of cell death including the Fas ligand.	Univ Nottingham Hosp, Sch Med & Surg Sci, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England; Royal Infirm, Dept Clin & Surg Sci Internal Med, Ctr Inflammat Res, Edinburgh EH3 9YW, Midlothian, Scotland; Univ London Univ Coll, Sch Med, Rayne Inst, Dept Med, London WC1E 6JJ, England	University of Nottingham; Royal Infirmary of Edinburgh; University of London; King's College London; University College London; UCL Medical School	Sugiyama, H (corresponding author), Univ Nottingham Hosp, Sch Med & Surg Sci, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England.		Sugiyama, Hitoshi/B-2252-2011	Sugiyama, Hitoshi/0000-0002-4127-6471				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; COHEN L, 1998, SCIENCE, V395, P292; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; DIAMOND JR, 1992, AM J KIDNEY DIS, V19, P292, DOI 10.1016/S0272-6386(13)80013-3; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUESDON F, 1995, BIOCHEM J, V307, P287, DOI 10.1042/bj3070287; Guijarro C, 1996, NEPHROL DIAL TRANSPL, V11, P990; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Jobson TM, 1998, J CLIN INVEST, V101, P2650, DOI 10.1172/JCI1876; KITAMURA M, 1994, J CLIN INVEST, V94, P497, DOI 10.1172/JCI117361; Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mooney A, 1997, J IMMUNOL, V159, P3949; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Sandau K, 1997, J IMMUNOL, V158, P4938; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; SAVILL J, 1996, KIDNEY INT S54, V49, P14; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; Sugiyama H, 1996, J AM SOC NEPHROL, V7, P2357; Sugiyama H, 1996, KIDNEY INT, V49, P103, DOI 10.1038/ki.1996.14; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yokoo T, 1997, J IMMUNOL, V159, P2886; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123	41	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19532	19537		10.1074/jbc.274.28.19532	http://dx.doi.org/10.1074/jbc.274.28.19532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391885	hybrid			2022-12-27	WOS:000081377300005
J	Brand, M; Yamamoto, K; Staub, A; Tora, L				Brand, M; Yamamoto, K; Staub, A; Tora, L			Identification of TATA-binding protein-free TAF(II)-containing complex subunits suggests a role in nucleosome acetylation and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; TFIID COMPLEX; POLYMERASE-II; ADA-COMPLEX; TRANSCRIPTION; GCN5; DISTINCT; CORE; TAFS; ACTIVATION	Recently we identified a novel human (h) multiprotein complex, called TATA-binding protein (TBP)-free TAF(II)containing complex (TFTC), which is able to nucleate RNA polymerase II transcription and can mediate transcriptional activation. Here we demonstrate that TFTC, similar to other TBP-free TAF(II), complexes (yeast SAGA, hSTAGA, and hPCAF) contains the acetyltransferase hGCN5 and is able to acetylate histones in both a free and a nucleosomal context. The recently described TRRAP cofactor for oncogenic transcription factor pathways was also characterized as a TFTC subunit, Furthermore, we identified four other previously uncharacterized subunits of TFTC: hADA3, hTAF(II)150, hSPT3, and hPAF65 beta. Thus, the polypeptide composition of TFTC suggests that TFTC is recruited to chromatin templates by activators to acetylate histones and thus may potentiate initiation and activation of transcription.	Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,CU Strasbourg, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), Univ Strasbourg, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,CU Strasbourg, BP 163, F-67404 Strasbourg, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				BELLARD M, 1989, METHOD ENZYMOL, V170, P317; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	33	166	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18285	18289		10.1074/jbc.274.26.18285	http://dx.doi.org/10.1074/jbc.274.26.18285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373431	hybrid			2022-12-27	WOS:000081056700023
J	Brosh, RM; Orren, DK; Nehlin, JO; Ravn, PH; Kenny, MK; Machwe, A; Bohr, VA				Brosh, RM; Orren, DK; Nehlin, JO; Ravn, PH; Kenny, MK; Machwe, A; Bohr, VA			Functional and physical interaction between WRN helicase and human replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; WERNER-SYNDROME PROTEIN; NUCLEOTIDE EXCISION-REPAIR; SYNDROME GENE-PRODUCT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SYNDROME CELLS; BLOOMS-SYNDROME; CALF THYMUS; EXONUCLEASE	The human premature aging disorder Werner syndrome (WS) is associated with a large number of symptoms displayed in normal aging. The WRN gene product, a DNA helicase, has been previously shown to unwind short DNA duplexes (less than or equal to 53 base pairs) in a reaction stimulated by single-stranded DNA-binding proteins. We have studied the helicase activity of purified WRN protein on a variety of DNA duplex substrates to characterize the unwinding properties of the enzyme in greater detail. WRN helicase can catalyze unwinding of long duplex DNA substrates up to 849 base pairs in a reaction dependent on human replication protein A (hRPA). Escherichia coli SSB and bacteriophage T4 gene 32 protein (gp32) completely failed to stimulate WRN helicase to unwind long DNA duplexes indicating a specific functional interaction between WRN and hRPA. So far, there have been no reports of any physical interactions between WRN helicase and other proteins. In support of the functional interaction, we demonstrate a direct interaction between WRN and hRPA by coimmunoprecipitation of purified proteins. The physical and functional interaction between WRN and hRPA suggests that the two proteins may function together in vivo in a pathway of DNA metabolism such as replication, recombination, or repair.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA; Aarhus Univ, DK-8000 Aarhus C, Denmark; Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Brosh, RM (corresponding author), NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Nehlin, Jan O./AAR-8721-2020	Nehlin, Jan O./0000-0001-6038-5027				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P1128, DOI 10.1093/nar/22.7.1128; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THOMMES P, 1992, J BIOL CHEM, V267, P6063; Watt PM, 1996, GENETICS, V144, P935; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YAN H, 1995, SCIENCE, V269, P1883, DOI 10.1126/science.7569932; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	53	245	247	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18341	18350		10.1074/jbc.274.26.18341	http://dx.doi.org/10.1074/jbc.274.26.18341			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373438	hybrid			2022-12-27	WOS:000081056700030
J	Kuno, K; Terashima, Y; Matsushima, K				Kuno, K; Terashima, Y; Matsushima, K			ADAMTS-1 is an active metalloproteinase associated extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; VENOM METALLOPROTEINASE; CONVERTING-ENZYME; MOLECULAR-CLONING; FAMILY PROTEIN; DISINTEGRIN; PRECURSOR; DOMAIN; FURIN	Cellular disintegrin and metalloproteinases (ADAMs) are a family of genes with a sequence similar to the snake venom metalloproteinases and disintegrins. ADAMTS-1 is a unique ADAM family protein with respect to the presence of thrombospondin type I motifs and the capacity to bind to the extracellular matrix. Because ADAMTS-1 has a potential zinc-binding motif in the metalloproteinase domain, we examined in this study whether ADAMTS-1 is an active metalloproteinase by means of the proteinase trapping mechanism of alpha(2)-macroglobulin. We found that the soluble type of ADAMTS-1 protein is able to form a covalent-binding complex with alpha(2)-macroglobulin. Furthermore, the point mutation within the zinc-binding motif of ADAMTS-1 protein eliminates its capacity to bind to alpha(2)-macroglobulin. These data demonstrate that the metalloproteinase domain of ADAMTS-1 is catalytically active. In addition, we showed that the removal of the pro-domain from the ADAMTS-1 precursor is impaired in the furin-deficient cell line, LoVo, and that the processing ability of the cells is restored by the co-expression of the furin cDNA. These data provide evidence that the ADAMTS-1 precursor is processed in vivo by furin endopeptidase in the secretory pathway. Consequently, ADAMTS-1 is an active metalloprotease that is associated with the extracellular matrix. This study strongly suggests that ADAMTS-1 may play a role in the inflammatory process through its protease activity.	Kanazawa Univ, Canc Res Inst, Dept Mol Pharmacol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 113, Japan	Kanazawa University; University of Tokyo	Kuno, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pharmacol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		KUNO, Kouji/D-8439-2015					ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEILEIN UAO, 1994, DEV GROWTH DIFFER, V36, P49; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1994, ANN NY ACAD SCI, V737, P172, DOI 10.1111/j.1749-6632.1994.tb44311.x; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447	37	127	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18821	18826		10.1074/jbc.274.26.18821	http://dx.doi.org/10.1074/jbc.274.26.18821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373500	hybrid			2022-12-27	WOS:000081056700092
J	Timson, DJ; Trayer, HR; Smith, KJ; Trayer, IP				Timson, DJ; Trayer, HR; Smith, KJ; Trayer, IP			Size and charge requirements for kinetic modulation and actin binding by alkali 1-type myosin essential light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MYOSIN; SUBFRAGMENT-1 ISOENZYMES; TROPONIN COMPLEX; HEAVY-CHAIN; AMINO-ACID; CONTRACTION; SPECTROSCOPY; EXPRESSION; POLYMERASE; RESONANCE	The alkali 1-type isoforms of myosin essential light chains from vertebrate striated muscles have an additional 40 or so amino acids at their N terminus compared with the alkali 2-type. Consequently two light chain isoenzymes of myosin subfragment-1 can be isolated. Using synthesized peptide mimics of the N-terminal region of alkali 1-type essential light chains, we have found by H-1 NMR that the major actin binding region occurred in the N-terminal four residues, APKK.... These results were confirmed by mutating this region of the human atrial essential light chain, resulting in altered actin-activated MgATPase kinetics when the recombinant light chains were hybridized into rabbit skeletal subfragment 1. Substitution of either Lys(3) or Lys(4) with Ala resulted in increased K-m and k(cat) and decreased actin binding las judged by chemical cross-linking. Replacement of Lys4 with Asp reduced actin binding and increased K-m and k(cat) still further. Alteration of Ala(1) to Val did not alter the kinetic parameters of the hybrid subfragment 1 or the essential light chain's ability to bind actin, Furthermore, we found a significant correlation between the apparent K-m for actin and the k(cat) for MgATP turnover for each mutant hybrid, strengthening our belief that the binding of actin by alkali I-type essential light chains results directly in modulation of the myosin motor.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Trayer, IP (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.		Timson, David/I-4014-2019	Timson, David/0000-0002-0985-8818				ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ANDREEV OA, 1995, BIOCHEMISTRY-US, V34, P14829, DOI 10.1021/bi00045a025; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARNOLD HH, 1988, EUR J BIOCHEM, V178, P53, DOI 10.1111/j.1432-1033.1988.tb14428.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRANK G, 1974, EUR J BIOCHEM, V44, P317; HENRY GD, 1985, EUR J BIOCHEM, V148, P75, DOI 10.1111/j.1432-1033.1985.tb08809.x; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; JIANG H, 1994, MOL CELL BIOCHEM, V135, P1, DOI 10.1007/BF00925956; LEVINE BA, 1979, CHEM MACROMOLECULES, V24, P77; LOWEY S, 1993, J BIOL CHEM, V268, P20414; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sweeney H. L., 1995, BIOPHYS J, V68, p112S; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; Timson DJ, 1998, EUR J BIOCHEM, V255, P654, DOI 10.1046/j.1432-1327.1998.2550654.x; Timson DJ, 1997, FEBS LETT, V400, P31, DOI 10.1016/S0014-5793(96)01314-2; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; TRAYER IP, 1991, PEPTIDES PROBES MUSC, P56; UENO H, 1984, J BIOCHEM-TOKYO, V96, P895, DOI 10.1093/oxfordjournals.jbchem.a134908; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, FEBS LETT, V49, P320, DOI 10.1016/0014-5793(75)80776-9; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	37	36	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18271	18277		10.1074/jbc.274.26.18271	http://dx.doi.org/10.1074/jbc.274.26.18271			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373429	hybrid			2022-12-27	WOS:000081056700021
J	Hou, ZL; Cashel, M; Fromm, HJ; Honzatko, RB				Hou, ZL; Cashel, M; Fromm, HJ; Honzatko, RB			Effecters of the stringent response target the active site of Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; IDENTIFICATION; 5'-PHOSPHATE; HYDANTOCIDIN; HADACIDIN; BINDING; MG2+; GDP	Guanosine 5'-diphosphate 3'-diphosphate (ppGpp), a pleiotropic effector of the stringent response, potently inhibits adenylosuccinate synthetase from Escherichia coli as an allosteric effector and/or as a competitive inhibitor with respect to GTP. Crystals of the synthetase grown in the presence of IMP, hadacidin, NO3- and Mg2+, then soaked with ppGpp, reveal electron density at the GTP pocket which is consistent with guanosine 5'-diphosphate 2':3'-cyclic monophosphate. Unlike ligand complexes of the synthetase involving IMP and GDP, the coordination of Mg2+ in this complex is octahedral with the side chain of Asp(13) in the inner sphere of the cation. The cyclic phosphoryl group interacts directly with the side chain of Lys(49) and indirectly through bridging water molecules with the side chains of Asn(295) and Arg(305). Th, synthetase either directly facilitates the formation of the cyclic nucleotide or scavenges trace amounts of the cyclic nucleotide from solution. Regardless of its mode of generation, the cyclic nucleotide binds far more tightly to the active site than does ppGpp. Conceivably, synthetase activity in vivo during the stringent response may be sensitive to the relative concentrations of several effecters, which together exercise precise control over the de novo synthesis of AMP.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	Iowa State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Honzatko, RB (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CASHEL M, 1969, J BIOL CHEM, V245, P2039; CHOE JY, 1999, IN PRESS BIOCHEMISTR; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; DONG Q, 1990, J BIOL CHEM, V265, P6235; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GALLANT J, 1971, J BIOL CHEM, V246, P5812; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KACKZA EA, 1962, BIOCHEMISTRY-US, V1, P340; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAPPER RD, 1973, J AM CHEM SOC, V95, P2880, DOI 10.1021/ja00790a025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; Lipmann F, 1976, Prog Nucleic Acid Res Mol Biol, V17, P1, DOI 10.1016/S0079-6603(08)60063-X; MARKHAM DG, 1977, ARCH BIOCHEM BIOPHYS, V184, P24; MARKHAM GD, 1978, J BIOL CHEM, V253, P6184; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; PAO CC, 1981, BIOCHIM BIOPHYS ACTA, V677, P358, DOI 10.1016/0304-4165(81)90247-6; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; SAENGER W, 1984, PRINCIPLES NUCL ACID, P167; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STAYTON MM, 1979, J BIOL CHEM, V254, P2579; TYAGI AK, 1980, CANCER RES, V40, P4390; Wang WY, 1998, J BIOL CHEM, V273, P16000, DOI 10.1074/jbc.273.26.16000	31	35	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17505	17510		10.1074/jbc.274.25.17505	http://dx.doi.org/10.1074/jbc.274.25.17505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364182	hybrid			2022-12-27	WOS:000080974300018
J	Chruscinski, AJ; Rohrer, DK; Schauble, E; Desai, KH; Bernstein, D; Kobilka, BK				Chruscinski, AJ; Rohrer, DK; Schauble, E; Desai, KH; Bernstein, D; Kobilka, BK			Targeted disruption of the beta 2 adrenergic receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RING PREPARATIONS; BETA-1-ADRENERGIC RECEPTOR; ESSENTIAL-HYPERTENSION; ADRENOCEPTOR SUBTYPE; CORONARY-ARTERIES; MICE; BETA-2-ADRENOCEPTORS; DOGS; BETA-1-ADRENOCEPTORS; STIMULATION	beta-Adrenergic receptors (beta-ARs) are members of the superfamily of G-protein-coupled receptors that mediate the effects of catecholamines in the sympathetic nervous system. Three distinct beta-AR subtypes have been identified (beta 1-AR, beta 2-AR, and beta 3-AR), In order to define further the role of the different P-AR subtypes, we have used gene targeting to inactivate selectively the beta 2-AR gene in mice. Based on intercrosses of heterozygous knockout (beta 2-AR +/-) mice, there is no prenatal lethality associated with this mutation. Adult knockout mice (beta 2-AR -/-) appear grossly normal and are fertile. Their resting heart rate and blood pressure are normal, and they have a normal chronotropic response to the beta-AR agonist isoproterenol, The hypotensive response to isoproterenol, however, is significantly blunted compared with wild type mice. Despite this defect in vasodilation, beta 2-AR -/- mice can still exercise normally and actually have a greater total exercise capacity than wild type mice. At comparable workloads, beta 2-AR -/- mice had a lower respiratory exchange ratio than wild type mice suggesting a difference in energy metabolism. beta 2-AR -/- mice become hypertensive during exercise and exhibit a greater hypertensive response to epinephrine compared with wild type mice. In summary, the primary physiologic consequences of the beta 2-AR gene disruption are observed only during the stress of exercise and are the result of alterations in both vascular tone and energy metabolism.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Roche Biosci, Dept Mol Pharmacol, Palo Alto, CA 94304 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; Roche Holding	Kobilka, BK (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990; Bernstein, Daniel/0000-0001-7761-5853	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLBORG G, 1985, AM J PHYSIOL, V248, pE540, DOI 10.1152/ajpendo.1985.248.5.E540; ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; BRODDE OE, 1991, PHARMACOL REV, V43, P203; BRODDE OE, 1992, J HYPERTENS, V10, pS133; DESAI KH, 1997, AM J PHYSIOL, pH1053; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; EISEN EJ, 1981, GROWTH, V45, P100; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FELDMAN RD, 1987, CAN J PHYSIOL PHARM, V65, P1666, DOI 10.1139/y87-261; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; Hatakeyama D J, 1988, Proc West Pharmacol Soc, V31, P171; ISSEKUTZ B, 1984, J APPL PHYSIOL, V57, P1754, DOI 10.1152/jappl.1984.57.6.1754; JOYNER AL, 1993, GENE TARGETING PRACT, P33; KAUMANN AJ, 1986, N-S ARCH PHARMACOL, V332, P406, DOI 10.1007/BF00500096; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NYBORG NCB, 1985, J CARDIOVASC PHARM, V7, P1113, DOI 10.1097/00005344-198511000-00016; ODONNELL SR, 1984, J PHARMACOL EXP THER, V228, P733; ODONNELL SR, 1984, BRIT J PHARMACOL, V81, P637, DOI 10.1111/j.1476-5381.1984.tb16129.x; OPIE LH, 1985, AM J CARDIOL, V55, pD95, DOI 10.1016/0002-9149(85)91062-8; ROGERS P, 1980, BRIT J NUTR, V43, P83, DOI 10.1079/BJN19800066; Rohrer DK, 1999, J BIOL CHEM, V274, P16701, DOI 10.1074/jbc.274.24.16701; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; SHEN YT, 1994, J PHARMACOL EXP THER, V268, P466; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN CM, 1995, J CLIN INVEST, V96, P579, DOI 10.1172/JCI118070; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; TAKEI M, 1992, JPN J PHARMACOL, V59, P23, DOI 10.1254/jjp.59.23; Timmermann B, 1998, KIDNEY INT, V53, P1455, DOI 10.1046/j.1523-1755.1998.00926.x; TODA N, 1990, J PHARMACOL EXP THER, V253, P518; VATNER SF, 1985, AM J PHYSIOL, V249, pH49, DOI 10.1152/ajpheart.1985.249.1.H49; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	35	242	249	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16694	16700		10.1074/jbc.274.24.16694	http://dx.doi.org/10.1074/jbc.274.24.16694			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358008	hybrid			2022-12-27	WOS:000080780400007
J	Sakata, N; Stoops, JD; Dixon, JL				Sakata, N; Stoops, JD; Dixon, JL			Cytosolic components are required for proteasomal degradation of newly synthesized apolipoprotein B in permeabilized HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; SECRETORY PROTEIN; CULTURED-CELLS; RAT-LIVER; G2 CELLS; UBIQUITIN; B100	Recent studies have proposed that post-translational degradation of apolipoprotein B100 (apoB) involves the cytosolic ubiquitin-proteasome pathway. In this study, immunocytochemistry indicated that endoplasmic reticulum (ER)-associated proteasome molecules were concentrated in perinuclear regions of digitonin-permeabilized HepG2 cells. Signals produced by antibodies that recognize both alpha- and beta-subunits of the proteasome co-localized in the ER with specific domains of apoB, The mechanism of apoB degradation in the ER by the ubiquitin-proteasome pathway was studied using pulse-chase labeling and digitonin-permeabilized cells. ApoB in permeabilized cells incubated at 37 degrees C in buffer alone was relatively stable. When permeabilized cells were incubated with both exogenous ATP and rabbit reticulocyte lysate (RRL) as a source of ubiquitin-proteasome factors, >50% of [H-3]apoB was degraded in 30 min. The degradation of apoB in the intact ER of permeabilized cells was much more rapid than that of extracted [H-3]apoB incubated with RRL and ATP in vitro, The degradation of apoB was reduced by clasto-lactacystin beta-lactone, a potent proteasome inhibitor, and by ubiquitin K48R mutant protein, an inhibitor of polyubiquitination. ApoB in HepG2 cells was ubiquitinated, and polyubiquitination of apoB was stimulated by incubation of permeabilized cells with RRL. These results suggest that newly synthesized apoB in the ER is accessible to the cytoplasmic ubiquitin-proteasome pathway and that factors in RRL stimulate polyubiquitination of apoB, leading to rapid degradation of apoB in permeabilized cells.	Univ Missouri, Dept Food Sci & Human Nutr, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Dixon, JL (corresponding author), Univ Missouri, Dept Food Sci & Human Nutr, 122 Eckles Hall, Columbia, MO 65211 USA.	DixonJ@missouri.edu	Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047586, R29HL047586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRUL ES, 1988, J LIPID RES, V29, P937; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; McCracken AA, 1998, ADV MOL CEL, V27, P165, DOI 10.1016/S1569-2558(08)60461-0; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sakata N, 1999, BBA-MOL CELL BIOL L, V1437, P71, DOI 10.1016/S1388-1981(98)00006-7; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	40	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17068	17074		10.1074/jbc.274.24.17068	http://dx.doi.org/10.1074/jbc.274.24.17068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358059	hybrid			2022-12-27	WOS:000080780400058
J	Wang, Q; Mullah, BK; Robishaw, JD				Wang, Q; Mullah, BK; Robishaw, JD			Ribozyme approach identifies a functional association between the G protein beta(1)gamma(7) subunits in the beta-adrenergic receptor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNIT; LIPID MODIFICATIONS; CDNA CLONES; SPECIFICITY; TRANSDUCTION; INCREASES; RHODOPSIN; BINDING; BRAIN	The complex role that the heterotrimeric G proteins play in signaling pathways has become increasingly apparent with the cloning of countless numbers of receptors, G proteins, and effecters. However, in most cases, the specific combinations of alpha and beta gamma subunits comprising the G proteins that participate in the most common signaling pathways, such as beta-adrenergic regulation of adenylyl cyclase activity, are not known. The extent of this problem is evident in the fact that the identities of the beta gamma subunits that combine with the alpha subunit of G(s) are only now being elucidated almost 20 years after its initial purification. In a previous study, we described the first use of a ribozyme strategy to suppress specifically the expression of the gamma(7) subunit of the G proteins, thereby identifying a specific role of this protein in coupling the beta-adrenergic receptor to stimulation of adenylyl cyclase activity in HEK 293 cells, In the present study, we explored the potential utility of a ribozyme approach directed against the gamma(7) subunit to identify functional associations with a particular beta and alpha(s) subunit of the G protein in this signaling pathway. Accordingly, HEK 293 cells were transfected with a ribozyme directed against the gamma(7) subunit, and the effects of this manipulation on levels of the beta and alpha(s) subunits were determined by immunoblot analysis. Among the five beta alpha(s) subunits detected in these cells, only the beta(1) subunit was coordinately reduced following treatment with the ribozyme directed against the gamma(7) subunit, thereby demonstrating a functional association between the beta(1) and gamma(7) subunits, The mechanism for coordinate suppression of the beta(1) subunit was due to a striking change in the half-life of the beta(1) monomer versus the beta(1) heterodimer complexed with the gamma(7) subunit, Neither the 52- nor 45-kDa subunits were suppressed following treatment with the ribozyme directed against the gamma(7) subunit, thereby providing insights into the assembly of the G(s) heterotrimer, Taken together, these data show the utility of a ribozyme approach to identify the role of not only the gamma subunits but also the beta subunits of the G proteins in signaling pathways.	Penn State Univ, Henry Hood MD Res Program, Coll Med, Weis Ctr Res, Danville, PA 17822 USA; Appl Biosyst Inc, Foster City, CA 94404 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Thermo Fisher Scientific; Applied Biosystems	Robishaw, JD (corresponding author), Penn State Univ, Henry Hood MD Res Program, Coll Med, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	jrobishaw@psghs.edu			NIGMS NIH HHS [GM58191, GM39867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058191, R29GM039867, R01GM039867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DUZIC E, 1992, J BIOL CHEM, V267, P24045; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FOSTER KA, 1991, MOL CELL BIOCHEM, V104, P63; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MOHR E, 1995, P NATL ACAD SCI USA, V92, P4377, DOI 10.1073/pnas.92.10.4377; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONG OC, 1997, GENOMICS, V15, P101; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RAY K, 1994, GENE, V149, P337, DOI 10.1016/0378-1119(94)90172-4; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Taylor JM, 1996, J BIOL CHEM, V271, P3336; Ueda H, 1997, J CELL SCI, V110, P1503; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	50	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17365	17371		10.1074/jbc.274.24.17365	http://dx.doi.org/10.1074/jbc.274.24.17365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358098	hybrid			2022-12-27	WOS:000080780400097
J	Dong, ZW; Zhong, Q; Chen, PL				Dong, ZW; Zhong, Q; Chen, PL			The Nijmegen breakage syndrome protein is essential for Mre11 phosphorylation upon DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-LINE; REPAIR; RECOMBINATION; COMPLEX; YEAST; BINDING; KINASE; RAD50; BRCA1	The Nijmegen breakage syndrome (NBS), a chromosomal instability disorder, is characterized in part by cellular hypersensitivity to ionizing radiation. Repair of DNA double-strand breaks by radiation is dependent on a multifunctional complex containing Rad50, Mre11, and the NBS1 gene product, p95 (NBS protein, nibrin). The role of p95 in these repair processes is unknown. Here it is demonstrated that Mre11 is hyperphosphorylated in a cell cycle-independent manner in response to treatment of cells with genotoxic agents including gamma irradiation. This response is abrogated in two independently established NBS cell lines that have undetectable levels of the p95 protein. NBS cells are also deficient for radiation-induced nuclear foci containing Mre11, while those with Rad51 are unaffected. An analysis of the kinetic relationship between Mre11 phosphorylation and the appearance of its radiation-induced foci indicates that the former precedes the latter. Together, these data suggest that specific phosphorylation of Mre11 is induced by DNA damage, and p95 is essential in this process, perhaps by recruiting specific kinases.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Chen, PL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X				ALANI E, 1989, GENETICS, V122, P47; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, CANCER RES, V56, P3168; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Goggins M, 1996, CANCER RES, V56, P5360; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Tomlinson GE, 1998, CANCER RES, V58, P3237; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	21	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	1999	274	28					19513	19516		10.1074/jbc.274.28.19513	http://dx.doi.org/10.1074/jbc.274.28.19513			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215HY	10391882	hybrid			2022-12-27	WOS:000081377300002
J	Benlagha, K; Guglielmi, P; Cooper, MD; Lassoued, K				Benlagha, K; Guglielmi, P; Cooper, MD; Lassoued, K			Modifications of Ig alpha and Ig beta expression as a function of B lineage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASES; IMMUNOGLOBULIN GENE REARRANGEMENT; CHAIN ALLELIC EXCLUSION; PSEUDO-LIGHT-CHAIN; HUMAN PRE-B; LYMPHOCYTES-B; CROSS-LINKING; HEAVY-CHAIN; MB-1 GENE	Transcription of the mb1 and B29 genes is initiated when lymphoid progenitors enter the B cell differentiation pathway, and their transmembrane Ig alpha and Ig beta products constitute essential signaling components of pre B and B cell antigen receptors. We analyzed Ig alpha/Ig beta biosynthesis, heterogeneity, and molecular interactions as a function of human B lineage differentiation in cell lines representative of the pro-B, pre-B, and B cell stages. All B lineage representatives produced a 36-kDa Ig beta form and three principal Ig alpha forms, transient 33/40-kDa species and a mature 44-kDa glycoprotein. Deglycosylation revealed a major Ig alpha core protein of 25 kDa and a minor 21-kDa Ig alpha protein, apparently the product of an alternatively spliced mRNA. In pro-B cells, the Ig alpha and Ig beta molecules existed primarily in separate unassembled pools, exhibited an immature glycosylation pattern, did not associate with surrogate Light chain proteins, and were retained intracellularly. Their unanticipated association with the Lyn protein-tyrosine kinase nevertheless suggests functional potential for the Ig alpha/Ig beta molecules in pro-B cells. Greater heterogeneity of the Iglu and Ig beta molecules in pre-B and B cell Lines was attributable to increased glycosylation complexity. Finally, the Ig alpha/Ig beta heterodimers associated with fully assembled IgM molecules as a terminal event in B cell receptor assembly.	Hop St Louis, Inst Hematol, Immunopathol Lab, F-75475 Paris 10, France; Inst Genet Mol, F-34293 Montpellier, France; Univ Alabama, Howard Hughes Med Inst, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Dept Pathol & Microbiol, Birmingham, AL 35294 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham	Lassoued, K (corresponding author), Hop St Louis, Inst Hematol, Immunopathol Lab, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Benlagha, Kamel/I-5035-2016; Benlagha, Kamel/GLQ-8342-2022	benlagha, kamel/0000-0002-3251-9195	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039816, R37AI039816] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39816] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; Brouns GS, 1996, J BIOL CHEM, V271, P19272, DOI 10.1074/jbc.271.32.19272; BROUNS GS, 1995, INT IMMUNOL, V7, P359, DOI 10.1093/intimm/7.3.359; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHEN CH, 1990, AVIAN CELLULAR IMMUN, P1; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, J IMMUNOL, V149, P2857; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; FINLEY HW, 1982, BLOOD, V60, P1305; FREIDRICH J, 1993, J IMMUNOL, V150, P2814; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; HA HJ, 1992, J IMMUNOL, V148, P1526; HASHIMOTO S, 1995, MOL IMMUNOL, V32, P651, DOI 10.1016/0161-5890(95)00023-8; HASHIMOTO S, 1993, J IMMUNOL, V150, P491; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KIYOTAKI M, 1987, J IMMUNOL, V138, P4150; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; Koyama M, 1997, INT IMMUNOL, V9, P1767, DOI 10.1093/intimm/9.11.1767; KOYAMA M, 1995, IMMUNOL LETT, V47, P151, DOI 10.1016/0165-2478(95)00071-X; Kuwahara K, 1996, INT IMMUNOL, V8, P1273, DOI 10.1093/intimm/8.8.1273; KUWAHARA K, 1993, BIOCHEM BIOPH RES CO, V197, P1563, DOI 10.1006/bbrc.1993.2656; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassoued K, 1996, J EXP MED, V183, P421, DOI 10.1084/jem.183.2.421; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MARUYAMA S, 1985, J IMMUNOL, V135, P192; MASON DY, 1991, J IMMUNOL, V147, P2474; MATSUO T, 1993, J IMMUNOL, V150, P3766; MULLER B, 1992, EUR J IMMUNOL, V22, P1621, DOI 10.1002/eji.1830220641; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NUSSENZWEIG MC, 1988, J EXP MED, V167, P1969, DOI 10.1084/jem.167.6.1969; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PULVERTAFT RJV, 1964, LANCET, V1, P238; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; VASILE S, 1994, MOL IMMUNOL, V31, P419, DOI 10.1016/0161-5890(94)90061-2; VENTIKARAMAN AR, 1991, NATURE, V352, P777; WIENANDS J, 1991, EUR J IMMUNOL, V21, P2373, DOI 10.1002/eji.1830211012; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOUN HY, 1994, J IMMUNOL, V153, P5127; YU LM, 1992, J IMMUNOL, V148, P633	62	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19389	19396		10.1074/jbc.274.27.19389	http://dx.doi.org/10.1074/jbc.274.27.19389			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383452	hybrid			2022-12-27	WOS:000081196300075
J	Febbraio, M; Abumrad, NA; Hajjar, DP; Sharma, K; Cheng, WL; Pearce, SFA; Silverstein, RL				Febbraio, M; Abumrad, NA; Hajjar, DP; Sharma, K; Cheng, WL; Pearce, SFA; Silverstein, RL			A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MACROPHAGE SCAVENGER RECEPTORS; ADIPOCYTE MEMBRANE-PROTEIN; PPAR-GAMMA ACTIVATORS; SR-BI; PREADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPOSITION; APOPTOTIC THYMOCYTES; EXPRESSION CLONING; BINDING-PROPERTIES	A null mutation in the scavenger receptor gene CD36 was created in mice by targeted homologous recombination. These mice produced no detectable CD36 protein, were viable, and bred normally. A significant decrease in binding and uptake of oxidized low density lipoprotein was observed in peritoneal macrophages of null mice as compared with those from control mice. CD36 null animals had a significant increase in fasting levels of cholesterol, nonesterified free fatty acids, and triacylglycerol. The increase in cholesterol was mainly within the high density lipoprotein fraction, while the increase in triacylglycerol was within the very low density lipoprotein fraction. Null animals had lower fasting serum glucose levels when compared with wild type controls. Uptake of H-3-labeled oleate was significantly reduced in adipocytes from null mice. However, the decrease was limited to the low ratios of fatty acid:bovine serum albumin, suggesting that CD36 was necessary for the high affinity component of the uptake process. The data provide evidence for a functional role for CD36 in lipoprotein/fatty acid metabolism that was previously underappreciated.	Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Cornell University; Cornell University; Cornell University; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Febbraio, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058559, P50HL056987, R01HL042540] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P0 HL56987, 2R01 HL42540, 1R29 HL58559-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ASHKENAS J, 1993, J LIPID RES, V34, P983; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCOLO G, 1973, CLIN CHEM, V19, P476; Calvo D, 1998, J LIPID RES, V39, P777; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DOI T, 1993, J BIOL CHEM, V268, P2126; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FADOK VA, 1992, J IMMUNOL, V148, P2207; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1992, BLOOD, V80, P1105; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HARMON CM, 1992, BIOCHEM SOC T, V20, P811, DOI 10.1042/bst0200811; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; Huh HY, 1996, BLOOD, V87, P2020; Hwang EH, 1998, J NUCL MED, V39, P1681; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RICHIERI GV, 1995, J LIPID RES, V36, P229; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Ryeom SW, 1996, J CELL SCI, V109, P387; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCANES CG, 1994, COMP BIOCHEM PHYS C, V107, P243, DOI 10.1016/1367-8280(94)90047-7; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SPITSBERG VL, 1995, EUR J BIOCHEM, V230, P872, DOI 10.1111/j.1432-1033.1995.tb20630.x; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TANDON NN, 1989, J BIOL CHEM, V264, P7576; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WANTANABE K, 1998, JPN CIRC J, V62, P541; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	97	622	641	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19055	19062		10.1074/jbc.274.27.19055	http://dx.doi.org/10.1074/jbc.274.27.19055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383407	hybrid			2022-12-27	WOS:000081196300030
J	Giovanni, A; Wirtz-Brugger, F; Keramaris, E; Slack, R; Park, DS				Giovanni, A; Wirtz-Brugger, F; Keramaris, E; Slack, R; Park, DS			Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F center dot DP, in B-amyloid-induced neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; DNA-DAMAGING AGENTS; RETINOBLASTOMA PROTEIN; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; PC12 CELLS; PROMOTE SURVIVAL; BETA-PEPTIDE; EXPRESSION; INHIBITORS	Previous evidence by others has indicated that a variety of cell cycle-related molecules are up-regulated in brains of Alzheimer's disease patients. The significance of this increase, however, is unclear. Accordingly, we examined the obligate nature of cyclin-dependent kinases and select downstream targets of these kinases in death of neurons evoked by B-amyloid (AB) protein. We present pharmacological and molecular biological evidence that cyclin dependent kinases, in particular Cdk4/6, are required for such neuronal death. In addition, we demonstrate that the substrate of Cdk4/6, pRb/ p107, is phosphorylated during AB treatment and that one target of pRb/p107, the E2F.DP complex, is required for AB-evoked neuronal death. These results provide evidence that cell cycle elements play a required role in death of neurons evoked by AB and suggest that these elements play an integral role in Alzheimer's disease-related neuronal death.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Hoechst Marion Roussel, Neurosci, Bridgewater, NJ 08807 USA	University of Ottawa	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835				BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Berry DE, 1996, ONCOGENE, V12, P1809; BURDICK D, 1992, J BIOL CHEM, V267, P546; Busser J, 1998, J NEUROSCI, V18, P2801; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COTMAN CW, 1994, BETA AMYLOID ITS CON, P305; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Fan GS, 1996, ONCOGENE, V12, P1909; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARK RJ, 1995, J NEUROSCI, V15, P6239; McShea A, 1997, AM J PATHOL, V150, P1933; NEVINS JR, 1992, SCIENCE, V258, P424; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLUHA W, 1996, MOL CELL BIOL, V16, P1334; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RUSH DK, 1992, NEUROBIOL AGING, V13, P591, DOI 10.1016/0197-4580(92)90061-2; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Vincent I, 1997, J NEUROSCI, V17, P3588; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850	42	210	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19011	19016		10.1074/jbc.274.27.19011	http://dx.doi.org/10.1074/jbc.274.27.19011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383401	hybrid			2022-12-27	WOS:000081196300024
J	Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS				Pandey, AV; Tekwani, BL; Singh, RL; Chauhan, VS			Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THALASSEMIC ERYTHROCYTES; PLASMODIUM-FALCIPARUM; RODENT MALARIA; QUINOLINE ANTIMALARIALS; DRUG ACCUMULATION; IN-VITRO; CHLOROQUINE; HEMATIN; MECHANISM; POLYMERIZATION	Endoperoxide antimalarials based on the ancient Chinese drug Qinghaosu (artemisinin) are currently our major hope in the fight against drug-resistant malaria. Rational drug design based on artemisinin and its analogues is slow as the mechanism of action of these antimalarials is not clear. Here we report that these drugs, at least in part, exert their effect by interfering with the plasmodial hemoglobin catabolic pathway and inhibition of heme polymerization. In an in vitro experiment we observed inhibition of digestive vacuole proteolytic activity of malarial parasite by artemisinin, These observations were further confirmed by ex vivo experiments showing accumulation of hemoglobin in the parasites treated with artemisinin, suggesting inhibition of hemoglobin degradation. We found artemisinin to be a potent inhibitor of heme polymerization activity mediated by Plasmodium yoelii lysates as well as Plasmodium falciparum histidine-rich protein II. Interaction of artemisinin with the purified malarial hemozoin in vitro resulted in the concentration-dependent breakdown of the malaria pigment. Our results presented here may explain the selective and rapid toxicity of these drugs on mature, hemozoin-containing, stages of malarial parasite. Since artemisinin and its analogues appear to have similar molecular targets as chloroquine despite having different structures, they can potentially bypass the quinoline resistance machinery of the malarial parasite, which causes sublethal accumulation of these drugs in resistant strains.	Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, New Delhi 110067, India; Cent Drug Res Inst, Div Biochem, Lucknow 226001, Uttar Pradesh, India; RML Avadh Univ, Dept Biochem, Faizabad 224001, Uttar Pradesh, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Chauhan, VS (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, Aruna Asaf Ali Marg,POB 10504, New Delhi 110067, India.	virender@icgeb.res.in	Pandey, Amit V/AAO-6442-2020; Pandey, Amit V/A-7223-2008; Chauhan, Virander S./K-5276-2019	Pandey, Amit V/0000-0001-8331-5902; Pandey, Amit V/0000-0001-8331-5902; 				Adams PA, 1996, BIOCHEM J, V318, P25, DOI 10.1042/bj3180025; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bohle DS, 1997, J BIOL CHEM, V272, P713, DOI 10.1074/jbc.272.2.713; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; CAILLARD V, 1992, EXP PARASITOL, V75, P449, DOI 10.1016/0014-4894(92)90258-C; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1987, J BIOL CHEM, V262, P15552; Fitch CD, 1996, MOL BIOCHEM PARASIT, V82, P261, DOI 10.1016/0166-6851(96)02744-2; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GEARY TG, 1989, AM J TROP MED HYG, V40, P240, DOI 10.4269/ajtmh.1989.40.240; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Grigorov M, 1997, J CHEM INF COMP SCI, V37, P124, DOI 10.1021/ci9601168; HIEN TT, 1993, LANCET, V341, P603; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Ignatushchenko MV, 1997, FEBS LETT, V409, P67, DOI 10.1016/S0014-5793(97)00405-5; Jefford CW, 1996, HELV CHIM ACTA, V79, P1475, DOI 10.1002/hlca.19960790520; KAMCHONWONGPAISAN S, 1994, J CLIN INVEST, V93, P467, DOI 10.1172/JCI116994; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P238, DOI 10.4269/ajtmh.1999.60.238; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B; Mohapatra PK, 1996, INDIAN J MED RES, V104, P284; Newton P, 1999, ANNU REV MED, V50, P179, DOI 10.1146/annurev.med.50.1.179; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Paitayatat S, 1997, J MED CHEM, V40, P633, DOI 10.1021/jm960767v; PANDEY AV, 1995, BIOMED RES-TOKYO, V16, P115, DOI 10.2220/biomedres.16.115; Pandey AV, 1999, ANAL BIOCHEM, V268, P159, DOI 10.1006/abio.1998.2997; Pandey AV, 1997, FEBS LETT, V402, P236, DOI 10.1016/S0014-5793(96)01536-0; Pandey AV, 1998, CURR SCI INDIA, V75, P911; Pandey AV, 1997, MOL BIOCHEM PARASIT, V90, P281, DOI 10.1016/S0166-6851(97)00161-8; Pandey AV, 1999, J PHARMACEUT BIOMED, V20, P203, DOI 10.1016/S0731-7085(99)00021-7; Pandey AV, 1996, FEBS LETT, V393, P189, DOI 10.1016/0014-5793(96)00881-2; PETERS W, 1986, ANN TROP MED PARASIT, V80, P483, DOI 10.1080/00034983.1986.11812054; Platel DFN, 1999, MOL BIOCHEM PARASIT, V98, P215, DOI 10.1016/S0166-6851(98)00170-4; Ridley RG, 1997, ANN TROP MED PARASIT, V91, P559, DOI 10.1080/00034989760932; SALAS F, 1995, INFECT IMMUN, V63, P2120, DOI 10.1128/IAI.63.6.2120-2125.1995; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHERR L, 1995, AIDS CARE, V7, P85; SHUKLA KL, 1995, J MOL GRAPHICS, V13, P215, DOI 10.1016/0263-7855(94)00001-9; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; Vattanaviboon P, 1998, MOL PHARMACOL, V53, P492, DOI 10.1124/mol.53.3.492; WELLEMS TE, 1992, NATURE, V355, P108, DOI 10.1038/355108a0; YANG YZ, 1993, BIOCHEM PHARMACOL, V46, P336, DOI 10.1016/0006-2952(93)90425-V	59	200	207	1	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19383	19388		10.1074/jbc.274.27.19383	http://dx.doi.org/10.1074/jbc.274.27.19383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383451	hybrid			2022-12-27	WOS:000081196300074
J	Allgayer, H; Wang, H; Gallick, GE; Crabtree, A; Mazar, A; Jones, T; Kraker, AJ; Boyd, DD				Allgayer, H; Wang, H; Gallick, GE; Crabtree, A; Mazar, A; Jones, T; Kraker, AJ; Boyd, DD			Transcriptional induction of the urokinase receptor gene by a constitutively active Src - Requirement of an upstream motif (-152/-135) bound with Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; CELL-LINE; POSTTRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; TUMOR PROMOTERS; GROWTH-FACTOR; COLON-CANCER; A431 CELLS; C-JUN; EXPRESSION	Since c-src overexpression increases colonic cell invasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colon cancers, the present study was undertaken: 1) to determine if a constitutively active Src regulates urokinase receptor expression and 2) to identify required cis-elements and trans-acting factors. SW480 colon cancer cells transfected with an expression plasmid (c-srcY527F) encoding a constitutively active Src protein manifested increased urokinase receptor gene expression and Src activity. Treatment of the src transfectants with a Src-inhibitor (PD173955) reduced urokinase receptor protein levels and laminin degradation. Inasmuch as we recently implicated an upstream region of the urokinase receptor promoter (-152/-135) in constitutive urokinase receptor expression, we determined its role for the induction by src, Whereas the activity of a CAT reporter driven by this region was stimulated by c-srcY527F, the u-PAR promoter mutated at the Spl-binding motif in the -152/-135 region was not. Nuclear extracts from the src transfectants demonstrated increased Spl binding to region -152/-135 compared with those from SW480 cells. Finally, endogenous urokinase receptor protein amounts in 10 colon cancers and corresponding normal colon correlated with Src specific activity. These data suggest that urokinase receptor gene expression is regulated by Src partly via increased Spl binding.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@notes.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906, R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [P01 DE11906, R01 DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; Barvian M. R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P176; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CASEY JR, 1994, BLOOD, V84, P1151; CONESE M, 1994, J BIOL CHEM, V269, P17886; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Ishidoh K, 1997, BIOCHEM BIOPH RES CO, V238, P665, DOI 10.1006/bbrc.1997.7349; JONES TR, 1998, Patent No. 121230; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KARIKO K, 1993, CANCER RES, V53, P3109; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Pories SE, 1998, GASTROENTEROLOGY, V114, P1287, DOI 10.1016/S0016-5085(98)70435-4; QUATTRONE A, 1995, CANCER RES, V55, P90; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Sillaber C, 1997, J BIOL CHEM, V272, P7824, DOI 10.1074/jbc.272.12.7824; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xing RH, 1997, CANCER RES, V57, P3585; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	55	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18428	18437		10.1074/jbc.274.26.18428	http://dx.doi.org/10.1074/jbc.274.26.18428			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373450	hybrid			2022-12-27	WOS:000081056700042
J	Yamazaki, T; Hamano, Y; Tashiro, H; Itoh, K; Nakano, H; Miyatake, S; Saito, T				Yamazaki, T; Hamano, Y; Tashiro, H; Itoh, K; Nakano, H; Miyatake, S; Saito, T			CAST, a novel CD3 epsilon-binding protein transducing activation signal for interleukin-2 production in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-BETA-CHAIN; ANTIGEN RECEPTOR; TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; CD3 COMPLEX; GRB2; MICE; PHOSPHOPROTEIN; EXPRESSION; CLONING	Antigen recognition through T cell receptor (TCR)CD3 complex transduces signals into T cells, which regulate activation, function, and differentiation of T cells. The TCR-CD3 complex is composed of two signaling modules represented by CD3 zeta and CD3 epsilon. Signaling through CD3 zeta has been extensively analyzed, but that via CD3 epsilon, which is also crucial in immature thymocyte development, is still not clearly understood. We isolated cDNA encoding a novel CD3 epsilon-binding protein CAST. CAST specifically interacts in vivo and in vitro with CD3 epsilon but not with CD3 zeta or FcR gamma via a unique membrane-proximal region of CD3 epsilon. CAST is composed of 512 amino acids including a single tyrosine and undergoes tyrosine phosphorylation upon TCR stimulation. Overexpression of two dominant-negative types of CAST, a minimum CD3 epsilon-binding domain and a tyrosine-mutant, strongly suppressed NFAT activation and interleukin-2 production. These results demonstrate that CAST serves as a component of preformed TCR complex and transduces activation signals upon TCR stimulation and represents a new signaling pathway via the CD3 epsilon-containing TCR signaling module.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan	Chiba University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Saito, Takashi/C-9684-2009	Saito, Takashi/0000-0001-9495-3547; Nakano, Hiroyasu/0000-0003-4843-1427				AOE T, 1994, INT IMMUNOL, V6, P1671, DOI 10.1093/intimm/6.11.1671; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSRELO XR, 1992, NATURE, V356, P68; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fusaki N, 1996, J IMMUNOL, V156, P1369; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KUWABARA I, 1994, J IMMUNOL, V152, P2148; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Levelt CN, 1995, IMMUNITY, V3, P667, DOI 10.1016/1074-7613(95)90056-X; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5450; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Takase K, 1997, J IMMUNOL, V159, P741; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	39	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18173	18180		10.1074/jbc.274.26.18173	http://dx.doi.org/10.1074/jbc.274.26.18173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373416	hybrid			2022-12-27	WOS:000081056700008
J	Yamin, R; Malgeri, EG; Sloane, JA; McGraw, WT; Abraham, CR				Yamin, R; Malgeri, EG; Sloane, JA; McGraw, WT; Abraham, CR			Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; CULTURED-CELLS; DISEASE BRAIN; CATHEPSIN-D; RAT-BRAIN; MONOCLONAL-ANTIBODIES; THIMET OLIGOPEPTIDASE; LIPOPROTEIN RECEPTOR; ENDOPEPTIDASE 24.15; PRECURSOR PROTEIN	We have investigated the functional relationship between metalloendopeptidase EC 3.4.24.15 (MP24.15) and the amyloid precursor protein involved in Alzheimer's disease (AD) and discovered that the enzyme promotes A beta degradation. We show here that conditioned medium (CM) of MP24.15 antisense-transfected SKNMC neuroblastoma has significantly higher levels of A beta, Furthermore, synthetic-A beta degradation was increased or decreased following incubation with CM of sense or antisense-transfected cells, respectively, Soluble A beta 1-42 was degraded more slowly than soluble A beta 1-40, while aggregated A beta 1-42 showed almost no degradation. Pretreatment of CM with serine proteinase inhibitors 4-(2-aminoethyl)benzenesulfonyl fluoride and diisopropyl fluorophosphate completely inhibited A beta degradation. Additionally, alpha(1)-antichymotrypsin (ACT), a serpin family inhibitor tightly associated with plaques and elevated in AD brain, blocked up to 60% of A beta degradation. Interestingly, incubation of CM of MP24.15-overexpressing cells with ACT formed an SDS-resistant ACT complex, suggesting an ACT-serine proteinase interaction. Recombinant MP24.15 alone did not degrade A beta, C-14-Diisopropyl fluorophosphate-radiolabeled CM from MP24.15-overexpressing cells contained increased levels of several active serine proteinases, suggesting that MP24.15 activates one or more A beta-degrading serine proteases. Thus, ACT may cause A beta accumulation by inhibiting an A beta-degrading enzyme or by direct binding to A beta, rendering it degradation-resistant. Identification of the A beta-degrading enzyme and MP24.15's role in its activation is underway. Pharmacological modulation of either enzyme may provide a means of regulating A beta in the brain.	Boston Univ, Sch Med, Dept Biochem & Med, Boston, MA 02118 USA	Boston University	Abraham, CR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K-6, Boston, MA 02118 USA.			Abraham, Carmela/0000-0002-6649-1960; Sloane, Jacob/0000-0003-0028-3031	NIA NIH HHS [AG00001, AG09905] Funding Source: Medline; NINDS NIH HHS [NS07152] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009905] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1990, NEUROBIOL AGING, V11, P123, DOI 10.1016/0197-4580(90)90045-2; ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; Bai JPF, 1996, J PHARM PHARMACOL, V48, P1180, DOI 10.1111/j.2042-7158.1996.tb03917.x; Banks WA, 1996, NEUROTOXICOL TERATOL, V18, P671, DOI 10.1016/S0892-0362(96)00084-0; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; Brown AM, 1996, J NEUROCHEM, V66, P2436; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Chevallier N, 1997, BRIT J PHARMACOL, V121, P556, DOI 10.1038/sj.bjp.0701151; Christie RH, 1996, AM J PATHOL, V148, P399; Conn KJ, 1996, J NEUROCHEM, V66, P2011; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1993, PEPTIDES, V14, P593, DOI 10.1016/0196-9781(93)90150-F; Du YS, 1997, J NEUROCHEM, V69, P299; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hamazaki H, 1996, FEBS LETT, V396, P139, DOI 10.1016/0014-5793(96)01087-3; HARADA S, 1993, ENDOCRINOLOGY, V132, P2293, DOI 10.1210/en.132.6.2293; HEALY DP, 1992, BRAIN RES, V571, P121, DOI 10.1016/0006-8993(92)90517-D; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; ICHAI C, 1994, J NEUROCHEM, V62, P645; Janciauskiene S, 1998, J BIOL CHEM, V273, P28360, DOI 10.1074/jbc.273.43.28360; KATZMAN R, 1994, ALZHEIMER DIS; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOJ A, 1985, ACUTE PHASE RESPONSE; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Matsumoto A, 1996, NEUROSCI LETT, V220, P159, DOI 10.1016/S0304-3940(96)13235-3; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; Mentlein R, 1998, J NEUROCHEM, V70, P721; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; Narita M, 1997, J NEUROCHEM, V69, P1904; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PAPASTOITSIS G, 1994, BIOCHEMISTRY-US, V33, P192, DOI 10.1021/bi00167a025; POTTER H, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P275; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TARASCON JM, 1995, Patent No. 5424205; THOMPSON A, 1995, BIOCHEM BIOPH RES CO, V213, P66, DOI 10.1006/bbrc.1995.2099; Thompson A, 1997, MOL BRAIN RES, V48, P206, DOI 10.1016/S0169-328X(97)00091-0; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; Waters SM, 1997, ANN NY ACAD SCI, V814, P30, DOI 10.1111/j.1749-6632.1997.tb46142.x; WISNIEWSKI HM, 1994, NEUROPATH APPL NEURO, V20, P192; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	51	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18777	18784		10.1074/jbc.274.26.18777	http://dx.doi.org/10.1074/jbc.274.26.18777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373494	hybrid			2022-12-27	WOS:000081056700086
J	Alejo, A; Andres, G; Vinuela, E; Salas, ML				Alejo, A; Andres, G; Vinuela, E; Salas, ML			The African swine fever virus prenyltransferase is an integral membrane trans-geranylgeranyl-diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN FARNESYLTRANSFERASE; DELTA-ANTIGEN; PURIFICATION; PRODUCT; ISOPRENYLATION; PRENYLATION; SEPARATION; BINDING; RELEASE	previous study, it was shown that the protein encoded by the gene B318L of African swine fever virus (ASFV) is a trans-prenyltransferase that catalyzes in vitro the condensation of farnesyl diphosphate and isopentenyl diphosphate to synthesize geranylgeranyl diphosphate and longer chain prenyl diphosphates (Alejo, A., Yanez, R. J., Rodriguez, J. M., Vinuela, II., and Salas, M. L. (1997) J. Biol. Chem. 272, 9417-9423), To investigate the in vivo function of the viral enzyme, we have determined, in this work, its subcellular localization and activity in cell extracts, Two systems were used in these studies: cells infected with ASFV and cells infected with a recombinant pseudo-Sindbis virus carrying the complete B318L gene. In this latter system, the trans-prenyltransferase was found to colocalize with the endoplasmic reticulum marker protein-disulfide isomerase, whereas in cells infected with ASFV, the viral enzyme was present in cytoplasmic viral assembly sites, associated with precursor viral membranes derived from the endoplasmic reticulum. In addition, after subcellular fractionation, the viral enzyme partitioned into the membrane fraction. Extraction of membrane proteins with alkaline carbonate and Triton X-114 indicated that the ASFV enzyme behaved as an integral membrane protein. The membrane enzyme synthesized predominantly all-trans-geranylgeranyl diphosphate from farnesyl diphosphate and isopentenyl diphosphate, These results indicate that the viral B318L protein is a trans-geranylgeranyl-diphosphate synthase, being the only enzyme of this type that is known to have a membrane localization.	Autonomous Univ Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, ML (corresponding author), Autonomous Univ Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Andres, German/E-2632-2016; Alejo, Ali/AAF-1477-2020	Andres, German/0000-0003-0265-5409; Alejo, Ali/0000-0002-1613-6063				Alejo A, 1997, J BIOL CHEM, V272, P9417, DOI 10.1074/jbc.272.14.9417; Andres G, 1997, J VIROL, V71, P2331; Andres G, 1998, J VIROL, V72, P8988; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; Costa J. V., 1990, Molecular Biology of Iridoviruses., P247; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; ERICSSON J, 1993, J BIOL CHEM, V268, P832; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; Garcia-Escudero R, 1998, J VIROL, V72, P3185; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Otto JC, 1996, J BIOL CHEM, V271, P4569; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rouiller I, 1998, J VIROL, V72, P2373, DOI 10.1128/JVI.72.3.2373-2387.1998; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; Tschantz WR, 1997, J BIOL CHEM, V272, P9989; VINUELA E, 1985, CURR TOP MICROBIOL, V116, P151; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	38	17	18	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18033	18039		10.1074/jbc.274.25.18033	http://dx.doi.org/10.1074/jbc.274.25.18033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364254	Green Published, hybrid			2022-12-27	WOS:000080974300090
J	McGee, AW; Bredt, DS				McGee, AW; Bredt, DS			Identification of an intramolecular interaction between the SH3 and guanylate kinase domains of PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS VULVAR INDUCTION; NITRIC-OXIDE SYNTHASE; TUMOR SUPPRESSOR GENE; POSTSYNAPTIC DENSITY; TYROSINE KINASE; PDZ DOMAINS; PROTEIN; FAMILY; DLG; LOCALIZATION	Postsynaptic density-95 (PSD-95/SAP-90) is a member of the membrane-associated guanylate kinase (MAGUK) family of proteins that assemble protein complexes at synapses and other cell junctions. MAGUKs comprise multiple protein-protein interaction motifs including PDZ, SH3 and guanylate kinase (GK) domains, and these binding sites mediate the scaffolding function of MAGUK proteins, Synaptic binding partners for the PDZ and GK domains of PSD-95 have been identified, but the role of the SH3 domain remains elusive. We now report that the SH3 domain of PSD-95 mediates a specific interaction with the GK domain. The GK domain lacks a poly-proline motif that typically binds to SH3 domains; instead, SH3/GK binding is a bi-domain interaction that requires both intact motifs. Although isolated SH3 and GK domains can bind in trans, experiments with intact PSD-95 molecules indicate that intramolecular SH3/GK binding dominates and prevents intermolecular associations. SH3/GK binding is conserved in the related Drosophila MAGUK protein DLG but is not detectable for Caenorhabditis elegans LIN-2. Many previously identified genetic mutations of MAGUKs in invertebrates occur in the SH3 or GK domains, and all of these mutations disrupt intramolecular SH3/GK binding.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Neurosci Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Bredt, David/J-4872-2012		NIGMS NIH HHS [R01 GM36017] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	23	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17431	17436		10.1074/jbc.274.25.17431	http://dx.doi.org/10.1074/jbc.274.25.17431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364172	hybrid			2022-12-27	WOS:000080974300008
J	Obrietan, K; Impey, S; Smith, D; Athos, J; Storm, DR				Obrietan, K; Impey, S; Smith, D; Athos, J; Storm, DR			Circadian regulation of cAMP response element-mediated gene expression in the Suprachiasmatic nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR ANTAGONISTS; C-FOS TRANSCRIPTION; CREB PHOSPHORYLATION; MESSENGER-RNA; GROWTH-FACTOR; BIOLOGICAL CLOCK; DROSOPHILA-MELANOGASTER; MEMBRANE DEPOLARIZATION; SOMATOSTATIN GENE; JUNB PROMOTER	A program of stringently-regulated gene expression is thought to be a fundamental component of the circadian clock Although recent work has implicated a role for E-box-dependent transcription in circadian rhythmicity, the contribution of other enhancer elements has yet to be assessed. Here, we report that cells of the supra-chiasmatic nuclei (SCN) exhibit a prominent circadian oscillation in cAMP response dement (CRE)-mediated gene expression. Maximal reporter gene expression occurred from late-subjective night to mid-subjective day. Cycling of CRE-dependent transcription was not observed in other brain regions, including the supraoptic nucleus and piriform cortex. Levels of the phospho-active form of the transcription factor CREB (P-CBEB) varied as a function of circadian time, peak P-CREB levels occurred during the mid- to late-subjective night. Furthermore, photic stimulation during the subjective might, but not during the subjective day, triggered a marked increase in CRE-mediated gene expression in the SCN. Reporter gene experiments showed that activation of the p44/42 mitogen-activated protein kinase signaling cascade is required for Ca2+-dependent stimulation of CRE-mediated transcription in the SCN. These findings reveal the CREB/CRE transcriptional pathway to be circadian-regulated within the SCN, and raise the possibility that this pathway provides signaling information essential for normal clock function.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, D-429 Hlth Sci Bldg,Box 357280, Seattle, WA 98195 USA.	dstorm@u.washington.edu			NIMH NIH HHS [F32 MH 11857-01] Funding Source: Medline; NINDS NIH HHS [NS 37056] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037056] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Amato SF, 1996, J IMMUNOL, V157, P146; Ban Y, 1997, J NEUROSCI, V17, P3920; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CARD JP, 1981, J NEUROSCI, V1, P1289; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; COLWELL CS, 1991, BRAIN RES, V554, P105, DOI 10.1016/0006-8993(91)90177-W; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1990, J BIOL CHEM, V265, P10274; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Ding JM, 1997, J NEUROSCI, V17, P667; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GLASS JD, 1993, AM J PHYSIOL, V265, pR504, DOI 10.1152/ajpregu.1993.265.3.R504; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAMADA T, 1993, AM J PHYSIOL, V265, pR1199, DOI 10.1152/ajpregu.1993.265.5.R1199; Hannibal J, 1997, J NEUROSCI, V17, P2637, DOI 10.1523/jneurosci.17-07-02637.1997; Hastings MH, 1996, PROG BRAIN RES, V111, P147, DOI 10.1016/S0079-6123(08)60406-9; Honma S, 1996, AM J PHYSIOL-REG I, V271, pR579, DOI 10.1152/ajpregu.1996.271.3.R579; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Iwasaki Y, 1997, ENDOCRINOLOGY, V138, P5266, DOI 10.1210/en.138.12.5266; KALSBEEK A, 1995, BRAIN RES, V682, P75, DOI 10.1016/0006-8993(95)00324-J; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; KYRIACOU CP, 1980, P NATL ACAD SCI-BIOL, V77, P6729, DOI 10.1073/pnas.77.11.6729; Liang FQ, 1998, NEUROSCI LETT, V242, P89, DOI 10.1016/S0304-3940(98)00062-7; LIOU SY, 1986, BRAIN RES BULL, V16, P527, DOI 10.1016/0361-9230(86)90182-6; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; PARDY K, 1992, J BIOL CHEM, V267, P21746; PIGGINS HD, 1995, J NEUROSCI, V15, P5612; PROSSER RA, 1994, MOL BRAIN RES, V25, P151, DOI 10.1016/0169-328X(94)90292-5; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shinohara K, 1998, NEUROREPORT, V9, P137, DOI 10.1097/00001756-199801050-00027; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tentler JJ, 1997, MOL ENDOCRINOL, V11, P859, DOI 10.1210/me.11.7.859; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VANDENPOL AN, 1993, NEUROSCIENCE, V56, P793, DOI 10.1016/0306-4522(93)90128-3; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANG J, 1994, MOL CELL NEUROSCI, V5, P97, DOI 10.1006/mcne.1994.1011; Yasui M, 1997, AM J PHYSIOL-RENAL, V272, pF443, DOI 10.1152/ajprenal.1997.272.4.F443; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	74	230	234	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17748	17756		10.1074/jbc.274.25.17748	http://dx.doi.org/10.1074/jbc.274.25.17748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364217	hybrid			2022-12-27	WOS:000080974300053
J	Shi, Y; Ratnayake, DB; Okamoto, K; Abe, N; Yamamoto, K; Nakayama, K				Shi, Y; Ratnayake, DB; Okamoto, K; Abe, N; Yamamoto, K; Nakayama, K			Genetic analyses of proteolysis, hemoglobin finding, and hemagglutination of Porphyromonas gingivalis - Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE LYS-GINGIPAIN; CYSTEINE PROTEINASE; ARG-GINGIPAIN; BACTEROIDES-GINGIVALIS; STRUCTURAL CHARACTERIZATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; EPITHELIAL-CELLS; BINDING PROTEIN; ENCODING GENES	Porphyromonas gingivalis produces arginine-specific cysteine proteinase (Arg-gingipain, RGP) and lysine-specific cysteine proteinase (Lys-gingipain, KGP) in the extracellular and cell-associated forms. Two separate genes (rgpA and rgpB) and a single gene (kgp) have been found to encode RGP and KGP, respectively. We constructed rgpA rgpB kgp triple mutants by homologous recombination with cloned rgp and kgp DNA interrupted by drug resistance gene markers. The triple mutants showed no RGP or KGP activity in either cell extracts or culture supernatants. The culture supernatants of the triple mutants grown in a rich medium had no proteolytic activity toward bovine serum albumin or gelatin derived from human type I collagen. Moreover, the mutants did not grow in a defined medium containing bovine serum albumin as the sole carbon/energy source. These results indicate that the proteolytic activity of P, gingivalis toward bovine serum albumin and gelatin derived from human type I collagen appears to be attributable to RGP and KGP. The hemagglutinin gene hagA of P. gingivalis possesses the adhesin domain regions responsible for hemagglutination and hemoglobin binding that are also located in the C-terminal ;regions of rgpA and kgp. A rgpA kgp hagA triple mutant constructed in this study exhibited no hemagglutination using sheep erythrocytes or hemoglobin binding activity, as determined by a solid-phase binding assay with horseradish peroxidase-conjugated human hemoglobin, indicating that the adhesin domains seem to be particularly important for P. gingivalis cells to agglutinate erythrocytes and bind hemoglobin, leading to heme acquisition.	Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Pharmacol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Nakayama, K (corresponding author), Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, 3-1-1, Fukuoka 8128582, Japan.							Aduse-Opoku J, 1998, INFECT IMMUN, V66, P1594, DOI 10.1128/IAI.66.4.1594-1600.1998; AduseOpoku J, 1997, J BACTERIOL, V179, P4778, DOI 10.1128/jb.179.15.4778-4788.1997; AMANO A, 1995, FEMS MICROBIOL LETT, V134, P63, DOI 10.1111/j.1574-6968.1995.tb07915.x; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; Booth V, 1997, J PERIODONTAL RES, V32, P54, DOI 10.1111/j.1600-0765.1997.tb01382.x; Curtis MA, 1996, INFECT IMMUN, V64, P2532, DOI 10.1128/IAI.64.7.2532-2539.1996; FELDHAUS MJ, 1991, J BACTERIOL, V173, P4540, DOI 10.1128/JB.173.14.4540-4543.1991; FLETCHER HM, 1995, INFECT IMMUN, V63, P1521, DOI 10.1128/IAI.63.4.1521-1528.1995; FUJIMURA S, 1995, FEMS IMMUNOL MED MIC, V10, P109; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; GMUR R, 1988, ORAL MICROBIOL IMMUN, V3, P181, DOI 10.1111/j.1399-302X.1988.tb00007.x; Haffajee A D, 1994, Periodontol 2000, V5, P78, DOI 10.1111/j.1600-0757.1994.tb00020.x; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; ISOGAI H, 1988, ARCH ORAL BIOL, V33, P479, DOI 10.1016/0003-9969(88)90028-3; Kadowaki T, 1998, J BIOL CHEM, V273, P29072, DOI 10.1074/jbc.273.44.29072; KATO T, 1992, J BACTERIOL, V174, P3889, DOI 10.1128/jb.174.12.3889-3895.1992; Kelly CG, 1997, CLIN EXP IMMUNOL, V110, P285; KISHORE AR, 1992, J MED MICROBIOL, V37, P341, DOI 10.1099/00222615-37-5-341; Kuboniwa M, 1998, BIOCHEM BIOPH RES CO, V249, P38, DOI 10.1006/bbrc.1998.8958; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepine G, 1996, ORAL MICROBIOL IMMUN, V11, P65, DOI 10.1111/j.1399-302X.1996.tb00339.x; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; Milner P, 1996, FEMS MICROBIOL LETT, V140, P125, DOI 10.1016/0378-1097(96)00159-0; MILOLAJCZYKPAWL.J, 1998, BIOL CHEM H-S, V379, P205; Nakayama K, 1996, J BACTERIOL, V178, P2818, DOI 10.1128/jb.178.10.2818-2824.1996; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; OGAWA T, 1994, INFECT IMMUN, V62, P3305, DOI 10.1128/IAI.62.8.3305-3310.1994; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; OKUDA K, 1981, CURR MICROBIOL, V6, P7, DOI 10.1007/BF01566718; PARK Y, 1993, INFECT IMMUN, V61, P4139, DOI 10.1128/IAI.61.10.4139-4146.1993; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; PIKE R, 1994, J BIOL CHEM, V269, P406; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; PROGULSKEFOX A, 1995, ORAL MICROBIOL IMMUN, V10, P311, DOI 10.1111/j.1399-302X.1995.tb00160.x; SHAH HN, 1987, CURR MICROBIOL, V15, P241, DOI 10.1007/BF01589374; Shibata Y, 1999, J BIOL CHEM, V274, P5012, DOI 10.1074/jbc.274.8.5012; Slakeski N, 1998, MICROBIOL-UK, V144, P1583, DOI 10.1099/00221287-144-6-1583; SLOTS J, 1978, INFECT IMMUN, V19, P254, DOI 10.1128/IAI.19.1.254-264.1978; Watanabe-Kato T, 1998, MICROB PATHOGENESIS, V24, P25, DOI 10.1006/mpat.1997.0170; YOSHIMURA F, 1984, J BACTERIOL, V160, P949, DOI 10.1128/JB.160.3.949-957.1984	44	286	298	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17955	17960		10.1074/jbc.274.25.17955	http://dx.doi.org/10.1074/jbc.274.25.17955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364243	hybrid			2022-12-27	WOS:000080974300079
J	Sun, LJ; Sun, TT; Lavker, RM				Sun, LJ; Sun, TT; Lavker, RM			Identification of a cytosolic NADP(+)-dependent isocitrate dehydrogenase that is preferentially expressed in bovine corneal epithelium - A corneal epithelial crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; MAJOR SOLUBLE-PROTEINS; K3 KERATIN GENE; ALDEHYDE DEHYDROGENASE; LENS CRYSTALLINS; STEM-CELLS; LIMBAL EPITHELIUM; NUCLEAR-PROTEIN; BETA-OXIDATION; BASAL CELLS	Recently, metabolic enzymes have been observed in both the lens and corneal epithelium at levels greatly exceeding what is necessary for normal metabolic functions. These proteins have been termed taxon-specific crystallins and are thought to play a role in maintaining tissue transparency. We report here that cytosolic NADP(+)-dependent isocitrate dehydrogenase (ICDH) represents a new corneal crystallin. Using suppression subtractive hybridization, we identified a gene (with a deduced amino acid sequence that showed 94% identity to rat cytosolic NADP(+)-dependent ICDH) that is preferentially expressed in bovine corneal epithelium. Northern blots established that its mRNA level in the corneal epithelium was 31-, 39-, 133-, 230-, and 929-fold more than in the liver, bladder epithelium, stomach epithelium, brain, and heart, respectively. This mRNA was detected primarily in corneal epithelial basal cells by in situ hybridization. SDS-polyacrylamide gel electrophoresis, two-dimensional gel analysis, and Western blotting showed that this protein was overexpressed in the corneal epithelium, constituting similar to 13% of the total soluble bovine corneal epithelial proteins. Enzyme assays showed a corresponding overabundance of this protein in bovine corneal epithelium, Taken together, these data indicate that bovine cytosolic ICDH fulfills the criteria for a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Epithelial Biol Unit,Ronald O Perelman Dept Derma, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Urol, New York, NY 10016 USA	University of Pennsylvania; New York University; New York University; New York University	Lavker, RM (corresponding author), Univ Penn, Sch Med, Dept Dermatol, Clin Res Bldg 235A,415 Curie Blvd, Philadelphia, PA 19104 USA.	lavker@mail.med.upenn.edu	Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063	NEI NIH HHS [EY6769] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ALEXANDER RJ, 1981, EXP EYE RES, V32, P205, DOI 10.1016/0014-4835(81)90009-9; ALGAR EM, 1991, ADV EXP MED BIOL, V284, P53; ALGAR EM, 1993, ENZYMOLOGY MOL BIOL, V4, P153; ANDERSON DE, 1991, AM J VET RES, V52, P784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai CX, 1997, J BIOL CHEM, V272, P12831, DOI 10.1074/jbc.272.19.12831; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CHALOINDUFAU C, 1990, CELL DIFFER DEV, V32, P97, DOI 10.1016/0922-3371(90)90103-4; CHEN JJY, 1990, INVEST OPHTH VIS SCI, V31, P1301; CHEN JJY, 1991, INVEST OPHTH VIS SCI, V32, P2219; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; COOPER D, 1985, LAB INVEST, V52, P243; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; COOPER DL, 1993, ENZYMOLOGY MOL BIOL, V4, P169; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; EBATO B, 1987, INVEST OPHTH VIS SCI, V28, P1450; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; Galvin S, 1989, Adv Dermatol, V4, P277; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Graw J, 1997, BIOL CHEM, V378, P1331; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HOLMES RS, 1986, EXP EYE RES, V43, P383, DOI 10.1016/S0014-4835(86)80075-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUANG AJW, 1991, INVEST OPHTH VIS SCI, V32, P96; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P552, DOI 10.1021/bi971958i; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JENNINGS GT, 1991, EUR J BIOCHEM, V198, P621, DOI 10.1111/j.1432-1033.1991.tb16059.x; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; JESTER JV, 1998, INVEST OPHTHALMOL  S, V39, P449; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; King G, 1998, J EXP ZOOL, V282, P12; KRUSE FE, 1993, INVEST OPHTH VIS SCI, V34, P2501; Lavker RM, 1998, J INVEST DERMATOL, V110, P917, DOI 10.1046/j.1523-1747.1998.00223.x; Lavker RM, 1998, INVEST OPHTH VIS SCI, V39, P301; LAVKER RM, 1991, INVEST OPHTH VIS SCI, V32, P1864; Lehrer MS, 1998, J CELL SCI, V111, P2867; LINDBERG K, 1993, INVEST OPHTH VIS SCI, V34, P2672; MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NUMATA O, 1991, BIOCHEM BIOPH RES CO, V174, P1028, DOI 10.1016/0006-291X(91)91522-E; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SILVERMAN B, 1981, EXP EYE RES, V33, P19, DOI 10.1016/S0014-4835(81)80078-4; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; TSENG SCG, 1982, CELL, V30, P361, DOI 10.1016/0092-8674(82)90234-3; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WEI ZG, 1993, INVEST OPHTH VIS SCI, V34, P1814; WINKLER BS, 1988, INVEST OPHTH VIS SCI, V29, P821; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WU RL, 1994, DIFFERENTIATION, V55, P137, DOI 10.1046/j.1432-0436.1994.5520137.x; WU RL, 1994, J BIOL CHEM, V269, P28450; ZIESKE JD, 1992, DEV BIOL, V151, P18, DOI 10.1016/0012-1606(92)90209-Y	65	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17334	17341		10.1074/jbc.274.24.17334	http://dx.doi.org/10.1074/jbc.274.24.17334			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358094	hybrid			2022-12-27	WOS:000080780400093
J	Ancellin, N; Hla, T				Ancellin, N; Hla, T			Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SWISS 3T3 FIBROBLASTS; LYSOPHOSPHATIDIC ACID; CELLULAR-RESPONSES; KINASE ACTIVATION; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; CELLS; PROLIFERATION; PATHWAYS	Sphingosine 1-phosphate (SPP) is a potent lipid mediator released upon cellular activation. In this report, pharmacological properties of the three G-protein-coupled receptors (GPCRs) for SPP, EDG-1, -3, and -5 are characterized using a Xenopus oocyte expression system, which lacks endogenous SPP receptors. Microinjection of the EDG-3 and EDG-5 but not EDG-1 mRNA conferred SPP-responsive intracellular calcium transients; however, the EDG-5 response was quantitatively much less. Go-expression of EDG-1 receptor with the chimeric G(alpha qi) protein conferred SPP responsiveness. G(alpha qi) or G(alpha q) co-injection also potentiated the EDG-5 and EDG-3 mediated responses to SPP. These data suggest that SPP receptors couple differentially to the G(q) and G(i) pathway. All three GPCRs were also activated by sphingosylphosphorylcholine, albeit at higher concentrations. None of the other related sphingolipids tested stimulated or blocked SPP-induced calcium responses. However, suramin, a polycyclic anionic compound, selectively antagonized SPP-activated calcium transients in EDG-3 expressing oocytes with an IC50 of 22 mu M, suggesting that it is an antagonist selective for the EDG-3 GPCR isotype. We conclude that the three SPP receptors signal differentially by coupling to different G-proteins. Furthermore, because only EDG-3 was antagonized by suramin, variations in receptor structure may determine differences in antagonist selectivity. This property may be exploited to synthesize receptor subtype-specific antagonists.	Univ Connecticut, Ctr Hlth, Sch Med, Dept Physiol,Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Sch Med, Dept Physiol,Ctr Vasc Biol, MC-3505,263 Farmington Ave, Farmington, CT 06030 USA.	hla@sun.uchc.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL54710] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BARNARD EA, 1987, NEUROCHEMISTRY PRACT, P243; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA T, 1999, IN PRESS BIOCH PHARM; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Klingler C, 1998, CELL SIGNAL, V10, P65, DOI 10.1016/S0898-6568(97)00077-6; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOCHEM, V121, P969; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	40	222	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18997	19002		10.1074/jbc.274.27.18997	http://dx.doi.org/10.1074/jbc.274.27.18997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383399	hybrid			2022-12-27	WOS:000081196300022
J	Lange, H; Kispal, G; Lill, R				Lange, H; Kispal, G; Lill, R			Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; FRIEDREICHS-ATAXIA; MOLECULAR-BIOLOGY; PROTEIN IMPORT; TRANSLOCATION; FERROCHELATASE; ACCUMULATION; HOMOLOG; IDENTIFICATION	The import of metals, iron in particular, into mitochondria is poorly understood. Iron in mitochondria is required for the biosynthesis of heme and various iron-sulfur proteins. We have developed an in vitro assay to follow the uptake of iron into isolated yeast mitochondria. By measuring the incorporation of iron into porphyrin by ferrochelatase in the matrix, we were able to define the mechanism of iron import. Iron uptake is driven energetically by a membrane potential across the inner membrane but does not require ATP, Only reduced iron is functional in generating heme, Iron cannot be preloaded in the mitochondrial matrix but rather has to be transported across the inner membrane simultaneously with the synthesis of hems, suggesting that ferrochelatase receives iron directly from the inner membrane, Transport of iron is inhibited by manganese but not by zinc, nickel, and copper ions, explaining why in vivo these ions are not incorporated into porphyrin. The inner membrane proteins Mmt1p and Mmt2p proposed to be involved in mitochondrial iron movement are not required for the supply of ferrochelatase with iron. Iron transport can be reconstituted efficiently in a membrane potential-dependent fashion in proteoliposomes that were formed from a detergent extract of mitochondria. Our biochemical analysis of iron import into yeast mitochondria provides the basis for the identification of components involved in transport.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Pecs, Sch Med, Inst Biochem, H-7624 Pecs, Hungary	Philipps University Marburg; University of Pecs	Lill, R (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 5, D-35033 Marburg, Germany.			Lill, Roland/0000-0002-8345-6518; Lange, Heike/0000-0002-8222-3448				ABBAS A, 1993, J BIOL CHEM, V268, P8541; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CEDERBAUM AI, 1972, J BIOL CHEM, V247, P4593; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; EGYED A, 1982, BIOCH PHYSL IRON, P103; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; KISPAL G, 1988, J BIOL CHEM, V263, P11145; KLAUSNER RD, 1994, FEBS LETT, V355, P109, DOI 10.1016/0014-5793(94)01111-7; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KONOPKA K, 1980, EUR J BIOCHEM, V107, P433; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; Labbe-Bois Rosine, 1994, V11, P413; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Reissbrodt R, 1997, J BACTERIOL, V179, P4538, DOI 10.1128/jb.179.14.4538-4544.1997; Sambrook J., 2002, MOL CLONING LAB MANU; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STRICKLAND EH, 1965, BIOCHIM BIOPHYS ACTA, V104, P596, DOI 10.1016/0304-4165(65)90367-3; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	46	131	136	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					18989	18996		10.1074/jbc.274.27.18989	http://dx.doi.org/10.1074/jbc.274.27.18989			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383398	hybrid			2022-12-27	WOS:000081196300021
J	Meuller, J; Rydstrom, J				Meuller, J; Rydstrom, J			The membrane topology of proton-pumping Escherichia coli transhydrogenase determined by cysteine labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE ALPHA-HELICES; POLYMERASE CHAIN-REACTION; RHODOSPIRILLUM-RUBRUM; BETA-SUBUNIT; AMINO-ACID; PROTEINS; ENZYME; PREDICTION	The membrane topology of proton-pumping nicotinamide-nucleotide transhydrogenase from Escherichia coli was determined by site-specific chemical labeling, A His-tagged cysteine-free transhydrogenase was used to introduce unique cysteines in positions corresponding to potential membrane loops. The cysteines mere reacted with fluorescent reagents, fluorescein 5-maleimide or 2-[(4'-maleimidyl)anilino]naphthalene-6-sulfonic acid, in both intact cells and inside-out vesicles. Labeled transhydrogenase was purified with a small-scale procedure using a metal affinity resin, and the amount of labeling was measured as fluorescence on UV-illuminated acrylamide gels. The difference in labeling between intact cells and inside-out vesicles was used to discriminate between a periplasmic and a cytosolic location of the residues. The membrane region was found to be composed of 13 helices (four in the alpha-subunit and nine in the beta-subunit), with the C terminus of the alpha-subunit and the N terminus of the beta-subunit facing the cytosolic and periplasmic sides, respectively. These results differ from previous models with regard to both number of helices and the relative location and orientation of certain helices. This study constitutes the first in which all transmembrane segments of transhydrogenase have been experimentally determined and provides an explanation for the different topologies of the mitochondrial and E. coli transhydrogenases.	Univ Gothenburg, Dept Chem, Div Biochem & Biophys, S-40530 Gothenburg, Sweden; Chalmers Univ Technol, S-40530 Gothenburg, Sweden	University of Gothenburg; Chalmers University of Technology	Rydstrom, J (corresponding author), Univ Gothenburg, Dept Chem, Div Biochem & Biophys, Medicinaregatan 9C,POB 462, S-40530 Gothenburg, Sweden.		Rydström, Jan/A-7683-2010					AHMAD S, 1992, EUR J BIOCHEM, V207, P733, DOI 10.1111/j.1432-1033.1992.tb17103.x; Bizouam T, 1997, BBA-BIOENERGETICS, V1322, P19, DOI 10.1016/S0005-2728(97)00065-0; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; CLARKE DM, 1985, J BACTERIOL, V162, P367, DOI 10.1128/JB.162.1.367-373.1985; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; GLAVAS NA, 1995, BIOCHEM BIOPH RES CO, V214, P230, DOI 10.1006/bbrc.1995.2279; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P47; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kimura T, 1997, J BIOL CHEM, V272, P580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Meuller J, 1997, BIOCHEM J, V324, P681, DOI 10.1042/bj3240681; Moore DD, 1995, GLOB MOB SURV; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROST B, 1995, PROTEIN SCI, V4, P521; TONG RCW, 1991, BIOCHIM BIOPHYS ACTA, V1080, P19, DOI 10.1016/0167-4838(91)90106-A; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P17020; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	38	45	46	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19072	19080		10.1074/jbc.274.27.19072	http://dx.doi.org/10.1074/jbc.274.27.19072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383409	hybrid			2022-12-27	WOS:000081196300032
J	Resendes, MC; Dobransky, T; Ferguson, SSG; Rylett, RJ				Resendes, MC; Dobransky, T; Ferguson, SSG; Rylett, RJ			Nuclear localization of the 82-kDa form of human choline acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; GENE-EXPRESSION; MESSENGER-RNA; RAT-BRAIN; IN-VIVO; PROTEIN; CELLS; ACETYLCHOLINE; ENZYME; IDENTIFICATION	Choline acetyltransferase is the enzyme catalyzing synthesis of the neurotransmitter acetylcholine in cholinergic neurons. In human, transcripts encoding two forms of the enzyme with apparent molecular masses of 69 and 82 kDa are found in brain and spinal cord; the 82-kDa form differs from the 69-kDa enzyme only in terms of a 118-amino acid extension on its amino terminus. Using green fluorescent protein-tagged choline acetyltransferase, we show that the 82-kDa enzyme is targeted to nuclei of cells, whereas the 69-kDa protein is found in cytoplasm. Expression of site-directed and deletion mutants of the 82-kDa isoform reveals that the extended amino terminus contains a nuclear localization signal in the first nine amino acids which targets the protein to nucleus. This represents the first report of a neurotransmitter-synthesizing enzyme that is localized to the cell nucleus.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada; John P Robarts Res Inst, Neurodegenerat Dis Grp, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.		Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; BADAMCHIAN M, 1986, NEUROCHEM INT, V9, P409, DOI 10.1016/0197-0186(86)90083-5; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; Chatterjee S, 1997, EXP CELL RES, V236, P346, DOI 10.1006/excr.1997.3746; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HERSH LB, 1984, J BIOL CHEM, V259, P1253; IRAURRALDE E, 1998, RNA NY, V4, P351; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LIND GJ, 1995, INVEST OPHTH VIS SCI, V36, P1492; Misawa H, 1997, MOL BRAIN RES, V44, P323, DOI 10.1016/S0169-328X(96)00231-8; MISAWA H, 1992, J BIOL CHEM, V267, P20392; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Moroianu J, 1997, CRIT REV EUKAR GENE, V7, P61, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.40; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ODA Y, 1992, MOL BRAIN RES, V16, P287, DOI 10.1016/0169-328X(92)90237-6; Oda Y, 1996, MOL BRAIN RES, V38, P135, DOI 10.1016/0169-328X(95)00280-6; Pahud G, 1998, EUR J NEUROSCI, V10, P1644, DOI 10.1046/j.1460-9568.1998.00177.x; PUJOL MJ, 1993, J NEUROCHEM, V60, P1422, DOI 10.1111/j.1471-4159.1993.tb03304.x; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RYLETT RJ, 1993, J NEUROCHEM, V61, P1388, DOI 10.1111/j.1471-4159.1993.tb13632.x; SALEM N, 1994, EUR J NEUROSCI, V6, P737, DOI 10.1111/j.1460-9568.1994.tb00985.x; SCHMIDT BM, 1993, J NEUROCHEM, V61, P1774, DOI 10.1111/j.1471-4159.1993.tb09815.x; SLEMMON JR, 1991, MOL BRAIN RES, V9, P245; TUCEK S, 1993, PROG BIOPHYS MOL BIO, V60, P59, DOI 10.1016/0079-6107(93)90013-A; WU DH, 1994, J NEUROCHEM, V62, P1653	31	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19417	19421		10.1074/jbc.274.27.19417	http://dx.doi.org/10.1074/jbc.274.27.19417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383456	hybrid			2022-12-27	WOS:000081196300079
J	Rachubinski, RA; Marcus, SL; Capone, JP				Rachubinski, RA; Marcus, SL; Capone, JP			The p56(lck)-interacting protein p62 stimulates transcription via the SV40 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-INDEPENDENT LIGAND; MURINE PERITONEAL-MACROPHAGES; UBIQUITOUS NUCLEAR PROTEINS; A170 STRESS PROTEIN; BINDING-PROTEIN; SH2 DOMAIN; MAMMALIAN-CELLS; INVITRO BINDING; GENE; ELEMENTS	p62 is a recently identified ubiquitin-binding, cytosolic phosphoprotein that interacts with several signal transduction molecules including the tyrosine kinase p56(lck) and the protein kinase C-zeta, p62 is therefore suggested to serve an important role in signal transduction in the cell, although the physiological function of p62 remains undefined. Here we demonstrate by transient transfection assays that p62 stimulates the transcription of reporter genes linked to the simian virus 40 (SV40) enhancer. A putative p62-responsive element was localized to the B domain of the distal 72-base pair repeat of the SV40 enhancer. p62 was unable to bind this element in vitro, nor was it able to activate transcription when directly tethered to a promoter, suggesting that p62 stimulates transcription via an indirect mechanism. Stimulation of transcription mediated by p62 was dependent on its amino-terminal region, which is also necessary for interaction with cell surface signaling molecules. These findings indicate that p62 may link extracellular signals directly to transcriptional responses, and identify the SV40 enhancer as a downstream target for signal transduction pathways in which p62 participates.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	McMaster University; University of Alberta	Capone, JP (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	caponej@fhs.csu.mcmaster.ca						ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; Ausubel FM, 1988, MOL REPROD DEV; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lee YH, 1998, FEBS LETT, V438, P297, DOI 10.1016/S0014-5793(98)01323-4; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; Marcus SL, 1996, J BIOL CHEM, V271, P27197, DOI 10.1074/jbc.271.44.27197; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yanagawa T, 1997, BIOCHEM BIOPH RES CO, V241, P157, DOI 10.1006/bbrc.1997.7783; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	33	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18278	18284		10.1074/jbc.274.26.18278	http://dx.doi.org/10.1074/jbc.274.26.18278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373430	hybrid			2022-12-27	WOS:000081056700022
J	Liao, WC; Haimovitz-Friedman, A; Persaud, RS; McLoughlin, M; Ehleiter, D; Zhang, N; Gatei, M; Lavin, M; Kolesnick, R; Fuks, Z				Liao, WC; Haimovitz-Friedman, A; Persaud, RS; McLoughlin, M; Ehleiter, D; Zhang, N; Gatei, M; Lavin, M; Kolesnick, R; Fuks, Z			Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; DEPENDENT PROTEIN-KINASE; CELL-CYCLE CHECKPOINT; EPSTEIN-BARR-VIRUS; DOUBLE-STRAND BREAKS; ATM-DEFICIENT MICE; IONIZING-RADIATION; MAMMALIAN-CELLS; SPHINGOLIPID BIOSYNTHESIS; CHROMOSOMAL-ABERRATIONS	DNA double-stranded breaks (dsb) activate surveillance systems that identify DNA damage and either initiate repair or signal cell death. Failure of cells to undergo appropriate death in response to DNA damage leads to misrepair, mutations, and neoplastic transformation. Pathways linking DNA dsb to reproductive or apoptotic death are virtually unknown. Here we report that metabolic incorporation of I-125-labeled 5-iodo-2'deoxyuridine, which produces DNA dsb, signaled de novo ceramide synthesis by post-translational activation of ceramide synthase (CS) and apoptosis. CS activation was obligatory, since fumonisin B1, a fungal pathogen that acts as a specific CS inhibitor, abrogated DNA damage-induced death. X-irradiation yielded similar results. Furthermore, inhibition of apoptosis using the peptide caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone did not affect CS activation, indicating this event is not a consequence of induction of apoptosis. ATM, the gene mutated in ataxia telangiectasia, isa member of the phosphatidylinositol 3-kinase family that constitutes the DNA damage surveillance/repair system. Epstein-Barr virus-immortalized B cell lines from six ataxia telangiectasia patients with different mutations exhibited radiation-induced CS activation, ceramide generation, and apoptosis, whereas three lines from normal patients failed to manifest these responses. Stable transfection of wild type ATM cDNA reversed these events, whereas antisense inactivation of ataxia telangiectasia-mutated gene product in normal B cells conferred the ataxia telangiectasia phenotype. We propose that one of the functions of ataxia telangiectasia-mutated gene product is to constrain activation of CS, thereby regulating DNA damage-induced apoptosis.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.		Lavin, Martin/F-5961-2014	Lavin, Martin/0000-0002-5940-4769	NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AllalunisTurner J, 1997, RADIAT RES, V147, P284, DOI 10.2307/3579334; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEDFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457, DOI 10.1016/0360-3016(91)90320-4; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHARLTON DE, 1986, RADIAT RES, V107, P163, DOI 10.2307/3576804; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Garzotto M, 1998, CANCER RES, V58, P2260; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Haimovitz-Friedman, 1996, Semin Radiat Oncol, V6, P273, DOI 10.1016/S1053-4296(96)80023-3; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOFER KG, 1975, INT J RADIAT BIOL, V28, P225, DOI 10.1080/09553007514550991; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; KASSIS AI, 1982, RADIAT RES, V90, P362, DOI 10.2307/3575714; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1993, ONCOGENE, V8, P3307; KINSELLA TJ, 1987, INT J RADIAT ONCOL, V13, P733, DOI 10.1016/0360-3016(87)90292-6; Krisch R E, 1978, Curr Top Radiat Res Q, V12, P355; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEMOTTE PK, 1984, CANCER RES, V44, P1337; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTIN RF, 1981, SCIENCE, V213, P896, DOI 10.1126/science.7256283; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; RADFORD IR, 1985, INT J RADIAT BIOL, V48, P555, DOI 10.1080/09553008514551611; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Telatar M, 1996, AM J HUM GENET, V59, P40; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; Vidair CA, 1996, CANCER RES, V56, P4116; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; YASUI LS, 1986, INT J RADIAT BIOL, V49, P601; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; ZHANG N, 1998, ONCOGENE, V58, P2260; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	73	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17908	17917		10.1074/jbc.274.25.17908	http://dx.doi.org/10.1074/jbc.274.25.17908			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364237	hybrid			2022-12-27	WOS:000080974300073
J	Maekawa, T; Bernier, F; Sato, M; Nomura, S; Singh, M; Inoue, Y; Tokunaga, T; Imai, H; Yokoyama, M; Reimold, A; Glimcher, LH; Ishii, S				Maekawa, T; Bernier, F; Sato, M; Nomura, S; Singh, M; Inoue, Y; Tokunaga, T; Imai, H; Yokoyama, M; Reimold, A; Glimcher, LH; Ishii, S			Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; TRANSCRIPTION FACTORS; GENE-EXPRESSION; BINDING PROTEIN; CDNA CLONES; CRE-BP1; ANGIOGENESIS; HYPOXIA; FAMILY; CREB	Mouse null mutants of transcription factor ATF-2 were generated by the gene targeting method. They died shortly after birth and displayed symptoms of severe respiratory distress with lungs filled with meconium, These features are similar to those of a severe type of human meconium aspiration syndrome. The increased expression of the hypoxia inducible genes suggests that hypoxia occurs in the mutant embryos and that it may lead to strong gasping respiration with: consequent aspiration of the amniotic fluid containing meconium. A reduced number of cytotrophoblast cells in the mutant placenta was found and may be responsible for an insufficient supply of oxygen prior to birth. Using the cDNA subtraction and microarray-based expression monitoring method, the expression level of the platelet-derived growth factor receptor a gene, which plays an important role in the proliferation of trophoblasts, was found to be low in the cytotrophoblasts of the mutant placenta. In addition, ATF-S can trans-activate the PDGF receptor a gene promoter in the co-transfection assay. These results indicate the important role of ATF-S in the formation of the placenta and the relationship between placental anomalies and neonatal respiratory distress. The ATF-S null mutants should enhance our understanding of the mechanism of severe neonatal respiratory distress.	RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0600815, Japan; Natl Inst Anim Ind, Inashiki, Ibaraki 3050901, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1940031, Japan; Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	RIKEN; Osaka University; Hokkaido University; National Agriculture & Food Research Organization - Japan; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Bernier, Francois/AAP-2174-2020; Bernier, Francois/V-7150-2018; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478	NIAID NIH HHS [AI32412] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032412] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFINK GB, 1995, ONCOGENE, V10, P1667; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BLOCK MF, 1981, OBSTET GYNECOL, V57, P37; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Floros J, 1998, ANNU REV PHYSIOL, V60, P365, DOI 10.1146/annurev.physiol.60.1.365; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENOUGH A, 1995, EARLY HUM DEV, V41, P183, DOI 10.1016/0378-3782(95)01625-D; GUPTA S, 1995, SCIENCE, V267, P339; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KATZ VL, 1992, AM J OBSTET GYNECOL, V166, P171, DOI 10.1016/0002-9378(92)91856-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; NOMURA N, 1993, J BIOL CHEM, V268, P4259; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKEDA J, 1991, ONCOGENE, V6, P1009; Thureen PJ, 1997, AM J OBSTET GYNECOL, V176, P967, DOI 10.1016/S0002-9378(97)70387-9; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; VANDAM H, 1997, EMBO J, V14, P31798; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	31	88	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17813	17819		10.1074/jbc.274.25.17813	http://dx.doi.org/10.1074/jbc.274.25.17813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364225	hybrid			2022-12-27	WOS:000080974300061
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SMOOTH-MUSCLE; ADENYLYL-CYCLASE; DEPENDENT PHOSPHORYLATION; PHOSPHOLIPASE C-BETA-3; KINASE-A; INHIBITION; MEMBRANES; PATHWAY; CELLS	We have shown recently that the 37-amino acid intracellular domain of the single-transmembrane, natriuretic peptide clearance receptor, NPR-C, which is devoid of kinase and guanylyl cyclase activities, activates selectively G(i1) and G(i2) in gastric and tenia coli smooth muscle. In this study, we have used synthetic peptide fragments of the N-terminal, C-terminal, and middle regions of the cytoplasmic domain of NPR-C to identify the G protein-activating sequence. A 17-amino acid peptide of the middle region (Arg(469)-Arg(485)), denoted Peptide 4, which possesses two N-terminal arginine residues and a C-terminal B-B-X-X-B motif (where B and X are basic and non-basic residues, respectively) bound selectively to G(i1) and G(i2), activated phospholipase C-beta 3 via the py subunits, inhibited adenylyl cyclase, :and induced smooth muscle contraction, in similar fashion to the selective NPR-C ligand, cANP4-23, A similar sequence (Peptide 3), but with a partial C-terminal motif, lead minimal activity. Sequences which possessed either the N-terminal basic residues (Peptide 1) or the C-terminal B-B-X-X-B motif (Peptide 2) were inactive. Peptide 2, however, inhibited G; protein activation and cellular responses mediated by the stimulatory Peptide 4 and by cANP4-23, suggesting that the B-B-X-X-B motif mediated binding but not activation of G protein, thus causing Peptide 2 to act as a competitive inhibitor of G protein activation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Murthy, KS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, POB 980711, Richmond, VA 23298 USA.				NIDDK NIH HHS [DK28300, DK15564] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564, R01DK028300] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; Bianciotti LG, 1998, BIOCHEM BIOPH RES CO, V247, P123, DOI 10.1006/bbrc.1998.8753; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAI LJ, 1993, AM J PHYSIOL, V265, pF592, DOI 10.1152/ajprenal.1993.265.4.F592; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; JAMISON RL, 1992, AM J KIDNEY DIS, V20, P519, DOI 10.1016/S0272-6386(12)70269-X; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; Murthy KS, 1996, MOL PHARMACOL, V50, P870; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V275, pC1409, DOI 10.1152/ajpcell.1998.275.6.C1409; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Teng BO, 1998, GASTROENTEROLOGY, V114, pA846, DOI 10.1016/S0016-5085(98)83447-1; Teng BQ, 1998, AM J PHYSIOL-GASTR L, V275, pG342, DOI 10.1152/ajpgi.1998.275.2.G342; UHING RJ, 1986, J BIOL CHEM, V261, P2140	31	86	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17587	17592		10.1074/jbc.274.25.17587	http://dx.doi.org/10.1074/jbc.274.25.17587			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364194	hybrid			2022-12-27	WOS:000080974300030
J	Tate, CG; Whiteley, E; Betenbaugh, MJ				Tate, CG; Whiteley, E; Betenbaugh, MJ			Molecular chaperones stimulate the functional expression of the cocaine-sensitive serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; DEPENDENT REDUCTASE ERP57; N-LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; P-GLYCOPROTEIN; INSECT CELLS; NOREPINEPHRINE TRANSPORTER; BACULOVIRUS EXPRESSION; CALNEXIN P88; CALRETICULIN	The serotonin transporter (SERT) is an N-glycosylated integral membrane protein that is predicted to contain 12 transmembrane regions. SERT is the major binding site in the brain for antidepressant drugs, and it also binds amphetamines and cocaine. The ability of various molecular chaperones to interact with a tagged version of SERT (Myc-SERT) was investigated using the baculovirus expression system. Overexpression of Myc-SERT using the baculovirus system led to substantial quantities of inactive transporter, together with small amounts of fully active and, therefore, correctly folded molecules. The high levels of inactive Myc-SERT probably arose because folding was rate-limiting due, perhaps, to insufficient molecular chaperones. Therefore, Myc-SERT was co-expressed with the endoplasmic reticulum (ER) molecular chaperones calnexin, calreticulin and immunoglobulin heavy chain binding protein (BiP), and the foldase, ERp57, The expression of functional Myc-SERT, as determined by an inhibitor binding assay, was enhanced nearly 3-fold by co-expressing calnexin, and to a lesser degree on co-expression of calreticulin and BiP, Go-expression of ERp57 did not increase the functional expression of Myc-SERT. A physical interaction between Myc-SERT-calnexin and Myc-SERT-calreticulin was demonstrated by co-immunoprecipitation. These associations were inhibited in vivo by deoxynojirimycin, an inhibitor of N-glycan precusor trimming that is known to prevent the calnexin/calreticulin-N-glycan interaction. Functional expression of the unglycosylated SERT mutant, SERT-QQ, was also increased on co-expression of calnexin, suggesting that the interaction between calnexin and SERT is not entirely dictated by the N-glycan, SERT is the first member of the neurotransmitter transporter family whose folding has been shown to be assisted by the molecular chaperones calnexin, calreticulin, and BiP.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	MRC Laboratory Molecular Biology; Johns Hopkins University	Tate, CG (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659; Tate, Christopher/0000-0002-2008-9183				ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hsu TA, 1997, BIOTECHNOL PROGR, V13, P96, DOI 10.1021/bp960088d; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Lenhard T, 1997, BIOCHEM BIOPH RES CO, V238, P823, DOI 10.1006/bbrc.1997.7395; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PIND S, 1994, J BIOL CHEM, V269, P12784; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Possee RD., 1992, BACULOVIRUS EXPRESSI; QIAN Y, 1995, J NEUROSCI, V15, P1261; RITZ MC, 1990, LIFE SCI, V46, P635, DOI 10.1016/0024-3205(90)90132-B; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Smith J, 1996, BIOTECHNIQUES, V20, P1082; SMITH JM, 1990, COMPUT APPL BIOSCI, V6, P93; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; TATE CG, 1994, J BIOL CHEM, V269, P26303; Tate CG, 1998, METHOD ENZYMOL, V296, P443; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG JB, 1995, J NEUROCHEM, V64, P1416; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WORRALL DM, 1994, BIOCHEM J, V297, P425, DOI 10.1042/bj2970425; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	56	73	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17551	17558		10.1074/jbc.274.25.17551	http://dx.doi.org/10.1074/jbc.274.25.17551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364189	hybrid			2022-12-27	WOS:000080974300025
J	Sun, XQ; Lee, J; Navas, T; Baldwin, DT; Stewart, TA; Dixit, VM				Sun, XQ; Lee, J; Navas, T; Baldwin, DT; Stewart, TA; Dixit, VM			RIP3, a novel apoptosis-inducing kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ADENOVIRUS-MEDIATED EXPRESSION; INDUCED CELL-DEATH; CASPASE-8 ACTIVATION; SIGNALING COMPLEX; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GENE-EXPRESSION; PROTEIN-KINASE; DOMAIN	RIPS is a novel gene product containing a N-terminal kinase domain that shares extensive homology with the corresponding domain in RIP (receptor-interacting protein) and RIPE. Unlike RIP, which has a C-terminal death domain, and RIPE, which has a C-terminal caspase activation and recruitment domain, RIPS has a unique C terminus. RIPS binds RIP through its unique C-terminal segment and by virtue of this interaction is recruited to the tumor necrosis factor (TNF) receptor-1 signaling complex. Previous studies have shown that RIP mediates TNF-induced activation of the anti-apoptotic NF-KB pathway. RIPS, however, attenuates both RIP and TNF receptor-1-induced NF-KB activation. Overexpression studies revealed RIPS to be a potent inducer of apoptosis, capable of selectively binding to large prodomain initiator caspases.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Endocrine Res, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, M-S40,1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jobin C, 1998, J IMMUNOL, V160, P410; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Soares MP, 1998, J IMMUNOL, V161, P4572; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	32	174	193	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16871	16875		10.1074/jbc.274.24.16871	http://dx.doi.org/10.1074/jbc.274.24.16871			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358032	hybrid			2022-12-27	WOS:000080780400031
J	Masse, E; Drolet, M				Masse, E; Drolet, M			Escherichia coli DNA topoisomerase I inhibits R-loop formation by relaxing transcription-induced negative supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPLATE; RNA; ELONGATION; MECHANISM; MUTANTS; VITRO	It has recently been shown that RNase H overproduction can partially compensate for the growth defect due to the absence of DNA topoisomerase I in Escherichia coli (Drolet, M,, Phoenix, P,, Menzel, R,, Masse, E,, Liu, L. F,, and Crouch, R, J, (1995) Proc. Natl, Acad. Sci, U, S, A. 92, 3526-3530), This result has suggested a model in which inhibitory R-loops occur during transcription in topA mutants. Results presented in this report further support this notion and demonstrate that transcription-induced supercoliing is involved in R-loop formation, First, we show that stable R-loop formation during in vitro transcription with E, coli RNA polymerase only occurs in the presence of DNA gyrase, Second, extensive R-loop formation in vivo, revealed by the production of RNase H-sensitive hypernegatively supercolied plasmid DNAs, is observed under conditions where topA mutants fail to grow. Furthermore, we have demonstrated that the coupling of transcription and translation in bacteria is an efficient way of preventing R-loop formation.	Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Drolet, M (corresponding author), Univ Montreal, Dept Microbiol & Immunol, CP 6128,Succursale Centreville, Montreal, PQ H3C 3J7, Canada.	Marc.Drolet@umontreal.ca	Drolet, Marc/M-1328-2019					DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; Sambrook J., 2002, MOL CLONING LAB MANU; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG JC, 1974, J MOL BIOL, V87, P797, DOI 10.1016/0022-2836(74)90085-0; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	17	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16659	16664		10.1074/jbc.274.23.16659	http://dx.doi.org/10.1074/jbc.274.23.16659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347234	hybrid			2022-12-27	WOS:000080668600094
J	Ried, S; Jager, C; Jeffers, M; Vande Woude, GF; Graeff, H; Schmitt, M; Lengyel, E				Ried, S; Jager, C; Jeffers, M; Vande Woude, GF; Graeff, H; Schmitt, M; Lengyel, E			Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor scatter factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; RHO-FAMILY PROTEINS; GRB2 BINDING-SITE; RAS TRANSFORMATION; MET PROTOONCOGENE; SIGNALING PATHWAY; EPITHELIAL-CELLS; OVARIAN-CANCER; ONCOGENIC RAS; PHORBOL-ESTER	Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector inducing invasion and metastasis of tumor cells that express the Met tyrosine kinase receptor, One of the effecters of HGF/SF is the urokinase-type plasminogen activator, a serine protease that facilitates tumor progression and metastasis by controlling the synthesis of the extracellular matrix degrading plasmin, Stimulation of NIH 3T3 cells that were stably trans fected with the human Met receptor (NIH 3T3-Met(hum)) with HGF/SF induced a trans-activation of the urokinase promoter and urokinase secretion. Induction of the urokinase promoter by HGF/SF via the Met receptor was blocked by co-expression of a dominant-negative Grb2 and Sos1 expression construct. Further, the expression of the catalytically inactive mutants of Ha-Ras, RhoA, c-Raf, and Erk2 or addition of the Mek1-specific inhibitor PD 098059 abrogated the stimulation of the urokinase promoter by HGF/SF. A sequence residing between -2109 and -1870 base pairs (bp) was critical for stimulation of the urokinase gene by HGF/SF. Mobility shift assays with oligonucleotides spanning an AP-1 site at -1880 bp or a combined PEA3/AP-1 site at -1967 bp showed binding of nuclear factors from NIH 3T3-Met(hum) cells. Expression of an expression plasmid that inhibits DNA binding of AP-1 proteins (A-Fos) abrogated inducible and basal activation of the urokinase promoter. Nuclear extract from unstimulated NIH 3T3-Met(hum) cells contained more JunD and showed a stronger JunD supershift with the AP-I oligonucleotides, compared with HGF/SF-stimulated cells. Consistent with the levels of JunD expression being functionally important for basal expression of the urokinase promoter, we found that overexpression of wild type JunD inhibited the induction of the urokinase promoter by HGF/SF. These data suggest that the induction of urokinase by HGF/SF is regulated by a Grb2/Sos1/Ha-Ras/c-Raf/RhoA/Mek1/ Erk2/c-Jun-dependent mitogen-activated protein kinase pathway.	Tech Univ Munich, Dept Obstet & Gynecol, D-81675 Munich, Germany; NCI, ABL Basic Res Program, NIH, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Technical University of Munich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lengyel, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, Ismaninger Str 22, D-81675 Munich, Germany.		Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Choong PFM, 1996, INT J CANCER, V69, P268, DOI 10.1002/(SICI)1097-0215(19960822)69:4<268::AID-IJC5>3.0.CO;2-V; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LIOTTA LA, 1981, CANCER RES, V41, P4629; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WARN R, 1995, NATURE, V376, P723, DOI 10.1038/376723a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WILHELM O, 1995, CLIN EXP METASTAS, V13, P296, DOI 10.1007/BF00133485; WILHELM O, 1988, CANCER RES, V48, P3507; WUN TC, 1982, J BIOL CHEM, V257, P3276; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMASHITA J, 1994, CANCER RES, V54, P1630; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16377	16386		10.1074/jbc.274.23.16377	http://dx.doi.org/10.1074/jbc.274.23.16377			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347197	hybrid			2022-12-27	WOS:000080668600057
J	Kim, YG; Lowenhaupt, K; Schwartz, T; Rich, A				Kim, YG; Lowenhaupt, K; Schwartz, T; Rich, A			The interaction between Z-DNA and the Zab domain of double-stranded RNA adenosine deaminase characterized using fusion nucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOKI CLEAVAGE DOMAIN; RESTRICTION-ENDONUCLEASE; BINDING DOMAIN; EDITING ENZYME; Z-ALPHA	Zab is a structurally defined protein domain that binds specifically to DNA in the Z conformation. It consists of amino acids 133-368 from the N terminus of human double-stranded RNA adenosine deaminase, which is implicated in RNA editing. Zab contains two motifs with related sequence, Z alpha and Z beta. Z alpha alone is capable of binding Z-DNA with high affinity, whereas Z beta alone has little DNA binding activity. Instead, Z beta modulates Z alpha binding, resulting in increased sequence specificity for alternating (dCdG)(n) as compared with (dCdA/ dTdG)(n). This relative specificity has previously been demonstrated with short oligonucleotides. Here we demonstrate that Zab can also bind tightly to (dCdGr)(n) stabilized in the Z form in supercoiled plasmids, Binding was assayed by monitoring cleavage of the plasmids using fusion nucleases, in which Z-DNA-binding peptides from the N terminus of double-stranded RNA adenosine deaminase are linked to the nuclease domain of FokI, A fusion nuclease containing Z alpha shows less sequence specificity, as well as less conformation specificity, than one containing Zab, Further, a construct in which Z beta has been replaced in Zab with Z alpha, cleaves Z-DNA regions in supercoiled plasmids more efficiently than the wild type but with little sequence specificity. We conclude that in the Zab domain, both Z alpha and Z beta contact DNA, Z alpha contributes contacts that produce conformation specificity but not sequence specificity. In contrast, Z beta contributes weakly to binding affinity but discriminates between sequences of Z-DNAs.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	cbeckman@mit.edu	Schwartz, Thomas/ABA-1770-2021	Schwartz, Thomas/0000-0001-8012-1512; /0000-0002-8187-6498				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANIFORD DB, 1983, J BIOMOL STRUCT DYN, V1, P593, DOI 10.1080/07391102.1983.10507467; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Huang BH, 1996, J PROTEIN CHEM, V15, P481, DOI 10.1007/BF01886856; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; Kim YG, 1998, BIOL CHEM, V379, P489, DOI 10.1515/bchm.1998.379.4-5.489; Kim YG, 1997, GENE, V203, P43, DOI 10.1016/S0378-1119(97)00489-7; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J	20	27	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19081	19086		10.1074/jbc.274.27.19081	http://dx.doi.org/10.1074/jbc.274.27.19081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383410	hybrid			2022-12-27	WOS:000081196300033
J	Evans, TC; Benner, J; Xu, MQ				Evans, TC; Benner, J; Xu, MQ			The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNPROTECTED PEPTIDES; CHEMICAL LIGATION; AUTOPROTEOLYSIS; MODULATION; SUPPORT; ELEMENT	Mini-inteins derived from Synechocystis sp. (Ssp DnaB intein) and Mycobacterium xenopi (Mxe GyrA intein) that have been modified to cleave peptide bonds at their C and N termini, respectively, were cloned in-frame to the N and C termini of a target protein. Peptide bond cleavage of the modified inteins generated an N-terminal cysteine and a C-terminal thioester on the same protein, These complementary reactive groups underwent intra- or intermolecular condensation to generate circular or polymeric protein species with a new peptide bond at the site of ligation, Three cyclic peptides, BBP, an organ specific localization peptide; RGD, an inhibitor of platelet aggregation; and CDR-H3/C2, which inhibits HIV-1 replication, were isolated using the two-intein system. BBP, RGD, and CDR-H3/C2 had masses of 977.1, 1119.9, and 2098.6 g/mol, respectively, as determined by matrix-assisted laser desorption-time of flight mass spectrometry, which agreed well with the values of 977.2, 1120.3, and 2098.3 g/mol, respectively, predicted for the cyclic species. This system was used to cyclize proteins as large as 395 amino acids. Furthermore, multimers of thioredoxin were formed upon concentration of the reactive species, indicating the potential to form novel biomaterials based on fibrous proteins.	New England Biolabs Inc, Beverly, MA 01915 USA		Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	xum@neb.com	Wood, David W/B-2992-2012					Camarero JA, 1998, J PEPT RES, V51, P303; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cotton GJ, 1999, J AM CHEM SOC, V121, P1100, DOI 10.1021/ja983804b; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; Holford M, 1998, STRUCTURE, V6, P951, DOI 10.1016/S0969-2126(98)00097-5; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; SOUTHWORTH MW, 1999, IN PRESS BIOTECHNIQU; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388; YAMAMOTO Y, 1995, CHEM LETT, P11, DOI 10.1246/cl.1995.11; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y	28	117	137	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18359	18363		10.1074/jbc.274.26.18359	http://dx.doi.org/10.1074/jbc.274.26.18359			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373440	hybrid			2022-12-27	WOS:000081056700032
J	Johnson, BW; Boise, LH				Johnson, BW; Boise, LH			Bcl-2 and caspase inhibition cooperate to inhibit tumor necrosis factor-alpha-induced cell death in a Bcl-2 cleavage-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; INDUCED APOPTOSIS; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; CD95 FAS/APO-1; PROTEIN; ACTIVATION; PHOSPHORYLATION; RELEASE; DOMAIN	The ability of proteins of the Bcl-2 family to either induce or inhibit apoptosis is dependent on both cell type and the apoptotic stimulus. We have shown in the murine pro-B cell line FL5.12 that Bcl-2 is incapable of inhibiting tumor necrosis factor alpha (TNF alpha)-induced cell death and is cleaved during this process. One potential explanation for this observation is that caspase activation directly or indirectly inhibits Bcl-2 function. It has been suggested that caspase cleavage of Bcl-2 is responsible for its inability to block certain cell deaths. Consistent with Bcl-2 cleavage being a caspase-mediated event, this cleavage is inhibitable by 50 mu M CBZ-Val-Ala-Asp-fluoromethylketone (zVAD-fmk). Furthermore, Bcl-2 can cooperate with the caspase inhibitor zVAD-fmk in a dose-dependent manner to block TNF alpha-induced cell death. Overexpression of Bcl-2 results in a 10-fold decrease in the amount of zVAD-fmk required to inhibit TNF alpha-induced apoptosis. However, cleavage-defective mutants (D31A and D34A) show no enhanced viability relative to wild-type Bcl-2 in response to TNF alpha-induced cell death and also show the same cooperativity with zVAD-fmk. These results suggest that Bcl-2 cleavage is not important for the inhibition of TNF alpha-induced cell death but do not preclude an involvement in a post-commitment phase of apoptosis.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA; Univ Miami, Sylvester Comprehens Canc Ctr, Sch Med, Miami, FL 33101 USA	University of Miami; University of Miami	Boise, LH (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, POB 016960 R-138, Miami, FL 33101 USA.		Boise, Lawrence/AAD-2314-2019					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Fang GF, 1998, CANCER RES, V58, P3202; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hawkins C J, 1997, Semin Immunol, V9, P25, DOI 10.1006/smim.1996.0052; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; REED JC, 1996, MECH LYMPHOCYTE ACTI, V6; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18552	18558		10.1074/jbc.274.26.18552	http://dx.doi.org/10.1074/jbc.274.26.18552			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373464	hybrid			2022-12-27	WOS:000081056700056
J	Kumar, S; Talis, AL; Howley, PM				Kumar, S; Talis, AL; Howley, PM			Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-C; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTION FACTOR TFIIH; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; E6 ONCOPROTEIN; COMPLEX-FORMATION; HUMAN HOMOLOGS; BINDING-SITES	The human papilloma virus E6-associated protein (E6AP) functions as a ubiquitin protein ligase (E3) in the E6-mediated ubiquitination of p53. E6AP is also an E3 in the absence of E6, but its normal cellular substrates have not yet been identified. Here we report the identification of HHR23A, one of the human homologues of the yeast DNA repair protein Rad23, as an E6-independent target of E6AP, HHR23A binds E6AP and is ubiquitinated in. vitro in an E6AP dependent manner. Ubiquitinated forms of endogenous HHR23A are detectable in mammalian cells. Overexpression of wild-type E6AP in vivo enhances the ubiquitination of HHR23A, whereas a dominant negative E6AP mutant inhibits HHR23A ubiquitination. Although HHR23A is a stable protein in nonsynchronized cells, its levels are regulated in a cell cycle-dependent manner, with specific degradation occurring during S phase. The S phase degradation of HHR23A could be blocked in vivo by dominant negative E6AP, providing direct evidence for the involvement of E6AP in the regulation of HHR23A. Consistent with a role of the HHR23 proteins in DNA repair, UV-induced DNA damage inhibited HHR23A degradation. Although the precise role of HHR23 proteins in DNA repair and cell cycle progression remains to be elucidated, our data suggest that E6AP-mediated ubiquitination of HHR23A may have important implications in DNA repair and cell cycle progression.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Howley, PM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R01CA064888] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; BOULIKAS T, 1996, ANTICANCER RES, V16, P673; CLEAVER JE, 1989, XERODERMA PIGMENTOSU, P2949; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUKURA T, 1997, NAT GENET, V15, P1; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1990, J BIOL CHEM, V265, P3685; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; VanderSpek PJ, 1996, GENOMICS, V31, P20, DOI 10.1006/geno.1996.0004; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	55	163	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18785	18792		10.1074/jbc.274.26.18785	http://dx.doi.org/10.1074/jbc.274.26.18785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373495	hybrid			2022-12-27	WOS:000081056700087
J	Lam, MHC; House, CM; Tiganis, T; Mitchelhill, KI; Sarcevic, B; Cures, A; Ramsay, R; Kemp, BE; Martin, TJ; Gillespie, MT				Lam, MHC; House, CM; Tiganis, T; Mitchelhill, KI; Sarcevic, B; Cures, A; Ramsay, R; Kemp, BE; Martin, TJ; Gillespie, MT			Phosphorylation at the cyclin-dependent kinases site (Thr(85)) of parathyroid hormone-related protein negatively regulates its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SV40 T-ANTIGEN; NUCLEOLAR LOCALIZATION; GROWTH-FACTORS; EXPRESSION; PEPTIDE; IDENTIFICATION; TRANSPORT; SEQUENCE; CHONDROCYTES	Parathyroid hormone-related protein (PTHrP) is expressed by a wide variety of cells and is considered to act as a secreted factor; however, evidence is accumulating for it to act in an intracrine manner. We have determined that PTHrP localizes to the nucleus at the G(1) phase of the cell cycle and is transported to the cytoplasm when cells divide. PTHrP contains a putative nuclear localization sequence (NLS) (residues 61-94) similar to that of SV40 T-antigen, which may be implicated in the nuclear import of the molecule. We identified that Thr(85) immediately prior to the NLS of PTHrP was phosphorylated by CDC2-CDK2 and phosphorylation was cell cycle-dependent. Mutation of Thr(85) to Ala(85) resulted in nuclear accumulation of PTHrP, while mutation to GIu(85) to mimic a phosphorylated residue resulted in localization of PTHrP to the cytoplasm. Combined, the data demonstrate that the intracellular localization of PTHrP is phosphorylation- and cell cycle-dependent, and such control further supports a potential intracellular role (10, 34, 35) for PTHrP.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Peter Maccallum Cancer Center	Gillespie, MT (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	m.gillespie@medicine.unimelb.edu.au	Tiganis, Tony/AAV-3495-2020; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Ramsay, Robert G/C-3291-2015	Tiganis, Tony/0000-0002-8065-9942; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Ramsay, Robert G/0000-0001-5003-0433; Gillespie, Matthew/0000-0001-6543-8909; Sarcevic, Boris/0000-0002-8063-1050				AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; Goltzman D, 1992, J Endocrinol Invest, V15, P43; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; HEATH JK, 1995, BIOCHEM J, V307, P159, DOI 10.1042/bj3070159; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.3.CO;2-D; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LI X, 1994, J BIOL CHEM, V269, P6263; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKANO K, 1995, ENDOCRINOLOGY, V136, P1782, DOI 10.1210/en.136.4.1782; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POON RYC, 1995, CURR BIOL, V5, P1243; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RANKIN W, 1995, BONE, V16, pS205; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613	37	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18559	18566		10.1074/jbc.274.26.18559	http://dx.doi.org/10.1074/jbc.274.26.18559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373465	hybrid			2022-12-27	WOS:000081056700057
J	Palma, E; Maggi, L; Barabino, B; Eusebi, F; Ballivet, M				Palma, E; Maggi, L; Barabino, B; Eusebi, F; Ballivet, M			Nicotinic acetylcholine receptors assembled from the alpha 7 and beta 3 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED HUMAN-CELLS; XENOPUS-LAEVIS OOCYTES; NEURONAL ALPHA(7); CHANNEL DOMAIN; FORMS; 5-HYDROXYTRYPTAMINE; MUTATION; MUTANTS; AGONIST; NACHRS	Intracellular recordings were performed in voltage-clamped Xenopus oocytes upon injection with a mixture of cDNAs encoding the beta 3 and mutant alpha 7 ((L247T)alpha 7) neuronal nicotinic acetylcholine receptor (nAChR) subunits. The expressed receptors maintained sensitivity to methyllycaconitine and to alpha-bungarotoxin but exhibited a functional profile strikingly different from that of the homomeric (L247T)alpha 7 receptor, The heteromeric (L247T)alpha 7 beta 3 nAChR had a lower apparent affinity and a faster rate of desensitization than L247Ta7 nAChR, exhibited nonlinearity in the I-V relationship, and was inhibited by 5-hydroxytryptamine, much like wild type alpha 7 ((WT)alpha 7) nAChR. Single channel recordings in cell-attached mode revealed unitary events with a slope conductance of 19 picosiemens and a lifetime of 5 ms, both values being much smaller than those of the homomeric receptor channel. Upon injection with a mixture of (WT)alpha 7 and beta 3 cDNAs, clear evidence was obtained for the plasma membrane assembly of heteromeric nAChRs, although ACh could not activate these receptors. It is concluded that beta 3, long believed to be an orphan subunit, readily co-assembles with other subunits to form heteromeric receptors, some of which may be negative regulators of cholinergic function.	Univ Rome La Sapienza, Ist Pasteur, Fondaz Cenci Bolognetti, I-00158 Rome, Italy; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00158 Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, Lab Biofis, I-00158 Rome, Italy; Univ Geneva, Dept Biochim, CH-1211 Geneva 4, Switzerland	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Geneva	Ballivet, M (corresponding author), Biochem Sci 2,30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Palma, Eleonora/A-2775-2010; maggi, laura/H-2535-2012	Palma, Eleonora/0000-0001-6026-927X; maggi, laura/0000-0002-0566-0433	Telethon [222/BI] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALBUQUERQUE EX, 1995, SEMIN NEUROSCI, V7, P91, DOI 10.1006/smns.1995.0011; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; Bertrand S, 1997, NEUROREPORT, V8, P3591, DOI 10.1097/00001756-199711100-00034; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CRABTREE G, 1997, SOC NEUR ABSTR, V23, P157; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; Fucile S, 1997, NEUROREPORT, V8, P2433, DOI 10.1097/00001756-199707280-00005; Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GARCIACOLUNGA J, 1995, P NATL ACAD SCI USA, V92, P2919, DOI 10.1073/pnas.92.7.2919; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; Jones S, 1997, J PHYSIOL-LONDON, V504, P603, DOI 10.1111/j.1469-7793.1997.603bd.x; LINDBLADH M, 1995, VEG HIST ARCHAEOBOT, V4, P153; MATTER JM, 1995, J NEUROSCI, V15, P5910; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; Palma E, 1997, P NATL ACAD SCI USA, V94, P1539, DOI 10.1073/pnas.94.4.1539; Palma E, 1996, P NATL ACAD SCI USA, V93, P11231, DOI 10.1073/pnas.93.20.11231; Palma E, 1997, P NATL ACAD SCI USA, V94, P9915, DOI 10.1073/pnas.94.18.9915; Ragozzino D, 1997, EUR J NEUROSCI, V9, P480, DOI 10.1111/j.1460-9568.1997.tb01625.x; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Sivilotti LG, 1997, J PHYSIOL-LONDON, V500, P123, DOI 10.1113/jphysiol.1997.sp022004; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; Williams BM, 1998, NAT NEUROSCI, V1, P557, DOI 10.1038/2792; WILLOUGHBY JJ, 1993, NEUROSCI LETT, V155, P136, DOI 10.1016/0304-3940(93)90691-D; Wonnacott S., 1993, METHODS NEUROSCI, P263	39	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18335	18340		10.1074/jbc.274.26.18335	http://dx.doi.org/10.1074/jbc.274.26.18335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373437	Green Published, hybrid			2022-12-27	WOS:000081056700029
J	Van Hermelen, V; Reynisdottir, S; Cianflone, K; Degerman, E; Hoffstedt, J; Nilsell, K; Sniderman, A; Arner, P				Van Hermelen, V; Reynisdottir, S; Cianflone, K; Degerman, E; Hoffstedt, J; Nilsell, K; Sniderman, A; Arner, P			Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; HUMAN ADIPOCYTES; ALTERNATIVE PATHWAY; IN-VIVO; ANTILIPOLYTIC AGENTS; INDUCED LIPOLYSIS; KINASE-C; REESTERIFICATION; METABOLISM	The effects of acylation-stimulating protein (ASP) and insulin on free fatty acid (FFA) release from isolated human fat cells and the signal transduction pathways to induce these effects were studied. ASP and insulin inhibited basal and norepinephrine-induced FFA release by stimulating fractional FFA re-esterification (both to the same extent) and by inhibiting FFA produced during lipolysis (ASP to a lesser extent than insulin). Protein kinase C inhibition influenced none of the effects of ASP or insulin. Phosphatidylinositol S-kinase inhibition counteracted the effects of insulin but not of ASP. Phosphodiesterase 3 (PDE3) activity was stimulated by ASP and insulin, whereas PDE4 activity was slightly increased by ASP only. Selective PDES inhibition reversed the effects of both ASP and insulin on fractional FFA re-esterification and lipolysis. Selective PDE4 inhibition slightly counteracted the ASP but not the effect of insulin on fractional FFA re-esterification and did not prevent the action of ASP or insulin on lipolysis. Thus, ASP and insulin play a major role in regulating FFA release from fat cells as follows: insulin by stimulating fractional FFA re-esterification and inhibiting lipolysis and ASP mainly by stimulating fractional FFA re-esterification. For both ASP and insulin these effects on FFA release are mediated by PDES, and for ASP PDE4 might also be involved. The signaling pathway preceding PDE is not known for ASP but involves phosphatidylinositol 3-kinase for insulin.	Huddinge Univ Hosp, MK Div, Ctr Metab & Endocrinol, Karolinska Inst,Dept Med, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Res Ctr, Dept Surg, S-14186 Huddinge, Sweden; McGill Univ, Royal Victoria Hosp, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signalling, S-22100 Lund, Sweden	Karolinska Institutet; Karolinska Institutet; McGill University; Royal Victoria Hospital; Lund University	Arner, P (corresponding author), Huddinge Univ Hosp, MK Div, Ctr Metab & Endocrinol, Karolinska Inst,Dept Med, M63, S-14186 Huddinge, Sweden.	peter.arner@medhs.ki.se		Arner, Peter/0000-0002-6208-6220				ARNER P, 1991, INT J OBESITY, V15, P327; ARNER P, 1974, BIOCHIM BIOPHYS ACTA, V369, P209, DOI 10.1016/0005-2760(74)90252-5; ARNER P, 1995, INT J OBESITY, V19, P435; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BALDO A, 1995, J LIPID RES, V36, P1415; BODEN G, 1993, DIABETES, V42, P1588, DOI 10.2337/diabetes.42.11.1588; BROOKS B, 1982, FEBS LETT, V146, P327, DOI 10.1016/0014-5793(82)80945-9; CAMPBELL PJ, 1994, AM J PHYSIOL, V266, pE600, DOI 10.1152/ajpendo.1994.266.4.E600; CAMPBELL PJ, 1992, AM J PHYSIOL, V263, pE1063; Cianflone K, 1997, CLIN BIOCHEM, V30, P301, DOI 10.1016/S0009-9120(97)00011-8; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; EDENS NK, 1990, J LIPID RES, V31, P1423; ENGFELDT P, 1983, J CLIN ENDOCR METAB, V56, P501, DOI 10.1210/jcem-56-3-501; Enoksson S, 1998, DIABETOLOGIA, V41, P560, DOI 10.1007/s001250050947; FRAYN KN, 1994, AM J PHYSIOL, V266, pE308, DOI 10.1152/ajpendo.1994.266.3.E308; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; HAGSTROMTOFT E, 1995, DIABETES, V44, P1170, DOI 10.2337/diabetes.44.10.1170; HELLMER J, 1989, ANAL BIOCHEM, V177, P132, DOI 10.1016/0003-2697(89)90027-4; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KATHER H, 1988, J BIOL CHEM, V263, P8803; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Large V, 1997, INT J OBESITY, V21, P78, DOI 10.1038/sj.ijo.0800368; LEIBEL RL, 1985, AM J PHYSIOL, V248, pE140, DOI 10.1152/ajpendo.1985.248.1.E140; LEIBEL RL, 1985, AM J CLIN NUTR, V42, P198, DOI 10.1093/ajcn/42.2.198; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; LINDGREN S, 1991, BIOCHEM PHARMACOL, V42, P545, DOI 10.1016/0006-2952(91)90317-X; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; LONNQVIST F, 1989, INT J OBESITY, V13, P137; LOW GK, 1961, J BIOL CHEM, V236, P1631; MANGANIELLO VC, 1971, J BIOL CHEM, V246, P2195; MARCUS C, 1987, J CLIN INVEST, V79, P1812, DOI 10.1172/JCI113022; Maslowska M, 1997, J LIPID RES, V38, P1; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; NASLUND B, 1993, J LIPID RES, V34, P633; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RICHELSEN B, 1992, MOL CELL ENDOCRINOL, V85, P73, DOI 10.1016/0303-7207(92)90126-Q; RODBELL M, 1964, J BIOL CHEM, V239, P375; Saleh J, 1998, J LIPID RES, V39, P884; SCHREIBER RD, 1978, J EXP MED, V148, P1722, DOI 10.1084/jem.148.6.1722; SHECHTER Y, 1984, ENDOCRINOLOGY, V115, P1787, DOI 10.1210/endo-115-5-1787; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Steinberg D, 1963, Biochem Soc Symp, V24, P111; Steinberg D, 1965, HANDB PHYSIOL, P335; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; VanHarmelen V, 1997, INT J OBESITY, V21, P972, DOI 10.1038/sj.ijo.0800504; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; WALSH MJ, 1989, J SURG RES, V46, P470, DOI 10.1016/0022-4804(89)90162-5; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; Zierath JR, 1998, DIABETOLOGIA, V41, P1343, DOI 10.1007/s001250051075	53	129	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18243	18251		10.1074/jbc.274.26.18243	http://dx.doi.org/10.1074/jbc.274.26.18243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373426	hybrid			2022-12-27	WOS:000081056700018
J	Lamprecht, C; Mueller, CR				Lamprecht, C; Mueller, CR			D-site binding protein transactivation requires the proline- and acid-rich domain and involves the coactivator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ADENOVIRUS E1A; BZIP PROTEIN; GENE; DBP; PROMOTER; EXPRESSION; FAMILY	The D-site binding protein (DBP) is a member of the proline- and acid-rich (PAR) domain subfamily of basic/ leucine zipper proteins and is involved in transcriptional regulation in the liver. Deletion analysis of the DBP protein was carried out in an effort to define the function of the conserved PAR domain. Internal deletions of the protein, i.e. removing portions of the PAR domain, resulted in a substantial loss in transactivation of a high affinity DBP reporter construct when assayed in Rep G2 cells. These same sequences conferred significant transactivation to GAL4 DNA binding domain fusion proteins, indicating that this region acts as part of an independent activation domain comprised of sequences in both the amino terminus and in the PAR domain of DBP. The coexpression of full-length expression constructs for both DBP and hepatic leukemia factor resulted in a dramatic increase in activation mediated by the GAL4-DBP fusion proteins, suggesting the involvement of a regulated coactivator in this process. DBP transactivation appears to be a p300-dependent process, as a 12 S E1A expression construct disrupted DBP-mediated transactivation, and a p300 expression vector, but not a CREB binding protein vector, was able to restore DBP transactivation. These results suggest that the PAR domain is required for DBP activation, which occurs through a regulated, p300-dependent process.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Newcombe K, 1998, BIOCHEM BIOPH RES CO, V245, P633, DOI 10.1006/bbrc.1998.8467; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; PICKETTS DJ, 1994, BLOOD, V84, P2992; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; Shutler G, 1996, GENOMICS, V34, P334, DOI 10.1006/geno.1996.0295; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847	25	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17643	17648		10.1074/jbc.274.25.17643	http://dx.doi.org/10.1074/jbc.274.25.17643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364202	hybrid			2022-12-27	WOS:000080974300038
J	Sala-Newby, GB; Skladanowski, AC; Newby, AC				Sala-Newby, GB; Skladanowski, AC; Newby, AC			The mechanism of adenosine formation in cells - Cloning of cytosolic 5 '-nucleotidase-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 5'-NUCLEOTIDASE; PIGEON HEART; DOG HEART; PURIFICATION; ENZYMES; NUCLEOTIDES; EXPRESSION; INHIBITORS; METABOLITE; CDNA	Adenosine increases blood flow and decreases excitatory nerve firing. In the heart, it reduces rate and force of contraction and preconditions the heart against injury by prolonged ischemia. Based on indirect kinetic arguments, an AMP-selective cytosolic 5'-nucleotidase designated cN-I has been implicated in adenosine formation during ATP breakdown. The molecular identity of cN-I is unknown, although an IMP/GMP-selective cytosolic 5'-nucleotidase (cN-II) and an ecto-5'-nucleotidase (e-N) have been cloned. We utilized the high abundance of cN-I in pigeon heart to purify a 40-kDa subunit for partial protein sequencing and subsequent cDNA cloning. We obtained a full-length clone encoding a novel 40-kDa peptide, unrelated to cN-II or e-N, that was most abundant in heart, brain, and breast muscle. Immunolocalization in heart showed a striated cytoplasmic location, suggesting association with contractile elements. Transient expression in COS-7 cells, generated a 5'-nucleotidase that catalyzed adenosine formation from AMP, which was increased during ATP catabolism, In conclusion, the cloning and expression of cN-I provides definitive evidence of its ability to produce adenosine during ATP breakdown.	Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Med Univ Gdansk, Dept Biochem, PL-80211 Gdansk, Poland	University of Bristol; Fahrenheit Universities; Medical University Gdansk	Newby, AC (corresponding author), Univ Bristol, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	A.Newby@bris.ac.uk	Skladanowski, Andrzej C. C/B-4687-2010	Skladanowski, Andrzej C. C/0000-0003-3408-1147				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; BERNE RM, 1964, PHYSIOL REV, V44, P1, DOI 10.1152/physrev.1964.44.1.1; COHEN MV, 1995, J MOL CELL CARDIOL, V27, P1527, DOI 10.1016/S0022-2828(95)90293-7; DARVISH A, 1993, AM J PHYSIOL, V264, pH1528; DARVISH A, 1993, HYPERTENSION, V21, P906, DOI 10.1161/01.HYP.21.6.906; Darvish A, 1996, CIRCULATION, V94, P722; DAVIS LG, 1995, BASIC METHODS MOL BI, P143; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; GORDON EL, 1986, J BIOL CHEM, V261, P5496; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; NEWBY AC, 1990, NEWS PHYSIOL SCI, V5, P67; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; NEWBY AC, 1981, BIOCHEM PHARMACOL, V30, P2611, DOI 10.1016/0006-2952(81)90589-X; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; POSNETT DN, 1989, METHOD ENZYMOL, V178, P739; Ralevic V, 1998, PHARMACOL REV, V50, P413; RICHARDSON PJ, 1987, NATURE, V327, P232, DOI 10.1038/327232a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHRADER J, 1990, CIRCULATION, V81, P389, DOI 10.1161/01.CIR.81.1.389; Skladanowski AC, 1996, AM J PHYSIOL-HEART C, V270, pH1493, DOI 10.1152/ajpheart.1996.270.4.H1493; SKLADANOWSKI AC, 1990, BIOCHEM J, V268, P117, DOI 10.1042/bj2680117; SKLADANOWSKI AC, 1991, ROLE ADENOSINE ADENI, P289; SMOLENSKI RT, 1990, J CHROMATOGR-BIOMED, V527, P414, DOI 10.1016/S0378-4347(00)82125-8; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1657, DOI 10.1177/27.12.392001; SUZUKI K, 1993, J BIOCHEM-TOKYO, V113, P607, DOI 10.1093/oxfordjournals.jbchem.a124090; TRUONG VL, 1988, BIOCHEM J, V253, P117, DOI 10.1042/bj2530117; YAMAZAKI Y, 1991, BIOCHEMISTRY-US, V30, P1503, DOI 10.1021/bi00220a009; YOKOTA R, 1995, AM J PHYSIOL-HEART C, V268, pH1149, DOI 10.1152/ajpheart.1995.268.3.H1149	31	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17789	17793		10.1074/jbc.274.25.17789	http://dx.doi.org/10.1074/jbc.274.25.17789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364222	hybrid			2022-12-27	WOS:000080974300058
J	Schwandner, R; Dziarski, R; Wesche, H; Rothe, M; Kirschning, CJ				Schwandner, R; Dziarski, R; Wesche, H; Rothe, M; Kirschning, CJ			Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; BACTERIAL PEPTIDOGLYCAN; CD14-DEPENDENT PATHWAY; STAPHYLOCOCCUS-AUREUS; SOLUBLE PEPTIDOGLYCAN; DROSOPHILA TOLL; LIPOPOLYSACCHARIDE; CD14; BINDING; GENE	The Life-threatening complications of sepsis in humans are elicited by infection with Gram-negative as well as Gram-positive bacteria. Recently, lipopolysaccharide (LPS), a major biologically active agent of Gram-negative bacteria, was shown to mediate cellular activation by a member of the human Toll-like receptor family, Toll-like receptor (TLR) 2. Here we investigate the mechanism of cellular activation by soluble peptidoglycan (sPGN) and lipoteichoic acid (LTA), main stimulatory components of Gram-positive bacteria, Like LPS, sPGN and LTA bind to the glycosylphosphatidylinositol-anchored membrane protein CD14 and induce activation of the transcription factor NF-kappa B in host cells like macrophages. We show that whole Gram-positive bacteria, sPGN and LTA induce the activation of NF-kappa B in HEK293 cells expressing TLR2 but not in cells expressing TLR1 or TLR4. The sPGN- and LTA-induced NF-kappa B activation was not inhibited by polymyxin B, an antibiotic that binds and neutralizes LPS. Coexpression together with membrane CD14 enhances sPGN signal transmission through TLR2. In contrast to LPS signaling, activation of TLR2 by sPGN and LTA does not require serum. These findings identify TLR2 as a signal transducer for sPGN and LTA in addition to LPS.	Tularik Inc, San Francisco, CA 94080 USA; Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Kirschning, CJ (corresponding author), DeveloGen AG, Rudolf Wissel Str 28, D-37079 Gottingen, Germany.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAZIL V, 1989, MOL IMMUNOL, V26, P657, DOI 10.1016/0161-5890(89)90048-5; Bernardo J, 1998, INFECT IMMUN, V66, P28, DOI 10.1128/IAI.66.1.28-35.1998; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; Downey J. S., 1998, FRONT BIOSCI, V3, pd468; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; FERNANDEZ C, 1983, SCAND J IMMUNOL, V18, P265, DOI 10.1111/j.1365-3083.1983.tb00867.x; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; Fischer W, 1997, EUR J BIOCHEM, V244, P913, DOI 10.1111/j.1432-1033.1997.00913.x; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P3484, DOI 10.1128/IAI.59.10.3484-3491.1991; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hattor Y, 1997, BIOCHEM BIOPH RES CO, V233, P375, DOI 10.1006/bbrc.1997.6462; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Tominaga K, 1997, MOL IMMUNOL, V34, P1147, DOI 10.1016/S0161-5890(97)00145-4; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vogel G, 1998, SCIENCE, V281, P1942, DOI 10.1126/science.281.5385.1942; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	38	1372	1434	1	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17406	17409		10.1074/jbc.274.25.17406	http://dx.doi.org/10.1074/jbc.274.25.17406			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364168	hybrid			2022-12-27	WOS:000080974300004
J	Zhi, N; Ohashi, N; Rikihisa, Y				Zhi, N; Ohashi, N; Rikihisa, Y			Multiple p44 genes encoding major outer membrane proteins are expressed in the human granulocytic ehrlichiosis agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC MULTIGENE FAMILY; ANAPLASMA-MARGINALE; ANTIGENIC VARIATION; NEISSERIA-GONORRHOEAE; RECOMBINANT PROTEIN; SURFACE PROTEIN-2; HUMORAL RESPONSE; NEW-YORK; CLONING; IDENTIFICATION	Human granulocytic ehrlichiosis (HGE) is caused by infection with an obligatory intracellular bacterium, the HGE agent. We previously cloned a gene encoding HGE agent 44-kDa major outer membrane protein and designated it p44, In this study, we (i) identified five different mRNAs that are transcribed from p44-homologous genes in the HGE agent cultivated in HL-60 cells; (ii) cloned genes corresponding to the mRNAs from the genomic DNA of the HGE agent; (iii) showed that the genes being expressed were not clustered in the HGE agent genome; (iv) estimated that a minimum copy number of the p44-homologous genes in the genome is 18; (v) detected two different P44-homologous proteins expressed by the HGE agent; and (vi) demonstrated existence of antibodies specific to the two proteins in sera from patients with HGE. These findings showed that p44 multigenes have several active expression sites and the expression is regulated at transcriptional level, suggesting a potentially unique mechanism for generating the diversity in major antigenic outer membrane proteins of the HGE agent. Characterization of p44-homologous genes expressed by the HGE agent in a tissue culture would assist in understanding a role of the p44 multigene family in pathogenesis and immune response in HGE.	Ohio State Univ, Coll Vet Med, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Rikihisa, Y (corresponding author), Ohio State Univ, Coll Vet Med, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.				NIAID NIH HHS [R01 AI40934] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040934] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asanovich KM, 1997, J INFECT DIS, V176, P1029, DOI 10.1086/516529; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; Dumler JS, 1996, J INFECT DIS, V173, P1027, DOI 10.1093/infdis/173.4.1027; French DM, 1998, INFECT IMMUN, V66, P1200, DOI 10.1128/IAI.66.3.1200-1207.1998; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Ijdo JW, 1997, J INFECT DIS, V176, P687, DOI 10.1086/514091; Ijdo JW, 1998, INFECT IMMUN, V66, P3264, DOI 10.1128/IAI.66.7.3264-3269.1998; Kim HY, 1998, J CLIN MICROBIOL, V36, P3278, DOI 10.1128/JCM.36.11.3278-3284.1998; Murphy CI, 1998, INFECT IMMUN, V66, P3711, DOI 10.1128/IAI.66.8.3711-3718.1998; OBERLE SM, 1993, GENE, V136, P291, DOI 10.1016/0378-1119(93)90482-I; Ohashi N, 1998, J CLIN MICROBIOL, V36, P2671, DOI 10.1128/JCM.36.9.2671-2680.1998; Ohashi N, 1998, INFECT IMMUN, V66, P132, DOI 10.1128/IAI.66.1.132-139.1998; PALMER GH, 1994, INFECT IMMUN, V62, P3808, DOI 10.1128/IAI.62.9.3808-3816.1994; PALMER GH, 1988, INFECT IMMUN, V56, P1526, DOI 10.1128/IAI.56.6.1526-1531.1988; Pusterla N, 1997, J CLIN MICROBIOL, V35, P2307, DOI 10.1128/JCM.35.9.2307-2309.1997; Pusterla N, 1998, J CLIN MICROBIOL, V36, P2035, DOI 10.1128/JCM.36.7.2035-2037.1998; RIKIHISA Y, 1992, J CLIN MICROBIOL, V30, P143, DOI 10.1128/JCM.30.1.143-148.1992; Rikihisa Y, 1997, J INFECT DIS, V175, P210, DOI 10.1093/infdis/175.1.210; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; Sambrook J., 2002, MOL CLONING LAB MANU; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; StGeme JW, 1996, J BACTERIOL, V178, P6281, DOI 10.1128/jb.178.21.6281-6287.1996; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zhi N, 1997, J CLIN MICROBIOL, V35, P2606, DOI 10.1128/JCM.35.10.2606-2611.1997; Zhi N, 1998, J CLIN MICROBIOL, V36, P1666, DOI 10.1128/JCM.36.6.1666-1673.1998	33	91	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17828	17836		10.1074/jbc.274.25.17828	http://dx.doi.org/10.1074/jbc.274.25.17828			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364227	hybrid			2022-12-27	WOS:000080974300063
J	Abe, T; Kakyo, M; Tokui, T; Nakagomi, R; Nishio, T; Nakai, D; Nomura, H; Unno, M; Suzuki, M; Naitoh, T; Matsuno, S; Yawo, H				Abe, T; Kakyo, M; Tokui, T; Nakagomi, R; Nishio, T; Nakai, D; Nomura, H; Unno, M; Suzuki, M; Naitoh, T; Matsuno, S; Yawo, H			Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; RAT-LIVER; BILE-ACID; MOLECULAR CHARACTERIZATION; PROSTAGLANDIN TRANSPORTER; SUBSTRATE-SPECIFICITY; TISSUE DISTRIBUTION; EXPRESSION CLONING; POLYPEPTIDE; PROTEIN	We have isolated a novel liver-specific organic anion transporter, LST-1, that is expressed exclusively in the human, rat, and mouse liver. LST-1 is a new gene family located between the organic anion transporter family and prostaglandin transporter. LST-1 transports taurocholate (K-m = 13.6 mu M) in a sodium-independent manner. LST-1 also shows broad substrate specificity. It transports conjugated steroids (dehydroepiandrosterone sulfate, estradiol-17 beta-glucuronide, and estrone-3-sulfate), eicosanoids (prostaglandin E-2, thromboxane B-2, leukotriene C-4, leukotriene E-4), and thyroid hormones (thyroxine, K-m = 3.0 mu M and triiodothyronine, K-m = 2.7 mu M), reflecting hepatic multispecificity. LST-1 is probably the most important transporter in human Liver for clearance of bile acids and organic anions because hepatic levels of another organic anion transporter, OATP, is very low. This is also the first report of the human molecule that transports thyroid hormones.	Tohoku Univ, Sch Med, Dept Neurophysiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Surg 1, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 9808575, Japan; Sankyo Co Ltd, Analyt & Metab Res Labs, Tokyo 1408710, Japan	Tohoku University; Tohoku University; Tohoku University; Daiichi Sankyo Company Limited	Abe, T (corresponding author), Tohoku Univ, Sch Med, Dept Neurophysiol, Aoba Ku, 2-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.		Unno, Michiaki/AAX-5246-2020; Unno, Michiaki/A-8633-2010; Naitoh, Takeshi/K-1693-2014; Yawo, Hiromu/I-4871-2015	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416; Naitoh, Takeshi/0000-0003-4169-6334; Yawo, Hiromu/0000-0002-4299-3288				ABE T, 1992, J BIOL CHEM, V267, P13361; Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; BECK CL, 1988, PHARMACOTHERAPY, V8, P183; Bossuyt X, 1996, J HEPATOL, V25, P733, DOI 10.1016/S0168-8278(96)80246-7; DEJONG M, 1994, AM J PHYSIOL, V266, pE768, DOI 10.1152/ajpendo.1994.266.5.E768; Dumont M, 1997, J HEPATOL, V27, P1051, DOI 10.1016/S0168-8278(97)80149-3; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAGIE L, 1992, ENDOCRINOLOGY, V130, P1211, DOI 10.1210/en.130.3.1211; KullakUblick GA, 1997, GASTROENTEROLOGY, V113, P1295, DOI 10.1053/gast.1997.v113.pm9322525; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lu R, 1996, J CLIN INVEST, V98, P1142, DOI 10.1172/JCI118897; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pardridge WM, 1998, HANDBK PHYS, V1, P335; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; SANDKER GW, 1994, BIOCHEM PHARMACOL, V47, P2193, DOI 10.1016/0006-2952(94)90255-0; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; Schuster VL, 1998, ANNU REV PHYSIOL, V60, P221, DOI 10.1146/annurev.physiol.60.1.221; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIRIBELLI C, 1990, BIOCHIM BIOPHYS ACTA, V1031, P261, DOI 10.1016/0304-4157(90)90012-2; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225	31	443	461	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17159	17163		10.1074/jbc.274.24.17159	http://dx.doi.org/10.1074/jbc.274.24.17159			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358072	hybrid			2022-12-27	WOS:000080780400071
J	Doliana, R; Mongiat, M; Bucciotti, F; Giacomello, E; Deutzmann, R; Volpin, D; Bressan, GM; Colombatti, A				Doliana, R; Mongiat, M; Bucciotti, F; Giacomello, E; Deutzmann, R; Volpin, D; Bressan, GM; Colombatti, A			EMILIN, a component of the elastic fiber and a new member of the C1q/Tumor necrosis factor superfamily of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BINDING-PROTEIN; MOLECULAR-CLONING; GLOBULAR DOMAIN; SUBCOMPONENT C1Q; SIGNAL PEPTIDES; LEUCINE-ZIPPER; CDNA SEQUENCE; COILED-COIL; B-CHAIN; GENE	EMILIN (elastin microfibril interface located protein) is an extracellular matrix glycoprotein abundantly expressed in elastin-rich tissues such as blood vessels, skin, heart, and lung. It occurs associated with elastic fibers at the interface between amorphous elastin and microfibrils, Avian EMILIN was extracted from 19-day-old embryonic chick aortas and associated blood vessels and purified by ion-exchange chromatography and gel filtration. Tryptic peptides were generated from EMILIN and sequenced, and degenerate inosine-containing oligonucleotide primers were designed from some peptides. A set of primers allowed the amplification of a 360-base pair reverse transcription polymerase chain reaction product from chick aorta mRNA, A probe based on a human homologue selected by comparison of the chick sequence with EST data base was used to select overlapping clones from both human aorta and kidney cDNA libraries. Here we present the cDNA sequence of the entire coding region of human EMILIN encompassing an open reading frame of 1016 amino acid residues. There was a high degree of homology (76% identity and 88% similarity) between the chick C terminus and the human sequence as well as between the N terminus of the mature chick protein where 10 of 12 residues, as determined by N-terminal sequencing, were identical or similar to the deduced N terminus of human EMILIN. The domain organization of human EMILIN includes a Clq-like globular domain at the C terminus, a collagenous stalk, and a longer segment in which at least four heptad repeats and a leucine zipper can be identified with a high potential for forming coiled-coil alpha helices, At the N terminus there is a cysteine-rich sequence stretch similar to a region of multimerin, a platelet and endothelial cell component, containing a partial epidermal growth factor-like motif, The native state of the recombinantly expressed EMILIN C1q-like domain to be used in cell adhesion was determined by CD spectra analysis, which indicated a high value of beta-sheet conformation. The EMILIN C1q-like domain promoted a high cell adhesion of the leiomyosarcoma cell line SK-UT-1, whereas the fibrosarcoma cell line HT1080 was negative.	Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; Univ Regensburg, Dept Biochem Genet & Microbiol, D-8400 Regensburg, Germany; Univ Padua, Ist Istol, I-35100 Padua, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	IRCCS Aviano (CRO); University of Regensburg; University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, Via Pedemontana Occidentale, I-33081 Aviano, Italy.		Doliana, Roberto/AAA-1479-2019; Bucciotti, Francesco/AAZ-1255-2020; Mongiat, Maurizio/H-8297-2018; Giacomello, Emiliana/E-3080-2018	Doliana, Roberto/0000-0002-8324-7564; Bucciotti, Francesco/0000-0002-4253-855X; Mongiat, Maurizio/0000-0001-6509-0068; colombatti, alfonso/0000-0002-3676-2379; Giacomello, Emiliana/0000-0003-3329-6269	Telethon [E.0704] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; CLEARY EG, 1996, STRUCTURE FUNCTION E, V2, P95; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; DAGAGORDINI D, 1987, HISTOCHEM J, V19, P623, DOI 10.1007/BF01676168; Davis JG, 1997, P NATL ACAD SCI USA, V94, P707, DOI 10.1073/pnas.94.2.707; Dedio J, 1998, J IMMUNOL, V160, P3534; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GIACOMELLO E, 1999, IN PRESS BIOTECHNIQU; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; Hatzinikolas G, 1998, J BIOL CHEM, V273, P29309, DOI 10.1074/jbc.273.45.29309; HAYWARD CPM, 1995, J BIOL CHEM, V270, P19217, DOI 10.1074/jbc.270.33.19217; HAYWARD CPM, 1991, BLOOD, V77, P2556; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KAUL M, 1995, J IMMUNOL, V155, P5795; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MENENDEZARIAS L, 1988, COMPUT APPL BIOSCI, V4, P479; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; PEARLMAN JA, 1994, FEBS LETT, V354, P183, DOI 10.1016/0014-5793(94)01119-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEERSCHKE EIB, 1993, J LEUKOCYTE BIOL, V53, P179, DOI 10.1002/jlb.53.2.179; Peerschke EIB, 1996, J IMMUNOL, V157, P4154; PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; Reid K B, 1989, Behring Inst Mitt, P8; REID KBM, 1985, BIOCHEM J, V231, P729, DOI 10.1042/bj2310729; ROAK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; SPESSOTTO P, 1999, IN PRESS METHODS MOL; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; Zhang SD, 1996, GENE DEV, V10, P1108, DOI 10.1101/gad.10.9.1108; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	62	71	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16773	16781		10.1074/jbc.274.24.16773	http://dx.doi.org/10.1074/jbc.274.24.16773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358019	hybrid			2022-12-27	WOS:000080780400018
J	Serebriiskii, I; Khazak, V; Golemis, EA				Serebriiskii, I; Khazak, V; Golemis, EA			A two-hybrid dual bait system to discriminate specificity of protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYBRID SYSTEM; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL INTERACTION; 2-HYBRID SYSTEM; GENE-PRODUCT; DNA-BINDING; LEXA GENE; YEAST; REPRESSOR; AFFINITY	Biological regulatory systems require the specific organization of proteins into multicomponent complexes. Two hybrid systems have been used to identify novel components of signaling networks based on interactions with defined partner proteins. An important issue in the use of two-hybrid systems has been the degree to which interacting proteins distinguish their biological partner from evolutionarily conserved related proteins and the degree to which observed interactions are specific. We adapted the basic two-hybrid strategy to create a novel dual bait system designed to allow single-step screening of libraries for proteins that interact with protein 1 of interest, fused to DNA binding domain A (LexA), but do not interact with protein 2, fused to DNA binding domain B (lambda cI), Using the selective interactions of Ras and Krev-1(Rap1A) with Raf, RalGDS, and Krit1 as a model, we systematically compared LexA- and cI-fused baits and reporters. The LexA and cI baits reporter systems are well matched for level of bait expression and sensitivity range for interaction detection and allow effective isolation of specifically interacting protein pairs against a nonspecific background. These reagents should prove useful to refine the selectivity of library screens, to reduce the isolation of false positives in such screens, and to perform directed analyses of sequence elements governing the interaction of a single protein with multiple partners.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COLEMIS EA, 1997, CURRENT PROTOCOLS MO; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P345; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Inouye C, 1997, GENETICS, V147, P479; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; MARKHAM BE, 1981, NUCLEIC ACIDS RES, V9, P4149, DOI 10.1093/nar/9.16.4149; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PTASHNE M, 1978, OPERON, P325; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; Sherman F., 1986, METHODS YEAST GENETI; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZARET KS, 1985, J BACTERIOL, V162, P579, DOI 10.1128/JB.162.2.579-583.1985; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	42	73	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17080	17087		10.1074/jbc.274.24.17080	http://dx.doi.org/10.1074/jbc.274.24.17080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358061	hybrid			2022-12-27	WOS:000080780400060
J	Takahashi, M; Shibata, H; Shimakawa, M; Miyamoto, M; Mukai, H; Ono, Y				Takahashi, M; Shibata, H; Shimakawa, M; Miyamoto, M; Mukai, H; Ono, Y			Characterization of a novel giant scaffolding protein, CG-NAP, that anchors multiple signaling enzymes to centrosome and the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; ZIPPER-LIKE SEQUENCES; KINASE-C; PKN; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION; DOMAIN; CELLS	A novel 450-kDa coiled-coil protein, CG-NAP (centrosome and Golgi localized PKN-associated protein), was identified as a protein that interacted with the regulatory region of the protein kinase PKN, having a catalytic domain homologous to that of protein kinase C. CG-NAP contains two sets of putative RII (regulatory subunit of protein kinase A)-binding motif, Indeed, CG-NAP tightly bound to RII alpha in HeLa cells. Furthermore, CG-NAP was coimmunoprecipitated with the catalytic subunit of protein phosphatase 2A (PP2A), when one of the B subunit of PP2A (PR130) was exogenously expressed in COS7 cells. CG-NAP also interacted with the catalytic subunit of protein phosphatase 1 in HeLa cells. Immunofluorescence analysis of HeLa cells revealed that CG-NAP was localized to centrosome throughout the cell cycle, the midbody at telophase, and the Golgi apparatus at interphase, where a certain population of PKN and RII alpha were found to be accumulated. These data indicate that CG-NAP serves as a novel scaffolding protein that assembles several protein kinases and phosphatases on centrosome and the Golgi apparatus, where physiological events, such as cell cycle progression and intracellular membrane traffic, may be regulated by phosphorylation state of specific protein substrates.	Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe 6578501, Japan	Kobe University; Kobe University	Ono, Y (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Nada Ku, 1-1 Rokkodai Cho, Kobe 6578501, Japan.			Mukai, Hideyuki/0000-0002-0167-8695				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHOI KY, 1994, CELL, V78, P499; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOXEY SJ, 1994, CELL, V76, P639; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Kawamata T, 1998, J NEUROSCI, V18, P7402; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lin JW, 1998, J NEUROSCI, V18, P2017; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Mukai H, 1996, P NATL ACAD SCI USA, V93, P10195, DOI 10.1073/pnas.93.19.10195; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; SHU HB, 1995, J CELL SCI, V108, P2955; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	43	204	207	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17267	17274		10.1074/jbc.274.24.17267	http://dx.doi.org/10.1074/jbc.274.24.17267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358086	hybrid			2022-12-27	WOS:000080780400085
J	Barlic, J; Khandaker, MH; Mahon, E; Andrews, J; DeVries, ME; Mitchell, GB; Rahimpour, R; Tan, CM; Ferguson, SSG; Kelvin, DJ				Barlic, J; Khandaker, MH; Mahon, E; Andrews, J; DeVries, ME; Mitchell, GB; Rahimpour, R; Tan, CM; Ferguson, SSG; Kelvin, DJ			beta-Arrestins regulate interleukin-8-induced CXCR1 internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR INTERNALIZATION; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; IL-8 RECEPTOR; PROTEIN; DYNAMIN; CHEMOKINES; CLATHRIN; DESENSITIZATION; NEUTROPHILS	The functional role of neutrophils during acute inflammatory responses is regulated by two high affinity interleukin-8 receptors (CXCR1 and CXCR2) that are rapidly desensitized and internalized upon binding their cognate chemokine ligands. The efficient re-expression of CXCR1 on the surface of neutrophils following agonist-induced internalization suggests that CXCR1 surface receptor turnover may involve regulatory pathways and intracellular factors similar to those regulating beta(2)-adrenergic receptor internalization and re-expression. To examine the internalization pathway utilized by ligand-activated CXCR1, a CXCR1-GFP construct was transiently expressed in two different cell lines, HEK 293 and RBL-2H3 cells. While interleukin-8 stimulation promoted CXCR1 sequestration in RBL-2H3 cells, receptor internalization in HEK 293 cells required co-expression of G protein-coupled receptor kinase 2 and beta-arrestin proteins. The importance of beta-arrestins in CXCR1 internalization was confirmed by the ability of a dominant negative beta-arrestin 1-V53D mutant to block internalization of CXCR1 in RBL-2H3 cells. A role for dynamin was also demonstrated by the lack of CXCR1 internalization in dynamin I-K44A dominant negative mutant-transfected RBL-2H3 cells. Agonist-promoted co-localization of transferrin and CXCR1-GFP in endosomes of RBL-2H3 cells confirmed that receptor internalization occurs via clathrin coated vesicles. Our data provides a direct Link between agonist-induced internalization of CXCR1 and a requirement for G protein-coupled receptor kinase 2, beta-arrestins, and dynamin during this process.	John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol Pharmacol & Toxicol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Kelvin, DJ (corresponding author), John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada.		Sawant, Kirti V/H-3778-2013					Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Khandaker MH, 1998, J IMMUNOL, V161, P1930; LEE J, 1992, J BIOL CHEM, V267, P16283; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sabroe I, 1997, J IMMUNOL, V158, P1361; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAM RL, 1993, BLOOD, V82, P2546; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	38	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16287	16294		10.1074/jbc.274.23.16287	http://dx.doi.org/10.1074/jbc.274.23.16287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347185	hybrid			2022-12-27	WOS:000080668600045
J	Edwards, SW; Limbird, LE				Edwards, SW; Limbird, LE			Role for the third intracellular loop in cell surface stabilization of the alpha(2A)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; MEMBRANE CYTOSKELETAL COMPLEX; POSTSYNAPTIC DENSITY PROTEIN; NITRIC-OXIDE SYNTHASE; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; DOWN-REGULATION	Previous studies have shown that alpha(2A)-adrenergic receptor (alpha(2A)-AR) retention at the basolateral surface of polarized MDCKII cells involves its third intracellular (3i loop). The present studies examining mutant alpha(2A)-ARs possessing short deletions of the 3i loop indicate that no single region can completely account for the accelerated surface turnover of the Delta 3i alpha(2A)-AR, suggesting that the entire 3i loop is involved in basolateral retention. Both wild-type and Delta 3i loop alpha(2A)-ARs are extracted from polarized Madin-Darby canine kidney (MDCK) cells with 0.2% Triton X-100 and with a similar concentration/response profile, suggesting that Triton X-100-resistant interactions of the alpha(2A)-AR with cytoskeletal proteins are not involved in receptor retention on the basolateral surface. The indistinguishable basolateral t(1/2) for either the wild-type or nonsense 3i loop alpha(2A)-AR suggests that the stabilizing properties of the alpha(2A)-AR 3i loop are not uniquely dependent on a specific sequence of amino acids. The accelerated turnover of Delta 3i alpha(2A)-AR cannot be attributed to alteration in agonist-elicited alpha(2A)-AR redistribution, because alpha(2A)-ARs are not down-regulated in response to agonist. Taken together, the present studies show that stabilization of the alpha(2A)-AR on the basolateral surface of MDCKII cells involves multiple mechanisms, with the third intracellular loop playing a central role in regulating these processes.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, MRBI 464, Nashville, TN 37232 USA.			Edwards, Stephen/0000-0002-7985-111X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25182] Funding Source: Medline; NIDDK NIH HHS [DK43879] Funding Source: Medline; NIGMS NIH HHS [GM07628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BROWN AM, 1993, J MEMBRANE BIOL, V131, P93, DOI 10.1007/BF02791318; CHOI KY, 1994, CELL, V78, P499; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DHARMSATHAPHORN K, 1984, GASTROENTEROLOGY, V86, P120; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1992, J BIOL CHEM, V267, P25473; Ferguson S S, 1998, Adv Pharmacol, V42, P420; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELD M, 1973, AM J PHYSIOL, V225, P852; GELLAI M, 1987, J PHARMACOL EXP THER, V240, P723; GELLAI M, 1990, AM J PHYSIOL, V259, pF1, DOI 10.1152/ajprenal.1990.259.1.F1; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GUYER CA, 1990, J BIOL CHEM, V265, P17307; Heck DA, 1998, LIFE SCI, V62, P1467, DOI 10.1016/S0024-3205(98)00091-5; Itokawa M, 1996, MOL PHARMACOL, V49, P560; JewellMotz EA, 1997, BIOCHEMISTRY-US, V36, P8858, DOI 10.1021/bi970487x; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MORO O, 1993, J BIOL CHEM, V268, P6862; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SAKO Y, 1995, J CELL BIOL, V129, P1559, DOI 10.1083/jcb.129.6.1559; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TARONE G, 1984, J CELL BIOL, V99, P512, DOI 10.1083/jcb.99.2.512; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; UHLEN S, 1995, PHARM COMMUN, V6, P155; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yan Z, 1997, J NEUROPHYSIOL, V77, P1003, DOI 10.1152/jn.1997.77.2.1003; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	51	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16331	16336		10.1074/jbc.274.23.16331	http://dx.doi.org/10.1074/jbc.274.23.16331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347190	hybrid			2022-12-27	WOS:000080668600050
J	Chaudhary, PM; Eby, MT; Jasmin, A; Hood, L				Chaudhary, PM; Eby, MT; Jasmin, A; Hood, L			Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; KAPPA-B ACTIVATION; CELL-DEATH; INDUCED APOPTOSIS; JNK ACTIVATION; TNF RECEPTOR-1; FAS; FADD; INTERACTS	Caspase-8 is the most proximal caspase in the caspase cascade and possesses a prodomain consisting of two homologous death effector domains (DEDs). We have discovered that caspase-8 and its homologs can physically interact with tumor necrosis factor receptor-associated factor family members and activate the c-Jun N-terminal kinase (JNK, or stress-activated protein kinase) pathway. This ability resides in the DED-containing prodomain of these proteins and is independent of their role as cell death proteases. A point mutant in the first DED of caspase-8 can block JNK activation induced by several death domain receptors, Inhibition of JNK activation blocks apoptosis mediated by caspase-10, Mach-related inducer of toxicity/cFLIP, and Fas/CD95, thereby suggesting a cooperative role of this pathway in the mediation of caspase-induced apoptosis.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Chaudhary, Preet/E-1970-2018					Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	41	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	1999	274	27					19211	19219		10.1074/jbc.274.27.19211	http://dx.doi.org/10.1074/jbc.274.27.19211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	212BK	10383428	hybrid			2022-12-27	WOS:000081196300051
J	Strassheim, D; May, LG; Varker, KA; Puhl, HL; Phelps, SH; Porter, RA; Aronstam, RS; Noti, JD; Williams, CL				Strassheim, D; May, LG; Varker, KA; Puhl, HL; Phelps, SH; Porter, RA; Aronstam, RS; Noti, JD; Williams, CL			M-3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; SMOOTH-MUSCLE MYOSIN; CELL LUNG-CARCINOMA; CADHERIN-MEDIATED ADHESION; OPERATED CALCIUM INFLUX; STRESS FIBER FORMATION; HAMSTER OVARY CELLS; GUINEA-PIG; TYROSINE PHOSPHORYLATION; CLOSTRIDIUM-BOTULINUM	Although muscarinic acetylcholine receptors (mAChR) regulate the activity of smooth muscle myosin, the effects of mAChR activation on cytoplasmic myosin have not been characterized. We found that activation of transfected human M-3 mAChR induces the phosphorylation of myosin light chains (MLC) and the formation of myosin-containing stress fibers in Chinese hamster ovary (CHO-m3) cells. Direct activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (PMA) also induces myosin light chain phosphorylation and myosin reorganization in CHO-m3 cells. Conventional (alpha), novel (delta), and atypical (iota) PKC isoforms are activated by mAChR stimulation or PMA treatment in CHO-m3 cells, as indicated by PKC translocation or degradation. mAChR-mediated myosin reorganization is abolished by inhibiting conventional PKC isoforms with Go6976 (IC50 = 0.4 mu M), calphostin C (IC50 = 2.4 mu M), or chelerythrine (IC50 = 8.0 mu M) Stable expression of dominant negative RhoA(Asn-19) diminishes, but does not abolish, mAChR-mediated myosin reorganization in the CHO-m3 cells. Similarly, mAChR-mediated myosin reorganization is diminished, but not abolished, in CHO-m3 cells which are multi-nucleate due to inactivation of Rho with C3 exoenzyme, Expression of dominant negative RhoA(Asn-19) Or inactivation of RhoA with C3 exoenzyme does not affect PMA-induced myosin reorganization. These findings indicate that the PKC-mediated pathway of myosin reorganization (induced either by M-3 mAChR activation or PMA treatment) can continue to operate even when RhoA activity is diminished in CHO-m3 cells. Conventional PKC isoforms and RhoA may participate in separate but parallel pathways induced by M-3 mAChR activation to regulate cytoplasmic myosin, Changes in cytoplasmic myosin elicited by M-3 mAChR activation may contribute to the unique ability of these receptors to regulate cell morphology, adhesion, and proliferation.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA; Guthrie Res Inst, Neurobiol Lab, Sayre, PA 18840 USA; Guthrie Res Inst, Mol Biol Lab, Sayre, PA 18840 USA; Guthrie Clin, Dept Surg, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA.	cwilliam@inet.guthrie.org	STRASSHEIM, DEREK/AHB-1158-2022	Puhl, Henry/0000-0003-3095-7201				Akopov SE, 1998, AM J PHYSIOL-HEART C, V275, pH930, DOI 10.1152/ajpheart.1998.275.3.H930; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; Bremerich DH, 1997, AM J PHYSIOL-LUNG C, V273, pL775, DOI 10.1152/ajplung.1997.273.4.L775; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Chang ZL, 1997, BIOCHEM PHARMACOL, V54, P833, DOI 10.1016/S0006-2952(97)00250-5; CHOI OH, 1994, J BIOL CHEM, V269, P536; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; Croxton TL, 1998, AM J PHYSIOL-LUNG C, V275, pL748, DOI 10.1152/ajplung.1998.275.4.L748; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; DETJEN K, 1995, P NATL ACAD SCI USA, V92, P10929, DOI 10.1073/pnas.92.24.10929; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDAKA H, 1988, ADV SEC MESS PHOSPH, V21, P95; IKEBE M, 1987, J BIOL CHEM, V262, P9569; JARVINEN M, 1987, EUR J CELL BIOL, V44, P238; JIAN X, 1994, J NEUROBIOL, V25, P1310, DOI 10.1002/neu.480251011; KAMM KE, 1989, J BIOL CHEM, V264, P21223; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOKUBU K, 1995, EUR J PHARM-MOLEC PH, V290, P19, DOI 10.1016/0922-4106(95)90012-8; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KREISBERG JI, 1997, AM J PHYSIOL, V251, pC505; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Lucius C, 1998, J PHYSIOL-LONDON, V506, P83, DOI 10.1111/j.1469-7793.1998.083bx.x; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Puhl HL, 1997, BIOCHEM PHARMACOL, V53, P1107, DOI 10.1016/S0006-2952(97)00089-0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Quigley RL, 1998, CHEST, V114, P839, DOI 10.1378/chest.114.3.839; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Satoh M, 1998, GEN PHARMACOL, V30, P103, DOI 10.1016/S0306-3623(97)00083-9; Savineau JP, 1997, FUNDAM CLIN PHARM, V11, P289, DOI 10.1111/j.1472-8206.1997.tb00841.x; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Shafer SH, 1999, EXP CELL RES, V248, P148, DOI 10.1006/excr.1998.4385; SingerLahat D, 1996, BIOCHEM PHARMACOL, V51, P495, DOI 10.1016/0006-2952(95)02226-0; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; STEPHENS EV, 1993, ONCOGENE, V8, P19; Takuwa Y, 1996, JPN HEART J, V37, P793; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; Tokman MG, 1997, CANCER RES, V57, P1785; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VUORI K, 1993, J BIOL CHEM, V268, P21459; WHITNEY G, 1995, J VASC SURG, V22, P37, DOI 10.1016/S0741-5214(95)70086-2; WILLIAMS CL, 1989, IN VITRO CELL DEV B, V25, P397; WILLIAMS CL, 1993, J CELL BIOL, V121, P643, DOI 10.1083/jcb.121.3.643; WILLIAMS CL, 1986, J EXP MED, V164, P1043, DOI 10.1084/jem.164.4.1043; WILLIAMS CL, 1991, CELL REGUL, V2, P373, DOI 10.1091/mbc.2.5.373; WOODS A, 1992, J CELL SCI, V101, P277; Yoshimura Y, 1997, Int J Urol, V4, P62, DOI 10.1111/j.1442-2042.1997.tb00142.x; Yuhan R, 1997, GASTROENTEROLOGY, V113, P1873, DOI 10.1016/S0016-5085(97)70006-4	78	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18675	18685		10.1074/jbc.274.26.18675	http://dx.doi.org/10.1074/jbc.274.26.18675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373480	hybrid			2022-12-27	WOS:000081056700072
J	Tasheva, ES; Funderburgh, ML; McReynolds, J; Funderburgh, JL; Conrad, GW				Tasheva, ES; Funderburgh, ML; McReynolds, J; Funderburgh, JL; Conrad, GW			The bovine mimecan gene - Molecular cloning and characterization of two major RNA transcripts generated by alternative use of two splice acceptor sites in the third exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR; OSTEOINDUCTIVE FACTOR; MESSENGER-RNAS; LUMICAN GENE; CORE PROTEIN; ORGANIZATION; ISOFORMS; BONE	Mimecan is a proteoglycan expressed by many connective tissues. It was originally isolated in a truncated form as a bone-associated glycoprotein, osteoglycin, and was considered an osteoinductive factor. Recently, we demonstrated that the full-length translation product of the cDNA encoding mimecan is a corneal keratan sulfate proteoglycan present in other tissues without keratan sulfate chains. We also described multiple mimecan mRNA transcripts generated by differential splicing and alternative polyadenylation, In this study, we isolated genomic clones and determined the genomic organization of the bovine mimecan gene. The gene is spread over >33 kilobases of continuous DNA sequence and contains eight exons, The newly discovered first exon, identified by 5'-rapid amplification of cDNA ends, consists of a 5'-untranslated region and is enriched in C + G nucleotides. Two transcription initiation sites starting at the first and at the second exons were determined by primer extension. Molecular characterization shows that alternatively spliced RNA isoforms are generated by the use of two distinct splice acceptor sites in the third exon situated 278 base pairs apart. We determined a partial genomic structure of the human mimecan gene and demonstrated two alternatively spliced RNA transcripts that are generated likewise. Despite the diversity of mimecan transcripts, the primary structure of the core protein is encoded from exons 3 to 8 and remains unchanged, indicating its functional importance. Using ribonuclease protection assay, we analyzed the patterns of spliced RNA expressed in cultured bovine keratocytes. We demonstrated that their expression is differentially modulated in a temporal manner by basic fibroblast growth factor.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Tasheva, ES (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.				NEI NIH HHS [EY00952, EY09368] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; BUSTURIA A, 1990, EMBO J, V9, P3551, DOI 10.1002/j.1460-2075.1990.tb07565.x; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DASH JR, 1993, CONNECT TISSUE RES, V30, P11; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Garcia F, 1998, GENOMICS, V50, P69, DOI 10.1006/geno.1998.5315; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Iwata Y, 1998, BIOCHEM J, V331, P959, DOI 10.1042/bj3310959; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KISS I, 1989, J BIOL CHEM, V264, P8126; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MOUNT S, 1982, NUCLEIC ACIDS RES, V19, P459; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAITTA B, 1992, J BIOL CHEM, V267, P6188; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shanahan CM, 1997, ARTERIOSCL THROM VAS, V17, P2437, DOI 10.1161/01.ATV.17.11.2437; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; Tasheva ES, 1999, DNA SEQUENCE, V10, P67, DOI 10.3109/10425179909033939; Tasheva ES, 1998, GENE, V218, P63, DOI 10.1016/S0378-1119(98)00390-4; TASHEVA ES, 1993, LEUKEMIA, V7, P318; Tasheva ES, 1997, J BIOL CHEM, V272, P32551, DOI 10.1074/jbc.272.51.32551; Tzanakakis GN, 1997, BIOCHIMIE, V79, P323, DOI 10.1016/S0300-9084(97)80026-0; UJITA M, 1995, GENE, V158, P237, DOI 10.1016/0378-1119(95)00070-M; VASSART G, 1985, MOL CELL ENDOCRINOL, V40, P89, DOI 10.1016/0303-7207(85)90162-5; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	47	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1999	274	26					18693	18701		10.1074/jbc.274.26.18693	http://dx.doi.org/10.1074/jbc.274.26.18693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	209PJ	10373482	hybrid			2022-12-27	WOS:000081056700074
J	Akasaki, T; Koga, H; Sumimoto, H				Akasaki, T; Koga, H; Sumimoto, H			Phosphoinositide 3-kinase-dependent and -independent activation of the small GTPase Rac2 in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; PROTEIN-KINASE-C; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SUPEROXIDE PRODUCTION; DEPENDENT ACTIVATION; GDP/GTP EXCHANGE; RHO-GTPASES	The small GTPase Rac participates in various cellular events such as cytoskeletal reorganization. It has remained, however, largely unknown about intracellular signaling pathways for Rac activation because of the lack of a simple and reliable assay to estimate the activation. Here we describe a novel method to detect the GTP-bound, active Rac in cells by pulling it down with the Rac-binding domain of the protein kinase PAK. Experiments using this method reveal that stimulation of human neutrophils with the G(i)-coupled receptor agonists N-formyl-methionyl-leucyl-phenylalanine (fMLP) and leukotriene B-4 (LTB4) leads to a rapid and transient increase in the GTP-bound state of Rac2, whereas phorbol myristate acetate (PMA) causes a slow but more sustained activation of Rac2. Pretreatment of cells with pertussis toxin results in defective activation of Rac2 in response to fMLP and LTB4, indicating that coupling of the receptors to G(i) plays a crucial role in the activation. Furthermore, the phosphoinositide 3-kinase (PI3K) inhibitors wortmannin and LY294002 block Rac2 activation elicited by the receptor agonists, but not that by PMA. Thus the G(i)-coupled receptors likely mediate Rac2 activation via PI3K, whereas PMA activates Rac2 in a PI3K-independent manner.	Kyushu Univ, Grad Sch Med Sci, Dept Biol & Mol Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Biol & Mol Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hirata M, 1998, JPN J PHARMACOL, V76, P255, DOI 10.1254/jjp.76.255; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OKADA T, 1994, J BIOL CHEM, V269, P3563; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1984, BIOCHIM BIOPHYS ACTA, V803, P271, DOI 10.1016/0167-4889(84)90117-4; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WATSON F, 1991, J BIOL CHEM, V266, P7432; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776	43	153	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18055	18059		10.1074/jbc.274.25.18055	http://dx.doi.org/10.1074/jbc.274.25.18055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364257	hybrid			2022-12-27	WOS:000080974300093
J	Liu, SCH; Wang, Q; Lienhard, GE; Keller, SR				Liu, SCH; Wang, Q; Lienhard, GE; Keller, SR			Insulin receptor substrate 3 is not essential for growth or glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-CELLS; PROTEIN; MICE; PHOSPHATASE; ADIPOCYTES; IRS-1; SHP-2; GENE; EXPRESSION; DISRUPTION	The insulin receptor substrates (IRS) 1 and 2 are required for normal growth and glucose homeostaisis in mice. To determine whether IRS-3, a recently cloned member of the IRS family, is also involved in the regulation of these, we have generated mice with a targeted disruption of the IRS-3 gene and characterized them. Compared with wild-type mice, the IRS-3-null mice showed normal body weight throughout development, normal blood glucose levels in the fed and fasted state and following an oral glucose bolus, and normal fed and fasted plasma insulin levels. IRS-3 is most abundant in adipocytes and is tyrosine-phosphorylated in response to insulin in these cells. Therefore, isolated adipocytes were analyzed for changes in insulin effects, Insulin-stimulated glucose transport in the adipocytes from the IRS-3-null mice was the same as in wild-type cells. The extent of tyrosine phosphorylation of IRS-1/2 following insulin stimulation was similar in adipocytes from IRS-3-null and wild-type mice, and the insulin-induced association of tyrosine-phosphorylated IRS-1/2 with phosphatidylinositol 3-kinase and SHP-2 was not detectably increased by IRS-3 deficiency. Thus, IRS-3 was not essential for normal growth, glucose homeostasis, and glucose transport in adipocytes, and in its absence no significant compensatory augmentation of insulin signaling through IRS-1/2 was evident.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Lienhard, GE (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1998, DIABETES, V47, pA66; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CUSHMAN SW, 1978, J LIPID RES, V19, P269; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DOLE VP, 1956, J CLIN INVEST, V19, P269; Fantin VR, 1999, ENDOCRINOLOGY, V140, P1329, DOI 10.1210/en.140.3.1329; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ross SA, 1998, BIOCHEM BIOPH RES CO, V247, P487, DOI 10.1006/bbrc.1998.8821; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; White MF, 1998, RECENT PROG HORM RES, V53, P119; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	30	126	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					18093	18099		10.1074/jbc.274.25.18093	http://dx.doi.org/10.1074/jbc.274.25.18093			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364263	hybrid			2022-12-27	WOS:000080974300099
J	Okamura-Ikeda, K; Fujiwara, K; Motokawa, Y				Okamura-Ikeda, K; Fujiwara, K; Motokawa, Y			Identification of the folate binding sites on the Escherichia coli T-protein of the glycine cleavage system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; SEQUENCE DETERMINATION; MOLECULAR-CLONING; DECARBOXYLASE; EXPRESSION; MUTAGENESIS; MECHANISM; COMPLEX; REGION; GENES	T-protein is a component of the glycine cleavage system and catalyzes the tetrahydrofolate-dependent reaction. To determine the folate-binding site on the enzyme, C-14-labeled methylenetetrahydropteroyltetraglutamate (5,10-CH2-H(4)PteGlu(4)) was enzymatically synthesized from methylenetetrahydrofolate (5,10-CH2-H(4)folate) and [U-C-14]glutamic acid and subjected to cross-linking with the recombinant Escherichia coli T-protein using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, a zero-length cross-linker between amino and carboxyl groups. The cross-linked product was digested with lysylendopeptidase, and the resulting peptides were separated by reversed-phase high performance liquid chromatography, Amino acid sequencing of the labeled peptides revealed that three lysine residues at positions 78, 81, and 352 were involved in the cross-linking with polyglutamate moiety of 5,10-CH2-H(4)PteGlu(4). The comparable experiment with 5,10-CH2-H(4)folate revealed that Lys-81 and Lys-352 were also involved in cross-linking with the monoglutamate form. Mutants with single or multiple replacement(s) of these lysine residues to glutamic acid were constructed by site-directed mutagenesis and subjected to kinetic analysis. The single mutation of Lys-352 caused similar increase (2-fold) in K-m values for both folate substrates, but that of Lys-81 affected greatly the K-m value for 5,10-CH2-H(4)PteGlu(4) rather than for 5,10-CH2-H(4)folate. It is postulated that Lys-352 may serve as the primary binding site to alpha-carboxyl group of the first glutamate residue nearest the p-aminobenzoic acid ring of 5,10-CH2-H(4)folate and 5,10-CH2-H(4)PteGlu(4), whereas Lys-81 may play a key role to hold the second glutamate residue through binding to alpha-carboxyl group of the second glutamate residue.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Motokawa, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Kuramotocho 3 Chome, Tokushima 7708503, Japan.							BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; BLAKLEY RL, 1960, BIOCHEM J, V77, P459, DOI 10.1042/bj0770459; BOGNAR AL, 1983, J BIOL CHEM, V258, P2574; BOURGUIGNON J, 1993, EUR J BIOCHEM, V217, P377, DOI 10.1111/j.1432-1033.1993.tb18256.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHLUMSKY LJ, 1995, J BIOL CHEM, V270, P18252, DOI 10.1074/jbc.270.31.18252; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V192, P766, DOI 10.1006/bbrc.1993.1480; KAMB A, 1992, BIOCHEMISTRY-US, V31, P9883, DOI 10.1021/bi00156a005; KISLIUK RL, 1957, J BIOL CHEM, V227, P805; KOPRIVA S, 1995, PLANT MOL BIOL, V27, P1215, DOI 10.1007/BF00020895; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MALEY GF, 1982, ARCH BIOCHEM BIOPHYS, V216, P551, DOI 10.1016/0003-9861(82)90244-2; MARAS B, 1994, J BIOL CHEM, V269, P18429; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MOTOKAWA Y, 1995, BIOTHIOLS HLTH DIS, P389; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OKAMURAIKEDA K, 1992, J BIOL CHEM, V267, P18284; OKAMURAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OSBORN MJ, 1960, J AM CHEM SOC, V82, P4921, DOI 10.1021/ja01503a043; Sambrook J., 2002, MOL CLONING LAB MANU; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOY J, 1990, J BIOL CHEM, V265, P2492	29	7	7	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17471	17477		10.1074/jbc.274.25.17471	http://dx.doi.org/10.1074/jbc.274.25.17471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364177	hybrid			2022-12-27	WOS:000080974300013
J	Sekimata, M; Kabuyama, Y; Emori, Y; Homma, Y				Sekimata, M; Kabuyama, Y; Emori, Y; Homma, Y			Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BINDING-PROTEIN; IN-VIVO; ACTIN; RAS; 5-KINASE; CALCIUM; RELEASE; DOMAIN	We recently cloned a novel signaling molecule, p122, that shows a GTPase-activating activity specific for Rho and the ability to enhance the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of phospholipase C delta 1 in vitro. Here we analyzed the in vivo function of p122, Microinjection of the GTPase-activating domain of p122 suppressed the formation of stress fibers and focal adhesions induced by lysophosphatidic acid, suggesting a GTPase-activating activity for Rho as in in vitro. Transfection of p122 also induced the disassembly of stress fibers and the morphological rounding of various; adherent cells. Analyses using deletion and point mutants demonstrated that the GTPase-activating domain of p122 is responsible for the morphological changes and detachment and that arginine residues at positions 668 and 710 and a lysine residue at position 706 in the GTPase-activating domain are essential. Using Fluo-3-based Ca2+ microscopy, we found that p122 evoked a rapid elevation of intracellular Ca2+ levels, suggesting that p122 stimulates the phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity of phospholipase C delta 1. These results demonstrate that p122 synergistically functions as a GTPase-activating protein specific for Rho and an activator of phospholipase C delta 1 in vivo and induces morphological changes and detachment through cytoskeletal reorganization.	Fukushima Med Coll, Inst Biomed Sci, Dept Biomol Sci, Fukushima 9601295, Japan; Univ Tokyo, Fac Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan	Fukushima Medical University; University of Tokyo	Homma, Y (corresponding author), Fukushima Med Coll, Inst Biomed Sci, Dept Biomol Sci, 1 Hikariga Oka, Fukushima 9601295, Japan.							Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PerezTerzic C, 1997, CELL CALCIUM, V21, P275, DOI 10.1016/S0143-4160(97)90115-9; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Tribioli C, 1996, P NATL ACAD SCI USA, V93, P695, DOI 10.1073/pnas.93.2.695; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218	30	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	1999	274	25					17757	17762		10.1074/jbc.274.25.17757	http://dx.doi.org/10.1074/jbc.274.25.17757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208DE	10364218	hybrid			2022-12-27	WOS:000080974300054
J	Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L				Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L			STAT protein recruitment and activation in c-Kit deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; STEM-CELL FACTOR; DNA-BINDING ACTIVITY; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; KINASE; ASSOCIATION	Stem cell factor (SCF) and its tyrosine kinase receptor, c-Kit, play a crucial role in regulating migration and proliferation of melanoblasts, germ cells, and hemopoietic cell progenitors by activating a number of intracellular signaling molecules. Here we report that SCF stimulation of myeloid cells or fibroblasts ectopically expressing c-Kit induces physical association with and tyrosine phosphorylation of three signal transducers and activators of transcription (STATs) as follows: STAT1 alpha, STAT5A, and STAT5B. Other STAT proteins are not recruited upon SCF stimulation. Recruitment of STATs leads to their dimerization, nuclear translocation, and binding to specific promoter-responsive elements. Whereas STAT1 alpha, possibly in the form of homodimers, binds to the sis-inducible DNA element, STAT5 proteins, either as STAT5A/STAT5B or STAT5/STAT1 alpha heterodimers, bind to the prolactin-inducible element of the beta-casein promoter. The tyrosine kinase activity of Kit appears essential for STAT activation since a kinase-defective mutant lacking a kinase insert domain was inactive in STAT signaling. However, another mutant that lacked the carboxyl-terminal region retained STAT1 alpha activation and nuclear translocation but was unable to fully activate STATE proteins, although it mediated their transient phosphorylation, These results indicate that different intracellular domains of c-Kit are involved in activation of the various STAT proteins.	Univ Turin, Dipartimento Med Interna, I-10126 Turin, Italy; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	University of Turin; Weizmann Institute of Science	Pegoraro, L (corresponding author), Univ Turin, Dipartimento Med Interna, Corso Dogliotti 14, I-10126 Turin, Italy.		YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016					AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FJETANI Y, 1997, ONCOGENE, V14, P751; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; HELM MH, 1995, SCIENCE, V267, P1347; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; Okimoto T, 1996, ONCOGENE, V12, P1625; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PEREZ A, 1997, J BIOL CHEM, V272, P25043; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Ryan JJ, 1997, EXP HEMATOL, V25, P357; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	48	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16965	16972		10.1074/jbc.274.24.16965	http://dx.doi.org/10.1074/jbc.274.24.16965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358045	hybrid			2022-12-27	WOS:000080780400044
J	Cierniewski, CS; Byzova, T; Papierak, M; Haas, TA; Niewiarowska, J; Zhang, L; Cieslak, M; Plow, EF				Cierniewski, CS; Byzova, T; Papierak, M; Haas, TA; Niewiarowska, J; Zhang, L; Cieslak, M; Plow, EF			Peptide ligands can bind to distinct sites in integrin alpha(IIb)beta(3) and elicit different functional responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRINOGEN GAMMA-CHAIN; VONWILLEBRAND-FACTOR; GPIIB-IIIA; RECOGNITION SITE; HUMAN-PLATELETS; ALPHA-CHAIN; ADHESION RECEPTOR; CRYSTAL-STRUCTURE; BETA-3 INTEGRINS	The spatial relationship between the binding sites for two cyclic peptides, cyclo(S,S)KYGCRGDWPC (cRGD) and cyclo(S,S)KYGCHarGDWPC (cHarGD), high affinity analogs for the RGD and HLGGAKQAGDV peptide ligands, in integrin alpha(IIb)beta(3) (GPIIb-IIIa) has been characterized. For this purpose, cRGD and cHarGD were labeled with fluorescein isothiocyanate and tetramethylrhodamine B-isothiocyanate, respectively, Both cyclic peptides were potent inhibitors of fibrinogen binding to alpha(IIb)beta(3), particularly in the presence of Mn2+; IC50 values for cRGD and cHarGD were 1 and < 0.1 nM in the presence of Mn2+. Direct binding experiments and fluorescence resonance energy transfer analysis using the purified receptor showed that both peptides interacted simultaneously with distinct sites in alpha(IIb)beta(3). The distance between these sites was estimated to be 6.1 +/- 0.5 nm, Although cRGD bound preferentially to one site and cHarGD to the other, the sites were not fully specific, and each cyclic peptide or its Linear counterpart could displace the other to some extent. The binding affinity of the cHarGD site was dramatically affected by Mn2+. cRGD, but not cHarGD, bound to recombinant beta(3)-(95-373) in a cation-dependent manner, indicating that the cRGD site is located entirely within this fragment. With intact platelets, binding of c-RGD and cHarGD to alpha(IIb)beta(3) resulted in distinct conformational alterations in the receptor as indicated by the differential exposure of Ligand-induced binding site epitopes and also induced the opposite on membrane fluidity as shown by electron paramagnetic resonance analyses using 5-doxylstearic acid as a spin probe, These data support the concept the two peptide Ligands bind to distinct sites in alpha(IIb)beta(3) and initiate different functional consequences within the receptor itself and within platelets.	Cleveland Clin Fdn, Joseoph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA; Med Univ Lodz, Dept Biophys, PL-90131 Lodz, Poland; Polish Acad Sci, Ctr Mol & Macromol Res, Dept Bioorgan Chem, PL-90131 Lodz, Poland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Medical University Lodz; Polish Academy of Sciences	Plow, EF (corresponding author), Cleveland Clin Fdn, Joseoph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.		Cieslak, Marcin/ABF-2494-2020	Cieslak, Marcin/0000-0002-9628-214X; Niewiarowska, Jolanta/0000-0003-0561-7766; Byzova, Tatiana/0000-0002-2615-875X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BRUNO J, 1992, BIOCHEMISTRY-US, V31, P7016, DOI 10.1021/bi00146a002; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DU XP, 1993, J BIOL CHEM, V268, P23087; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAVERSTICK DM, 1985, BLOOD, V66, P946; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MULLER B, 1993, J BIOL CHEM, V268, P6800; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PARISE LV, 1985, J BIOL CHEM, V260, P698; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PIETU G, 1984, NATURE, V308, P648, DOI 10.1038/308648a0; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, BLOOD, V66, P26; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PLOW EF, 1985, BLOOD, V66, P724; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; TANGEMANN K, 1995, FEBS LETT, V358, P179, DOI 10.1016/0014-5793(94)01411-S; TIMMONS S, 1984, P NATL ACAD SCI-BIOL, V81, P4935, DOI 10.1073/pnas.81.15.4935; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; Wagner CL, 1996, BLOOD, V88, P907; Watala C, 1996, EUR J BIOCHEM, V235, P281, DOI 10.1111/j.1432-1033.1996.00281.x; WILLIAMS S, 1987, THROMB RES, V46, P457, DOI 10.1016/0049-3848(87)90133-2; Zar JH., 1999, BIOSTAT ANAL	75	79	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16923	16932		10.1074/jbc.274.24.16923	http://dx.doi.org/10.1074/jbc.274.24.16923			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358039	hybrid			2022-12-27	WOS:000080780400038
J	Murakami, A; Thurlow, J; Dickson, C				Murakami, A; Thurlow, J; Dickson, C			Retinoic acid-regulated expression of fibroblast growth factor 3 requires the interaction between a novel transcription factor and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE INT-2; BINDING PROTEIN; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; MOUSE; FAMILY; DIFFERENTIATION; PROMOTER	fgf-3 shows a complex spatial-temporal pattern of transcription during mouse development, and the gene product appears to be an important intercellular signaling molecule. Here we show that the major enhancer, which is obligatory for transcription, is composed of three elements with different properties. Both functional analyses in undifferentiated and differentiated F9 cells and characterization of DNA-protein complexes in vitro have identified the sequence motifs GTGACT(C), ATTGT, and GATA as the key transcription factor binding sites. The GTGACT(C) motif, while not essential, is required for full enhancer activity. However, binding at ATTGT is crucial for transcriptional activity and is required for cooperative binding at the proximal GATA site. The GATA binding site mediates the retinoic acid/ dibutyryl cyclic AMP stimulation of transcription and correlates with the binding of Gata-4 which is induced by retinoic acid in differentiating F9 cells. The ATTGT and GATA motifs are inactive when placed separately on a minimal thymidine kinase (TK) promoter, but together they act as a strong retinoic acid-regulated enhancer. In undifferentiated F9 cells, gata-4 expression stimulates the fgf-3 promoter, whereas in differentiated F9 cells already expressing gata-4, no further increase in promoter activity was observed.	Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England; Kyoto Univ, Inst Virus Res, Dept Virol Oncol, Sakyo Ku, Kyoto 6068507, Japan	Cancer Research UK; Kyoto University	Dickson, C (corresponding author), Imperial Canc Res Fund, Lincolns Inn Fields, POB 123, London WC2A 3PX, England.	C.Dickson@icrf.icnet.uk						ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bielinska M, 1997, MECH DEVELOP, V65, P43, DOI 10.1016/S0925-4773(97)00053-1; BIELINSKA M, 1995, BIOCHEM J, V307, P183, DOI 10.1042/bj3070183; Brown T., 1997, CURRENT PROTOCOLS MO; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO LC, 1991, EMBO J, V10, P1187; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jiang YM, 1998, DEV GENET, V22, P263, DOI 10.1002/(SICI)1520-6408(1998)22:3<263::AID-DVG8>3.0.CO;2-4; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wang CY, 1996, MOL CELL BIOL, V16, P712; WANG SY, 1994, J BIOL CHEM, V269, P607; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J	40	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17242	17248		10.1074/jbc.274.24.17242	http://dx.doi.org/10.1074/jbc.274.24.17242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358083	hybrid			2022-12-27	WOS:000080780400082
J	Rohrer, DK; Chruscinski, A; Schauble, EH; Bernstein, D; Kobilka, BK				Rohrer, DK; Chruscinski, A; Schauble, EH; Bernstein, D; Kobilka, BK			Cardiovascular and metabolic alterations in mice lacking both beta 1-and beta 2-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; TARGETED DISRUPTION; STIMULATION; EXERCISE; GENE; RAT; CATECHOLAMINES; PROPRANOLOL; 5-HYDROXYTRYPTAMINE	The activation state of beta-adrenergic receptors (beta-ARs) in vivo is an important determinant of hemodynamic status, cardiac performance, and metabolic rate. In order to achieve homeostasis in vivo, the cellular signals generated by beta-AR activation are integrated with signals from a number of other distinct receptors and signaling pathways. We have utilized genetic knockout models to test directly the role of beta 1- and/or beta 2-AR expression on these homeostatic control mechanisms. Despite total absence of beta 1- and beta 2-ARs, the predominant cardiovascular beta-adrenergic subtypes, basal heart rate, blood pressure, and metabolic rate do not differ from wild type controls. However, stimulation of beta-AR function by beta-AR agonists or exercise reveals significant impairments in chronotropic range, vascular reactivity, and metabolic rate. Surprisingly, the blunted chronotropic and metabolic response to exercise seen in pll beta 2-AR double knockouts fails to impact maximal exercise capacity. Integrating the results from single beta 1- and beta 2-AR knockouts as well as the beta 1-/beta 2-AR double knockout suggest that in the mouse, beta-AR stimulation of cardiac inotropy and chronotropy is mediated almost exclusively by the beta 1-AR, whereas vascular relaxation and metabolic rate are controlled by all three beta-ARs (beta 1-, beta 2-, and beta 3-AR), Compensatory alterations in cardiac muscarinic receptor density and vascular beta 3-AR responsiveness are also observed in beta 1-/beta 2-AR double knockouts. In addition to its ability to define P-AR subtype-specific functions, this genetic approach is also useful in identifying adaptive alterations that serve to maintain critical physiological setpoints such as heart rate, blood pressure, and metabolic rate when cellular signaling mechanisms are perturbed.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Roche Biosci, Dept Mol Pharmacol, Palo Alto, CA 94304 USA; Stanford Univ, Dept Pediat, Div Pediat Cardiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Roche Holding; Stanford University	Kobilka, BK (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990; Bernstein, Daniel/0000-0001-7761-5853	NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEVILACQUA M, 1989, AM J CARDIOL, V63, P853, DOI 10.1016/0002-9149(89)90056-8; BOSNJAK ZJ, 1991, ANESTHESIOLOGY, V74, P340, DOI 10.1097/00000542-199102000-00022; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; BRISTOW MR, 1982, MOL PHARMACOL, V21, P671; BRODDE OE, 1988, J HYPERTENS, V6, pS497, DOI 10.1097/00004872-198812040-00157; BRODDE OE, 1992, BASIC RES CARDIOL, V87, P1; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P383, DOI 10.1113/jphysiol.1977.sp011958; CLINE WH, 1981, J PHARMACOL EXP THER, V216, P104; Davy M, 1997, CELL MOL LIFE SCI, V53, P263, DOI 10.1007/PL00000601; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; Desai KH, 1996, CIRCULATION, V94, P1800; DiBello V, 1995, INT J SPORTS MED, V16, P498, DOI 10.1055/s-2007-973044; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; ELLINGSEN O, 1987, CIRC RES, V60, P540, DOI 10.1161/01.RES.60.4.540; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ENDOH M, 1989, BASIC RES CARDIOL, V84, P69, DOI 10.1007/BF02650348; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GALBO H, 1976, J APPL PHYSIOL, V40, P855, DOI 10.1152/jappl.1976.40.6.855; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; GLAUBIGER G, 1977, BIOCHEM BIOPH RES CO, V78, P720, DOI 10.1016/0006-291X(77)90238-8; Gotshall RW, 1996, INT J SPORTS MED, V17, P17; JUHLINDANNFELT A, 1983, ACTA MED SCAND, P49; KEMMOTSU O, 1973, ANESTHESIOLOGY, V39, P470, DOI 10.1097/00000542-197311000-00003; LANDS A. M., 1967, LIFE SCI, V6, P2241, DOI 10.1016/0024-3205(67)90031-8; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LINK RE, 1995, MOL PHARMACOL, V48, P48; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; LYNCH C, 1986, ANESTHESIOLOGY, V64, P620, DOI 10.1097/00000542-198605000-00013; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Malinowska B, 1997, BRIT J PHARMACOL, V122, P1307, DOI 10.1038/sj.bjp.0701516; MCLEOD AA, 1983, CIRCULATION, V67, P1076, DOI 10.1161/01.CIR.67.5.1076; OPIE LH, 1985, AM J CARDIOL, V55, pD95, DOI 10.1016/0002-9149(85)91062-8; PEPPERL DJ, 1994, HDB RECEPTORS CHANNE, P45; ROGUS EM, 1977, BIOCHIM BIOPHYS ACTA, V464, P347, DOI 10.1016/0005-2736(77)90009-8; Rohrer DK, 1998, ANNU REV PHARMACOL, V38, P351, DOI 10.1146/annurev.pharmtox.38.1.351; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; ROHRER DK, 1998, HYPERTENSION HEART F, P129; Shen YT, 1996, J PHARMACOL EXP THER, V278, P1435; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Strosberg AD, 1995, OBES RES, V3, pS501, DOI 10.1002/j.1550-8528.1995.tb00219.x; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Thomas AJ, 1997, METHOD INFORM MED, V36, P372; UUSITUPA M, 1982, ANN CLIN RES, V14, P165; Zaizen H, 1996, HEART VESSELS, V11, P10, DOI 10.1007/BF01744594	48	207	214	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					16701	16708		10.1074/jbc.274.24.16701	http://dx.doi.org/10.1074/jbc.274.24.16701			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358009	hybrid			2022-12-27	WOS:000080780400008
J	Tanaka, H; Yoshimura, Y; Nozaki, M; Yomogida, K; Tsuchida, J; Tosaka, Y; Habu, T; Nakanishi, T; Okada, M; Nojima, H; Nishimune, Y				Tanaka, H; Yoshimura, Y; Nozaki, M; Yomogida, K; Tsuchida, J; Tosaka, Y; Habu, T; Nakanishi, T; Okada, M; Nojima, H; Nishimune, Y			Identification and characterization of a haploid germ cell-specific nuclear protein kinase (Haspin) in spermatid nuclei and its effects on somatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSGENIC MICE; CDNA LIBRARIES; GENE; EXPRESSION; TESTIS; SPERMATOGENESIS; CLONING; DNA; SEQUENCE	We have cloned the entire coding region of a mouse germ cell-specific cDNA encoding a unique protein kinase whose catalytic domain contains only three consensus subdomains (I-III) instead of the normal 12. The protein possesses intrinsic Ser/Thr kinase activity and is exclusively expressed in haploid germ cells, localizing only in their nuclei, and was thus named Haspin (for haploid germ cell-Specific nuclear protein kinase). Western blot analysis showed that specific antibodies recognized a protein of M-r 83,000 in the testis, Ectopically expressed Haspin was detected exclusively in the nuclei of cultured somatic cells, Even in the absence of kinase activity, however, Haspin caused cell cycle arrest at G(1), resulting in growth arrest of the transfected somatic cells. In a DNA binding experiment, approximately one-half of wild-type Haspin was able to bind to a DNA-cellulose column, whereas the other half was not. In contrast, all of the deletion mutant Haspin that lacked autophosphorylation bound to the DNA column. Thus, the DNA-binding activity of Haspin may, in some way, be associated with its kinase activity. These observations suggest that Haspin has some critical roles in cell cycle cessation and differentiation of haploid germ cells.	Osaka Univ, Dept Sci, Lab Anim Expt, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Prot Metabol, Osaka 5650871, Japan; Osaka Univ, Genoma Informat Res Ctr, Dept Expt Genome Res, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Nishimune, Y (corresponding author), Osaka Univ, Dept Sci, Lab Anim Expt, 3-1 Yamadaka, Osaka 5650871, Japan.		Habu, Toshiyuki/ABC-6644-2021	Habu, Toshiyuki/0000-0003-4131-3938; Yoshimura, Yasuhide/0000-0002-9121-8667				Bellve A.R., 1983, P55; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BOISSONNEAULT G, 1993, MOL CELL BIOL, V13, P4323, DOI 10.1128/MCB.13.7.4323; Chatterjee S, 1997, EXP CELL RES, V236, P346, DOI 10.1006/excr.1997.3746; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUKAWA K, 1993, EMBO J, V12, P97, DOI 10.1002/j.1460-2075.1993.tb05635.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; Grimes SR, 1997, MOL BIOL REP, V24, P175, DOI 10.1023/A:1006807716339; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDARAN MA, 1989, GENE, V75, P39, DOI 10.1016/0378-1119(89)90381-8; HIDAKA K, 1995, BIOCHEM BIOPH RES CO, V213, P555, DOI 10.1006/bbrc.1995.2167; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KERR SM, 1994, MAMM GENOME, V5, P557, DOI 10.1007/BF00354930; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Matsui M, 1997, MAMM GENOME, V8, P873, DOI 10.1007/s003359900602; MONACO L, 1996, SIGNAL TRANSDUCTION, P70; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN Z, 1996, SIGNAL TRANSDUCTION, P30; TANAKA H, 1994, FEBS LETT, V355, P4, DOI 10.1016/0014-5793(94)01155-9; Tsuchida J, 1998, DEV BIOL, V197, P67, DOI 10.1006/dbio.1998.8885; WAKASUGI N, 1974, J REPROD FERTIL, V41, P85, DOI 10.1530/jrf.0.0410085; WISNIEWSKI J, 1993, EUR J BIOCHEM, V212, P137, DOI 10.1111/j.1432-1033.1993.tb17643.x	44	90	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	1999	274	24					17049	17057		10.1074/jbc.274.24.17049	http://dx.doi.org/10.1074/jbc.274.24.17049			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204TL	10358056	hybrid			2022-12-27	WOS:000080780400055
J	Fry, AM; Arnaud, L; Nigg, EA				Fry, AM; Arnaud, L; Nigg, EA			Activity of the human centrosomal kinase, Nek2, depends on an unusual leucine zipper dimerization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PROTEIN-KINASE; CELL-CYCLE REGULATION; NIMA-RELATED KINASES; ASPERGILLUS-NIDULANS; COILED-COIL; MITOTIC REGULATOR; GAMMA-TUBULIN; EXPRESSION PATTERN; VERTEBRATE CELLS; DNA	Nek2 is a human cell cycle-regulated kinase that is structurally related to the mitotic regulator, NIMA, of Aspergillus nidulans. Localization studies have shown that Nek2 is a core component of the centrosome, the microtubule organizing center of the cell, and functional approaches suggest a possible role for Nek2 in centrosome separation at the G(2)/m transition. Here, we have investigated the importance of an unusual leucine zipper coiled-coil motif present in the C-terminal noncatalytic domain of the Nek2 kinase. Glycerol gradient centrifugation indicated that endogenous Nek2 is present in HeLa cells as a salt-resistant 6 S complex, the predicted size of a Nek2 homodimer. Recombinant Nek2 overexpressed in insect cells also formed a 6 S complex, whereas a Nek2 mutant specifically lacking the leucine zipper motif was monomeric. Using yeast two-hybrid interaction analyses and coprecipitation assays, we found that Nek2 can indeed form homodimers both in vivo and in vitro and that this dimerization specifically required the leucine zipper motif. Moreover, deletion of the leucine zipper prevented a trans-autophosphorylation reaction on the C-terminal domain of Nek2 and strongly reduced Nek2 kinase activity on exogenous substrates. Finally, we emphasize that the Nek2 leucine zipper described here differs from classical leucine zippers in that it exhibits a radically different arrangement of hydrophobic and charged amino acids. Thus, this study reveals not only an important mechanism for the regulation of the Nek2 kinase but, furthermore, highlights an unusual organization of a leucine zipper dimerization motif.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	amf5@le.ac.uk		nigg, erich/0000-0003-4835-5719				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gallant P, 1995, J CELL SCI, P21; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HARPER JW, 1993, CELL, V75, P805; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; Moudjou M, 1996, J CELL SCI, V109, P875; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; Paoletti A, 1996, J CELL SCI, V109, P3089; Rhee K, 1997, DEVELOPMENT, V124, P2167; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	47	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	1999	274	23					16304	16310		10.1074/jbc.274.23.16304	http://dx.doi.org/10.1074/jbc.274.23.16304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202TQ	10347187	hybrid, Green Published			2022-12-27	WOS:000080668600047
